Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cell

ABSTRACT

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

This application is a continuation of U.S. application Ser. No.17/464,528, filed Sep. 1, 2021, which is a divisional of U.S.application Ser. No. 16/256,731, filed Jan. 24, 2019, now U.S. Pat. No.11,149,076, which is a divisional of U.S. application Ser. No.15/094,674, filed Apr. 8, 2016, now U.S. Pat. No. 10,253,086, whichclaims priority to U.S. Ser. No. 62/144,615, filed Apr. 8, 2015, U.S.Ser. No. 62/144,497, filed Apr. 8, 2015, U.S. Ser. No. 62/144,639, filedApr. 8, 2015, U.S. Ser. No. 62/207,255, filed Aug. 19, 2015, U.S. Ser.No. 62/263,423, filed Dec. 4, 2015, the contents of each of which areincorporated herein by reference in their entireties.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in XML format and is hereby incorporated byreference in its entirety. Said XML copy, created on Feb. 8, 2023, isnamed N2067-707221 SL.txt and is 2,429,163 bytes in size.

FIELD OF THE INVENTION

The present invention relates generally to the use of T cells engineeredto express a Chimeric Antigen Receptor (CAR), optionally in combinationwith a B cell inhibitor, e.g., one or more inhibitors of CD10, CD19,CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a to treat adisease associated with expression of the Cluster of Differentiation 19protein (CD19).

BACKGROUND OF THE INVENTION

Many patients with B cell malignancies are incurable with standardtherapy. In addition, traditional treatment options often have seriousside effects. Attempts have been made in cancer immunotherapy, however,several obstacles render this a very difficult goal to achieve clinicaleffectiveness. Although hundreds of so-called tumor antigens have beenidentified, these are generally derived from self and thus are poorlyimmunogenic. Furthermore, tumors use several mechanisms to renderthemselves hostile to the initiation and propagation of immune attack.

Recent developments using chimeric antigen receptor (CAR) modifiedautologous T cell (CART) therapy, which relies on redirecting T cells toa suitable cell-surface molecule on cancer cells such as B cellmalignancies, show promising results in harnessing the power of theimmune system to treat B cell malignancies and other cancers (see, e.g.,Sadelain et al., Cancer Discovery 3:388-398 (2013)). The clinicalresults of the murine derived CART19 (i.e., “CTL019”) have shown promisein establishing complete remissions in patients suffering with CLL aswell as in childhood ALL (see, e.g., Kalos et al., Sci Transl Med3:95ra73 (2011), Porter et al., NEJM 365:725-733 (2011), Grupp et al.,NEJM 368:1509-1518 (2013)). Besides the ability for the chimeric antigenreceptor on the genetically modified T cells to recognize and destroythe targeted cells, a successful therapeutic T cell therapy needs tohave the ability to proliferate and persist over time, in order tosurvey for leukemic relapse. The variable quality of T cells, resultingfrom anergy, suppression, or exhaustion, will have effects onCAR-transformed T cells' performance, over which skilled practitionershave limited control at this time. To be effective, CAR transformedpatient T cells need to persist and maintain the ability to proliferatein response to the cognate antigen. It has been shown that ALL patient Tcells perform can do this with CART19 comprising a murine scFv (see,e.g., Grupp et al., NEJM 368:1509-1518 (2013)).

SUMMARY OF THE INVENTION

The disclosure features, at least in part, a method of treating adisorder associated with expression of the Cluster of Differentiation 19protein (CD19) (e.g., OMIM Acc. No. 107265, Swiss Prot. Acc No. P15391).In certain embodiments, the disorder is a cancer, e.g., a hematologicalcancer. In some embodiments, the method comprises administering aChimeric Antigen Receptor (CAR) molecule that binds CD19 in combinationwith a B-cell inhibitor, for example, one or more (e.g., one, two, threeor more) B-cell inhibitors. In some embodiments, the B-cell inhibitor ischosen from an inhibitor of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3,or ROR1, or a combination thereof. In some embodiments, the combinationmaintains or has better clinical effectiveness as compared to eithertherapy alone. In some embodiments, the methods herein involve the useof engineered cells, e.g., T cells, to express a CAR molecule that bindsCD19, in combination with a B-cell inhibitor (e.g., an antibody (e.g., amono- or bispecific antibody) to a second B target, e.g., CD10, CD19,CD20, CD22, CD34, CD123, FLT-3, or ROR1) or a CAR-expressing cell e.g.,a CAR-expressing immune effector cell, that binds to the second B celltarget, or a combination thereof) to treat the disorder associated withexpression of CD19. The disclosure additionally features novel antigenbinding domains and CAR molecules directed to CD20 and CD22, and uses,e.g., as monotherapies or in combination therapies.

Accordingly, in one aspect, the invention pertains to a method oftreating a subject (e.g., a mammal) having a disease associated withexpression of CD19. The method comprises administering to the subject aCD19 inhibitor, e.g., a CAR molecule that binds CD19 described herein,in combination with a B-cell inhibitor. For instance, the methodcomprises administering to the subject an effective number of one ormore cells that express a CAR molecule that binds CD19, e.g., a CARmolecule that binds CD19 described herein (e.g., a wild-type or mutantCD19), in combination with a B-cell inhibitor. In certain embodiments,the B-cell inhibitor is chosen from a CD10 inhibitor, e.g., one or moreCD10 inhibitors described herein; a CD20 inhibitor, e.g., one or moreCD20 inhibitor described herein; a CD22 inhibitor, e.g., one or moreCD22 inhibitors described herein; a CD34 inhibitor, e.g., one or moreCD34 inhibitors described herein; a CD123 inhibitor, e.g., one or moreCD123 inhibitor described herein; a FLT-3 inhibitor, e.g., one or moreFLT-3 inhibitors described herein; an ROR1 inhibitor, e.g., one or moreROR1 inhibitor described herein; a CD79b inhibitor, e.g., one or moreCD79b inhibitor described herein; a CD179b inhibitor, e.g., one or moreCD179b inhibitor described herein; a CD79a inhibitor, e.g., one or moreCD79a inhibitor described herein or any combination thereof. In certainaspects, a method of treating a subject having a B-cell leukemia orB-cell lymphoma, comprising administering to the subject an effectivenumber of one or more cells that express a CAR molecule that binds CD19,in combination with one or more inhibitors of CD10, CD20, CD22, CD34,CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a is disclosed.

In a related aspect, the present disclosure provides a method ofreducing the proliferation of CD19-expressing cells, e.g., byadministering to a subject, e.g., a patient in need thereof, acombination therapy as described herein, e.g., a CD19 inhibitor incombination with a B-cell inhibitor, e.g., one or more B-cell inhibitorsas described herein. In another aspect, the present disclosure providesa method of selectively killing CD19-expressing cells, e.g., byadministering to a subject, e.g., a patient in need thereof, acombination therapy as described herein, e.g., a CD19 inhibitor incombination with a B-cell inhibitor, e.g., one or more B-cell inhibitorsas described herein. In certain aspects, the disclosure provides amethod of providing an anti-tumor immunity in a subject, e.g., a mammal,comprising administering to the mammal an effective amount of acombination (e.g., one or more CAR-expressing cells) as describedherein.

In an aspect, the disclosure provides a method of preventing aCD19-negative relapse in a mammal, comprising administering to themammal one or more B-cell inhibitors, wherein the B-cell inhibitorcomprises an inhibitor of one or more of CD10, CD20, CD22, CD34, CD123,FLT-3, ROR1, CD79b, CD179b, or CD79a.

In another aspect, the disclosure provides a method of treating asubject having a disease associated with expression of CD19, e.g., DLBCL(e.g. primary DLBCL). The method comprises administering to the subjectan effective number of one or more cells that express a CAR moleculethat binds CD19, e.g., a CD19 CAR, optionally in combination with a PD1inhibitor. Optionally, the subject has, or is identified as having, atleast 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%of cancer cells, e.g., DLBCL cells, which are CD3+/PD1+.

In an aspect, the disclosure provides a method of treating a subjecthaving a disease associated with expression of CD19, e.g., DLBCL. Themethod comprises administering to the subject an effective number of oneor more cells that express a CAR molecule that binds CD19, e.g., a CD19CAR, in combination with a PD-L1 inhibitor. Optionally, the subject has,or is identified as having, less than 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%,3%, 2%, or 1% of cells in the cancer, e.g., cancer microenvironment, aredouble positive for CD19 and PD-L1.

In an aspect, the disclosure provides one or more B-cell inhibitors,wherein the B-cell inhibitor comprises an inhibitor of one or more ofCD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a, foruse in the treatment of a subject having a disease associated withexpression of CD19, and wherein said subject has received, is receivingor is about to receive a cell that expresses a CAR molecule that bindsCD19, e.g., a CD19 CAR.

Timing and Dosage of the Combination Administration

The one or more therapies described herein can be administered to thesubject substantially at the same time or in any order. For instance, aCD19 inhibitor, e.g., a CD19 CAR-expressing cell described herein, theone or more B-cell inhibitor, and/or optionally the at least oneadditional therapeutic agent can be administered simultaneously, in thesame or in separate compositions, or sequentially.

For sequential administration, the CAR-expressing cell described herein(e.g., a CD19 CAR-expressing cell, a CD20 CAR-expressing cell, or a CD22CAR-expressing cell) can be administered first, and the additional agentcan be administered second, or the order of administration can bereversed. In some embodiments, the first therapy (e.g., a CAR-expressingcell such as a CD19 CART cell, CD20 CART cell, or CD22 CART cell) iscontinued when the second therapy is introduced, and in otherembodiments the first therapy is withdrawn before, after, or at the sametime as the second therapy is introduced. In instances of sequentialadministration, in some embodiments, the second therapy is initiatedafter a predetermined amount of time, or after the subject displays oneor more indications that relapse has occurred or is likely to occur. Theindication can be, e.g., the presence of cancer cells having adisturbance in the target of the first therapy, e.g., CD19, CD20, orCD22. The disturbance may be, e.g., a frameshift mutation and/or apremature stop codon.

In other embodiments, the two or more therapies (e.g., a CD19CAR-expressing cell and a B-cell inhibitor) are administeredsimultaneously. Without being bound by theory, in some embodiments,simultaneous administration of the therapies can reduce the likelihoodof relapse and/or delay relapse.

When administered in combination, the first therapy (e.g., CAR therapy,e.g., CAR-expressing cell directed against CD19, CD20, or CD22) and theadditional agent (e.g., second or third agent, e.g., a B-cellinhibitor), or all, can be administered in an amount or dose that ishigher, lower, or the same as the amount or dosage of each agent usedindividually, e.g., as a monotherapy. In certain embodiments, theadministered amount or dosage of the first therapy, second therapy,optionally a third therapy, or all, is lower (e.g., at least 20%, atleast 30%, at least 40%, or at least 50%) than the amount or dosage ofeach agent used individually, e.g., as a monotherapy. In otherembodiments, the amount or dosage of the first therapy, second therapy,optionally a third therapy, or all, that results in a desired effect(e.g., treatment of cancer) is lower (e.g., at least 20%, at least 30%,at least 40%, or at least 50% lower) than the amount or dosage of eachagent used individually, e.g., as a monotherapy, required to achieve thesame therapeutic effect. In certain embodiments, the lower dose resultsin reduced side effects compared to those seen when the regular(monotherapy) dose is administered.

In an embodiment, the therapy comprises a population of cells. Inembodiments, the cells are immune effector cells, e.g., CAR-expressingcells.

Alternatively, or in combination with the methods described herein,methods are disclosed that comprise a diagnostic step or a patientselection step, for instance as described below.

In one aspect, the invention provides a method of evaluating a subject,e.g., a patient, for relapser status (e.g. a relapser or a non-relapserafter a CAR-therapy). In one embodiment, the method identifies asubject, e.g., a patient, who has relapsed (“relapser”) or who is arelikely to relapse, or who has not relapsed (“non-relapser”) or who islikely not to relapse, after treatment with a CAR therapy (e.g., a CD19CART therapy, e.g., described herein, e.g., a CTL019 therapy). In anembodiment, relapser status (e.g. relapser or non-relapser after a CARTtherapy) is determined by assaying for one or more characteristics ofCD19.

In one embodiment, the one or more characteristics of CD19 include analteration in a nucleic acid sequence (e.g., a mutation such as aninsertion, a deletion, or a substitution, or a combination thereof), analteration in a nucleic acid level, an alteration in a protein sequence,or an alteration in a protein level, or a combination thereof. In oneembodiment, a relapser has one or more mutations in CD19, e.g., one ormore mutations (e.g. insertions or deletions) in exon 2 of CD19. In anembodiment, a relapser has one or more mutations in exon 1, exon 2, exon3, exon 4, exon 5, exon 6, or exon 7 of CD19. In an embodiment, themutation produces a premature stop codon, e.g., by an insertion ordeletion leading to a frameshift, e.g., in exon 2 of CD19. In anembodiment, the mutation is a mutation of Table 31.

In an embodiment, the characteristic of CD19 is compared to a referencecharacteristic. For example, when the characteristic is a sequence(e.g., protein or nucleic acid sequence from a biological sample), thereference characteristic can be a wild-type sequence (e.g., protein ornucleic acid sequence) of CD19. The characteristic may be the percent ofcells in the sample having a mutant sequence. When the characteristic isa level (e.g., protein or nucleic acid level), the referencecharacteristic can be a wild-type level (e.g., protein or nucleic acidlevel) of CD19. The characteristic may be the level of protein ornucleic acid in the sample. The characteristic may be the percentage ofcells in the sample that have a level of protein or nucleic acid that isabove a given threshold.

In an embodiment, methods are provided for identifying a subject havingcancer, e.g., a hematological cancer, such as, e.g., CLL or ALL, asbeing a relapser or non-relapser after a treatment that comprises a CARtherapy, e.g., a CD19 CART therapy. The method comprises: (1) acquiringa sample from the subject (e.g., an apheresis sample obtained from theblood of the subject; and/or e.g., a manufactured product sample, e.g.,genetically engineered T cells obtained from the blood of the subject);(2) determining a characteristic of CD19, e.g., a sequence or level asdescribed herein; and (3) (optionally) comparing the determinedcharacteristic of CD19 to a reference characteristic; wherein thedifference, e.g., statistically significant difference, between thedetermined characteristic compared to the reference characteristic ispredictive of relapse to the CAR therapy; and (4) identifying thesubject as a relapser or non-relapser to the CAR therapy, e.g., based onthe determined characteristic of CD19. In one embodiment, the presenceor absence of the characteristic of CD19 is the presence or absence of apremature stop codon, e.g., by an insertion or deletion leading to aframeshift. In an embodiment, the presence of the characteristic of CD19is a mutation of Table 31.

In an embodiment, the provided methods comprise (1) acquiring a samplefrom the subject (e.g., an apheresis sample obtained from the blood ofthe subject; and/or, e.g., a manufactured product sample, e.g.,genetically engineered T cells obtained from the blood of the subject,e.g., a manufactured CART19 product); (2) determining a characteristicof CD19, e.g., a sequence or level as described herein; and (3)(optionally) comparing the determined characteristic of CD19 to areference characteristic; wherein the presence of the characteristic ofCD19 (e.g., the difference, e.g., a statistically significantdifference, between the determined characteristic compared to thereference characteristic) is predictive of relapse to the CAR therapy.In one embodiment, the presence of the characteristic of CD19 is thepresence of a premature stop codon, e.g., by an insertion or deletionleading to a frameshift. In an embodiment, the presence of thecharacteristic of CD19 is a mutation of Table 31.

In an embodiment, methods are provided for determining the relapse of asubject having cancer, e.g., a hematological cancer such as CLL or ALL,after a treatment comprising a CAR therapy, e.g., a CD19 CAR therapy asdescribed herein. The method comprises determining a characteristic ofCD19 in a sample obtained prior to relapse. In an embodiment, thepresence of the characteristic of CD19 (e.g., the difference, e.g., astatistically significant difference, between the determinedcharacteristic compared to the reference characteristic) is indicativeof relapse after CAR therapy. In one embodiment, the presence of thecharacteristic of CD19 is the presence of a premature stop codon, e.g.,by an insertion or deletion leading to a frameshift. In an embodiment,the presence of the characteristic of CD19 is a mutation of Table 31.

In an embodiment, methods are provided for evaluating a subject havingcancer, e.g., a hematological cancer such as CLL or ALL. The methodcomprises acquiring a value of relapser status for the subject thatcomprises a measure of one or characteristics of CD19, e.g., one or moreof the characteristics of CD19 as described herein, thereby evaluatingthe subject.

In an embodiment, methods are provided for evaluating or monitoring theeffectiveness of a CAR therapy, e.g., a CD19 CART therapy, in a subjecthaving cancer comprising acquiring a value of relapser status for thesubject that comprises a measure of one or more characteristic of CD19,e.g., one or more of the characteristics of CD19 as described herein,thereby evaluating or monitoring the effectiveness of the CAR therapy inthe subject

In an embodiment, methods are provided for providing a prediction forsuccess rate of a CAR therapy, e.g., a CD19 CART therapy, e.g.,described herein, in a subject having cancer, said method comprisingsteps of providing a biological sample from the subject; determining oneor more characteristic of CD19, e.g., one or more of the characteristicsof CD19 as described herein; and based on the characteristic determined,providing a prognosis to the subject.

In some aspects, the present disclosure provides, e.g., a method of, orassay for, identifying a subject having cancer as having an increased ordecreased likelihood to respond to a treatment that comprises a chimericantigen receptor (CAR) therapy, the method comprising:

-   -   (1) acquiring a sample from the subject;    -   (2) determining a value for one or more of:        -   (i) a level of one or more markers listed in Table 29 in the            sample;        -   (ii) a characteristic of CD19, e.g., a mutation, e.g., a            mutation causing a frameshift or a premature stop codon or            both, or        -   (iii) a level or activity of T_(REG) cells; and    -   (3) (optionally) comparing the determined value, e.g., the        level, activity or characteristic of (i), (ii) or (iii) or a        combination thereof, to a reference value, wherein the        difference, e.g., a statistically significant difference,        between the determined value compared to the reference value, is        predictive of the subject's responsiveness to the CAR therapy;        and    -   (4) identifying the subject as a complete responder, partial        responder or non-responder, or relapse or non-relapser to the        CAR therapy based on the determined value.

In certain embodiments, any of the aforesaid methods can further includethe following:

-   -   (i) administering to the subject a therapeutically effective        dose of a CAR therapy, e.g., a therapy comprising a        CD19-expressing cell, if no difference, e.g., no statistically        significant difference, is detected in the value for one, two or        more (all) of (i) the level or activity of one or more markers        listed in Table 29; (ii) the characteristic of CD19, e.g., a        mutation, e.g., a mutation causing a frameshift or a premature        stop codon or both, or (iii) the level of T_(REG) cells in a        biological sample;    -   (ii) administering to the subject a therapeutically effective        dose of a CAR therapy, e.g., a therapy comprising a        CD19-expressing cell and one or more B-cell inhibitor (e.g., one        or more inhibitors of CD10, CD20, CD22, CD34, CD123, FLT-3, or        ROR1 as described herein), if a difference, e.g., a        statistically significant difference, is detected in the value        for one, two or more (all) of (i) the level or activity of one        or more markers listed in Table 29; (ii) the characteristic of        CD19, e.g., a mutation, e.g., a mutation causing a frameshift or        a premature stop codon or both, or (iii) the level of T_(REG)        cells in a biological sample; or    -   (iii) discontinuing a first therapy, e.g., a therapy comprising        a CD19-expressing cell, and administering a second therapy,        e.g., one or more B-cell inhibitor (e.g., one or more inhibitors        of CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1 as described        herein), if a difference, e.g., a statistically significant        difference, is detected in the value for one, two or more (or        all) of (i) the level or activity of one or more markers listed        in Table 29; (ii) the characteristic of CD19, e.g., a mutation,        e.g., a mutation causing a frameshift or a premature stop codon        or both, or (iii) the level of T_(REG) cells in a biological        sample.

The administration steps (i)-(iii) can be performed before or after thepatient evaluation steps, as described in exemplary embodiments below.

In certain aspects, a method for treating a subject having cancer isdisclosed. The method comprises:

-   -   (a) acquiring, e.g., determining, if the subject has a value for        one, two or more (all) of:        -   (i) a level of one or more markers listed in Table 29;        -   (ii) a characteristic of CD19, e.g., a mutation causing a            frameshift or a premature stop codon or both, or        -   (iii) a level or activity of T_(REG) cells in a biological            sample, and    -   (b) responsive to said value, further include the following:        -   (i) administering to the subject a therapeutically effective            dose of a CAR therapy, e.g., a therapy comprising a            CD19-expressing cell, if no difference, e.g., no            statistically significant difference, is detected in one,            two or more (or all) of (i) the level or activity of one or            more markers listed in Table 29; (ii) the characteristic of            CD19, e.g., a mutation, e.g., a mutation causing a            frameshift or a premature stop codon or both, or (iii) the            level of T_(REG) cells in a biological sample;        -   (ii) administering to the subject a therapeutically            effective dose of a CAR therapy, e.g., a therapy comprising            a CD19-expressing cell and one or more B-cell inhibitor            (e.g., one or more inhibitors of CD10, CD20, CD22, CD34,            CD123, FLT-3, or ROR1 as described herein), if a difference,            e.g., a statistically significant difference, is detected in            one, two or more (or all) of (i) the level or activity of            one or more markers listed in Table 29; (ii) the            characteristic of CD19, e.g., a mutation, e.g., a mutation            causing a frameshift or a premature stop codon or both,            or (iii) the level of T_(REG) cells in a biological sample;            or        -   (iii) discontinuing a first therapy, e.g., a therapy            comprising a CD19-expressing cell, and administering a            second therapy, e.g., one or more B-cell inhibitor (e.g.,            one or more inhibitors of CD10, CD20, CD22, CD34, CD123,            FLT-3, or ROR1 as described herein), if a difference, e.g.,            a statistically significant difference, is detected in one            or more of (i) the level or activity of one or more markers            listed in Table 29; (ii) the characteristic of CD19, e.g., a            mutation, e.g., a mutation causing a frameshift or a            premature stop codon or both, or (iii) the level of T_(REG)            cells in a biological sample.

In another aspect, a method for treating a subject having cancer isprovided. The method includes:

-   -   (a) administering to a subject a therapeutically effective dose        of a CAR therapy, e.g., a therapy comprising a CD19-expressing        cell,    -   (b) acquiring a value for (e.g., determining if the subject        has), one, two or more (all) of:        -   (I) a level of one or more markers listed in Table 29;        -   (II) a characteristic of CD19, e.g., a mutation, e.g., a            mutation causing a frameshift or a premature stop codon or            both, or        -   (III) a level or activity of T_(REG) cells in a biological            sample, and    -   (c) in response to the value or determination in step (b)        (I-III), performing one or more of the following:        -   (i) administering to the subject a therapeutically effective            dose of a CAR therapy, e.g., a therapy comprising a            CD19-expressing cell, if no difference, e.g., no            statistically significant difference, is detected in one or            more of (I) the level or activity of one or more markers            listed in Table 29; (II) the characteristic of CD19, e.g., a            mutation, e.g., a mutation causing a frameshift or a            premature stop codon or both, or (III) the level of T_(REG)            cells in a biological sample;        -   (ii) administering to the subject a therapeutically            effective dose of a CAR therapy, e.g., a therapy comprising            a CD19-expressing cell and one or more B-cell inhibitor            (e.g., one or more inhibitors of CD10, CD20, CD22, CD34,            CD123, FLT-3, or ROR1 as described herein), if a difference,            e.g., a statistically significant difference, is detected in            one or more of (I) the level or activity of one or more            markers listed in Table 29; (II) the characteristic of CD19,            e.g., a mutation, e.g., a mutation causing a frameshift or a            premature stop codon or both, or (III) the level of T_(REG)            cells in a biological sample; or        -   (iii) discontinuing a first therapy, e.g., a therapy            comprising a CD19-expressing cell, and administering a            second therapy, e.g., one or more B-cell inhibitor (e.g.,            one or more inhibitors of CD10, CD20, CD22, CD34, CD123,            FLT-3, or ROR1 as described herein), if a difference, e.g.,            a statistically significant difference, is detected in one            or more of (I) the level or activity of one or more markers            listed in Table 29; (II) the characteristic of CD19, e.g., a            mutation, e.g., a mutation causing a frameshift or a            premature stop codon or both, or (III) the level of T_(REG)            cells in a biological sample.

In some embodiments of any of the aforesaid methods, the sample is abiological sample selected from a blood, plasma, or a serum sample. In aparticular embodiment, a biological sample is a blood sample. In oneembodiment, the sample is an apheresis sample, e.g., T cells obtainedfrom the blood of the subject. In an embodiment, the sample is amanufactured product sample, e.g. genetically engineered T cellsobtained from the blood of the subject, e.g., a manufactured CARproduct, e.g., a manufactured CART19 product.

In an embodiment, the methods herein can be used to determine if apatient is likely to respond to CAR therapy (e.g., CD19 CART), e.g., ifa patient who has not received CAR therapy is likely to respond to CARtherapy, or if a patient who has received CAR therapy is likely torespond to continued CAR therapy. In general, the same CD19characteristics that predict relapse predict that a patient is lesslikely to respond to a CD19 CAR therapy. A patient who is identified asless likely to respond to a CD19 CAR therapy can be administered adifferent type of therapy, such as B-cell inhibitor (e.g., one or moreinhibitors of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b,or CD79a as described herein).

In another aspect, a method for treating a subject having cancer, e.g.,a hematological cancer, is provided. In an embodiment, the methodincludes determining if a subject has a difference, e.g., statisticallysignificant difference, in a characteristic of CD19 relative to areference characteristic, and if there is a difference, e.g.,statistically significant difference between the determinedcharacteristic and reference characteristic, administering to thesubject a therapeutically effective dose of a CAR therapy, e.g., CART,thereby treating the subject. In an embodiment, the characteristic isCD19 sequence, e.g., protein or nucleic acid sequence. In an embodiment,the method comprises assaying for the presence or absence offrameshifted CD19, e.g., CD19 comprising a premature stop codon.

In embodiments of any of the aforesaid methods, the treatment comprisesadministering a CD19 CAR-expressing cell, optionally in combination withone or more B-cell inhibitors. In an embodiment, the CD19 CAR therapy isadministered simultaneously with one or more B-cell inhibitors (e.g.,one or more inhibitors of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1,CD79b, CD179b, or CD79a as described herein). In an embodiment, the CD19CAR therapy is administered before the one or more of B-cell inhibitors.In an embodiment, the CD19 CAR therapy is administered after the one ormore of B-cell inhibitors.

In an embodiment, wherein there is a difference between the determinedcharacteristic and reference characteristic, the method comprisesmodifying the CAR product prior to infusion into the subject. In anembodiment, wherein there is a different between the determinedcharacteristic and the reference characteristic, the method comprisesmodifying the manufacture of a CAR product prior to infusion into thesubject. In an embodiment, if there is a difference between thedetermined characteristic and reference characteristic the methodcomprises adjusting the CAR infusion dose to achieve an anticancereffect.

In an embodiment, the methods of treatment comprise determining if asubject has an increased likelihood to respond to a CAR therapy, e.g., aCD19 CART therapy, e.g., a CD19 CART therapy described herein, bycomparing a characteristic of CD19 in a sample from the subject relativeto a reference characteristic, wherein a difference in thecharacteristic relative to the reference characteristic is indicative ofan increased likelihood of response; and administering to the subject atherapeutically effective dose of a CAR therapy, thereby treating thesubject.

In an embodiment, the methods of treatment comprise obtaining a samplefrom a subject; determining a characteristic of CD19 (e.g., the presenceor absence of a frameshift or premature stop codon), relative to areference characteristic; and administering a therapeutically effectivedose of a CAR expressing cell, if the subject is identified as having astatistically significant difference between the CD19 characteristic ofthe sample and a reference characteristic in the sample.

The CD19 characteristic can be used to design a treatment for thepatient. For example, in an embodiment, when a patient sample compriseswild-type CD19, the patient is administered a CD19 inhibitor, e.g., aCD19 CAR-expressing cell, e.g., a CD19 CART. In an embodiment, when apatient sample comprises mutant CD19, e.g., frameshifted CD19, e.g.,CD19 comprising a premature stop codon, the patient is administered atherapy other than a CD19 inhibitor, e.g., the patient is administeredanother B-cell inhibitor. In an embodiment, when a patient samplecomprises at least normal levels of CD19, the patient is administered aCD19 inhibitor, e.g., a CD19 CAR-expressing cell, e.g., a CD19 CART. Inan embodiment, when a patient sample comprises lower than normal levelsof CD19, the patient is administered a therapy other than a CD19inhibitor, e.g., the patient is administered another B-cell inhibitor(e.g., one or more inhibitors of CD10, CD20, CD22, CD34, CD123, FLT-3,ROR1, CD79b, CD179b, or CD79a as described herein).

In an embodiment, the methods of treatment comprise acquiring a value ofrelapser status for the subject that comprises a measure of a CD19characteristic, and responsive to a determination of relapser status,performing one, two, three four or more of: (1) identifying the subjectas a relapse or non-relapser; (2) administering a CAR therapy; (3)selecting or altering a dosing of a CAR therapy; (4) selecting oraltering the schedule or time course of a CAR therapy; (5)administering, e.g., to a relapser, an additional agent in combinationwith the CAR therapy, e.g., administering one or more B-cell inhibitors;or a checkpoint inhibitor, e.g., a checkpoint inhibitor describedherein, or a kinase inhibitor, e.g., a kinase inhibitor describedherein; (6) administering to a relapser a therapy that increases thenumber of naïve T cells in the subject prior to treatment with a CARtherapy; modifying a manufacturing process of a CAR therapy, e.g.,enrich for naïve T cells prior to introducing a nucleic acid encoding aCAR, e.g., for a subject identified as a relapser; or (7) selecting analternative therapy, e.g., a standard of care for a particular cancer(e.g., as described herein), e.g., for a relapser; thereby treatingcancer in the subject.

In some embodiments, the method comprises administering one, two, threeor more B-cell inhibitors (e.g., one or more inhibitors of CD10, CD20,CD22, CD34, CD123, FLT-3, or ROR1 as described herein). For instance, inan embodiment, the method includes administering a CD19 inhibitor, e.g.,a cell expressing a CD19 CAR, in combination with a CD10 inhibitor, orany combination of a CD10 inhibitor and an inhibitor of CD20, CD22,CD34, CD123, FLT-3, or ROR1 as described herein. In another embodiment,the method includes administering a CD19 inhibitor, e.g., a cellexpressing a CD19 CAR, in combination with a CD20 inhibitor, or anycombination of a CD20 inhibitor and an inhibitor of CD10, CD22, CD34,CD123, FLT-3, or ROR1 as described herein. In another embodiment, themethod includes administering a CD19 inhibitor, e.g., a cell expressinga CD19 CAR, in combination with a CD22 inhibitor, or any combination ofa CD22 inhibitor and an inhibitor of CD10, CD20, CD34, CD123, FLT-3, orROR1 as described herein. In another embodiment, the method includesadministering a CD19 inhibitor, e.g., a cell expressing a CD19 CAR, incombination with a CD34 inhibitor, or any combination of a CD34inhibitor and an inhibitor of CD10, CD20, CD22, CD123, FLT-3, or ROR1 asdescribed herein. In another embodiment, the method includesadministering a CD19 inhibitor, e.g., a cell expressing a CD19 CAR incombination with a CD123 inhibitor, or any combination of a CD123inhibitor and an inhibitor of CD10, CD20, CD34, CD22, FLT-3, or ROR1 asdescribed herein. In another embodiment, the method includesadministering a CD19 inhibitor, e.g., a cell expressing a CD19 CAR, incombination with a FLT-3 inhibitor, or any combination of a FLT-3inhibitor and an inhibitor of CD10, CD20, CD34, CD123, or ROR1 asdescribed herein. In another embodiment, the method includesadministering a CD19 inhibitor, e.g., a cell expressing a CD19 CAR, incombination with a ROR1 inhibitor, or any combination of a ROR1inhibitor and an inhibitor of CD10, CD20, CD34, CD123, or FLT-3, asdescribed herein. In some embodiments, the method comprisesadministering one, two, three or more B-cell inhibitors (e.g., one ormore inhibitors of CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1, CD79b,CD179b, or CD79a as described herein).

In some embodiments, the methods of treatment described herein furthercomprise one or both of: determining a level of an immune checkpointmolecule (e.g., PD-L1, PD1, LAG3, or TIM3) in a patient sample; andadministering an immune checkpoint inhibitor (e.g., an inhibitor of oneor more of PD-L1, PD1, LAG3, and TIM3) to the patient. For example, themethod can comprise treating a patient with one or more CAR-expressingcells described herein (e.g., CD19 CAR in combination with a B-cellinhibitor, CD20 CAR, or CD22 CAR) and determining the level of an immunecheckpoint molecule in the patient before or after the treatment. Insome embodiments, the method comprises administering the immunecheckpoint inhibitor to a patient that has elevated levels of the immunecheckpoint molecule compared to a reference level, e.g., administering aPD-L1 inhibitor in response to elevated PD-L1 levels, administering aPD1 inhibitor in response to elevated PD1 levels, administering a LAG3inhibitor in response to elevated LAG3 levels, or administering a TIM3inhibitor in response to elevated TIM3 levels. In some embodiments, themethod comprises administering an immune checkpoint inhibitor to apatient who has received, is receiving, or is about to receive therapywith one or more CAR-expressing cells described herein (e.g., CD19 CARin combination with a B-cell inhibitor, CD20 CAR, or CD22 CAR), whereinthe patient has, or is identified as having, elevated levels of theimmune checkpoint molecule compared to a reference level.

Compositions

In some aspects, the present disclosure provides, e.g., a compositioncomprising: (i) one or more cells that express a CAR molecule that bindsCD19, e.g., a CAR molecule that binds CD19 described herein, e.g., aCD19 CAR, and (ii) a B-cell inhibitor, e.g., one or more inhibitors ofCD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1. In embodiments, (i) and(ii) are provided separately, and in embodiments, (i) and (ii) areadmixed.

In some aspects, the present disclosure provides, e.g., a nucleic acidencoding: (i) a CAR molecule that binds CD19, e.g., a CAR molecule thatbinds CD19 described herein, e.g., a CD19 CAR, and (ii) one or moreB-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22,CD34, CD123, FLT-3, or ROR1. In some aspects, the present disclosureprovides, e.g., a nucleic acid encoding: (i) a CAR molecule that bindsCD19, e.g., a CAR molecule that binds CD19 described herein, e.g., aCD19 CAR, and (ii) a CAR molecule that binds a B-cell antigen, e.g., oneor more of CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1. Inembodiments, the nucleic acid comprises RNA or DNA.

In some aspects, the present disclosure provides, e.g., a nucleic acidencoding: (i) a CAR molecule that binds CD19, e.g., a CAR molecule thatbinds CD19 described herein, e.g., a CD19 CAR, and (ii) a CAR moleculethat binds a B-cell antigen, e.g., one or more of CD10, CD20, CD22,CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. In embodiments, thenucleic acid comprises RNA or DNA. In embodiments, the nucleic acidsequences encoding (i) and (ii) are situated in the same orientation,e.g., transcription of the nucleic acid sequences encoding (i) and (ii)proceeds in the same direction. In embodiments, the nucleic acidsequences encoding (i) and (ii) are situated in different orientations.In embodiments, a single promoter controls expression of the nucleicacid sequences encoding (i) and (ii). In embodiments, a nucleic acidencoding a protease cleavage site (such as a T2A, P2A, E2A, or F2Acleavage site) is situated between the nucleic acid sequences encoding(i) and (ii). In embodiments, the protease cleavage site is placed suchthat a cell can express a fusion protein comprising (i) and (ii), whichprotein is subsequently processed into two peptides by proteolyticcleavage. In some embodiments, the nucleic acid sequences encoding (i)is upstream of the nucleic acid sequences encoding (ii), or the nucleicacid sequences encoding (ii) is upstream of the nucleic acid sequencesencoding (i). In embodiments, a first promoter controls expression ofthe nucleic acid sequence encoding (i) and a second promoter controlsexpression of the nucleic acid sequence encoding (ii). In embodiments,the nucleic acid is a plasmid. In embodiments, the nucleic acidcomprises a viral packaging element. In some aspects, the presentdisclosure provides a cell, e.g., an immune effector cell, comprisingthe nucleic acid described herein, e.g., a nucleic acid comprising (i)and (ii) as described above. The cell may comprise a protease (e.g.,endogenous or exogenous) that cleaves a T2A, P2A, E2A, or F2A cleavagesite.

In some aspects, the present disclosure provides, e.g., a compositioncomprising: (i) a first nucleic acid encoding a CAR molecule that bindsCD19, e.g., a CAR molecule that binds CD19 described herein, e.g., aCD19 CAR, and (ii) a second nucleic acid encoding one or more B-cellinhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34,CD123, FLT-3, or ROR1. In some aspects, the present disclosure provides,e.g., a composition comprising: (i) a first nucleic acid encoding a CARmolecule that binds CD19, e.g., a CAR molecule that binds CD19 describedherein, e.g., a CD19 CAR, and (ii) a CAR molecule that binds a B-cellantigen, e.g., one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, orROR1. In embodiments, the first nucleic acid and second nucleic acideach comprises RNA or DNA.

In some aspects, the present disclosure provides, e.g., a vectorcomprising a nucleic acid or nucleic acids as described herein. Thepresent disclosure also provides, in certain aspects, a cell comprisinga vector or nucleic acid as described herein.

This disclosure also provides, in certain aspects, a compositioncomprising one or more immune effector cells and: (i) a first nucleicacid encoding, or a first polypeptide comprising, a CAR molecule thatbinds CD19, e.g., a CAR molecule that binds CD19 described herein, e.g.,a CD19 CAR, and (ii) a second nucleic acid encoding, or a secondpolypeptide comprising, a CAR molecule that binds a B-cell antigen,e.g., one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b,CD179b, or CD79a. In embodiments, the first nucleic acid or firstpolypeptide and the second nucleic acid or second polypeptide are eachcontained within, e.g., expressed by, a first immune effector cell. Inembodiments, the composition comprises a first immune effector cellcontaining e.g., expressing the first nucleic acid or first polypeptideand a second immune effector cell containing e.g., expressing the secondnucleic acid or second polypeptide. In embodiments, the composition doesnot comprise a cell containing, e.g., expressing, both of the firstnucleic acid or first polypeptide and the second nucleic acid or secondpolypeptide.

Manufacturing

In certain aspects, the disclosure provides a method of making a cell,comprising transducing an immune effector cell, e.g., a T cell or NKcell, with a vector as described herein, e.g., a vector encoding a CAR.In certain aspects, the disclosure provides a method of making a cell,comprising introducing a nucleic acid as described herein (e.g., anucleic acid encoding a CAR) into an immune effector cell, e.g., a Tcell or NK cell. In certain aspects, the disclosure provides a method ofgenerating a population of RNA-engineered cells comprising introducingan in vitro transcribed RNA or synthetic RNA into a cell, where the RNAcomprises a nucleic acid as described herein, e.g., a nucleic acidencoding a CAR.

In some embodiments, the methods of making disclosed herein furthercomprise contacting the population of cells, (e.g., CD19 CAR-expressingcells, CD20 CAR-expressing cells, CD22 CAR-expressing cells, B-cellinhibitor cells, or both of CD19 CAR-expressing cells and B-cellinhibitor cells), with a nucleic acid encoding a telomerase subunit,e.g., hTERT. The nucleic acid encoding the telomerase subunit can beDNA.

In some embodiments, the method of making disclosed herein furthercomprises culturing the population of cells, (e.g., CD19 CAR-expressingcells, CD20 CAR-expressing cells, CD22 CAR-expressing cells, B-cellinhibitor cells, or both of CD19 CAR-expressing cells and B-cellinhibitor cells), in serum comprising 2% hAB serum.

Indications

In one embodiment, the disease associated with CD19 expression isselected from a proliferative disease such as a cancer or malignancy ora precancerous condition such as a myelodysplasia, a myelodysplasticsyndrome or a preleukemia, or is a non-cancer related indicationassociated with expression of CD19. In one embodiment, the disease is asolid or a liquid tumor. In one embodiment, the cancer is a pancreaticcancer. In one embodiment, the disease is a hematologic cancer. In oneembodiment, the hematologic cancer is a leukemia. In one embodiment, thecancer is selected from the group consisting of one or more acuteleukemias including but not limited to B-cell acute lymphoid leukemia(BALL), T-cell acute lymphoid leukemia (TALL), small lymphocyticleukemia (SLL), acute lymphoid leukemia (ALL) (e.g., relapsing andrefractory ALL); one or more chronic leukemias including but not limitedto chronic myelogenous leukemia (CIVIL), and chronic lymphocyticleukemia (CLL). Additional hematologic cancers or conditions include,but are not limited to mantle cell lymphoma (MCL), B cell prolymphocyticleukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt'slymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cellleukemia, small cell- or a large cell-follicular lymphoma, malignantlymphoproliferative conditions, MALT lymphoma, Marginal zone lymphoma,multiple myeloma, myelodysplasia and myelodysplastic syndrome,non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma,plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and“preleukemia.” Preleukemia encompasses a diverse collection ofhematological conditions united by ineffective production (or dysplasia)of myeloid blood cells In embodiments, a disease associated with CD19expression include, but not limited to atypical and/or non-classicalcancers, malignancies, precancerous conditions or proliferative diseasesexpressing CD19; and any combination thereof.

In one embodiment, the disease associated with expression of CD19 is alymphoma, e.g., MCL or Hodgkin lymphoma. In one embodiment, the diseaseassociated with expression of CD19 is leukemia, e.g., SLL, CLL and/orALL.

In one embodiment, the disease associated with a tumor antigen, e.g., atumor antigen described herein, is selected from a proliferative diseasesuch as a cancer or malignancy or a precancerous condition such as amyelodysplasia, a myelodysplastic syndrome or a preleukemia, or is anon-cancer related indication associated with expression of a tumorantigen described herein. In an embodiment, the disease associated witha tumor antigen described herein is a solid tumor, e.g., a solid tumordescribed herein, e.g., prostatic, colorectal, pancreatic, cervical,gastric, ovarian, head, or lung cancer.

In an embodiment, the cancer is chosen from AML, ALL, B-ALL, T-ALL,B-cell prolymphocytic leukemia, chronic lymphocytic leukemia, CIVIL,hairy cell leukemia, Hodgkin lymphoma, mast cell disorder,myelodysplastic syndrome, myeloproliferative neoplasm, plasma cellmyeloma, plasmacytoid dendritic cell neoplasm, or a combination thereof.

In an embodiment, the subject (e.g., a subject to be treated with a CD19CAR, optionally in combination with a second agent such as a PD1inhibitor or PD-L1 inhibitor) has, or is identified as having, at least5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% ofcancer cells, e.g., DLBCL cells, which are CD3+/PD1+.

In an embodiment, the subject has relapsed or is identified as havingrelapsed after treatment with the one or more cells that express a CARmolecule that binds CD19, e.g., a CD19 CAR. In an embodiment, thesubject has relapsed or is identified as having relapsed based on one ormore of reappearance of blasts in the blood, bone marrow (>5%), or anyextramedullary site, after a complete response. In an embodiment, thesubject has relapsed or is identified as having relapsed based ondetection of CD19-blasts above a predetermined threshold, e.g., over 1%,2%, 3%, 4%, 5%, or 10%.

Car Therapies

In certain embodiments, the method of treatment comprises a CAR therapy,e.g., administration of one or more cells that express one or more CARmolecules. A cell expressing one or more CAR molecules can be an immuneeffector cell, e.g., a T cell or NK cell. In an embodiment, the subjectis a human.

In one embodiment, the cell expressing the CAR molecule comprises avector that includes a nucleic acid sequence encoding the CAR molecule.In one embodiment, the vector is selected from the group consisting of aDNA, an RNA, a plasmid, a lentivirus vector, adenoviral vector, or aretrovirus vector. In one embodiment, the vector is a lentivirus vector.In one embodiment, the vector further comprises a promoter. In oneembodiment, the promoter is an EF-1 promoter. In one embodiment, theEF-1 promoter comprises a sequence of SEQ ID NO: 100. In one embodiment,the vector is an in vitro transcribed vector, e.g., a vector thattranscribes RNA of a nucleic acid molecule described herein. In oneembodiment, the nucleic acid sequence in the in vitro vector furthercomprises a poly(A) tail, e.g., a poly A tail described herein, e.g.,comprising about 150 adenosine bases. In one embodiment, the nucleicacid sequence in the in vitro vector further comprises a 3′UTR, e.g., a3′ UTR described herein, e.g., comprising at least one repeat of a 3′UTRderived from human beta-globulin. In one embodiment, the nucleic acidsequence in the in vitro vector further comprises promoter. In oneembodiment, the nucleic acid sequence comprises a T2A sequence.

In one embodiment, the cell expressing the CAR molecule is a celldescribed herein, e.g., a human T cell or a human NK cell, e.g., a humanT cell described herein or a human NK cell described herein. In oneembodiment, the human T cell is a CD8+ T cell. In one embodiment, thehuman T cell is a CD4+ T cell. In one embodiment, the human T cell is aCD4+/CD8+ T cell. In one embodiment the human T cell is a mixture ofCD8+ and CD4+ T cells. In one embodiment, the cell is an autologous Tcell. In one embodiment, the cell is an allogeneic T cell. In oneembodiment, the cell is a T cell and the T cell is diacylglycerol kinase(DGK) deficient. In one embodiment, the cell is a T cell and the T cellis Ikaros deficient. In one embodiment, the cell is a T cell and the Tcell is both DGK and Ikaros deficient.

In another embodiment, the cell expressing the CAR molecule, e.g., asdescribed herein, can further express another agent, e.g., an agentwhich enhances the activity of a CAR-expressing cell.

In one embodiment, the method includes administering a cell expressingthe CAR molecule, as described herein, in combination with an agentwhich enhances the activity of a CAR-expressing cell, wherein the agentis a cytokine, e.g., IL-7, IL-15, IL-21, or a combination thereof. Thecytokine can be delivered in combination with, e.g., simultaneously orshortly after, administration of the CAR-expressing cell. Alternatively,the cytokine can be delivered after a prolonged period of time afteradministration of the CAR-expressing cell, e.g., after assessment of thesubject's response to the CAR-expressing cell.

For example, in one embodiment, the agent that enhances the activity ofa CAR-expressing cell can be an agent which inhibits an immuneinhibitory molecule. Examples of immune inhibitory molecules includePD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/orCEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGFR beta. Inone embodiment, the agent that inhibits an immune inhibitory moleculecomprises a first polypeptide, e.g., an inhibitory molecule, associatedwith a second polypeptide that provides a positive signal to the cell,e.g., an intracellular signaling domain described herein. In oneembodiment, the agent comprises a first polypeptide, e.g., of an immuneinhibitory molecule such as PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g.,CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1,CD160, 2B4 or TGFR beta, or a fragment of any of these (e.g., at least aportion of the extracellular domain of any of these), and a secondpolypeptide which is an intracellular signaling domain described herein(e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28,e.g., as described herein) and/or a primary signaling domain (e.g., aCD3 zeta signaling domain described herein). In one embodiment, theagent comprises a first polypeptide of PD1 or a fragment thereof (e.g.,at least a portion of the extracellular domain of PD1), and a secondpolypeptide of an intracellular signaling domain described herein (e.g.,a CD28 signaling domain described herein and/or a CD3 zeta signalingdomain described herein).

In one embodiment, lymphocyte infusion, for example allogeneiclymphocyte infusion, is used in the treatment of the cancer, wherein thelymphocyte infusion comprises at least one CD19 CAR-expressing celldescribed herein and optionally at least one cell expressing a CARdirected against a B-cell antigen. In one embodiment, autologouslymphocyte infusion is used in the treatment of the cancer, wherein theautologous lymphocyte infusion comprises at least one CD19-expressingcell and optionally at least one cell expressing a CAR directed againsta B-cell antigen.

In one embodiment, the CAR expressing cell, e.g., T cell, isadministered to a subject that has received a previous stem celltransplantation, e.g., autologous stem cell transplantation, or asubject that has received a previous dose of melphalan.

In one embodiment, the cell expressing the CAR molecule, e.g., a CARmolecule described herein, is administered in combination with an agentthat ameliorates one or more side effect associated with administrationof a cell expressing a CAR molecule or with administration of the B-cellinhibitor, e.g., an agent described herein.

In one embodiment, the cell expressing the CAR molecule, e.g., a CD19CAR molecule described herein, and the B-cell inhibitor are administeredin combination with an additional agent that treats the diseaseassociated with CD19, e.g., an additional agent described herein.

In one embodiment, the cells expressing a CAR molecule, e.g., a CARmolecule described herein, are administered at a dose and/or dosingschedule described herein.

In one embodiment, the CAR molecule is introduced into T cells, e.g.,using in vitro transcription, and the subject (e.g., human) receives aninitial administration of cells comprising a CAR molecule, and one ormore subsequent administrations of cells comprising a CAR molecule,wherein the one or more subsequent administrations are administered lessthan 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 daysafter the previous administration. In one embodiment, more than oneadministration of cells comprising a CAR molecule are administered tothe subject (e.g., human) per week, e.g., 2, 3, or 4 administrations ofcells comprising a CAR molecule are administered per week. In oneembodiment, the subject (e.g., human subject) receives more than oneadministration of cells comprising a CAR molecule per week (e.g., 2, 3or 4 administrations per week) (also referred to herein as a cycle),followed by a week of no administration of cells comprising a CARmolecule, and then one or more additional administration of cellscomprising a CAR molecule (e.g., more than one administration of thecells comprising a CAR molecule per week) is administered to thesubject. In another embodiment, the subject (e.g., human subject)receives more than one cycle of cells comprising a CAR molecule, and thetime between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3 days. Inone embodiment, the cells comprising a CAR molecule are administeredevery other day for 3 administrations per week. In one embodiment, thecells comprising a CAR molecule are administered for at least two,three, four, five, six, seven, eight or more weeks.

In one embodiment, the therapy described herein (e.g., a CD20 CARtherapy, a CD22 CAR therapy, or a combination of the B-cell inhibitorand the cells expressing a CD19 CAR molecule, e.g., a CD19 CAR moleculedescribed herein) are administered as a first line treatment for thedisease, e.g., the cancer, e.g., the cancer described herein. In anotherembodiment, the therapy described herein (e.g., a CD20 CAR therapy, aCD22 CAR therapy, or a combination of the B-cell inhibitor and the cellsexpressing a CD19 CAR molecule, e.g., a CD19 CAR molecule describedherein) are administered as a second, third, fourth line treatment forthe disease, e.g., the cancer, e.g., the cancer described herein.

In one embodiment, a population of cells described herein isadministered. In some embodiments the population of cells is isolated orpurified.

In one embodiment, the method includes administering a population ofcells, a plurality of which comprise a CAR molecule described herein. Insome embodiments, the population of CAR-expressing cells comprises amixture of cells expressing different CARs. For example, in oneembodiment, the population of CAR-expressing cells can include a firstcell expressing a CAR having an anti-CD19 binding domain describedherein, and a second cell expressing a CAR having a different B-cellantigen binding domain. In embodiments, the first and second cellpopulations are T cells. In embodiments, the first and secondpopulations of T cells are the same isotype, e.g., are both CD4+ Tcells, or are both CD8+ T cells. In other embodiments, the first andsecond populations of T cells are different isotypes, e.g., the firstpopulation comprises CD4+ T cells and the second population comprisesCD8+ T cells. In embodiments, the first and second populations of Tcells are cell types described in WO2012/129514, which is hereinincorporated by reference in its entirety. As another example, apopulation of cells can comprise a single cell type that expresses botha CAR having an anti-CD19 binding domain described herein and a CARhaving a different B-cell antigen binding domain. As another example, apopulation of cells can comprise a single cell type that expresses a CARhaving two or more (e.g., 2, 3, 4, or 5) B-cell antigen binding domains,e.g., is a bispecific CAR, e.g., as described herein. As anotherexample, the population of CAR-expressing cells can include a first cellexpressing a CAR that includes an anti-CD19 binding domain, e.g., asdescribed herein, and a second cell expressing a CAR that includes anantigen binding domain to a target other than CD19 (e.g., CD10, CD20,CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, CD79a, or mesothelin). Inone embodiment, the population of CAR-expressing cells includes, e.g., afirst cell expressing a CAR that includes a primary intracellularsignaling domain, and a second cell expressing a CAR that includes asecondary signaling domain. In one embodiment, the population ofCAR-expressing cells includes, e.g., a first cell expressing a CAR thatincludes a first secondary signaling domain, and a second cellexpressing a CAR that includes a secondary signaling domain differentfrom the first secondary signaling domain.

As an example, when the first B-cell inhibitor is a CD19 CAR-expressingcell and the second B-cell inhibitor is a CD10 CAR-expressing cell, thefirst CAR and second CAR may be expressed by the same cell type ordifferent types. For instance, in some embodiments, the cell expressinga CD19 CAR is a CD4+ T cell and the cell expressing a CD10 CAR is a CD8+T cell, or the cell expressing a CD19 CAR is a CD8+ T cell and the cellexpressing a CD10 CAR is a CD4+ T cell. In other embodiments, the cellexpressing a CD19 CAR is a T cell and the cell expressing a CD10 CAR isa NK cell, or the cell expressing a CD19 CAR is a NK cell and the cellexpressing a CD10 CAR is a T cell. In other embodiments, the cellexpressing a CD19 CAR and the cell expressing a CD10 CAR are both NKcells or are both T cells, e.g., are both CD4+ T cells, or are both CD8+T cells. In yet other embodiments, a single cell expresses the CD19 CARand CD10 CAR, and this cell is, e.g., a NK cell or a T cell such as aCD4+ T cell or CD8+ T cell. The first CAR and second CAR can comprisethe same or different intracellular signaling domains. For instance, insome embodiments the CD19 CAR comprises a CD3 zeta signaling domain andthe CD10 CAR comprises a costimulatory domain, e.g., a 41BB, CD27 orCD28 costimulatory domain, while in some embodiments, the CD19 CARcomprises a costimulatory domain, e.g., a 41BB, CD27 or CD28costimulatory domain and the CD10 CAR comprises a CD3 zeta signalingdomain. In other embodiments, each of the CD19 CAR and the CD10 CARcomprises the same type of primary signaling domain, e.g., a CD3 zetasignaling domain, but the CD19 CAR and the CD10 CAR comprise differentcostimulatory domains, e.g., (1) the CD19 CAR comprises a 41BBcostimulatory domain and the CD10 CAR comprises a differentcostimulatory domain e.g., a CD27 costimulatory domain, (2) the CD19 CARcomprises a CD27 costimulatory domain and the CD10 CAR comprises adifferent costimulatory domain e.g., a 41BB costimulatory domain, (3)the CD19 CAR comprises a 41BB costimulatory domain and the CD10 CARcomprises a CD28 costimulatory domain, (4) the CD19 CAR comprises a CD28costimulatory domain and the CD10 CAR comprises a differentcostimulatory domain e.g., a 41BB costimulatory domain, (5) the CD19 CARcomprises a CD27 costimulatory domain and the CD10 CAR comprises a CD28costimulatory domain, or (6) the CD19 CAR comprises a CD28 costimulatorydomain and the CD10 CAR comprises a CD27 costimulatory domain. Inanother embodiment, a cell comprises a CAR that comprises both a CD19antigen-binding domain and a CD10 antigen-binding domain, e.g., abispecific antibody.

As another example, when the first B-cell inhibitor is a CD19CAR-expressing cell and the second B-cell inhibitor is a CD20CAR-expressing cell, the first CAR and second CAR may be expressed bythe same cell type or different types. For instance, in someembodiments, the cell expressing a CD19 CAR is a CD4+ T cell and thecell expressing a CD20 CAR is a CD8+ T cell, or the cell expressing aCD19 CAR is a CD8+ T cell and the cell expressing a CD20 CAR is a CD4+ Tcell. In other embodiments, the cell expressing a CD19 CAR is a T celland the cell expressing a CD20 CAR is a NK cell, or the cell expressinga CD19 CAR is a NK cell and the cell expressing a CD20 CAR is a T cell.In other embodiments, the cell expressing a CD19 CAR and the cellexpressing a CD20 CAR are both NK cells or are both T cells, e.g., areboth CD4+ T cells, or are both CD8+ T cells. In yet other embodiments, asingle cell expresses the CD19 CAR and CD20 CAR, and this cell is, e.g.,a NK cell or a T cell such as a CD4+ T cell or CD8+ T cell. The firstCAR and second CAR can comprise the same or different intracellularsignaling domains. For instance, in some embodiments the CD19 CARcomprises a CD3 zeta signaling domain and the CD20 CAR comprises acostimulatory domain, e.g., a 41BB, CD27 or CD28 costimulatory domain,while in some embodiments, the CD19 CAR comprises a costimulatorydomain, e.g., a 41BB, CD27 or CD28 costimulatory domain and the CD20 CARcomprises a CD3 zeta signaling domain. In other embodiments, each of theCD19 CAR and the CD20 CAR comprises the same type of primary signalingdomain, e.g., a CD3 zeta signaling domain, but the CD19 CAR and the CD20CAR comprise different costimulatory domains, e.g., (1) the CD19 CARcomprises a 41BB costimulatory domain and the CD20 CAR comprises adifferent costimulatory domain e.g., a CD27 costimulatory domain, (2)the CD19 CAR comprises a CD27 costimulatory domain and the CD20 CARcomprises a different costimulatory domain e.g., a 41BB costimulatorydomain, (3) the CD19 CAR comprises a 41BB costimulatory domain and theCD20 CAR comprises a CD28 costimulatory domain, (4) the CD19 CARcomprises a CD28 costimulatory domain and the CD20 CAR comprises adifferent costimulatory domain e.g., a 41BB costimulatory domain, (5)the CD19 CAR comprises a CD27 costimulatory domain and the CD20 CARcomprises a CD28 costimulatory domain, or (6) the CD19 CAR comprises aCD28 costimulatory domain and the CD20 CAR comprises a CD27costimulatory domain. In another embodiment, a cell comprises a CAR thatcomprises both a CD19 antigen-binding domain and a CD20 antigen-bindingdomain, e.g., a bispecific antibody.

As another example, when the first B-cell inhibitor is a CD19CAR-expressing cell and the second B-cell inhibitor is a CD22CAR-expressing cell, the first CAR and second CAR may be expressed bythe same cell type or different types. For instance, in someembodiments, the cell expressing a CD19 CAR is a CD4+ T cell and thecell expressing a CD22 CAR is a CD8+ T cell, or the cell expressing aCD19 CAR is a CD8+ T cell and the cell expressing a CD22 CAR is a CD4+ Tcell. In other embodiments, the cell expressing a CD19 CAR is a T celland the cell expressing a CD22 CAR is a NK cell, or the cell expressinga CD19 CAR is a NK cell and the cell expressing a CD22 CAR is a T cell.In other embodiments, the cell expressing a CD19 CAR and the cellexpressing a CD22 CAR are both NK cells or are both T cells, e.g., areboth CD4+ T cells, or are both CD8+ T cells. In yet other embodiments, asingle cell expresses the CD19 CAR and CD22 CAR, and this cell is, e.g.,a NK cell or a T cell such as a CD4+ T cell or CD8+ T cell. The firstCAR and second CAR can comprise the same or different intracellularsignaling domains. For instance, in some embodiments the CD19 CARcomprises a CD3 zeta signaling domain and the CD22 CAR comprises acostimulatory domain, e.g., a 41BB, CD27 or CD28 costimulatory domain,while in some embodiments, the CD19 CAR comprises a costimulatorydomain, e.g., a 41BB, CD27 or CD28 costimulatory domain and the CD22 CARcomprises a CD3 zeta signaling domain. In other embodiments, each of theCD19 CAR and the CD22 CAR comprises the same type of primary signalingdomain, e.g., a CD3 zeta signaling domain, but the CD19 CAR and the CD22CAR comprise different costimulatory domains, e.g., (1) the CD19 CARcomprises a 41BB costimulatory domain and the CD22 CAR comprises adifferent costimulatory domain e.g., a CD27 costimulatory domain, (2)the CD19 CAR comprises a CD27 costimulatory domain and the CD22 CARcomprises a different costimulatory domain e.g., a 41BB costimulatorydomain, (3) the CD19 CAR comprises a 41BB costimulatory domain and theCD22 CAR comprises a CD28 costimulatory domain, (4) the CD19 CARcomprises a CD28 costimulatory domain and the CD22 CAR comprises adifferent costimulatory domain e.g., a 41BB costimulatory domain, (5)the CD19 CAR comprises a CD27 costimulatory domain and the CD22 CARcomprises a CD28 costimulatory domain, or (6) the CD19 CAR comprises aCD28 costimulatory domain and the CD22 CAR comprises a CD27costimulatory domain. In another embodiment, a cell comprises a CAR thatcomprises both a CD19 antigen-binding domain and a CD22 antigen-bindingdomain, e.g., a bispecific antibody.

As another example, when the first B-cell inhibitor is a CD19CAR-expressing cell and the second B-cell inhibitor is a CD34CAR-expressing cell, the first CAR and second CAR may be expressed bythe same cell type or different types. For instance, in someembodiments, the cell expressing a CD19 CAR is a CD4+ T cell and thecell expressing a CD34 CAR is a CD8+ T cell, or the cell expressing aCD19 CAR is a CD8+ T cell and the cell expressing a CD34 CAR is a CD4+ Tcell. In other embodiments, the cell expressing a CD19 CAR is a T celland the cell expressing a CD34 CAR is a NK cell, or the cell expressinga CD19 CAR is a NK cell and the cell expressing a CD34 CAR is a T cell.In other embodiments, the cell expressing a CD19 CAR and the cellexpressing a CD34 CAR are both NK cells or are both T cells, e.g., areboth CD4+ T cells, or are both CD8+ T cells. In yet other embodiments, asingle cell expresses the CD19 CAR and CD34 CAR, and this cell is, e.g.,a NK cell or a T cell such as a CD4+ T cell or CD8+ T cell. The firstCAR and second CAR can comprise the same or different intracellularsignaling domains. For instance, in some embodiments the CD19 CARcomprises a CD3 zeta signaling domain and the CD34 CAR comprises acostimulatory domain, e.g., a 41BB, CD27 or CD28 costimulatory domain,while in some embodiments, the CD19 CAR comprises a costimulatorydomain, e.g., a 41BB, CD27 or CD28 costimulatory domain and the CD34 CARcomprises a CD3 zeta signaling domain. In other embodiments, each of theCD19 CAR and the CD34 CAR comprises the same type of primary signalingdomain, e.g., a CD3 zeta signaling domain, but the CD19 CAR and the CD34CAR comprise different costimulatory domains, e.g., (1) the CD19 CARcomprises a 41BB costimulatory domain and the CD34 CAR comprises adifferent costimulatory domain e.g., a CD27 costimulatory domain, (2)the CD19 CAR comprises a CD27 costimulatory domain and the CD34 CARcomprises a different costimulatory domain e.g., a 41BB costimulatorydomain, (3) the CD19 CAR comprises a 41BB costimulatory domain and theCD34 CAR comprises a CD28 costimulatory domain, (4) the CD19 CARcomprises a CD28 costimulatory domain and the CD34 CAR comprises adifferent costimulatory domain e.g., a 41BB costimulatory domain, (5)the CD19 CAR comprises a CD27 costimulatory domain and the CD34 CARcomprises a CD28 costimulatory domain, or (6) the CD19 CAR comprises aCD28 costimulatory domain and the CD34 CAR comprises a CD27costimulatory domain. In another embodiment, a cell comprises a CAR thatcomprises both a CD19 antigen-binding domain and a CD34 antigen-bindingdomain, e.g., a bispecific antibody.

As another example, when the first B-cell inhibitor is a CD19CAR-expressing cell and the second B-cell inhibitor is a CD123CAR-expressing cell, the first CAR and second CAR may be expressed bythe same cell type or different types. For instance, in someembodiments, the cell expressing a CD19 CAR is a CD4+ T cell and thecell expressing a CD123 CAR is a CD8+ T cell, or the cell expressing aCD19 CAR is a CD8+ T cell and the cell expressing a CD123 CAR is a CD4+T cell. In other embodiments, the cell expressing a CD19 CAR is a T celland the cell expressing a CD123 CAR is a NK cell, or the cell expressinga CD19 CAR is a NK cell and the cell expressing a CD123 CAR is a T cell.In other embodiments, the cell expressing a CD19 CAR and the cellexpressing a CD123 CAR are both NK cells or are both T cells, e.g., areboth CD4+ T cells, or are both CD8+ T cells. In yet other embodiments, asingle cell expresses the CD19 CAR and CD123 CAR, and this cell is,e.g., a NK cell or a T cell such as a CD4+ T cell or CD8+ T cell. Thefirst CAR and second CAR can comprise the same or differentintracellular signaling domains. For instance, in some embodiments theCD19 CAR comprises a CD3 zeta signaling domain and the CD123 CARcomprises a costimulatory domain, e.g., a 41BB, CD27 or CD28costimulatory domain, while in some embodiments, the CD19 CAR comprisesa costimulatory domain, e.g., a 41BB, CD27 or CD28 costimulatory domainand the CD123 CAR comprises a CD3 zeta signaling domain. In otherembodiments, each of the CD19 CAR and the CD123 CAR comprises the sametype of primary signaling domain, e.g., a CD3 zeta signaling domain, butthe CD19 CAR and the CD123 CAR comprise different costimulatory domains,e.g., (1) the CD19 CAR comprises a 41BB costimulatory domain and theCD123 CAR comprises a different costimulatory domain e.g., a CD27costimulatory domain, (2) the CD19 CAR comprises a CD27 costimulatorydomain and the CD123 CAR comprises a different costimulatory domaine.g., a 41BB costimulatory domain, (3) the CD19 CAR comprises a 41BBcostimulatory domain and the CD123 CAR comprises a CD28 costimulatorydomain, (4) the CD19 CAR comprises a CD28 costimulatory domain and theCD123 CAR comprises a different costimulatory domain e.g., a 41BBcostimulatory domain, (5) the CD19 CAR comprises a CD27 costimulatorydomain and the CD123 CAR comprises a CD28 costimulatory domain, or (6)the CD19 CAR comprises a CD28 costimulatory domain and the CD123 CARcomprises a CD27 costimulatory domain. In another embodiment, a cellcomprises a CAR that comprises both a CD19 antigen-binding domain and aCD123 antigen-binding domain, e.g., a bispecific antibody.

As another example, when the first B-cell inhibitor is a CD19CAR-expressing cell and the second B-cell inhibitor is a FLT-3CAR-expressing cell, the first CAR and second CAR may be expressed bythe same cell type or different types. For instance, in someembodiments, the cell expressing a CD19 CAR is a CD4+ T cell and thecell expressing a FLT-3 CAR is a CD8+ T cell, or the cell expressing aCD19 CAR is a CD8+ T cell and the cell expressing a FLT-3 CAR is a CD4+T cell. In other embodiments, the cell expressing a CD19 CAR is a T celland the cell expressing a FLT-3 CAR is a NK cell, or the cell expressinga CD19 CAR is a NK cell and the cell expressing a FLT-3 CAR is a T cell.In other embodiments, the cell expressing a CD19 CAR and the cellexpressing a FLT-3 CAR are both NK cells or are both T cells, e.g., areboth CD4+ T cells, or are both CD8+ T cells. In yet other embodiments, asingle cell expresses the CD19 CAR and FLT-3 CAR, and this cell is,e.g., a NK cell or a T cell such as a CD4+ T cell or CD8+ T cell. Thefirst CAR and second CAR can comprise the same or differentintracellular signaling domains. For instance, in some embodiments theCD19 CAR comprises a CD3 zeta signaling domain and the FLT-3 CARcomprises a costimulatory domain, e.g., a 41BB, CD27 or CD28costimulatory domain, while in some embodiments, the CD19 CAR comprisesa costimulatory domain, e.g., a 41BB, CD27 or CD28 costimulatory domainand the FLT-3 CAR comprises a CD3 zeta signaling domain. In otherembodiments, each of the CD19 CAR and the FLT-3 CAR comprises the sametype of primary signaling domain, e.g., a CD3 zeta signaling domain, butthe CD19 CAR and the FLT-3 CAR comprise different costimulatory domains,e.g., (1) the CD19 CAR comprises a 41BB costimulatory domain and theFLT-3 CAR comprises a different costimulatory domain e.g., a CD27costimulatory domain, (2) the CD19 CAR comprises a CD27 costimulatorydomain and the FLT-3 CAR comprises a different costimulatory domaine.g., a 41BB costimulatory domain, (3) the CD19 CAR comprises a 41BBcostimulatory domain and the FLT-3 CAR comprises a CD28 costimulatorydomain, (4) the CD19 CAR comprises a CD28 costimulatory domain and theFLT-3 CAR comprises a different costimulatory domain e.g., a 41BBcostimulatory domain, (5) the CD19 CAR comprises a CD27 costimulatorydomain and the FLT-3 CAR comprises a CD28 costimulatory domain, or (6)the CD19 CAR comprises a CD28 costimulatory domain and the FLT-3 CARcomprises a CD27 costimulatory domain. In another embodiment, a cellcomprises a CAR that comprises both a CD19 antigen-binding domain and aFLT-3 antigen-binding domain, e.g., a bispecific antibody.

As another example, when the first B-cell inhibitor is a CD19CAR-expressing cell and the second B-cell inhibitor is a ROR1CAR-expressing cell, the first CAR and second CAR may be expressed bythe same cell type or different types. For instance, in someembodiments, the cell expressing a CD19 CAR is a CD4+ T cell and thecell expressing a ROR1 CAR is a CD8+ T cell, or the cell expressing aCD19 CAR is a CD8+ T cell and the cell expressing a ROR1 CAR is a CD4+ Tcell. In other embodiments, the cell expressing a CD19 CAR is a T celland the cell expressing a ROR1 CAR is a NK cell, or the cell expressinga CD19 CAR is a NK cell and the cell expressing a ROR1 CAR is a T cell.In other embodiments, the cell expressing a CD19 CAR and the cellexpressing a ROR1 CAR are both NK cells or are both T cells, e.g., areboth CD4+ T cells, or are both CD8+ T cells. In yet other embodiments, asingle cell expresses the CD19 CAR and ROR1 CAR, and this cell is, e.g.,a NK cell or a T cell such as a CD4+ T cell or CD8+ T cell. The firstCAR and second CAR can comprise the same or different intracellularsignaling domains. For instance, in some embodiments the CD19 CARcomprises a CD3 zeta signaling domain and the ROR1 CAR comprises acostimulatory domain, e.g., a 41BB, CD27 or CD28 costimulatory domain,while in some embodiments, the CD19 CAR comprises a costimulatorydomain, e.g., a 41BB, CD27 or CD28 costimulatory domain and the ROR1 CARcomprises a CD3 zeta signaling domain. In other embodiments, each of theCD19 CAR and the ROR1 CAR comprises the same type of primary signalingdomain, e.g., a CD3 zeta signaling domain, but the CD19 CAR and the ROR1CAR comprise different costimulatory domains, e.g., (1) the CD19 CARcomprises a 41BB costimulatory domain and the ROR1 CAR comprises adifferent costimulatory domain e.g., a CD27 costimulatory domain, (2)the CD19 CAR comprises a CD27 costimulatory domain and the ROR1 CARcomprises a different costimulatory domain e.g., a 41BB costimulatorydomain, (3) the CD19 CAR comprises a 41BB costimulatory domain and theROR1 CAR comprises a CD28 costimulatory domain, (4) the CD19 CARcomprises a CD28 costimulatory domain and the ROR1 CAR comprises adifferent costimulatory domain e.g., a 41BB costimulatory domain, (5)the CD19 CAR comprises a CD27 costimulatory domain and the ROR1 CARcomprises a CD28 costimulatory domain, or (6) the CD19 CAR comprises aCD28 costimulatory domain and the ROR1 CAR comprises a CD27costimulatory domain. In another embodiment, a cell comprises a CAR thatcomprises both a CD19 antigen-binding domain and a ROR1 antigen-bindingdomain, e.g., a bispecific antibody.

More generally, when the first B-cell inhibitor comprises a CD19 CAR andthere is a second B-cell inhibitor e.g., which comprises a second CAR,the first CAR and the second B-cell inhibitor may be expressed by thesame cell type or different types. For instance, in some embodiments,the cell expressing a CD19 CAR is a CD4+ T cell and the cell expressingthe second B-cell inhibitor is a CD8+ T cell, or the cell expressing aCD19 CAR is a CD8+ T cell and the cell expressing the second B-cellinhibitor is a CD4+ T cell. In other embodiments, the cell expressing aCD19 CAR is a T cell and the cell expressing a second B-cell inhibitoris a NK cell, or the cell expressing a CD19 CAR is a NK cell and thecell expressing a second B-cell inhibitor is a T cell. In otherembodiments, the cell expressing a CD19 CAR and the cell expressing asecond B-cell inhibitor are both NK cells or are both T cells, e.g., areboth CD4+ T cells, or are both CD8+ T cells. In yet other embodiments, asingle cell expresses the CD19 CAR and the second B-cell inhibitor, andthis cell is, e.g., a NK cell or a T cell such as a CD4+ T cell or CD8+T cell. The first CAR and second CAR can comprise the same or differentintracellular signaling domains. For instance, in some embodiments theCD19 CAR comprises a CD3 zeta signaling domain and second B-cellinhibitor (or CAR), comprises a costimulatory domain, e.g., a 41BB, CD27or CD28 costimulatory domain, while in some embodiments, the CD19 CARcomprises a costimulatory domain, e.g., a 41BB, CD27 or CD28costimulatory domain and the second B-cell inhibitor (or second CAR),comprises a CD3 zeta signaling domain. In other embodiments, each of theCD19 CAR and the second B-cell inhibitor (or second CAR), comprises thesame type of primary signaling domain, e.g., a CD3 zeta signalingdomain, but the CD19 CAR and the second B-cell inhibitor comprisedifferent costimulatory domains, e.g., (1) the CD19 CAR comprises a 41BBcostimulatory domain and the second B-cell inhibitor (or second CAR),comprises a different costimulatory domain e.g., a CD27 costimulatorydomain, (2) the CD19 CAR comprises a CD27 costimulatory domain and thesecond B-cell inhibitor (or second CAR) comprises a differentcostimulatory domain e.g., a 41BB costimulatory domain, (3) the CD19 CARcomprises a 41BB costimulatory domain and the second B-cell inhibitor(or second CAR), comprises a CD28 costimulatory domain, (4) the CD19 CARcomprises a CD28 costimulatory domain and the second B-cell inhibitor(or second CAR) comprises a different costimulatory domain e.g., a 41BBcostimulatory domain, (5) the CD19 CAR comprises a CD27 costimulatorydomain and the second B-cell inhibitor (or second CAR), comprises a CD28costimulatory domain, or (6) the CD19 CAR comprises a CD28 costimulatorydomain and the second B-cell inhibitor (or second CAR), comprises a CD27costimulatory domain. In another embodiment, a cell comprises a CAR thatcomprises both a CD19 antigen-binding domain and an antigen-bindingdomain directed to a second antigen, e.g., a bispecific antibody.

In one embodiment, the 4-1BB costimulatory domain comprises a sequenceof SEQ ID NO: 16. In one embodiment, the 4-1BB costimulatory domaincomprises an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 20, 10 or 5modifications (e.g., substitutions) of an amino acid sequence of SEQ IDNO: 16, or a sequence with 95-99% identity to an amino acid sequence ofSEQ ID NO:16. In one embodiment, the 4-1BB costimulatory domain isencoded by a nucleic acid sequence of SEQ ID NO:60, or a sequence with95-99% identity thereof.

In one embodiment, the CD27 costimulatory domain comprises a sequence ofSEQ ID NO: 16. In one embodiment, the CD27 costimulatory domaincomprises an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 20, 10 or 5modifications (e.g., substitutions) of an amino acid sequence of SEQ IDNO: 16, or a sequence with 95-99% identity to an amino acid sequence ofSEQ ID NO:16. In one embodiment, the CD27 costimulatory domain isencoded by a nucleic acid sequence of SEQ ID NO:17, or a sequence with95-99% identity thereof.

In one embodiment, the CD28 costimulatory domain comprises a sequence ofSEQ ID NO: 1317. In one embodiment, the CD28 costimulatory domaincomprises an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 20, 10 or 5modifications (e.g., substitutions) of an amino acid sequence of SEQ IDNO: 1317, or a sequence with 95-99% identity to an amino acid sequenceof SEQ ID NO:1317. In one embodiment, the CD28 costimulatory domain isencoded by a nucleic acid sequence of SEQ ID NO:1318, or a sequence with95-99% identity thereof.

In one embodiment, the wild-type ICOS costimulatory domain comprises asequence of SEQ ID NO: 1319. In one embodiment, the wild-type ICOScostimulatory domain comprises an amino acid sequence having at leastone, two or three modifications (e.g., substitutions) but not more than20, 10 or 5 modifications (e.g., substitutions) of an amino acidsequence of SEQ ID NO: 1319, or a sequence with 95-99% identity to anamino acid sequence of SEQ ID NO: 1319. In one embodiment, the wild-typeICOS costimulatory domain is encoded by a nucleic acid sequence of SEQID NO: 1320, or a sequence with 95-99% identity thereof.

In one embodiment, the Y to F mutant ICOS costimulatory domain comprisesa sequence of SEQ ID NO: 1321. In one embodiment, the Y to F mutant ICOScostimulatory domain comprises an amino acid sequence having at leastone, two or three modifications (e.g., substitutions) but not more than20, 10 or 5 modifications (e.g., substitutions) of an amino acidsequence of SEQ ID NO: 1321, or a sequence with 95-99% identity to anamino acid sequence of SEQ ID NO: 1321. In one embodiment, the Y to Fmutant ICOS costimulatory domain is encoded by a nucleic acid sequencewith 95-99% identity to a nucleic acid sequence of SEQ ID NO:1320(wherein SEQ ID NO: 1320 encodes wild-type ICOS).

In embodiments, the primary signaling domain comprises a functionalsignaling domain of CD3 zeta. In embodiments, the functional signalingdomain of CD3 zeta comprises SEQ ID NO: 17 (mutant CD3 zeta) or SEQ IDNO: 43 (wild-type human CD3 zeta).

In one embodiment, the method includes administering a population ofcells wherein at least one cell in the population expresses a CAR, e.g.,having an anti-CD19 domain described herein, and an agent which enhancesthe activity of a CAR-expressing cell, e.g., a second cell expressingthe agent which enhances the activity of a CAR-expressing cell. Forexample, in one embodiment, the agent can be an agent which inhibits animmune inhibitory molecule. Examples of immune inhibitory moleculesinclude PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/orCEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGFR beta. Inone embodiment, the agent that inhibits an immune inhibitory moleculecomprises a first polypeptide, e.g., an inhibitory molecule, associatedwith a second polypeptide that provides a positive signal to the cell,e.g., an intracellular signaling domain described herein. In oneembodiment, the agent comprises a first polypeptide, e.g., of aninhibitory molecule such as PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g.,CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1,CD160, 2B4 or TGFR beta, or a fragment of any of these (e.g., at least aportion of an extracellular domain of any of these), and a secondpolypeptide which is an intracellular signaling domain described herein(e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28,e.g., as described herein) and/or a primary signaling domain (e.g., aCD3 zeta signaling domain described herein). In one embodiment, theagent comprises a first polypeptide of PD1 or a fragment thereof (e.g.,at least a portion of the extracellular domain of PD1), and a secondpolypeptide of an intracellular signaling domain described herein (e.g.,a CD28 signaling domain described herein and/or a CD3 zeta signalingdomain described herein).

In an embodiment, the B-cell inhibitor comprises an inhibitor of one ormore of CD10, CD19, CD20, CD22, CD34, FLT-3, or ROR1. In an embodiment,the B-cell inhibitor comprises an effective number of one or more cellsthat express a CAR molecule that binds one or more of CD10, CD20, CD22,CD34, FLT-3, ROR1, CD79b, CD179b, or CD79a. In an embodiment, the B-cellinhibitor comprises a CD123 CAR. In an embodiment, the B cell inhibitorcomprises one or more cells that express a CAR molecule that bindsCD123. In an embodiment, the disease is a CD19-negative cancer, e.g., aCD19-negative relapsed cancer. In an embodiment, the CD19 CAR-expressingcell is administered simultaneously with, before, or after the one ormore B-cell inhibitor.

In an embodiment, the method further comprises administering a CD19inhibitor, e.g., a CD19 CAR-expressing cell. In an embodiment, the CD19inhibitor comprises a CD19 CAR and the B-cell inhibitor comprises aCD123 CAR. In an embodiment, the CD19 CAR or CD123 CAR comprises a splitintracellular signaling domain such that full activation of the cell,e.g., the population of immune effector cells, occurs when both the CD19CAR and CD123 CAR bind to a target cell, e.g., a target CD19+CD123+ cell(e.g., a B-ALL blast cell), compared to activation when the CD19 CAR andCD123 CAR bind to a target cell that expresses one of CD19 or CD123(e.g., a hematopoietic stem cell). In an embodiment, the CD comprises a4-1BB signaling domain and the CD19 CAR comprises a CD3 zeta signalingdomain. In an embodiment, the CD123CAR comprises a costimulatory domain,e.g., a 4-1BB signaling domain, and the CD19 CAR comprises a primarysignaling domain, e.g., a CD3 zeta signaling domain. In an embodiment,the CD123CAR comprises a primary signaling domain, e.g., a CD3 zetasignaling domain, and the CD19 CAR comprises a costimulatory domain,e.g., a 4-1BB signaling domain. In an embodiment, the B cell inhibitorcomprises a CAR (e.g., a CAR directed against CD10, CD20, CD22, CD34,CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a) which comprises acostimulatory domain, and the CD19 CAR comprises a primary signalingdomain. In an embodiment, the B cell inhibitor comprises a CAR (e.g., aCAR directed against CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b,CD179b, or CD79a) which comprises a primary signalling domain, and theCD19 CAR comprises a costimulatory domain. In an embodiment, the B-cellinhibitor comprises one or more cells that express a CAR molecule thatbinds CD123, and wherein a CD19 CAR-expressing cell is administeredsimultaneously with the B-cell inhibitor. In an embodiment, the CD123CARcomprises a 4-1BB signaling domain and the CD19 CAR comprises a CD3 zetasignaling domain.

In an embodiment, the method further comprises transplanting a cell,e.g., a hematopoietic stem cell, or a bone marrow, into the mammal.

In another aspect, the invention pertains to a cell expressing a CARmolecule described herein, e.g., a CD19 CAR molecule, for use as amedicament in combination with a B-cell inhibitor, e.g., a B-cellinhibitor described herein. In another aspect, the invention pertains toa B-cell inhibitor described herein for use as a medicament incombination with a cell expressing a CAR molecule, e.g., a CD19 CARmolecule, described herein.

In another aspect, the invention pertains to a cell expressing a CARmolecule described herein, e.g., a CD19 CAR molecule, for use incombination with a B-cell inhibitor, e.g., a B-cell inhibitor describedherein, in the treatment of a disease expressing CD19. In anotheraspect, the invention pertains to a B-cell inhibitor described hereinfor use in combination with a cell expressing a CAR molecule describedherein, e.g., a CD19 CAR molecule, in the treatment of a diseaseexpressing CD19. In another aspect, the invention pertains to a cellexpressing a CAR molecule described herein, e.g., a CD19 CAR molecule,for use in combination with a B-cell inhibitor, e.g., a B-cell inhibitordescribed herein, in the treatment of a cancer, e.g., a cancer describedherein.

In one embodiment, the method includes administering a population ofcells wherein at least one cell in the population expresses a therapyherein (e.g., a CD20 CAR, a CD22 CAR, or a CAR having an anti-CD19domain described herein in combination with a B-cell inhibitor) and anagent which enhances the activity of a CAR-expressing cell, wherein theagent is a cytokine, e.g., IL-7, IL-15, IL-21, or a combination thereof.The cytokine can be delivered in combination with, e.g., simultaneouslyor shortly after, administration of the CAR-expressing cell(s).Alternatively, the cytokine can be delivered after a prolonged period oftime after administration of the CAR-expressing cell(s), e.g., afterassessment of the subject's response to the CAR-expressing cell(s).Related compositions for use and methods of making a medicament are alsoprovided.

In one embodiment, the cells described herein (e.g., cells expressing aCD20 CAR molecule, cells expressing a CD22 CAR molecule, or cellsexpressing a CD19 CAR molecule, e.g., a CD19 CAR molecule describedherein, combination with a B-cell inhibitor) are administered incombination with an agent that increases the efficacy of a cellexpressing a CAR molecule or one of the inhibitors, e.g., an agentdescribed herein.

In one embodiment, the cells described herein (e.g., cells expressing aCD20 CAR molecule, cells expressing a CD22 CAR molecule, or expressing aCD19 CAR molecule, e.g., a CD19 CAR molecule described herein, incombination with a B-cell inhibitor) are administered in combinationwith an agent that ameliorates one or more side effect associated withadministration of a cell expressing a CAR molecule or one of theinhibitors, e.g., an agent described herein.

In one embodiment, the cells expressing a CD19 CAR molecule, e.g., aCD19 CAR molecule described herein, are administered in combination witha B-cell inhibitor, and an agent that treats Hodgkin lymphoma, e.g., anagent described herein.

In some aspects, the disclosure provides a method of treating a patientwho is a non-responder, partial responder, or relapser to a CD19inhibitor, e.g., a CD19 CAR therapy, comprising administering to thepatient a B-cell inhibitor, e.g., a B-cell inhibitor as describedherein, e.g., an inhibitor of one or more of (e.g., 2, 3, 4, 5, 6, 7, 8,9, or all of) CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b,or CD79a. In embodiments, the B-cell inhibitor is a CAR-expressing cell(e.g., T cell or NK cell) that is an inhibitor of one or more of (e.g.,2, 3, 4, 5, 6, or all of) CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1.In embodiments, the patient has, or is identified as having, aCD19-negative cancer cell and a cancer cell that is positive for one ormore of (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or all of) CD10, CD20, CD22,CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. In embodiments, themethod further comprises administering to the patient a B-cell inhibitorfor which the cancer cell is positive, e.g., an inhibitor of one or moreof (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or all of) the CD10, CD20, CD22, CD34,CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a for which the cancer cell ispositive. In embodiments, the method further comprises one or both of astep of determining whether the patient comprises a CD19-negative cancercell, and a step of determining whether the patient comprises a cancercell that is positive for one or more of (e.g., 2, 3, 4, 5, 6, 7, 8, 9,or all of) CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, orCD79a. In embodiments, the subject has or is identified as having apopulation of tumor or cancer cells that test negative for CD19expression as measured by binding to an anti-CD19 antibody, e.g., anantibody with the same specificity as any of the CAR molecules in Table2 or Table 3.

In another aspect, the invention features a composition comprising acell expressing a Chimeric Antigen Receptor (CAR) molecule that bindsCD19, in combination with a B-cell inhibitor, e.g., a B-cell inhibitorchosen from an inhibitor of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3,ROR1, CD79b, CD179b, or CD79a, or a combination thereof. TheCAR-expressing cell and the B-cell inhibitor can be present in a singledose form, or as two or more dose forms.

In an embodiment, the composition is a pharmaceutically acceptablecomposition.

In embodiments, the compositions disclosed herein (e.g., nucleic acids,vectors, or cells) are for use as a medicament.

In embodiments, the compositions disclosed herein are use in thetreatment of a disease associated with expression of a B-cell antigen(e.g., CD19), e.g., a B-cell leukemia or lymphoma.

CD19 Inhibitors

In embodiments, the CD19 inhibitor is a small molecule, an antibody, afragment of an antibody, or a cell therapy.

In some embodiments, the CD19 inhibitor (e.g., a cell therapy or anantibody) is administered in combination with, or is present in acomposition together with, a B cell inhibitor, e.g., one or moreinhibitors of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b,CD179b, or CD79a.

In one embodiment, the cell expresses a CAR molecule comprising ananti-CD19 binding domain (e.g., a murine or humanized antibody orantibody fragment that specifically binds to CD19), a transmembranedomain, and an intracellular signaling domain (e.g., an intracellularsignaling domain comprising a costimulatory domain and/or a primarysignaling domain). In one embodiment, the CAR comprises an antibody orantibody fragment which includes an anti-CD19 binding domain describedherein (e.g., a murine or humanized antibody or antibody fragment thatspecifically binds to CD19 as described herein), a transmembrane domaindescribed herein, and an intracellular signaling domain described herein(e.g., an intracellular signaling domain comprising a costimulatorydomain and/or a primary signaling domain described herein).

In one embodiment, the CAR molecule comprises an anti-CD19 bindingdomain comprising one or more (e.g., all three) light chaincomplementarity determining region 1 (LC CDR1), light chaincomplementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) of an anti-CD19 bindingdomain described herein, and one or more (e.g., all three) heavy chaincomplementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of an anti-CD19 bindingdomain described herein, e.g., an anti-CD19 binding domain comprisingone or more, e.g., all three, LC CDRs and one or more, e.g., all three,HC CDRs. In one embodiment, the anti-CD19 binding domain comprises oneor more (e.g., all three) heavy chain complementarity determining region1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2),and heavy chain complementarity determining region 3 (HC CDR3) of ananti-CD19 binding domain described herein, e.g., the anti-CD19 bindingdomain has two variable heavy chain regions, each comprising a HC CDR1,a HC CDR2 and a HC CDR3 described herein. In one embodiment, theanti-CD19 binding domain comprises a murine light chain variable regiondescribed herein (e.g., in Table 3) and/or a murine heavy chain variableregion described herein (e.g., in Table 3). In one embodiment, theanti-CD19 binding domain is a scFv comprising a murine light chain and amurine heavy chain of an amino acid sequence of Table 3. In anembodiment, the anti-CD19 binding domain (e.g., an scFv) comprises: alight chain variable region comprising an amino acid sequence having atleast one, two or three modifications (e.g., substitutions) but not morethan 30, 20 or 10 modifications (e.g., substitutions) of an amino acidsequence of a light chain variable region provided in Table 3, or asequence with 95-99% identity with an amino acid sequence of Table 3;and/or a heavy chain variable region comprising an amino acid sequencehaving at least one, two or three modifications (e.g., substitutions)but not more than 30, 20 or 10 modifications (e.g., substitutions) of anamino acid sequence of a heavy chain variable region provided in Table3, or a sequence with 95-99% identity to an amino acid sequence of Table3. In one embodiment, the anti-CD19 binding domain comprises a sequenceof SEQ ID NO:59, or a sequence with 95-99% identity thereof. In oneembodiment, the anti-CD19 binding domain is a scFv, and a light chainvariable region comprising an amino acid sequence described herein,e.g., in Table 3, is attached to a heavy chain variable regioncomprising an amino acid sequence described herein, e.g., in Table 3,via a linker, e.g., a linker described herein. In one embodiment, theanti-CD19 binding domain includes a (Gly₄-Ser)n linker, wherein n is 1,2, 3, 4, 5, or 6, e.g., 3 or 4 (SEQ ID NO: 53). The light chain variableregion and heavy chain variable region of a scFv can be, e.g., in any ofthe following orientations: light chain variable region-linker-heavychain variable region or heavy chain variable region-linker-light chainvariable region.

In one embodiment, the CAR molecule comprises a humanized anti-CD19binding domain that includes one or more (e.g., all three) light chaincomplementarity determining region 1 (LC CDR1), light chaincomplementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) of a humanized anti-CD19binding domain described herein, and one or more (e.g., all three) heavychain complementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a humanized anti-CD19binding domain described herein, e.g., a humanized anti-CD19 bindingdomain comprising one or more, e.g., all three, LC CDRs and one or more,e.g., all three, HC CDRs. In one embodiment, the humanized anti-CD19binding domain comprises at least HC CDR2. In one embodiment, thehumanized anti-CD19 binding domain comprises one or more (e.g., allthree) heavy chain complementarity determining region 1 (HC CDR1), heavychain complementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a humanized anti-CD19binding domain described herein, e.g., the humanized anti-CD19 bindingdomain has two variable heavy chain regions, each comprising a HC CDR1,a HC CDR2 and a HC CDR3 described herein. In one embodiment, thehumanized anti-CD19 binding domain comprises at least HC CDR2. In oneembodiment, the light chain variable region comprises one, two, three orall four framework regions of VK3_L25 germline sequence. In oneembodiment, the light chain variable region has a modification (e.g.,substitution, e.g., a substitution of one or more amino acid found inthe corresponding position in the murine light chain variable region ofSEQ ID NO: 58, e.g., a substitution at one or more of positions 71 and87). In one embodiment, the heavy chain variable region comprises one,two, three or all four framework regions of VH4_4-59 germline sequence.In one embodiment, the heavy chain variable region has a modification(e.g., substitution, e.g., a substitution of one or more amino acidfound in the corresponding position in the murine heavy chain variableregion of SEQ ID NO: 58, e.g., a substitution at one or more ofpositions 71, 73 and 78). In one embodiment, the humanized anti-CD19binding domain comprises a light chain variable region described herein(e.g., in Table 2) and/or a heavy chain variable region described herein(e.g., in Table 2). In one embodiment, the humanized anti-CD19 bindingdomain is a scFv comprising a light chain and a heavy chain of an aminoacid sequence of Table 2. In an embodiment, the humanized anti-CD19binding domain (e.g., an scFv) comprises: a light chain variable regioncomprising an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 30, 20 or 10modifications (e.g., substitutions) of an amino acid sequence of a lightchain variable region provided in Table 2, or a sequence with 95-99%identity with an amino acid sequence of Table 2; and/or a heavy chainvariable region comprising an amino acid sequence having at least one,two or three modifications (e.g., substitutions) but not more than 30,20 or 10 modifications (e.g., substitutions) of an amino acid sequenceof a heavy chain variable region provided in Table 2, or a sequence with95-99% identity to an amino acid sequence of Table 2. In one embodiment,the humanized anti-CD19 binding domain comprises a sequence selectedfrom a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ IDNO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9,SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12, or a sequence with 95-99%identity thereof. In one embodiment, the humanized anti-CD19 bindingdomain is a scFv, and a light chain variable region comprising an aminoacid sequence described herein, e.g., in Table 2, is attached to a heavychain variable region comprising an amino acid sequence describedherein, e.g., in Table 2, via a linker, e.g., a linker described herein.In one embodiment, the humanized anti-CD19 binding domain includes a(Gly₄-Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, e.g., 3 or 4 (SEQID NO: 53). The light chain variable region and heavy chain variableregion of a scFv can be, e.g., in any of the following orientations:light chain variable region-linker-heavy chain variable region or heavychain variable region-linker-light chain variable region.

In one embodiment, the CAR molecule comprises an anti-CD19 bindingdomain that includes one or more (e.g., 2, 3, 4, 5, or 6) LC CDR1, LCCDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3 of a construct of Table 4and 5, e.g., murine_CART19, humanized_CART19 a, humanized_CART19 b, orhumanized_CART19 c.

In one embodiment, the CAR molecule comprises a leader sequence, e.g., aleader sequence described herein, e.g., a leader sequence of SEQ ID NO:13, or having 95-99% identity thereof; an anti-CD19 binding domaindescribed herein, e.g., an anti-CD19 binding domain comprising a LCCDR1, a LC CDR2, a LC CDR3, a HC CDR1, a HC CDR2 and a HC CDR3 describedherein, e.g., a murine anti-CD19 binding domain described in Table 3, ahumanized anti-CD19 binding domain described in Table 2, or a sequencewith 95-99% identity thereof; a hinge region, e.g., a hinge regiondescribed herein, e.g., a hinge region of SEQ ID NO:14 or having 95-99%identity thereof; a transmembrane domain, e.g., a transmembrane domaindescribed herein, e.g., a transmembrane domain having a sequence of SEQID NO:15 or a sequence having 95-99% identity thereof; an intracellularsignaling domain, e.g., an intracellular signaling domain describedherein (e.g., an intracellular signaling domain comprising acostimulatory domain and/or a primary signaling domain). In oneembodiment, the intracellular signaling domain comprises a costimulatorydomain, e.g., a costimulatory domain described herein, e.g., a 4-1BBcostimulatory domain having a sequence of SEQ ID NO:16 or SEQ ID NO:51,or having 95-99% identity thereof, and/or a primary signaling domain,e.g., a primary signaling domain described herein, e.g., a CD3 zetastimulatory domain having a sequence of SEQ ID NO:17 or SEQ ID NO:43, orhaving 95-99% identity thereof.

In one embodiment, the CAR molecule comprises (e.g., consists of) anamino acid sequence of SEQ ID NO:58, SEQ ID NO:31, SEQ ID NO:32, SEQ IDNO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ IDNO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 or SEQ ID NO:42, or anamino acid sequence having at least one, two, three, four, five, 10, 15,20 or 30 modifications (e.g., substitutions) but not more than 60, 50 ormodifications (e.g., substitutions) of an amino acid sequence of SEQ IDNO:58, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ IDNO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ IDNO:40, SEQ ID NO:41 or SEQ ID NO:42, or an amino acid sequence having85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequenceof SEQ ID NO:58, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34,SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39,SEQ ID NO:40, SEQ ID NO:41 or SEQ ID NO:42.

The present invention relates generally, in some aspects, to the use ofcells, e.g., T cells or natural killer (NK) cells, engineered to expressa CAR in combination with one or more B-cell inhibitors to treat adisease associated with expression of the Cluster of Differentiation 19protein (CD19). In some embodiments, the B-cell inhibitor is aninhibitor of one or more of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3,ROR1, CD79b, CD179b, or CD79a.

In some embodiments, the CD19 inhibitor comprises an antibody moleculehaving, e.g., an antibody molecule having a CD19-binding sequence asdescribed herein. For instance, the antibody molecule may comprise CDRsor a VH and VL as described in any of Tables 2, 3, 4, and 5, or asequence with homology thereto, e.g., having 95-99% identity thereto.The antibody molecule may comprise a CD19-binding region having asequence described in this section, e.g., in the context of a CAR.

In embodiments, the B-cell inhibitor is chosen from an inhibitorynucleic acid, a soluble ligand, an antibody or antigen-binding fragmentthereof, a CAR, or a CAR-expressing cell that binds to one or moreB-cell antigens, e.g., one or more of CD10, CD19, CD20, CD22, CD34,CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a.

CD20 Binding Domains and Inhibitors

In some aspects, the present disclosure provides a CD20 inhibitor orbinding domain, e.g., a CD20 inhibitor or binding domain as describedherein. The disclosure also provides a nucleic acid encoding the CD20binding domain, e.g., encoding a CAR comprising the CD20 binding domain.The composition may also comprise a second agent, e.g., an anti-CD19CAR-expressing cell or a CD19 binding domain. The agents may be, e.g.,encoded by a single nucleic acid or different nucleic acids.

In some aspects, a CD20 inhibitor or binding domain is administered as amonotherapy. In some aspects, the CD20 inhibitor or binding domain isadministered in combination with a second agent such as an anti-CD19CAR-expressing cell.

The CD20 inhibitor may be, e.g., a small molecule, antibody orantigen-binding fragment thereof, a CAR or a CAR-expressing cell. In oneembodiment, the CD20 inhibitor is an anti-CD20 antibody or fragmentthereof. In an embodiment, the antibody is a monospecific antibody andin another embodiment the antibody is a bispecific antibody. In anembodiment, the CD20 inhibitor is a chimeric mouse/human monoclonalantibody, e.g., rituximab. In an embodiment, the CD20 inhibitor is ahuman monoclonal antibody such as ofatumumab. In an embodiment, the CD20inhibitor is a humanized antibody such as ocrelizumab, veltuzumab,obinutuzumab, ocaratuzumab, or PRO131921 (Genentech). In an embodiment,the CD20 inhibitor is a fusion protein comprising a portion of ananti-CD20 antibody, such as TRU-015 (Trubion Pharmaceuticals).

In one embodiment, the CD20 inhibitor is an anti-CD20 expressing cell,e.g., CD20 CART or CD20-expressing NK cell.

In some embodiments, the CD20-CAR comprises an optional leader sequence(e.g., an optional leader sequence described herein), an extracellularantigen binding domain, a hinge (e.g., hinge described herein), atransmembrane domain (e.g., transmembrane domain described herein), andan intracellular stimulatory domain (e.g., intracellular stimulatorydomain described herein). In one embodiment, an exemplary CD20 CARconstruct comprises an optional leader sequence (e.g., a leader sequencedescribed herein), an extracellular antigen binding domain, a hinge, atransmembrane domain, an intracellular costimulatory domain (e.g., anintracellular costimulatory domain described herein) and anintracellular stimulatory domain.

In one embodiment, the CD20 binding domain comprises one or more (e.g.,all three) light chain complementarity determining region 1 (LC CDR1),light chain complementarity determining region 2 (LC CDR2), and lightchain complementarity determining region 3 (LC CDR3) of a CD20 bindingdomain described herein, and/or one or more (e.g., all three) heavychain complementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a CD20 binding domaindescribed herein, e.g., a CD20 binding domain comprising one or more,e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.These CDRs may be, e.g., those of Table 12A, 12B, and/or Table 13. Inone embodiment, the CD20 binding domain comprises one or more (e.g., allthree) heavy chain complementarity determining region 1 (HC CDR1), heavychain complementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a CD20 binding domaindescribed herein, e.g., the CD20 binding domain has two variable heavychain regions, each comprising a HC CDR1, a HC CDR2 and a HC CDR3described herein. In one embodiment, the CD20 binding domain comprises alight chain variable region described herein (e.g., in Table 15A or 15B)and/or a heavy chain variable region described herein (e.g., in Table14A or 14B). In one embodiment, the CD20 binding domain comprises aheavy chain variable region described herein (e.g., in Table 14A or14B), e.g., at least two heavy chain variable regions described herein(e.g., in Table 14A or 14B). In one embodiment, the CD20 binding domainis a scFv comprising a light chain and a heavy chain of an amino acidsequence of Table 14A or 14B or 15A or 15B. In an embodiment, the CD20binding domain (e.g., an scFv) comprises: a light chain variable regioncomprising an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 30, 20 or 10modifications (e.g., substitutions) of an amino acid sequence of a lightchain variable region provided in Table 15A or 15B, or a sequence with95-99% identity with an amino acid sequence of Table 15A or 15B; and/ora heavy chain variable region comprising an amino acid sequence havingat least one, two or three modifications (e.g., substitutions) but notmore than 30, 20 or 10 modifications (e.g., substitutions) of an aminoacid sequence of a heavy chain variable region provided in Table 14A or14B, or a sequence with 95-99% identity to an amino acid sequence ofTable 14A or 14B. The CD20 binding domain may be part of, e.g., anantibody molecule or a CAR molecule.

In one embodiment, the CAR molecule comprises an anti-CD20 bindingdomain that includes one or more (e.g., 2, 3, 4, 5, or 6) LC CDR1, LCCDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3 of a construct of Table12A, 12B, and/or 13, e.g., CAR20-1, CAR20-2, CAR20-3, CAR20-4, CAR20-5,CAR20-6, CAR20-7, CAR20-8, CAR20-9, CAR20-10, CAR20-11, CAR20-12,CAR20-13, CAR20-14, CAR20-15, or CAR20-16.

In one embodiment, the CAR molecule comprises an anti-CD22 bindingdomain that includes a VL and/or VH of a construct of Table 14A or 14Band 15A or 15B, e.g., CAR20-1, CAR20-2, CAR20-3, CAR20-4, CAR20-5,CAR20-6, CAR20-7, CAR20-8, CAR20-9, CAR20-10, CAR20-11, CAR20-12,CAR20-13, CAR20-14, CAR20-15, or CAR20-16.

The CD20 scFv may be preceded by an optional leader sequence such asprovided in SEQ ID NO: 13, and followed by an optional hinge sequencesuch as provided in SEQ ID NO: 14 or SEQ ID NO:45 or SEQ ID NO:47 or SEQID NO:49, a transmembrane region such as provided in SEQ ID NO:15, anintracellular signalling domain that includes SEQ ID NO:16 or SEQ IDNO:51 and a CD3 zeta sequence that includes SEQ ID NO:17 or SEQ IDNO:43, e.g., wherein the domains are contiguous with and in the samereading frame to form a single fusion protein.

Further embodiments include a nucleotide sequence that encodes apolypeptide of any of Tables 11A-15B Further embodiments include anucleotide sequence that encodes a polypeptide any of Tables 11A-15B,and each of the domains of SEQ ID NOS: 13, 14, 15, 16, 17, andoptionally 51.

In one embodiment, the CD20 binding domain is characterized byparticular functional features or properties of an antibody or antibodyfragment. For example, in one embodiment, the portion of a CARcomposition of the invention that comprises an antigen binding domainspecifically binds human CD20 or a fragment thereof.

In one embodiment, the CD20 binding domain is a fragment, e.g., a singlechain variable fragment (scFv). In one embodiments, the CD20 bindingdomain is a Fv, a Fab, a (Fab′)2, or a bi-functional (e.g. bi-specific)hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105(1987)). In one aspect, the antibodies and fragments thereof of theinvention binds a CD20 protein or a fragment thereof with wild-type orenhanced affinity. In some instances, a human scFv can be derived from adisplay library.

In one embodiment, the CD20 binding domain, e.g., scFv comprises atleast one mutation such that the mutated scFv confers improved stabilityto the CART20 construct. In another embodiment, the CD20 binding domain,e.g., scFv comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutationsarising, e.g., from the humanization process, such that the mutated scFvconfers improved stability to the CART20 construct.

In some embodiments, the CD20 inhibitor comprises an antibody moleculehaving, e.g., an antibody molecule having a CD20-binding sequence asdescribed herein. For instance, the antibody molecule may comprise CDRsor a VH and VL as described in any of Tables 11A-15B, or a sequence withhomology thereto, e.g., having 95-99% identity thereto. The antibodymolecule may comprise a CD20-binding region having a sequence describedin this section, e.g., in the context of a CAR.

In one aspect, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and CD20 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a CD20 CAR.

In some aspects, a binding domain or antibody molecule described hereinbinds the same (or substantially the same) or an overlapping (orsubstantially overlapping) epitope with a second antibody molecule toCD20, wherein the second antibody molecule is an antibody moleculedescribed herein, e.g., an antibody molecule chosen from Tables 11A-15B.In some embodiments, a binding domain or antibody molecule describedherein competes for binding, and/or binds the same (or substantially thesame) or overlapping (or substantially overlapping) epitope, with asecond antibody molecule to CD20, wherein the second antibody moleculeis an antibody molecule described herein, e.g., an antibody moleculechosen from Tables 11A-15B, e.g., as determined by the methods describedin Example 25. In some embodiments, a biparatopic CD20 binding domainbinds a first epitope, e.g., an epitope bound by an antibody moleculechosen from Tables 11A-15B, and the biparatopic binding domain alsobinds a second epitope, e.g., a second epitope bound by an antibodymolecule chosen from Tables 11A-15B. In some aspects, the presentdisclosure provides a method of treatment comprising administering afirst CD20 binding domain that binds a first epitope, e.g., an epitopebound by an antibody molecule chosen from Tables 11A-15B and a secondCD20 binding domain that binds a second epitope, e.g., a second epitopebound by an antibody molecule chosen from Tables 11A-15B. In someembodiments, the CD20 binding domains are part of CAR molecules, e.g.,expressed by a CAR-expressing cell.

CD22 Binding Domains and Inhibitors

In some aspects, the present disclosure provides a CD22 inhibitor orbinding domain, e.g., a CD22 inhibitor or binding domain as describedherein. The disclosure also provides a nucleic acid encoding the CD22binding domain, e.g., encoding a CAR comprising the CD22 binding domain.The composition may also comprise a second agent, e.g., an anti-CD19CAR-expressing cell or a CD19 binding domain. The agents may be, e.g.,encoded by a single nucleic acid or different nucleic acids.

In some aspects, a CD22 inhibitor or binding domain is administered as amonotherapy. In some aspects, the CD22 inhibitor or binding domain isadministered in combination with a second agent such as an anti-CD19CAR-expressing cell.

The CD22 inhibitor may be, e.g., a small molecule, antibody orantigen-binding fragment thereof, a CAR or a CAR-expressing cell. In oneembodiment, the CD22 inhibitor is an anti-CD22 antibody or fragmentthereof. In an embodiment, the antibody is a monospecific antibody andin another embodiment the antibody is a bispecific antibody. In anembodiment, the antibody is a monospecific antibody, optionallyconjugated to a second agent such as a chemotherapeutic agent. Forinstance, in an embodiment the antibody is an anti-CD22 monoclonalantibody-MMAE conjugate (e.g., DCDT2980S). In an embodiment, theantibody is an scFv of an anti-CD22 antibody, e.g., an scFv of antibodyRFB4. This scFv can be fused to all of or a fragment of Pseudomonasexotoxin-A (e.g., BL22). In an embodiment, the antibody is a humanizedanti-CD22 monoclonal antibody (e.g., epratuzumab). In an embodiment, theantibody or fragment thereof comprises the Fv portion of an anti-CD22antibody, which is optionally covalently fused to all or a fragment or(e.g., a 38 KDa fragment of) Pseudomonas exotoxin-A (e.g., moxetumomabpasudotox). In an embodiment, the anti-CD22 antibody is ananti-CD19/CD22 bispecific antibody, optionally conjugated to a toxin.For instance, in one embodiment, the anti-CD22 antibody comprises ananti-CD19/CD22 bispecific portion, (e.g., two scFv ligands, recognizinghuman CD19 and CD22) optionally linked to all of or a portion ofdiphtheria toxin (DT), e.g., first 389 amino acids of diphtheria toxin(DT), DT 390, e.g., a ligand-directed toxin such as DT2219ARL). Inanother embodiment, the bispecific portion (e.g., anti-CD19/anti-CD22)is linked to a toxin such as deglycosylated ricin A chain (e.g.,Combotox).

In one embodiment, the CD22 inhibitor is an anti-CD22 expressing cell,e.g., a CD22 CART or CD22-expressing NK cell.

In one aspect, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and CD22 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a CD22 CAR. As another example, thepopulation of CAR T cells can include a single population expressingmore than one, e.g., 2, 3, 4, 5, or 6 or more, CARs, e.g., a CD19 CARand a CD22 CAR.

In some embodiments, the CD22-CAR comprises an optional leader sequence(e.g., an optional leader sequence described herein), an extracellularantigen binding domain, a hinge (e.g., hinge described herein), atransmembrane domain (e.g., transmembrane domain described herein), andan intracellular stimulatory domain (e.g., intracellular stimulatorydomain described herein). In one embodiment, an exemplary CD22 CARconstruct comprises an optional leader sequence (e.g., a leader sequencedescribed herein), an extracellular antigen binding domain, a hinge, atransmembrane domain, an intracellular costimulatory domain (e.g., anintracellular costimulatory domain described herein) and anintracellular stimulatory domain.

In one embodiment, the CD22 binding domain comprises one or more (e.g.,all three) light chain complementarity determining region 1 (LC CDR1),light chain complementarity determining region 2 (LC CDR2), and lightchain complementarity determining region 3 (LC CDR3) of a CD22 bindingdomain described herein, and/or one or more (e.g., all three) heavychain complementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a CD22 binding domaindescribed herein, e.g., a CD22 binding domain comprising one or more,e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.These CDRs may be, e.g., one or more CDRs of Table 7A, 7B, 7C, 8A and/or8B. In one embodiment, the CD22 binding domain comprises one or more(e.g., all three) heavy chain complementarity determining region 1 (HCCDR1), heavy chain complementarity determining region 2 (HC CDR2), andheavy chain complementarity determining region 3 (HC CDR3) of a CD22binding domain described herein, e.g., the CD22 binding domain has twovariable heavy chain regions, each comprising a HC CDR1, a HC CDR2 and aHC CDR3 described herein. In one embodiment, the CD22 binding domaincomprises a light chain variable region described herein (e.g., in Table10A or 10B) and/or a heavy chain variable region described herein (e.g.,in Table 9A or 9B). In one embodiment, the CD22 binding domain comprisesa heavy chain variable region described herein (e.g., in Table 9A or9B), e.g., at least two heavy chain variable regions described herein(e.g., in Table 9A or 9B). In one embodiment, the CD22 binding domain isa scFv comprising a light chain and a heavy chain of an amino acidsequence of Table 9A or 9B and 10A or 10B. In an embodiment, the CD22binding domain (e.g., an scFv) comprises: a light chain variable regioncomprising an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 30, 20 or 10modifications (e.g., substitutions) of an amino acid sequence of a lightchain variable region provided in Table 10A or 10B, or a sequence with95-99% identity with an amino acid sequence of Table 10A or 10B; and/ora heavy chain variable region comprising an amino acid sequence havingat least one, two or three modifications (e.g., substitutions) but notmore than 30, 20 or 10 modifications (e.g., substitutions) of an aminoacid sequence of a heavy chain variable region provided in Table 9A or9B, or a sequence with 95-99% identity to an amino acid sequence ofTable 9A or 9B. The CD22 binding domain may be part of, e.g., anantibody molecule or a CAR molecule.

In one embodiment, the CAR molecule comprises an anti-CD22 bindingdomain that includes one or more (e.g., 2, 3, 4, 5, or 6) LC CDR1, LCCDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3 of a construct of Table 7A,7B, 7C, 8A and/or 8B, e.g., m971, CAR22-1, CAR22-2, CAR22-3, CAR22-4,CAR22-5, CAR22-6, CAR22-7, CAR22-8, CAR22-9, CAR22-10, CAR22-11,CAR22-12, CAR22-13, CAR22-14, CAR22-15, CAR22-16, CAR22-17, CAR22-18,CAR22-19, CAR22-20, CAR22-21, CAR22-22, CAR22-23, CAR22-24, CAR22-25,CAR22-26, CAR22-27, CAR22-28, CAR22-29, CAR22-30, CAR22-31, CAR22-32,CAR22-33, CAR22-34, CAR22-35, CAR22-36, CAR22-37, or CAR22-38.

In one embodiment, the CAR molecule comprises an anti-CD22 bindingdomain that includes a VL and/or VH of a construct of Table 9A, 9B, 10A,and/or 10B, e.g., m971, CAR22-1, CAR22-2, CAR22-3, CAR22-4, CAR22-5,CAR22-6, CAR22-7, CAR22-8, CAR22-9, CAR22-10, CAR22-11, CAR22-12,CAR22-13, CAR22-14, CAR22-15, CAR22-16, CAR22-17, CAR22-18, CAR22-19,CAR22-20, CAR22-21, CAR22-22, CAR22-23, CAR22-24, CAR22-25, CAR22-26,CAR22-27, CAR22-28, CAR22-29, CAR22-30, CAR22-31, CAR22-32, CAR22-33,CAR22-34, CAR22-35, CAR22-36, CAR22-37, or CAR22-38, or a sequence with95-99% identity thereto.

The scFv may be preceded by an optional leader sequence such as providedin SEQ ID NO: 13, and followed by an optional hinge sequence such asprovided in SEQ ID NO: 14 or SEQ ID NO:45 or SEQ ID NO:47 or SEQ IDNO:49, a transmembrane region such as provided in SEQ ID NO:15, anintracellular signalling domain that includes SEQ ID NO:16 or SEQ IDNO:51 and a CD3 zeta sequence that includes SEQ ID NO:17 or SEQ IDNO:43, e.g., wherein the domains are contiguous with and in the samereading frame to form a single fusion protein.

Further embodiments include a nucleotide sequence that encodes apolypeptide of any of Tables 6A-10B. Further embodiments include anucleotide sequence that encodes a polypeptide of any of Tables 6A-10B,and each of the domains of SEQ ID NOS: 13, 14, 15, 16, 17, andoptionally 51.

In one embodiment, the CD22 binding domain is characterized byparticular functional features or properties of an antibody or antibodyfragment. For example, in one embodiment, the portion of a CARcomposition of the invention that comprises an antigen binding domainspecifically binds human CD22 or a fragment thereof.

In one embodiment, the CD22 binding domain is a fragment, e.g., a singlechain variable fragment (scFv). In one embodiments, the CD22 bindingdomain is a Fv, a Fab, a (Fab′)2, or a bi-functional (e.g. bi-specific)hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105(1987)). In one aspect, the antibodies and fragments thereof of theinvention binds a CD22 protein or a fragment thereof with wild-type orenhanced affinity. In some instances, a human scFv can be derived from adisplay library.

In one embodiment, the CD22 binding domain, e.g., scFv comprises atleast one mutation such that the mutated scFv confers improved stabilityto the CART22 construct. In another embodiment, the CD22 binding domain,e.g., scFv comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutationsarising, e.g., from the humanization process such that the mutated scFvconfers improved stability to the CART22 construct.

In some embodiments, the CD22 inhibitor comprises an antibody moleculehaving, e.g., an antibody molecule having a CD22-binding sequence asdescribed herein. For instance, the antibody molecule may comprise CDRsor a VH and VL as described in any of Tables 6A-10B, or a sequence withhomology thereto, e.g., having 95-99% identity thereto. The antibodymolecule may comprise a CD22-binding region having a sequence describedin this section, e.g., in the context of a CAR.

In one embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and CD22 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a CD22 CAR.

In some aspects, a binding domain or antibody molecule described hereinbinds the same (or substantially the same) or an overlapping (orsubstantially overlapping) epitope with a second antibody molecule toCD22, wherein the second antibody molecule is an antibody moleculedescribed herein, e.g., an antibody molecule chosen from Tables 6A-10B.In some embodiments, a binding domain or antibody molecule describedherein competes for binding, and/or binds the same (or substantially thesame) or overlapping (or substantially overlapping) epitope, with asecond antibody molecule to CD22, wherein the second antibody moleculeis an antibody molecule described herein, e.g., an antibody moleculechosen from Tables 6A-10B, e.g., as determined by the methods describedin Example 25. In some embodiments, a biparatopic CD22 binding domainbinds a first epitope, e.g., an epitope bound by an antibody moleculechosen from Tables 6A-10B, and the biparatopic binding domain also bindsa second epitope, e.g., a second epitope bound by an antibody moleculechosen from Tables 6A-10B. In some aspects, the present disclosureprovides a method of treatment comprising administering a first CD22binding domain that binds a first epitope, e.g., an epitope bound by anantibody molecule chosen from Tables 6A-10B and a second CD22 bindingdomain that binds a second epitope, e.g., a second epitope bound by anantibody molecule chosen from Tables 6A-10B. In some embodiments, theCD22 binding domains are part of CAR molecules, e.g., expressed by aCAR-expressing cell.

In some embodiments, a CD22 binding domain binds to one or more ofIg-like domains 1, 2, 3, 4, 5, 6, or 7 of CD22. In some embodiments, theCD22 binding domain binds to domains 1 and 2; to domains 3 and 4; or todomains 5, 6, and 7. In some aspects, this disclosure provides a methodof treating a CD19-negative cancer, e.g., a leukemia, e.g., an ALL,e.g., B-ALL, comprising administering a CD22 inhibitor, e.g., a CD22binding domain or CD22 CAR-expressing cell described herein. In someembodiments, the method includes a step of determining whether thecancer is CD19-negative. In some embodiments, the subject has received aCD19 inhibitor, e.g., a CD19 CAR-expressing cell, and is resistant,relapsed, or refractory to the CD19 inhibitor.

ROR1 Inhibitors

The ROR1 inhibitor may be, e.g., a small molecule, antibody, or fragmentthereof. In one embodiment, the ROR1 inhibitor is an anti-ROR1 antibodyor fragment thereof. In one embodiment, the anti-ROR1 antibody orfragment thereof is a monoclonal antibody, e.g., cirmtuzumab.

In one embodiment, the ROR1 inhibitor is an anti-ROR1 expressing cell,e.g., ROR1 CART or ROR1-expressing NK cell.

In some embodiments, the ROR1-CAR comprises an optional leader sequence(e.g., an optional leader sequence described herein), an extracellularantigen binding domain, a hinge (e.g., hinge described herein), atransmembrane domain (e.g., transmembrane domain described herein), andan intracellular stimulatory domain (e.g., intracellular stimulatorydomain described herein). In one embodiment, an exemplary ROR1 CARconstruct comprises an optional leader sequence (e.g., a leader sequencedescribed herein), an extracellular antigen binding domain, a hinge, atransmembrane domain, an intracellular costimulatory domain (e.g., anintracellular costimulatory domain described herein) and anintracellular stimulatory domain.

In one embodiment the ROR1 binding domain comprises an scFv portion,e.g., a human scFv portion. The scFv the scFv may be preceded by anoptional leader sequence such as provided in SEQ ID NO: 13, and followedby an optional hinge sequence such as provided in SEQ ID NO: 14 or SEQID NO:45 or SEQ ID NO:47 or SEQ ID NO:49, a transmembrane region such asprovided in SEQ ID NO:15, an intracellular signalling domain thatincludes SEQ ID NO:16 or SEQ ID NO:51 and a CD3 zeta sequence thatincludes SEQ ID NO:17 or SEQ ID NO:43, e.g., wherein the domains arecontiguous with and in the same reading frame to form a single fusionprotein.

In some embodiments, the present disclosure encompasses a recombinantnucleic acid construct comprising a nucleic acid molecule encoding aROR1 CAR, wherein the nucleic acid molecule comprises the nucleic acidsequence encoding a ROR1 binding domain, e.g., described herein, e.g.,that is contiguous with and in the same reading frame as a nucleic acidsequence encoding an intracellular signaling domain. An exemplaryintracellular signaling domain that can be used in the CAR includes, butis not limited to, one or more intracellular signaling domains of, e.g.,CD3-zeta, CD28, 4-1BB, and the like. In some instances, the CAR cancomprise any combination of CD3-zeta, CD28, 4-1BB, and the like.

In one embodiment, the ROR1 binding domain is characterized byparticular functional features or properties of an antibody or antibodyfragment. For example, in one embodiment, the portion of a CARcomposition of the invention that comprises an antigen binding domainspecifically binds human ROR1 or a fragment thereof. In certainembodiments, the scFv is contiguous with and in the same reading frameas a leader sequence. In one aspect the leader sequence is thepolypeptide sequence provided as SEQ ID NO:13.

In one embodiment, the ROR1 binding domain is a fragment, e.g., a singlechain variable fragment (scFv). In one embodiments, the ROR1 bindingdomain is a Fv, a Fab, a (Fab′)2, or a bi-functional (e.g. bi-specific)hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105(1987)). In one aspect, the antibodies and fragments thereof of theinvention binds a ROR1 protein or a fragment thereof with wild-type orenhanced affinity. In some instances, a human scFv can be derived from adisplay library.

In one embodiment, the ROR1 binding domain, e.g., scFv comprises atleast one mutation such that the mutated scFv confers improved stabilityto the ROR1 CART construct. In another embodiment, the ROR1 bindingdomain, e.g., scFv comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10mutations arising from the humanization process such that the mutatedscFv confers improved stability to the ROR1 CART construct.

In one embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and ROR1 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a ROR1 CAR.

CD123 Inhibitors

The CD123 inhibitor may be, e.g., a small molecule, antibody, orfragment thereof (e.g., a monospecific or bispecific antibody orfragment thereof); a recombinant protein, e.g., fusion protein, thatbinds to CD123; inhibitory nucleic acid; or a cell expressing a CD123CAR, e.g., a CD123 CART.

In one embodiment, the CD123 inhibitor is a recombinant protein, e.g.,comprising the natural ligand (or a fragment) of the CD123 receptor,e.g., SL-401 (also called DT3881L3; University of Texas SouthwesternMedical Center).

In another embodiment, the CD123 inhibitor is an anti-CD123 antibody orfragment thereof, e.g., a monoclonal antibody (e.g., a monospecific orbispecific antibody or fragment thereof), such as CSL360 (CSL Limited),CSL362 (CSL Limited), or MGD006 (MacroGenics).

In one embodiment, the CD123 inhibitor is an anti-CD123 CAR expressingcell, e.g., CD123 CART or CD123 CAR-expressing NK cell.

In some embodiments, the CD123-CAR comprises an optional leader sequence(e.g., an optional leader sequence described herein), an extracellularantigen binding domain, a hinge (e.g., hinge described herein), atransmembrane domain (e.g., transmembrane domain described herein), andan intracellular stimulatory domain (e.g., intracellular stimulatorydomain described herein). In one embodiment, an exemplary CD123 CARconstruct comprises an optional leader sequence (e.g., a leader sequencedescribed herein), an extracellular antigen binding domain, a hinge, atransmembrane domain, an intracellular costimulatory domain (e.g., anintracellular costimulatory domain described herein) and anintracellular stimulatory domain.

In one embodiment, the CD123 binding domain comprises one or more (e.g.,all three) light chain complementarity determining region 1 (LC CDR1),light chain complementarity determining region 2 (LC CDR2), and lightchain complementarity determining region 3 (LC CDR3) of a CD20 bindingdomain described herein, and/or one or more (e.g., all three) heavychain complementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a CD123 binding domaindescribed herein, e.g., a CD123 binding domain comprising one or more,e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.These CDRs may be, e.g., those of any of Tables 17, 18, 26, or 27. Inone embodiment, the CD123 binding domain comprises one or more (e.g.,all three) heavy chain complementarity determining region 1 (HC CDR1),heavy chain complementarity determining region 2 (HC CDR2), and heavychain complementarity determining region 3 (HC CDR3) of a CD123 bindingdomain described herein, e.g., the CD123 binding domain has two variableheavy chain regions, each comprising a HC CDR1, a HC CDR2 and a HC CDR3described herein. In one embodiment, the CD123 binding domain comprisesa light chain variable region described herein and/or a heavy chainvariable region described herein. In one embodiment, the CD123 bindingdomain comprises a heavy chain variable region described herein, e.g.,at least two heavy chain variable regions described herein. In oneembodiment, the CD123 binding domain is a scFv comprising a light chainand a heavy chain of an amino acid sequence of Table 16 or 25. In anembodiment, the CD123 binding domain (e.g., an scFv) comprises: a lightchain variable region comprising an amino acid sequence having at leastone, two or three modifications (e.g., substitutions) but not more than30, 20 or 10 modifications (e.g., substitutions) of an amino acidsequence of a light chain variable region in Table 16 or 25, or asequence with 95-99% identity with a light chain variable region inTable 16 or 25; and/or a heavy chain variable region comprising an aminoacid sequence having at least one, two or three modifications (e.g.,substitutions) but not more than 30, 20 or 10 modifications (e.g.,substitutions) of an amino acid sequence of a heavy chain variableregion in Table 16 or 25, or a sequence with 95-99% identity to a heavychain variable region in Table 16 or 25.

In one embodiment, the CAR molecule comprises an anti-CD123 bindingdomain that includes one or more (e.g., 2, 3, 4, 5, or 6) LC CDR1, LCCDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3 of a construct of Table 17and 18, e.g., CAR123-1, CAR123-2, CAR123-3, or CAR123-4. In oneembodiment, the CAR molecule comprises an anti-CD123 binding domain thatincludes one or more (e.g., 2, 3, 4, 5, or 6) LC CDR1, LC CDR2, LC CDR3,HC CDR1, HC CDR2, and HC CDR3 of a construct of Table 26 and 27, e.g.,hzCAR123.

The CD123 scFv may be preceded by an optional leader sequence such asprovided in SEQ ID NO: 13, and followed by an optional hinge sequencesuch as provided in SEQ ID NO: 14 or SEQ ID NO:45 or SEQ ID NO:47 or SEQID NO:49, a transmembrane region such as provided in SEQ ID NO:15, anintracellular signalling domain that includes SEQ ID NO:16 or SEQ IDNO:51 and a CD3 zeta sequence that includes SEQ ID NO:17 or SEQ IDNO:43, e.g., wherein the domains are contiguous with and in the samereading frame to form a single fusion protein.

Further embodiments include a nucleotide sequence that encodes apolypeptide of any of Tables 16-27. Further embodiments include anucleotide sequence that encodes a polypeptide any of Tables 16-27, andeach of the domains of SEQ ID NOS: 13, 14, 15, 16, 17, and optionally51.

In one embodiment, the CD123 binding domain is characterized byparticular functional features or properties of an antibody or antibodyfragment. For example, in one embodiment, the portion of a CARcomposition of the invention that comprises an antigen binding domainspecifically binds human CD123 or a fragment thereof.

In one embodiment, the CD123 binding domain is a fragment, e.g., asingle chain variable fragment (scFv). In one embodiments, the CD123binding domain is a Fv, a Fab, a (Fab′)2, or a bi-functional (e.g.bi-specific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J.Immunol. 17, 105 (1987)). In one aspect, the antibodies and fragmentsthereof of the invention binds a CD123 protein or a fragment thereofwith wild-type or enhanced affinity. In some instances, a human scFv canbe derived from a display library.

In one embodiment, the CD123 binding domain, e.g., scFv comprises atleast one mutation such that the mutated scFv confers improved stabilityto the CART123 construct. In another embodiment, the CD123 bindingdomain, e.g., scFv comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10mutations arising, e.g., from the humanization process, such that themutated scFv confers improved stability to the CART123 construct.

In some embodiments, the CD123 inhibitor comprises an antibody molecule,e.g., an antibody molecule having a CD123-binding sequence as describedherein. For instance, the antibody molecule may comprise CDRs or a VHand VL as described in any of Tables 16-27, or a sequence with homologythereto, e.g., having 95-99% identity thereto. The antibody molecule maycomprise a CD123-binding region having a sequence described in thissection, e.g., in the context of a CAR.

In one embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and CD123 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a CD123 CAR.

CD10 Inhibitors

The CD10 inhibitor may be, e.g., a small molecule, antibody, or fragmentthereof (e.g., a monospecific or bispecific antibody or fragmentthereof); a recombinant protein, e.g., fusion protein, that binds toCD10; inhibitory nucleic acid; or a cell expressing a CD10 CAR, e.g., aCD10 CART.

In an embodiment, the CD10 inhibitor comprises a small molecule, such assacubitril (Novartis), valsartan/sacubritril (Novartis), omapatrilat(Bristol-Myers Squibb), RB-101, UK-414,495 (Pfizer), or apharmaceutically acceptable salt or a derivative thereof.

In one embodiment, the CD10 inhibitor is an anti-CD10 CAR expressingcell, e.g., CD10 CART or CD10 CAR-expressing NK cell.

In one embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and CD10 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a CD10 CAR.

CD34 Inhibitors

The CD34 inhibitor may be, e.g., a small molecule, antibody, or fragmentthereof (e.g., a monospecific or bispecific antibody or fragmentthereof); a recombinant protein, e.g., fusion protein, that binds toCD34; inhibitory nucleic acid; or a cell expressing a CD34 CAR, e.g., aCD34 CART.

In an embodiment, the CD34 inhibitor comprises a monoclonal antibody orfragment thereof that targets CD34 or an immunoliposome comprising ananti-CD34 monoclonal antibody or fragment thereof.

In one embodiment, the CD34 inhibitor is an anti-CD34 CAR-expressingcell, e.g., CD34 CART or CD34 CAR-expressing NK cell.

In one embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and CD34 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a CD34 CAR.

FLT-3 Inhibitors

The FLT-3 inhibitor may be, e.g., a small molecule, antibody, orfragment thereof (e.g., a monospecific or bispecific antibody orfragment thereof); a recombinant protein, e.g., fusion protein, thatbinds to FLT-3; inhibitory nucleic acid; or a cell expressing a FLT-3CAR, e.g., a FLT-3 CART.

In some embodiments, the FLT-3 inhibitor comprises a small molecule,such as quizartinib (Ambit Biosciences), midostaurin (TechnischeUniversitat Dresden), sorafenib (Bayer and Onyx Pharmaceuticals),sunitinib (Pfizer), lestaurtinib (Cephalon), or a pharmaceuticallyacceptable salt or derivative thereof.

In one embodiment, the FLT-3 inhibitor is an anti-FLT-3 CAR expressingcell, e.g., FLT-3 CART or FLT-3 CAR-expressing NK cell.

In one embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and FLT-3 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a FLT-3 CAR.

CD79b Inhibitors

In certain embodiments, the CD19 CAR-expressing cell is administeredwith a CD79b inhibitor. The CD79b inhibitor can be, e.g., a smallmolecule, antibody, or fragment thereof (e.g., a monospecific orbispecific antibody or fragment thereof); a recombinant protein, e.g.,fusion protein, that binds to CD79b; inhibitory nucleic acid; or a cellexpressing a CD79b CAR, e.g., a CD79b CAR-expressing T cell or NK cell.In one embodiment, the CD79b inhibitor is an anti-CD79b CAR expressingcell, e.g., CD79b CART or CD79b CAR-expressing NK cell. Exemplary CD79binhibitors are described in more detail below.

In an embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells or CAR-expressing NK cells,comprising a mixture of cells expressing CD19 CARs and CD79b CARs. Forexample, in one embodiment, the population of CAR-expressing cellsincludes a first cell expressing a CD19 CAR and a second cell expressinga CD79b CAR.

CD179b Inhibitors

In certain embodiments, the CD19 CAR-expressing cell is administeredwith a CD179b inhibitor. The CD179b inhibitor can be, e.g., a smallmolecule, antibody, or fragment thereof (e.g., a monospecific orbispecific antibody or fragment thereof); a recombinant protein, e.g.,fusion protein, that binds to CD179b; inhibitory nucleic acid; or a cellexpressing a CD179b CAR, e.g., a CD179b CAR-expressing T cell or NKcell. In one embodiment, the CD79b inhibitor is an anti-CD179b CARexpressing cell, e.g., CD179b CART or CD179b CAR-expressing NK cell.Exemplary CD179b inhibitors are described in more detail below.

In an embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells or CAR-expressing NK cells,comprising a mixture of cells expressing CD19 CARs and CD179b CARs. Forexample, in one embodiment, the population of CAR-expressing cellsincludes a first cell expressing a CD20 CAR and a second cell expressinga CD179b CAR.

C79a Inhibitors

In certain embodiments, the CD19 CAR-expressing cell is administeredwith a CD79a inhibitor. The CD79a inhibitor can be, e.g., a smallmolecule, antibody, or fragment thereof (e.g., a monospecific orbispecific antibody or fragment thereof); a recombinant protein, e.g.,fusion protein, that binds to CD79a; inhibitory nucleic acid; or a cellexpressing a CD79a CAR, e.g., a CD79a CAR-expressing T cell or NK cell.In one embodiment, the CD79a inhibitor is an anti-CD79a CAR expressingcell, e.g., CD79a CART or CD79a CAR-expressing NK cell. Exemplary CD79ainhibitors are described in more detail below.

In an embodiment, the present disclosure provides a population ofCAR-expressing cells, e.g., CART cells or CAR-expressing NK cells,comprising a mixture of cells expressing CD19 CARs and CD79a CARs. Forexample, in one embodiment, the population of CAR-expressing cellsincludes a first cell expressing a CD19 CAR and a second cell expressinga CD79a CAR.

Car Molecules

The binding domains described herein (e.g., binding domains against oneor more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, orCD79a) may further comprise one or more additional amino acid sequences.

In one embodiment, the CAR molecule comprises a transmembrane domain ofa protein selected from the group consisting of the alpha, beta or zetachain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8,CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.In one embodiment, the transmembrane domain comprises a sequence of SEQID NO: 15. In one embodiment, the transmembrane domain comprises anamino acid sequence having at least one, two or three modifications(e.g., substitutions) but not more than 20, 10 or 5 modifications (e.g.,substitutions) of an amino acid sequence of SEQ ID NO: 15, or a sequencewith 95-99% identity to an amino acid sequence of SEQ ID NO: 15.

In one embodiment, the binding domain is connected to the transmembranedomain by a hinge region, e.g., a hinge region described herein. In oneembodiment, the encoded hinge region comprises SEQ ID NO:14 or SEQ IDNO:45, or a sequence with 95-99% identity thereof.

In one embodiment, the CAR molecule further comprises a sequenceencoding a costimulatory domain, e.g., a costimulatory domain describedherein. In one embodiment, the costimulatory domain comprises afunctional signaling domain of a protein selected from the groupconsisting of OX40, CD2, CD27, CD28, ICAM-1, LFA-1 (CD11a/CD18), ICOS(CD278), and 4-1BB (CD137). In one embodiment, the costimulatory domaincomprises a sequence of SEQ ID NO: 16. In one embodiment, thecostimulatory domain comprises a sequence of SEQ ID NO:51. In oneembodiment, the costimulatory domain comprises an amino acid sequencehaving at least one, two or three modifications (e.g., substitutions)but not more than 20, 10 or 5 modifications (e.g., substitutions) of anamino acid sequence of SEQ ID NO: 16 or SEQ ID NO:51, or a sequence with95-99% identity to an amino acid sequence of SEQ ID NO: 16 or SEQ IDNO:51. In one embodiment, the costimulatory domain comprises afunctional signaling domain of a protein selected from the groupconsisting of MHC class I molecule, TNF receptor proteins,Immunoglobulin-like proteins, cytokine receptors, integrins, signalinglymphocytic activation molecules (SLAM proteins), activating NK cellreceptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28,CD30, CD40, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, ICAM-1,ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80(KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta,IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6,VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM,CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D,NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84,CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100(SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3),BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a,and a ligand that specifically binds with CD83. In embodiments, thecostimulatory domain comprises 4-1BB, CD27, CD28, or ICOS.

In one embodiment, the CAR molecule further comprises a sequenceencoding an intracellular signaling domain, e.g., an intracellularsignaling domain described herein. In one embodiment, the intracellularsignaling domain comprises a functional signaling domain of 4-1BB and/ora functional signaling domain of CD3 zeta. In one embodiment, theintracellular signaling domain comprises the sequence of SEQ ID NO: 16and/or the sequence of SEQ ID NO:17. In one embodiment, theintracellular signaling domain comprises the sequence of SEQ ID NO:16and/or the sequence of SEQ ID NO:43. In one embodiment, theintracellular signaling domain comprises a functional signaling domainof CD27 and/or a functional signaling domain of CD3 zeta. In oneembodiment, the intracellular signaling domain comprises the sequence ofSEQ ID NO: 51 and/or the sequence of SEQ ID NO:17. In one embodiment,the intracellular signaling domain comprises the sequence of SEQ IDNO:51 and/or the sequence of SEQ ID NO:43. In one embodiment, theintracellular signaling domain comprises an amino acid sequence havingat least one, two or three modifications (e.g., substitutions) but notmore than 20, 10 or 5 modifications (e.g., substitutions) of an aminoacid sequence of SEQ ID NO:16 or SEQ ID NO:51 and/or an amino acidsequence of SEQ ID NO:17 or SEQ ID NO:43, or a sequence with 95-99%identity to an amino acid sequence of SEQ ID NO:16 or SEQ ID NO:51and/or an amino acid sequence of SEQ ID NO:17 or SEQ ID NO:43. In oneembodiment, the intracellular signaling domain comprises the sequence ofSEQ ID NO:16 or SEQ ID NO:51 and the sequence of SEQ ID NO: 17 or SEQ IDNO:43, wherein the sequences comprising the intracellular signalingdomain are expressed in the same frame and as a single polypeptidechain.

In one embodiment, the CAR molecule further comprises a leader sequence,e.g., a leader sequence described herein. In one embodiment, the leadersequence comprises an amino acid sequence of SEQ ID NO: 13, or asequence with 95-99% identity to an amino acid sequence of SEQ ID NO:13.

In one aspect, the CAR (e.g., a CD19 CAR, a ROR1 CAR, a CD20 CAR, a CD22CAR, a CD123 CAR, a CD10 CAR, a CD34 CAR, a FLT-3 CAR, a CD79b CAR, aCD179b CAR, or a CD79a CAR) comprises an optional leader sequence (e.g.,an optional leader sequence described herein), an extracellular antigenbinding domain, a hinge (e.g., hinge described herein), a transmembranedomain (e.g., transmembrane domain described herein), and anintracellular stimulatory domain (e.g., intracellular stimulatory domaindescribed herein). In one aspect an exemplary CAR construct comprises anoptional leader sequence (e.g., a leader sequence described herein), anextracellular antigen binding domain, a hinge, a transmembrane domain,an intracellular costimulatory domain (e.g., an intracellularcostimulatory domain described herein) and an intracellular stimulatorydomain.

Bispecific Antibodies

A bispecific antibody molecule (which can be, e.g., administered aloneor as a portion of a CAR) can comprise two VH regions and two VLregions. In some embodiments, the upstream antibody or portion thereof(e.g. scFv) is arranged with its VH (VH₁) upstream of its VL (VL₁) andthe downstream antibody or portion thereof (e.g. scFv) is arranged withits VL (VL₂) upstream of its VH (VH₂), such that the overall bispecificantibody molecule has the arrangement VH₁-VL₁-VL₂-VH₂. In otherembodiments, the upstream antibody or portion thereof (e.g. scFv) isarranged with its VL (VL₁) upstream of its VH (VH₁) and the downstreamantibody or portion thereof (e.g. scFv) is arranged with its VH (VH₂)upstream of its VL (VL₂), such that the overall bispecific antibodymolecule has the arrangement VL₁-VH₁-VH₂-VL₂.

Bispecific CD22/CD19 Inhibitors

In an embodiment, the B-cell inhibitor comprises a bispecificCAR19/CAR22 antibody molecule. For instance, in some embodiments, theB-cell inhibitor comprises one or more amino acid sequences of Table 28,or a sequence having 95-99% identity thereto. Further provided arenucleic acids according to Table 28, or a sequence having 95-99%identity thereto. In an embodiment, the B-cell inhibitor comprises aCD19-specific antibody molecule of Table 2 or 3 (or a sequence having95-99% identity thereto) and a CD22-specific antibody molecule of Table6A or 6B (or a sequence having 95-99% identity thereto). In anembodiment, the B-cell inhibitor comprises a CD19-specific antibodymolecule having one or more CDRs of Table 4 or 5 (or a sequence having1, 2, 3, 4, 5, or 6 alterations e.g., substitutions thereto) and aCD22-specific antibody molecule having CDRs of Table 7A, 7B, 7C, 8A or8B (or a sequence having 1, 2, 3, 4, 5, or 6 alterations e.g.,substitutions thereto).

mTOR Inhibitors

In one embodiment, the cells expressing a CAR molecule, e.g., a CD19 CARmolecule, a CD20 CAR molecule, or a CD22 CAR molecule e.g., a CARmolecule described herein, optionally administered in combination with aB-cell inhibitor, are co-administered with a low, immune enhancing doseof an mTOR inhibitor. While not wishing to be bound by theory, it isbelieved that treatment with a low, immune enhancing, dose (e.g., a dosethat is insufficient to completely suppress the immune system butsufficient to improve immune function) is accompanied by a decrease inPD-1 positive T cells or an increase in PD-1 negative cells. PD-1positive T cells, but not PD-1 negative T cells, can be exhausted byengagement with cells which express a PD-1 ligand, e.g., PD-L1 or PD-L2.

In an embodiment this approach can be used to optimize the performanceof CAR cells described herein in the subject. While not wishing to bebound by theory, it is believed that, in an embodiment, the performanceof endogenous, non-modified immune effector cells, e.g., T cells, isimproved. While not wishing to be bound by theory, it is believed that,in an embodiment, the performance of a CAR expressing cell is improved.In other embodiments, cells, e.g., T cells, which have, or will beengineered to express a CAR, can be treated ex vivo by contact with anamount of an mTOR inhibitor that increases the number of PD1 negativeimmune effector cells, e.g., T cells or increases the ratio of PD1negative immune effector cells, e.g., T cells/PD1 positive immuneeffector cells, e.g., T cells.

In an embodiment, administration of a low, immune enhancing, dose of anmTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, or acatalytic inhibitor, is initiated prior to administration of an CARexpressing cell described herein, e.g., T cells. In an embodiment, theCAR cells are administered after a sufficient time, or sufficientdosing, of an mTOR inhibitor, such that the level of PD1 negative immuneeffector cells, e.g., T cells, or the ratio of PD1 negative immuneeffector cells, e.g., T cells/PD1 positive immune effector cells, e.g.,T cells, has been, at least transiently, increased.

In an embodiment, the cell, e.g., T cell, to be engineered to express aCAR, is harvested after a sufficient time, or after sufficient dosing ofthe low, immune enhancing, dose of an mTOR inhibitor, such that thelevel of PD1 negative immune effector cells, e.g., T cells, or the ratioof PD1 negative immune effector cells, e.g., T cells/PD1 positive immuneeffector cells, e.g., T cells, in the subject or harvested from thesubject has been, at least transiently, increased.

Additional features or embodiments of the compositions or methodsdescribed herein include one or more of the following:

In embodiments, the B-cell inhibitor comprises an inhibitor of one ormore of CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1. In embodiments,the B-cell inhibitor comprises an effective number of one or more cellsthat express a CAR molecule that binds one or more of CD10, CD20, CD22,CD34, CD123, FLT-3, or ROR1.

In embodiments, the one or more cells that express a CAR molecule thatbinds CD19 are administered concurrently with, before, or after the oneor more B-cell inhibitors.

In embodiments, the subject has or is identified as having a difference,e.g., a statistically significant difference, between a determined levelcompared to a reference level of one or more markers listed in Table 29in a biological sample.

In embodiments, the subject has or is identified as having a differencebetween a determined characteristic compared to a referencecharacteristic, in a characteristic of CD19, e.g., a mutation causing aframeshift or a premature stop codon or both, in a biological sample.

In embodiments, the subject has or is identified as having a difference,e.g., a statistically significant difference, between a determined levelcompared to a reference level of Treg cells in a biological sample.

In an embodiment, the method comprises administering to the subject atherapeutically effective dose of a chimeric antigen receptor (CAR)therapy, e.g., a CAR therapy as described herein, e.g., a therapycomprising a CD19 CAR-expressing cell and optionally one or more B-cellinhibitor, and if the subject is identified as having a difference,e.g., a statistically significant difference, between a determined levelcompared to a reference level, or a determined characteristic comparedto a reference characteristic, in one or more of (i) a level or activityof one or more markers listed in Table 29; (ii) a characteristic ofCD19, e.g., a mutation, e.g., a mutation causing a frameshift or apremature stop codon or both, or (iii) a level of MEG cells in abiological sample. In an embodiment, the method comprises determining ifthe subject has a difference, e.g., a statistically significantdifference, between a determined level compared to a reference level, ora determined characteristic compared to a reference characteristic, inone or more of (i) a level of one or more markers listed in Table 29;(ii) a characteristic of CD19, e.g., a mutation, e.g., a mutationcausing a frameshift or a premature stop codon or both, or (iii) a levelor activity of MEG cells in a biological sample, and administering tothe subject a therapeutically effective dose of a chimeric antigenreceptor (CAR) therapy, e.g., a CAR therapy as described herein, e.g., atherapy comprising a CD19 CAR-expressing cell and optionally one or moreB-cell inhibitor. In an embodiment, the method comprises determining ifthe subject has a difference, e.g., a statistically significantdifference, between a determined level compared to a reference level, ora determined characteristic compared to a reference characteristic, inone or more of (i) a level of one or more markers listed in Table 29;(ii) a characteristic of CD19, e.g., a mutation, e.g., a mutationcausing a frameshift or a premature stop codon or both, or (iii) a levelor activity of T_(REG) cells in a biological sample, and administeringto the subject a therapeutically effective dose of a chimeric antigenreceptor (CAR) therapy, e.g., a CAR therapy as described herein, e.g., atherapy comprising a CD19 CAR-expressing cell and optionally one or moreB-cell inhibitor. In an embodiment, the method comprises administeringto a subject a therapeutically effective dose of a chimeric antigenreceptor (CAR) therapy, e.g., a CAR therapy as described herein, e.g., atherapy comprising a CD19 CAR-expressing cell, determining if thesubject has a difference, e.g., a statistically significant difference,between a determined level compared to a reference level, or adetermined characteristic compared to a reference characteristic, in oneor more of (i) a level of one or more markers listed in Table 29; (ii) acharacteristic of CD19, e.g., a mutation, e.g., a mutation causing aframeshift or a premature stop codon or both, or (iii) a level oractivity of MEG cells in a biological sample, and if the difference ispresent, administering to a subject a therapeutically effective dose ofone or more B-cell inhibitor.

In embodiments, the subject has or is identified as having an increase,e.g., a statistically significant increase, between a determined leveland to a reference level of Treg cells in a biological sample.

In embodiments, the subject has relapsed or is identified as havingrelapsed after treatment with the one or more cells that express a CARmolecule that binds CD19, e.g., a CD19 CAR.

In embodiments, the B-cell inhibitor comprises an effective number ofone or more cells that express: a CAR molecule that binds CD10, e.g., aCD10 CAR as described herein; a CAR molecule that binds CD20, e.g., aCD20 CAR as described herein; a CAR molecule that binds CD22, e.g., aCD22 CAR as described herein; a CAR molecule that binds CD34, e.g., aCD34 CAR as described herein; a CAR molecule that binds CD123, e.g., aCD123 CAR as described herein; a CAR molecule that binds FLT-3, e.g., aFLT-3 CAR as described herein; or a CAR molecule that binds ROR1, e.g.,an ROR1 CAR as described herein.

In embodiments, the CD19 inhibitor comprises an antibody or antibodyfragment which includes a CD19 binding domain, a transmembrane domain,and an intracellular signaling domain comprising a stimulatory domain,and wherein said CD19 binding domain comprises one or more of (e.g., allthree of) light chain complementarity determining region 1 (LC CDR1),light chain complementarity determining region 2 (LC CDR2), and lightchain complementarity determining region 3 (LC CDR3) of any CD19 lightchain binding domain amino acid sequence listed in Tables 2 or 3, andone or more of (e.g., all three of) heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3) of any CD19 heavy chain binding domain amino acid sequencelisted in Tables 2 or 3.

In embodiments, a CD19 CAR comprises light chain variable region listedin Tables 2 or 3 and any heavy chain variable region listed Tables 2 or3.

In embodiments, the CD19 inhibitor comprises a CD19 binding domain whichcomprises a sequence selected from a group consisting of SEQ ID NO:1,SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ IDNO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ IDNO:12, or a sequence with 95-99% identity thereof. In embodiments, theCD19 CAR comprises a polypeptide of SEQ ID NO:58.

In embodiments, the B-cell inhibitor comprises a CD20 CAR whichcomprises an antibody or antibody fragment which includes a CD20 bindingdomain, a transmembrane domain, and an intracellular signaling domaincomprising a stimulatory domain, and wherein said CD20 binding domaincomprises one or more of light chain complementarity determining region1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2),and light chain complementarity determining region 3 (LC CDR3) of anyCD20 light chain binding domain amino acid sequence listed in Table 13,and one or more of heavy chain complementarity determining region 1 (HCCDR1), heavy chain complementarity determining region 2 (HC CDR2), andheavy chain complementarity determining region 3 (HC CDR3) of any CD20heavy chain binding domain amino acid sequence listed in Table 12A or12B.

In embodiments, the B-cell inhibitor comprises a CD22 CAR whichcomprises an antibody or antibody fragment which includes a CD22 bindingdomain, a transmembrane domain, and an intracellular signaling domaincomprising a stimulatory domain, and wherein said CD22 binding domaincomprises one or more of light chain complementarity determining region1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2),and light chain complementarity determining region 3 (LC CDR3) of anyCD22 light chain binding domain amino acid sequence listed in Table 8A,8B, 10A and/or 10B, and one or more of heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3) of any CD22 heavy chain binding domain amino acid sequencelisted in Table 7A, 7B, 7C, 9A, and/or 9B.

In embodiments, the CD22 CAR comprises any light chain variable regionlisted in Table 10A or 10B. In embodiments, the CD22 CAR comprises anyheavy chain variable region listed in Table 9A or 9B. In embodiments,the CD22 CAR comprises any light chain variable region listed in Table10A or 10B and any heavy chain variable region listed Table 9A or 9B.

In embodiments, the B-cell inhibitor comprises a CAR which comprises anantibody or antibody fragment which includes an antigen binding domain,a transmembrane domain, and an intracellular signaling domain comprisinga stimulatory domain, and wherein said antigen binding domain comprisesone or more of (e.g., all of) light chain complementarity determiningregion 1 (LC CDR1), light chain complementarity determining region 2 (LCCDR2), and light chain complementarity determining region 3 (LC CDR3),and one or more of (e.g., all of) heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3).

In embodiments, the B-cell inhibitor comprises a CAR which comprises ascFv. In embodiments, the B-cell inhibitor comprises a CAR whichcomprises a transmembrane domain that comprises a transmembrane domainof a protein selected from the group consisting of the alpha, beta orzeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5,CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 andCD154. In embodiments, the antigen binding domain is connected to thetransmembrane domain by a hinge region. In embodiments, the hinge regioncomprises SEQ ID NO:14, or a sequence with 95-99% identity thereof. Inembodiments, the costimulatory domain is a functional signaling domainobtained from a protein selected from the group consisting of OX40, CD2,CD27, CD28, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), and 4-1BB (CD137).In embodiments, the costimulatory domain is a functional signalingdomain obtained from a protein selected from the group consisting of MHCclass I molecule, TNF receptor proteins, Immunoglobulin-like proteins,cytokine receptors, integrins, signaling lymphocytic activationmolecules (SLAM proteins), activating NK cell receptors, BTLA, a Tollligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, ICAM-1, LFA-1(CD11a/CD18), 4-1BB (CD137), B7-H3, ICAM-1, ICOS (CD278), GITR, BAFFR,LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30,NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha,ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD,CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c,ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2,TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile),CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69,SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8),SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligandthat specifically binds with CD83. In embodiments, the costimulatorydomain comprises a sequence of SEQ ID NO:16 or SEQ ID NO:51. Inembodiments, the intracellular signaling domain comprises a functionalsignaling domain of 4-1BB and/or a functional signaling domain of CD3zeta.

In embodiments, the intracellular signaling domain comprises thesequence of SEQ ID NO: 16 and/or the sequence of SEQ ID NO:17 or SEQ IDNO:43. In embodiments, the CAR further comprises a leader sequence. Inembodiments, the leader sequence comprises SEQ ID NO: 13.

In embodiments, the cells that express the CAR molecule comprise T cellsor NK cells.

In embodiments, the disease associated with CD19 expression is selectedfrom a proliferative disease such as a cancer or malignancy or aprecancerous condition such as a myelodysplasia, a myelodysplasticsyndrome or a preleukemia, or is a non-cancer related indicationassociated with expression of CD19. In embodiments, the disease is oneor more of a hematologic cancer, acute leukemia, B-cell acute lymphoidleukemia (BALL), T-cell acute lymphoid leukemia (TALL), smalllymphocytic leukemia (SLL), acute lymphoid leukemia (ALL); chronicleukemia, chronic myelogenous leukemia (CIVIL), or chronic lymphocyticleukemia (CLL).

In embodiments, the method further comprises administering an agent thatincreases the efficacy of a cell expressing a CAR molecule. Inembodiments, the method further comprises administering an agent thatameliorates one or more side effects associated with administration of acell expressing a CAR molecule. In embodiments, the cells expressing aCAR molecule are administered in combination with an agent that treatsthe disease associated with CD19.

In embodiments, in accordance with a method described herein, e.g., amethod of providing anti-tumor immunity to a mammal, or method oftreating a mammal, a mammal is a non-responder, partial responder, orcomplete responder to a previously administered cancer therapy, e.g., aCD19 CAR therapy or a cancer therapy other than a CD19 CAR-expressingcell. In embodiments, the mammal is a non-relapser, partial relapse, orcomplete relapse to a previously administered cancer therapy, e.g., aCD19 CAR therapy or a cancer therapy other than a CD19 CAR-expressingcell. In embodiments, the mammal comprises a CD19-negative cancer cellor a CD19-positive cancer cell, optionally wherein the mammal furthercomprises a CD22-positive, CD123-positive, FLT-3-positive,ROR-1-positive, CD79b-positive, CD179b-positive, CD79a-positive,CD10-positive, CD34-positive, and/or CD20-positive cancer cell. Inembodiments, the mammal has a relapsed ALL cancer. In embodiments, themammal was previously administered a CD19 CAR-expressing cell and isrefractory to CD19 CAR treatment.

In embodiments, the agent is an mTOR inhibitor and the subject isadministered a low, immune enhancing, dose of an mTOR inhibitor, e.g.,RAD001 or rapamycin. In embodiments, the mTOR inhibitor is a RAD001. Inembodiments, the dose comprises an allosteric and a catalytic mTORinhibitor. In embodiments, the mTOR inhibitor is administered for anamount of time sufficient to decrease the proportion of PD-1 positive Tcells, increase the proportion of PD-1 negative T cells, or increase theratio of PD-1 negative T cells/PD-1 positive T cells, in the peripheralblood of the subject, or in a preparation of T cells isolated from thesubject.

In embodiments, the immune effector cell, e.g., T cell, to be engineeredto express a CAR, is harvested after a sufficient time, or aftersufficient dosing of the low, immune enhancing, dose of an mTORinhibitor, such that the level of PD1 negative immune effector cells,e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g.,T cells/PD1 positive immune effector cells, e.g., T cells, in thesubject or harvested from the subject has been, at least transiently,increased. In embodiments, the dose of an mTOR inhibitor is associatedwith mTOR inhibition of at least 5 but no more than 90%, e.g., asmeasured by p70 S6 K inhibition. In embodiments, the dose of an mTORinhibitor is associated with mTOR inhibition of at least 10% but no morethan 40%, e.g., as measured by p70 S6 K inhibition.

In an embodiment, the method further comprises administering acheckpoint inhibitor. In embodiments, the subject receives apre-treatment of with an agent, e.g., an mTOR inhibitor, and/or acheckpoint inhibitor, prior to the initiation of a CART therapy. Inembodiments, the subject receives concurrent treatment with an agent,e.g., an mTOR inhibitor, and/or a checkpoint inhibitor. In embodiments,the subject receives treatment with an agent, e.g., an mTOR inhibitor,and/or a checkpoint inhibitor, post-CART therapy.

In embodiments, the determined level or determined characteristic isacquired before, at the same time, or during a course of CART therapy.

In embodiments, the method comprises assaying a gene signature thatindicates whether the subject is likely to relapse, or has relapsed. Inembodiments, the method comprises assaying a gene signature in a subjectprior to treatment with a CAR-expressing cell, e.g., CART treatment(e.g., a CART19 treatment, e.g., CTL019 therapy) that predicts relapseto CAR treatment. In embodiments, the level of one or more markers isthe level of at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 markers listed inTable 29. In embodiments, the level of the marker comprises an mRNAlevel or a level of a soluble protein.

In embodiments, the characteristic of CD19 is a mutation in exon 2,e.g., a mutation causing a frameshift or a premature stop codon or both.In embodiments, the level of T_(REG) cells is determined by staining asample for a marker expressed by T_(REG) cells. In embodiments, thelevel of T_(REG) cells is the level of Treg cells in a relevant locationin the subject's body, e.g., in a cancer microenvironment.

In embodiments, the method further comprises decreasing the T_(REG)signature in the subject prior to apheresis. In embodiments, the methodfurther comprises decreasing the T_(REG) signature in the subject, e.g.,by administering cyclophosphamide, an anti-GITR antibody, or both to thesubject. In embodiments, the method comprises pre-treating a subjectwith cyclophosphamide, an anti-GITR antibody, or both, prior tocollection of cells for CAR-expressing cell product manufacturing. Inembodiments, the method further comprises obtaining a sample from thesubject, wherein the sample comprises a cellular fraction (e.g., whichcomprises blood), a tissue fraction, an apheresis sample, or a bonemarrow sample.

In embodiments, the cell expresses an inhibitory molecule that comprisesa first polypeptide that comprises at least a portion of an inhibitorymolecule, associated with a second polypeptide that comprises a positivesignal from an intracellular signaling domain. In embodiments, theinhibitory molecule comprise first polypeptide that comprises at least aportion of PD1 and a second polypeptide comprising a costimulatorydomain and primary signaling domain.

In embodiments, the method comprises assaying a gene signature thatindicates whether a subject treated with the cell is likely to relapse,or has relapsed. In embodiments, the method comprises assaying the genesignature in the cell prior to infusion into the subject. Inembodiments, the method further comprises decreasing the T_(REG)signature of a population of cells comprising the transduced cell. Inembodiments, decreasing the T_(REG) signature comprises performingCD25-depletion on the population of cells.

In embodiments, the subject is a mammal, e.g., a human.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein (e.g., sequence databasereference numbers) are incorporated by reference in their entirety. Forexample, all GenBank, Unigene, and Entrez sequences referred to herein,e.g., in any Table herein, are incorporated by reference. Unlessotherwise specified, the sequence accession numbers specified herein,including in any Table herein, refer to the database entries current asof Apr. 8, 2015. When one gene or protein references a plurality ofsequence accession numbers, all of the sequence variants areencompassed.

In addition, the materials, methods, and examples are illustrative onlyand not intended to be limiting.

Headings, sub-headings or numbered or lettered elements, e.g., (a), (b),(i) etc, are presented merely for ease of reading. The use of headingsor numbered or lettered elements in this document does not require thesteps or elements be performed in alphabetical order or that the stepsor elements are necessarily discrete from one another.

Other features, objects, and advantages of the invention will beapparent from the description and drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B are schematics of representative CARs.

FIG. 2 contains images of immunohistochemical analysis of a Hodgkinlymphoma showing CD19 expressing cells present in the tumor. The leftpanel is at 1× magnification and the right panel is at 20×magnification.

FIG. 3 is a schematic diagram of the experimental set-up for a study toassess the therapeutic efficacy of CART19 treatment in patients withHodgkin lymphoma.

FIGS. 4A, 4B, 4C, and 4D show flow cytometry analysis of PD1 and CAR19expression on T cells. FIGS. 4A and 4B are representative flow cytometryprofiles demonstrating the distribution of PD-1 and CAR19 expression onCD4+ T cells from subjects that are complete responders (CR) ornon-responders (NR) to CART therapy. FIG. 4C is a graph showing thepercent of PD1 cells in the CD4+ T cell population from groups ofsubjects with different responses to CART therapy. FIG. 4D is a graphshowing the percent of PD1 cells in the CD8+ T cell population fromgroups of subjects with different responses to CART therapy.

FIGS. 5A and 5B show the distribution of PD1 expression in CD4 andCAR19-expressing cells (FIG. 5A) or CD8 and CAR19-expressing cells (FIG.5B) from groups of subjects with different responses to CART therapy.

FIG. 6 shows flow cytometry analysis of PD1, CAR 19, LAG3, and TIM3expression on T cells from subjects that are complete responders (CR) ornon-responders (NR) to CART therapy.

FIGS. 7A and 7B show the distribution of PD1 and LAG3 expression (FIG.7A) or PD1 and TIM3 expression (FIG. 7B) from groups of subjects withdifferent responses to CART therapy.

FIG. 8 shows the plasma cell IgA immunophenotyping from a myelomapatient who received CART19, demonstrating the response to CART19therapy.

FIGS. 9A and 9B show IL-7 receptor (CD127) expression on cancer celllines and CART cells. Expression of CD127 was measured by flow cytometryanalysis in three cancer cell lines: RL (mantle cell lymphoma), JEKO(also known as Jeko-1, mantle cell lymphoma), and Nalm-6 (B-ALL) (FIG.9A). CD127 expression was measured by flow cytometry analysis on CD3positive (CART) cells that had been infused and circulating in NSG mice(FIG. 9B).

FIGS. 10A, 10B, and 10C show the anti-tumor response after CART19treatment and subsequent IL-7 treatment. NSG mice engrafted with aluciferase-expressing mantle lymphoma cell line (RL-luc) at Day 0 weretreated with varying dosages of CART19 cells at Day 6, and tumor burdenwas monitored. Mice were divided into 4 groups and received no CART19cells, 0.5×10⁶ CART19 cells (CART19 0.5E6), 1×10⁶ CART19 cells (CART191E6), or 2×10⁶ CART19 cells (CART19 2E6). Tumor burden after CARTtreatment was measured by detection of bioluminescence (mean BLI) (FIG.10A). Mice receiving 0.5×10⁶ CART19 cells (CART19 0.5E6) or 1×10⁶ CART19cells (CART19 1E6) were randomized to receive recombinant human IL-7(rhIL-7) or not. Tumor burden, represented here by mean bioluminescence(BLI), was monitored for the three mice (#3827, #3829, and #3815,receiving the indicated initial CART19 dose) from FIG. 10A that weretreated with IL-7 starting at Day 85 (FIG. 10B). IL-7 was administeredthrough IP injection 3 times weekly. Tumor burden, represented here bymean bioluminescence (BLI) before Day 85 (PRE) and after Day 115 (POST)was compared between mice that did not receive IL-7 (CTRL) and mice thatreceived IL-7 treatment (IL-7) (FIG. 10C).

FIGS. 11A and 11B show the T cell dynamics after IL-7 treatment. Thelevel of human T cells detected in the blood was monitored for each ofthe mice receiving IL-7 or control mice (FIG. 11A). The level of CART19cells (CD3+ cells) detected in the blood was measured before (PRE) and14 days after (Day 14) initiation of IL-7 treatment (FIG. 11B).

FIG. 12 depicts the structures of two exemplary RCAR configurations. Theantigen binding members comprise an antigen binding domain, atransmembrane domain, and a switch domain. The intracellular bindingmembers comprise a switch domain, a co-stimulatory signaling domain anda primary signaling domain. The two configurations demonstrate that thefirst and second switch domains described herein can be in differentorientations with respect to the antigen binding member and theintracellular binding member. Other RCAR configurations are furtherdescribed herein.

FIG. 13 depicts two constructs for bispecific CARs with anti-C22 andanti-CD19 binding domains. “4G4S” represents the linker sequenceGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 1311).

FIG. 14 is a graph depicting the activity of bispecific CD19/CD22 CARconstructs in an NFAT assay.

FIGS. 15A, 15B, and 15C are graphs showing the extent of CAR T-cellactivation (measured by relative luminescence) in the presence ofvarious tumor target cell lines. FIG. 15A shows CAR T-cell activation inthe presence of CD20 expressing target cell line, Daudi. FIG. 15B showsCAR T-cell activation in the presence of CD20 expressing target cellline, Raji. FIG. 15C shows CAR T-cell activation in the presence of anon CD20 expressing negative control, K562.

FIG. 16 is an exemplary schematic illustrating an overview of the genesignature analysis. Briefly, for each gene set, a 2-group statisticalmodel was applied to determine whether the meta-gene was statisticallydifferent between the CRs, PRs, and NRs. CRs are more like restingT_(EFF) cells, whereas NR are more like activated T_(EFF) cells. Genesupregulated in activated versus resting T_(EFF) cells are alsoupregulated in NRs.

FIG. 17 depicts exemplary results (p=0.000215) illustrating that T_(REG)genes have high expression levels in samples from pediatric patients whowere complete responders who became relapsers (R) compared to completeresponders (CR) who did not relapse. The x-axis is samples by responsegroup where CR=complete responder without relapse and R=relapser. They-axis is normalized meta-gene expression scores.

FIGS. 18A, 18B, and 18C are graphs showing CAR T-cell activation in thepresence of tumor target cell lines. In FIG. 18A, CAR-expressing JNLcells were mixed with the Daudi CD22 expressing target cell line at theindicated E:T ratios. In FIG. 18B, CAR-expressing JNL cells were mixedwith the Raji CD22 expressing target cell line at the indicated E:Tratios. In FIG. 18C, CAR-expressing JNL cells were mixed with thenegative control K562 cell line at the indicated E:T ratios.

FIGS. 19A, 19B, 19C, and 19D are a graph showing primary T-cellsexpression of chimeric antigen receptor on the cell surface.Protein-L-biotin/SA-PE (FIG. 19A and FIG. 19B) and rhCD22-Fc/anti-Fc488(FIGS. 19C and 19D) were used to determine CAR surface expressionlevels. Cells with no CAR were used as a negative control.

FIGS. 20A, 20B, 20C, 20D, 20E, and 20F are graphs showing a primaryT-cell tumor target killing assay. Primary T-cells activated andtransduced with CD22 CAR were mixed with target cell lines stablyexpressing luciferase at the ratios indicated and target cell killingwas measured. The percent killing was normalized to hCD22-8 (28.8%transduction). CD22-expressing cell lines Raji (FIG. 20A), SEM (FIG.20B), K562-hCD22 (FIG. 20C), Daudi (FIG. 20D), and Nalm6 (FIG. 20E) wereused to test the function CD22 CAR clones in comparison with positivecontrol CD22 CAR m971 (m971-HL), negative control CAR m971-LH, anduntransduced T-cells as a negative control. K562 cell line does notexpress CD22 and was used as a negative control (FIG. 20F).

FIGS. 21A, 21B, 21C, 21D, 21E, and 21F are graphs showing induction of asignificant proinflammatory cytokine response by CD22 CAR clones.Primary T-cell killing assays were used to determine the ability of CD22CAR clone to produce the proinflammatory cytokines IFN-g, IL-2 and TNFa.Effector cells were co-cultured for 20 hours with each of the differenttarget cell lines, normalized to 28.8% transduction. Supernatants weretaken from different cultures with varying E:T ratios of 2.5:1 and 10:1from Raji CD22 expressing target cells (FIG. 21A), Nalm6 CD22 expressingtarget cells (FIG. 21B), Daudi CD22 expressing target cells (FIG. 21C),SEM CD22 expressing target cells (FIG. 21D), K562-hCD22 CD22 expressingtarget cells (FIG. 21E), and K562 non-CD22 expressing cells (negativecontrol) (FIG. 21F).

FIG. 22 is a graph depicting the expression of various B-cell antigensin relapsed ALL is a graph depicting the expression of various B-cellantigens in relapsed ALL as detected by flow cytometry. Samples from 16r/r patients were screened by multiparametric flow cytometry for thefollowing markers: CD19 (16 pts), CD22 (16 pts), CD123 (16 pts), FLT-3(9 pts), ROR-1 (3 pts), CD79b (15 pts), CD179b (8 pts), CD79a (16 pts),CD10 (16 pts), CD34 (16 pts), and CD20 (16 pts). CD22 and CD123 werehighly (>60%) and homogeneously expressed in the blasts of r/r ALLpatients (bar indicates median % expression, respectively 99.50%,98.80%, 95.70%, 72.00%, 47.00%, 15.00%, 13.45%, 4.200%, 98.00%, 87.65%,and 7.00%). For each patient, the percentage of cells expressing themarker indicated is shown as a single data point.

FIG. 23 is a set of graphs showing is a set of graphs showing expressionof CD22 and CD123 in 6 patients relapsing with CD19-negative leukemia,both before CART19 treatment (baseline) and after (CD19-neg relapse). Inall analyses, the population of interest was gated based on forward vs.side scatter characteristics followed by singlet gating, and live cellswere gated using Live Dead Aqua (Invitrogen). Time gating was includedfor quality control. The gating strategy included: time gating→SSClow→singlets→live→CD45dim CD10+.

FIG. 24 is a set of graphs showing the expression of CD22 in in blastsfrom patient relapsing with CD19-neg disease after CART19 treatment(clinical trials UPCC04409/CHP959, patient UPN indicated in the squaredbox). The top row shows the CD19 and CD22 expression in blasts beforeCART19 treatment while the bottom row shows the disease phenotype atrelapse. CD22 expression was maintained also at relapse when CD19expression was lost.

FIG. 25 is a set of graphs showing the expression of CD123 in is a setof graphs showing expression of CD123 in blasts from patient relapsingwith CD19-neg disease after CART19 treatment (clinical trialsUPCC04409/CHP959, patient UPN indicated in the squared box). The top rowshows the CD19 and CD123 expression in blasts before CART19 treatmentwhile the bottom row shows the disease phenotype at relapse. CD123expression was maintained at relapse in most of the patients while CD19expression was lost.

FIG. 26 is a graph showing the median expression of CD19, CD22 and CD123before and after CART19 treatment in patients relapsing with aCD19-negative disease. CD19 expression was lost at relapse (94.25% vs.0%, p=0.0009), while CD22 (99.20% vs. 97.30%, p=ns) and CD123 (63.00%vs. 48.75%, p=ns) were still expressed. For each patient, the percentageof cells expressing the marker indicated is shown as a single datapoint.

FIGS. 27A and 27B are a series of graphs showing CD22 expression insamples from 16 r/r patients and 4 patients relapsing with CD19-negativedisease after treatment with CART19 therapy. Samples were screened bymultiparametric flow cytometry for the B cell marker, CD22. CD22 washighly (>60%) and homogeneously expressed in the blasts of 11/15 r/r ALLpatients (FIG. 27A). CD22 was positive in 4/4 patients relapsing withCD19-negative leukemia, both before CART19 treatment (baseline) andafter (CD19-neg relapse) (2 pts shown) (FIG. 27B). Gating strategy: SSClow→singlets→live→CD45dim

FIGS. 28A, 28B, and 28C are a series of graphs showing the effect ofCD22 CART on CD19 and CD22 expression. Schema of the two CAR22constructs that were generated using different chain orientations (H toL and L to H) is shown (FIG. 28A). The anti-CD22 scFv (m971) was codonoptimized and cloned in the murine CAR19 vector containing CD8 hinge,41-BB costimulatory and CD3 zeta signaling domains (FIG. 28A). Theexpression of CD19, CD22 and isotype control on NALM6 ALL cell line isshown as mean fluorescence intensity (MFI) (FIG. 28B) andantibody-binding capacity (ABC) (FIG. 28C). In NALM-6 the expression ofCD19 was higher than CD22. However, in most primary ALL samples the CD19and CD22 expressions were similar (see FIG. 27A).

FIGS. 29A, 29B, and 29C are a series of graphs showing normal donor Tcell expansions for generating CART22 and CART19 (together with UTDcells). Population doublings (PD) versus days in culture: at the end ofthe expansion (day 11) CART22 and control T cells reached around 4.5 PD,with no significant difference in comparison to CART19 or UTD cells(FIG. 29A). T cell volume (fl) versus days in culture: at day 6 therewas peak volume (around 450 fl) while in the following days the volumedecreased down to 300 fl when the cells are harvested and frozen. Nosignificant different was observed versus CART19 or UTD cells (FIG.29B). CAR expression on CD4-positive and CD8-positive T-cells at day 11of expansion is shown in FIG. 29C. Gating for CAR expression is based onUTD. Gating strategy: FSS vs SSC lymphocytes→singlets→live→CD3+.

FIG. 30 is a series of graphs showing a CD107a degranulation assay withintra-cytoplasmic cytokine production. CART19, CART22 HtoL and LtoH wereco-cultured with different targets (alone, PMA/IONOMYCIN, MOLM-14 andNALM-6). CART19 and CART22 HtoL show high levels of CD107adegranulation, IL-2, IFNg and TNFa production when co-cultured with theALL cell line (NALM-6) but not when co-cultured with negative controls.UTD and CART22 LtoH did not show degranulation nor cytokine productions.Gating strategy: FSS vs SSC lymphocytes→singlets→live→CD3+.

FIG. 31 is a graph showing a luciferase-based killing assay. CART22 andCART19 HtoL but not UTD cells were able to lyse NALM-6 cells whenco-cultured os for 24 hours. A direct correlation between cytotoxicactivity and E:T ratios was observed, with better anti-leukemia effectat 2:1 E:T ratio (78% and 75% killing for CART19 and CART22).

FIGS. 32A and 32B are a series of graphs showing a CFSE-basedproliferation assay. Co-culture for 5 days of CART22 and CART19 with theALL cell line NALM-6 led to significant T cell proliferation (94% and92.9% respectively). Controls are also shown (TCM=media alone,P-I=PMA/Ionomycin, MOLM-14) (FIG. 32A). In histograms showing thedynamics of CFSE dilution in CART19 and CART22, most of T cellsunderwent multiple proliferative cycles (FIG. 32B). Gating strategy: FSSvs SSC lymphocytes→singlets→live→CD3+.

FIG. 33 is a series of graphs showing cytokine production. CART22,CART19 and UTD were incubated for 24 hours with different irradiatedtargets (alone, PMA/Ionomycin, MOLM-14 and NALM-6). When co-culturedwith the ALL cell line NALM-6 only CART22 and CART19 HtoL were able torelease multiple cytokines (here shown IFNg, IL-2, GM-CSF, TNFa andMIP1b). Results are shown as mean intensity fluorescence (MFI).

FIGS. 34A and 34B are a series of graphs showing T-cell degranulationwith primary ALL blasts. CART22, CART19 and UTD cells were co-incubatedfor 4 hours with blasts derived from an ALL patient (CHP-959-101) atbaseline and after CART19 treatment when the patient relapsed with aCD19-neg disease. Both CART19 and CART22 were able to degranulate atbaseline (when blasts are CD19+ and CD22+) but at relapse only CART22was degranulating (when the disease is CD19-neg) (FIG. 34A). Dot-plotsshowing CD107a degranulation in CD8-pos and CD8-neg CART19 and CART22effector after incubation with CHP101 sample at relapse demonstrate onlyCART22 showed degranulation in both CD8 and CD4 T cells (FIG. 34B).Gating strategy: FSS vs SSC lymphocytes→singlets→live→CD3+.

FIGS. 35A, 35B, 35C, and 35D are a series of graphs showing in vivoCART22 efficacy against NALM-6. A. Schema of the experiment: 1 millionNALM-6 luciferase+ cells/mouse were injected i.v. in NSG mice. After 6days tumor engraftment was assessed by bioluminescence. Mice were thenrandomized to receive untransduced T cells or different doses of CART22(from 1.25 to 5 million total cells/mouse, with 75% CAR expression).Mice were then monitored for tumor burden, PB T cell expansion, andsurvival (FIG. 35A). Tumor burden by bioluminescence (BLI) detected adose-related anti leukemia response. Mice receiving 5e⁶ CART22 cellsshowed better tumor control (FIG. 35B). CART22 treated mice showed astatistically significant better overall survival (OS) in comparison tomice treated with UTD cells. For OS there was a significant correlationbetween higher dose of CART22 and better OS (FIG. 35C). T-cell in vivoexpansion was monitored weekly by retro-orbital bleedings. One weekafter T cell infusion mice receiving the higher dose of CART22 showedbetter CART expansion (median of 12 T cells/μl) (FIG. 35D).

FIGS. 36A and 36B are a series of graphs showing an in vivo comparisonbetween CART22 and CART19 against NALM-6. Schema of the experiment: 1million NALM-6 luciferase+ cells/mouse were injected i.v. in NSG mice.After 6 days tumor engraftment was assessed by bioluminescence. Micewere then randomized to receive untransduced T cells, CART19 or CART22(5 million total cells, with 75% CAR expression). Mice were thenmonitored for tumor burden, PB T cell expansion, and survival (FIG.36A). Tumor burden by bioluminescence (BLI) demonstrated anti leukemiaresponse in both CART22 and CART19 treated mice, while UTD mice rapidlyprogressed (FIG. 36B). CART19 treated mice showed better overallsurvival (OS) in comparison to CART22, possibly due to the differenttarget expression in NALM-6 (CD19>>CD22) (FIG. 36C).

FIGS. 37A and 37B are a series of graphs showing an in vivo comparisonbetween CART22 and CART19 in a model of primary ALL. The blasts of aprimary ALL patient (JH331) were passaged in vivo and transduced withluciferase to follow tumor burden. Schema of the experiment: 1 millionJH331 luciferase+ cells/mouse were injected i.v. in NSG mice. After 14days tumor engraftment was assessed by bioluminescence. Mice were thenrandomized to receive untransduced T cells, CART19 or CART22 (5 milliontotal cells, with 75% CAR expression). Mice were then monitored fortumor burden, PB T cell expansion, and survival (FIG. 37A). Tumor burdenby bioluminescence (BLI) detected anti leukemia response in both CART22and CART19 treated mice, while UTD mice rapidly progressed (FIG. 37B).

FIGS. 38A, 38B, and 38C are a series of images showing tissuemicroarrays for CD22 expression on 28 human normal tissues byimmunohistochemistry staining. Lymphoid organs resulted positive forCD22 expression (tonsil, lymph node, spleen and thymus) (FIG. 38A).Non-lymphoid organs showed no expression of CD22 (FIG. 38B).CD22-positive resident B-cells were observed in multiple tissues (FIG.38C). *=non-specific staining.

FIGS. 39A, 39B, 39C and 39D are a graph showing CD22 RNA-expression datafrom GeneAtlas U133A. CD22 expression was observed at high level inB-cells, tonsil and lymph node. B-lymphoblast and leukemia/lymphoma celllines were also highly positive.

FIG. 40 is a series of graphs showing a 51-Chromium-release assay forCART22 toxicity. Both CART22 and CART19 but not UTD cells triggered thelysis of the ALL cell line NALM-6. No cytotoxic effect of CART22 wasobserved in any normal tissue (CD34+, human neuronal progenitors orneurons and keratinocytes) or control (K562 cell line).

FIG. 41 shows a graphical representation of CAR expression in JNL cellstransduced with anti-CD123 CAR constructs as evaluated by FACS andreported as the percent of cells showing signal above the level ofsignal in untransduced (CAR negative) cells using Protein L as adetection reagent.

FIGS. 42A, 42B, and 42C show graphical representations of CD123 CARactivity in JNL cells. Anti-CD123 CAR constructs were evaluated foractivity using a Jurkat cell line containing the luciferase reporterdriven by the NFAT promoter (termed JNL cells). CAR activity is measuredas activation of this NFAT-driven reporter.

FIGS. 43A and 43B show CD123 expressing and activity. FIG. 43A shows agraphical representation of CD123 CAR expression in primary T-cells.Percentage of cells transduced (expressing the anti-CD123 CAR on thecell surface) and their relative fluorescence intensity of expressionwere determined by flow cytometric analysis on a BD LSRFortessa orBD-FACSCanto using Protein L as a detection reagent. Gating histogramplots of relative fluorescent intensity from that FACS for signal aboveunstained cells shows the percentage of transduced T cells. Transductionresulted in a range of CAR positive cells from 12-42%. FIG. 43B shows agraphical representation of CD123-CART-mediated cell killing. T cellkilling was directed towards CD123-expressing MOLM13 acute myelogenousleukemia cells stably expressing luciferase. Untransduced T cells wereused to determine non-specific background killing levels. The cytolyticactivities of CART-CD123 were measured over a range of effector:targetcell ratios of 4:1 and 2-fold downward dilutions of T cells whereeffectors were defined as T cells expressing the anti-CD123 chimericreceptor. Assays were initiated by mixing an appropriate number of Tcells with a constant number of targets cells. After 20 hours luciferasesignal was measured using the Bright-Glo™ Luciferase Assay on theEnVision instrument.

FIGS. 44A and 44B show transduction efficiency of T cells withCD123-CARs. FIG. 44A shows transduction efficiency of T cells with 1172and 1176. FIG. 44B shows transduction efficiency of T cells with CD123CARs 2-4.

FIG. 45 shows flow cytometry of CD123 CARs 2-4 and 1172 and 1176 todetermine the CD4:CD8 ratio.

FIGS. 46A, 46B and 46C show degranulation of CD123 CARs 2-4 and 1172 and1176 upon exposure to CD123+ tumor cells.

FIG. 47 shows a graphical representation of a luciferase assay to assesscytotoxicity of CART cells (NVS 2-4, 1172 and 1176 clones) towards tumortarget cells (MOLM14).

FIG. 48 shows a comparison of tumor burden in NSG mice injected withluciferase expressing MOLM14 cells at D6 (before CART injection) and atday 13 (6 days post injection with NVS 2-4, 1172 or 1176 clones) or atday 20.

FIGS. 49A, 49B, 49C, 49D, 49E, and 49F show CD123 is highly expressed inCD19-neg B-cell acute lymphoblastic leukemia relapses occurring afterCART19 treatment. FIG. 49A shows expression of CD123 compared to CD19 in42 relapsing/refractory ALL samples. FIG. 49B shows CD123 and CD19co-expression in B-ALL blasts. Gated on blasts (SSC low, singlet, live,CD45dim). FIG. 49C shows the gating strategy for the leukemia stem cell(LSC). CD123 is highly expressed in this subset. FIG. 49D shows CD123and CD19 co-expression and results from FISH analysis. FIGS. 49E and 49Fshow the comparison of CD19 and CD123 expression at baseline or afterrelapse.

FIGS. 50A, 50B, 50C, 50D, 50E, and 50F shows results from various invitro assays using T cells expressing a CD19 CAR (CAR19) or a CD123 CAR(CAR123). FIG. 50A shows CD19 and CD123 expression; FIG. 50B shows aCD107a degranulation assay; FIG. 50C shows the capability for targetedcell killing; FIGS. 50D and 50E shows proliferation capacity; FIG. 50Fshows cytokine production for the indicated cytokines.

FIGS. 51A, 51B, and 51C show that CART cells expressing CD19 CAR (CAR19)or CD123 CAR (CAR123) had an anti-tumor effect in an in vivo mousemodel. FIG. 51A shows the tumor burden represented by bioluminescentimaging; FIG. 51B shows the overall survival curve of mice receivingCART therapy; and FIG. 51C shows the expansion of CART123 cells in theperipheral blood.

FIGS. 52A, 52B, 52C, 52D, 52E, and 52F show that CART123 is active in anin vivo mouse model of antigen-loss relapse. FIG. 52A shows theexperimental schema; FIG. 52B shows disease progression as representedby bioluminescent imaging in baseline and relapse disease with respectto CD19 expression (top graph) and in response to treatment with CART19therapy (bottom graph); FIG. 52C shows bioluminescent images of miceadministered untransduced T cells or CART19 cells; FIG. 52D shows theexperimental schema for treating with CART19 or CART123; FIG. 52E showsthe disease progression; and FIG. 52F shows the overall survival of thetreated mice.

FIGS. 53A, 53B, and 53C show ALL-CART interactions in skull bone marrowof xenograft mice. FIG. 53A shows the experimental schema; FIG. 53Bshows representative multiphoton XY plane images of CART19 cells andCART123 cells interacting with ALL tumor engineered to express eitherCD19 and CD123 or CD123 alone (motile cells are indicated in dashedcircles, non-motile cells are indicated with the arrows); and FIG. 53Cis a graphic representation of the microscopy images.

FIGS. 54A, 54B, and 54C show the prevention of CD19-neg relapses usingCART19 and CART123. FIG. 54A shows the experimental schema; FIG. 54Bshows the disease progression (tumor burden as represented by BLI) ofmice treated with untransduced T cells (top graph), CART19 (middlegraph), or the combination of CART19 and CART123 (bottom graph); andFIG. 54C shows the overall survival from this experiment.

FIGS. 55A and 55B, show T cells expressing both CAR19 and CAR123 (FIG.55A) and the results from a degranulation assay (FIG. 55B).

FIGS. 56A and 56B show characterization of ALL blasts. FIG. 56A showsexpression of various markers CD19, CD123, CD10, CD34, and CD20; andFIG. 56B shows the gating strategy for sorting CD19−CD123+ cells.

FIGS. 57A, 57B, 57C, and 57D show anti-leukemia activity of CART123.FIG. 57A shows the expression of CD19 and CD123 on the NALM6 cells; FIG.57B shows the tumor burden (as represented by BLI) in response to CART19or CART123 therapy; FIG. 57C shows the overall survival of miceadministered CART19 or CART123; and FIG. 57D shows the overall survivalof mice administered varying doses of CART123.

FIGS. 58A and 58B show the characterization of the in vivo model ofantigen-loss relapse. FIG. 58A shows the expression of CD123 in CD19negative relapse disease; and FIG. 58B shows the degranulation assay ofCART19 or CART123 cells when cultured with baseline or relapse cells invitro.

FIG. 59 shows that the proliferation of CAR-expressing, transduced Tcells is enhanced by low doses of RAD001 in a cell culture system. CARTswere co-cultured with NALM6 (Nalm-6) cells in the presence of differentconcentrations of RAD001 (nM). The number of CAR-positive CD3-positive Tcells (black) and total T cells (white) was assessed after 4 days ofco-culture.

FIG. 60 depicts tumor growth measurements of NALM6-luc cells with dailyRAD001 dosing at 0.3, 1, 3, and 10 mg/kg (mpk) or vehicle dosing.Circles denote the vehicle; squares denote the 10 mg/kg dose of RAD001;triangles denote the 3 mg/kg dose of RAD001, inverted triangles denotethe 1 mg/kg dose of RAD001; and diamonds denote the 0.3 mg/kg dose ofRAD001.

FIGS. 61A and 61B show pharmacokinetic curves showing the amount ofRAD001 in the blood of NSG mice with NALM6 tumors. FIG. 61A shows day 0PK following the first dose of RAD001. FIG. 61B shows Day 14 PKfollowing the final RAD001 dose. Diamonds denote the 10 mg/kg dose ofRAD001; squares denote the 1 mg/kg dose of RAD001; triangles denote the3 mg/kg dose of RAD001; and x's denote the 10 mg/kg dose of RAD001.

FIGS. 62A and 62B show in vivo proliferation of humanized CD19 CARTcells with and without RAD001 dosing. Low doses of RAD001 (0.003 mg/kg)daily lead to an enhancement in CAR T cell proliferation, above thenormal level of huCAR19 proliferation. FIG. 62A shows CD4+ CAR T cells;FIG. 62B shows CD8+ CAR T cells. Circles denote PBS; squares denotehuCTL019; triangles denote huCTL019 with 3 mg/kg RAD001; invertedtriangles denote huCTL019 with 0.3 mg/kg RAD001; diamonds denotehuCTL019 with 0.03 mg/kg RAD001; and circles denote huCTL019 with 0.003mg/kg RAD001.

FIG. 63 shows multiplex FIHC AQUA analysis showing significantdifference between CD3+/PD-1+ cell populations in primary and secondaryhuman DLBCL patient samples.

FIG. 64 shows AQUA analysis showing various levels of CD19 (lower panel)and PD-L1 (upper panel) in primary and secondary sites of DLBCL samples.A total of 40 human DLBCL patient samples, 25 primary and 15 secondarysites, were subjected to multiplex FIHC and followed by AQUA analysis toidentify expression levels of CD19 and PD-L1 proteins.

FIG. 65 shows a schematic of two populations of CAR-expressing cells. Inthe population on the left (pooled), each cell expresses one type ofCAR. In the population on the right (bicistronic CAR), each cellexpresses two types of CAR.

FIG. 66 shows diagrams of bicistronic CARs. The upper CAR has a CD19 CARand a CD22 CAR, separated by a P2A protease cleavage site. The lower CARhas a CD19 CAR and a CD123 CAR, separated by a P2A protease cleavagesite.

FIG. 67 shows co-expression of CD19 and CD22 CARs from a bicistronicvector.

FIG. 68A shows co-expression of CD19 and CD123 CARs from a bicistronicvector.

FIG. 68B shows the anti-leukemic effect of these cells.

FIG. 69 shows the tumor burden in mice bearing CD19-negative B-ALLxenografts after treatment with a UTD control, CART19, or CART22.

FIG. 70 shows the expression of PD-L1, PD1, LAG3, and TIM3 (from left toright in each set of four bars) in lymph node and bone marrow samplesfrom five CR patients, one unclassified patient, and six PD patients.

FIG. 71 is a graph showing the activation (in RLU) of several CD22 CARconstructs in the presence and absence of a m971 competitor.

FIG. 72 is a graph showing the activation (in RLU) of additional CD22CAR constructs.

FIG. 73 shows three bar graphs indicating CD22 CAR activity in anIFN-gamma assay.

FIG. 74 shows binding activity of CD22-64 and CD22-65 CARs.

FIG. 75 is a diagram mapping the epitopes bound by various CD22 scFvs.

DETAILED DESCRIPTION Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the invention pertains.

The term “a” and “an” refers to one or to more than one (i.e., to atleast one) of the grammatical object of the article. By way of example,“an element” means one element or more than one element.

The term “about” when referring to a measurable value such as an amount,a temporal duration, and the like, is meant to encompass variations of±20% or in some instances ±10%, or in some instances ±5%, or in someinstances ±1%, or in some instances ±0.1% from the specified value, assuch variations are appropriate to perform the disclosed methods.

The term “apheresis” as used herein refers to the art-recognizedextracorporeal process by which the blood of a donor or patient isremoved from the donor or patient and passed through an apparatus thatseparates out selected particular constituent(s) and returns theremainder to the circulation of the donor or patient, e.g., byretransfusion. Thus, “an apheresis sample” refers to a sample obtainedusing apheresis.

The term “bioequivalent” refers to an amount of an agent other than thereference compound (e.g., RAD001), required to produce an effectequivalent to the effect produced by the reference dose or referenceamount of the reference compound (e.g., RAD001). In an embodiment theeffect is the level of mTOR inhibition, e.g., as measured by P70 S6kinase inhibition, e.g., as evaluated in an in vivo or in vitro assay,e.g., as measured by an assay described herein, e.g., the Boulay assay,or measurement of phosphorylated S6 levels by western blot. In anembodiment, the effect is alteration of the ratio of PD-1 positive/PD-1negative T cells, as measured by cell sorting. In an embodiment abioequivalent amount or dose of an mTOR inhibitor is the amount or dosethat achieves the same level of P70 S6 kinase inhibition as does thereference dose or reference amount of a reference compound. In anembodiment, a bioequivalent amount or dose of an mTOR inhibitor is theamount or dose that achieves the same level of alteration in the ratioof PD-1 positive/PD-1 negative T cells as does the reference dose orreference amount of a reference compound.

The term “inhibition” or “inhibitor” includes a reduction in a certainparameter, e.g., an activity, of a given molecule, e.g., CD20, CD10,CD19, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. Forexample, inhibition of an activity, e.g., an activity of CD20, CD10,CD19, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a, of atleast 5%, 10%, 20%, 30%, 40%, or more is included by this term. Thus,inhibition need not be 100%. Activities for the inhibitors can bedetermined as described herein or by assays known in the art. A “B-cellinhibitor” is a molecule, e.g., a small molecule, antibody, CAR or cellcomprising a CAR, which causes the reduction in a certain parameter,e.g., an activity, e.g., growth or proliferation, of a B-cell, or whichcauses a reduction in a certain parameter, e.g., an activity, of amolecule associated with a B cell. Non-limiting examples of moleculesassociated with a B cell include proteins expressed on the surface of Bcells, e.g., CD20, CD10, CD19, CD22, CD34, CD123, FLT-3, ROR1, CD79b,CD179b, or CD79a.

The term “Chimeric Antigen Receptor” or alternatively a “CAR” refers toa set of polypeptides, typically two in the simplest embodiments, whichwhen in an immune effector cell, provides the cell with specificity fora target cell, typically a cancer cell, and with intracellular signalgeneration. In some embodiments, a CAR comprises at least anextracellular antigen binding domain, a transmembrane domain and acytoplasmic signaling domain (also referred to herein as “anintracellular signaling domain”) comprising a functional signalingdomain derived from a stimulatory molecule and/or costimulatory moleculeas defined below. In some embodiments, the set of polypeptides are inthe same polypeptide chain, e.g., comprise a chimeric fusion protein. Insome embodiments, the set of polypeptides are not contiguous with eachother, e.g., are in different polypeptide chains. In some embodiments,the set of polypeptides include a dimerization switch that, upon thepresence of a dimerization molecule, can couple the polypeptides to oneanother, e.g., can couple an antigen binding domain to an intracellularsignaling domain. In one aspect, the stimulatory molecule of the CAR isthe zeta chain associated with the T cell receptor complex (e.g., CD3zeta). In one aspect, the cytoplasmic signaling domain comprises aprimary signaling domain (e.g., a primary signaling domain of CD3-zeta).In one aspect, the cytoplasmic signaling domain further comprises one ormore functional signaling domains derived from at least onecostimulatory molecule as defined below. In one aspect, thecostimulatory molecule is chosen from the costimulatory moleculesdescribed herein, e.g., 4-1BB (i.e., CD137), CD27, and/or CD28. In oneaspect, the CAR comprises a chimeric fusion protein comprising anextracellular antigen binding domain, a transmembrane domain and anintracellular signaling domain comprising a functional signaling domainderived from a stimulatory molecule. In one aspect, the CAR comprises achimeric fusion protein comprising an extracellular antigen bindingdomain, a transmembrane domain and an intracellular signaling domaincomprising a functional signaling domain derived from a costimulatorymolecule and a functional signaling domain derived from a stimulatorymolecule. In one aspect, the CAR comprises a chimeric fusion proteincomprising an extracellular antigen binding domain, a transmembranedomain and an intracellular signaling domain comprising two functionalsignaling domains derived from one or more costimulatory molecule(s) anda functional signaling domain derived from a stimulatory molecule. Inone aspect, the CAR comprises a chimeric fusion protein comprising anextracellular antigen binding domain, a transmembrane domain and anintracellular signaling domain comprising at least two functionalsignaling domains derived from one or more costimulatory molecule(s) anda functional signaling domain derived from a stimulatory molecule. Inone aspect the CAR comprises an optional leader sequence at theamino-terminus (N-ter) of the CAR fusion protein. In one aspect, the CARfurther comprises a leader sequence at the N-terminus of theextracellular antigen binding domain, wherein the leader sequence isoptionally cleaved from the antigen binding domain (e.g., a scFv) duringcellular processing and localization of the CAR to the cellularmembrane.

The phrase “disease associated with expression of CD20” as used hereinincludes but is not limited to, a disease associated with expression ofCD20 (e.g., wild-type or mutant CD20) or condition associated with cellswhich express, or at any time expressed, CD20 (e.g., wild-type or mutantCD20) including, e.g., a proliferative disease such as a cancer ormalignancy or a precancerous condition such as a myelodysplasia, amyelodysplastic syndrome or a preleukemia; or a noncancer relatedindication associated with cells which express CD20 (e.g., wild-type ormutant CD20). For the avoidance of doubt, a disease associated withexpression of CD20 may include a condition associated with cells whichdo not presently express CD20, e.g., because CD20 expression has beendownregulated, e.g., due to treatment with a molecule targeting CD20,e.g., a CD20 CAR, but which at one time expressed CD20. In one aspect, acancer associated with expression of CD20 is a hematological cancer. Inone aspect, a hematological cancer includes but is not limited to AML,myelodysplastic syndrome, ALL, hairy cell leukemia, Prolymphocyticleukemia, Chronic myeloid leukemia, Hodgkin lymphoma, Blasticplasmacytoid dendritic cell neoplasm, and the like. Further diseaseassociated with expression of CD20 expression include, but are notlimited to, e.g., atypical and/or non-classical cancers, malignancies,precancerous conditions or proliferative diseases associated withexpression of CD20. Non-cancer related indications associated withexpression of CD20 may also be included. In some embodiments, theCD20-expressing cells express, or at any time expressed, CD20 mRNA. Inan embodiment, the CD20-expressing cells produce a CD20 protein (e.g.,wild-type or mutant), and the CD20 protein may be present at normallevels or reduced levels. In an embodiment, the CD20-expressing cellsproduced detectable levels of a CD20 protein at one point, andsubsequently produced substantially no detectable CD20 protein.

The phrase “disease associated with expression of CD22” as used hereinincludes but is not limited to, a disease associated with expression ofCD22 (e.g., wild-type or mutant CD22) or condition associated with cellswhich express, or at any time expressed, CD22 (e.g., wild-type or mutantCD22) including, e.g., a proliferative disease such as a cancer ormalignancy or a precancerous condition such as a myelodysplasia, amyelodysplastic syndrome or a preleukemia; or a noncancer relatedindication associated with cells which express CD22 (e.g., wild-type ormutant CD22). For the avoidance of doubt, a disease associated withexpression of CD22 may include a condition associated with cells whichdo not presently express CD22, e.g., because CD22 expression has beendownregulated, e.g., due to treatment with a molecule targeting CD22,e.g., a CD22 CAR, but which at one time expressed CD22. In one aspect, acancer associated with expression of CD22 is a hematological cancer. Inone aspect, a hematological cancer includes but is not limited to AML,myelodysplastic syndrome, ALL, hairy cell leukemia, Prolymphocyticleukemia, Chronic myeloid leukemia, Hodgkin lymphoma, Blasticplasmacytoid dendritic cell neoplasm, and the like. Further diseaseassociated with expression of CD22 expression include, but are notlimited to, e.g., atypical and/or non-classical cancers, malignancies,precancerous conditions or proliferative diseases associated withexpression of CD22. Non-cancer related indications associated withexpression of CD22 may also be included. In some embodiments, theCD22-expressing cells express, or at any time expressed, CD22 mRNA. Inan embodiment, the CD22-expressing cells produce a CD22 protein (e.g.,wild-type or mutant), and the CD22 protein may be present at normallevels or reduced levels. In an embodiment, the CD22-expressing cellsproduced detectable levels of a CD22 protein at one point, andsubsequently produced substantially no detectable CD22 protein.

As used herein, unless otherwise specified, the terms “prevent,”“preventing” and “prevention” refer to an action that occurs before thesubject begins to suffer from the condition, or relapse of thecondition. Prevention need not result in a complete prevention of thecondition; partial prevention or reduction of the condition or a symptomof the condition, or reduction of the risk of developing the condition,is encompassed by this term.

Administered “in combination”, as used herein, means that two (or more)different treatments are delivered to the subject during the course ofthe subject's affliction with the disorder, e.g., the two or moretreatments are delivered after the subject has been diagnosed with thedisorder and before the disorder has been cured or eliminated ortreatment has ceased for other reasons. In some embodiments, thedelivery of one treatment is still occurring when the delivery of thesecond begins, so that there is overlap in terms of administration. Thisis sometimes referred to herein as “simultaneous” or “concurrentdelivery”. In other embodiments, the delivery of one treatment endsbefore the delivery of the other treatment begins. In some embodimentsof either case, the treatment is more effective because of combinedadministration. For example, the second treatment is more effective,e.g., an equivalent effect is seen with less of the second treatment, orthe second treatment reduces symptoms to a greater extent, than would beseen if the second treatment were administered in the absence of thefirst treatment, or the analogous situation is seen with the firsttreatment. In some embodiments, delivery is such that the reduction in asymptom, or other parameter related to the disorder is greater than whatwould be observed with one treatment delivered in the absence of theother. The effect of the two treatments can be partially additive,wholly additive, or greater than additive. The delivery can be such thatan effect of the first treatment delivered is still detectable when thesecond is delivered. In one embodiment, the CAR-expressing cell isadministered at a dose and/or dosing schedule described herein, and theB-cell inhibitor, or agent that enhances the activity of the CD19CAR-expressing cell is administered at a dose and/or dosing scheduledescribed herein.

“Derived from” as that term is used herein, indicates a relationshipbetween a first and a second molecule. It generally refers to structuralsimilarity between the first molecule and a second molecule and does notconnote or include a process or source limitation on a first moleculethat is derived from a second molecule. For example, in the case of anintracellular signaling domain that is derived from a CD3zeta molecule,the intracellular signaling domain retains sufficient CD3zeta structuresuch that is has the required function, namely, the ability to generatea signal under the appropriate conditions. It does not connote orinclude a limitation to a particular process of producing theintracellular signaling domain, e.g., it does not mean that, to providethe intracellular signaling domain, one must start with a CD3zetasequence and delete unwanted sequence, or impose mutations, to arrive atthe intracellular signaling domain.

The term “signaling domain” refers to the functional portion of aprotein which acts by transmitting information within the cell toregulate cellular activity via defined signaling pathways by generatingsecond messengers or functioning as effectors by responding to suchmessengers.

As used herein, the term “CD19” refers to the Cluster of Differentiation19 protein, which is an antigenic determinant detectable on leukemiaprecursor cells. The human and murine amino acid and nucleic acidsequences can be found in a public database, such as GenBank, UniProtand Swiss-Prot. For example, the amino acid sequence of human CD19 canbe found as UniProt/Swiss-Prot Accession No. P15391 and the nucleotidesequence encoding of the human CD19 can be found at Accession No. NM001178098. As used herein, “CD19” includes proteins comprisingmutations, e.g., point mutations, fragments, insertions, deletions andsplice variants of full length wild-type CD19. CD19 is expressed on mostB lineage cancers, including, e.g., acute lymphoblastic leukemia,chronic lymphocyte leukemia and non-Hodgkin lymphoma. Other cells withexpress CD19 are provided below in the definition of “disease associatedwith expression of CD19.” It is also an early marker of B cellprogenitors. See, e.g., Nicholson et al. Mol. Immun. 34 (16-17):1157-1165 (1997). In one aspect the antigen-binding portion of the CARTrecognizes and binds an antigen within the extracellular domain of theCD19 protein. In one aspect, the CD19 protein is expressed on a cancercell.

The term “antibody,” as used herein, refers to a protein, or polypeptidesequence derived from an immunoglobulin molecule which specificallybinds with an antigen. Antibodies can be polyclonal or monoclonal,multiple or single chain, or intact immunoglobulins, and may be derivedfrom natural sources or from recombinant sources. Antibodies can betetramers of immunoglobulin molecules.

The term “antibody fragment” refers to at least one portion of anantibody, that retains the ability to specifically interact with (e.g.,by binding, steric hindrance, stabilizing/destabilizing, spatialdistribution) an epitope of an antigen. Examples of antibody fragmentsinclude, but are not limited to, Fab, Fab′, F(ab′)₂, Fv fragments, scFvantibody fragments, disulfide-linked Fvs (sdFv), a Fd fragmentconsisting of the VH and CH1 domains, linear antibodies, single domainantibodies such as sdAb (either VL or VH), camelid VHH domains,multi-specific antibodies formed from antibody fragments such as abivalent fragment comprising two Fab fragments linked by a disulfidebridge at the hinge region, and an isolated CDR or other epitope bindingfragments of an antibody. An antigen binding fragment can also beincorporated into single domain antibodies, maxibodies, minibodies,nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR andbis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology23:1126-1136, 2005). Antigen binding fragments can also be grafted intoscaffolds based on polypeptides such as a fibronectin type III (Fn3)(seeU.S. Pat. No. 6,703,199, which describes fibronectin polypeptideminibodies).

The term “scFv” refers to a fusion protein comprising at least oneantibody fragment comprising a variable region of a light chain and atleast one antibody fragment comprising a variable region of a heavychain, wherein the light and heavy chain variable regions arecontiguously linked, e.g., via a synthetic linker, e.g., a shortflexible polypeptide linker, and capable of being expressed as a singlechain polypeptide, and wherein the scFv retains the specificity of theintact antibody from which it is derived. Unless specified, as usedherein an scFv may have the VL and VH variable regions in either order,e.g., with respect to the N-terminal and C-terminal ends of thepolypeptide, the scFv may comprise VL-linker-VH or may compriseVH-linker-VL.

The term “complementarity determining region” or “CDR,” as used herein,refers to the sequences of amino acids within antibody variable regionswhich confer antigen specificity and binding affinity. For example, ingeneral, there are three CDRs in each heavy chain variable region (e.g.,HCDR1, HCDR2, and HCDR3) and three CDRs in each light chain variableregion (LCDR1, LCDR2, and LCDR3). The precise amino acid sequenceboundaries of a given CDR can be determined using any of a number ofwell-known schemes, including those described by Kabat et al. (1991),“Sequences of Proteins of Immunological Interest,” 5th Ed. Public HealthService, National Institutes of Health, Bethesda, MD (“Kabat” numberingscheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numberingscheme), or a combination thereof. Under the Kabat numbering scheme, insome embodiments, the CDR amino acid residues in the heavy chainvariable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and95-102 (HCDR3); and the CDR amino acid residues in the light chainvariable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and89-97 (LCDR3). Under the Chothia numbering scheme, in some embodiments,the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2),and 95-102 (HCDR3); and the CDR amino acid residues in the VL arenumbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). In a combinedKabat and Chothia numbering scheme, in some embodiments, the CDRscorrespond to the amino acid residues that are part of a Kabat CDR, aChothia CDR, or both. For instance, in some embodiments, the CDRscorrespond to amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and95-102 (HCDR3) in a VH, e.g., a mammalian VH, e.g., a human VH; andamino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in aVL, e.g., a mammalian VL, e.g., a human VL.

As used herein, the term “binding domain” or “antibody molecule” refersto a protein, e.g., an immunoglobulin chain or fragment thereof,comprising at least one immunoglobulin variable domain sequence. Theterm “binding domain” or “antibody molecule” encompasses antibodies andantibody fragments. In an embodiment, an antibody molecule is amultispecific antibody molecule, e.g., it comprises a plurality ofimmunoglobulin variable domain sequences, wherein a first immunoglobulinvariable domain sequence of the plurality has binding specificity for afirst epitope and a second immunoglobulin variable domain sequence ofthe plurality has binding specificity for a second epitope. In anembodiment, a multispecific antibody molecule is a bispecific antibodymolecule. A bispecific antibody has specificity for no more than twoantigens. A bispecific antibody molecule is characterized by a firstimmunoglobulin variable domain sequence which has binding specificityfor a first epitope and a second immunoglobulin variable domain sequencethat has binding specificity for a second epitope.

The portion of the CAR of the invention comprising an antibody orantibody fragment thereof may exist in a variety of forms where theantigen binding domain is expressed as part of a contiguous polypeptidechain including, for example, a single domain antibody fragment (sdAb),a single chain antibody (scFv), a humanized antibody, or bispecificantibody (Harlow et al., 1999, In: Using Antibodies: A LaboratoryManual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989,In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York;Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird etal., 1988, Science 242:423-426). In one aspect, the antigen bindingdomain of a CAR composition of the invention comprises an antibodyfragment. In a further aspect, the CAR comprises an antibody fragmentthat comprises a scFv.

The term “antibody heavy chain,” refers to the larger of the two typesof polypeptide chains present in antibody molecules in their naturallyoccurring conformations, and which normally determines the class towhich the antibody belongs.

The term “antibody light chain,” refers to the smaller of the two typesof polypeptide chains present in antibody molecules in their naturallyoccurring conformations. Kappa (κ) and lambda (λ) light chains refer tothe two major antibody light chain isotypes.

The term “recombinant antibody” refers to an antibody which is generatedusing recombinant DNA technology, such as, for example, an antibodyexpressed by a bacteriophage or yeast expression system. The term shouldalso be construed to mean an antibody which has been generated by thesynthesis of a DNA molecule encoding the antibody and which DNA moleculeexpresses an antibody protein, or an amino acid sequence specifying theantibody, wherein the DNA or amino acid sequence has been obtained usingrecombinant DNA or amino acid sequence technology which is available andwell known in the art.

The term “antigen” or “Ag” refers to a molecule that provokes an immuneresponse. This immune response may involve either antibody production,or the activation of specific immunologically-competent cells, or both.The skilled artisan will understand that any macromolecule, includingvirtually all proteins or peptides, can serve as an antigen.Furthermore, antigens can be derived from recombinant or genomic DNA. Askilled artisan will understand that any DNA, which comprises anucleotide sequences or a partial nucleotide sequence encoding a proteinthat elicits an immune response therefore encodes an “antigen” as thatterm is used herein. Furthermore, one skilled in the art will understandthat an antigen need not be encoded solely by a full length nucleotidesequence of a gene. It is readily apparent that the present inventionincludes, but is not limited to, the use of partial nucleotide sequencesof more than one gene and that these nucleotide sequences are arrangedin various combinations to encode polypeptides that elicit the desiredimmune response. Moreover, a skilled artisan will understand that anantigen need not be encoded by a “gene” at all. It is readily apparentthat an antigen can be generated synthesized or can be derived from abiological sample, or might be macromolecule besides a polypeptide. Sucha biological sample can include, but is not limited to a tissue sample,a tumor sample, a cell or a fluid with other biological components.

The terms “compete” or “cross-compete” are used interchangeably hereinto refer to the ability of an antibody molecule to interfere withbinding of an antibody molecule, e.g., an anti-CD20 or CD22 antibodymolecule provided herein, to a target, e.g., human CD20 or CD22. Theinterference with binding can be direct or indirect (e.g., through anallosteric modulation of the antibody molecule or the target). Theextent to which an antibody molecule is able to interfere with thebinding of another antibody molecule to the target, and thereforewhether it can be said to compete, can be determined using a competitionbinding assay, e.g., as described herein. In some embodiments, acompetition binding assay is a quantitative competition assay. In someembodiments, a first antibody molecule is said to compete for binding tothe target with a second antibody molecule when the binding of the firstantibody molecule to the target is reduced by 10% or more, e.g., 20% ormore, 30% or more, 40% or more, 50% or more, 55% or more, 60% or more,65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% ormore, 95% or more, 98% or more, 99% or more in a competition bindingassay (e.g., a competition assay described herein).

As used herein, the term “epitope” refers to the moieties of an antigen(e.g., human CD20 or CD22) that specifically interact with an antibodymolecule. Such moieties, referred to herein as epitopic determinants,typically comprise, or are part of, elements such as amino acid sidechains or sugar side chains. An epitopic determinate can be defined,e.g., by methods known in the art or disclosed herein, e.g., bycrystallography or by hydrogen-deuterium exchange. At least one or someof the moieties on the antibody molecule, that specifically interactwith an epitopic determinant, are typically located in a CDR(s).Typically an epitope has a specific three dimensional structuralcharacteristics. Typically an epitope has specific chargecharacteristics. Some epitopes are linear epitopes while others areconformational epitopes.

The term “anti-cancer effect” refers to a biological effect which can bemanifested by various means, including but not limited to, e.g., adecrease in tumor volume, a decrease in the number of cancer cells, adecrease in the number of metastases, an increase in life expectancy,decrease in cancer cell proliferation, decrease in cancer cell survival,or amelioration of various physiological symptoms associated with thecancerous condition. An “anti-cancer effect” can also be manifested bythe ability of the peptides, polynucleotides, cells and antibodiesdescribed herein in prevention of the occurrence of cancer in the firstplace. The term “anti-tumor effect” refers to a biological effect whichcan be manifested by various means, including but not limited to, e.g.,a decrease in tumor volume, a decrease in the number of tumor cells, adecrease in tumor cell proliferation, or a decrease in tumor cellsurvival.

The term “autologous” refers to any material derived from the sameindividual to whom it is later to be re-introduced into the individual.

The term “allogeneic” refers to any material derived from a differentanimal of the same species as the individual to whom the material isintroduced. Two or more individuals are said to be allogeneic to oneanother when the genes at one or more loci are not identical. In someaspects, allogeneic material from individuals of the same species may besufficiently unlike genetically to interact antigenically

The term “xenogeneic” refers to a graft derived from an animal of adifferent species.

The term “cancer” refers to a disease characterized by the uncontrolledgrowth of aberrant cells. Cancer cells can spread locally or through thebloodstream and lymphatic system to other parts of the body. Examples ofvarious cancers are described herein and include but are not limited to,breast cancer, prostate cancer, ovarian cancer, cervical cancer, skincancer, pancreatic cancer, colorectal cancer, renal cancer, livercancer, brain cancer, lymphoma, leukemia, lung cancer and the like. Theterms “tumor” and “cancer” are used interchangeably herein, e.g., bothterms encompass solid and liquid, e.g., diffuse or circulating, tumors.As used herein, the term “cancer” or “tumor” includes premalignant, aswell as malignant cancers and tumors.

The terms “cancer associated antigen” or “tumor antigen” or“proliferative disorder antigen” or “antigen associated with aproliferative disorder” interchangeably refers to a molecule (typicallyprotein, carbohydrate or lipid) that is preferentially expressed on thesurface of a cancer cell, either entirely or as a fragment (e.g.,MHC/peptide), in comparison to a normal cell, and which is useful forthe preferential targeting of a pharmacological agent to the cancercell. In some embodiments, a tumor antigen is a marker expressed by bothnormal cells and cancer cells, e.g., a lineage marker, e.g., CD19 on Bcells. In certain aspects, the tumor antigens of the present inventionare derived from, cancers including but not limited to primary ormetastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, livercancer, non-Hodgkin lymphoma, Hodgkin lymphoma, leukemias, uterinecancer, cervical cancer, bladder cancer, kidney cancer andadenocarcinomas such as breast cancer, prostate cancer, ovarian cancer,pancreatic cancer, and the like. In some embodiments, the tumor antigenis an antigen that is common to a specific proliferative disorder. Insome embodiments, a cancer-associated antigen is a cell surface moleculethat is overexpressed in a cancer cell in comparison to a normal cell,for instance, 1-fold over expression, 2-fold overexpression, 3-foldoverexpression or more in comparison to a normal cell. In someembodiments, a cancer-associated antigen is a cell surface molecule thatis inappropriately synthesized in the cancer cell, for instance, amolecule that contains deletions, additions or mutations in comparisonto the molecule expressed on a normal cell. In some embodiments, acancer-associated antigen will be expressed exclusively on the cellsurface of a cancer cell, entirely or as a fragment (e.g., MHC/peptide),and not synthesized or expressed on the surface of a normal cell. Insome embodiments, the CARs of the present invention includes CARscomprising an antigen binding domain (e.g., antibody or antibodyfragment) that binds to a MHC presented peptide. Normally, peptidesderived from endogenous proteins fill the pockets of Majorhistocompatibility complex (MHC) class I molecules, and are recognizedby T cell receptors (TCRs) on CD8+ T lymphocytes. The MHC class Icomplexes are constitutively expressed by all nucleated cells. Incancer, virus-specific and/or tumor-specific peptide/MHC complexesrepresent a unique class of cell surface targets for immunotherapy.TCR-like antibodies targeting peptides derived from viral or tumorantigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2have been described (see, e.g., Sastry et al., J Virol. 201185(5):1935-1942; Sergeeva et al., Blood, 2011 117(16):4262-4272; Vermaet al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther2001 8(21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33;Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example,TCR-like antibody can be identified from screening a library, such as ahuman scFv phage displayed library.

The phrase “disease associated with expression of CD19” includes, but isnot limited to, a disease associated with expression of CD19 (e.g.,wild-type or mutant CD19) or condition associated with cells whichexpress, or at any time expressed, CD19 (e.g., wild-type or mutant CD19)including, e.g., proliferative diseases such as a cancer or malignancyor a precancerous condition such as a myelodysplasia, a myelodysplasticsyndrome or a preleukemia; or a noncancer related indication associatedwith cells which express CD19. For the avoidance of doubt, a diseaseassociated with expression of CD19 may include a condition associatedwith cells which do not presently express CD19, e.g., because CD19expression has been downregulated, e.g., due to treatment with amolecule targeting CD19, e.g., a CD19 CAR, but which at one timeexpressed CD19. In one aspect, a cancer associated with expression ofCD19 is a hematological cancer. In one aspect, the hematological canceris a leukemia or a lymphoma. In one aspect, a cancer associated withexpression of CD19 includes cancers and malignancies including, but notlimited to, e.g., one or more acute leukemias including but not limitedto, e.g., B-cell acute Lymphoid Leukemia (BALL), T-cell acute LymphoidLeukemia (TALL), acute lymphoid leukemia (ALL); one or more chronicleukemias including but not limited to, e.g., chronic myelogenousleukemia (CIVIL), Chronic Lymphoid Leukemia (CLL). Additional cancers orhematologic conditions associated with expression of CD19 comprise, butare not limited to, e.g., B cell prolymphocytic leukemia, blasticplasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse largeB cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell-or a large cell-follicular lymphoma, malignant lymphoproliferativeconditions, MALT lymphoma, mantle cell lymphoma (MCL), Marginal zonelymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome,non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma,plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and“preleukemia” which are a diverse collection of hematological conditionsunited by ineffective production (or dysplasia) of myeloid blood cells,and the like. Further diseases associated with expression of CD19expression include, but not limited to, e.g., atypical and/ornon-classical cancers, malignancies, precancerous conditions orproliferative diseases associated with expression of CD19. Non-cancerrelated indications associated with expression of CD19 include, but arenot limited to, e.g., autoimmune disease, (e.g., lupus), inflammatorydisorders (allergy and asthma) and transplantation. In some embodiments,the CD19-expressing cells express, or at any time expressed, CD19 mRNA.In an embodiment, the CD19-expressing cells produce a CD19 protein(e.g., wild-type or mutant), and the CD19 protein may be present atnormal levels or reduced levels. In an embodiment, the CD19-expressingcells produced detectable levels of a CD19 protein at one point, andsubsequently produced substantially no detectable CD19 protein.

The term “conservative sequence modifications” refers to amino acidmodifications that do not significantly affect or alter the bindingcharacteristics of the antibody or antibody fragment containing theamino acid sequence. Such conservative modifications include amino acidsubstitutions, additions and deletions. Modifications can be introducedinto an antibody or antibody fragment of the invention by standardtechniques known in the art, such as site-directed mutagenesis andPCR-mediated mutagenesis. Conservative amino acid substitutions are onesin which the amino acid residue is replaced with an amino acid residuehaving a similar side chain. Families of amino acid residues havingsimilar side chains have been defined in the art. These families includeamino acids with basic side chains (e.g., lysine, arginine, histidine),acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polarside chains (e.g., glycine, asparagine, glutamine, serine, threonine,tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine,valine, leucine, isoleucine, proline, phenylalanine, methionine),beta-branched side chains (e.g., threonine, valine, isoleucine) andaromatic side chains (e.g., tyrosine, phenylalanine, tryptophan,histidine). Thus, one or more amino acid residues within a CAR of theinvention can be replaced with other amino acid residues from the sameside chain family and the altered CAR can be tested using the functionalassays described herein.

The term “stimulation,” refers to a primary response induced by bindingof a stimulatory molecule (e.g., a TCR/CD3 complex or CAR) with itscognate ligand (or tumor antigen in the case of a CAR) thereby mediatinga signal transduction event, such as, but not limited to, signaltransduction via the TCR/CD3 complex or signal transduction via theappropriate NK receptor or signaling domains of the CAR. Stimulation canmediate altered expression of certain molecules.

The term “stimulatory molecule,” refers to a molecule expressed by animmune cell, e.g., T cell, NK cell, or B cell) that provides thecytoplasmic signaling sequence(s) that regulate activation of the immunecell in a stimulatory way for at least some aspect of the immune cellsignaling pathway. In one aspect, the signal is a primary signal that isinitiated by, for instance, binding of a TCR/CD3 complex with an MEWmolecule loaded with peptide, and which leads to mediation of a T cellresponse, including, but not limited to, proliferation, activation,differentiation, and the like. A primary cytoplasmic signaling sequence(also referred to as a “primary signaling domain”) that acts in astimulatory manner may contain a signaling motif which is known asimmunoreceptor tyrosine-based activation motif or ITAM. Examples of anITAM containing cytoplasmic signaling sequence that is of particular usein the invention includes, but is not limited to, those derived from CD3zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc EpsilonRib), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12.In a specific CAR of the invention, the intracellular signaling domainin any one or more CARS of the invention comprises an intracellularsignaling sequence, e.g., a primary signaling sequence of CD3-zeta. In aspecific CAR of the invention, the primary signaling sequence ofCD3-zeta is the sequence provided as SEQ ID NO:17, or the equivalentresidues from a non-human species, e.g., mouse, rodent, monkey, ape andthe like. In a specific CAR of the invention, the primary signalingsequence of CD3-zeta is the sequence as provided in SEQ ID NO:43, or theequivalent residues from a non-human species, e.g., mouse, rodent,monkey, ape and the like.

The term “antigen presenting cell” or “APC” refers to an immune systemcell such as an accessory cell (e.g., a B-cell, a dendritic cell, andthe like) that displays a foreign antigen complexed with majorhistocompatibility complexes (WIC's) on its surface. T-cells mayrecognize these complexes using their T-cell receptors (TCRs). APCsprocess antigens and present them to T-cells.

“Immune effector cell,” as that term is used herein, refers to a cellthat is involved in an immune response, e.g., in the promotion of animmune effector response. Examples of immune effector cells include Tcells, e.g., alpha/beta T cells and gamma/delta T cells, B cells,natural killer (NK) cells, natural killer T (NK-T) cells, mast cells,and myeloid-derived phagocytes.

“Immune effector function or immune effector response,” as that term isused herein, refers to function or response, e.g., of an immune effectorcell, that enhances or promotes an immune attack of a target cell. E.g.,an immune effector function or response refers a property of a T or NKcell that promotes killing or the inhibition of growth or proliferation,of a target cell. In the case of a T cell, primary stimulation andco-stimulation are examples of immune effector function or response.

The term “effector function” refers to a specialized function of a cell.Effector function of a T cell, for example, may be cytolytic activity orhelper activity including the secretion of cytokines.

An “intracellular signaling domain,” as the term is used herein, refersto an intracellular portion of a molecule. The intracellular signalingdomain can generate a signal that promotes an immune effector functionof the CAR containing cell, e.g., a CART cell. Examples of immuneeffector function, e.g., in a CART cell, include cytolytic activity andhelper activity, including the secretion of cytokines. In embodiments,the intracellular signal domain is the portion of the protein whichtransduces the effector function signal and directs the cell to performa specialized function. While the entire intracellular signaling domaincan be employed, in many cases it is not necessary to use the entirechain. To the extent that a truncated portion of the intracellularsignaling domain is used, such truncated portion may be used in place ofthe intact chain as long as it transduces the effector function signal.The term intracellular signaling domain is thus meant to include anytruncated portion of the intracellular signaling domain sufficient totransduce the effector function signal.

In an embodiment, the intracellular signaling domain can comprise aprimary intracellular signaling domain. Exemplary primary intracellularsignaling domains include those derived from the molecules responsiblefor primary stimulation, or antigen dependent simulation. In anembodiment, the intracellular signaling domain can comprise acostimulatory intracellular domain. Exemplary costimulatoryintracellular signaling domains include those derived from moleculesresponsible for costimulatory signals, or antigen independentstimulation. For example, in the case of a CART, a primary intracellularsignaling domain can comprise a cytoplasmic sequence of a T cellreceptor, and a costimulatory intracellular signaling domain cancomprise cytoplasmic sequence from co-receptor or costimulatorymolecule.

A primary intracellular signaling domain can comprise a signaling motifwhich is known as an immunoreceptor tyrosine-based activation motif orITAM. Examples of ITAM containing primary cytoplasmic signalingsequences include, but are not limited to, those derived from CD3 zeta,FcR gamma, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (FcEpsilon Rib), CD3 gamma, CD3 delta, CD3 epsilon, CD22, CD79a, CD79b,CD278 (“ICOS”), FcεRI, CD66d, CD32, DAP10 and DAP12.

The term “zeta” or alternatively “zeta chain”, “CD3-zeta” or “TCR-zeta”is defined as the protein provided as GenBank Acc. No. BAG36664.1, orthe equivalent residues from a non-human species, e.g., mouse, rodent,monkey, ape and the like, and a “zeta stimulatory domain” oralternatively a “CD3-zeta stimulatory domain” or a “TCR-zeta stimulatorydomain” is defined as the amino acid residues from the cytoplasmicdomain of the zeta chain, or functional derivatives thereof, that aresufficient to functionally transmit an initial signal necessary for Tcell activation. In one aspect the cytoplasmic domain of zeta comprisesresidues 52 through 164 of GenBank Acc. No. BAG36664.1 or the equivalentresidues from a non-human species, e.g., mouse, rodent, monkey, ape andthe like, that are functional orthologs thereof. In one aspect, the“zeta stimulatory domain” or a “CD3-zeta stimulatory domain” is thesequence provided as SEQ ID NO:17. In one aspect, the “zeta stimulatorydomain” or a “CD3-zeta stimulatory domain” is the sequence provided asSEQ ID NO:43.

The term “costimulatory molecule” refers to the cognate binding partneron a T cell that specifically binds with a costimulatory ligand, therebymediating a costimulatory response by the T cell, such as, but notlimited to, proliferation. Costimulatory molecules are cell surfacemolecules other than antigen receptors or their ligands that contributeto an efficient immune response. Costimulatory molecules include, butare not limited to an MHC class I molecule, TNF receptor proteins,Immunoglobulin-like proteins, cytokine receptors, integrins, signallinglymphocytic activation molecules (SLAM proteins), activating NK cellreceptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28,CD30, CD40, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, ICAM-1,ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80(KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta,IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6,VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM,CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D,NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84,CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100(SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3),BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a,and a ligand that specifically binds with CD83.

A costimulatory intracellular signaling domain refers to theintracellular portion of a costimulatory molecule. The intracellularsignaling domain can comprise the entire intracellular portion, or theentire native intracellular signaling domain, of the molecule from whichit is derived, or a functional fragment or derivative thereof.

The term “4-1BB” refers to a member of the TNFR superfamily with anamino acid sequence provided as GenBank Acc. No. AAA62478.2, or theequivalent residues from a non-human species, e.g., mouse, rodent,monkey, ape and the like; and a “4-1BB costimulatory domain” is definedas amino acid residues 214-255 of GenBank Acc. No. AAA62478.2, or theequivalent residues from a non-human species, e.g., mouse, rodent,monkey, ape and the like. In one aspect, the “4-1BB costimulatorydomain” is the sequence provided as SEQ ID NO:16 or the equivalentresidues from a non-human species, e.g., mouse, rodent, monkey, ape andthe like.

The term “encoding” refers to the inherent property of specificsequences of nucleotides in a polynucleotide, such as a gene, a cDNA, oran mRNA, to serve as templates for synthesis of other polymers andmacromolecules in biological processes having either a defined sequenceof nucleotides (e.g., rRNA, tRNA and mRNA) or a defined sequence ofamino acids and the biological properties resulting therefrom. Thus, agene, cDNA, or RNA, encodes a protein if transcription and translationof mRNA corresponding to that gene produces the protein in a cell orother biological system. Both the coding strand, the nucleotide sequenceof which is identical to the mRNA sequence and is usually provided insequence listings, and the non-coding strand, used as the template fortranscription of a gene or cDNA, can be referred to as encoding theprotein or other product of that gene or cDNA.

Unless otherwise specified, a “nucleotide sequence encoding an aminoacid sequence” includes all nucleotide sequences that are degenerateversions of each other and that encode the same amino acid sequence. Thephrase nucleotide sequence that encodes a protein or a RNA may alsoinclude introns to the extent that the nucleotide sequence encoding theprotein may in some version contain an intron(s).

The term “effective amount” or “therapeutically effective amount” areused interchangeably herein, and refer to an amount of a compound,formulation, material, or composition, as described herein effective toachieve a particular biological result.

The term “endogenous” refers to any material from or produced inside anorganism, cell, tissue or system.

The term “exogenous” refers to any material introduced from or producedoutside an organism, cell, tissue or system.

The term “expression” refers to the transcription and/or translation ofa particular nucleotide sequence driven by a promoter.

The term “transfer vector” refers to a composition of matter whichcomprises an isolated nucleic acid and which can be used to deliver theisolated nucleic acid to the interior of a cell. Numerous vectors areknown in the art including, but not limited to, linear polynucleotides,polynucleotides associated with ionic or amphiphilic compounds,plasmids, and viruses. Thus, the term “transfer vector” includes anautonomously replicating plasmid or a virus. The term should also beconstrued to further include non-plasmid and non-viral compounds whichfacilitate transfer of nucleic acid into cells, such as, for example, apolylysine compound, liposome, and the like. Examples of viral transfervectors include, but are not limited to, adenoviral vectors,adeno-associated virus vectors, retroviral vectors, lentiviral vectors,and the like.

The term “expression vector” refers to a vector comprising a recombinantpolynucleotide comprising expression control sequences operativelylinked to a nucleotide sequence to be expressed. An expression vectorcomprises sufficient cis-acting elements for expression; other elementsfor expression can be supplied by the host cell or in an in vitroexpression system. Expression vectors include all those known in theart, including cosmids, plasmids (e.g., naked or contained in liposomes)and viruses (e.g., lentiviruses, retroviruses, adenoviruses, andadeno-associated viruses) that incorporate the recombinantpolynucleotide.

The term “lentivirus” refers to a genus of the Retroviridae family.Lentiviruses are unique among the retroviruses in being able to infectnon-dividing cells; they can deliver a significant amount of geneticinformation into the DNA of the host cell, so they are one of the mostefficient methods of a gene delivery vector. HIV, SIV, and FIV are allexamples of lentiviruses.

The term “lentiviral vector” refers to a vector derived from at least aportion of a lentivirus genome, including especially a self-inactivatinglentiviral vector as provided in Milone et al., Mol. Ther. 17(8):1453-1464 (2009). Other examples of lentivirus vectors that may be usedin the clinic, include but are not limited to, e.g., the LENTIVECTOR®gene delivery technology from Oxford BioMedica, the LENTIMAX™ vectorsystem from Lentigen and the like. Nonclinical types of lentiviralvectors are also available and would be known to one skilled in the art.

The term “homologous” or “identity” refers to the subunit sequenceidentity between two polymeric molecules, e.g., between two nucleic acidmolecules, such as, two DNA molecules or two RNA molecules, or betweentwo polypeptide molecules. When a subunit position in both of the twomolecules is occupied by the same monomeric subunit; e.g., if a positionin each of two DNA molecules is occupied by adenine, then they arehomologous or identical at that position. The homology between twosequences is a direct function of the number of matching or homologouspositions; e.g., if half (e.g., five positions in a polymer ten subunitsin length) of the positions in two sequences are homologous, the twosequences are 50% homologous; if 90% of the positions (e.g., 9 of 10),are matched or homologous, the two sequences are 90% homologous.

“Humanized” forms of non-human (e.g., murine) antibodies are chimericimmunoglobulins, immunoglobulin chains or fragments thereof (such as Fv,Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies)which contain minimal sequence derived from non-human immunoglobulin.For the most part, humanized antibodies and antibody fragments thereofare human immunoglobulins (recipient antibody or antibody fragment) inwhich residues from a complementarity-determining region (CDR) of therecipient are replaced by residues from a CDR of a non-human species(donor antibody) such as mouse, rat or rabbit having the desiredspecificity, affinity, and capacity. In some instances, Fv frameworkregion (FR) residues of the human immunoglobulin are replaced bycorresponding non-human residues. Furthermore, a humanizedantibody/antibody fragment can comprise residues which are found neitherin the recipient antibody nor in the imported CDR or frameworksequences. These modifications can further refine and optimize antibodyor antibody fragment performance. In general, the humanized antibody orantibody fragment thereof will comprise substantially all of at leastone, and typically two, variable domains, in which all or substantiallyall of the CDR regions correspond to those of a non-human immunoglobulinand all or a significant portion of the FR regions are those of a humanimmunoglobulin sequence. The humanized antibody or antibody fragment canalso comprise at least a portion of an immunoglobulin constant region(Fc), typically that of a human immunoglobulin. For further details, seeJones et al., Nature, 321: 522-525, 1986; Reichmann et al., Nature, 332:323-329, 1988; Presta, Curr. Op. Struct. Biol., 2: 593-596, 1992.

“Fully human” refers to an immunoglobulin, such as an antibody orantibody fragment, where the whole molecule is of human origin orconsists of an amino acid sequence identical to a human form of theantibody or immunoglobulin.

The term “isolated” means altered or removed from the natural state. Forexample, a nucleic acid or a peptide naturally present in a livinganimal is not “isolated,” but the same nucleic acid or peptide partiallyor completely separated from the coexisting materials of its naturalstate is “isolated.” An isolated nucleic acid or protein can exist insubstantially purified form, or can exist in a non-native environmentsuch as, for example, a host cell.

In the context of the present invention, the following abbreviations forthe commonly occurring nucleic acid bases are used. “A” refers toadenosine, “C” refers to cytosine, “G” refers to guanosine, “T” refersto thymidine, and “U” refers to uridine.

The term “operably linked” or “transcriptional control” refers tofunctional linkage between a regulatory sequence and a heterologousnucleic acid sequence resulting in expression of the latter. Forexample, a first nucleic acid sequence is operably linked with a secondnucleic acid sequence when the first nucleic acid sequence is placed ina functional relationship with the second nucleic acid sequence. Forinstance, a promoter is operably linked to a coding sequence if thepromoter affects the transcription or expression of the coding sequence.Operably linked DNA sequences can be contiguous with each other and,e.g., where necessary to join two protein coding regions, are in thesame reading frame.

The term “parenteral” administration of an immunogenic compositionincludes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular(i.m.), or intrasternal injection, intratumoral, or infusion techniques.

The term “nucleic acid” or “polynucleotide” refers to deoxyribonucleicacids (DNA) or ribonucleic acids (RNA) and polymers thereof in eithersingle- or double-stranded form. The term “nucleic acid” includes agene, cDNA, or an mRNA. In one embodiment, the nucleic acid molecule issynthetic (e.g., chemically synthesized) or recombinant. Unlessspecifically limited, the term encompasses nucleic acids containinganalogues or derivatives of natural nucleotides that have similarbinding properties as the reference nucleic acid and are metabolized ina manner similar to naturally occurring nucleotides. Unless otherwiseindicated, a particular nucleic acid sequence also implicitlyencompasses conservatively modified variants thereof (e.g., degeneratecodon substitutions), alleles, orthologs, SNPs, and complementarysequences as well as the sequence explicitly indicated. Specifically,degenerate codon substitutions may be achieved by generating sequencesin which the third position of one or more selected (or all) codons issubstituted with mixed-base and/or deoxyinosine residues (Batzer et al.,Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem.260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98(1994)).

The terms “peptide,” “polypeptide,” and “protein” are usedinterchangeably, and refer to a compound comprised of amino acidresidues covalently linked by peptide bonds. A protein or peptide mustcontain at least two amino acids, and no limitation is placed on themaximum number of amino acids that can comprise a protein's or peptide'ssequence. Polypeptides include any peptide or protein comprising two ormore amino acids joined to each other by peptide bonds. As used herein,the term refers to both short chains, which also commonly are referredto in the art as peptides, oligopeptides and oligomers, for example, andto longer chains, which generally are referred to in the art asproteins, of which there are many types. “Polypeptides” include, forexample, biologically active fragments, substantially homologouspolypeptides, oligopeptides, homodimers, heterodimers, variants ofpolypeptides, modified polypeptides, derivatives, analogs, fusionproteins, among others. A polypeptide includes a natural peptide, arecombinant peptide, or a combination thereof.

The term “promoter” refers to a DNA sequence recognized by the syntheticmachinery of the cell, or introduced synthetic machinery, required toinitiate the specific transcription of a polynucleotide sequence.

The term “promoter/regulatory sequence” refers to a nucleic acidsequence which is required for expression of a gene product operablylinked to the promoter/regulatory sequence. In some instances, thissequence may be the core promoter sequence and in other instances, thissequence may also include an enhancer sequence and other regulatoryelements which are required for expression of the gene product. Thepromoter/regulatory sequence may, for example, be one which expressesthe gene product in a tissue specific manner.

The term “constitutive” promoter refers to a nucleotide sequence which,when operably linked with a polynucleotide which encodes or specifies agene product, causes the gene product to be produced in a cell undermost or all physiological conditions of the cell.

The term “inducible” promoter refers to a nucleotide sequence which,when operably linked with a polynucleotide which encodes or specifies agene product, causes the gene product to be produced in a cellsubstantially only when an inducer which corresponds to the promoter ispresent in the cell.

The term “tissue-specific” promoter refers to a nucleotide sequencewhich, when operably linked with a polynucleotide encodes or specifiedby a gene, causes the gene product to be produced in a cellsubstantially only if the cell is a cell of the tissue typecorresponding to the promoter.

The term “flexible polypeptide linker” or “linker” as used in thecontext of a scFv refers to a peptide linker that consists of aminoacids such as glycine and/or serine residues used alone or incombination, to link variable heavy and variable light chain regionstogether. In one embodiment, the flexible polypeptide linker is aGly/Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser)n,where n is a positive integer equal to or greater than 1. For example,n=1, n=2, n=3. n=4, n=5, n=6, n=7, n=8, n=9 and n=10 (SEQ ID NO:105). Inone embodiment, the flexible polypeptide linkers include, but are notlimited to, (Gly₄ Ser)₄ (SEQ ID NO:106) or (Gly₄ Ser)₃ (SEQ ID NO:107).In another embodiment, the linkers include multiple repeats of(Gly₂Ser), (GlySer) or (Gly₃Ser) (SEQ ID NO:108). Also included withinthe scope of the invention are linkers described in WO2012/138475,incorporated herein by reference.

As used herein, a 5′ cap (also termed an RNA cap, an RNA7-methylguanosine cap or an RNA m⁷G cap) is a modified guaninenucleotide that has been added to the “front” or 5′ end of a eukaryoticmessenger RNA shortly after the start of transcription. The 5′ capconsists of a terminal group which is linked to the first transcribednucleotide. Its presence is important for recognition by the ribosomeand protection from RNases. Cap addition is coupled to transcription,and occurs co-transcriptionally, such that each influences the other.Shortly after the start of transcription, the 5′ end of the mRNA beingsynthesized is bound by a cap-synthesizing complex associated with RNApolymerase. This enzymatic complex catalyzes the chemical reactions thatare required for mRNA capping. Synthesis proceeds as a multi-stepbiochemical reaction. The capping moiety can be modified to modulatefunctionality of mRNA such as its stability or efficiency oftranslation.

As used herein, “in vitro transcribed RNA” refers to RNA, e.g., mRNA,that has been synthesized in vitro. Generally, the in vitro transcribedRNA is generated from an in vitro transcription vector. The in vitrotranscription vector comprises a template that is used to generate thein vitro transcribed RNA.

As used herein, a “poly(A)” is a series of adenosines attached bypolyadenylation to the mRNA. In some embodiments of a construct fortransient expression, the polyA is between 50 and 5000 (SEQ ID NO: 28),e.g., greater than 64, e.g., greater than 100, e.g., than 300 or 400.Poly(A) sequences can be modified chemically or enzymatically tomodulate mRNA functionality such as localization, stability orefficiency of translation.

As used herein, “polyadenylation” refers to the covalent linkage of apolyadenylyl moiety, or its modified variant, to a messenger RNAmolecule. In eukaryotic organisms, most messenger RNA (mRNA) moleculesare polyadenylated at the 3′ end. The 3′ poly(A) tail is a long sequenceof adenine nucleotides (often several hundred) added to the pre-mRNAthrough the action of an enzyme, polyadenylate polymerase. In highereukaryotes, the poly(A) tail is added onto transcripts that contain aspecific sequence, the polyadenylation signal. The poly(A) tail and theprotein bound to it aid in protecting mRNA from degradation byexonucleases. Polyadenylation is also important for transcriptiontermination, export of the mRNA from the nucleus, and translation.Polyadenylation occurs in the nucleus immediately after transcription ofDNA into RNA, but additionally can also occur later in the cytoplasm.After transcription has been terminated, the mRNA chain is cleavedthrough the action of an endonuclease complex associated with RNApolymerase. The cleavage site is usually characterized by the presenceof the base sequence AAUAAA near the cleavage site. After the mRNA hasbeen cleaved, adenosine residues are added to the free 3′ end at thecleavage site.

As used herein, “transient” refers to expression of a non-integratedtransgene for a period of hours, days or weeks, wherein the period oftime of expression is less than the period of time for expression of thegene if integrated into the genome or contained within a stable plasmidreplicon in the host cell.

The term “signal transduction pathway” refers to the biochemicalrelationship between a variety of signal transduction molecules thatplay a role in the transmission of a signal from one portion of a cellto another portion of a cell. The phrase “cell surface receptor”includes molecules and complexes of molecules capable of receiving asignal and transmitting signal across the membrane of a cell.

The term “subject” is intended to include living organisms in which animmune response can be elicited (e.g., mammals, human).

The term, a “substantially purified” cell refers to a cell that isessentially free of other cell types. A substantially purified cell alsorefers to a cell which has been separated from other cell types withwhich it is normally associated in its naturally occurring state. Insome instances, a population of substantially purified cells refers to ahomogenous population of cells. In other instances, this term referssimply to cell that have been separated from the cells with which theyare naturally associated in their natural state. In some aspects, thecells are cultured in vitro. In other aspects, the cells are notcultured in vitro.

The term “therapeutic” as used herein means a treatment. A therapeuticeffect is obtained by reduction, suppression, remission, or eradicationof a disease state.

The term “prophylaxis” as used herein means the prevention of orprotective treatment for a disease or disease state.

In the context of the present invention, “tumor antigen” or“hyperproliferative disorder antigen” or “antigen associated with ahyperproliferative disorder” refers to antigens that are common tospecific hyperproliferative disorders. In certain aspects, thehyperproliferative disorder antigens of the present invention arederived from, cancers including but not limited to primary or metastaticmelanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer,non-Hodgkin lymphoma, Hodgkin lymphoma, leukemias, uterine cancer,cervical cancer, bladder cancer, kidney cancer and adenocarcinomas suchas breast cancer, prostate cancer, ovarian cancer, pancreatic cancer,and the like.

The term “transfected” or “transformed” or “transduced” refers to aprocess by which exogenous nucleic acid is transferred or introducedinto the host cell. A “transfected” or “transformed” or “transduced”cell is one which has been transfected, transformed or transduced withexogenous nucleic acid. The cell includes the primary subject cell andits progeny.

A subject “responds” to treatment if a parameter of a cancer (e.g., ahematological cancer, e.g., cancer cell growth, proliferation and/orsurvival) in the subject is retarded or reduced by a detectable amount,e.g., about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more asdetermined by any appropriate measure, e.g., by mass, cell count orvolume. In one example, a subject responds to treatment if the subjectexperiences a life expectancy extended by about 5%, 10%, 20%, 30%, 40%,50% or more beyond the life expectancy predicted if no treatment isadministered. In another example, a subject responds to treatment, ifthe subject has an increased disease-free survival, overall survival orincreased time to progression. Several methods can be used to determineif a patient responds to a treatment including, for example, criteriaprovided by NCCN Clinical Practice Guidelines in Oncology (NCCNGuidelines®). For example, in the context of B-ALL, a complete responseor complete responder, may involve one or more of: <5% BM blast, >1000neutrophil/ANC (/μL). >100,000 platelets (/μL) with no circulatingblasts or extramedullary disease (no lymphadenopathy, splenomegaly,skin/gum infiltration/testicular mass/CNS involvement), Trilineagehematopoiesis, and no recurrence for 4 weeks. A partial responder mayinvolve one or more of >50% reduction in BM blast, >1000 neutrophil/ANC(/μL). >100,000 platelets (/μL). A non-responder can show diseaseprogression, e.g., >25% in BM blasts.

“Refractory” as used herein refers to a disease, e.g., cancer, that doesnot respond to a treatment. In embodiments, a refractory cancer can beresistant to a treatment before or at the beginning of the treatment. Inother embodiments, the refractory cancer can become resistant during atreatment. A refractory cancer is also called a resistant cancer.

The term “relapse” as used herein refers to reappearance of a cancerafter an initial period of responsiveness (e.g., complete response orpartial response). The initial period of responsiveness may involve thelevel of cancer cells falling below a certain threshold, e.g., below20%, 1%, 10%, 5%, 4%, 3%, 2%, or 1%. The reappearance may involve thelevel of cancer cells rising above a certain threshold, e.g., above 20%,1%, 10%, 5%, 4%, 3%, 2%, or 1%. For example, e.g., in the context ofB-ALL, the reappearance may involve, e.g., a reappearance of blasts inthe blood, bone marrow (>5%), or any extramedullary site, after acomplete response. A complete response, in this context, may involve <5%BM blast. More generally, in an embodiment, a response (e.g., completeresponse or partial response) can involve the absence of detectable MRD(minimal residual disease). In an embodiment, the initial period ofresponsiveness lasts at least 1, 2, 3, 4, 5, or 6 days; at least 1, 2,3, or 4 weeks; at least 1, 2, 3, 4, 6, 8, 10, or 12 months; or at least1, 2, 3, 4, or 5 years.

In some embodiments, a therapy that includes a CD19 inhibitor, e.g., aCD19 CAR therapy, may relapse or be refractory to treatment. The relapseor resistance can be caused by CD19 loss (e.g., an antigen lossmutation) or other CD19 alteration that reduces the level of CD19 (e.g.,caused by clonal selection of CD19-negative clones). A cancer thatharbors such CD19 loss or alteration is referred to herein as a“CD19-negative cancer” or a “CD19-negative relapsed cancer”). It shallbe understood that a CD19-negative cancer need not have 100% loss ofCD19, but a sufficient reduction to reduce the effectiveness of a CD19therapy such that the cancer relapses or becomes refractory. In someembodiments, a CD19-negative cancer results from a CD19 CAR therapy.

The term “specifically binds,” refers to an antibody, or a ligand, whichrecognizes and binds with a binding partner (e.g., a stimulatory tumorantigen) protein present in a sample, but which antibody or ligand doesnot substantially recognize or bind other molecules in the sample.

As used herein, the term “pharmaceutically acceptable salt” refers tothose salts which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of subjects without unduetoxicity, irritation, allergic response and the like, and arecommensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, Berge et al.describes pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences (1977) 66:1-19.

“Regulatable chimeric antigen receptor (RCAR),” as that term is usedherein, refers to a set of polypeptides, typically two in the simplestembodiments, which when in a RCARX cell, provides the RCARX cell withspecificity for a target cell, typically a cancer cell, and withregulatable intracellular signal generation or proliferation, which canoptimize an immune effector property of the RCARX cell. An RCARX cellrelies at least in part, on an antigen binding domain to providespecificity to a target cell that comprises the antigen bound by theantigen binding domain. In an embodiment, an RCAR includes adimerization switch that, upon the presence of a dimerization molecule,can couple an intracellular signaling domain to the antigen bindingdomain.

“Membrane anchor” or “membrane tethering domain”, as that term is usedherein, refers to a polypeptide or moiety, e.g., a myristoyl group,sufficient to anchor an extracellular or intracellular domain to theplasma membrane.

“Switch domain,” as that term is used herein, e.g., when referring to anRCAR, refers to an entity, typically a polypeptide-based entity, that,in the presence of a dimerization molecule, associates with anotherswitch domain. The association results in a functional coupling of afirst entity linked to, e.g., fused to, a first switch domain, and asecond entity linked to, e.g., fused to, a second switch domain. A firstand second switch domain are collectively referred to as a dimerizationswitch. In embodiments, the first and second switch domains are the sameas one another, e.g., they are polypeptides having the same primaryamino acid sequence, and are referred to collectively as ahomodimerization switch. In embodiments, the first and second switchdomains are different from one another, e.g., they are polypeptideshaving different primary amino acid sequences, and are referred tocollectively as a heterodimerization switch. In embodiments, the switchis intracellular. In embodiments, the switch is extracellular. Inembodiments, the switch domain is a polypeptide-based entity, e.g., FKBPor FRB-based, and the dimerization molecule is small molecule, e.g., arapalogue. In embodiments, the switch domain is a polypeptide-basedentity, e.g., an scFv that binds a myc peptide, and the dimerizationmolecule is a polypeptide, a fragment thereof, or a multimer of apolypeptide, e.g., a myc ligand or multimers of a myc ligand that bindto one or more myc scFvs. In embodiments, the switch domain is apolypeptide-based entity, e.g., myc receptor, and the dimerizationmolecule is an antibody or fragments thereof, e.g., myc antibody.

“Dimerization molecule,” as that term is used herein, e.g., whenreferring to an RCAR, refers to a molecule that promotes the associationof a first switch domain with a second switch domain. In embodiments,the dimerization molecule does not naturally occur in the subject, ordoes not occur in concentrations that would result in significantdimerization. In embodiments, the dimerization molecule is a smallmolecule, e.g., rapamycin or a rapalogue, e.g., RAD001.

The term “low, immune enhancing, dose” when used in conjunction with anmTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001 orrapamycin, or a catalytic mTOR inhibitor, refers to a dose of mTORinhibitor that partially, but not fully, inhibits mTOR activity, e.g.,as measured by the inhibition of P70 S6 kinase activity. Methods forevaluating mTOR activity, e.g., by inhibition of P70 S6 kinase, arediscussed herein. The dose is insufficient to result in complete immunesuppression but is sufficient to enhance the immune response. In anembodiment, the low, immune enhancing, dose of mTOR inhibitor results ina decrease in the number of PD-1 positive T cells and/or an increase inthe number of PD-1 negative T cells, or an increase in the ratio of PD-1negative T cells/PD-1 positive T cells. In an embodiment, the low,immune enhancing, dose of mTOR inhibitor results in an increase in thenumber of naive T cells. In an embodiment, the low, immune enhancing,dose of mTOR inhibitor results in one or more of the following:

-   -   an increase in the expression of one or more of the following        markers: CD62L^(high), CD127^(high), CD27⁺, and BCL2, e.g., on        memory T cells, e.g., memory T cell precursors;    -   a decrease in the expression of KLRG1, e.g., on memory T cells,        e.g., memory T cell precursors; and    -   an increase in the number of memory T cell precursors, e.g.,        cells with any one or combination of the following        characteristics: increased CD62L^(high), increased CD127^(high),        increased CD27⁺, decreased KLRG1, and increased BCL2;        wherein any of the changes described above occurs, e.g., at        least transiently, e.g., as compared to a non-treated subject.

Ranges: throughout this disclosure, various aspects of the invention canbe presented in a range format. It should be understood that thedescription in range format is merely for convenience and brevity andshould not be construed as an inflexible limitation on the scope of theinvention. Accordingly, the description of a range should be consideredto have specifically disclosed all the possible subranges as well asindividual numerical values within that range. For example, descriptionof a range such as from 1 to 6 should be considered to have specificallydisclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numberswithin that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. Asanother example, a range such as 95-99% identity, includes somethingwith 95%, 96%, 97%, 98% or 99% identity, and includes subranges such as96-99%, 96-98%, 96-97%, 97-99%, 97-98% and 98-99% identity. This appliesregardless of the breadth of the range.

DESCRIPTION

CD19 Inhibitors and Binding Domains

Provided herein are compositions of matter and methods of use for thetreatment of a disease such as cancer using CD19 chimeric antigenreceptors (CAR). The methods include, inter alia, administering a CD19CAR described herein in combination with another agent such as B-cellinhibitor. The methods also include, e.g., administering a CD19 CARdescribed herein to treat a lymphoma such as Hodgkin lymphoma.

In one aspect, the invention provides a number of chimeric antigenreceptors (CAR) comprising an antibody or antibody fragment engineeredfor specific binding to a CD19 protein. In one aspect, the inventionprovides a cell (e.g., T cell) engineered to express a CAR, wherein theCAR T cell (“CART”) exhibits an anticancer property. In one aspect acell is transformed with the CAR and the CAR is expressed on the cellsurface. In some embodiments, the cell (e.g., T cell) is transduced witha viral vector encoding a CAR. In some embodiments, the viral vector isa retroviral vector. In some embodiments, the viral vector is alentiviral vector. In some such embodiments, the cell may stably expressthe CAR. In another embodiment, the cell (e.g., T cell) is transfectedwith a nucleic acid, e.g., mRNA, cDNA, DNA, encoding a CAR. In some suchembodiments, the cell may transiently express the CAR.

In one aspect, the anti-CD19 protein binding portion of the CAR is ascFv antibody fragment. In one aspect such antibody fragments arefunctional in that they retain the equivalent binding affinity, e.g.,they bind the same antigen with comparable affinity, as the IgG antibodyfrom which it is derived. In one aspect such antibody fragments arefunctional in that they provide a biological response that can include,but is not limited to, activation of an immune response, inhibition ofsignal-transduction origination from its target antigen, inhibition ofkinase activity, and the like, as will be understood by a skilledartisan. In one aspect, the anti-CD19 antigen binding domain of the CARis a scFv antibody fragment that is humanized compared to the murinesequence of the scFv from which it is derived. In one aspect, theparental murine scFv sequence is the CAR19 construct provided in PCTpublication WO2012/079000 and provided herein as SEQ ID NO:59. In oneembodiment, the anti-CD19 binding domain is a scFv described inWO2012/079000 and provided in SEQ ID NO:59, or a sequence at least 95%,e.g., 95-99%, identical thereto. In an embodiment, the anti-CD19 bindingdomain is part of a CAR construct provided in PCT publicationWO2012/079000 and provided herein as SEQ ID NO:58, or a sequence atleast 95%, e.g., 95%-99%, identical thereto. In an embodiment, theanti-CD19 binding domain comprises at least one (e.g., 2, 3, 4, 5, or 6)CDRs selected from Table 4 and/or Table 5.

In some aspects, the antibodies of the invention are incorporated into achimeric antigen receptor (CAR). In one aspect, the CAR comprises thepolypeptide sequence provided as SEQ ID NO: 12 in PCT publicationWO2012/079000, and provided herein as SEQ ID NO: 58, wherein the scFvdomain is substituted by one or more sequences selected from SEQ ID NOS:1-12. In one aspect, the scFv domains of SEQ ID NOS:1-12 are humanizedvariants of the scFv domain of SEQ ID NO:59, which is an scFv fragmentof murine origin that specifically binds to human CD19. Humanization ofthis mouse scFv may be desired for the clinical setting, where themouse-specific residues may induce a human-anti-mouse antigen (HAMA)response in patients who receive CART19 treatment, e.g., treatment withT cells transduced with the CAR19 construct.

In one aspect, the anti-CD19 binding domain, e.g., humanized scFv,portion of a CAR of the invention is encoded by a transgene whosesequence has been codon optimized for expression in a mammalian cell. Inone aspect, entire CAR construct of the invention is encoded by atransgene whose entire sequence has been codon optimized for expressionin a mammalian cell. Codon optimization refers to the discovery that thefrequency of occurrence of synonymous codons (i.e., codons that code forthe same amino acid) in coding DNA is biased in different species. Suchcodon degeneracy allows an identical polypeptide to be encoded by avariety of nucleotide sequences. A variety of codon optimization methodsis known in the art, and include, e.g., methods disclosed in at leastU.S. Pat. Nos. 5,786,464 and 6,114,148.

In one aspect, the humanized CAR19 comprises the scFv portion providedin SEQ ID NO:1. In one aspect, the humanized CAR19 comprises the scFvportion provided in SEQ ID NO:2. In one aspect, the humanized CAR19comprises the scFv portion provided in SEQ ID NO:3. In one aspect, thehumanized CAR19 comprises the scFv portion provided in SEQ ID NO:4. Inone aspect, the humanized CAR19 comprises the scFv portion provided inSEQ ID NO:5. In one aspect, the humanized CAR19 comprises the scFvportion provided in SEQ ID NO:6. In one aspect, the humanized CAR19comprises the scFv portion provided in SEQ ID NO:7. In one aspect, thehumanized CAR19 comprises the scFv portion provided in SEQ ID NO:8. Inone aspect, the humanized CAR19 comprises the scFv portion provided inSEQ ID NO:9. In one aspect, the humanized CAR19 comprises the scFvportion provided in SEQ ID NO:10. In one aspect, the humanized CAR19comprises the scFv portion provided in SEQ ID NO:11. In one aspect, thehumanized CAR19 comprises the scFv portion provided in SEQ ID NO:12.

In one aspect, the CARs of the invention combine an antigen bindingdomain of a specific antibody with an intracellular signaling molecule.For example, in some aspects, the intracellular signaling moleculeincludes, but is not limited to, CD3-zeta chain, 4-1BB and CD28signaling modules and combinations thereof. In one aspect, the CD19 CARcomprises a CAR selected from the sequence provided in one or more ofSEQ ID NOS: 31-42. In one aspect, the CD19 CAR comprises the sequenceprovided in SEQ ID NO:31. In one aspect, the CD19 CAR comprises thesequence provided in SEQ ID NO:32. In one aspect, the CD19 CAR comprisesthe sequence provided in SEQ ID NO:33. In one aspect, the CD19 CARcomprises the sequence provided in SEQ ID NO:34. In one aspect, the CD19CAR comprises the sequence provided in SEQ ID NO:35. In one aspect, theCD19 CAR comprises the sequence provided in SEQ ID NO:36. In one aspect,the CD19 CAR comprises the sequence provided in SEQ ID NO:37. In oneaspect, the CD19 CAR comprises the sequence provided in SEQ ID NO:38. Inone aspect, the CD19 CAR comprises the sequence provided in SEQ IDNO:39. In one aspect, the CD19 CAR comprises the sequence provided inSEQ ID NO:40. In one aspect, the CD19 CAR comprises the sequenceprovided in SEQ ID NO:41. In one aspect, the CD19 CAR comprises thesequence provided in SEQ ID NO:42.

Thus, in one aspect, the antigen binding domain comprises a humanizedantibody or an antibody fragment. In one embodiment, the humanizedanti-CD19 binding domain comprises one or more (e.g., all three) lightchain complementarity determining region 1 (LC CDR1), light chaincomplementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) of a murine or humanizedanti-CD19 binding domain described herein, and/or one or more (e.g., allthree) heavy chain complementarity determining region 1 (HC CDR1), heavychain complementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a murine or humanizedanti-CD19 binding domain described herein, e.g., a humanized anti-CD19binding domain comprising one or more, e.g., all three, LC CDRs and oneor more, e.g., all three, HC CDRs. In one embodiment, the humanizedanti-CD19 binding domain comprises one or more (e.g., all three) heavychain complementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a murine or humanizedanti-CD19 binding domain described herein, e.g., the humanized anti-CD19binding domain has two variable heavy chain regions, each comprising aHC CDR1, a HC CDR2 and a HC CDR3 described herein. In one embodiment,the humanized anti-CD19 binding domain comprises a humanized light chainvariable region described herein (e.g., in Table 2) and/or a humanizedheavy chain variable region described herein (e.g., in Table 2). In oneembodiment, the humanized anti-CD19 binding domain comprises a humanizedheavy chain variable region described herein (e.g., in Table 2), e.g.,at least two humanized heavy chain variable regions described herein(e.g., in Table 2). In one embodiment, the anti-CD19 binding domain is ascFv comprising a light chain and a heavy chain of an amino acidsequence of Table 2. In an embodiment, the anti-CD19 binding domain(e.g., an scFv) comprises: a light chain variable region comprising anamino acid sequence having at least one, two or three modifications(e.g., substitutions) but not more than 30, 20 or 10 modifications(e.g., substitutions) of an amino acid sequence of a light chainvariable region provided in Table 2, or a sequence with 95-99% identitywith an amino acid sequence of Table 2; and/or a heavy chain variableregion comprising an amino acid sequence having at least one, two orthree modifications (e.g., substitutions) but not more than 30, 20 or 10modifications (e.g., substitutions) of an amino acid sequence of a heavychain variable region provided in Table 2, or a sequence with 95-99%identity to an amino acid sequence of Table 2. In one embodiment, thehumanized anti-CD19 binding domain comprises a sequence selected from agroup consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4,SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ IDNO:10, SEQ ID NO:11, and SEQ ID NO:12, or a sequence with 95-99%identity thereof. In one embodiment, the nucleic acid sequence encodingthe humanized anti-CD19 binding domain comprises a sequence selectedfrom a group consisting of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ IDNO:70, SEQ ID NO:71 and SEQ ID NO:72, or a sequence with 95-99% identitythereof. In one embodiment, the humanized anti-CD19 binding domain is ascFv, and a light chain variable region comprising an amino acidsequence described herein, e.g., in Table 2, is attached to a heavychain variable region comprising an amino acid sequence describedherein, e.g., in Table 2, via a linker, e.g., a linker described herein.In one embodiment, the humanized anti-CD19 binding domain includes a(Gly₄-Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, e.g., 3 or 4 (SEQID NO:53). The light chain variable region and heavy chain variableregion of a scFv can be, e.g., in any of the following orientations:light chain variable region-linker-heavy chain variable region or heavychain variable region-linker-light chain variable region.

In one aspect, the antigen binding domain portion comprises one or moresequence selected from SEQ ID NOS:1-12. In one aspect the humanized CARis selected from one or more sequence selected from SEQ ID NOS: 31-42.In some aspects, a non-human antibody is humanized, where specificsequences or regions of the antibody are modified to increase similarityto an antibody naturally produced in a human or fragment thereof.

In one embodiment, the CAR molecule comprises an anti-CD19 bindingdomain comprising one or more (e.g., all three) light chaincomplementarity determining region 1 (LC CDR1), light chaincomplementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) of an anti-CD19 bindingdomain described herein, and one or more (e.g., all three) heavy chaincomplementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of an anti-CD19 bindingdomain described herein, e.g., an anti-CD19 binding domain comprisingone or more, e.g., all three, LC CDRs and one or more, e.g., all three,HC CDRs. In one embodiment, the anti-CD19 binding domain comprises oneor more (e.g., all three) heavy chain complementarity determining region1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2),and heavy chain complementarity determining region 3 (HC CDR3) of ananti-CD19 binding domain described herein, e.g., the anti-CD19 bindingdomain has two variable heavy chain regions, each comprising a HC CDR1,a HC CDR2 and a HC CDR3 described herein.

In one aspect, the anti-CD19 binding domain is characterized byparticular functional features or properties of an antibody or antibodyfragment. For example, in one aspect, the portion of a CAR compositionof the invention that comprises an antigen binding domain specificallybinds human CD19. In one aspect, the invention relates to an antigenbinding domain comprising an antibody or antibody fragment, wherein theantibody binding domain specifically binds to a CD19 protein or fragmentthereof, wherein the antibody or antibody fragment comprises a variablelight chain and/or a variable heavy chain that includes an amino acidsequence of SEQ ID NO: 1-12 or SEQ ID NO:59. In one aspect, the antigenbinding domain comprises an amino acid sequence of an scFv selected fromSEQ ID NOs: 1-12 or SEQ ID NO:59. In certain aspects, the scFv iscontiguous with and in the same reading frame as a leader sequence. Inone aspect the leader sequence is the polypeptide sequence provided asSEQ ID NO:13.

In one aspect, the portion of the CAR comprising the antigen bindingdomain comprises an antigen binding domain that targets CD19. In oneaspect, the antigen binding domain targets human CD19. In one aspect,the antigen binding domain of the CAR has the same or a similar bindingspecificity as, or includes, the FMC63 scFv fragment described inNicholson et al. Mol. Immun. 34 (16-17): 1157-1165 (1997). In oneaspect, the portion of the CAR comprising the antigen binding domaincomprises an antigen binding domain that targets a B-cell antigen, e.g.,a human B-cell antigen. A CD19 antibody molecule can be, e.g., anantibody molecule (e.g., a humanized anti-CD19 antibody molecule)described in WO2014/153270, which is incorporated herein by reference inits entirety. WO2014/153270 also describes methods of assaying thebinding and efficacy of various CART constructs.

In one embodiment, the anti-CD19 binding domain comprises a murine lightchain variable region described herein (e.g., in Table 3) and/or amurine heavy chain variable region described herein (e.g., in Table 3).In one embodiment, the anti-CD19 binding domain is a scFv comprising amurine light chain and a murine heavy chain of an amino acid sequence ofTable 3. In an embodiment, the anti-CD19 binding domain (e.g., an scFv)comprises: a light chain variable region comprising an amino acidsequence having at least one, two or three modifications (e.g.,substitutions) but not more than 30, 20 or 10 modifications (e.g.,substitutions) of an amino acid sequence of a light chain variableregion provided in Table 3, or a sequence with 95-99% identity with anamino acid sequence of Table 3; and/or a heavy chain variable regioncomprising an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 30, 20 or 10modifications (e.g., substitutions) of an amino acid sequence of a heavychain variable region provided in Table 3, or a sequence with 95-99%identity to an amino acid sequence of Table 3. In one embodiment, theanti-CD19 binding domain comprises a sequence of SEQ ID NO:59, or asequence with 95-99% identity thereof. In one embodiment, the anti-CD19binding domain is a scFv, and a light chain variable region comprisingan amino acid sequence described herein, e.g., in Table 3, is attachedto a heavy chain variable region comprising an amino acid sequencedescribed herein, e.g., in Table 3, via a linker, e.g., a linkerdescribed herein. In one embodiment, the antigen binding domain includesa (Gly₄-Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, e.g., 3 or 4(SEQ ID NO: 53). The light chain variable region and heavy chainvariable region of a scFv can be, e.g., in any of the followingorientations: light chain variable region-linker-heavy chain variableregion or heavy chain variable region-linker-light chain variableregion.

Furthermore, the present invention provides (among other things) CD19CAR compositions, optionally in combination with a B-cell inhibitor, andtheir use in medicaments or methods for treating, among other diseases,cancer or any malignancy or autoimmune diseases involving cells ortissues which express CD19.

In one aspect, the CAR of the invention can be used to eradicateCD19-expressing normal cells, thereby applicable for use as a cellularconditioning therapy prior to cell transplantation. In one aspect, theCD19-expressing normal cell is a CD19-expressing normal stem cell andthe cell transplantation is a stem cell transplantation.

In one aspect, the invention provides a cell (e.g., T cell) engineeredto express a chimeric antigen receptor (CAR), wherein the CAR-expressingcell, e.g., CAR T cell (“CART”) exhibits an anticancer property. Asuitable antigen is CD19. In one aspect, the antigen binding domain ofthe CAR comprises a partially humanized anti-CD19 antibody fragment. Inone aspect, the antigen binding domain of the CAR comprises a partiallyhumanized anti-CD19 antibody fragment comprising an scFv. Accordingly,the invention provides (among other things) a CD19-CAR that comprises ahumanized anti-CD19 binding domain and is engineered into an immuneeffector cell, e.g., a T cell or an NK cell, and methods of their usefor adoptive therapy.

In one aspect, the CAR, e.g., CD19-CAR comprises at least oneintracellular domain selected from the group of a CD137 (4-1BB)signaling domain, a CD28 signaling domain, a CD3zeta signal domain, andany combination thereof. In one aspect, the CAR, e.g., CD19-CARcomprises at least one intracellular signaling domain is from one ormore co-stimulatory molecule(s) other than a CD137 (4-1BB) or CD28.

The present invention encompasses, but is not limited to, a recombinantDNA construct comprising sequences encoding a CAR, wherein the CARcomprises an antibody or antibody fragment that binds specifically toCD19, CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1, e.g., human CD19,CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1, wherein the sequence ofthe antibody fragment is contiguous with and in the same reading frameas a nucleic acid sequence encoding an intracellular signaling domain.The intracellular signaling domain can comprise a costimulatorysignaling domain and/or a primary signaling domain, e.g., a zeta chain.The costimulatory signaling domain refers to a portion of the CARcomprising at least a portion of the intracellular domain of acostimulatory molecule. In one embodiment, the antigen binding domain isa murine antibody or antibody fragment described herein. In oneembodiment, the antigen binding domain is a humanized antibody orantibody fragment.

In specific aspects, a CAR construct of the invention comprises a scFvdomain selected from the group consisting of SEQ ID NOS:1-12 or an scFVdomain of SEQ ID NO:59, wherein the scFv may be preceded by an optionalleader sequence such as provided in SEQ ID NO: 13, and followed by anoptional hinge sequence such as provided in SEQ ID NO:14 or SEQ ID NO:45or SEQ ID NO:47 or SEQ ID NO:49, a transmembrane region such as providedin SEQ ID NO:15, an intracellular signalling domain that includes SEQ IDNO:16 or SEQ ID NO:51 and a CD3 zeta sequence that includes SEQ ID NO:17or SEQ ID NO:43, wherein the domains are contiguous with and in the samereading frame to form a single fusion protein. Also included in theinvention (among other things) is a nucleotide sequence that encodes thepolypeptide of each of the scFv fragments selected from the groupconsisting of SEQ IS NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ IDNO:5, SEQ IS NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:59. Also included in theinvention (among other things) is a nucleotide sequence that encodes thepolypeptide of each of the scFv fragments selected from the groupconsisting of SEQ IS NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ IDNO:5, SEQ IS NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:59, and each of the domains ofSEQ ID NOS: 13-17, plus an encoded CD19 CAR fusion protein of theinvention. In one aspect an exemplary CD19 CAR constructs comprise anoptional leader sequence, an extracellular antigen binding domain, ahinge, a transmembrane domain, and an intracellular stimulatory domain.In one aspect an exemplary CD19 CAR construct comprises an optionalleader sequence, an extracellular antigen binding domain, a hinge, atransmembrane domain, an intracellular costimulatory domain and anintracellular stimulatory domain. In some embodiments, specific CD19 CARconstructs containing humanized scFv domains of the invention areprovided as SEQ ID NOS: 31-42, or a murine scFv domain as provided asSEQ ID NO:59.

Full-length CAR sequences are also provided herein as SEQ ID NOS: 31-42and 58, as shown in Table 2 and Table 3.

An exemplary leader sequence is provided as SEQ ID NO: 13. An exemplaryhinge/spacer sequence is provided as SEQ ID NO: 14 or SEQ ID NO:45 orSEQ ID NO:47 or SEQ ID NO:49. An exemplary transmembrane domain sequenceis provided as SEQ ID NO:15. An exemplary sequence of the intracellularsignaling domain of the 4-1BB protein is provided as SEQ ID NO: 16. Anexemplary sequence of the intracellular signaling domain of CD27 isprovided as SEQ ID NO:51. An exemplary CD3zeta domain sequence isprovided as SEQ ID NO: 17 or SEQ ID NO:43. These sequences may be used,e.g., in combination with an scFv that recognizes one or more of CD19,CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1.

Exemplary sequences of various scFv fragments and other CAR componentsare provided herein. It is noted that these CAR components (e.g., of SEQID NO: 121, or a sequence of Table 2, 3, 6, 11A, 11B, 16, or 25) withouta leader sequence (e.g., without the amino acid sequence of SEQ ID NO:13 or a nucleotide sequence of SEQ ID NO: 54), are also provided herein.

In embodiments, the CAR sequences described herein contain a Q/K residuechange in the signal domain of the co-stimulatory domain derived fromCD3zeta chain.

In one aspect, the present invention encompasses a recombinant nucleicacid construct comprising a nucleic acid molecule encoding a CAR,wherein the nucleic acid molecule comprises the nucleic acid sequenceencoding an anti-CD19 binding domain, e.g., described herein, that iscontiguous with and in the same reading frame as a nucleic acid sequenceencoding an intracellular signaling domain. In one aspect, the anti-CD19binding domain is selected from one or more of SEQ ID NOS:1-12 and 58.In one aspect, the anti-CD19 binding domain is encoded by a nucleotideresidues 64 to 813 of the sequence provided in one or more of SEQ IDNOS:61-72 and 97. In one aspect, the anti-CD19 binding domain is encodedby a nucleotide residues 64 to 813 of SEQ ID NO:61. In one aspect, theanti-CD19 binding domain is encoded by a nucleotide residues 64 to 813of SEQ ID NO:62. In one aspect, the anti-CD19 binding domain is encodedby a nucleotide residues 64 to 813 of SEQ ID NO:63. In one aspect, theanti-CD19 binding domain is encoded by a nucleotide residues 64 to 813of SEQ ID NO:64. In one aspect, the anti-CD19 binding domain is encodedby a nucleotide residues 64 to 813 of SEQ ID NO:65. In one aspect, theanti-CD19 binding domain is encoded by a nucleotide residues 64 to 813of SEQ ID NO:66. In one aspect, the anti-CD19 binding domain is encodedby a nucleotide residues 64 to 813 of SEQ ID NO:67. In one aspect, theanti-CD19 binding domain is encoded by a nucleotide residues 64 to 813of SEQ ID NO:68. In one aspect, the anti-CD19 binding domain is encodedby a nucleotide residues 64 to 813 of SEQ ID NO:69. In one aspect, theanti-CD19 binding domain is encoded by a nucleotide residues 64 to 813of SEQ ID NO:70. In one aspect, the anti-CD19 binding domain is encodedby a nucleotide residues 64 to 813 of SEQ ID NO:71. In one aspect, theanti-CD19 binding domain is encoded by a nucleotide residues 64 to 813of SEQ ID NO:72.

Provided herein are CD19 inhibitors and combination therapies. In someembodiments, the CD19 inhibitor (e.g., a cell therapy or an antibody) isadministered in combination with a B cell inhibitor, e.g., one or moreinhibitors of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, or ROR1. ACD19 inhibitor includes but is not limited to a CD19 CAR-expressingcell, e.g., a CD19 CART cell, or an anti-CD19 antibody (e.g., ananti-CD19 mono- or bispecific antibody) or a fragment or conjugatethereof. In an embodiment, the CD19 inhibitor is administered incombination with a B-cell inhibitor, e.g., a CAR-expressing celldescribed herein.

Numerous CD19 CAR-expressing cells are described in this disclosure. Forinstance, in some embodiments, a CD19 inhibitor includes an anti-CD19CAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD19CAR construct described in Table 2 or encoded by a CD19 binding CARcomprising a scFv, CDRs, or VH and VL chains described in Tables 2, 4,or 5. For example, an anti-CD19 CAR-expressing cell, e.g., CART, is agenerated by engineering a CD19-CAR (that comprises a CD19 bindingdomain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. Also provided herein are methods of use of the CAR-expressingcells described herein for adoptive therapy.

In one embodiment, an antigen binding domain comprises one, two three(e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2 and HC CDR3, froman antibody listed herein, e.g., in Table 2, 4, or 5 and/or one, two,three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2 and LC CDR3,from an antibody listed herein, e.g., in Table 2, 4, or 5. In oneembodiment, the antigen binding domain comprises a heavy chain variableregion and/or a variable light chain region of an antibody listed ordescribed above.

In an embodiment, the CD19 binding domain (e.g., an scFv) comprises: alight chain variable region comprising an amino acid sequence having atleast one, two or three modifications (e.g., substitutions) but not morethan 30, 20 or 10 modifications (e.g., substitutions) of an amino acidsequence of a light chain variable region provided in Table 2, or asequence with 95-99% identity with an amino acid sequence of Table 2;and/or a heavy chain variable region comprising an amino acid sequencehaving at least one, two or three modifications (e.g., substitutions)but not more than 30, 20 or 10 modifications (e.g., substitutions) of anamino acid sequence of a heavy chain variable region provided in Table2, or a sequence with 95-99% identity to an amino acid sequence of Table2. In embodiments, the CD19 binding domain comprises one or more CDRs(e.g., one each of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LCCDR3) of Table 4 or Table 5, or CDRs having one, two, three, four, five,or six modifications (e.g., substitutions) of one or more of the CDRs.

Exemplary anti-CD19 antibodies or fragments or conjugates thereofinclude but are not limited to blinatumomab, SAR3419 (Sanofi), MEDI-551(MedImmune LLC), Combotox, DT2219ARL (Masonic Cancer Center), MOR-208(also called XmAb-5574; MorphoSys), XmAb-5871 (Xencor), MDX-1342(Bristol-Myers Squibb), SGN-CD19A (Seattle Genetics), and AFM11 (AffimedTherapeutics). See, e.g., Hammer. MAbs. 4.5(2012): 571-77. Blinatomomabis a bispecific antibody comprised of two scFvs—one that binds to CD19and one that binds to CD3. Blinatomomab directs T cells to attack cancercells. See, e.g., Hammer et al.; Clinical Trial Identifier No.NCT00274742 and NCT01209286. MEDI-551 is a humanized anti-CD19 antibodywith a Fc engineered to have enhanced antibody-dependent cell-mediatedcytotoxicity (ADCC). See, e.g., Hammer et al.; and Clinical TrialIdentifier No. NCT01957579. Combotox is a mixture of immunotoxins thatbind to CD19 and CD22. The immunotoxins are made up of scFv antibodyfragments fused to a deglycosylated ricin A chain. See, e.g., Hammer etal.; and Herrera et al. J. Pediatr. Hematol. Oncol. 31.12(2009):936-41;Schindler et al. Br. J. Haematol. 154.4(2011):471-6. DT2219ARL is abispecific immunotoxin targeting CD19 and CD22, comprising two scFvs anda truncated diphtheria toxin. See, e.g., Hammer et al.; and ClinicalTrial Identifier No. NCT00889408. SGN-CD19A is an antibody-drugconjugate (ADC) comprised of an anti-CD19 humanized monoclonal antibodylinked to a synthetic cytotoxic cell-killing agent, monomethylauristatin F (MMAF). See, e.g., Hammer et al.; and Clinical TrialIdentifier Nos. NCT01786096 and NCT01786135. SAR3419 is an anti-CD19antibody-drug conjugate (ADC) comprising an anti-CD19 humanizedmonoclonal antibody conjugated to a maytansine derivative via acleavable linker. See, e.g., Younes et al. J. Clin. Oncol. 30.2(201:2):2776-82; Hammer et al.; Clinical Trial Identifier No. NCT00549185; andBlanc et al. Clin Cancer Res. 2011; 17:6448-58. XmAb-5871 is anFc-engineered, humanized anti-CD19 antibody. See, e.g., Hammer et al.MDX-1342 is a human Fc-engineered anti-CD19 antibody with enhanced ADCC.See, e.g., Hammer et al. In embodiments, the antibody molecule is abispecific anti-CD19 and anti-CD3 molecule. For instance, AFM11 is abispecific antibody that targets CD19 and CD3. See, e.g., Hammer et al.;and Clinical Trial Identifier No. NCT02106091. In some embodiments, ananti-CD19 antibody described herein is conjugated or otherwise bound toa therapeutic agent, e.g., a chemotherapeutic agent, peptide vaccine(such as that described in Izumoto et al. 2008 J Neurosurg 108:963-971),immunosuppressive agent, or immunoablative agent, e.g., cyclosporin,azathioprine, methotrexate, mycophenolate, FK506, CAMPATH, anti-CD3antibody, cytoxin, fludarabine, rapamycin, mycophenolic acid, steroid,FR901228, or cytokine.

Exemplary anti-CD19 antibody molecules (including antibodies orfragments or conjugates thereof) can include a scFv, CDRs, or VH and VLchains described in Tables 2, 4, or 5. In an embodiment, theCD19-binding antibody molecule comprises: a light chain variable regioncomprising an amino acid sequence having at least one, two or threemodifications (e.g., substitutions) but not more than 30, 20 or 10modifications (e.g., substitutions) of an amino acid sequence of a lightchain variable region provided in Table 2, or a sequence with 95-99%identity with an amino acid sequence of Table 2; and/or a heavy chainvariable region comprising an amino acid sequence having at least one,two or three modifications (e.g., substitutions) but not more than 30,20 or 10 modifications (e.g., substitutions) of an amino acid sequenceof a heavy chain variable region provided in Table 2, or a sequence with95-99% identity to an amino acid sequence of Table 2. In embodiments,the CD19-binding antibody molecule comprises one or more CDRs (e.g., oneeach of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3) ofTable 4 or Table 5, or CDRs having one, two, three, four, five, or sixmodifications (e.g., substitutions) of one or more of the CDRs. Theantibody molecule may be, e.g., an isolated antibody molecule.

In one embodiment, an antigen binding domain against CD19 is an antigenbinding portion, e.g., CDRs, of an antigen binding domain described in aTable herein. In one embodiment, a CD19 antigen binding domain can befrom any CD19 CAR, e.g., LG-740; U.S. Pat. Nos. 8,399,645; 7,446,190; Xuet al., Leuk Lymphoma. 2013 54(2):255-260(2012); Cruz et al., Blood122(17):2965-2973 (2013); Brentjens et al., Blood, 118(18):4817-4828(2011); Kochenderfer et al., Blood 116(20):4099-102 (2010); Kochenderferet al., Blood 122 (25):4129-39(2013); and 16th Annu Meet Am Soc Gen CellTher (ASGCT) (May 15-18, Salt Lake City) 2013, Abst 10, each of which isherein incorporated by reference in its entirety.

In one embodiment, the CAR T cell that specifically binds to CD19 hasthe USAN designation TISAGENLECLEUCEL-T. CTL019 is made by a genemodification of T cells is mediated by stable insertion via transductionwith a self-inactivating, replication deficient Lentiviral (LV) vectorcontaining the CTL019 transgene under the control of the EF-1 alphapromoter. CTL019 can be a mixture of transgene positive and negative Tcells that are delivered to the subject on the basis of percenttransgene positive T cells.

In one aspect the nucleic acid sequence of a CAR construct of theinvention is selected from one or more of SEQ ID NOS:85-96. In oneaspect the nucleic acid sequence of a CAR construct is SEQ ID NO:85. Inone aspect the nucleic acid sequence of a CAR construct is SEQ ID NO:86.In one aspect the nucleic acid sequence of a CAR construct is SEQ IDNO:87. In one aspect the nucleic acid sequence of a CAR construct is SEQID NO:88. In one aspect the nucleic acid sequence of a CAR construct isSEQ ID NO:89. In one aspect the nucleic acid sequence of a CAR constructis SEQ ID NO:90. In one aspect the nucleic acid sequence of a CARconstruct is SEQ ID NO:91. In one aspect the nucleic acid sequence of aCAR construct is SEQ ID NO:92. In one aspect the nucleic acid sequenceof a CAR construct is SEQ ID NO:93. In one aspect the nucleic acidsequence of a CAR construct is SEQ ID NO:94. In one aspect the nucleicacid sequence of a CAR construct is SEQ ID NO:95. In one aspect thenucleic acid sequence of a CAR construct is SEQ ID NO:96. In one aspectthe nucleic acid sequence of a CAR construct is SEQ ID NO:97. In oneaspect the nucleic acid sequence of a CAR construct is SEQ ID NO:98. Inone aspect the nucleic acid sequence of a CAR construct is SEQ ID NO:99.

CD20 Inhibitors and Binding Domains

As used herein, the term “CD20” refers to an antigenic determinant knownto be detectable on B cells. Human CD20 is also called membrane-spanning4-domains, subfamily A, member 1 (MS4A1). The human and murine aminoacid and nucleic acid sequences can be found in a public database, suchas GenBank, UniProt and Swiss-Prot. For example, the amino acid sequenceof human CD20 can be found at Accession Nos. NP_690605.1 andNP_068769.2, and the nucleotide sequence encoding transcript variants 1and 3 of the human CD20 can be found at Accession No. NM_152866.2 andNM_021950.3, respectively. As used herein, “CD20” includes proteinscomprising mutations, e.g., point mutations, fragments, insertions,deletions and splice variants of full length wild-type CD20. In oneaspect the antigen-binding portion of the CAR recognizes and binds anantigen within the extracellular domain of the CD20 protein. In oneaspect, the CD20 protein is expressed on a cancer cell.

In some aspects, the present disclosure provides a CD20 inhibitor orbinding domain, e.g., a CD20 inhibitor or binding domain as describedherein. The disclosure also provides a nucleic acid encoding the CD20binding domain, or a CAR comprising the CD20 binding domain. A CD20inhibitor includes but is not limited to a CD20 CAR-expressing cell,e.g., a CD20 CART cell or an anti-CD20 antibody (e.g., an anti-CD20mono- or bispecific antibody) or a fragment thereof. The composition mayalso comprise a second agent, e.g., an anti-CD19 CAR-expressing cell ora CD19 binding domain. The agents may be, e.g., encoded by a singlenucleic acid or different nucleic acids.

In some aspects, a CD20 inhibitor or binding domain is administered as amonotherapy. In some aspects, the CD20 inhibitor or binding domain isadministered in combination with a second agent such as an anti-CD19CAR-expressing cell. In an embodiment, the CD20 inhibitor isadministered in combination with a CD19 inhibitor, e.g., a CD19CAR-expressing cell, e.g., a CAR-expressing cell described herein e.g.,a cell expressing a CAR comprising an antibody binding domain that ismurine, human, or humanized.

CD20 CAR-Expressing Cells, e.g., CARTs

In an embodiment, the CD20 antibody molecule comprises: a light chainvariable region comprising an amino acid sequence having at least one,two or three modifications (e.g., substitutions) but not more than 30,20 or 10 modifications (e.g., substitutions) of an amino acid sequenceof a light chain variable region provided in Table 15A or 15B, or asequence with 95-99% identity with an amino acid sequence of Table 15Aor 15B; and/or a heavy chain variable region comprising an amino acidsequence having at least one, two or three modifications (e.g.,substitutions) but not more than 30, 20 or 10 modifications (e.g.,substitutions) of an amino acid sequence of a heavy chain variableregion provided in Table 14A or 14B, or a sequence with 95-99% identityto an amino acid sequence of Table 14A or 14B. In one embodiment, theCD20 antibody molecule comprises one or more (e.g., two or all three)light chain complementarity determining region 1 (LC CDR1), light chaincomplementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) of a CD20 binding domaindescribed herein, and/or one or more (e.g., all three) heavy chaincomplementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a CD20 binding domaindescribed herein, e.g., a CD20 binding domain comprising one or more,e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.These CDRs may be, e.g., those of Table 12A, 12B, and/or Table 13, or asequence substantially identical thereto. In an embodiment, the CD20antibody molecule comprises one or more CDRs (e.g., a HC CDR1, HC CDR2,HC CDR3, LC CDR1, LC CDR2, or LC CDR3) comprising an amino acid sequencehaving one, two, three, four, five, or six modifications (e.g.,substitutions) of an amino acid sequence of Table 12A, 12B, and/or Table13. The antibody molecule may be, e.g., an isolated antibody molecule.

In some embodiments, a CD20 inhibitor includes an anti-CD20CAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD20CAR construct described in Table 11A or 11B, or a sequence substantiallyidentical thereto, or encoded by a CD20 binding CAR comprising a scFv,CDRs, or VH and VL chains described in Tables 11A-15B, or a sequencesubstantially identical thereto. For example, an anti-CD20CAR-expressing cell, e.g., CART, is a generated by engineering aCD20-CAR (that comprises a CD20 binding domain) into a cell (e.g., a Tcell or NK cell), e.g., for administration in combination with aCAR-expressing cell described herein. Also provided herein are methodsof use of the CAR-expressing cells described herein for adoptivetherapy.

In an embodiment, the CD20 binding domain (e.g., an scFv) comprises: alight chain variable region comprising an amino acid sequence having atleast one, two or three modifications (e.g., substitutions) but not morethan 30, 20 or 10 modifications (e.g., substitutions) of an amino acidsequence of a light chain variable region provided in Table 15A or 15B,or a sequence with 95-99% identity with an amino acid sequence of Table15A or 15B; and/or a heavy chain variable region comprising an aminoacid sequence having at least one, two or three modifications (e.g.,substitutions) but not more than 30, 20 or 10 modifications (e.g.,substitutions) of an amino acid sequence of a heavy chain variableregion provided in Table 14A or 14B, or a sequence with 95-99% identityto an amino acid sequence of Table 14A or 14B.

In one embodiment, the CD20 binding domain comprises one or more (e.g.,two or all three) light chain complementarity determining region 1 (LCCDR1), light chain complementarity determining region 2 (LC CDR2), andlight chain complementarity determining region 3 (LC CDR3) of a CD20binding domain described herein, and/or one or more (e.g., all three)heavy chain complementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a CD20 binding domaindescribed herein, e.g., a CD20 binding domain comprising one or more,e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.These CDRs may be, e.g., those of Table 12A, 12B, and/or Table 13, or asequence substantially identical thereto. In an embodiment, the CD20binding domain (e.g., an scFv) comprises one or more CDRs (e.g., a HCCDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, or LC CDR3) comprising anamino acid sequence having one, two, three, four, five, or sixmodifications (e.g., substitutions) of an amino acid sequence of Table12A, 12B, and/or Table 13.

In some embodiments, the CAR comprises an antibody or antibody fragmentwhich includes a CD20 binding domain, a transmembrane domain, and anintracellular signaling domain. The CD20 binding domain may comprise oneor more of light chain complementarity determining region 1 (LC CDR1),light chain complementarity determining region 2 (LC CDR2), and lightchain complementarity determining region 3 (LC CDR3) of any CD20 lightchain binding domain amino acid sequence listed in Table 13, 15A, or15B, and one or more of heavy chain complementarity determining region 1(HC CDR1), heavy chain complementarity determining region 2 (HC CDR2),and heavy chain complementarity determining region 3 (HC CDR3) of anyCD20 heavy chain binding domain amino acid sequence listed in Table 12A,12B, 14A, or 14B.

In an embodiment, the CD20 binding domain comprises six CDRs (e.g., oneeach of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3) ofany one of CAR20-1, CAR20-2, CAR20-3, CAR20-4, CAR20-5, CAR20-6,CAR20-7, CAR20-8, CAR20-9, CAR20-10, CAR20-11, CAR20-12, CAR20-13,CAR20-14, CAR20-15, or CAR20-16, or a sequence substantially identicalthereto. In an embodiment, the CD20 binding domain comprises three CDRs(e.g., one each of a HC CDR1, HC CDR2, and HC CDR3, or one each of a LCCDR1, LC CDR2, and LC CDR3) of any one of CAR20-1, CAR20-2, CAR20-3,CAR20-4, CAR20-5, CAR20-6, CAR20-7, CAR20-8, CAR20-9, CAR20-10,CAR20-11, CAR20-12, CAR20-13, CAR20-14, CAR20-15, or CAR20-16, or asequence substantially identical thereto.

In one embodiment, the CD20 binding domain comprises a light chainvariable region described herein (e.g., in Table 15A or 15B) and/or aheavy chain variable region described herein (e.g., in Table 14A or14B), or a sequence substantially identical thereto. In an embodiment,the CD20 binding domain (e.g., an scFv) comprises: a light chainvariable region comprising an amino acid sequence having at least one,two or three modifications (e.g., substitutions) but not more than 30,20 or 10 modifications (e.g., substitutions) of an amino acid sequenceof a light chain variable region provided in Table 15A or 15B, or asequence with 95-99% identity with an amino acid sequence of Table 15Aor 15B; and/or a heavy chain variable region comprising an amino acidsequence having at least one, two or three modifications (e.g.,substitutions) but not more than 30, 20 or 10 modifications (e.g.,substitutions) of an amino acid sequence of a heavy chain variableregion provided in Table 14A or 14B, or a sequence with 95-99% identityto an amino acid sequence of Table 14A or 14B.

Further embodiments include a nucleotide sequence that encodes apolypeptide described in this section. For example, further embodimentsinclude a nucleotide sequence that encodes a polypeptide of any ofTables 11A-15B. For instance, the nucleotide sequence can comprise a CARconstruct or scFv of Table 11A or 11B. The nucleotide may encode a VH ofTable 14A or 14B, a VL of Table 15A or 15B, or both. The nucleotide mayencode one or more of (e.g., two or three of) a VH CDR1, VH CDR2, or VHCDR3 of Table 12A or 12B and/or the nucleotide may encode one or more of(e.g., two or three of) a VL CDR1, VL CDR2, or VL CDR3 of Table 13. Thenucleotide sequence can also include one or more of, e.g., all of thedomains of SEQ ID NOS: 13, 14, 15, 16, 17, and 51.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells, comprising a mixture of cells expressing CD19CARs and CD20 CARs. For example, in one embodiment, the population ofCART cells can include a first cell expressing a CD19 CAR and a secondcell expressing a CD20 CAR. In one embodiment, the population ofCAR-expressing cells includes, e.g., a first cell expressing a CAR(e.g., a CD19 CAR, a ROR1 CAR, a CD20 CAR, or a CD22 CAR) that includesa primary intracellular signaling domain, and a second cell expressing aCAR (e.g., a CD19 CAR, a ROR1 CAR, a CD20 CAR, or a CD22 CAR)) thatincludes a secondary signaling domain.

The CD20 CAR may also comprise one or more of a transmembrane domain,e.g., a transmembrane domain as described herein, an intracellularsignaling domain, e.g., intracellular signaling domain as describedherein, a costimulatory domain, e.g., a costimulatory domain asdescribed herein, a leader sequence, e.g. a leader sequence as describedherein, or a hinge, e.g., a hinge as described herein.

Exemplary anti-CD20 antibodies include but are not limited to rituximab,ofatumumab, ocrelizumab, veltuzumab, obinutuzumab, TRU-015 (TrubionPharmaceuticals), ocaratuzumab, and Pro131921 (Genentech). See, e.g.,Lim et al. Haematologica. 95.1(2010):135-43.

In some embodiments, the anti-CD20 antibody comprises rituximab.Rituximab is a chimeric mouse/human monoclonal antibody IgG1 kappa thatbinds to CD20 and causes cytolysis of a CD20 expressing cell, e.g., asdescribed in accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. In some embodiments, rituximab can be used to treat B-cellmalignancies, such as non-Hodgkin lymphoma (NHL) (e.g., follicular NHL,diffuse large B-cell lymphoma) and chronic lymphocytic leukemia (CLL).In other embodiments, rituximab can be used to treat autoimmunediseases, such as rheumatoid arthritis, multiple sclerosis, systemiclupus erythematosus, chronic inflammatory demyelinating polyneuropathy,autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia,idiopathic thrombocytopenic purpura (ITP), Evans syndrome, vasculitis,bullous skin disorders, type 1 diabetes mellitus, Sjogren's syndrome,anti-NMDA receptor encephalitis and Devic's disease, Graves'ophthalmopathy, and autoimmune pancreatitis. In some embodiments,rituximab can be used to treat transplant rejection.

In some embodiments, rituximab is administered intravenously, e.g., asan intravenous infusion. For example, each infusion provides about500-2000 mg (e.g., about 500-550, 550-600, 600-650, 650-700, 700-750,750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1100, 1100-1200,1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800,1800-1900, or 1900-2000 mg) of rituximab.

In some embodiments, rituximab is administered at a dose of 150 mg/m² to750 mg/m², e.g., about 150-175 mg/m², 175-200 mg/m², 200-225 mg/m²,225-250 mg/m², 250-300 mg/m², 300-325 mg/m², 325-350 mg/m², 350-375mg/m², 375-400 mg/m², 400-425 mg/m², 425-450 mg/m², 450-475 mg/m²,475-500 mg/m², 500-525 mg/m², 525-550 mg/m², 550-575 mg/m², 575-600mg/m², 600-625 mg/m², 625-650 mg/m², 650-675 mg/m², or 675-700 mg/m²,where m² indicates the body surface area of the subject.

In some embodiments, rituximab is administered at a dosing interval ofat least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, or more. For example,rituximab is administered at a dosing interval of at least 0.5 weeks,e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8 weeks, or more.

In some embodiments, rituximab is administered at a dose and dosinginterval described herein for a period of time, e.g., at least 2 weeks,e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20 weeks, or greater. For example, rituximab is administered ata dose and dosing interval described herein for a total of at least 4doses per treatment cycle (e.g., at least 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, or more doses per treatment cycle).

In some aspects, the anti-CD20 antibody comprises ofatumumab. Ofatumumabis an anti-CD20 IgG1κ human monoclonal antibody with a molecular weightof approximately 149 kDa. For example, ofatumumab is generated usingtransgenic mouse and hybridoma technology and is expressed and purifiedfrom a recombinant murine cell line (NS0). See, e.g.,accessdatafda.gov/drugsatfda_docs/label/2009/125326lbl.pdf; and ClinicalTrial Identifier number NCT01363128, NCT01515176, NCT01626352, andNCT01397591.

Ofatumumab can be used to treat diseases such as CLL, non-Hodgkinlymphoma (NHL) (e.g., follicular NHL and DLBCL), B-Cell ProlymphocyticLeukemia, Acute Lymphoblastic Leukemia (ALL), mantle cell lymphoma,rheumatoid arthritis, and multiple sclerosis.

In some embodiments, ofatumumab is administered as an intravenousinfusion. For example, each infusion provides about 150-3000 mg (e.g.,about 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500,500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900,900-950, 950-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800,1800-2000, 2000-2200, 2200-2400, 2400-2600, 2600-2800, or 2800-3000 mg)of ofatumumab.

In some embodiments, ofatumumab is administered at a dosing interval ofat least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, or more. For example,ofatumumab is administered at a dosing interval of at least 1 week,e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28, 20, 22, 24, 26,28, 30 weeks, or more.

In some embodiments, ofatumumab is administered at a dose and dosinginterval described herein for a period of time, e.g., at least 1 week,e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 22, 24, 26, 28, 30, 40, 50, 60 weeks or greater, or 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12 months or greater, or 1, 2, 3, 4, 5 years orgreater. For example, ofatumumab is administered at a dose and dosinginterval described herein for a total of at least 2 doses per treatmentcycle (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 18, 20, or more doses per treatment cycle).

In some aspects, the anti-CD20 antibody comprises ocrelizumab.Ocrelizumab is a humanized anti-CD20 monoclonal antibody, e.g., asdescribed in Clinical Trials Identifier Nos. NCT00077870, NCT01412333,NCT00779220, NCT00673920, NCT01194570, and Kappos et al. Lancet.19.378(2011):1779-87. For example, ocrelizumab can be used to treatdiseases such as rheumatoid arthritis, multiple sclerosis, and lupus.

In some embodiments, ocrelizumab is administered as an intravenousinfusion. For example, each infusion provides about 50-2000 mg (e.g.,about 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400,400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800,800-850, 850-900, 900-950, 950-1000, 1000-1100, 1100-1200, 1200-1300,1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800, 1800-1900, or1900-2000 mg) of ocrelizumab.

In some embodiments, ocrelizumab is administered at a dosing interval ofat least 7 days, e.g., 7, 14, 21, 28, 35 days, or more. For example,ocrelizumab is administered at a dosing interval of at least 1 week,e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28, 20, 22, 24, 26,28, 30 weeks, or more.

In some embodiments, ocrelizumab is administered at a dose and dosinginterval described herein for a period of time, e.g., at least 2 weeks,e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 22, 24, 26, 28, 30, 40, 50, 60 weeks or greater, or 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12 months or greater, or 1, 2, 3, 4, 5 yearsor greater. For example, ocrelizumab is administered at a dose anddosing interval described herein for a total of at least 4 doses pertreatment cycle (e.g., at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 18, 20, or more doses per treatment cycle).

In some aspects, the anti-CD20 antibody comprises veltuzumab. Veltuzumabis a humanized monoclonal antibody against CD20. See, e.g., ClinicalTrial Identifier No. NCT00547066, NCT00546793, NCT01101581, andGoldenberg et al. Leuk Lymphoma. 51(5)(2010):747-55. For example,veltuzumab can be used to treat NHL (e.g., DLBCL, follicular lymphoma),CLL, and autoimmune diseases such as immune Thrombocytopenic Purpura(ITP).

In some embodiments, veltuzumab is administered subcutaneously orintravenously, e.g., as an intravenous infusion. In some embodiments,veltuzumab is administered at a dose of 50-800 mg/m², e.g., about 50-60,60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140,140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-225, 225-250,250-275, 275-300, 300-325, 325-350, 350-375, 375-400, 400-425, 425-450,450-475, 475-500, 500-525, 525-550, 550-575, 575-600, 600-625, 625-650,650-675, 675-700, 700-725, 725-750, 750-775, or 775-800 mg/m². In someembodiments, a dose of 50-400 mg, e.g., 50, 75, 100, 125, 150, 175, 200,225, 250, 275, 300, 325, 350, 375, or 400 mg of veltuzumab isadministered.

In some embodiments, veltuzumab is administered at a dosing interval ofat least 7 days, e.g., 7, 14, 21, 28, 35 days, or more. For example,veltuzumab is administered at a dosing interval of at least 1 week,e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28, 20, 22, 24, 26,28, weeks, or more.

In some embodiments, veltuzumab is administered at a dose and dosinginterval described herein for a period of time, e.g., at least 2 weeks,e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 22, 24, 26, 28, 30, 40, 50, 60 weeks or greater, or 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12 months or greater, or 1, 2, 3, 4, 5 yearsor greater. For example, veltuzumab is administered at a dose and dosinginterval described herein for a total of at least 4 doses per treatmentcycle (e.g., at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18,20, or more doses per treatment cycle).

In some aspects, the anti-CD20 antibody comprises GA101. GA101 (alsocalled obinutuzumab or R05072759) is a humanized and glyco-engineeredanti-CD20 monoclonal antibody. For example, GA101 can be used to treatdiseases such as B-cell lymphoid malignancies, e.g., CLL, non-Hodgkinlymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL). See, e.g.,Robak. Curr. Opin. Investig. Drugs. 10.6(2009):588-96; Clinical TrialIdentifier Numbers: NCT01995669, NCT01889797, NCT02229422, andNCT01414205; andaccessdata.fda.gov/drugsatfda_docs/label/2013/125486s000lbl.pdf.

In some embodiments, GA101 is administered intravenously, e.g., as anintravenous infusion. For example, each infusion provides about 100-3000mg (e.g., about 100-150, 150-200, 200-250, 250-500, 300-350, 350-400,400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800,800-850, 850-900, 900-950, 950-1000, 1000-1200, 1200-1400, 1400-1600,1600-1800, 1800-2000, 2000-2200, 2200-2400, 2400-2600, 2600-2800, or2800-3000 mg) of GA101.

In some embodiments, GA101 is administered at a dosing interval of atleast 7 days, e.g., 7, 14, 21, 28, 35 days, or more. For example, GA101is administered at a dosing interval of at least 1 week, e.g., 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28, 20, 22, 24, 26, 28, 30 weeks,or more. For example, GA101 is administered at a dosing interval of atleast 1 month, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or moremonths. In some embodiments, GA101 is administered at a dosing intervalof 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days.

In some embodiments, GA101 is administered at a dose and dosing intervaldescribed herein for a period of time, e.g., at least 1 week, e.g., 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22,24, 26, 28, 30, 40, 50, 60 weeks or greater, or 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12 months or greater, or 1, 2, 3, 4, 5 years or greater. Forexample, GA101 is administered at a dose and dosing interval describedherein for a total of at least 2 doses per treatment cycle (e.g., atleast 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, ormore doses per treatment cycle).

In some aspects, the anti-CD20 antibody comprises AME-133v. AME-133v(also called LY2469298 or ocaratuzumab) is a humanized IgG1 monoclonalantibody against CD20 with increased affinity for the FcγRIIIa receptorand an enhanced antibody dependent cellular cytotoxicity (ADCC) activitycompared with rituximab. See, e.g., Robak et al. BioDrugs25.1(2011):13-25. In some embodiments, AME-133v can be used to treatcancers such as NHL, e.g., follicular lymphoma. See, e.g., Forero-Torreset al. Clin Cancer Res. 18.5(2012):1395-403.

In some aspects, the anti-CD20 antibody comprises PRO131921. PRO131921is a humanized anti-CD20 monoclonal antibody engineered to have betterbinding to FcγRIIIa and enhanced ADCC compared with rituximab. See,e.g., Robak et al. BioDrugs 25.1(2011):13-25; and Casulo et al. ClinImmunol. 154.1(2014):37-46. In some embodiments, PRO131921 can be usedto treat NHL. See, e.g., Clinical Trial Identifier No. NCT00452127. Insome embodiments, PRO131921 is administered intravenously, e.g., as anintravenous infusion. In some embodiments, PRO131921 is administered ata dose of 15 mg/m² to 1000 mg/m², e.g., about 15-20, 20-25, 25-30,30-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 70-75, 75-80,80-85, 85-90, 90-95, 95-100, 100-125, 125-150, 150-175, 175-200,200-226, 225-250, 250-300, 300-325, 325-350, 350-375, 375-400, 400-425,425-450, 450-475, 475-500, 500-525, 525-550, 550-575, 575-600, 600-625,625-650, 650-675, 675-700, 700-725, 725-750, 750-775, 775-800, 800-825,825-850, 850-875, 875-900, 900-925, 925-950, 950-975, or 975-1000 mg/m²,where m² indicates the body surface area of the subject.

In some aspects, the anti-CD20 antibody comprises TRU-015. TRU-015 is ananti-CD20 fusion protein derived from domains of an antibody againstCD20. TRU-015 is smaller than monoclonal antibodies, but retainsFc-mediated effector functions. See, e.g., Robak et al. BioDrugs25.1(2011):13-25. TRU-015 contains an anti-CD20 single-chain variablefragment (scFv) linked to human IgG1 hinge, CH2, and CH3 domains butlacks CH1 and CL domains. In some embodiments, TRU-015 can be used totreat B-cell lymphomas and rheumatoid arthritis. In some cases, TRU-015is administered intravenously, e.g., as an intravenous infusion. In someembodiments, TRU-015 is administered at a dose of 0.01-30 mg/kg, e.g.,0.01-0.015, 0.015-0.05, 0.05-0.15, 0.15-0.5, 0.5-1, 1-1.5, 1.5-2.5,2.5-5, 5-10, 10-15, 15-20, 20-25, or 25-30 mg/kg body weight. In someembodiments, TRU-015 is administered at a dosing interval of at least 1day, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days apart.See, e.g., Burge et al. Olin Tiler. 30.10(2008):1806-16.

In some embodiments, an anti-CD20 antibody described herein isconjugated or otherwise bound to a therapeutic agent, e.g., achemotherapeutic agent (e.g., cytoxan, fludarabine, histone deacetylaseinhibitor, demethylating agent, peptide vaccine, anti-tumor antibiotic,tyrosine kinase inhibitor, alkylating agent, anti-microtubule oranti-mitotic agent, CD20 antibody, or CD20 antibody drug conjugatedescribed herein), anti-allergic agent, anti-nausea agent (oranti-emetic), pain reliever, or cytoprotective agent described herein.

CD22 Inhibitors and Binding Domains

As used herein, the term “CD22,” refers to an antigenic determinantknown to be detectable on leukemia precursor cells. The human and murineamino acid and nucleic acid sequences can be found in a public database,such as GenBank, UniProt and Swiss-Prot. For example, the amino acidsequences of isoforms 1-5 human CD22 can be found at Accession Nos. NP001762.2, NP 001172028.1, NP 001172029.1, NP 001172030.1, and NP001265346.1, respectively, and the nucleotide sequence encoding variants1-5 of the human CD22 can be found at Accession No. NM 001771.3, NM001185099.1, NM 001185100.1, NM 001185101.1, and NM 001278417.1,respectively. As used herein, “CD22” includes proteins comprisingmutations, e.g., point mutations, fragments, insertions, deletions andsplice variants of full length wild-type CD22. In one aspect theantigen-binding portion of the CAR recognizes and binds an antigenwithin the extracellular domain of the CD22 protein. In one aspect, theCD22 protein is expressed on a cancer cell.

In some aspects, the present disclosure provides a CD22 inhibitor orbinding domain, e.g., a CD22 inhibitor or binding domain as describedherein. The disclosure also provides a nucleic acid encoding the CD22binding domain, or a CAR comprising the CD22 binding domain. A CD22inhibitor includes but is not limited to a CD22 CAR-expressing cell,e.g., a CD22 CART cell or an anti-CD22 antibody (e.g., an anti-CD22mono- or bispecific antibody) or a fragment thereof. The composition mayalso comprise a second agent, e.g., an anti-CD19 CAR-expressing cell ora CD19 binding domain. The agents may be, e.g., encoded by a singlenucleic acid or different nucleic acids.

In some aspects, a CD22 inhibitor or binding domain is administered as amonotherapy. In some aspects, the CD22 inhibitor or binding domain isadministered in combination with a second agent such as an anti-CD19CAR-expressing cell. In an embodiment, the CD22 inhibitor isadministered in combination with a CD19 inhibitor, e.g., a CD19CAR-expressing cell, e.g., a CAR-expressing cell described herein e.g.,a cell expressing a CAR comprising an antibody binding domain that ismurine, human, or humanized.

CD22 CAR-Expressing Cells, e.g., CARTs

In one embodiment, the CD22 inhibitor is a CD22 CAR-expressing cell,e.g., a CD22-CAR that comprises a CD22 binding domain and is engineeredinto a cell (e.g., T cell or NK cell) for administration in combinationwith CD19 CAR-expressing cell, e.g., CART, and methods of their use foradoptive therapy.

In another aspect, the present invention provides a population ofCAR-expressing cells, e.g., CART cells, comprising a mixture of cellsexpressing CD19 CARs and CD22 CARs. For example, in one embodiment, thepopulation of CART cells can include a first cell expressing a CD19 CARand a second cell expressing a CD22 CAR. In one embodiment, thepopulation of CAR-expressing cells includes, e.g., a first cellexpressing a CAR (e.g., a CD19 CAR or CD22 CAR) that includes a primaryintracellular signaling domain, and a second cell expressing a CAR(e.g., a CD19 CAR or CD22 CAR) that includes a secondary signalingdomain.

In one aspect, the CD22-CAR comprises an optional leader sequence (e.g.,an optional leader sequence described herein), an extracellular antigenbinding domain, a hinge (e.g., hinge described herein), a transmembranedomain (e.g., transmembrane domain described herein), and anintracellular stimulatory domain (e.g., intracellular stimulatory domaindescribed herein). In one aspect an exemplary CD22 CAR constructcomprises an optional leader sequence (e.g., a leader sequence describedherein), an extracellular antigen binding domain, a hinge, atransmembrane domain, an intracellular costimulatory domain (e.g., anintracellular costimulatory domain described herein) and anintracellular stimulatory domain.

In one aspect, the CAR22 binding domain comprises the scFv portion of anamino acid sequence (or encoded by a nucleotide sequence) provided inany of SEQ ID NOs: 200-428. In one aspect, the CAR22 binding domaincomprises the scFv portion provided in any of SEQ ID NOs: 203, 209, 215,221, 227, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298,304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382,388, 394, 400, 406, 412, 418, or 423.

In specific aspects, a CAR construct of the invention comprises a scFvdomain selected from the group consisting of SEQ ID NOS: 203, 209, 215,221, 227, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298,304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382,388, 394, 400, 406, 412, 418, or 423, wherein the scFv may be precededby an optional leader sequence such as provided in SEQ ID NO: 13, andfollowed by an optional hinge sequence such as provided in SEQ ID NO:14or SEQ ID NO:45 or SEQ ID NO:47 or SEQ ID NO:49, a transmembrane regionsuch as provided in SEQ ID NO:15, an intracellular signalling domainthat includes SEQ ID NO:16 or SEQ ID NO:51 and a CD3 zeta sequence thatincludes SEQ ID NO:17 or SEQ ID NO:43, e.g., wherein the domains arecontiguous with and in the same reading frame to form a single fusionprotein. In some embodiments, the scFv domain is a human scFv domainselected from the group consisting of SEQ ID NOS: 203, 209, 215, 221,227, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298, 304,310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388,394, 400, 406, 412, 418, or 423.

Also included in the invention is a nucleotide sequence that encodes thepolypeptide of each of the scFv fragments selected from the groupconsisting of SEQ ID NO: 203, 209, 215, 221, 227, 232, 238, 244, 250,256, 262, 268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328, 334,340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, or423. Also included in the invention is a nucleotide sequence thatencodes the polypeptide of each of the scFv fragments selected from thegroup consisting of SEQ ID NO: 203, 209, 215, 221, 227, 232, 238, 244,250, 256, 262, 268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328,334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412,418, or 423, and each of the domains of SEQ ID NOS: 13-17, plus theencoded CD22 CAR of the invention.

In some embodiments, full-length CD22 CAR sequences are also providedherein as SEQ ID NOS: 207, 213, 219, 225, 230, 236, 242, 248, 254, 260,266, 272, 278, 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344,350, 356, 362, 368, 374, 380, 386, 392, 398, 404, 410, 416, 422, or 427,as shown in Table 6A or 6B.

In one aspect, the present invention encompasses a recombinant nucleicacid construct comprising a nucleic acid molecule encoding a CAR,wherein the nucleic acid molecule comprises the nucleic acid sequenceencoding a CD22 binding domain, e.g., described herein, e.g., that iscontiguous with and in the same reading frame as a nucleic acid sequenceencoding an intracellular signaling domain. In one aspect, a CD22binding domain is selected from one or more of SEQ ID NOS: 203, 209,215, 221, 227, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292,298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376,382, 388, 394, 400, 406, 412, 418, or 423. In one aspect, the presentinvention encompasses a recombinant nucleic acid construct comprising anucleic acid molecule encoding a CAR, wherein the nucleic acid moleculecomprises a nucleic acid sequence encoding a CD22 binding domain, e.g.,wherein the sequence is contiguous with and in the same reading frame asthe nucleic acid sequence encoding an intracellular signaling domain. Anexemplary intracellular signaling domain that can be used in the CARincludes, but is not limited to, one or more intracellular signalingdomains of, e.g., CD3-zeta, CD28, 4-1BB, and the like. In someinstances, the CAR can comprise any combination of CD3-zeta, CD28,4-1BB, and the like.

In one aspect, the nucleic acid sequence of a CAR construct of theinvention comprises the CAR construct of one or more of SEQ ID NOS: 200,208, 214, 220, 226, 231, 237, 243, 249, 255, 261, 267, 273, 279, 285,291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369,375, 381, 387, 393, 399, 405, 411, 417, 422, or 428. In one aspect, thenucleic acid sequence of a CAR construct of the invention comprises anscFv-encoding sequence of one or more of SEQ ID NOs: 204, 210, 216, 222,116, 233, 239, 245, 251, 257, 263, 269, 275, 281, 287, 293, 299, 305,311, 317, 323, 329, 335, 341, 347, 353, 359, 365, 371, 377, 383, 389,395, 401, 407, 413, 117, or 424.

In some instances, it is beneficial for the antigen binding domain to bederived from the same species in which the CAR will ultimately be usedin. For example, for use in humans, it may be beneficial for the antigenbinding domain of the CAR to comprise human or humanized residues forthe antigen binding domain of an antibody or antibody fragment. Thus, inone aspect, the antigen binding domain comprises a human antibody or anantibody fragment. In one embodiment, the human CD22 binding domaincomprises one or more (e.g., all three) light chain complementaritydetermining region 1 (LC CDR1), light chain complementarity determiningregion 2 (LC CDR2), and light chain complementarity determining region 3(LC CDR3) of a human CD22 binding domain described herein, and/or one ormore (e.g., all three) heavy chain complementarity determining region 1(HC CDR1), heavy chain complementarity determining region 2 (HC CDR2),and heavy chain complementarity determining region 3 (HC CDR3) of ahuman CD22 binding domain described herein, e.g., a human CD22 bindingdomain comprising one or more, e.g., all three, LC CDRs and one or more,e.g., all three, HC CDRs. In one embodiment, the human CD22 bindingdomain comprises one or more (e.g., all three) heavy chaincomplementarity determining region 1 (HC CDR1), heavy chaincomplementarity determining region 2 (HC CDR2), and heavy chaincomplementarity determining region 3 (HC CDR3) of a human CD22 bindingdomain described herein, e.g., the human CD22 binding domain has twovariable heavy chain regions, each comprising a HC CDR1, a HC CDR2 and aHC CDR3 described herein. In one embodiment, the human CD22 bindingdomain comprises a human light chain variable region described herein(e.g., in Table 6A, 6B, 10A or 10B) and/or a human heavy chain variableregion described herein (e.g., in Table 6A, 6B, 9A or 9B). In oneembodiment, the human CD22 binding domain comprises a human heavy chainvariable region described herein (e.g., in Table 6A, 6B, 9A or 9B),e.g., at least two human heavy chain variable regions described herein(e.g., in Table 6A, 8B, 9A or 9B). In one embodiment, the CD22 bindingdomain is a scFv comprising a light chain and a heavy chain of an aminoacid sequence of Table 6A, 6B, 9A, 9B, 10A, or 10B. In an embodiment,the CD22 binding domain (e.g., an scFv) comprises: a light chainvariable region comprising an amino acid sequence having at least one,two or three modifications (e.g., substitutions) but not more than 30,20 or 10 modifications (e.g., substitutions) of an amino acid sequenceof a light chain variable region provided in Table 6A, 6B, 10A, or 10B,or a sequence with 95-99% identity with an amino acid sequence of Table6A, 6B, 10A, or 10B; and/or a heavy chain variable region comprising anamino acid sequence having at least one, two or three modifications(e.g., substitutions) but not more than 30, 20 or 10 modifications(e.g., substitutions) of an amino acid sequence of a heavy chainvariable region provided in Table 6A, 6B, 9A, or 9B, or a sequence with95-99% identity to an amino acid sequence of Table 6A, 6B, 9A or 9B. Inone embodiment, the human CD22 binding domain comprises a sequenceselected from a group consisting of SEQ ID NO: 203, 209, 215, 221, 227,232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298, 304, 310,316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394,400, 406, 412, 418, or 423, or a sequence with 95-99% identity thereof.In one embodiment, the human CD22 binding domain is a scFv, and a lightchain variable region comprising an amino acid sequence describedherein, e.g., in Table 6A, 6B, 10A, or 10B, is attached to a heavy chainvariable region comprising an amino acid sequence described herein,e.g., in Table 6A, 6B, 9A, or 9B, via a linker, e.g., a linker describedherein. In one embodiment, the human CD22 binding domain includes a(Gly₄-Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, e.g., 3 or 4 (SEQID NO:53). The light chain variable region and heavy chain variableregion of a scFv can be, e.g., in any of the following orientations:light chain variable region-linker-heavy chain variable region or heavychain variable region-linker-light chain variable region.

In one aspect, the CD22 binding domain is characterized by particularfunctional features or properties of an antibody or antibody fragment.For example, in one aspect, the portion of a CAR composition of theinvention that comprises an antigen binding domain specifically bindshuman CD22 or a fragment thereof. In one aspect, the invention relatesto an antigen binding domain comprising an antibody or antibodyfragment, wherein the antibody binding domain specifically binds to aCD22 protein or fragment thereof, wherein the antibody or antibodyfragment comprises a variable heavy chain that includes an amino acidsequence of any of SEQ ID NOs: 700, 701, 702, 703, 704, 705, 706, 707,708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721,722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735,736, 737, or 738, and/or a variable light chain that includes an aminoacid sequence of any of SEQ ID NOs 739, 740, 741, 742, 743, 744, 745,746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759,760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773,774, 775, 776, or 777. In certain aspects, the scFv is contiguous withand in the same reading frame as a leader sequence. In one aspect theleader sequence is the polypeptide sequence provided as SEQ ID NO:13.

In embodiments, the CAR comprises an antibody or antibody fragment whichincludes a CD22 binding domain, a transmembrane domain, and anintracellular signaling domain. In embodiments, the CD22 binding domaincomprises one or more of light chain complementarity determining region1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2),and light chain complementarity determining region 3 (LC CDR3) of anyCD22 light chain binding domain amino acid sequence listed in Table 8A,8B, 10A or 10B, and one or more of heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3) of any CD22 heavy chain binding domain amino acid sequencelisted in Table 7A, 7B, 7C, 9A, or 9B.

In one aspect, the CD22 binding domain is a fragment, e.g., a singlechain variable fragment (scFv). In one aspect, the CD22 binding domainis a Fv, a Fab, a (Fab′)2, or a bi-functional (e.g. bi-specific) hybridantibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)).In one aspect, the antibodies and fragments thereof of the inventionbinds a CD22 protein or a fragment thereof with wild-type or enhancedaffinity.

In some instances, a human scFv can be derived from a display library.

In one embodiment, the CD22 binding domain, e.g., scFv comprises atleast one mutation such that the mutated scFv confers improved stabilityto the CART22 construct. In another embodiment, the CD22 binding domain,e.g., scFv comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutationsarising, e.g., from the humanization process such that the mutated scFvconfers improved stability to the CART22 construct.

In one aspect, the present invention contemplates modifications of thestarting antibody or fragment (e.g., scFv) amino acid sequence thatgenerate functionally equivalent molecules. For example, the VH or VL ofa CD22 binding domain, e.g., scFv, comprised in the CAR can be modifiedto retain at least about 70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%,79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99% identity of the starting VH or VLframework region of the CD22 binding domain, e.g., scFv. The presentinvention contemplates modifications of the entire CAR construct, e.g.,modifications in one or more amino acid sequences of the various domainsof the CAR construct in order to generate functionally equivalentmolecules. The CAR construct can be modified to retain at least about70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99% identity of the starting CAR construct.

In an embodiment, the CD22 binding domain comprises six CDRs (e.g., oneeach of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3) ofany one of CAR22-1, CAR22-2, CAR22-3, CAR22-4, CAR22-5, CAR22-6,CAR22-7, CAR22-8, CAR22-9, CAR22-10, CAR22-11, CAR22-12, CAR22-13,CAR22-14, CAR22-15, or CAR22-16, CAR22-17, CAR22-18, CAR22-19, CAR22-20,CAR22-21, CAR22-22, CAR22-23, CAR22-24, CAR22-25, CAR22-26, CAR22-27,CAR22-28, CAR22-29, CAR22-30, CAR22-31, CAR22-32, CAR22-33, CAR22-34,CAR22-35, CAR22-36, CAR22-37, or CAR22-38 (e.g., as described in Table7A, 7B, 7C, 8A and/or 8B), or a sequence substantially identicalthereto. In an embodiment, the CD22 binding domain comprises three CDRs(e.g., one each of a HC CDR1, HC CDR2, and HC CDR3, or one each of a LCCDR1, LC CDR2, and LC CDR3) of any one of CAR22-1, CAR22-2, CAR22-3,CAR22-4, CAR22-5, CAR22-6, CAR22-7, CAR22-8, CAR22-9, CAR22-10,CAR22-11, CAR22-12, CAR22-13, CAR22-14, CAR22-15, or CAR22-16, CAR22-17,CAR22-18, CAR22-19, CAR22-20, CAR22-21, CAR22-22, CAR22-23, CAR22-24,CAR22-25, CAR22-26, CAR22-27, CAR22-28, CAR22-29, CAR22-30, CAR22-31,CAR22-32, CAR22-33, CAR22-34, CAR22-35, CAR22-36, CAR22-37, or CAR22-38(e.g., as described in Table 7A, 7B, 7C, 8A and/or 8B), or a sequencesubstantially identical thereto.

Further embodiments include a nucleotide sequence that encodes apolypeptide described in this section. For example, further embodimentsinclude a nucleotide sequence that encodes a polypeptide of any ofTables 6A-10B. For instance, the nucleotide sequence can comprise a CARconstruct or scFv of Table 6A or 6B. The nucleotide may encode a VH ofTable 9A or 9B, a VL or Table 10A or 10B, or both. The nucleotide mayencode one or more of (e.g., two or three of) a VH CDR1, VH CDR2, or VHCDR3 of Table 7A, 7B, or 7C and/or the nucleotide may encode one or moreof (e.g., two or three of) a VL CDR1, VL CDR2, or VL CDR3 of Table 8A or8B. The nucleotide sequence can also include one or more of, e.g., allof the domains of SEQ ID NOS: 13, 14, 15, 16, 17, and 51.

The CD22 CAR may also comprise one or more of a transmembrane domain,e.g., a transmembrane domain as described herein, an intracellularsignaling domain, e.g., intracellular signaling domain as describedherein, a costimulatory domain, e.g., a costimulatory domain asdescribed herein, a leader sequence, e.g. a leader sequence as describedherein, or a hinge, e.g., a hinge as described herein.

In one embodiment, the CD22 inhibitor is a CD22 inhibitor describedherein. The CD22 inhibitor can be, e.g., an anti-CD22 antibody (e.g., ananti-CD22 mono- or bispecific antibody), a small molecule, or a CD22CART. In some embodiments the anti-CD22 antibody is conjugated orotherwise bound to a therapeutic agent. Exemplary therapeutic agentsinclude, e.g., microtubule disrupting agents (e.g., monomethylauristatin E) and toxins (e.g., diphtheria toxin or Pseudomonasexotoxin-A, ricin). In an embodiment, the CD22 inhibitor is administeredin combination with a CD19 inhibitor, e.g., a CD19 CAR-expressing cell,e.g., a CAR-expressing cell described herein e.g., a cell expressing aCAR comprising an antibody binding domain that is murine, human, orhumanized.

In one embodiment, the anti-CD22 antibody is selected from ananti-CD19/CD22 bispecific ligand-directed toxin (e.g., two scFv ligands,recognizing human CD19 and CD22, linked to the first 389 amino acids ofdiphtheria toxin (DT), DT 390, e.g., DT2219ARL); anti-CD22 monoclonalantibody-MMAE conjugate (e.g., DCDT2980S); scFv of an anti-CD22 antibodyRFB4 fused to a fragment of Pseudomonas exotoxin-A (e.g., BL22);deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 (e.g.,Combotox); humanized anti-CD22 monoclonal antibody (e.g., epratuzumab);or the Fv portion of an anti-CD22 antibody covalently fused to a 38 KDafragment of Pseudomonas exotoxin-A (e.g., moxetumomab pasudotox).

In one embodiment, the anti-CD22 antibody is an anti-CD19/CD22bispecific ligand-directed toxin (e.g., DT2219ARL) and theanti-CD19/CD22 bispecific ligand-directed toxin is administered at adose of about 1 μg/kg, 2 μg/kg, 3 μg/kg, 4 μg/kg, 5 μg/kg, 6 μg/kg, 7μg/kg, 8 μg/kg, 9 μg/kg, 10 μg/kg, 11 μg/kg, 12 μg/kg, 13 μg/kg, 14μg/kg, 15 μg/kg, 20 μg/kg, 25 μg/kg, 30 μg/kg, 40 μg/kg, 60 μg/kg, 80μg/kg, 100 μg/kg, 120 μg/kg, 140 μg/kg, 160 μg/kg, 180 μg/kg, 200 μg/kg,220 μg/kg, 250 μg/kg, 300 μg/kg, 350 μg/kg, 400 μg/kg, 450 μg/kg, 500μg/kg, 600 μg/kg, 700 μg/kg, 800 μg/kg, 900 μg/kg, 1 mg·kg (e.g., 30μg/kg, 40 μg/kg, 60 μg/kg, or 80 μg/kg) for a period of time, e.g.,every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more days. In someembodiments, the anti-CD19/CD22 bispecific ligand-directed toxin isadministered via intravenous infusion.

In one embodiment, the anti-CD22 antibody is BL22 and BL22 isadministered at a dose of about 1 μg/kg, 2 μg/kg, 3 μg/kg, 4 μg/kg, 5μg/kg, 6 μg/kg, 7 μg/kg, 8 μg/kg, 9 μg/kg, 10 μg/kg, 11 μg/kg, 12 μg/kg,13 μg/kg, 14 μg/kg, 15 μg/kg, 20 μg/kg, 25 μg/kg, 30 μg/kg, 40 μg/kg, 60μg/kg, 80 μg/kg, 100 μg/kg, 120 μg/kg, 140 μg/kg, 160 μg/kg, 180 μg/kg,200 μg/kg, 220 μg/kg, 250 μg/kg, 300 μg/kg, 350 μg/kg, 400 μg/kg, 450μg/kg, 500 μg/kg, 600 μg/kg, 700 μg/kg, 800 μg/kg, 900 μg/kg, 1 mg·kg(e.g., 3 μg/kg, 30 μg/kg, 40 μg/kg, or 50 μg/kg) for a period of time,e.g., every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more days. In someembodiments, BL22 is administered daily, every other day, every third,day, or every fourth day for a period of time, e.g., for a 4 day cycle,a 6 day cycle, an 8 day cycle, a 10 day cycle, a 12 day cycle, or a 14day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ormore cycles of BL22 are administered. In some embodiments, BL22 isadministered via intravenous infusion.

In one embodiment, the anti-CD22 antibody is a deglycosylated ricin Achain-conjugated anti-CD19/anti-CD22 (e.g., Combotox) and thedeglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 isadministered at a dose of about 500 μg/m², 600 μg/m², 700 μg/m², 800μg/m², 900 μg/m², 1 mg/m², 2 mg/m², 3 mg/m², 4 mg/m², 5 mg/m², 6 mg/m²,or 7 mg/m² for a period of time, e.g., every 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, or 12 or more days. In some embodiments, the deglycosylatedricin A chain-conjugated anti-CD19/anti-CD22 is administered daily,every other day, every third, day, or every fourth day for a period oftime, e.g., for a 4 day cycle, a 6 day cycle, an 8 day cycle, a 10 daycycle, a 12 day cycle, or a 14 day cycle (e.g., every other day for 6days). In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or morecycles of the deglycosylated ricin A chain-conjugatedanti-CD19/anti-CD22 are administered. In some embodiments, thedeglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 isadministered via intravenous infusion.

In one embodiment, the anti-CD22 antibody is a humanized anti-CD22monoclonal antibody (e.g., epratuzumab) and the humanized anti-CD22monoclonal antibody is administered at a dose of about 10 mg/m²/week, 20mg/m²/week, 50 mg/m²/week, 100 mg/m²/week, 120 mg/m²/week, 140mg/m²/week, 160 mg/m²/week, 180 mg/m²/week, 200 mg/m²/week, 220mg/m²/week, 250 mg/m²/week, 260 mg/m²/week, 270 mg/m²/week, 280mg/m²/week, 290 mg/m²/week, 300 mg/m²/week, 305 mg/m²/week, 310mg/m²/week, 320 mg/m²/week, 325 mg/m²/week, 330 mg/m²/week, 335mg/m²/week, 340 mg/m²/week, 345 mg/m²/week, 350 mg/m²/week, 355mg/m²/week, 360 mg/m²/week, 365 mg/m²/week, 370 mg/m²/week, 375mg/m²/week, 380 mg/m²/week, 385 mg/m²/week, 390 mg/m²/week, 400mg/m²/week, 410 mg/m²/week, 420 mg/m²/week, 430 mg/m²/week, 440mg/m²/week, 450 mg/m²/week, 460 mg/m²/week, 470 mg/m²/week, 480mg/m²/week, 490 mg/m²/week, 500 mg/m²/week, 600 mg/m²/week, 700mg/m²/week, 800 mg/m²/week, 900 mg/m²/week, 1 g/m²/week, or 2 g/m²/week(e.g., 360 mg/m²/week or 480 mg/m²/week) for a period of time, e.g.,every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more weeks. In someembodiments a first dose is lower than subsequent doses (e.g. a firstdose of 360 mg/m²/week followed by subsequent doses of 370 mg/m²/week).In some embodiments, the humanized anti-CD22 monoclonal antibody isadministered via intravenous infusion.

In one embodiment, the anti-CD22 antibody is moxetumomab pasudotox andmoxetumomab pasudotox is administered at a dose of about 1 μg/kg, 2μg/kg, 3 μg/kg, 4 μg/kg, 5 μg/kg, 6 μg/kg, 7 μg/kg, 8 μg/kg, 9 μg/kg, 10μg/kg, 11 μg/kg, 12 μg/kg, 13 μg/kg, 14 μg/kg, 15 μg/kg, 20 μg/kg, 25μg/kg, 30 μg/kg, 40 μg/kg, 60 μg/kg, 80 μg/kg, 100 μg/kg, 120 μg/kg, 140μg/kg, 160 μg/kg, 180 μg/kg, 200 μg/kg, 220 μg/kg, 250 μg/kg, 300 μg/kg,350 μg/kg, 400 μg/kg, 450 μg/kg, 500 μg/kg (e.g., 5 μg/kg, 10 μg/kg, 20μg/kg, 30 μg/kg, 40 μg/kg, or 50 μg/kg) a period of time, e.g., every 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more days. In some embodiments,the moxetumomab pasudotox is administered daily, every other day, everythird, day, or every fourth day for a period of time, e.g., for a 4 daycycle, a 6 day cycle, an 8 day cycle, a 10 day cycle, a 12 day cycle, ora 14 day cycle (e.g., every other day for 6 days). In one embodiment, 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of the moxetumomabpasudotox are administered. In some embodiments, the moxetumomabpasudotox is administered via intravenous infusion.

In an embodiment, a CD22 antibody molecule comprises six CDRs (e.g., oneeach of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3) ofany one of CAR22-1, CAR22-2, CAR22-3, CAR22-4, CAR22-5, CAR22-6,CAR22-7, CAR22-8, CAR22-9, CAR22-10, CAR22-11, CAR22-12, CAR22-13,CAR22-14, CAR22-15, or CAR22-16, CAR22-17, CAR22-18, CAR22-19, CAR22-20,CAR22-21, CAR22-22, CAR22-23, CAR22-24, CAR22-25, CAR22-26, CAR22-27,CAR22-28, CAR22-29, CAR22-30, CAR22-31, CAR22-32, CAR22-33, CAR22-34,CAR22-35, CAR22-36, CAR22-37, or CAR22-38 (e.g., as described in Table7A, 7B, 7C, 8A and/or 8B), or a sequence substantially identicalthereto. In an embodiment, a CD22 antibody molecule comprises three CDRs(e.g., one each of a HC CDR1, HC CDR2, and HC CDR3, or one each of a LCCDR1, LC CDR2, and LC CDR3) of any one of CAR22-1, CAR22-2, CAR22-3,CAR22-4, CAR22-5, CAR22-6, CAR22-7, CAR22-8, CAR22-9, CAR22-10,CAR22-11, CAR22-12, CAR22-13, CAR22-14, CAR22-15, or CAR22-16, CAR22-17,CAR22-18, CAR22-19, CAR22-20, CAR22-21, CAR22-22, CAR22-23, CAR22-24,CAR22-25, CAR22-26, CAR22-27, CAR22-28, CAR22-29, CAR22-30, CAR22-31,CAR22-32, CAR22-33, CAR22-34, CAR22-35, CAR22-36, CAR22-37, or CAR22-38(e.g., as described in Table 7A, 7B, 7C, 8A, and/or 8B), or a sequencesubstantially identical thereto. In an embodiment, a CD22 antibodymolecule comprises a heavy chain variable region, a light chain variableregion, or both of a heavy chain variable region and light chainvariable region, or an scFv, as described in Table 6A or 6B, or asequence substantially identical thereto. In embodiments, the CD22antibody molecule is an isolated antibody molecule.

ROR1 Inhibitors

As used herein, the term “ROR1” refers to an antigenic determinant knownto be detectable on leukemia precursor cells. The human and murine aminoacid and nucleic acid sequences can be found in a public database, suchas GenBank, UniProt and Swiss-Prot. For example, the amino acidsequences of isoforms land 2 precursors of human ROR1 can be found atAccession Nos. NP_005003.2 and NP_001077061.1, respectively, and themRNA sequences encoding them can be found at Accession Nos. NM_005012.3and NM_001083592.1, respectively. As used herein, “ROR1” includesproteins comprising mutations, e.g., point mutations, fragments,insertions, deletions and splice variants of full length wild-type ROR1.In one aspect the antigen-binding portion of the CAR recognizes andbinds an antigen within the extracellular domain of the ROR1 protein. Inone aspect, the ROR1 protein is expressed on a cancer cell.

Also provided herein are ROR1 inhibitors and combination therapies. ROR1inhibitors include but are not limited to anti-ROR1 CAR-expressingcells, e.g. CARTs, and anti-ROR antibodies (e.g., an anti-ROR1 mono- orbispecific antibody) and fragments thereof. In some embodiments,anti-ROR1 inhibitors can be used to treat B-cell malignancies (e.g.,leukemias, such as CLL, and B-cell lymphomas, such as mantle celllymphoma; ALL; small lymphocytic lymphoma; marginal cell B-Celllymphoma; and Burkett's Lymphoma) or epithelial cancers (e.g., breastcancer, renal cell carcinoma, lung cancer, colorectal cancers, ovariancancer, and melanoma). In an embodiment, the CD20 inhibitor isadministered in combination with a CD19 inhibitor, e.g., a CD19CAR-expressing cell, e.g., a CAR-expressing cell described herein, e.g.,a cell expressing a CAR comprising an antibody binding domain that ismurine, human, or humanized.

An exemplary anti-ROR1 inhibitor is described in Hudecek, et al. Clin.Cancer Res. 19.12(2013):3153-64, incorporated herein by reference. Forexample, an anti-ROR1 inhibitor includes the anti-ROR1 CARTs describedin Hudecek et al. (for example, generated as described in Hudecek et al.at page 3155, first full paragraph, incorporated herein by reference).In other examples, an anti-ROR1 inhibitor includes an antibody orfragment thereof comprising the VH and/or VL sequences of the 2A2 andR12 anti-ROR1 monoclonal antibodies described in Hudecek et al. atparagraph bridging pages 3154-55; Baskar et al. MAbs 4(2012):349-61; andYang et al. PLoS ONE 6(2011):e21018, incorporated herein by reference.

In other embodiments, a ROR1 inhibitor includes an antibody or fragmentthereof (e.g., single chain variable fragment (scFv)) that targets ROR1,including those described in US 2013/0101607, e.g., SEQ ID NOs: 1 or 2of US 2013/0101607, incorporated herein by reference. In someembodiments, anti-ROR1 antibody fragments (e.g., scFvs) are conjugatedor fused to a biologically active molecule, e.g., to form a chimericantigen receptor (CAR) that directs immune cells, e.g., T cells torespond to ROR1-expressing cells.

In some embodiments, an exemplary ROR1 inhibitor includes an anti-ROR1monoclonal antibody called UC-961 (Cirmtuzumab). See, e.g., ClinicalTrial Identifier No. NCT02222688. Cirmtuzumab can be used to treatcancers, such as chronic lymphocytic leukemia (CLL), ovarian cancer, andmelanoma. See, e.g., Hojjat-Farsangi et al. PLoS One. 8(4): e61167; andNCT02222688.

In some embodiments, cirmtuzumab is administered intravenously, e.g., asan intravenous infusion. For example, each infusion provides about700-7000 μg (e.g., 700-750, 750-800, 800-850, 850-900, 900-950,950-1000, 1000-1500, 1500-2000, 2000-2500, 2500-3000, 3000-3500,3500-4000, 4000-4500, 4500-5000, 5000-5500, 5500-6000, 6000-6500, or6500-7000 μg) of cirmtuzumab. In other embodiments, cirmtuzumab isadministered at a dose of 10-100 μg/kg body weight, e.g., 10-15, 15-20,20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70,70-75, 75-80, 80-85, 85-90, 90-95, or 95-100 μg/kg body weight. In oneembodiment, cirmtuzumab is administered at a starting dose of 15 μg/kgbody weight.

In some embodiments, cirmtuzumab is administered at a dosing interval ofat least 7 days, e.g., 7, 14, 21, 28, 35 days, or more. For example,cirmtuzumab is administered at a dosing interval of at least 1 week,e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28, 20, 22, 24, 26,28, 30 weeks, or more.

In some embodiments, cirmtuzumab is administered at a dose and dosinginterval described herein for a period of time, e.g., at least 1 week,e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 22, 24, 26, 28, 30, 40, 50, 60 weeks or greater, or 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12 months or greater, or 1, 2, 3, 4, 5 years orgreater. For example, cirmtuzumab is administered at a dose and dosinginterval described herein for a total of at least 2 doses per treatmentcycle (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 18, 20, or more doses per treatment cycle).

In some embodiments, the anti-ROR1 antibody is conjugated or otherwisebound to a therapeutic agent.

In some embodiments, a ROR1 inhibitor includes an anti-ROR1CAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-ROR1CAR construct or encoded by a ROR1 binding CAR comprising a scFv, CDRs,or VH and VL chains. For example, an anti-ROR1 CAR-expressing cell,e.g., CART is a generated by engineering a ROR1-CAR (that comprises aROR1 binding domain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. Also provided herein are methods of use of the CAR-expressingcells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells, comprising a mixture of cells expressing CD19CARs and ROR1 CARs. For example, in one embodiment, the population ofCART cells can include a first cell expressing a CD19 CAR and a secondcell expressing a ROR1 CAR.

CD123 Inhibitors

CD123 is also called the alpha-chain of the interleukin-3 receptor(IL-3RA). The IL-3 receptor (IL-3R) is a heterodimer composed of alphaand beta chains. IL-3R is a membrane receptor. The IL-3Ra chain is aglycoprotein of 360 amino acid residues. Abnormalities of CD123 arefrequently observed in some leukemic disorders. CD123 is overexpressedin multiple hematologic malignancies, e.g., acute myeloid and B-lymphoidleukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairycell leukemia.

As used herein, the term “CD123” refers to an antigenic determinantknown to be detectable on some malignant hematological cancer cells,e.g., leukemia cells. The human and murine amino acid and nucleic acidsequences can be found in a public database, such as GenBank, UniProtand Swiss-Prot. For example, the amino acid sequences of human CD123 canbe found at Accession Nos. NP_002174.1 (isoform 1 precursor);NP_001254642.1 (isoform 2 precursor), and the mRNA sequences encodingthem can be found at Accession Nos. NM_002183.3 (variant 1);NM_001267713.1 (variant 2). As used herein, “CD123” includes proteinscomprising mutations, e.g., point mutations, fragments, insertions,deletions and splice variants of full length wild-type CD123. In oneaspect the antigen-binding portion of the CAR recognizes and binds anantigen within the extracellular domain of the CD123 protein. In oneaspect, the CD123 protein is expressed on a cancer cell.

Provided herein are CD123 inhibitors and combination therapies. CD123inhibitors include but are not limited to small molecules, recombinantproteins, anti-CD123 CAR-expressing cells, e.g. CARTs, and anti-CD123antibodies (e.g., an anti-CD123 mono- or bispecific antibody) andfragments thereof. In some embodiments, anti-CD123 inhibitors can beused to treat a B-cell malignancy described herein. In an embodiment,the CD123 inhibitor is administered in combination with a CD19inhibitor, e.g., a CD19 CAR-expressing cell, e.g., a CAR-expressing celldescribed herein, e.g., a cell expressing a CAR comprising an antibodybinding domain that is murine, human, or humanized.

In one embodiment, the CD123 inhibitor is a recombinant protein, e.g.,comprising the natural ligand (or a fragment) of the CD123 receptor. Forexample, the recombinant protein is SL-401 (also called DT3881L3;University of Texas Southwestern Medical Center), which is a fusionprotein comprising human IL-3 fused to a truncated diphtheria toxin.See, e.g., Testa et al. Biomark Res. 2014; 2: 4; and Clinical TrialIdentifier No. NCT00397579.

In another embodiment, the CD123 inhibitor is an anti-CD123 antibody orfragment thereof. In one embodiment, the anti-CD123 antibody or fragmentthereof comprises a monoclonal antibody, e.g., a monospecific orbispecific antibody or fragment thereof. For example, the anti-CD123antibody or fragment thereof comprises CSL360 (CSL Limited). CSL360 is arecombinant chimeric monoclonal antibody that binds to CD123. In someembodiments, CSL360 is administered intravenously, e.g., by intravenousinfusion. For example, CSL360 is administered at a dose of 0.1-10 mg/kg,e.g., 0.1-0.5 mg/kg, 0.5-1 mg/kg, 1-5 mg/kg, or 5-10 mg/kg. See, e.g.,Clinical Trial Identifier No. NCT01632852; and Testa et al.

In another embodiment, the CD123 antibody or fragment thereof comprisesCSL362 (CSL Limited). CSL362 is a humanized monoclonal antibody thattargets the CD123 and is optimized for enhanced activation of antibodydependent cell-mediated cytotoxicity (ADCC). In some embodiments, CSL362is administered intravenously, e.g., by intravenous infusion. In someexamples, CSL362 is administered at a dose of 0.1-12 mg/kg, e.g.,0.1-0.2 mg/kg, 0.2-0.5 mg/kg, 0.5-1 mg/kg, 1-6 mg/kg, or 6-12 mg/kg.See, e.g., Clinical Trial Identifier No. NCT01632852.

In one embodiment, the CD123 antibody or fragment thereof comprises abispecific antibody, e.g., MGD006 (MacroGenics). MGD006 is a bispecificantibody that targets CD123 and CD3. See, e.g., Clinical TrialIdentifier No. NCT02152956.

In some embodiments, the CD123 inhibitor is conjugated or otherwisebound to a therapeutic agent.

In some embodiments, a CD123 inhibitor includes an anti-CD123CAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD123CAR construct or encoded by a CD123 binding CAR comprising a scFv, CDRs,or VH and VL chains. For example, an anti-CD123 CAR-expressing cell,e.g., CART is a generated by engineering a CD123-CAR (that comprises aCD123 binding domain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. In an embodiment, the anti-CD123 CAR construct comprises a scFvsequence, e.g., a scFv sequence provided in US 2014/0322212 A1,incorporated herein by reference. In one embodiment, the anti-CD123binding domain is a scFv described in US 2014/0322212 A1. In anembodiment, the anti-CD123 binding domain is part of a CAR constructprovided in US 2014/0322212 A1. Also provided herein are methods of useof the CAR-expressing cells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells, comprising a mixture of cells expressing CD19CARs and CD123 CARs. For example, in one embodiment, the population ofCART cells can include a first cell expressing a CD19 CAR and a secondcell expressing a CD123 CAR.

CD10 Inhibitors

Cluster of differentiation 10 (CD10) is also called Neprilysin, membranemetallo-endopeptidase (MME), neutral endopeptidase (NEP), and commonacute lymphoblastic leukemia antigen (CALLA). CD10 is an enzyme encodedby the membrane metallo-endopeptidase (MME) gene. CD10 is expressed onleukemic cells of pre-B phenotype and is a common acute lymphocyticleukemia antigen.

As used herein, the term “CD10” refers to an antigenic determinant knownto be detectable on leukemia cells. The human and murine amino acid andnucleic acid sequences can be found in a public database, such asGenBank, UniProt and Swiss-Prot. For example, the amino acid sequencesof human CD10 can be found at Accession Nos. NP_009218.2; NP_000893.2;NP_009219.2; NP_009220.2, and the mRNA sequences encoding them can befound at Accession Nos. NM_007287.2 (variant 1bis); NM_000902.3 (variant1); NM_007288.2 (variant 2a); NM_007289.2 (variant 2b). As used herein,“CD10” includes proteins comprising mutations, e.g., point mutations,fragments, insertions, deletions and splice variants of full lengthwild-type CD10. In one aspect the antigen-binding portion of the CARrecognizes and binds an antigen within the extracellular domain of theCD10 protein. In one aspect, the CD10 protein is expressed on a cancercell.

Also provided herein are CD10 inhibitors and combination therapies. CD10inhibitors include but are not limited to small molecules, recombinantproteins, anti-CD10 CAR-expressing cells, e.g. CARTs, and anti-CD10antibodies (e.g., an anti-CD10 mono- or bispecific antibody) andfragments thereof. In some embodiments, anti-CD10 inhibitors can be usedto treat a B-cell malignancy described herein. In an embodiment, theCD10 inhibitor is administered in combination with a CD19 inhibitor,e.g., a CD19 CAR-expressing cell, e.g., a CAR-expressing cell describedherein, e.g., a cell expressing a CAR comprising an antibody bindingdomain that is murine, human, or humanized.

In an embodiment, the CD10 inhibitor comprises sacubitril (AHU-377;Novartis)(4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoicacid), or a pharmaceutically acceptable salt or a derivative thereof.The structure of sacubitril is shown below.

In another embodiment, the CD10 inhibitor comprisesvalsartan/sacubritril (LCZ696; Novartis) or a pharmaceuticallyacceptable salt or a derivative thereof. Valsartan/sacubritril is acombination drug comprising a 1:1 mixture of valsartan and sacubitril.The structure of valsartan((S)-3-methyl-2-(N-{[2′-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoicacid) is shown below.

In an embodiment, the CD10 inhibitor comprises omapatrilat(Bristol-Myers Squibb)((4S,7S,10aS)-5-oxo-4-{[(2S)-3-phenyl-2-sulfanylpropanoyl]amino}-2,3,4,7,8,9,10,10a-octahydropyrido[6,1-b][1,3]thiazepine-7-carboxylicacid), or a pharmaceutically acceptable salt or a derivative thereof.The structure of omapatrilat is shown below.

In an embodiment, the CD10 inhibitor comprises RB-101 (benzylN-(3-{[(2S)-2-amino-4-(methylthio)butyl]dithio}-2-benzylpropanoyl)-L-phenylalaninate),or a pharmaceutically acceptable salt or a derivative thereof. Thestructure of RB-101 is shown below.

In an embodiment, the CD10 inhibitor comprises UK-414,495 (Pfizer)((R)-2-({1-[(5-ethyl-1,3,4-thiadiazol-2-yl)carbamoyl]cyclopentyl}methyl)valericacid), or a pharmaceutically acceptable salt or a derivative thereof.The structure of UK-414,495 is shown below.

In some embodiments, the CD10 inhibitor is conjugated or otherwise boundto a therapeutic agent.

In some embodiments, a CD10 inhibitor includes an anti-CD10CAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD10CAR construct or encoded by a CD10 binding CAR comprising a scFv, CDRs,or VH and VL chains. For example, an anti-CD10 CAR-expressing cell,e.g., CART is a generated by engineering a CD10-CAR (that comprises aCD10 binding domain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. Also provided herein are methods of use of the CAR-expressingcells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells, comprising a mixture of cells expressing CD19CARs and CD10 CARs. For example, in one embodiment, the population ofCART cells can include a first cell expressing a CD19 CAR and a secondcell expressing a CD10 CAR.

CD34 Inhibitors

Cluster of differentiation 34 (CD34) is also called hematopoieticprogenitor cell antigen CD34 and is a cell surface glycoprotein thatfunctions as a cell-cell adhesion factor. CD34 is sometimes expressed onsome cancers/tumors, e.g., alveolar soft part sarcoma, preB-ALL, AML,AML-M7, dermatofibrosarcoma protuberans, gastrointestinal stromaltumors, giant cell fibroblastoma, granulocytic sarcoma, Kaposi'ssarcoma, liposarcoma, malignant fibrous histiocytoma, malignantperipheral nerve sheath tumors, mengingeal hemangiopericytomas,meningiomas, neurofibromas, schwannomas, and papillary thyroidcarcinoma.

As used herein, the term “CD34” refers to an antigenic determinant knownto be detectable on hematopoietic stem cells and some cancer cells. Thehuman and murine amino acid and nucleic acid sequences can be found in apublic database, such as GenBank, UniProt and Swiss-Prot. For example,the amino acid sequences of human CD34 can be found at Accession Nos.NP_001020280.1 (isoform a precursor); NP_001764.1 (isoform b precursor),and the mRNA sequences encoding them can be found at Accession Nos.NM_001025109.1 (variant 1); NM_001773.2 (variant 2). As used herein,“CD34” includes proteins comprising mutations, e.g., point mutations,fragments, insertions, deletions and splice variants of full lengthwild-type CD34. In one aspect the antigen-binding portion of the CARrecognizes and binds an antigen within the extracellular domain of theCD34 protein. In one aspect, the CD34 protein is expressed on a cancercell.

Also provided herein are CD34 inhibitors and combination therapies. CD34inhibitors include but are not limited to small molecules, recombinantproteins, anti-CD34 CAR-expressing cells, e.g. CARTs, and anti-CD34antibodies (e.g., an anti-CD34 mono- or bispecific antibody) andfragments thereof. In some embodiments, anti-CD34 inhibitors can be usedto treat a B-cell malignancy described herein. In an embodiment, theCD34 inhibitor is administered in combination with a CD19 inhibitor,e.g., a CD19 CAR-expressing cell, e.g., a CAR-expressing cell describedherein, e.g., a cell expressing a CAR comprising an antibody bindingdomain that is murine, human, or humanized.

In an embodiment, the CD34 inhibitor comprises an antibody or fragmentthereof, e.g., the My-10 monoclonal antibody or an immunoliposomecomprising the My-10 monoclonal antibody, as described in Mercadal etal. Biochim. Biophys. Acta. 1371.1(1998):17-23. In other embodiments,the CD34 inhibitor comprises an immunoliposome containing a cancer drug,e.g., doxorubicin, that is targeted to CD34-expressing cells, asdescribed in Carrion et al. Life Sci. 75.3(2004):313-28. In anembodiment, the CD34 inhibitor comprises a monoclonal antibody againstCD34 as described in Maleki et al. Hum. Antibodies. 22(2013):1-8. Inanother embodiment, the CD34 inhibitor comprises a monoclonal antibodythat targets CD34, as described in Maleki et al. Cell J.16.3(2014):361-66.

In some embodiments, the CD34 inhibitor is conjugated or otherwise boundto a therapeutic agent.

In some embodiments, a CD34 inhibitor includes an anti-CD34CAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD34CAR construct or encoded by a CD34 binding CAR comprising a scFv, CDRs,or VH and VL chains. For example, an anti-CD34 CAR-expressing cell,e.g., CART is a generated by engineering a CD34-CAR (that comprises aCD34 binding domain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. Also provided herein are methods of use of the CAR-expressingcells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells, comprising a mixture of cells expressing CD19CARs and CD34 CARs. For example, in one embodiment, the population ofCART cells can include a first cell expressing a CD19 CAR and a secondcell expressing a CD34 CAR.

FLT-3 Inhibitors

Fms-like tyrosine kinase 3 (FLT-3), also called Cluster ofdifferentiation antigen 135 (CD135), receptor-type tyrosine-proteinkinase FLT3, or fetal liver kinase-2 (Flk2), is a receptor tyrosinekinase. FLT-3 is a cytokine receptor for the ligand, cytokine Flt3ligand (FLT3L). FLT-3 is expressed on the surface of many hematopoieticprogenitor cells and is important for lymphocyte development. The FLT3gene is commonly mutated in leukemia, e.g., acute myeloid leukemia(AML).

As used herein, the term “FLT-3” refers to an antigenic determinantknown to be detectable on hematopoietic progenitor cells and some cancercells, e.g., leukemia cells. The human and murine amino acid and nucleicacid sequences can be found in a public database, such as GenBank,UniProt and Swiss-Prot. For example, the amino acid sequences of humanFLT-3 can be found at Accession Nos. NP_004110.2, and the mRNA sequencesencoding them can be found at Accession Nos. NM_004119.2. As usedherein, “FLT-3” includes proteins comprising mutations, e.g., pointmutations, fragments, insertions, deletions and splice variants of fulllength wild-type FLT-3. In one aspect the antigen-binding portion of theCAR recognizes and binds an antigen within the extracellular domain ofthe FLT-3 protein. In one aspect, the FLT-3 protein is expressed on acancer cell.

Also provided herein are FLT-3 inhibitors and combination therapies.FLT-3 inhibitors include but are not limited to small molecules,recombinant proteins, anti-FLT-3 CAR-expressing cells, e.g. CARTs, andanti-FLT-3 antibodies (e.g., an anti-FLT-3 mono- or bispecific antibody)and fragments thereof. In some embodiments, anti-FLT-3 inhibitors can beused to treat a B-cell malignancy described herein. In an embodiment,the FLT-3 inhibitor is administered in combination with a CD19inhibitor, e.g., a CD19 CAR-expressing cell, e.g., a CAR-expressing celldescribed herein, e.g., a cell expressing a CAR comprising an antibodybinding domain that is murine, human, or humanized.

In some embodiments, the FLT-3 inhibitor comprises quizartinib (AC220;Ambit Biosciences) or a pharmaceutically acceptable salt or a derivativethereof. Quizartinib is a small molecule receptor tyrosine kinaseinhibitor. The structure of quizartinib(1-(5-(tert-Butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea)is shown below.

In some embodiments, the FLT-3 inhibitor comprises midostaurin is(PKC412; Technische Universitat Dresden) or a pharmaceuticallyacceptable salt or a derivative thereof. Midostaurin is a protein kinaseinhibitor that is a semi-synthetic derivative of staurosporine, analkaloid from the bacterium Streptomyces staurosporeus.

The structure of midostaurin((9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiamzonine-1-one)is shown below.

In some embodiments, midostaurin is administered orally, e.g., at a doseof about 25-200 mg, e.g., about 25-50 mg, 50-100 mg, 100-150 mg, or150-200 mg. For example, midostaurin is administered, e.g., orally, at adose of about 25-200 mg twice daily, e.g., about 25-50 mg, 50-100 mg,100-150 mg, or 150-200 mg twice daily. See, e.g., Clinical TrialIdentifier No. NCT01830361.

In an embodiment, the FLT-3 inhibitor comprises sorafenib (Bayer andOnyx Pharmaceuticals) or a pharmaceutically acceptable salt or aderivative thereof. Sorafenib is a small molecular inhibitor of multipletyrosine protein kinases (e.g., VEGFR and PDGFR), Raf kinases (e.g.,C-Raf and B-Raf), and some intracellular serine/threonine kinases (e.g.C-Raf, wild-type B-Raf, and mutant B-Raf). See, e.g.,labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Thestructure of sorafenib(4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide) is shown below.

In some embodiments, the FLT-3 inhibitor comprises sunitinib (previouslyknown as SU11248; Pfizer) or a pharmaceutically acceptable salt orderivative thereof. Sunitinib is a small molecule oral drug thatinhibits multiple receptor tyrosine kinases, including FLT3. Sunitinibhas been approved by the Food and Drug Administration (FDA) for thetreatment of renal cell carcinoma (RCC) and imatinib-resistantgastrointestinal stromal tumor (GIST). The structure of sunitinib(N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide)is shown below.

In some embodiments, the FLT-3 inhibitor comprises lestaurtinib(CEP-701; Cephalon) or a pharmaceutically acceptable salt or derivativethereof. Lestaurtinib is a tyrosine kinase inhibitor that isstructurally related to staurosporine. The structure of lestaurtinib((9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one) is shown below.

In some embodiments, lestaurtinib is administered orally, e.g., at adose of about 40-100 mg twice a day, e.g., about 40-60 mg, 50-70 mg,60-80 mg, 70-90 mg, or 80-100 mg twice a day. See, e.g., Clinical TrialIdentifier No. NCT00079482; or NCT00030186.

In some embodiments, the FLT-3 inhibitor is conjugated or otherwisebound to a therapeutic agent.

In some embodiments, a FLT-3 inhibitor includes an anti-FLT-3CAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-FLT-3CAR construct or encoded by a FLT-3 binding CAR comprising a scFv, CDRs,or VH and VL chains. For example, an anti-FLT-3 CAR-expressing cell,e.g., CART is a generated by engineering a FLT-3-CAR (that comprises aFLT-3 binding domain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. Also provided herein are methods of use of the CAR-expressingcells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells, comprising a mixture of cells expressing CD19CARs and FLT-3 CARs. For example, in one embodiment, the population ofCART cells can include a first cell expressing a CD19 CAR and a secondcell expressing a FLT-3 CAR.

In one embodiment the antigen binding domain CAR (e.g., a CD19, ROR1,CD20, CD22, CD123, CD10, CD34, or FLT-3 antigen binding domain)comprises an scFv portion, e.g., a human scFv portion. The scFv may bepreceded by an optional leader sequence such as provided in SEQ ID NO:13, and followed by an optional hinge sequence such as provided in SEQID NO: 14 or SEQ ID NO:45 or SEQ ID NO:47 or SEQ ID NO:49, atransmembrane region such as provided in SEQ ID NO:15, an intracellularsignaling domain that includes SEQ ID NO:16 or SEQ ID NO:51 and a CD3zeta sequence that includes SEQ ID NO:17 or SEQ ID NO:43, e.g., whereinthe domains are contiguous with and in the same reading frame to form asingle fusion protein.

In some embodiments, the present disclosure encompasses a recombinantnucleic acid construct comprising a nucleic acid molecule encoding a CAR(e.g., a CD19 CAR, a ROR1 CAR, a CD20 CAR, a CD22 CAR, a CD123 CAR, aCD10 CAR, a CD34 CAR, or a FLT-3 CAR), wherein the nucleic acid moleculecomprises the nucleic acid sequence encoding an antigen binding domain,e.g., described herein, e.g., that is contiguous with and in the samereading frame as a nucleic acid sequence encoding an intracellularsignaling domain. An exemplary intracellular signaling domain that canbe used in the CAR includes, but is not limited to, one or moreintracellular signaling domains of, e.g., CD3-zeta, CD28, 4-1BB, and thelike. In some instances, the CAR can comprise any combination ofCD3-zeta, CD28, 4-1BB, and the like.

In one embodiment, the antigen binding domain (e.g., a CD19, ROR1, CD20,CD22, CD123, CD10, CD34, or FLT-3 antigen binding domain) ischaracterized by particular functional features or properties of anantibody or antibody fragment. For example, in one embodiment, theportion of a CAR composition of the invention that comprises an antigenbinding domain specifically binds a human B-cell antigen (e.g., CD19,ROR1, CD20, CD22, CD123, CD10, CD34, or FLT-3) or a fragment thereof. Incertain embodiments, the scFv is contiguous with and in the same readingframe as a leader sequence. In one aspect the leader sequence is thepolypeptide sequence provided as SEQ ID NO:13.

In one embodiment, the antigen binding domain is a fragment, e.g., asingle chain variable fragment (scFv). In one embodiments, the antigenbinding domain is a Fv, a Fab, a (Fab′)2, or a bi-functional (e.g.bi-specific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J.Immunol. 17, 105 (1987)). In one aspect, the antibodies and fragmentsthereof of the invention binds a B-cell protein or a fragment thereofwith wild-type or enhanced affinity. In some instances, a human scFv canbe derived from a display library.

In one embodiment, the antigen binding domain, e.g., scFv comprises atleast one mutation such that the mutated scFv confers improved stabilityto the CAR construct. In another embodiment, the antigen binding domain,e.g., scFv comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutationsarising from, e.g., the humanization process such that the mutated scFvconfers improved stability to the CAR construct.

In one embodiment, the population of CAR-expressing cells includes,e.g., a first cell expressing a CAR (e.g., a CD19 CAR, a ROR1 CAR, aCD20 CAR, a CD22 CAR, a CD123 CAR, a CD10 CAR, a CD34 CAR, or a FLT-3CAR) that includes a primary intracellular signaling domain, and asecond cell expressing a CAR (e.g., a CD19 CAR, a ROR1 CAR, a CD20 CAR,a CD22 CAR, a CD123 CAR, a CD10 CAR, a CD34 CAR, or a FLT-3 CAR)) thatincludes a secondary signaling domain.

CD79b Inhibitors

As used herein, the term “CD79b” refers to an antigenic determinantknown to be detectable on some malignant hematological cancer cells,e.g., leukemia cells. The human and murine amino acid and nucleic acidsequences can be found in a public database, such as GenBank, UniProtand Swiss-Prot. For example, the amino acid sequences of human CD79b canbe found at Accession Nos. NP_000617.1 (isoform 1 precursor),NP_067613.1 (isoform 2 precursor), or NP_001035022.1 (isoform 3precursor), and the mRNA sequences encoding them can be found atAccession Nos. NM_900626.2 (transcript variant 1), NM_021602.2(transcript variant 2), or NM_001039933.1 (transcript variant 3). Asused herein, “CD79b” includes proteins comprising mutations, e.g., pointmutations, fragments, insertions, deletions and splice variants of fulllength wild-type CD79b. In one aspect the antigen-binding portion of theCAR recognizes and binds an antigen within the extracellular domain ofthe CD79b protein. In one aspect, the CD79b protein is expressed on acancer cell. In embodiments, the CD79b protein is a wild-type CD79bprotein; in other embodiments, the CD79b protein is a mutant CD79bprotein.

CD79b is also called immunoglobulin-associated beta, which is acomponent of the B lymphocyte antigen receptor multimeric complex. CD79bforms a heterodimer with another accessory protein called CD79a(immunoglobulin-associated alpha), and the heterodimer complexes withsurface immunoglobulins on B cells. CD79b is important for the assemblyof and surface expression of the B lymphocyte antigen receptor. CD79band CD79a are important for pre-B-cell and B-cell development. Mutationand aberrant CD79b expression occurs in many B-CLL cells and may becorrelated with the loss of surface expression and/or defectivesignaling of B lymphocyte antigen receptor in B-CLL. See, e.g., Thompsonet al. Blood 90.4(1997):1387-94. In some cases, overexpression of amutant form or splice variant of CD79b has been correlated withdiminished B lymphocyte antigen receptor in B-CLL and other lymphoidmalignancies. See, Cragg et al. Blood 100.9(2002):3065-76.

Provided herein are CD79b inhibitors and combination therapies. CD79binhibitors include but are not limited to small molecules, recombinantproteins, anti-CD79b CAR-expressing cells, e.g. CARTs, and anti-CD79bantibodies (e.g., an anti-CD79b mono- or bispecific antibody) andfragments thereof. In some embodiments, anti-CD79b inhibitors can beused to treat a B-cell malignancy described herein. In an embodiment,the CD79b inhibitor is administered in combination with a CD19inhibitor, e.g., a CD19 CAR-expressing cell, e.g., a CAR-expressing celldescribed herein, e.g., a cell expressing a CAR comprising an antibodybinding domain that is murine, human, or humanized.

In an embodiment, the CD79b inhibitor is an anti-CD79b antibody orfragment thereof. In one embodiment, the anti-79b antibody or fragmentthereof comprises a monoclonal antibody, e.g., a monospecific orbispecific antibody or fragment thereof. For example, the anti-CD79bantibody or fragment thereof comprises an anti-CD79b antibody drugconjugate such as polatuzumab vedotin (Roche). In embodiments,polatuzumab vedotin is used to treat a cancer, e.g., NHL, e.g.,follicular lymphoma or DLBCL, e.g., relapsed or refractory follicularlymphoma or DLBCL. See, e.g., NCT02257567. In embodiments, theanti-CD79b antibody or fragment thereof is a bispecific antibodycomprising components that bind to CD32B and D79B, such as MGD010(MacroGenics). See, e.g., NCT02376036.

In some embodiments, the CD79b inhibitor is conjugated or otherwisebound to a therapeutic agent.

In some embodiments, a CD79b inhibitor includes an anti-CD79bCAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD79bCAR construct or encoded by a CD79b binding CAR comprising a scFv, CDRs,or VH and VL chains. For example, an anti-CD79b CAR-expressing cell,e.g., CART is a generated by engineering a CD79b-CAR (that comprises aCD79b binding domain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. Also provided herein are methods of use of the CAR-expressingcells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells or CAR-expressing NK cells, comprising a mixtureof cells expressing CD19 CARs and CD79b CARs. For example, in oneembodiment, the population of CAR-expressing cells can include a firstcell expressing a CD19 CAR and a second cell expressing a CD79b CAR.

C179b Inhibitors

As used herein, the term “CD179b” refers to an antigenic determinantknown to be detectable on some malignant hematological cancer cells,e.g., leukemia cells. The human and murine amino acid and nucleic acidsequences can be found in a public database, such as GenBank, UniProtand Swiss-Prot. For example, the amino acid sequences of human CD179bcan be found at Accession Nos. NP_064455.1 (isoform a precursor) orNP_690594.1 (isoform b precursor), and the mRNA sequences encoding themcan be found at Accession Nos. NM_020070.3 (transcript variant 1) orNM_152855.2 (transcript variant 2). As used herein, “CD179b” includesproteins comprising mutations, e.g., point mutations, fragments,insertions, deletions and splice variants of full length wild-typeCD179b. In one aspect the antigen-binding portion of the CAR recognizesand binds an antigen within the extracellular domain of the CD179bprotein. In one aspect, the CD179b protein is expressed on a cancercell. In embodiments, the CD179b protein is a wild-type CD179b protein;in other embodiments, the CD179b protein is a mutant CD179b protein.

CD179b is also called immunoglobulin lambda-like polypeptide 1 (IGLL1).CD179b is a subunit of a heterodimeric light chain that complexes with amembrane-bound Ig mu heavy chain. Together, the light chain and heavychain form the preB cell receptor. Mutations in CD179b have beencorrelated with B cell deficiency and agammaglobulinemia. CD179b isexpressed in some cancer cells, e.g., precursor B-cell lymphoblasticlymphoma cells.

Provided herein are CD179b inhibitors and combination therapies. CD179binhibitors include but are not limited to small molecules, recombinantproteins, anti-CD179b CAR-expressing cells, e.g. CARTs, and anti-CD179bantibodies (e.g., an anti-CD179b mono- or bispecific antibody) andfragments thereof. In some embodiments, anti-CD179b inhibitors can beused to treat a B-cell malignancy described herein. In an embodiment,the CD179b inhibitor is administered in combination with a CD20inhibitor, e.g., a CD19 CAR-expressing cell, e.g., a CAR-expressing celldescribed herein, e.g., a cell expressing a CAR comprising an antibodybinding domain that is murine, human, or humanized.

In an embodiment, the CD179b inhibitor is an anti-CD179b antibody orfragment thereof. In one embodiment, the anti-179b antibody or fragmentthereof comprises a monoclonal antibody, e.g., a monospecific orbispecific antibody or fragment thereof.

In some embodiments, the CD179b inhibitor is conjugated or otherwisebound to a therapeutic agent.

In some embodiments, a CD179b inhibitor includes an anti-CD179bCAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD179bCAR construct or encoded by a CD179b binding CAR comprising a scFv,CDRs, or VH and VL chains. For example, an anti-CD179b CAR-expressingcell, e.g., CART is a generated by engineering a CD179b-CAR (thatcomprises a CD179b binding domain) into a cell (e.g., a T cell or NKcell), e.g., for administration in combination with a CAR-expressingcell described herein. Also provided herein are methods of use of theCAR-expressing cells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells or CAR-expressing NK cells, comprising a mixtureof cells expressing CD19 CARs and CD179b CARs. For example, in oneembodiment, the population of CAR-expressing cells can include a firstcell expressing a CD19 CAR and a second cell expressing a CD179b CAR.

CD79a Inhibitors

As used herein, the term “CD79a” refers to an antigenic determinantknown to be detectable on some malignant hematological cancer cells,e.g., leukemia cells. The human and murine amino acid and nucleic acidsequences can be found in a public database, such as GenBank, UniProtand Swiss-Prot. For example, the amino acid sequences of human CD79a canbe found at Accession Nos. NP_001774.1 (isoform 1 precursor) orNP_067612.1 (isoform 2 precursor), and the mRNA sequences encoding themcan be found at Accession Nos. NM_001783.3 (transcript variant 1) orNM_021601.3 (transcript variant 2). As used herein, “CD79a” includesproteins comprising mutations, e.g., point mutations, fragments,insertions, deletions and splice variants of full length wild-typeCD79a. In one aspect the antigen-binding portion of the CAR recognizesand binds an antigen within the extracellular domain of the CD79aprotein. In one aspect, the CD79a protein is expressed on a cancer cell.In embodiments, the CD79a protein is a wild-type CD79a protein; in otherembodiments, the CD79a protein is a mutant CD79a protein.

CD79a is also called immunoglobulin-associated alpha. CD79aheterodimerizes with CD79b to form a component of the B lymphocyteantigen receptor multimeric complex. CD79a is expressed in manyhematological cancers, e.g., acute leukemias (e.g., B-cell Lymphomas,and Myelomas.

Provided herein are CD79a inhibitors and combination therapies. CD79ainhibitors include but are not limited to small molecules, recombinantproteins, anti-CD79a CAR-expressing cells, e.g. CARTs, and anti-CD79aantibodies (e.g., an anti-CD79a mono- or bispecific antibody) andfragments thereof. In some embodiments, anti-CD79a inhibitors can beused to treat a B-cell malignancy described herein. In an embodiment,the CD79a inhibitor is administered in combination with a CD19inhibitor, e.g., a CD19 CAR-expressing cell, e.g., a CAR-expressing celldescribed herein, e.g., a cell expressing a CAR comprising an antibodybinding domain that is murine, human, or humanized.

In an embodiment, the CD79a inhibitor is an anti-CD79a antibody orfragment thereof. In one embodiment, the anti-CD79a antibody or fragmentthereof comprises a monoclonal antibody, e.g., a monospecific orbispecific antibody or fragment thereof. For example, the anti-CD79aantibody or fragment thereof comprises an anti-CD79a antibody orfragment thereof (e.g., variable regions or CDRs) described in Polson etal. Blood 1102(2007):616-23, incorporated herein by reference. Forexample, the anti-CD79a antibody or fragment thereof comprises the 7H7,15E4, or 16C11 antibody or fragment thereof (e.g., variable regions orCDRs) described in Polson et al. See Id.

In some embodiments, the CD79a inhibitor is conjugated or otherwisebound to a therapeutic agent.

In some embodiments, a CD79a inhibitor includes an anti-CD79aCAR-expressing cell, e.g., CART, e.g., a cell expressing an anti-CD79aCAR construct or encoded by a CD79a binding CAR comprising a scFv, CDRs,or VH and VL chains. For example, an anti-CD79a CAR-expressing cell,e.g., CART is a generated by engineering a CD79a-CAR (that comprises aCD79a binding domain) into a cell (e.g., a T cell or NK cell), e.g., foradministration in combination with a CAR-expressing cell describedherein. Also provided herein are methods of use of the CAR-expressingcells described herein for adoptive therapy.

In another aspect, provided herein is a population of CAR-expressingcells, e.g., CART cells or CAR-expressing NK cells, comprising a mixtureof cells expressing CD19 CARs and CD79a CARs. For example, in oneembodiment, the population of CAR-expressing cells can include a firstcell expressing a CD20 CAR and a second cell expressing a CD79a CAR.

CAR Therapies

The inhibitors herein, e.g., CAR-expressing cells directed against CD10,CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a, maycomprise one or more of the compositions described herein, e.g., atransmembrane domain, intracellular signaling domain, costimulatorydomain, leader sequence, or hinge.

In one aspect, the present invention encompasses a recombinant nucleicacid construct comprising a transgene encoding a CAR. In someembodiments, the nucleic acid molecule comprises a nucleic acid sequenceencoding an anti-CD19 binding domain selected from one or more of SEQ IDNOS:61-72, wherein the sequence is contiguous with and in the samereading frame as the nucleic acid sequence encoding an intracellularsignaling domain. An exemplary intracellular signaling domain that canbe used in the CAR includes, but is not limited to, one or moreintracellular signaling domains of, e.g., CD3-zeta, CD28, 4-1BB, and thelike. In some instances, the CAR can comprise any combination ofCD3-zeta, CD28, 4-1BB, and the like.

In one aspect, the present invention contemplates modifications of thestarting antibody or fragment (e.g., scFv) amino acid sequence thatgenerate functionally equivalent molecules. For example, the VH or VL ofan antigen binding domain, e.g., scFv, comprised in the CAR can bemodified to retain at least about 70%, 71%. 72%. 73%, 74%, 75%, 76%,77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity of the starting VHor VL framework region of the antigen binding domain, e.g., scFv. Thepresent invention contemplates modifications of the entire CARconstruct, e.g., modifications in one or more amino acid sequences ofthe various domains of the CAR construct in order to generatefunctionally equivalent molecules. The CAR construct can be modified toretain at least about 70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%,80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% identity of the starting CAR construct. Thepresent invention also contemplates modifications of CDRs, e.g.,modifications in one or more amino acid sequences of one or more CDRs ofa CAR construct in order to generate functionally equivalent molecules.For instance, the CDR may have, e.g., up to and including 1, 2, 3, 4, 5,or 6 alterations (e.g., substitutions) relative to a CDR sequenceprovided herein.

The nucleic acid sequences coding for the desired molecules can beobtained using recombinant methods known in the art, such as, forexample by screening libraries from cells expressing the gene, byderiving the gene from a vector known to include the same, or byisolating directly from cells and tissues containing the same, usingstandard techniques. Alternatively, the nucleic acid of interest can beproduced synthetically, rather than cloned.

The present invention includes, among other things, retroviral andlentiviral vector constructs expressing a CAR that can be directlytransduced into a cell.

The present invention also includes an RNA construct that can bedirectly transfected into a cell. A method for generating mRNA for usein transfection involves in vitro transcription (IVT) of a template withspecially designed primers, followed by polyA addition, to produce aconstruct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ capand/or Internal Ribosome Entry Site (IRES), the nucleic acid to beexpressed, and a polyA tail, typically 50-2000 bases in length (SEQ IDNO:118). RNA so produced can efficiently transfect different kinds ofcells. In one embodiment, the template includes sequences for the CAR.In an embodiment, an RNA CAR vector is transduced into a T cell byelectroporation.

Antigen Binding Domain

In one aspect, the CAR of the invention comprises a target-specificbinding element otherwise referred to as an antigen binding domain. Thechoice of moiety depends upon the type and number of ligands that definethe surface of a target cell. For example, the antigen binding domainmay be chosen to recognize a ligand that acts as a cell surface markeron target cells associated with a particular disease state. Thusexamples of cell surface markers that may act as ligands for the antigenbinding domain in a CAR of the invention include those associated withviral, bacterial and parasitic infections, autoimmune disease and cancercells. The antigen-binding domain can bind, e.g., one or more of CD10,CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a.

In one aspect, the CAR-mediated T-cell response can be directed to anantigen of interest by way of engineering an antigen binding domain thatspecifically binds a desired antigen into the CAR.

The antigen binding domain (e.g., an antigen-binding domain that bindsone or more of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b,CD179b, or CD79a) can be any domain that binds to the antigen includingbut not limited to a monoclonal antibody, a polyclonal antibody, arecombinant antibody, a murine antibody, a human antibody, a humanizedantibody, and a functional fragment thereof, including but not limitedto a single-domain antibody such as a heavy chain variable domain (VH),a light chain variable domain (VL) and a variable domain (VHH) ofcamelid derived nanobody, and to an alternative scaffold known in theart to function as antigen binding domain, such as a recombinantfibronectin domain, and the like.

In some instances, it is beneficial for the antigen binding domain to bederived from the same species in which the CAR will ultimately be usedin. For example, for use in humans, it may be beneficial for the antigenbinding domain (e.g., an antigen-binding domain that binds one or moreof CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, orCD79a) of the CAR to comprise human or humanized residues for theantigen binding domain of an antibody or antibody fragment.

A humanized antibody can be produced using a variety of techniques knownin the art, including but not limited to, CDR-grafting (see, e.g.,European Patent No. EP 239,400; International Publication No. WO91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089, eachof which is incorporated herein in its entirety by reference), veneeringor resurfacing (see, e.g., European Patent Nos. EP 592,106 and EP519,596; Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnickaet al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al.,1994, PNAS, 91:969-973, each of which is incorporated herein by itsentirety by reference), chain shuffling (see, e.g., U.S. Pat. No.5,565,332, which is incorporated herein in its entirety by reference),and techniques disclosed in, e.g., U.S. Patent Application PublicationNo. US2005/0042664, U.S. Patent Application Publication No.US2005/0048617, U.S. Pat. Nos. 6,407,213, 5,766,886, InternationalPublication No. WO 9317105, Tan et al., J. Immunol., 169:1119-25 (2002),Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods,20(3):267-79 (2000), Baca et al., J. Biol. Chem., 272(16):10678-84(1997), Roguska et al., Protein Eng., 9(10):895-904 (1996), Couto etal., Cancer Res., 55 (23 Supp):5973s-5977s (1995), Couto et al., CancerRes., 55(8):1717-22 (1995), Sandhu J S, Gene, 150(2):409-10 (1994), andPedersen et al., J. Mol. Biol., 235(3):959-73 (1994), each of which isincorporated herein in its entirety by reference. Often, frameworkresidues in the framework regions will be substituted with thecorresponding residue from the CDR donor antibody to alter, for exampleimprove, antigen binding. These framework substitutions are identifiedby methods well-known in the art, e.g., by modeling of the interactionsof the CDR and framework residues to identify framework residuesimportant for antigen binding and sequence comparison to identifyunusual framework residues at particular positions. (See, e.g., Queen etal., U.S. Pat. No. 5,585,089; and Riechmann et al., 1988, Nature,332:323, which are incorporated herein by reference in theirentireties.)

A humanized antibody or antibody fragment has one or more amino acidresidues remaining in it from a source which is nonhuman. These nonhumanamino acid residues are often referred to as “import” residues, whichare typically taken from an “import” variable domain. As providedherein, humanized antibodies or antibody fragments comprise one or moreCDRs from nonhuman immunoglobulin molecules and framework regionswherein the amino acid residues comprising the framework are derivedcompletely or mostly from human germline. Multiple techniques forhumanization of antibodies or antibody fragments are well-known in theart and can essentially be performed following the method of Winter andco-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al.,Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536(1988)), by substituting rodent CDRs or CDR sequences for thecorresponding sequences of a human antibody, i.e., CDR-grafting (EP239,400; PCT Publication No. WO 91/09967; and U.S. Pat. Nos. 4,816,567;6,331,415; 5,225,539; 5,530,101; 5,585,089; 6,548,640, the contents ofwhich are incorporated herein by reference herein in their entirety). Insuch humanized antibodies and antibody fragments, substantially lessthan an intact human variable domain has been substituted by thecorresponding sequence from a nonhuman species. Humanized antibodies areoften human antibodies in which some CDR residues and possibly someframework (FR) residues are substituted by residues from analogous sitesin rodent antibodies. Humanization of antibodies and antibody fragmentscan also be achieved by veneering or resurfacing (EP 592,106; EP519,596; Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnickaet al., Protein Engineering, 7(6):805-814 (1994); and Roguska et al.,PNAS, 91:969-973 (1994)) or chain shuffling (U.S. Pat. No. 5,565,332),the contents of which are incorporated herein by reference herein intheir entirety.

The choice of human variable domains, both light and heavy, to be usedin making the humanized antibodies is to reduce antigenicity. Accordingto the so-called “best-fit” method, the sequence of the variable domainof a rodent antibody is screened against the entire library of knownhuman variable-domain sequences. The human sequence which is closest tothat of the rodent is then accepted as the human framework (FR) for thehumanized antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothiaet al., J. Mol. Biol., 196:901 (1987), the contents of which areincorporated herein by reference herein in their entirety). Anothermethod uses a particular framework derived from the consensus sequenceof all human antibodies of a particular subgroup of light or heavychains. The same framework may be used for several different humanizedantibodies (see, e.g., Nicholson et al. Mol. Immun. 34 (16-17):1157-1165 (1997); Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285(1992); Presta et al., J. Immunol., 151:2623 (1993), the contents ofwhich are incorporated herein by reference herein in their entirety). Insome embodiments, the framework region, e.g., all four frameworkregions, of the heavy chain variable region are derived from a VH4_4-59germline sequence. In one embodiment, the framework region can comprise,one, two, three, four or five modifications, e.g., substitutions, e.g.,from the amino acid at the corresponding murine sequence (e.g., of SEQID NO:59). In one embodiment, the framework region, e.g., all fourframework regions of the light chain variable region are derived from aVK3_1.25 germline sequence. In one embodiment, the framework region cancomprise, one, two, three, four or five modifications, e.g.,substitutions, e.g., from the amino acid at the corresponding murinesequence (e.g., of SEQ ID NO:59).

In some aspects, the portion of a CAR composition of the invention thatcomprises an antibody fragment is humanized with retention of highaffinity for the target antigen and other favorable biologicalproperties. According to one aspect of the invention, humanizedantibodies and antibody fragments are prepared by a process of analysisof the parental sequences and various conceptual humanized productsusing three-dimensional models of the parental and humanized sequences.Three-dimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, e.g., theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind the target antigen. In this way, FR residues canbe selected and combined from the recipient and import sequences so thatthe desired antibody or antibody fragment characteristic, such asincreased affinity for the target antigen, is achieved. In general, theCDR residues are directly and most substantially involved in influencingantigen binding.

A humanized antibody or antibody fragment may retain a similar antigenicspecificity as the original antibody, e.g., in the present invention,the ability to bind human CD19, CD20, or CD22. In some embodiments, ahumanized antibody or antibody fragment may have improved affinityand/or specificity of binding to human CD19, CD20, or CD22.

In one aspect, the binding domain (e.g., an antigen-binding domain thatbinds one or more of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1,CD79b, CD179b, or CD79a) is a fragment, e.g., a single chain variablefragment (scFv). In one aspect, the binding domain is a Fv, a Fab, a(Fab′)2, or a bi-functional (e.g. bi-specific) hybrid antibody (e.g.,Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)). In one aspect,the antibodies and fragments thereof of the invention binds a CD19,CD20, or CD22 protein with wild-type or enhanced affinity.

In some instances, scFvs can be prepared according to method known inthe art (see, for example, Bird et al., (1988) Science 242:423-426 andHuston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). ScFvmolecules can be produced by linking VH and VL regions together usingflexible polypeptide linkers. The scFv molecules comprise a linker(e.g., a Ser-Gly linker) with an optimized length and/or amino acidcomposition. The linker length can greatly affect how the variableregions of a scFv fold and interact. In fact, if a short polypeptidelinker is employed (e.g., between 5-10 amino acids) intrachain foldingis prevented. Interchain folding is also required to bring the twovariable regions together to form a functional epitope binding site. Forexamples of linker orientation and size see, e.g., Hollinger et al. 1993Proc Natl Acad. Sci. U.S.A. 90:6444-6448, U.S. Patent ApplicationPublication Nos. 2005/0100543, 2005/0175606, 2007/0014794, and PCTpublication Nos. WO2006/020258 and WO2007/024715, is incorporated hereinby reference.

An scFv can comprise a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or moreamino acid residues between its VL and VH regions. The linker sequencemay comprise any naturally occurring amino acid. In some embodiments,the linker sequence comprises amino acids glycine and serine. In anotherembodiment, the linker sequence comprises sets of glycine and serinerepeats such as (Gly₄Ser)n, where n is a positive integer equal to orgreater than 1 (SEQ ID NO:18). In one embodiment, the linker can be(Gly₄Ser)₄ (SEQ ID NO:106) or (Gly₄Ser)₃ (SEQ ID NO:107). Variation inthe linker length may retain or enhance activity, giving rise tosuperior efficacy in activity studies.

In some embodiments, the amino acid sequence of the antigen bindingdomain (e.g., an antigen-binding domain that binds one or more of CD10,CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a) orother portions or the entire CAR) can be modified, e.g., an amino acidsequence described herein can be modified, e.g., by a conservativesubstitution. Families of amino acid residues having similar side chainshave been defined in the art, including basic side chains (e.g., lysine,arginine, histidine), acidic side chains (e.g., aspartic acid, glutamicacid), uncharged polar side chains (e.g., glycine, asparagine,glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains(e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan), beta-branched side chains (e.g., threonine,valine, isoleucine) and aromatic side chains (e.g., tyrosine,phenylalanine, tryptophan, histidine).

Percent identity in the context of two or more nucleic acids orpolypeptide sequences, refers to two or more sequences that are thesame. Two sequences are “substantially identical” if two sequences havea specified percentage of amino acid residues or nucleotides that arethe same (e.g., 60% identity, optionally 70%, 71%. 72%. 73%, 74%, 75%,76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity over aspecified region, or, when not specified, over the entire sequence),when compared and aligned for maximum correspondence over a comparisonwindow, or designated region as measured using one of the followingsequence comparison algorithms or by manual alignment and visualinspection. Optionally, the identity exists over a region that is atleast about 50 nucleotides (or 10 amino acids) in length, or over aregion that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 ormore amino acids) in length.

For sequence comparison, typically one sequence acts as a referencesequence, to which test sequences are compared. When using a sequencecomparison algorithm, test and reference sequences are entered into acomputer, subsequence coordinates are designated, if necessary, andsequence algorithm program parameters are designated. Default programparameters can be used, or alternative parameters can be designated. Thesequence comparison algorithm then calculates the percent sequenceidentities for the test sequences relative to the reference sequence,based on the program parameters. Methods of alignment of sequences forcomparison are well known in the art. Optimal alignment of sequences forcomparison can be conducted, e.g., by the local homology algorithm ofSmith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homologyalignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol.48:443, by the search for similarity method of Pearson and Lipman,(1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerizedimplementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA inthe Wisconsin Genetics Software Package, Genetics Computer Group, 575Science Dr., Madison, WI), or by manual alignment and visual inspection(see, e.g., Brent et al., (2003) Current Protocols in MolecularBiology).

Two examples of algorithms that are suitable for determining percentsequence identity and sequence similarity are the BLAST and BLAST 2.0algorithms, which are described in Altschul et al., (1977) Nuc. AcidsRes. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol.215:403-410, respectively. Software for performing BLAST analyses ispublicly available through the National Center for BiotechnologyInformation.

The percent identity between two amino acid sequences can also bedetermined using the algorithm of E. Meyers and W. Miller, (1988)Comput. Appl. Biosci. 4:11-17) which has been incorporated into theALIGN program (version 2.0), using a PAM120 weight residue table, a gaplength penalty of 12 and a gap penalty of 4. In addition, the percentidentity between two amino acid sequences can be determined using theNeedleman and Wunsch (1970) J. Mol. Biol. 48:444-453) algorithm whichhas been incorporated into the GAP program in the GCG software package(available at www.gcg.com), using either a Blossom 62 matrix or a PAM250matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a lengthweight of 1, 2, 3, 4, 5, or 6.

In one aspect, the present invention contemplates modifications of thestarting antibody or fragment (e.g., scFv) amino acid sequence thatgenerate functionally equivalent molecules. For example, the VH or VL ofa binding domain (e.g., an antigen-binding domain that binds one or moreof CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, orCD79a), e.g., scFv, comprised in the CAR can be modified to retain atleast about 70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%,82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99% identity of the starting VH or VL framework region ofthe anti-CD19 binding domain, e.g., scFv. More broadly, the VH or VL ofa B-cell antigen binding domain, to CD10, CD20, CD22, CD34, CD123,FLT-3, or ROR1, e.g., scFv, comprised in the CAR can be modified toretain at least about 70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%,80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, 99% identity of the starting VH or VL frameworkregion of the antigen binding domain, e.g., scFv. The present inventioncontemplates modifications of the entire CAR construct, e.g.,modifications in one or more amino acid sequences of the various domainsof the CAR construct in order to generate functionally equivalentmolecules. The CAR construct can be modified to retain at least about70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99% identity of the starting CAR construct.

Bispecific CARs

In an embodiment a multispecific antibody molecule is a bispecificantibody molecule. A bispecific antibody has specificity for no morethan two antigens. A bispecific antibody molecule is characterized by afirst immunoglobulin variable domain sequence which has bindingspecificity for a first epitope and a second immunoglobulin variabledomain sequence that has binding specificity for a second epitope. In anembodiment the first and second epitopes are on the same antigen, e.g.,the same protein (or subunit of a multimeric protein). In an embodimentthe first and second epitopes overlap. In an embodiment the first andsecond epitopes do not overlap. In an embodiment the first and secondepitopes are on different antigens, e.g., different proteins (ordifferent subunits of a multimeric protein). In an embodiment abispecific antibody molecule comprises a heavy chain variable domainsequence and a light chain variable domain sequence which have bindingspecificity for a first epitope and a heavy chain variable domainsequence and a light chain variable domain sequence which have bindingspecificity for a second epitope. In an embodiment a bispecific antibodymolecule comprises a half antibody having binding specificity for afirst epitope and a half antibody having binding specificity for asecond epitope. In an embodiment a bispecific antibody moleculecomprises a half antibody, or fragment thereof, having bindingspecificity for a first epitope and a half antibody, or fragmentthereof, having binding specificity for a second epitope. In anembodiment a bispecific antibody molecule comprises a scFv, or fragmentthereof, have binding specificity for a first epitope and a scFv, orfragment thereof, have binding specificity for a second epitope. In anembodiment the first epitope is located on CD19 and the second epitopeis located on CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1.

In certain embodiments, the antibody molecule is a multi-specific (e.g.,a bispecific or a trispecific) antibody molecule. Protocols forgenerating bispecific or heterodimeric antibody molecules are known inthe art; including but not limited to, for example, the “knob in a hole”approach described in, e.g., U.S. Pat. No. 5,731,168; the electrostaticsteering Fc pairing as described in, e.g., WO 09/089004, WO 06/106905and WO 2010/129304; Strand Exchange Engineered Domains (SEED)heterodimer formation as described in, e.g., WO 07/110205; Fab armexchange as described in, e.g., WO 08/119353, WO 2011/131746, and WO2013/060867; double antibody conjugate, e.g., by antibody cross-linkingto generate a bi-specific structure using a heterobifunctional reagenthaving an amine-reactive group and a sulfhydryl reactive group asdescribed in, e.g., U.S. Pat. No. 4,433,059; bispecific antibodydeterminants generated by recombining half antibodies (heavy-light chainpairs or Fabs) from different antibodies through cycle of reduction andoxidation of disulfide bonds between the two heavy chains, as describedin, e.g., U.S. Pat. No. 4,444,878; trifunctional antibodies, e.g., threeFab′ fragments cross-linked through sulfhydryl reactive groups, asdescribed in, e.g., U.S. Pat. No. 5,273,743; biosynthetic bindingproteins, e.g., pair of scFvs cross-linked through C-terminal tailspreferably through disulfide or amine-reactive chemical cross-linking,as described in, e.g., U.S. Pat. No. 5,534,254; bifunctional antibodies,e.g., Fab fragments with different binding specificities dimerizedthrough leucine zippers (e.g., c-fos and c-jun) that have replaced theconstant domain, as described in, e.g., U.S. Pat. No. 5,582,996;bispecific and oligospecific mono- and oligovalent receptors, e.g.,VH-CH1 regions of two antibodies (two Fab fragments) linked through apolypeptide spacer between the CH1 region of one antibody and the VHregion of the other antibody typically with associated light chains, asdescribed in, e.g., U.S. Pat. No. 5,591,828; bispecific DNA-antibodyconjugates, e.g., crosslinking of antibodies or Fab fragments through adouble stranded piece of DNA, as described in, e.g., U.S. Pat. No.5,635,602; bispecific fusion proteins, e.g., an expression constructcontaining two scFvs with a hydrophilic helical peptide linker betweenthem and a full constant region, as described in, e.g., U.S. Pat. No.5,637,481; multivalent and multispecific binding proteins, e.g., dimerof polypeptides having first domain with binding region of Ig heavychain variable region, and second domain with binding region of Ig lightchain variable region, generally termed diabodies (higher orderstructures are also encompassed creating for bispecific, trispecific, ortetraspecific molecules, as described in, e.g., U.S. Pat. No. 5,837,242;minibody constructs with linked VL and VH chains further connected withpeptide spacers to an antibody hinge region and CH3 region, which can bedimerized to form bispecific/multivalent molecules, as described in,e.g., U.S. Pat. No. 5,837,821; VH and VL domains linked with a shortpeptide linker (e.g., 5 or 10 amino acids) or no linker at all in eitherorientation, which can form dimers to form bispecific diabodies; trimersand tetramers, as described in, e.g., U.S. Pat. No. 5,844,094; String ofVH domains (or VL domains in family members) connected by peptidelinkages with crosslinkable groups at the C-terminus further associatedwith VL domains to form a series of FVs (or scFvs), as described in,e.g., U.S. Pat. No. 5,864,019; and single chain binding polypeptideswith both a VH and a VL domain linked through a peptide linker arecombined into multivalent structures through non-covalent or chemicalcrosslinking to form, e.g., homobivalent, heterobivalent, trivalent, andtetravalent structures using both scFV or diabody type format, asdescribed in, e.g., U.S. Pat. No. 5,869,620. Additional exemplarymultispecific and bispecific molecules and methods of making the sameare found, for example, in U.S. Pat. Nos. 5,910,573, 5,932,448,5,959,083, 5,989,830, 6,005,079, 6,239,259, 6,294,353, 6,333,396,6,476,198, 6,511,663, 6,670,453, 6,743,896, 6,809,185, 6,833,441,7,129,330, 7,183,076, 7,521,056, 7,527,787, 7,534,866, 7,612,181,US2002004587A1, US2002076406A1, US2002103345A1, US2003207346A1,US2003211078A1, US2004219643A1, US2004220388A1, US2004242847A1,US2005003403A1, US2005004352A1, US2005069552A1, US2005079170A1,US2005100543A1, US2005136049A1, US2005136051A1, US2005163782A1,US2005266425A1, US2006083747A1, US2006120960A1, US2006204493A1,US2006263367A1, US2007004909A1, US2007087381A1, US2007128150A1,US2007141049A1, US2007154901A1, US2007274985A1, US2008050370A1,US2008069820A1, US2008152645A1, US2008171855A1, US2008241884A1,US2008254512A1, US2008260738A1, US2009130106A1, US2009148905A1,US2009155275A1, US2009162359A1, US2009162360A1, US2009175851A1,US2009175867A1, US2009232811A1, US2009234105A1, US2009263392A1,US2009274649A1, EP346087A2, WO0006605A2, WO02072635A2, WO04081051A1,WO06020258A2, WO2007044887A2, WO2007095338A2, WO2007137760A2,WO2008119353A1, WO2009021754A2, WO2009068630A1, WO9103493A1,WO9323537A1, WO9409131A1, WO9412625A2, WO9509917A1, WO9637621A2,WO9964460A1. The contents of the above-referenced applications areincorporated herein by reference in their entireties.

Within each antibody or antibody fragment (e.g., scFv) of a bispecificantibody molecule, the VH can be upstream or downstream of the VL. Insome embodiments, the upstream antibody or antibody fragment (e.g.,scFv) is arranged with its VH (VH₁) upstream of its VL (VL₁) and thedownstream antibody or antibody fragment (e.g., scFv) is arranged withits VL (VL₂) upstream of its VH (VH₂), such that the overall bispecificantibody molecule has the arrangement VH₁-VL₁-VL₂-VH₂. In otherembodiments, the upstream antibody or antibody fragment (e.g., scFv) isarranged with its VL (VL₁) upstream of its VH (VH₁) and the downstreamantibody or antibody fragment (e.g., scFv) is arranged with its VH (VH₂)upstream of its VL (VL₂), such that the overall bispecific antibodymolecule has the arrangement VL₁-VH₁-VH₂-VL₂. Optionally, a linker isdisposed between the two antibodies or antibody fragments (e.g., scFvs),e.g., between VL₁ and VL₂ if the construct is arranged asVH₁-VL₁-VL₂-VH₂, or between VH₁ and VH₂ if the construct is arranged asVL₁-VH₁-VH₂-VL₂. The linker may be a linker as described herein, e.g., a(Gly₄-Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, e.g., 4 (SEQ IDNO: 53). In general, the linker between the two scFvs should be longenough to avoid mispairing between the domains of the two scFvs.Optionally, a linker is disposed between the VL and VH of the firstscFv. Optionally, a linker is disposed between the VL and VH of thesecond scFv. In constructs that have multiple linkers, any two or moreof the linkers can be the same or different. Accordingly, in someembodiments, a bispecific CAR comprises VLs, VHs, and optionally one ormore linkers in an arrangement as described herein.

In certain embodiments the antibody molecule is a bispecific antibodymolecule having a first binding specificity for a first B-cell epitopeand a second binding specificity for another B-cell antigen. Forinstance, in some embodiments the bispecific antibody molecule has afirst binding specificity for CD19 and a second binding specificity forone or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b,CD179b, or CD79a. In some embodiments the bispecific antibody moleculehas a first binding specificity for CD19 and a second bindingspecificity for CD22.

Chimeric TCR

In one aspect, the antibodies and antibody fragments disclosed herein(e.g., those directed against CD10, CD19, CD20, CD22, CD34, CD123,FLT-3, ROR1, CD79b, CD179b, or CD79a) can be grafted to one or moreconstant domain of a T cell receptor (“TCR”) chain, for example, a TCRalpha or TCR beta chain, to create an chimeric TCR that bindsspecifically to a cancer associated antigen. Without being bound bytheory, it is believed that chimeric TCRs will signal through the TCRcomplex upon antigen binding. For example, an scFv as disclosed herein,can be grafted to the constant domain, e.g., at least a portion of theextracellular constant domain, the transmembrane domain and thecytoplasmic domain, of a TCR chain, for example, the TCR alpha chainand/or the TCR beta chain. As another example, an antibody fragment, forexample a VL domain as described herein, can be grafted to the constantdomain of a TCR alpha chain, and an antibody fragment, for example a VHdomain as described herein, can be grafted to the constant domain of aTCR beta chain (or alternatively, a VL domain may be grafted to theconstant domain of the TCR beta chain and a VH domain may be grafted toa TCR alpha chain). As another example, the CDRs of an antibody orantibody fragment, e.g., the CDRs of an antibody or antibody fragment asdescribed in any of the Tables herein may be grafted into a TCR alphaand/or beta chain to create a chimeric TCR that binds specifically to acancer associated antigen. For example, the LC CDRs disclosed herein maybe grafted into the variable domain of a TCR alpha chain and the HC CDRsdisclosed herein may be grafted to the variable domain of a TCR betachain, or vice versa. Such chimeric TCRs may be produced by anyappropriate method (For example, Willemsen R A et al, Gene Therapy 2000;7: 1369-1377; Zhang T et al, Cancer Gene Ther 2004; 11: 487-496; Aggenet al, Gene Ther. 2012 April; 19(4):365-74).

Non-Antibody Scaffolds

In embodiments, the antigen binding domain comprises a non antibodyscaffold, e.g., a fibronectin, ankyrin, domain antibody, lipocalin,small modular immuno-pharmaceutical, maxybody, Protein A, or affilin.The non antibody scaffold has the ability to bind to target antigen on acell. In embodiments, the antigen binding domain is a polypeptide orfragment thereof of a naturally occurring protein expressed on a cell.In some embodiments, the antigen binding domain comprises a non-antibodyscaffold. A wide variety of non-antibody scaffolds can be employed solong as the resulting polypeptide includes at least one binding regionwhich specifically binds to the target antigen on a target cell.

Non-antibody scaffolds include: fibronectin (Novartis, MA), ankyrin(Molecular Partners AG, Zurich, Switzerland), domain antibodies(Domantis, Ltd., Cambridge, MA, and Ablynx nv, Zwijnaarde, Belgium),lipocalin (Pieris Proteolab AG, Freising, Germany), small modularimmuno-pharmaceuticals (Trubion Pharmaceuticals Inc., Seattle, WA),maxybodies (Avidia, Inc., Mountain View, CA), Protein A (Affibody AG,Sweden), and affilin (gamma-crystallin or ubiquitin) (Scil ProteinsGmbH, Halle, Germany).

Fibronectin scaffolds can be based on fibronectin type III domain (e.g.,the tenth module of the fibronectin type III (¹⁰Fn3 domain)). Thefibronectin type III domain has 7 or 8 beta strands which aredistributed between two beta sheets, which themselves pack against eachother to form the core of the protein, and further containing loops(analogous to CDRs) which connect the beta strands to each other and aresolvent exposed. There are at least three such loops at each edge of thebeta sheet sandwich, where the edge is the boundary of the proteinperpendicular to the direction of the beta strands (see U.S. Pat. No.6,818,418). Because of this structure, this non-antibody scaffold mimicsantigen binding properties that are similar in nature and affinity tothose of antibodies. These scaffolds can be used in a loop randomizationand shuffling strategy in vitro that is similar to the process ofaffinity maturation of antibodies in vivo.

The ankyrin technology is based on using proteins with ankyrin derivedrepeat modules as scaffolds for bearing variable regions which can beused for binding to different targets. The ankyrin repeat module is a 33amino acid polypeptide consisting of two anti-parallel α-helices and aβ-turn. Binding of the variable regions is mostly optimized by usingribosome display.

Avimers are derived from natural A-domain containing protein such asHER3. These domains are used by nature for protein-protein interactionsand in human over 250 proteins are structurally based on A-domains.Avimers consist of a number of different “A-domain” monomers (2-10)linked via amino acid linkers. Avimers can be created that can bind tothe target antigen using the methodology described in, for example, U.S.Patent Application Publication Nos. 20040175756; 20050053973;20050048512; and 20060008844.

Affibody affinity ligands are small, simple proteins composed of athree-helix bundle based on the scaffold of one of the IgG-bindingdomains of Protein A. Protein A is a surface protein from the bacteriumStaphylococcus aureus. This scaffold domain consists of 58 amino acids,13 of which are randomized to generate affibody libraries with a largenumber of ligand variants (See e.g., U.S. Pat. No. 5,831,012). Affibodymolecules mimic antibodies, they have a molecular weight of 6 kDa,compared to the molecular weight of antibodies, which is 150 kDa. Inspite of its small size, the binding site of affibody molecules issimilar to that of an antibody.

Protein epitope mimetics (PEM) are medium-sized, cyclic, peptide-likemolecules (MW 1-2 kDa) mimicking beta-hairpin secondary structures ofproteins, the major secondary structure involved in protein-proteininteractions. Antigen binding domains, e.g., those comprising scFv,single domain antibodies, or camelid antibodies, can be directed to anytarget receptor/ligand described herein, e.g., the PD1 receptors, PD-L1or PD-L2.

In an embodiment the antigen binding domain comprises the extracellulardomain, or a counter-ligand binding fragment thereof, of molecule thatbinds a counterligand on the surface of a target cell.

An antigen binding domain can comprise the extracellular domain of aninhibitory receptor. Engagement with a counterligand of the coinhibitorymolecule is redirected into an optimization of immune effector response.

An antigen binding domain can comprise the extracellular domain of acostimulatory molecule, referred to as a Costimulatory ECD domain,Engagement with a counter ligand of the costimulatory molecule resultsin optimization of immune effector response.

Transmembrane Domain

With respect to the transmembrane domain, in various embodiments, a CARcan be designed to comprise a transmembrane domain that is attached tothe extracellular domain of the CAR. A transmembrane domain can includeone or more additional amino acids adjacent to the transmembrane region,e.g., one or more amino acid associated with the extracellular region ofthe protein from which the transmembrane was derived (e.g., 1, 2, 3, 4,5, 6, 7, 8, 9, 10 up to amino acids of the extracellular region) and/orone or more additional amino acids associated with the intracellularregion of the protein from which the transmembrane protein is derived(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of theintracellular region). In one aspect, the transmembrane domain is onethat is associated with one of the other domains of the CAR, e.g., inone embodiment, the transmembrane domain may be from the same proteinthat the signaling domain, costimulatory domain or the hinge domain isderived from. In another aspect, the transmembrane domain is not derivedfrom the same protein that any other domain of the CAR is derived from.In some instances, the transmembrane domain can be selected or modifiedby amino acid substitution to avoid binding of such domains to thetransmembrane domains of the same or different surface membraneproteins, e.g., to minimize interactions with other members of thereceptor complex. In one aspect, the transmembrane domain is capable ofhomodimerization with another CAR on the cell surface of aCAR-expressing cell. In a different aspect the amino acid sequence ofthe transmembrane domain may be modified or substituted so as tominimize interactions with the binding domains of the native bindingpartner present in the same CAR-expressing cell.

The transmembrane domain may be derived either from a natural or from arecombinant source. Where the source is natural, the domain may bederived from any membrane-bound or transmembrane protein. In one aspectthe transmembrane domain is capable of signaling to the intracellulardomain(s) whenever the CAR has bound to a target. A transmembrane domainof particular use in this invention may include at least thetransmembrane region(s) of e.g., the alpha, beta or zeta chain of theT-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16,CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. In someembodiments, a transmembrane domain may include at least thetransmembrane region(s) of, e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a,CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR),SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2Rgamma, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6,CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b,ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1(CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9(CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108),SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR,PAG/Cbp, NKG2D, NKG2C, or CD19.

In some instances, the transmembrane domain can be attached to theextracellular region of the CAR, e.g., the antigen binding domain of theCAR, via a hinge, e.g., a hinge from a human protein. For example, inone embodiment, the hinge can be a human Ig (immunoglobulin) hinge,e.g., an IgG4 hinge, an IgD hinge, a GS linker (e.g., a GS linkerdescribed herein), a KIR2DS2 hinge, or a CD8a hinge. In one embodiment,the hinge or spacer comprises (e.g., consists of) the amino acidsequence of SEQ ID NO:14. In one aspect, the transmembrane domaincomprises (e.g., consists of) a transmembrane domain of SEQ ID NO: 15.

In one aspect, the hinge or spacer comprises an IgG4 hinge. For example,in one embodiment, the hinge or spacer comprises a hinge of the aminoacid sequence

(SEQ ID NO: 45) ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKM.In some embodiments, the hinge or spacer comprises a hinge encoded by anucleotide sequence of

(SEQ ID NO: 46) GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATG.

In one aspect, the hinge or spacer comprises an IgD hinge. For example,in one embodiment, the hinge or spacer comprises a hinge of the aminoacid sequence

(SEQ ID NO: 47) RWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDH.In some embodiments, the hinge or spacer comprises a hinge encoded by anucleotide sequence of

(SEQ ID NO: 48) AGGTGGCCCGAAAGTCCCAAGGCCCAGGCATCTAGTGTTCCTACTGCACAGCCCCAGGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTACGCGCAATACTGGCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGAAAGAAGAACAGGAAGAGAGGGAGACCAAGACCCCTGAATGTCCATCCCATACCCAGCCGCTGGGCGTCTATCTCTTGACTCCCGCAGTACAGGACTTGTGGCTTAGAGATAAGGCCACCTTTACATGTTTCGTCGTGGGCTCTGACCTGAAGGATGCCCATTTGACTTGGGAGGTTGCCGGAAAGGTACCCACAGGGGGGGTTGAGGAAGGGTTGCTGGAGCGCCATTCCAATGGCTCTCAGAGCCAGCACTCAAGACTCACCCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCACATGTACTCTAAATCATCCTAGCCTGCCCCCACAGCGTCTGATGGCCCTTAGAGAGCCAGCCGCCCAGGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCAGTAGTGATCCCCCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGGCTTTAGCCCGCCCAACATCTTGCTCATGTGGCTGGAGGACCAGCGAGAAGTGAACACCAGCGGCTTCGCTCCAGCCCGGCCCCCACCCCAGCCGGGTTCTACCACATTCTGGGCCTGGAGTGTCTTAAGGGTCCCAGCACCACCTAGCCCCCAGCCAGCCACATACACCTGTGTTGTGTCCCATGAAGATAGCAGGACCCTGCTAAATGCTTCTAGGAGTCTGGAGGTTTCCTACGTGACTGACCATT.

In one aspect, the transmembrane domain may be recombinant, in whichcase it will comprise predominantly hydrophobic residues such as leucineand valine. In one aspect a triplet of phenylalanine, tryptophan andvaline can be found at each end of a recombinant transmembrane domain.

Optionally, a short oligo- or polypeptide linker, between 2 and 10 aminoacids in length may form the linkage between the transmembrane domainand the cytoplasmic region of the CAR. A glycine-serine doublet providesa particularly suitable linker. For example, in one aspect, the linkercomprises the amino acid sequence of GGGGSGGGGS (SEQ ID NO:49). In someembodiments, the linker is encoded by a nucleotide sequence of

(SEQ ID NO: 50) GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC.

In one aspect, the hinge or spacer comprises a KIR2DS2 hinge.

Cytoplasmic Domain

The cytoplasmic domain or region of the CAR includes an intracellularsignaling domain. An intracellular signaling domain is generallyresponsible for activation of at least one of the normal effectorfunctions of the immune cell in which the CAR has been introduced.

Examples of intracellular signaling domains for use in the CAR of theinvention include the cytoplasmic sequences of the T cell receptor (TCR)and co-receptors that act in concert to initiate signal transductionfollowing antigen receptor engagement, as well as any derivative orvariant of these sequences and any recombinant sequence that has thesame functional capability.

It is known that signals generated through the TCR alone areinsufficient for full activation of the T cell and that a secondaryand/or costimulatory signal is also required. Thus, T cell activationcan be said to be mediated by two distinct classes of cytoplasmicsignaling sequences: those that initiate antigen-dependent primaryactivation through the TCR (primary intracellular signaling domains) andthose that act in an antigen-independent manner to provide a secondaryor costimulatory signal (secondary cytoplasmic domain, e.g., acostimulatory domain).

A primary signaling domain regulates primary activation of the TCRcomplex either in a stimulatory way, or in an inhibitory way. Primaryintracellular signaling domains that act in a stimulatory manner maycontain signaling motifs which are known as immunoreceptortyrosine-based activation motifs or ITAMs.

Examples of ITAM containing primary intracellular signaling domains thatare of particular use in the invention include those of CD3 zeta, commonFcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc Epsilon Rib), CD3 gamma,CD3 delta, CD3 epsilon, CD79a, CD79b, CD278 (also known as “ICOS”),FcεRI, DAP10, DAP12, and CD66d. In one embodiment, a CAR of theinvention comprises an intracellular signaling domain, e.g., a primarysignaling domain of CD3-zeta.

In one embodiment, a primary signaling domain comprises a modified ITAMdomain, e.g., a mutated ITAM domain which has altered (e.g., increasedor decreased) activity as compared to the native ITAM domain. In oneembodiment, a primary signaling domain comprises a modifiedITAM-containing primary intracellular signaling domain, e.g., anoptimized and/or truncated ITAM-containing primary intracellularsignaling domain. In an embodiment, a primary signaling domain comprisesone, two, three, four or more ITAM motifs.

Further examples of molecules containing a primary intracellularsignaling domain that are of particular use in the invention includethose of DAP10, DAP12, and CD32.

Costimulatory Signaling Domain

The intracellular signalling domain of the CAR can comprise the CD3-zetasignaling domain by itself or it can be combined with any other desiredintracellular signaling domain(s) useful in the context of a CAR of theinvention. For example, the intracellular signaling domain of the CARcan comprise a CD3 zeta chain portion and a costimulatory signalingdomain. The costimulatory signaling domain refers to a portion of theCAR comprising the intracellular domain of a costimulatory molecule. Inone embodiment, the intracellular domain is designed to comprise thesignaling domain of CD3-zeta and the signaling domain of CD28. In oneaspect, the intracellular domain is designed to comprise the signalingdomain of CD3-zeta and the signaling domain of ICOS.

A costimulatory molecule can be a cell surface molecule other than anantigen receptor or its ligands that is required for an efficientresponse of lymphocytes to an antigen. Examples of such moleculesinclude CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD1, ICOS,lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT,NKG2C, B7-H3, and a ligand that specifically binds with CD83, and thelike. For example, CD27 costimulation has been demonstrated to enhanceexpansion, effector function, and survival of human CART cells in vitroand augments human T cell persistence and antitumor activity in vivo(Song et al. Blood. 2012; 119(3):696-706). Further examples of suchcostimulatory molecules include MHC class I molecule, TNF receptorproteins, Immunoglobulin-like proteins, cytokine receptors, integrins,signaling lymphocytic activation molecules (SLAM proteins), activatingNK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27,CD28, CD30, CD40, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3,ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7,NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2Rbeta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D,ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1,ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7,NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4),CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1,CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150,IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76,PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

The intracellular signaling sequences within the cytoplasmic portion ofthe CAR of the invention may be linked to each other in a random orspecified order. Optionally, a short oligo- or polypeptide linker, forexample, between 2 and 10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, oramino acids) in length may form the linkage between intracellularsignaling sequence. In one embodiment, a glycine-serine doublet can beused as a suitable linker. In one embodiment, a single amino acid, e.g.,an alanine, a glycine, can be used as a suitable linker.

In one aspect, the intracellular signaling domain is designed tocomprise two or more, e.g., 2, 3, 4, 5, or more, costimulatory signalingdomains. In an embodiment, the two or more, e.g., 2, 3, 4, 5, or more,costimulatory signaling domains, are separated by a linker molecule,e.g., a linker molecule described herein. In one embodiment, theintracellular signaling domain comprises two costimulatory signalingdomains. In some embodiments, the linker molecule is a glycine residue.In some embodiments, the linker is an alanine residue.

In one aspect, the intracellular signaling domain is designed tocomprise the signaling domain of CD3-zeta and the signaling domain ofCD28. In one aspect, the intracellular signaling domain is designed tocomprise the signaling domain of CD3-zeta and the signaling domain of4-1BB. In one aspect, the signaling domain of 4-1BB is a signalingdomain of SEQ ID NO: 16. In one aspect, the signaling domain of CD3-zetais a signaling domain of SEQ ID NO: 17.

In one aspect, the intracellular signaling domain is designed tocomprise the signaling domain of CD3-zeta and the signaling domain ofCD27. In one aspect, the signaling domain of CD27 comprises an aminoacid sequence of

(SEQ ID NO: 51) QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP.In one aspect, the signalling domain of CD27 is encoded by a nucleicacid sequence of

(SEQ ID NO: 52) AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCC.

Natural Killer Cell Receptor (NKR) CARs

In an embodiment, a CAR molecule described herein comprises one or morecomponents of a natural killer cell receptor (NKR), thereby forming anNKR-CAR. The NKR component can be a transmembrane domain, a hingedomain, or a cytoplasmic domain from any of the following natural killercell receptors: killer cell immunoglobulin-like receptor (KIR), e.g.,KIR2DL1, KIR2DL2/L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2,KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1/S1, KIR3DL2, KIR3DL3, KIR2DP1, andKIR3DP1; natural cytotoxicity receptor (NCR), e.g., NKp30, NKp44, NKp46;signaling lymphocyte activation molecule (SLAM) family of immune cellreceptors, e.g., CD48, CD229, 2B4, CD84, NTB-A, CRACC, BLAME, andCD2F-10; Fc receptor (FcR), e.g., CD16, and CD64; and Ly49 receptors,e.g., LY49A, LY49C. The NKR-CAR molecules described herein may interactwith an adaptor molecule or intracellular signaling domain, e.g., DAP12.Exemplary configurations and sequences of CAR molecules comprising NKRcomponents are described in International Publication No. WO2014/145252,the contents of which are hereby incorporated by reference.

Strategies for Regulating Chimeric Antigen Receptors

In some embodiments, a regulatable CAR (RCAR) where the CAR activity canbe controlled is desirable to optimize the safety and efficacy of a CARtherapy. There are many ways CAR activities can be regulated. Forexample, inducing apoptosis using, e.g., a caspase fused to adimerization domain (see, e.g., Di et al., N Engl. J. Med. 2011 Nov. 3;365(18):1673-1683), can be used as a safety switch in the CAR therapy ofthe instant invention. In one embodiment, the cells (e.g., T cells or NKcells) expressing a CAR of the present invention further comprise aninducible apoptosis switch, wherein a human caspase (e.g., caspase 9) ora modified version is fused to a modification of the human FKB proteinthat allows conditional dimerization. In the presence of a smallmolecule, such as a rapalog (e.g., AP 1903, AP20187), the induciblecaspase (e.g., caspase 9) is activated and leads to the rapid apoptosisand death of the cells (e.g., T cells or NK cells) expressing a CAR ofthe present invention. Examples of a caspase-based inducible apoptosisswitch (or one or more aspects of such a switch) have been described in,e.g., US2004040047; US20110286980; US20140255360; WO1997031899;WO2014151960; WO2014164348; WO2014197638; WO2014197638; all of which areincorporated by reference herein.

In another example, CAR-expressing cells can also express an inducibleCaspase-9 (iCaspase-9) molecule that, upon administration of a dimerizerdrug (e.g., rimiducid (also called AP1903 (Bellicum Pharmaceuticals) orAP20187 (Ariad)) leads to activation of the Caspase-9 and apoptosis ofthe cells. The iCaspase-9 molecule contains a chemical inducer ofdimerization (CID) binding domain that mediates dimerization in thepresence of a CID. This results in inducible and selective depletion ofCAR-expressing cells. In some cases, the iCaspase-9 molecule is encodedby a nucleic acid molecule separate from the CAR-encoding vector(s). Insome cases, the iCaspase-9 molecule is encoded by the same nucleic acidmolecule as the CAR-encoding vector. The iCaspase-9 can provide a safetyswitch to avoid any toxicity of CAR-expressing cells. See, e.g., Song etal. Cancer Gene Ther. 2008; 15(10):667-75; Clinical Trial Id. No.NCT02107963; and Di Stasi et al. N. Engl. J. Med. 2011; 365:1673-83.

Alternative strategies for regulating the CAR therapy of the instantinvention include utilizing small molecules or antibodies thatdeactivate or turn off CAR activity, e.g., by deleting CAR-expressingcells, e.g., by inducing antibody dependent cell-mediated cytotoxicity(ADCC). For example, CAR-expressing cells described herein may alsoexpress an antigen that is recognized by molecules capable of inducingcell death, e.g., ADCC or complement-induced cell death. For example,CAR expressing cells described herein may also express a receptorcapable of being targeted by an antibody or antibody fragment. Examplesof such receptors include EpCAM, VEGFR, integrins (e.g., integrins avβ3,α4, αI¾β3, α4β7, α5β1, αvβ3, αv), members of the TNF receptorsuperfamily (e.g., TRAIL-R1, TRAIL-R2), PDGF Receptor, interferonreceptor, folate receptor, GPNMB, ICAM-1, HLA-DR, CEA, CA-125, MUC1,TAG-72, IL-6 receptor, 5T4, GD2, GD3, CD2, CD3, CD4, CD5, CD11,CD11a/LFA-1, CD15, CD18/ITGB2, CD19, CD20, CD22, CD23/lgE Receptor,CD25, CD28, CD30, CD33, CD38, CD40, CD41, CD44, CD51, CD52, CD62L, CD74,CD80, CD125, CD147/basigin, CD152/CTLA-4, CD154/CD40L, CD195/CCR5,CD319/SLAMF7, and EGFR, and truncated versions thereof (e.g., versionspreserving one or more extracellular epitopes but lacking one or moreregions within the cytoplasmic domain).

For example, a CAR-expressing cell described herein may also express atruncated epidermal growth factor receptor (EGFR) which lacks signalingcapacity but retains the epitope that is recognized by molecules capableof inducing ADCC, e.g., cetuximab (ERBITUX®), such that administrationof cetuximab induces ADCC and subsequent depletion of the CAR-expressingcells (see, e.g., WO2011/056894, and Jonnalagadda et al., Gene Ther.2013; 20(8)853-860). Another strategy includes expressing a highlycompact marker/suicide gene that combines target epitopes from both CD32and CD20 antigens in the CAR-expressing cells described herein, whichbinds rituximab, resulting in selective depletion of the CAR-expressingcells, e.g., by ADCC (see, e.g., Philip et al., Blood. 2014;124(8)1277-1287). Other methods for depleting CAR-expressing cellsdescribed herein include administration of CAMPATH, a monoclonalanti-CD52 antibody that selectively binds and targets maturelymphocytes, e.g., CAR-expressing cells, for destruction, e.g., byinducing ADCC. In other embodiments, the CAR-expressing cell can beselectively targeted using a CAR ligand, e.g., an anti-idiotypicantibody. In some embodiments, the anti-idiotypic antibody can causeeffector cell activity, e.g., ADCC or ADC activities, thereby reducingthe number of CAR-expressing cells. In other embodiments, the CARligand, e.g., the anti-idiotypic antibody, can be coupled to an agentthat induces cell killing, e.g., a toxin, thereby reducing the number ofCAR-expressing cells. Alternatively, the CAR molecules themselves can beconfigured such that the activity can be regulated, e.g., turned on andoff, as described below.

In other embodiments, a CAR-expressing cell described herein may alsoexpress a target protein recognized by the T cell depleting agent. Inone embodiment, the target protein is CD20 and the T cell depletingagent is an anti-CD20 antibody, e.g., rituximab. In such embodiment, theT cell depleting agent is administered once it is desirable to reduce oreliminate the CAR-expressing cell, e.g., to mitigate the CAR inducedtoxicity. In other embodiments, the T cell depleting agent is ananti-CD52 antibody, e.g., alemtuzumab.

In an aspect, a RCAR comprises a set of polypeptides, typically two inthe simplest embodiments, in which the components of a standard CARdescribed herein, e.g., an antigen binding domain and an intracellularsignaling domain, are partitioned on separate polypeptides or members.In some embodiments, the set of polypeptides include a dimerizationswitch that, upon the presence of a dimerization molecule, can couplethe polypeptides to one another, e.g., can couple an antigen bindingdomain to an intracellular signaling domain. In one embodiment, a CAR ofthe present invention utilizes a dimerization switch as those describedin, e.g., WO2014127261, which is incorporated by reference herein.Additional description and exemplary configurations of such regulatableCARs are provided herein and in International Publication No. WO2015/090229, hereby incorporated by reference in its entirety.

In some embodiments, an RCAR involves a switch domain, e.g., a FKBPswitch domain, as set out SEQ ID NO: 122, or comprise a fragment of FKBPhaving the ability to bind with FRB, e.g., as set out in SEQ ID NO: 123.In some embodiments, the RCAR involves a switch domain comprising a FRBsequence, e.g., as set out in SEQ ID NO: 124, or a mutant FRB sequence,e.g., as set out in any of SEQ ID Nos. 125-130.

(SEQ ID NO: 122) D V P D Y A S L G G P S S P K K K R K V S R G V QV E T I S P G D G R T F P K R G Q T C V V H Y T GM L E D G K K F D S S R D R N K P F K F M L G KQ E V I R G W E E G V A Q M S V G Q R A K L T I SP D Y A Y G A T G H P G I I P P H A T L V F D V E L L K L E T S Y(SEQ ID NO: 123) V Q V E T I S P G D G R T F P K R G Q T C V V H YT G M L E D G K K F D S S R D R N K P F K F M LG K Q E V I R G W E E G V A Q M S V G Q R A K LT I S P D Y A Y G A T G H P G I I P P H A T L V F D V E L L K L E T S(SEQ ID NO: 124) ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMERGPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA WDLYYHVFRR ISK

TABLE 1 Exemplary mutant FRB having increasedaffinity for a dimerization molecule. SEQ ID FRB mutantAmino Acid Sequence NO: E2032I mutantILWHEMWHEGLIEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGR 125DLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKTS E2032L mutantILWHEMWHEGLLEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGR 126DLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKTS T2098L mutantILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGR 127DLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRISKTS E2032, T2098 ILWHEMWHEGL XEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGR 128 mutantDLMEAQEWCRKYMKSGNVKDL X QAWDLYYHVFRRISKTS E2032I, T2098LILWHEMWHEGLIEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGR 129 mutantDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRISKTS E2032L, T2098LILWHEMWHEGLLEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGR 130 mutantDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRISKTS

Split CAR

In some embodiments, the CAR-expressing cell uses a split CAR. The splitCAR approach is described in more detail in publications WO2014/055442and WO2014/055657. Briefly, a split CAR system comprises a cellexpressing a first CAR having a first antigen binding domain and acostimulatory domain (e.g., 41BB), and the cell also expresses a secondCAR having a second antigen binding domain and an intracellularsignaling domain (e.g., CD3 zeta). When the cell encounters the firstantigen, the costimulatory domain is activated, and the cellproliferates. When the cell encounters the second antigen, theintracellular signaling domain is activated and cell-killing activitybegins. Thus, the CAR-expressing cell is only fully activated in thepresence of both antigens.

RNA Transfection

Disclosed herein are methods for producing an in vitro transcribed RNACAR. The present invention also includes (among other things) a CARencoding RNA construct that can be directly transfected into a cell. Amethod for generating mRNA for use in transfection can involve in vitrotranscription (IVT) of a template with specially designed primers,followed by polyA addition, to produce a construct containing 3′ and 5′untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome EntrySite (IRES), the nucleic acid to be expressed, and a polyA tail,typically 50-2000 bases in length (SEQ ID NO:118). RNA so produced canefficiently transfect different kinds of cells. In one aspect, thetemplate includes sequences for the CAR.

In one aspect the CAR is encoded by a messenger RNA (mRNA). In oneaspect the mRNA encoding the CAR is introduced into an immune effectorcell, e.g., a T cell or a NK cell, for production of a CAR-expressingcell, e.g., a CART cell or a CAR NK cell.

In one embodiment, the in vitro transcribed RNA CAR can be introduced toa cell as a form of transient transfection. The RNA is produced by invitro transcription using a polymerase chain reaction (PCR)-generatedtemplate. DNA of interest from any source can be directly converted byPCR into a template for in vitro mRNA synthesis using appropriateprimers and RNA polymerase. The source of the DNA can be, for example,genomic DNA, plasmid DNA, phage DNA, cDNA, synthetic DNA sequence or anyother appropriate source of DNA. A desired temple for in vitrotranscription is a CAR of the present invention. For example, thetemplate for the RNA CAR comprises an extracellular region comprising asingle chain variable domain of an anti-tumor antibody; a hinge region,a transmembrane domain (e.g., a transmembrane domain of CD8a); and acytoplasmic region that includes an intracellular signaling domain,e.g., comprising the signaling domain of CD3-zeta and the signalingdomain of 4-1BB.

In one embodiment, the DNA to be used for PCR contains an open readingframe. The DNA can be from a naturally occurring DNA sequence from thegenome of an organism. In one embodiment, the nucleic acid can includesome or all of the 5′ and/or 3′ untranslated regions (UTRs). The nucleicacid can include exons and introns. In one embodiment, the DNA to beused for PCR is a human nucleic acid sequence. In another embodiment,the DNA to be used for PCR is a human nucleic acid sequence includingthe 5′ and 3′ UTRs. The DNA can alternatively be an artificial DNAsequence that is not normally expressed in a naturally occurringorganism. An exemplary artificial DNA sequence is one that containsportions of genes that are ligated together to form an open readingframe that encodes a fusion protein. The portions of DNA that areligated together can be from a single organism or from more than oneorganism.

PCR is used to generate a template for in vitro transcription of mRNAwhich is used for transfection. Methods for performing PCR are wellknown in the art. Primers for use in PCR are designed to have regionsthat are substantially complementary to regions of the DNA to be used asa template for the PCR. “Substantially complementary,” as used herein,refers to sequences of nucleotides where a majority or all of the basesin the primer sequence are complementary, or one or more bases arenon-complementary, or mismatched. Substantially complementary sequencesare able to anneal or hybridize with the intended DNA target underannealing conditions used for PCR. The primers can be designed to besubstantially complementary to any portion of the DNA template. Forexample, the primers can be designed to amplify the portion of a nucleicacid that is normally transcribed in cells (the open reading frame),including 5′ and 3′ UTRs. The primers can also be designed to amplify aportion of a nucleic acid that encodes a particular domain of interest.In one embodiment, the primers are designed to amplify the coding regionof a human cDNA, including all or portions of the 5′ and 3′ UTRs.Primers useful for PCR can be generated by synthetic methods that arewell known in the art. “Forward primers” are primers that contain aregion of nucleotides that are substantially complementary tonucleotides on the DNA template that are upstream of the DNA sequencethat is to be amplified. “Upstream” is used herein to refer to alocation 5, to the DNA sequence to be amplified relative to the codingstrand. “Reverse primers” are primers that contain a region ofnucleotides that are substantially complementary to a double-strandedDNA template that are downstream of the DNA sequence that is to beamplified. “Downstream” is used herein to refer to a location 3′ to theDNA sequence to be amplified relative to the coding strand.

Any DNA polymerase useful for PCR can be used in the methods disclosedherein. The reagents and polymerase are commercially available from anumber of sources.

Chemical structures with the ability to promote stability and/ortranslation efficiency may also be used. The RNA in some embodiments has5′ and 3′ UTRs. In one embodiment, the 5′ UTR is between one and 3000nucleotides in length. The length of 5′ and 3′ UTR sequences to be addedto the coding region can be altered by different methods, including, butnot limited to, designing primers for PCR that anneal to differentregions of the UTRs. Using this approach, one of ordinary skill in theart can modify the 5′ and 3′ UTR lengths required to achieve optimaltranslation efficiency following transfection of the transcribed RNA.

The 5′ and 3′ UTRs can be the naturally occurring, endogenous 5′ and 3′UTRs for the nucleic acid of interest. Alternatively, UTR sequences thatare not endogenous to the nucleic acid of interest can be added byincorporating the UTR sequences into the forward and reverse primers orby any other modifications of the template. The use of UTR sequencesthat are not endogenous to the nucleic acid of interest can be usefulfor modifying the stability and/or translation efficiency of the RNA.For example, it is known that AU-rich elements in 3′ UTR sequences candecrease the stability of mRNA. Therefore, 3′ UTRs can be selected ordesigned to increase the stability of the transcribed RNA based onproperties of UTRs that are well known in the art.

In one embodiment, the 5′ UTR can contain the Kozak sequence of theendogenous nucleic acid. Alternatively, when a 5′ UTR that is notendogenous to the nucleic acid of interest is being added by PCR asdescribed above, a consensus Kozak sequence can be redesigned by addingthe 5′ UTR sequence. Kozak sequences can increase the efficiency oftranslation of some RNA transcripts, but does not appear to be requiredfor all RNAs to enable efficient translation. The requirement for Kozaksequences for many mRNAs is known in the art. In other embodiments the5′ UTR can be 5′UTR of an RNA virus whose RNA genome is stable in cells.In other embodiments various nucleotide analogues can be used in the 3′or 5′ UTR to impede exonuclease degradation of the mRNA.

To enable synthesis of RNA from a DNA template without the need for genecloning, a promoter of transcription should be attached to the DNAtemplate upstream of the sequence to be transcribed. When a sequencethat functions as a promoter for an RNA polymerase is added to the 5′end of the forward primer, the RNA polymerase promoter becomesincorporated into the PCR product upstream of the open reading framethat is to be transcribed. In one embodiment, the promoter is a T7polymerase promoter, as described elsewhere herein. Other usefulpromoters include, but are not limited to, T3 and SP6 RNA polymerasepromoters. Consensus nucleotide sequences for T7, T3 and SP6 promotersare known in the art.

In an embodiment, the mRNA has both a cap on the 5′ end and a 3′ poly(A)tail which determine ribosome binding, initiation of translation andstability mRNA in the cell. On a circular DNA template, for instance,plasmid DNA, RNA polymerase produces a long concatameric product whichis not suitable for expression in eukaryotic cells. The transcription ofplasmid DNA linearized at the end of the 3′ UTR results in normal sizedmRNA which is not effective in eukaryotic transfection even if it ispolyadenylated after transcription.

On a linear DNA template, phage T7 RNA polymerase can extend the 3′ endof the transcript beyond the last base of the template (Schenborn andMierendorf, Nuc Acids Res., 13:6223-36 (1985); Nacheva andBerzal-Herranz, Eur. J. Biochem., 270:1485-65 (2003).

The conventional method of integration of polyA/T stretches into a DNAtemplate is molecular cloning. However polyA/T sequence integrated intoplasmid DNA can cause plasmid instability, which is why plasmid DNAtemplates obtained from bacterial cells are often highly contaminatedwith deletions and other aberrations. This makes cloning procedures notonly laborious and time consuming but often not reliable. That is why amethod which allows construction of DNA templates with polyA/T 3′stretch without cloning highly desirable.

The polyA/T segment of the transcriptional DNA template can be producedduring PCR by using a reverse primer containing a polyT tail, such as100T tail (SEQ ID NO: 29) (size can be 50-5000 T (SEQ ID NO: 30)), orafter PCR by any other method, including, but not limited to, DNAligation or in vitro recombination. Poly(A) tails also provide stabilityto RNAs and reduce their degradation. Generally, the length of a poly(A)tail positively correlates with the stability of the transcribed RNA. Inone embodiment, the poly(A) tail is between 100 and 5000 adenosines (SEQID NO: 57).

Poly(A) tails of RNAs can be further extended following in vitrotranscription with the use of a poly(A) polymerase, such as E. colipolyA polymerase (E-PAP). In one embodiment, increasing the length of apoly(A) tail from 100 nucleotides to between 300 and 400 nucleotides(SEQ ID NO: 104) results in about a two-fold increase in the translationefficiency of the RNA. Additionally, the attachment of differentchemical groups to the 3′ end can increase mRNA stability. Suchattachment can contain modified/artificial nucleotides, aptamers andother compounds. For example, ATP analogs can be incorporated into thepoly(A) tail using poly(A) polymerase. ATP analogs can further increasethe stability of the RNA.

5′ caps on also provide stability to RNA molecules. In an embodiment,RNAs produced by the methods disclosed herein include a 5′ cap. The 5′cap is provided using techniques known in the art and described herein(Cougot, et al., Trends in Biochem. Sci., 29:436-444 (2001); Stepinski,et al., RNA, 7:1468-95 (2001); Elango, et al., Biochim. Biophys. Res.Commun., 330:958-966 (2005)).

The RNAs produced by the methods disclosed herein can also contain aninternal ribosome entry site (IRES) sequence. The IRES sequence may beany viral, chromosomal or artificially designed sequence which initiatescap-independent ribosome binding to mRNA and facilitates the initiationof translation. Any solutes suitable for cell electroporation, which cancontain factors facilitating cellular permeability and viability such assugars, peptides, lipids, proteins, antioxidants, and surfactants can beincluded.

RNA can be introduced into target cells using any of a number ofdifferent methods, for instance, commercially available methods whichinclude, but are not limited to, electroporation (Amaxa Nucleofector-II(Amaxa Biosystems, Cologne, Germany)), (ECM 830 (BTX) (HarvardInstruments, Boston, Mass.) or the Gene Pulser II (BioRad, Denver,Colo.), Multiporator (Eppendort, Hamburg Germany), cationic liposomemediated transfection using lipofection, polymer encapsulation, peptidemediated transfection, or biolistic particle delivery systems such as“gene guns” (see, for example, Nishikawa, et al. Hum Gene Ther.,12(8):861-70 (2001).

Non-Viral Delivery Methods

In some aspects, non-viral methods can be used to deliver a nucleic acidencoding a CAR described herein into a cell or tissue or a subject.

In some embodiments, the non-viral method includes the use of atransposon (also called a transposable element). In some embodiments, atransposon is a piece of DNA that can insert itself at a location in agenome, for example, a piece of DNA that is capable of self-replicatingand inserting its copy into a genome, or a piece of DNA that can bespliced out of a longer nucleic acid and inserted into another place ina genome. For example, a transposon comprises a DNA sequence made up ofinverted repeats flanking genes for transposition.

Exemplary methods of nucleic acid delivery using a transposon include aSleeping Beauty transposon system (SBTS) and a piggyBac (PB) transposonsystem. See, e.g., Aronovich et al. Hum. Mol. Genet. 20.R1(2011):R14-20;Singh et al. Cancer Res. 15(2008):2961-2971; Huang et al. Mol. Ther.16(2008):580-589; Grabundzija et al. Mol. Ther. 18(2010):1200-1209;Kebriaei et al. Blood. 122.21(2013):166; Williams. Molecular Therapy16.9(2008):1515-16; Bell et al. Nat. Protoc. 2.12(2007):3153-65; andDing et al. Cell. 122.3(2005):473-83, all of which are incorporatedherein by reference.

The SBTS includes two components: 1) a transposon containing a transgeneand 2) a source of transposase enzyme. The transposase can transpose thetransposon from a carrier plasmid (or other donor DNA) to a target DNA,such as a host cell chromosome/genome. For example, the transposasebinds to the carrier plasmid/donor DNA, cuts the transposon (includingtransgene(s)) out of the plasmid, and inserts it into the genome of thehost cell. See, e.g., Aronovich et al.

Exemplary transposons include a pT2-based transposon. See, e.g.,Grabundzija et al. Nucleic Acids Res. 41.3(2013):1829-47; and Singh etal. Cancer Res. 68.8(2008): 2961-2971, all of which are incorporatedherein by reference. Exemplary transposases include a Tc 1/mariner-typetransposase, e.g., the SB10 transposase or the SB11 transposase (ahyperactive transposase which can be expressed, e.g., from acytomegalovirus promoter). See, e.g., Aronovich et al.; Kebriaei et al.;and Grabundzija et al., all of which are incorporated herein byreference.

Use of the SBTS permits efficient integration and expression of atransgene, e.g., a nucleic acid encoding a CAR described herein.Provided herein are methods of generating a cell, e.g., T cell or NKcell, that stably expresses a CAR described herein, e.g., using atransposon system such as SBTS.

In accordance with methods described herein, in some embodiments, one ormore nucleic acids, e.g., plasmids, containing the SBTS components aredelivered to a cell (e.g., T or NK cell). For example, the nucleicacid(s) are delivered by standard methods of nucleic acid (e.g., plasmidDNA) delivery, e.g., methods described herein, e.g., electroporation,transfection, or lipofection. In some embodiments, the nucleic acidcontains a transposon comprising a transgene, e.g., a nucleic acidencoding a CAR described herein. In some embodiments, the nucleic acidcontains a transposon comprising a transgene (e.g., a nucleic acidencoding a CAR described herein) as well as a nucleic acid sequenceencoding a transposase enzyme. In other embodiments, a system with twonucleic acids is provided, e.g., a dual-plasmid system, e.g., where afirst plasmid contains a transposon comprising a transgene, and a secondplasmid contains a nucleic acid sequence encoding a transposase enzyme.For example, the first and the second nucleic acids are co-deliveredinto a host cell.

In some embodiments, cells, e.g., T or NK cells, are generated thatexpress a CAR described herein by using a combination of gene insertionusing the SBTS and genetic editing using a nuclease (e.g., Zinc fingernucleases (ZFNs), Transcription Activator-Like Effector Nucleases(TALENs), the CRISPR/Cas system, or engineered meganucleasere-engineered homing endonucleases).

In some embodiments, use of a non-viral method of delivery permitsreprogramming of cells, e.g., T or NK cells, and direct infusion of thecells into a subject. Advantages of non-viral vectors include but arenot limited to the ease and relatively low cost of producing sufficientamounts required to meet a patient population, stability during storage,and lack of immunogenicity.

Nucleic Acid Constructs Encoding a CAR, e.g., a CD19 CAR, CD20 CAR, orCD22 CAR

The present invention also provides nucleic acid molecules encoding oneor more CAR constructs described herein, e.g., CD19 CAR, CD20 CAR, orCD22 CAR. In one aspect, the nucleic acid molecule is provided as amessenger RNA transcript. In one aspect, the nucleic acid molecule isprovided as a DNA construct.

Accordingly, in one aspect, the invention pertains to an isolatednucleic acid molecule encoding a chimeric antigen receptor (CAR),wherein the CAR comprises a binding domain (e.g., that binds CD19, CD20,or CD22) a transmembrane domain, and an intracellular signaling domaincomprising a stimulatory domain, e.g., a costimulatory signaling domainand/or a primary signaling domain, e.g., zeta chain.

In one embodiment, the binding domain is an anti-CD19 binding domaindescribed herein, e.g., an anti-CD19 binding domain which comprises asequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2,SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ IDNO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ IDNO:59, or a sequence with 95-99% identity thereof.

In one embodiment, the nucleic acid comprises CD22-encoding a nucleicacid set out in Table 6A or a sequence with 95-99% identity thereof. Inone embodiment, the nucleic acid is a nucleic acid encoding an aminoacid sequence set out in any of Tables 6A-10B or a sequence with 95-99%identity thereof.

In one embodiment, the nucleic acid comprises CD20-encoding a nucleicacid set out in Table 11A or a sequence with 95-99% identity thereof. Inone embodiment, the nucleic acid is a nucleic acid encoding an aminoacid sequence set out in any of Tables 11A-15B or a sequence with 95-99%identity thereof.

In one embodiment, the transmembrane domain is transmembrane domain of aprotein selected from the group consisting of the alpha, beta or zetachain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8,CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.In one embodiment, the transmembrane domain comprises a sequence of SEQID NO: 15, or a sequence with 95-99% identity thereof. In oneembodiment, the anti-CD19 binding domain is connected to thetransmembrane domain by a hinge region, e.g., a hinge described herein.In one embodiment, the hinge region comprises SEQ ID NO:14 or SEQ IDNO:45 or SEQ ID NO:47 or SEQ ID NO:49, or a sequence with 95-99%identity thereof. In one embodiment, the isolated nucleic acid moleculefurther comprises a sequence encoding a costimulatory domain. In oneembodiment, the costimulatory domain is a functional signaling domain ofa protein selected from the group consisting of OX40, CD27, CD28,ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), and 4-1BB (CD137). In oneembodiment, the costimulatory domain is a functional signaling domain ofa protein selected from the group consisting of MHC class I molecule,TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors,integrins, signaling lymphocytic activation molecules (SLAM proteins),activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2,CD7, CD27, CD28, CD30, CD40, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137),B7-H3, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2,SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha,CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4,IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL,CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18,LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4(CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160(BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM(SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS,SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.In one embodiment, the costimulatory domain comprises a sequence of SEQID NO:16, or a sequence with 95-99% identity thereof. In one embodiment,the intracellular signaling domain comprises a functional signalingdomain of 4-1BB and a functional signaling domain of CD3 zeta. In oneembodiment, the intracellular signaling domain comprises the sequence ofSEQ ID NO: 16 or SEQ ID NO:51, or a sequence with 95-99% identitythereof, and the sequence of SEQ ID NO: 17 or SEQ ID NO:43, or asequence with 95-99% identity thereof, wherein the sequences comprisingthe intracellular signaling domain are expressed in the same frame andas a single polypeptide chain.

In another aspect, the invention pertains to an isolated nucleic acidmolecule encoding a CAR construct comprising a leader sequence of SEQ IDNO: 13, a scFv domain having a sequence selected from the groupconsisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ IDNO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:59, (or a sequence with 95-99%identity thereof), a hinge region of SEQ ID NO:14 or SEQ ID NO:45 or SEQID NO:47 or SEQ ID NO:49 (or a sequence with 95-99% identity thereof), atransmembrane domain having a sequence of SEQ ID NO: 15 (or a sequencewith 95-99% identity thereof), a 4-1BB costimulatory domain having asequence of SEQ ID NO:16 or a CD27 costimulatory domain having asequence of SEQ ID NO:51 (or a sequence with 95-99% identity thereof),and a CD3 zeta stimulatory domain having a sequence of SEQ ID NO:17 orSEQ ID NO:43 (or a sequence with 95-99% identity thereof).

In another aspect, the invention pertains to an isolated polypeptidemolecule encoded by the nucleic acid molecule. In one embodiment, theisolated polypeptide molecule comprises a sequence selected from thegroup consisting of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:59 or asequence with 95-99% identity thereof.

In another aspect, the invention pertains to a nucleic acid moleculeencoding a chimeric antigen receptor (CAR) molecule that comprises ananti-CD19 binding domain, a transmembrane domain, and an intracellularsignaling domain comprising a stimulatory domain, and wherein saidanti-CD19 binding domain comprises a sequence selected from the groupconsisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ IDNO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:59, or a sequence with 95-99%identity thereof.

In one embodiment, the encoded CAR molecule (e.g., CD19 CAR, CD20 CAR,or CD22 CAR) further comprises a sequence encoding a costimulatorydomain. In one embodiment, the costimulatory domain is a functionalsignaling domain of a protein selected from the group consisting ofOX40, CD27, CD28, ICAM-1, LFA-1 (CD11a/CD18) and 4-1BB (CD137). In oneembodiment, the costimulatory domain comprises a sequence of SEQ IDNO:16. In one embodiment, the transmembrane domain is a transmembranedomain of a protein selected from the group consisting of the alpha,beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4,CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137and CD154. In one embodiment, the transmembrane domain comprises asequence of SEQ ID NO:15. In one embodiment, the intracellular signalingdomain comprises a functional signaling domain of 4-1BB and a functionalsignaling domain of zeta. In one embodiment, the intracellular signalingdomain comprises the sequence of SEQ ID NO: 16 and the sequence of SEQID NO: 17, wherein the sequences comprising the intracellular signalingdomain are expressed in the same frame and as a single polypeptidechain. In one embodiment, the anti-CD19 binding domain is connected tothe transmembrane domain by a hinge region. In one embodiment, the hingeregion comprises SEQ ID NO:14. In one embodiment, the hinge regioncomprises SEQ ID NO:45 or SEQ ID NO:47 or SEQ ID NO:49.

In another aspect, the invention pertains to an encoded CAR moleculecomprising a leader sequence of SEQ ID NO: 13, a scFv domain having asequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2,SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ IDNO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and SEQ IDNO:59, or a sequence with 95-99% identity thereof, a hinge region of SEQID NO:14 or SEQ ID NO:45 or SEQ ID NO:47 or SEQ ID NO:49, atransmembrane domain having a sequence of SEQ ID NO: 15, a 4-1BBcostimulatory domain having a sequence of SEQ ID NO:16 or a CD27costimulatory domain having a sequence of SEQ ID NO:51, and a CD3 zetastimulatory domain having a sequence of SEQ ID NO:17 or SEQ ID NO:43. Inone embodiment, the encoded CAR molecule comprises a sequence selectedfrom a group consisting of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:59, or asequence with 95-99% identity thereof.

The nucleic acid sequences coding for the desired molecules can beobtained using recombinant methods known in the art, such as, forexample by screening libraries from cells expressing the gene, byderiving the gene from a vector known to include the same, or byisolating directly from cells and tissues containing the same, usingstandard techniques. Alternatively, the gene of interest can be producedsynthetically, rather than cloned.

The present invention also provides vectors in which a DNA of thepresent invention is inserted. Vectors derived from retroviruses such asthe lentivirus are suitable tools to achieve long-term gene transfersince they allow long-term, stable integration of a transgene and itspropagation in daughter cells. Lentiviral vectors have the addedadvantage over vectors derived from onco-retroviruses such as murineleukemia viruses in that they can transduce non-proliferating cells,such as hepatocytes. They also have the added advantage of lowimmunogenicity. A retroviral vector may also be, e.g., a gammaretroviralvector. A gammaretroviral vector may include, e.g., a promoter, apackaging signal (w), a primer binding site (PBS), one or more (e.g.,two) long terminal repeats (LTR), and a transgene of interest, e.g., agene encoding a CAR. A gammaretroviral vector may lack viral structuralgens such as gag, pol, and env. Exemplary gammaretroviral vectorsinclude Murine Leukemia Virus (MLV), Spleen-Focus Forming Virus (SFFV),and Myeloproliferative Sarcoma Virus (MPSV), and vectors derivedtherefrom. Other gammaretroviral vectors are described, e.g., in TobiasMaetzig et al., “Gammaretroviral Vectors: Biology, Technology andApplication” Viruses. 2011 June; 3(6): 677-713.

In another embodiment, the vector comprising the nucleic acid encodingthe desired CAR of the invention is an adenoviral vector (A5/35). Inanother embodiment, the expression of nucleic acids encoding CARs can beaccomplished using of transposons such as sleeping beauty, crispr, CAS9,and zinc finger nucleases. See below June et al. 2009 Nature ReviewsImmunology 9.10: 704-716, is incorporated herein by reference.

A vector may also include, e.g., a signal sequence to facilitatesecretion, a polyadenylation signal and transcription terminator (e.g.,from Bovine Growth Hormone (BGH) gene), an element allowing episomalreplication and replication in prokaryotes (e.g. SV40 origin and ColE1or others known in the art) and/or elements to allow selection (e.g.,ampicillin resistance gene and/or zeocin marker).

In brief summary, the expression of natural or synthetic nucleic acidsencoding CARs is typically achieved by operably linking a nucleic acidencoding the CAR polypeptide or portions thereof to a promoter, andincorporating the construct into an expression vector. The vectors canbe suitable for replication and integration eukaryotes. Typical cloningvectors contain transcription and translation terminators, initiationsequences, and promoters useful for regulation of the expression of thedesired nucleic acid sequence.

In some aspects, the expression constructs of the present invention mayalso be used for nucleic acid immunization and gene therapy, usingstandard gene delivery protocols. Methods for gene delivery are known inthe art. See, e.g., U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466,incorporated by reference herein in their entireties. In anotherembodiment, the invention provides a gene therapy vector.

The nucleic acid can be cloned into a number of types of vectors. Forexample, the nucleic acid can be cloned into a vector including, but notlimited to a plasmid, a phagemid, a phage derivative, an animal virus,and a cosmid. Vectors of particular interest include expression vectors,replication vectors, probe generation vectors, and sequencing vectors.

Further, the expression vector may be provided to a cell in the form ofa viral vector. Viral vector technology is well known in the art and isdescribed, for example, in Sambrook et al., 2012, MOLECULAR CLONING: ALABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY), and inother virology and molecular biology manuals. Viruses, which are usefulas vectors include, but are not limited to, retroviruses, adenoviruses,adeno-associated viruses, herpes viruses, and lentiviruses. In general,a suitable vector contains an origin of replication functional in atleast one organism, a promoter sequence, convenient restrictionendonuclease sites, and one or more selectable markers, (e.g., WO01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).

A number of viral based systems have been developed for gene transferinto mammalian cells. For example, retroviruses provide a convenientplatform for gene delivery systems. A selected gene can be inserted intoa vector and packaged in retroviral particles using techniques known inthe art. The recombinant virus can then be isolated and delivered tocells of the subject either in vivo or ex vivo. A number of retroviralsystems are known in the art. In some embodiments, adenovirus vectorsare used. A number of adenovirus vectors are known in the art. In oneembodiment, lentivirus vectors are used.

Additional promoter elements, e.g., enhancers, regulate the frequency oftranscriptional initiation. Typically, these are located in the region30-110 bp upstream of the start site, although a number of promotershave been shown to contain functional elements downstream of the startsite as well. The spacing between promoter elements frequently isflexible, so that promoter function is preserved when elements areinverted or moved relative to one another. In the thymidine kinase (tk)promoter, the spacing between promoter elements can be increased to 50bp apart before activity begins to decline. Depending on the promoter,it appears that individual elements can function either cooperatively orindependently to activate transcription. Exemplary promoters include theCMV IE gene, EF-1α, ubiquitin C, or phosphoglycerokinase (PGK)promoters. In an embodiment, the promoter is a PGK promoter, e.g., atruncated PGK promoter as described herein.

An example of a promoter that is capable of expressing a CAR transgenein a mammalian T cell is the EF1a promoter. The native EF1a promoterdrives expression of the alpha subunit of the elongation factor-1complex, which is responsible for the enzymatic delivery of aminoacyltRNAs to the ribosome. The EF1a promoter has been extensively used inmammalian expression plasmids and has been shown to be effective indriving CAR expression from transgenes cloned into a lentiviral vector.See, e.g., Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). In oneaspect, the EF1a promoter comprises the sequence provided as SEQ IDNO:100.

Another example of a promoter is the immediate early cytomegalovirus(CMV) promoter sequence. This promoter sequence is a strong constitutivepromoter sequence capable of driving high levels of expression of anypolynucleotide sequence operatively linked thereto. However, otherconstitutive promoter sequences may also be used, including, but notlimited to the simian virus 40 (SV40) early promoter, mouse mammarytumor virus (MMTV), human immunodeficiency virus (HIV) long terminalrepeat (LTR) promoter, MoMuLV promoter, an avian leukemia viruspromoter, an Epstein-Barr virus immediate early promoter, a Rous sarcomavirus promoter, as well as human gene promoters such as, but not limitedto, the actin promoter, the myosin promoter, the elongation factor-1αpromoter, the hemoglobin promoter, and the creatine kinase promoter.Further, the invention should not be limited to the use of constitutivepromoters. Inducible promoters are also contemplated as part of theinvention. The use of an inducible promoter provides a molecular switchcapable of turning on expression of the polynucleotide sequence which itis operatively linked when such expression is desired, or turning offthe expression when expression is not desired. Examples of induciblepromoters include, but are not limited to a metallothionine promoter, aglucocorticoid promoter, a progesterone promoter, and a tetracyclinepromoter.

Another example of a promoter is the phosphoglycerate kinase (PGK)promoter. In embodiments, a truncated PGK promoter (e.g., a PGK promoterwith one or more, e.g., 1, 2, 5, 10, 100, 200, 300, or 400, nucleotidedeletions when compared to the wild-type PGK promoter sequence) may bedesired. The nucleotide sequences of exemplary PGK promoters areprovided below.

WT PGK Promoter: (SEQ ID NO: 1323)ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGCCGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCGGGTAGCGCCAGCCGCGCGACGGTAACGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGCGGCGCTTGGCGTTCCTTGGAAGGGCTGAATCCCCGCCTCGTCCTTCGCAGCGGCCCCCCGGGTGTTCCCATCGCCGCTTCTAGGCCCACTGCGACGCTTGCCTGCACTTCTTACACGCTCTGGGTCCCAGCCGCGGCGACGCAAAGGGCCTTGGTGCGGGTCTCGTCGGCGCAGGGACGCGTTTGGGTCCCGACGGAACCTTTTCCGCGTT GGGGTTGGGGCACCATAAGCT

Exemplary Truncated PGK Promoters:

PGK100: (SEQ ID NO: 1324)ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCC GGGTGTGATGGCGGGGTGPGK200: (SEQ ID NO: 1325)ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGCCGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCGGGTAGC GCCAGCCGCGCGACGGTAACGPGK300: (SEQ ID NO: 1326)ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGCCGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCGGGTAGCGCCAGCCGCGCGACGGTAACGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGCGGCGCTTGGCGTTCCTTGGAAGGGCTGAATCCCCG PGK400: (SEQ ID NO: 1327)ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTACGCCTTGTGGCGCGCCCGTCCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGCCGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCGGGTAGCGCCAGCCGCGCGACGGTAACGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGCGGCGCTTGGCGTTCCTTGGAAGGGCTGAATCCCCGCCTCGTCCTTCGCAGCGGCCCCCCGGGTGTTCCCATCGCCGCTTCTAGGCCCACTGCGACGCTTGCCTGCACTTCTTACACGCTCTGGGTCCCAGCCG

A vector may also include, e.g., a signal sequence to facilitatesecretion, a polyadenylation signal and transcription terminator (e.g.,from Bovine Growth Hormone (BGH) gene), an element allowing episomalreplication and replication in prokaryotes (e.g. SV40 origin and ColE1or others known in the art) and/or elements to allow selection (e.g.,ampicillin resistance gene and/or zeocin marker).

In order to assess the expression of a CAR polypeptide or portionsthereof, the expression vector to be introduced into a cell can alsocontain either a selectable marker gene or a reporter gene or both tofacilitate identification and selection of expressing cells from thepopulation of cells sought to be transfected or infected through viralvectors. In other aspects, the selectable marker may be carried on aseparate piece of DNA and used in a co-transfection procedure. Bothselectable markers and reporter genes may be flanked with appropriateregulatory sequences to enable expression in the host cells. Usefulselectable markers include, for example, antibiotic-resistance genes,such as neo and the like.

Reporter genes are used for identifying potentially transfected cellsand for evaluating the functionality of regulatory sequences. Ingeneral, a reporter gene is a gene that is not present in or expressedby the recipient organism or tissue and that encodes a polypeptide whoseexpression is manifested by some easily detectable property, e.g.,enzymatic activity. Expression of the reporter gene is assayed at asuitable time after the DNA has been introduced into the recipientcells. Suitable reporter genes may include genes encoding luciferase,beta-galactosidase, chloramphenicol acetyl transferase, secretedalkaline phosphatase, or the green fluorescent protein gene (e.g.,Ui-Tei et al., 2000 FEBS Letters 479: 79-82). Suitable expressionsystems are well known and may be prepared using known techniques orobtained commercially. In general, the construct with the minimal 5′flanking region showing the highest level of expression of reporter geneis identified as the promoter. Such promoter regions may be linked to areporter gene and used to evaluate agents for the ability to modulatepromoter-driven transcription.

In embodiments, the vector may comprise two or more nucleic acidsequences encoding a CAR, e.g., a first CAR that binds to CD19 and asecond CAR, e.g., an inhibitory CAR or a CAR that specifically binds toa second antigen, e.g., CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1,CD79b, CD179b, or CD79a. In such embodiments, the two or more nucleicacid sequences encoding the CAR are encoded by a single nucleic moleculein the same frame and as a single polypeptide chain. In this aspect, thetwo or more CARs, can, e.g., be separated by one or more peptidecleavage sites. (e.g., an auto-cleavage site or a substrate for anintracellular protease). Examples of peptide cleavage sites include thefollowing, wherein the GSG residues are optional:

T2A: (SEQ ID NO: 1328) (GSG)EGRGSLLTCGDVEENPGP P2A: (SEQ ID NO: 1329)(GSG)ATNFSLLKQAGDVEENPGP E2A: (SEQ ID NO: 1330)(GSG)QCTNYALLKLAGDVESNPGP F2A: (SEQ ID NO: 1331)(GSG)VKQTLNFDLLKLAGDVESNPGP

Methods of introducing and expressing genes into a cell are known in theart. In the context of an expression vector, the vector can be readilyintroduced into a host cell, e.g., mammalian, bacterial, yeast, orinsect cell by any method in the art. For example, the expression vectorcan be transferred into a host cell by physical, chemical, or biologicalmeans.

Physical methods for introducing a polynucleotide into a host cellinclude calcium phosphate precipitation, lipofection, particlebombardment, microinjection, electroporation, and the like. Methods forproducing cells comprising vectors and/or exogenous nucleic acids arewell-known in the art. See, for example, Sambrook et al., 2012,MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring HarborPress, NY). A suitable method for the introduction of a polynucleotideinto a host cell is calcium phosphate transfection

Biological methods for introducing a polynucleotide of interest into ahost cell include the use of DNA and RNA vectors. Viral vectors, andespecially retroviral vectors, have become the most widely used methodfor inserting genes into mammalian, e.g., human cells. Other viralvectors can be derived from lentivirus, poxviruses, herpes simplex virusI, adenoviruses and adeno-associated viruses, and the like. See, forexample, U.S. Pat. Nos. 5,350,674 and 5,585,362.

Chemical means for introducing a polynucleotide into a host cell includecolloidal dispersion systems, such as macromolecule complexes,nanocapsules, microspheres, beads, and lipid-based systems includingoil-in-water emulsions, micelles, mixed micelles, and liposomes. Anexemplary colloidal system for use as a delivery vehicle in vitro and invivo is a liposome (e.g., an artificial membrane vesicle). Other methodsof state-of-the-art targeted delivery of nucleic acids are available,such as delivery of polynucleotides with targeted nanoparticles or othersuitable sub-micron sized delivery system.

In the case where a non-viral delivery system is utilized, an exemplarydelivery vehicle is a liposome. The use of lipid formulations iscontemplated for the introduction of the nucleic acids into a host cell(in vitro, ex vivo or in vivo). In another aspect, the nucleic acid maybe associated with a lipid. The nucleic acid associated with a lipid maybe encapsulated in the aqueous interior of a liposome, interspersedwithin the lipid bilayer of a liposome, attached to a liposome via alinking molecule that is associated with both the liposome and theoligonucleotide, entrapped in a liposome, complexed with a liposome,dispersed in a solution containing a lipid, mixed with a lipid, combinedwith a lipid, contained as a suspension in a lipid, contained orcomplexed with a micelle, or otherwise associated with a lipid. Lipid,lipid/DNA or lipid/expression vector associated compositions are notlimited to any particular structure in solution. For example, they maybe present in a bilayer structure, as micelles, or with a “collapsed”structure. They may also simply be interspersed in a solution, possiblyforming aggregates that are not uniform in size or shape. Lipids arefatty substances which may be naturally occurring or synthetic lipids.For example, lipids include the fatty droplets that naturally occur inthe cytoplasm as well as the class of compounds which contain long-chainaliphatic hydrocarbons and their derivatives, such as fatty acids,alcohols, amines, amino alcohols, and aldehydes.

Lipids suitable for use can be obtained from commercial sources. Forexample, dimyristyl phosphatidylcholine (“DMPC”) can be obtained fromSigma, St. Louis, MO; dicetyl phosphate (“DCP”) can be obtained from K &K Laboratories (Plainview, NY); cholesterol (“Choi”) can be obtainedfrom Calbiochem-Behring; dimyristyl phosphatidylglycerol (“DMPG”) andother lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham,AL.). Stock solutions of lipids in chloroform or chloroform/methanol canbe stored at about −20° C. Chloroform is used as the only solvent sinceit is more readily evaporated than methanol. “Liposome” is a genericterm encompassing a variety of single and multilamellar lipid vehiclesformed by the generation of enclosed lipid bilayers or aggregates.Liposomes can be characterized as having vesicular structures with aphospholipid bilayer membrane and an inner aqueous medium. Multilamellarliposomes have multiple lipid layers separated by aqueous medium. Theyform spontaneously when phospholipids are suspended in an excess ofaqueous solution. The lipid components undergo self-rearrangement beforethe formation of closed structures and entrap water and dissolvedsolutes between the lipid bilayers (Ghosh et al., 1991 Glycobiology 5:505-10). However, compositions that have different structures insolution than the normal vesicular structure are also encompassed. Forexample, the lipids may assume a micellar structure or merely exist asnonuniform aggregates of lipid molecules. Also contemplated arelipofectamine-nucleic acid complexes.

Regardless of the method used to introduce exogenous nucleic acids intoa host cell or otherwise expose a cell to the inhibitor of the presentinvention, in order to confirm the presence of the recombinant DNAsequence in the host cell, a variety of assays may be performed. Suchassays include, for example, “molecular biological” assays well known tothose of skill in the art, such as Southern and Northern blotting,RT-PCR and PCR; “biochemical” assays, such as detecting the presence orabsence of a particular peptide, e.g., by immunological means (ELISAsand Western blots) or by assays described herein to identify agentsfalling within the scope of the invention.

The present invention further provides a vector comprising a CARencoding nucleic acid molecule. In one aspect, a CAR vector can bedirectly transduced into a cell, e.g., a T cell. In one aspect, thevector is a cloning or expression vector, e.g., a vector including, butnot limited to, one or more plasmids (e.g., expression plasmids, cloningvectors, minicircles, minivectors, double minute chromosomes),retroviral and lentiviral vector constructs. In one aspect, the vectoris capable of expressing the CAR construct in mammalian T cells. In oneaspect, the mammalian T cell is a human T cell.

Immune Effector Cells Expressing a CAR

In another aspect, the present invention provides a population ofCAR-expressing cells. In some embodiments, the population ofCAR-expressing cells comprises a cell that expresses one or more CARsdescribed herein. In some embodiments, the population of CAR-expressingcells comprises a mixture of cells expressing different CARs.

For example, in one embodiment, the population of CART cells can includea first cell expressing a CAR having an antigen binding domain to atumor antigen described herein, e.g., CD19, and a second cell expressinga CAR having a different antigen binding domain, e.g., an antigenbinding domain to a different tumor antigen described herein, e.g., anantigen binding domain to a tumor antigen described herein that differsfrom the tumor antigen bound by the antigen binding domain of the CARexpressed by the first cell, e.g., CD10, CD20, CD22, CD34, CD123, FLT-3,ROR1, CD79b, CD179b, or CD79a.

As another example, the population of CAR-expressing cells can include afirst cell expressing a CAR that includes an antigen binding domain to atumor antigen described herein, and a second cell expressing a CAR thatincludes an antigen binding domain to a target other than a tumorantigen as described herein. In one embodiment, the population ofCAR-expressing cells includes, e.g., a first cell expressing a CAR thatincludes a primary intracellular signaling domain, and a second cellexpressing a CAR that includes a secondary signaling domain. Either oneor both of the CAR expressing cells can have a truncated PGK promoter,e.g., as described herein, operably linked to the nucleic acid encodingthe CAR.

In another aspect, the present invention provides a population of cellswherein at least one cell in the population expresses a CAR having anantigen binding domain to a tumor antigen described herein, and a secondcell expressing another agent, e.g., an agent which enhances theactivity of a CAR-expressing cell. The CAR expressing cells of thepopulation can have a truncated PGK promoter, e.g., as described herein,operably linked to the nucleic acid encoding the CAR. In one embodiment,the agent can be an agent which inhibits an inhibitory molecule.Inhibitory molecules, e.g., PD-1, can, in some embodiments, decrease theability of a CAR-expressing cell to mount an immune effector response.Examples of inhibitory molecules include PD-1, PD-L1, PD-L2, CTLA4,TIM3, CEACAM (CEACAM-1, CEACAM-3, and/or CEACAM-5), LAG3, VISTA, BTLA,TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM(TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GALS,adenosine, and TGFR (e.g., TGFRbeta). In one embodiment, the agent whichinhibits an inhibitory molecule comprises a first polypeptide, e.g., aninhibitory molecule, associated with a second polypeptide that providesa positive signal to the cell, e.g., an intracellular signaling domaindescribed herein. In one embodiment, the agent comprises a firstpolypeptide, e.g., of an inhibitory molecule such as PD1, PD-L1, CTLA4,TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5), LAG3, VISTA,BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or a fragment of any ofthese, and a second polypeptide which is an intracellular signalingdomain described herein (e.g., comprising a costimulatory domain (e.g.,41BB, CD27, OX40 or CD28, e.g., as described herein) and/or a primarysignaling domain (e.g., a CD3 zeta signaling domain described herein).In one embodiment, the agent comprises a first polypeptide of PD-1 or afragment thereof, and a second polypeptide of an intracellular signalingdomain described herein (e.g., a CD28 signaling domain described hereinand/or a CD3 zeta signaling domain described herein).

Co-Expression of CAR with Other Molecules or Agents

Co-Expression of a Second CAR

In one aspect, the CAR-expressing cell described herein can furthercomprise a second CAR, e.g., a second CAR that includes a differentantigen binding domain, e.g., to the same target (CD19) or a differenttarget (e.g., CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b,or CD79a). In one embodiment, the second CAR includes an antigen bindingdomain to a target expressed on acute myeloid leukemia cells, such as,e.g., CD20, CD22, ROR1, CD10, CD33, CLL-1, CD34, CD123, FLT3, CD79b,CD179b, and CD79a. In one embodiment, the CAR-expressing cell comprisesa first CAR that targets a first antigen and includes an intracellularsignaling domain having a costimulatory signaling domain but not aprimary signaling domain, and a second CAR that targets a second,different, antigen and includes an intracellular signaling domain havinga primary signaling domain but not a costimulatory signaling domain.While not wishing to be bound by theory, placement of a costimulatorysignaling domain, e.g., 4-1BB, CD28, CD27 or OX-40, onto the first CAR,and the primary signaling domain, e.g., CD3 zeta, on the second CAR canlimit the CAR activity to cells where both targets are expressed. In oneembodiment, the CAR expressing cell comprises a first CD19 CAR thatincludes a CD19 binding domain, a transmembrane domain and acostimulatory domain and a second CAR that targets an antigen other thanCD19 (e.g., an antigen expressed on AML, cells, e.g., CD22, CD20, ROR1,CD10, CD33, CLL-1, CD34, CD123, FLT3, CD79b, CD179b, or CD79a) andincludes an antigen binding domain, a transmembrane domain and a primarysignaling domain. In another embodiment, the CAR expressing cellcomprises a first CD19 CAR that includes a CD19 binding domain, atransmembrane domain and a primary signaling domain and a second CARthat targets an antigen other than CD19 (e.g., an antigen expressed onAML cells, e.g., CD22, CD20, ROR1, CD10, CD33, CD123, CLL-1, CD34, FLT3,CD79b, CD179b, or CD79a) and includes an antigen binding domain to theantigen, a transmembrane domain and a costimulatory signaling domain.

In one aspect, the CAR-expressing cell described herein can furthercomprise a second CAR, e.g., a second CAR that includes a differentantigen binding domain, e.g., to the same target (e.g., CD19) or adifferent target (e.g., a target other than CD19, e.g., CD10, CD20,CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a). In oneembodiment, the CAR-expressing cell comprises a first CAR that targets afirst antigen and includes an intracellular signaling domain having acostimulatory signaling domain but not a primary signaling domain, and asecond CAR that targets a second, different, antigen and includes anintracellular signaling domain having a primary signaling domain but nota costimulatory signaling domain. Placement of a costimulatory signalingdomain, e.g., 4-1BB, CD28, CD27, OX-40 or ICOS, onto the first CAR, andthe primary signaling domain, e.g., CD3 zeta, on the second CAR canlimit the CAR activity to cells where both targets are expressed. In oneembodiment, the CAR expressing cell comprises a first CAR that includesan antigen binding domain, a transmembrane domain and a costimulatorydomain and a second CAR that targets another antigen and includes anantigen binding domain, a transmembrane domain and a primary signalingdomain. In another embodiment, the CAR expressing cell comprises a firstCAR that includes an antigen binding domain, a transmembrane domain anda primary signaling domain and a second CAR that targets another antigenand includes an antigen binding domain to the antigen, a transmembranedomain and a costimulatory signaling domain.

In one embodiment, the CAR-expressing cell comprises an XCAR describedherein (e.g., CD19 CAR, CD20 CAR, or CD22 CAR) and an inhibitory CAR. Inone embodiment, the CAR-expressing cell comprises a CD19 CAR describedherein and an inhibitory CAR. In one embodiment, the inhibitory CARcomprises an antigen binding domain that binds an antigen found onnormal cells but not cancer cells, e.g., normal cells that also expressCD19. In one embodiment, the inhibitory CAR comprises the antigenbinding domain, a transmembrane domain and an intracellular domain of aninhibitory molecule. For example, the intracellular domain of theinhibitory CAR can be an intracellular domain PD-1, PD-L1, PD-L2, CTLA4,TIM3, CEACAM (CEACAM-1, CEACAM-3, and/or CEACAM-5), LAG3, VISTA, BTLA,TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM(TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GALS,adenosine, and TGFR (e.g., TGFRbeta).

In one embodiment, when the CAR-expressing cell comprises two or moredifferent CARs, the antigen binding domains of the different CARs can besuch that the antigen binding domains do not interact with one another.For example, a cell expressing a first and second CAR can have anantigen binding domain of the first CAR, e.g., as a fragment, e.g., anscFv, that does not form an association with the antigen binding domainof the second CAR, e.g., the antigen binding domain of the second CAR isa VHH.

Co-Expression of an Agent that Enhances CAR Activity

In another aspect, the CAR-expressing cell described herein can furtherexpress another agent, e.g., an agent that enhances the activity orfitness of a CAR-expressing cell.

For example, in one embodiment, the agent can be an agent which inhibitsa molecule that modulates or regulates, e.g., inhibits, T cell function.In some embodiments, the molecule that modulates or regulates T cellfunction is an inhibitory molecule. Inhibitory molecules, e.g., PD1,can, in some embodiments, decrease the ability of a CAR-expressing cellto mount an immune effector response. Examples of inhibitory moleculesinclude PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD160,2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270),KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g.,TGFR beta).

In one embodiment, an inhibitory nucleic acid, e.g., an inhibitorynucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clusteredregularly interspaced short palindromic repeats (CRISPR), atranscription-activator like effector nuclease (TALEN), or a zinc fingerendonuclease (ZFN), e.g., as described herein, can be used to inhibitexpression of a molecule that modulates or regulates, e.g., inhibits,T-cell function in the CAR-expressing cell. In an embodiment the agentis an shRNA, e.g., an shRNA described herein. In an embodiment, theagent that modulates or regulates, e.g., inhibits, T-cell function isinhibited within a CAR-expressing cell. For example, a dsRNA moleculethat inhibits expression of a molecule that modulates or regulates,e.g., inhibits, T-cell function is linked to the nucleic acid thatencodes a component, e.g., all of the components, of the CAR.

In one embodiment, the agent which inhibits an inhibitory moleculecomprises a first polypeptide, e.g., an inhibitory molecule, associatedwith a second polypeptide that provides a positive signal to the cell,e.g., an intracellular signaling domain described herein. In oneembodiment, the agent comprises a first polypeptide, e.g., of aninhibitory molecule such as PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM(e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT,LAIR1, CD160, 2B4, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1),HVEM (TNFRSF14 or CD270), KIR, A2aR, MEW class I, MHC class II, GAL9,adenosine, or TGFR (e.g., TGFR beta), or a fragment of any of these(e.g., at least a portion of an extracellular domain of any of these),and a second polypeptide which is an intracellular signaling domaindescribed herein (e.g., comprising a costimulatory domain (e.g., 41BB,CD27 or CD28, e.g., as described herein) and/or a primary signalingdomain (e.g., a CD3 zeta signaling domain described herein). In oneembodiment, the agent comprises a first polypeptide of PD1 or a fragmentthereof (e.g., at least a portion of an extracellular domain of PD1),and a second polypeptide of an intracellular signaling domain describedherein (e.g., a CD28 signaling domain described herein and/or a CD3 zetasignaling domain described herein). PD1 is an inhibitory member of theCD28 family of receptors that also includes CD28, CTLA-4, ICOS, andBTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells(Agata et al. 1996 Int. Immunol 8:765-75). Two ligands for PD1, PD-L1and PD-L2 have been shown to downregulate T cell activation upon bindingto PD1 (Freeman et a. 2000 J Exp Med 192:1027-34; Latchman et al. 2001Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blanket al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004Clin Cancer Res 10:5094). Immune suppression can be reversed byinhibiting the local interaction of PD1 with PD-L1.

In one embodiment, the agent comprises the extracellular domain (ECD) ofan inhibitory molecule, e.g., Programmed Death 1 (PD1), can be fused toa transmembrane domain and intracellular signaling domains such as 41BBand CD3 zeta (also referred to herein as a PD1 CAR). In one embodiment,the PD1 CAR, when used in combinations with a CD19 CAR described herein,improves the persistence of the T cell. In one embodiment, the CAR is aPD1 CAR comprising the extracellular domain of PD1 indicated asunderlined in SEQ ID NO: 121. In one embodiment, the PD1 CAR comprisesthe amino acid sequence of SEQ ID NO:121.

(SEQ ID NO: 121) Malpvtalllplalllhaarppgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterraevptahpspsprpagqfqtlvtttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr.

In one embodiment, the PD1 CAR comprises the amino acid sequenceprovided below (SEQ ID NO:119).

(SEQ ID NO: 119) pgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelniterraevptahpspsprpagqfqtlvtttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr.

Tin one embodiment, the agent comprises a nucleic acid sequence encodingthe PD1 CAR, e.g., the PD1 CAR described herein. In one embodiment, thenucleic acid sequence for the PD1 CAR is shown below, with the PD1 ECDunderlined below in SEQ ID NO: 120

(SEQ ID NO: 120) atggccctccctgtcactgccctgcttctccccctcgcactcctgctccacgccgctagaccacccggatggtttctggactctccggatcgcccgtggaatcccccaaccttctcaccggcactcttggttgtgactgagggcgataatgcgaccttcacgtgctcgttctccaacacctccgaatcattcgtgctgaactggtaccgcatgagcccgtcaaaccagaccgacaagctcgccgcgtttccggaagatcggtcgcaaccgggacaggattgtcggttccgcgtgactcaactgccgaatggcagagacttccacatgagcgtggtccgcgctaggcgaaacgactccgggacctacctgtgcggagccatctcgctggcgcctaaggcccaaatcaaagagagcttgagggccgaactgagagtgaccgagcgcagagctgaggtgccaactgcacatccatccccatcgcctcggcctgcggggcagtttcagaccctggtcacgaccactccggcgccgcgcccaccgactccggccccaactatcgcgagccagcccctgtcgctgaggccggaagcatgccgccctgccgccggaggtgctgtgcatacccggggattggacttcgcatgcgacatctacatttgggctcctctcgccggaacttgtggcgtgctccttctgtccctggtcatcaccctgtactgcaagcggggtcggaaaaagcttctgtacattttcaagcagcccttcatgaggcccgtgcaaaccacccaggaggaggacggttgctcctgccggttccccgaagaggaagaaggaggttgcgagctgcgcgtgaagttctcccggagcgccgacgcccccgcctataagcagggccagaaccagctgtacaacgaactgaacctgggacggcgggaagagtacgatgtgctggacaagcggcgcggccgggaccccgaaatgggcgggaagcctagaagaaagaaccctcaggaaggcctgtataacgagctgcagaaggacaagatggccgaggcctactccgaaattgggatgaagggagagcggcggaggggaaaggggcacgacggcctgtaccaaggactgtccaccgccaccaaggacacatacgatgccctgcacatgcaggcccttccccctcgc.

In another example, in one embodiment, the agent which enhances theactivity of a CAR-expressing cell can be a costimulatory molecule orcostimulatory molecule ligand. Examples of costimulatory moleculesinclude MHC class I molecule, BTLA and a Toll ligand receptor, as wellas OX40, CD27, CD28, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), and 4-1BB(CD137). Further examples of such costimulatory molecules includeICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30,NKp46, CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7Ralpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f,ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX,CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2,TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile),CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69,SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8),SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligandthat specifically binds with CD83., e.g., as described herein. Examplesof costimulatory molecule ligands include CD80, CD86, CD40L, ICOSL,CD70, OX40L, 4-1BBL, GITRL, and LIGHT. In embodiments, the costimulatorymolecule ligand is a ligand for a costimulatory molecule different fromthe costimulatory molecule domain of the CAR. In embodiments, thecostimulatory molecule ligand is a ligand for a costimulatory moleculethat is the same as the costimulatory molecule domain of the CAR. In anembodiment, the costimulatory molecule ligand is 4-1BBL. In anembodiment, the costimulatory ligand is CD80 or CD86. In an embodiment,the costimulatory molecule ligand is CD70. In embodiments, aCAR-expressing immune effector cell described herein can be furtherengineered to express one or more additional costimulatory molecules orcostimulatory molecule ligands.

Co-Expression of CAR with a Chemokine Receptor

In embodiments, the CAR-expressing cell described herein furthercomprises a chemokine receptor molecule. Transgenic expression ofchemokine receptors CCR2b or CXCR2 in T cells enhances trafficking toCCL2- or CXCL1-secreting solid tumors including melanoma andneuroblastoma (Craddock et al., J Immunother. 2010 October; 33(8):780-8and Kershaw et al., Hum Gene Ther. 2002 Nov. 1; 13(16):1971-80). Thus,without wishing to be bound by theory, it is believed that chemokinereceptors expressed in CAR-expressing cells that recognize chemokinessecreted by tumors, e.g., solid tumors, can improve homing of theCAR-expressing cell to the tumor, facilitate the infiltration of theCAR-expressing cell to the tumor, and enhances antitumor efficacy of theCAR-expressing cell. The chemokine receptor molecule can comprise anaturally occurring or recombinant chemokine receptor or achemokine-binding fragment thereof. A chemokine receptor moleculesuitable for expression in a CAR-expressing cell described hereininclude a CXC chemokine receptor (e.g., CXCR1, CXCR2, CXCR3, CXCR4,CXCR5, CXCR6, or CXCR7), a CC chemokine receptor (e.g., CCR1, CCR2,CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, or CCR11), a CX3Cchemokine receptor (e.g., CX3CR1), a XC chemokine receptor (e.g., XCR1),or a chemokine-binding fragment thereof. In one embodiment, thechemokine receptor molecule to be expressed with a CAR described hereinis selected based on the chemokine(s) secreted by the tumor. In oneembodiment, the CAR-expressing cell described herein further comprises,e.g., expresses, a CCR2b receptor or a CXCR2 receptor. In an embodiment,the CAR described herein and the chemokine receptor molecule are on thesame vector or are on two different vectors. In embodiments where theCAR described herein and the chemokine receptor molecule are on the samevector, the CAR and the chemokine receptor molecule are each undercontrol of two different promoters or are under the control of the samepromoter.

Conditional Expression of Immune Response-Enhancing Agents

Also provided herein are compositions and methods for conditionallyexpressing an agent that enhances the immune response or activity of aCAR-expressing cell described herein.

In one aspect, the present disclosure features an immune effector cellthat is engineered to constitutively express a CAR, also referred toherein as a nonconditional CAR. In one embodiment, a nonconditional CARas described herein comprises an antigen binding domain that binds to acancer associated antigen, e.g., CD19, CD10, CD20, CD22, CD34, CD123,FLT-3, or ROR1. In embodiments, the nonconditional CAR-expressing immuneeffector cell further comprises a conditionally-expressed agent thatenhances the therapeutic efficacy, e.g., the immune response, of theCAR-expressing immune effector cell. In such embodiments, the expressionof the conditionally expressed agent occurs upon activation of thenonconditional CAR-expressing immune effector cell, e.g., upon bindingof the nonconditional CAR molecule to its target, e.g., a cancerassociated antigen, e.g., CD19, CD10, CD20, CD22, CD34, CD123, FLT-3, orROR1.

Immune response-enhancing agents as described herein can becharacterized by one or more of the following: 1) targets or binds to adifferent cancer associated antigen than that targeted by thenonconditional CAR; 2) inhibits the expression or activity of an immunecheckpoint or inhibitory molecule; and/or 3) activates the expressionand/or secretion of a component that enhances immune response oractivation of an immune effector cell. The immune response-enhancingagent can be a polypeptide or a nucleic acid, e.g., a nucleic acid thatencodes a polypeptide that enhances immune response. Examples ofconditionally expressed agents that enhance the immune response include,but are not limited to, an additional CAR (referred to as a conditionalCAR); a TCR-based molecule (e.g., a TCR-CAR); an inhibitor of an immunecheckpoint or an inhibitory molecule; and/or a cytokine. In embodiments,the conditional CAR binds to a different cancer associated antigen thanthat targeted by the nonconditional CAR. In embodiments, the inhibitorof an immune checkpoint or inhibitory molecule described herein is anantibody or antigen binding fragment thereof, an inhibitory nucleic acid(e.g., an siRNA or shRNA), or a small molecule that inhibits ordecreases the activity of an immune checkpoint or inhibitory moleculeselected from PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80,CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR,MHC class I, MHC class II, GALS, adenosine, or TGFR beta. Inembodiments, the cytokine comprises IL-2, IL-7, IL-15, or IL-21, orfunctional fragments or derivatives thereof.

In embodiments, the immune effector cell comprises a nonconditional CARand one or more conditional CARs, where the conditional CAR binds to adifferent cancer associated antigen than that targeted by thenonconditional CAR. By way of example, in one embodiment, an immuneeffector cell comprises a nonconditional CAR that binds to CD19 and oneor more conditional CARs that bind to CD10, CD20, CD22, CD34, CD123,FLT-3, or ROR1, or a combination thereof. In another embodiment, animmune effector cell comprises a nonconditional CAR that binds to CD10,CD20, CD22, CD34, CD123, FLT-3, or ROR1 and a conditional CAR that bindsto CD19.

Conditional expression of the agent that enhances the immune responseupon activation of the CAR-expressing immune effector cell is achievedby operatively linking an activation-conditional control region to theagent that enhances the immune response (e.g., to a nucleic acidsequence encoding such an agent). In one embodiment, the activationconditional control region comprises a promoter sequence that initiatesexpression, e.g., transcription, of the operatively linked immuneresponse enhancing agent upon activation of the immune effector cell. Inone embodiment, the activation conditional control region comprises oneor more regulatory sequences (e.g., a transcription factor bindingsequence or site) that facilitate the initiation of expression uponactivation of the immune effector cell. In embodiments, theactivation-conditional control region comprises a promoter sequenceand/or one or more transcription factor binding sequences from apromoter or regulatory sequence of a gene that is upregulated upon oneor more of the following: immune effector cell (e.g., T cell)activation, T-cell differentiation, T-cell polarization, or helper Tcell development. Examples of such genes include, but are not limitedto, NFAT (nuclear factor of activated T cells), ATF2 (activatingtranscription factor 2), NF-κB (nuclear factor-KB), IL-2, IL-2 receptor(IL-2R), IL-3, GM-CSF, IL-4, IL-10, and IFN-γ.

In one embodiment, the activation-conditional control region comprisesone or more, e.g., 1, 2, 3, 4, 5, 6, or more, NFAT binding sequences orsites. In embodiments, the NFAT-binding sequence in the promotercomprises (5′-GGAAA-3′) (SEQ ID NO: 1312), optionally situated in alonger consensus sequence of 5′ (A/T)GGAAA(A/N)(A/T/C)N 3′ (SEQ ID NO:1313). In embodiments, the NFAT-binding sequence is a κb-like sequencesuch as GGGACT (SEQ ID NO: 1314). (See, Gibson et al., The Journal ofImmunology, 2007, 179: 3831-3840.)

In one embodiment, the activation-conditional control region furthercomprises an IL-2 promoter (or a minimal IL-2 promoter), an IL-2Rpromoter, an ATF2 promoter, or a NF-κB promoter, or any functionalfragment or derivative thereof. In one embodiment, theactivation-conditional control region comprises one or more NFAT-bindingsequences, e.g., 3 or 6 NFAT-binding sequences, and an IL-2 promoter,e.g., an IL-2 minimal promoter. In one embodiment, theactivation-conditional control region comprises the sequence of

(SEQ ID NO: 1315) AGCTTGGATCCAAGAGGAAAATTTGTTTCATACAGAAGGCGTTAAGAGGAAAATTTGTTTCATACAGAAGGCGTTAAGAGGAAAATTTGTTTCATACAGA AGGCGTTCAAGCTTGTCGAC.

Sources of Cells

Prior to expansion and genetic modification or other modification, asource of cells, e.g., T cells or natural killer (NK) cells, can beobtained from a subject. Examples of subjects include humans, monkeys,chimpanzees, dogs, cats, mice, rats, and transgenic species thereof. Tcells can be obtained from a number of sources, including peripheralblood mononuclear cells, bone marrow, lymph node tissue, cord blood,thymus tissue, tissue from a site of infection, ascites, pleuraleffusion, spleen tissue, and tumors.

In certain aspects of the present disclosure, immune effector cells,e.g., T cells, can be obtained from a unit of blood collected from asubject using any number of techniques known to the skilled artisan,such as Ficoll™ separation. In one aspect, cells from the circulatingblood of an individual are obtained by apheresis. The apheresis producttypically contains lymphocytes, including T cells, monocytes,granulocytes, B cells, other nucleated white blood cells, red bloodcells, and platelets. In one aspect, the cells collected by apheresismay be washed to remove the plasma fraction and, optionally, to placethe cells in an appropriate buffer or media for subsequent processingsteps. In one embodiment, the cells are washed with phosphate bufferedsaline (PBS). In an alternative embodiment, the wash solution lackscalcium and may lack magnesium or may lack many if not all divalentcations.

Initial activation steps in the absence of calcium can lead to magnifiedactivation. As those of ordinary skill in the art would readilyappreciate a washing step may be accomplished by methods known to thosein the art, such as by using a semi-automated “flow-through” centrifuge(for example, the Cobe 2991 cell processor, the Baxter CytoMate, or theHaemonetics Cell Saver 5) according to the manufacturer's instructions.After washing, the cells may be resuspended in a variety ofbiocompatible buffers, such as, for example, Ca-free, Mg-free PBS,PlasmaLyte A, or other saline solution with or without buffer.Alternatively, the undesirable components of the apheresis sample may beremoved and the cells directly resuspended in culture media.

It is recognized that the methods of the application can utilize culturemedia conditions comprising 5% or less, for example 2%, human AB serum,and employ known culture media conditions and compositions, for examplethose described in Smith et al., “Ex vivo expansion of human T cells foradoptive immunotherapy using the novel Xeno-free CTS Immune Cell SerumReplacement” Clinical & Translational Immunology (2015) 4, e31;doi:10.1038/cti.2014.31.

In one aspect, T cells are isolated from peripheral blood lymphocytes bylysing the red blood cells and depleting the monocytes, for example, bycentrifugation through a PERCOLL™ gradient or by counterflow centrifugalelutriation.

The methods described herein can include, e.g., selection of a specificsubpopulation of immune effector cells, e.g., T cells, that are a Tregulatory cell-depleted population, CD25+ depleted cells, using, e.g.,a negative selection technique, e.g., described herein. In someembodiments, the population of T regulatory depleted cells contains lessthan 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells.

In one embodiment, T regulatory cells, e.g., CD25+ T cells, are removedfrom the population using an anti-CD25 antibody, or fragment thereof, ora CD25-binding ligand, IL-2. In one embodiment, the anti-CD25 antibody,or fragment thereof, or CD25-binding ligand is conjugated to asubstrate, e.g., a bead, or is otherwise coated on a substrate, e.g., abead. In one embodiment, the anti-CD25 antibody, or fragment thereof, isconjugated to a substrate as described herein.

In one embodiment, the T regulatory cells, e.g., CD25+ T cells, areremoved from the population using CD25 depletion reagent from Miltenyi™.In one embodiment, the ratio of cells to CD25 depletion reagent is 1e7cells to 20 uL, or 1e7 cells to 15 uL, or 1e7 cells to 10 uL, or 1e7cells to 5 uL, or 1e7 cells to 2.5 uL, or 1e7 cells to 1.25 uL. In oneembodiment, e.g., for T regulatory cells, e.g., CD25+ depletion, greaterthan 500 million cells/ml is used. In a further aspect, a concentrationof cells of 600, 700, 800, or 900 million cells/ml is used.

In one embodiment, the population of immune effector cells to bedepleted includes about 6×10⁹ CD25+ T cells. In other aspects, thepopulation of immune effector cells to be depleted include about 1×10⁹to 1×10¹⁰ CD25+ T cell, and any integer value in between. In oneembodiment, the resulting population T regulatory depleted cells has2×10⁹ T regulatory cells, e.g., CD25+ cells, or less (e.g., 1×10⁹,5×10⁸, 1×10⁸, 5×10⁷, 1×10⁷, or less CD25+ cells).

In one embodiment, the T regulatory cells, e.g., CD25+ cells, areremoved from the population using the CliniMAC system with a depletiontubing set, such as, e.g., tubing 162-01. In one embodiment, theCliniMAC system is run on a depletion setting such as, e.g.,DEPLETION2.1.

Without wishing to be bound by a particular theory, decreasing the levelof negative regulators of immune cells (e.g., decreasing the number ofunwanted immune cells, e.g., T_(REG) cells), in a subject prior toapheresis or during manufacturing of a CAR-expressing cell productsignificantly reduces the risk of subject relapse. For example, methodsof depleting T_(REG) cells are known in the art. Methods of decreasingT_(REG) cells include, but are not limited to, cyclophosphamide,anti-GITR antibody (an anti-GITR antibody described herein),CD25-depletion, mTOR inhibitor, and combinations thereof.

In some embodiments, the manufacturing methods comprise reducing thenumber of (e.g., depleting) T_(REG) cells prior to manufacturing of theCAR-expressing cell. For example, manufacturing methods comprisecontacting the sample, e.g., the apheresis sample, with an anti-GITRantibody and/or an anti-CD25 antibody (or fragment thereof, or aCD25-binding ligand), e.g., to deplete T_(REG) cells prior tomanufacturing of the CAR-expressing cell (e.g., T cell, NK cell)product.

Without wishing to be bound by a particular theory, decreasing the levelof negative regulators of immune cells (e.g., decreasing the number ofunwanted immune cells, e.g., T_(REG) cells), in a subject prior toapheresis or during manufacturing of a CAR-expressing cell product canreduce the risk of a T_(REG) relapse. In an embodiment, a subject ispre-treated with one or more therapies that reduce T_(REG) cells priorto collection of cells for CAR-expressing cell product manufacturing,thereby reducing the risk of subject relapse to CAR-expressing celltreatment. In an embodiment, methods of decreasing T_(REG) cellsinclude, but are not limited to, administration to the subject of one ormore of cyclophosphamide, anti-GITR antibody, CD25-depletion, or acombination thereof. In an embodiment, methods of decreasing T_(REG)cells include, but are not limited to, administration to the subject ofone or more of cyclophosphamide, anti-GITR antibody, CD25-depletion,mTOR inhibitor, or a combination thereof. Administration of one or moreof cyclophosphamide, anti-GITR antibody, CD25-depletion, or acombination thereof, can occur before, during or after an infusion ofthe CAR-expressing cell product. Administration of one or more ofcyclophosphamide, anti-GITR antibody, CD25-depletion, mTOR inhibitor, ora combination thereof, can occur before, during or after an infusion ofthe CAR-expressing cell product.

In some embodiments, the manufacturing methods comprise reducing thenumber of (e.g., depleting) T_(REG) cells prior to manufacturing of theCAR-expressing cell. For example, manufacturing methods comprisecontacting the sample, e.g., the apheresis sample, with an anti-GITRantibody and/or an anti-CD25 antibody (or fragment thereof, or aCD25-binding ligand), e.g., to deplete T_(REG) cells prior tomanufacturing of the CAR-expressing cell (e.g., T cell, NK cell)product.

In an embodiment, a subject is pre-treated with one or more therapiesthat reduce T_(REG) cells prior to collection of cells forCAR-expressing cell product manufacturing, thereby reducing the risk ofsubject relapse to CAR-expressing cell treatment. In an embodiment,methods of decreasing T_(REG) cells include, but are not limited to,administration to the subject of one or more of cyclophosphamide,anti-GITR antibody, CD25-depletion, or a combination thereof.Administration of one or more of cyclophosphamide, anti-GITR antibody,CD25-depletion, or a combination thereof, can occur before, during orafter an infusion of the CAR-expressing cell product.

In an embodiment, a subject is pre-treated with cyclophosphamide priorto collection of cells for CAR-expressing cell product manufacturing,thereby reducing the risk of subject relapse to CAR-expressing celltreatment. In an embodiment, a subject is pre-treated with an anti-GITRantibody prior to collection of cells for CAR-expressing cell productmanufacturing, thereby reducing the risk of subject relapse toCAR-expressing cell treatment.

In one embodiment, the population of cells to be removed are neither theregulatory T cells or tumor cells, but cells that otherwise negativelyaffect the expansion and/or function of CART cells, e.g. cellsexpressing CD14, CD11b, CD33, CD15, or other markers expressed bypotentially immune suppressive cells. In one embodiment, such cells areenvisioned to be removed concurrently with regulatory T cells and/ortumor cells, or following said depletion, or in another order.

The methods described herein can include more than one selection step,e.g., more than one depletion step. Enrichment of a T cell population bynegative selection can be accomplished, e.g., with a combination ofantibodies directed to surface markers unique to the negatively selectedcells. One method is cell sorting and/or selection via negative magneticimmunoadherence or flow cytometry that uses a cocktail of monoclonalantibodies directed to cell surface markers present on the cellsnegatively selected. For example, to enrich for CD4+ cells by negativeselection, a monoclonal antibody cocktail can include antibodies toCD14, CD20, CD11b, CD16, HLA-DR, and CD8.

The methods described herein can further include removing cells from thepopulation which express a tumor antigen, e.g., a tumor antigen thatdoes not comprise CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14 orCD11b, to thereby provide a population of T regulatory depleted, e.g.,CD25+ depleted, and tumor antigen depleted cells that are suitable forexpression of a CAR, e.g., a CAR described herein. In one embodiment,tumor antigen expressing cells are removed simultaneously with the Tregulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, orfragment thereof, and an anti-tumor antigen antibody, or fragmentthereof, can be attached to the same substrate, e.g., bead, which can beused to remove the cells or an anti-CD25 antibody, or fragment thereof,or the anti-tumor antigen antibody, or fragment thereof, can be attachedto separate beads, a mixture of which can be used to remove the cells.In other embodiments, the removal of T regulatory cells, e.g., CD25+cells, and the removal of the tumor antigen expressing cells issequential, and can occur, e.g., in either order.

Also provided are methods that include removing cells from thepopulation which express a check point inhibitor, e.g., a check pointinhibitor described herein, e.g., one or more of PD1+ cells, LAG3+cells, and TIM3+ cells, to thereby provide a population of T regulatorydepleted, e.g., CD25+ depleted cells, and check point inhibitor depletedcells, e.g., PD1+, LAG3+ and/or TIM3+ depleted cells. Exemplary checkpoint inhibitors include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g.,CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAMECD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 orCD270), KIR, A2aR, MHC class I, MHC class II, GALS, adenosine, and TGFR(e.g., TGFRbeta), e.g., as described herein. In one embodiment, checkpoint inhibitor expressing cells are removed simultaneously with the Tregulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, orfragment thereof, and an anti-check point inhibitor antibody, orfragment thereof, can be attached to the same bead which can be used toremove the cells, or an anti-CD25 antibody, or fragment thereof, and theanti-check point inhibitor antibody, or fragment thereof, can beattached to separate beads, a mixture of which can be used to remove thecells. In other embodiments, the removal of T regulatory cells, e.g.,CD25+ cells, and the removal of the check point inhibitor expressingcells is sequential, and can occur, e.g., in either order.

Methods described herein can include a positive selection step Forexample, T cells can be isolated by incubation with anti-CD3/anti-CD28(e.g., 3×28)-conjugated beads, such as DYNABEADS® M-450 CD3/CD28 T, fora time period sufficient for positive selection of the desired T cells.In one aspect, the time period is about 30 minutes. In a further aspect,the time period ranges from 30 minutes to 36 hours or longer and allinteger values there between. In a further aspect, the time period is atleast 1, 2, 3, 4, 5, or 6 hours. In yet another aspect, the time periodis 10 to 24 hours. In one aspect, the incubation time period is 24hours. Longer incubation times may be used to isolate T cells in anysituation where there are few T cells as compared to other cell types,such in isolating tumor infiltrating lymphocytes (TIL) from tumor tissueor from immunocompromised individuals. Further, use of longer incubationtimes can increase the efficiency of capture of CD8+ T cells. Thus, bysimply shortening or lengthening the time T cells are allowed to bind tothe CD3/CD28 beads and/or by increasing or decreasing the ratio of beadsto T cells (as described further herein), subpopulations of T cells canbe preferentially selected for or against at culture initiation or atother time points during the process. Additionally, by increasing ordecreasing the ratio of anti-CD3 and/or anti-CD28 antibodies on thebeads or other surface, subpopulations of T cells can be preferentiallyselected for or against at culture initiation or at other desired timepoints.

In one embodiment, a T cell population can be selected that expressesone or more of IFN-γ, TNFα, IL-17A, IL-2, IL-3, IL-4, GM-CSF, IL-10,IL-13, granzyme B, and perforin, or other appropriate molecules, e.g.,other cytokines. Methods for screening for cell expression can bedetermined, e.g., by the methods described in PCT Publication No.: WO2013/126712.

For isolation of a desired population of cells by positive or negativeselection, the concentration of cells and surface (e.g., particles suchas beads) can be varied. In certain aspects, it may be desirable tosignificantly decrease the volume in which beads and cells are mixedtogether (e.g., increase the concentration of cells), to ensure maximumcontact of cells and beads. For example, in one aspect, a concentrationof about 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml,6 billion/ml, or 5 billion/ml is used. In one aspect, a concentration of1 billion cells/ml is used. In one aspect, a concentration of cells from75, 80, 85, 90, 95, or 100 million cells/ml is used. In further aspects,concentrations of 125 or 150 million cells/ml can be used.

Using high concentrations can result in increased cell yield, cellactivation, and cell expansion. Further, use of high cell concentrationsallows more efficient capture of cells that may weakly express targetantigens of interest, such as CD28-negative T cells, or from sampleswhere there are many tumor cells present (e.g., leukemic blood, tumortissue, etc.). Such populations of cells may have therapeutic value andwould be desirable to obtain. For example, using high concentration ofcells allows more efficient selection of CD8+ T cells that normally haveweaker CD28 expression.

In a related aspect, it may be desirable to use lower concentrations ofcells. By significantly diluting the mixture of T cells and surface(e.g., particles such as beads), interactions between the particles andcells is minimized. This selects for cells that express high amounts ofdesired antigens to be bound to the particles. For example, CD4+ T cellsexpress higher levels of CD28 and are more efficiently captured thanCD8+ T cells in dilute concentrations. In one aspect, the concentrationof cells used is 5×10⁶/ml. In other aspects, the concentration used canbe from about 1×10⁵/ml to 1×10⁶/ml, and any integer value in between.

In other aspects, the cells may be incubated on a rotator for varyinglengths of time at varying speeds at either 2-10° C. or at roomtemperature.

T cells for stimulation can also be frozen after a washing step. Wishingnot to be bound by theory, the freeze and subsequent thaw step providesa more uniform product by removing granulocytes and to some extentmonocytes in the cell population. After the washing step that removesplasma and platelets, the cells may be suspended in a freezing solution.While many freezing solutions and parameters are known in the art andwill be useful in this context, one method involves using PBS containing20% DMSO and 8% human serum albumin, or culture media containing 10%Dextran 40 and 5% Dextrose, 20% Human Serum Albumin and 7.5% DMSO, or31.25% Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 10% Dextran 40 and5% Dextrose, 20% Human Serum Albumin, and 7.5% DMSO or other suitablecell freezing media containing for example, Hespan and PlasmaLyte A, thecells then are frozen to −80° C. at a rate of 1° per minute and storedin the vapor phase of a liquid nitrogen storage tank. Other methods ofcontrolled freezing may be used as well as uncontrolled freezingimmediately at −20° C. or in liquid nitrogen.

In certain aspects, cryopreserved cells are thawed and washed asdescribed herein and allowed to rest for one hour at room temperatureprior to activation using the methods of the present invention.

Also contemplated in the context of the invention is the collection ofblood samples or apheresis product from a subject at a time period priorto when the expanded cells as described herein might be needed. As such,the source of the cells to be expanded can be collected at any timepoint necessary, and desired cells, such as T cells, isolated and frozenfor later use in immune effector cell therapy for any number of diseasesor conditions that would benefit from immune effector cell therapy, suchas those described herein. In one aspect a blood sample or an apheresisis taken from a generally healthy subject. In certain aspects, a bloodsample or an apheresis is taken from a generally healthy subject who isat risk of developing a disease, but who has not yet developed adisease, and the cells of interest are isolated and frozen for lateruse. In certain aspects, the T cells may be expanded, frozen, and usedat a later time. In certain aspects, samples are collected from apatient shortly after diagnosis of a particular disease as describedherein but prior to any treatments. In a further aspect, the cells areisolated from a blood sample or an apheresis from a subject prior to anynumber of relevant treatment modalities, including but not limited totreatment with agents such as natalizumab, efalizumab, antiviral agents,chemotherapy, radiation, immunosuppressive agents, such as cyclosporin,azathioprine, methotrexate, mycophenolate, and FK506, antibodies, orother immunoablative agents such as CAMPATH, anti-CD3 antibodies,cytoxan, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid,steroids, FR901228, and irradiation.

In a further aspect of the present invention, T cells are obtained froma patient directly following treatment that leaves the subject withfunctional T cells. In this regard, it has been observed that followingcertain cancer treatments, in particular treatments with drugs thatdamage the immune system, shortly after treatment during the period whenpatients would normally be recovering from the treatment, the quality ofT cells obtained may be optimal or improved for their ability to expandex vivo. Likewise, following ex vivo manipulation using the methodsdescribed herein, these cells may be in a preferred state for enhancedengraftment and in vivo expansion. Thus, it is contemplated within thecontext of the present invention to collect blood cells, including Tcells, dendritic cells, or other cells of the hematopoietic lineage,during this recovery phase. Further, in certain aspects, mobilization(for example, mobilization with GM-CSF) and conditioning regimens can beused to create a condition in a subject wherein repopulation,recirculation, regeneration, and/or expansion of particular cell typesis favored, especially during a defined window of time followingtherapy. Illustrative cell types include T cells, B cells, dendriticcells, and other cells of the immune system.

In one embodiment, the immune effector cells expressing a CAR molecule,e.g., a CAR molecule described herein, are obtained from a subject thathas received a low, immune enhancing dose of an mTOR inhibitor. In anembodiment, the population of immune effector cells, e.g., T cells, tobe engineered to express a CAR, are harvested after a sufficient time,or after sufficient dosing of the low, immune enhancing, dose of an mTORinhibitor, such that the level of PD1 negative immune effector cells,e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g.,T cells/PD1 positive immune effector cells, e.g., T cells, in thesubject or harvested from the subject has been, at least transiently,increased.

In other embodiments, population of immune effector cells, e.g., Tcells, which have, or will be engineered to express a CAR, can betreated ex vivo by contact with an amount of an mTOR inhibitor thatincreases the number of PD1 negative immune effector cells, e.g., Tcells or increases the ratio of PD1 negative immune effector cells,e.g., T cells/PD1 positive immune effector cells, e.g., T cells.

In one embodiment, a T cell population is diacylglycerol kinase(DGK)-deficient. DGK-deficient cells include cells that do not expressDGK RNA or protein, or have reduced or inhibited DGK activity.DGK-deficient cells can be generated by genetic approaches, e.g.,administering RNA-interfering agents, e.g., siRNA, shRNA, miRNA, toreduce or prevent DGK expression. Alternatively, DGK-deficient cells canbe generated by treatment with DGK inhibitors described herein.

In one embodiment, a T cell population is Ikaros-deficient.Ikaros-deficient cells include cells that do not express Ikaros RNA orprotein, or have reduced or inhibited Ikaros activity, Ikaros-deficientcells can be generated by genetic approaches, e.g., administeringRNA-interfering agents, e.g., siRNA, shRNA, miRNA, to reduce or preventIkaros expression. Alternatively, Ikaros-deficient cells can begenerated by treatment with Ikaros inhibitors, e.g., lenalidomide.

In embodiments, a T cell population is DGK-deficient andIkaros-deficient, e.g., does not express DGK and Ikaros, or has reducedor inhibited DGK and Ikaros activity. Such DGK and Ikaros-deficientcells can be generated by any of the methods described herein.

In an embodiment, the NK cells are obtained from the subject. In anotherembodiment, the NK cells are an NK cell line, e.g., NK-92 cell line(Conkwest).

Allogeneic CAR

In embodiments described herein, the immune effector cell can be anallogeneic immune effector cell, e.g., T cell or NK cell. For example,the cell can be an allogeneic T cell, e.g., an allogeneic T cell lackingexpression of a functional T cell receptor (TCR) and/or human leukocyteantigen (HLA), e.g., HLA class I and/or HLA class II.

A T cell lacking a functional TCR can be, e.g., engineered such that itdoes not express any functional TCR on its surface, engineered such thatit does not express one or more subunits that comprise a functional TCR(e.g., engineered such that it does not express (or exhibits reducedexpression) of TCR alpha, TCR beta, TCR gamma, TCR delta, TCR epsilon,and/or TCR zeta) or engineered such that it produces very littlefunctional TCR on its surface (e.g., engineered such that it does notexpress (or exhibits reduced expression) of TCR alpha, TCR beta, TCRgamma, TCR delta, TCR epsilon, and/or TCR zeta). Alternatively, the Tcell can express a substantially impaired TCR, e.g., by expression ofmutated or truncated forms of one or more of the subunits of the TCR.The term “substantially impaired TCR” means that this TCR will notelicit an adverse immune reaction in a host.

A T cell described herein can be, e.g., engineered such that it does notexpress a functional HLA on its surface. For example, a T cell describedherein, can be engineered such that cell surface expression HLA, e.g.,HLA class 1 and/or HLA class II, is downregulated. In some embodiments,downregulation of HLA may be accomplished by reducing or eliminatingexpression of beta-2 microglobulin (B2M).

In some embodiments, the T cell can lack a functional TCR and afunctional HLA, e.g., HLA class I and/or HLA class II.

Modified T cells that lack expression of a functional TCR and/or HLA canbe obtained by any suitable means, including a knock out or knock downof one or more subunit of TCR or HLA. For example, the T cell caninclude a knock down of TCR and/or HLA using siRNA, shRNA, clusteredregularly interspaced short palindromic repeats (CRISPR)transcription-activator like effector nuclease (TALEN), or zinc fingerendonuclease (ZFN).

In some embodiments, the allogeneic cell can be a cell which does notexpress or expresses at low levels an inhibitory molecule, e.g. a cellengineered by any method described herein. For example, the cell can bea cell that does not express or expresses at low levels an inhibitorymolecule, e.g., that can decrease the ability of a CAR-expressing cellto mount an immune effector response. Examples of inhibitory moleculesinclude PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80,CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR,MHC class I, MHC class II, GAL9, adenosine, and TGFR (e.g., TGFR beta).Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA,RNA or protein level, can optimize a CAR-expressing cell performance. Inembodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleicacid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clustered regularlyinterspaced short palindromic repeats (CRISPR), atranscription-activator like effector nuclease (TALEN), or a zinc fingerendonuclease (ZFN), e.g., as described herein, can be used.

siRNA and shRNA to Inhibit TCR or HLA

In some embodiments, TCR expression and/or HLA expression can beinhibited using siRNA or shRNA that targets a nucleic acid encoding aTCR and/or HLA, and/or an inhibitory molecule described herein (e.g.,PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/orCEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86,B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHCclass I, MHC class II, GAL9, adenosine, and TGFR beta), in a T cell.

Expression systems for siRNA and shRNAs, and exemplary shRNAs, aredescribed, e.g., in paragraphs 649 and 650 of International ApplicationWO2015/142675, filed Mar. 13, 2015, which is incorporated by referencein its entirety

CRISPR to Inhibit TCR or HLA

“CRISPR” or “CRISPR to TCR and/or HLA” or “CRISPR to inhibit TCR and/orHLA” as used herein refers to a set of clustered regularly interspacedshort palindromic repeats, or a system comprising such a set of repeats.“Cas”, as used herein, refers to a CRISPR-associated protein. A“CRISPR/Cas” system refers to a system derived from CRISPR and Cas whichcan be used to silence or mutate a TCR and/or HLA gene, and/or aninhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4,TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA,BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4(VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II,GAL9, adenosine, and TGFR beta).

The CRISPR/Cas system, and uses thereof, are described, e.g., inparagraphs 651-658 of International Application WO2015/142675, filedMar. 13, 2015, which is incorporated by reference in its entirety.

TALEN to Inhibit TCR and/or HLA

“TALEN” or “TALEN to HLA and/or TCR” or “TALEN to inhibit HLA and/orTCR” refers to a transcription activator-like effector nuclease, anartificial nuclease which can be used to edit the HLA and/or TCR gene,and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2,CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3,VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4(VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, WIC class I, WIC class II,GAL9, adenosine, and TGFR beta).

TALENs, TALEs, and uses thereof, are described, e.g., in paragraphs659-665 of International Application WO2015/142675, filed Mar. 13, 2015,which is incorporated by reference in its entirety.

Zinc Finger Nuclease to Inhibit HLA and/or TCR

“ZFN” or “Zinc Finger Nuclease” or “ZFN to HLA and/or TCR” or “ZFN toinhibit HLA and/or TCR” refer to a zinc finger nuclease, an artificialnuclease which can be used to edit the HLA and/or TCR gene, and/or aninhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4,TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA,BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4(VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, WIC class I, MHC class II,GAL9, adenosine, and TGFR beta).

ZFNs, and uses thereof, are described, e.g., in paragraphs 666-671 ofInternational Application WO2015/142675, filed Mar. 13, 2015, which isincorporated by reference in its entirety.

Telomerase Expression

While not wishing to be bound by any particular theory, in someembodiments, a therapeutic T cell has short term persistence in apatient, due to shortened telomeres in the T cell; accordingly,transfection with a telomerase gene can lengthen the telomeres of the Tcell and improve persistence of the T cell in the patient. See CarlJune, “Adoptive T cell therapy for cancer in the clinic”, Journal ofClinical Investigation, 117:1466-1476 (2007). Thus, in an embodiment, animmune effector cell, e.g., a T cell, ectopically expresses a telomerasesubunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g.,hTERT. In some aspects, this disclosure provides a method of producing aCAR-expressing cell, comprising contacting a cell with a nucleic acidencoding a telomerase subunit, e.g., the catalytic subunit oftelomerase, e.g., TERT, e.g., hTERT. The cell may be contacted with thenucleic acid before, simultaneous with, or after being contacted with aconstruct encoding a CAR.

In one aspect, the disclosure features a method of making a populationof immune effector cells (e.g., T cells or NK cells). In an embodiment,the method comprises: providing a population of immune effector cells(e.g., T cells or NK cells), contacting the population of immuneeffector cells with a nucleic acid encoding a CAR; and contacting thepopulation of immune effector cells with a nucleic acid encoding atelomerase subunit, e.g., hTERT, under conditions that allow for CAR andtelomerase expression.

In an embodiment, the nucleic acid encoding the telomerase subunit isDNA. In an embodiment, the nucleic acid encoding the telomerase subunitcomprises a promoter capable of driving expression of the telomerasesubunit.

In an embodiment, hTERT has the amino acid sequence of GenBank ProteinID AAC51724.1 (Meyerson et al., “hEST2, the Putative Human TelomeraseCatalytic Subunit Gene, Is Up-Regulated in Tumor Cells and duringImmortalization” Cell Volume 90, Issue 4, 22 Aug. 1997, Pages 785-795)as follows:

(SEQ ID NO: 1332) MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRGCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD

In an embodiment, the hTERT has a sequence at least 80%, 85%, 90%, 95%,96{circumflex over ( )}, 97%, 98%, or 99% identical to the sequence ofSEQ ID NO: 1332. In an embodiment, the hTERT has a sequence of SEQ IDNO: 1332. In an embodiment, the hTERT comprises a deletion (e.g., of nomore than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, theC-terminus, or both. In an embodiment, the hTERT comprises a transgenicamino acid sequence (e.g., of no more than 5, 10, 15, 20, or 30 aminoacids) at the N-terminus, the C-terminus, or both.

In an embodiment, the hTERT is encoded by the nucleic acid sequence ofGenBank Accession No. AF018167 (Meyerson et al., “hEST2, the PutativeHuman Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cellsand during Immortalization” Cell Volume 90, Issue 4, 22 Aug. 1997, Pages785-795):

(SEQ ID NO: 1333)    1caggcagcgt ggtcctgctg cgcacgtggg aagccctggc cccggccacc cccgcgatgc   61cgcgcgctcc ccgctgccga gccgtgcgct ccctgctgcg cagccactac cgcgaggtgc  121tgccgctggc cacgttcgtg cggcgcctgg ggccccaggg ctggcggctg gtgcagcgcg  181gggacccggc ggctttccgc gcgctggtgg cccagtgcct ggtgtgcgtg ccctgggacg  241cacggccgcc ccccgccgcc ccctccttcc gccaggtgtc ctgcctgaag gagctggtgg  301cccgagtgct gcagaggctg tgcgagcgcg gcgcgaagaa cgtgctggcc ttcggcttcg  361cgctgctgga cggggcccgc gggggccccc ccgaggcctt caccaccagc gtgcgcagct  421acctgcccaa cacggtgacc gacgcactgc gggggagcgg ggcgtggggg ctgctgttgc  481gccgcgtggg cgacgacgtg ctggttcacc tgctggcacg ctgcgcgctc tttgtgctgg  541tggctcccag ctgcgcctac caggtgtgcg ggccgccgct gtaccagctc ggcgctgcca  601ctcaggcccg gcccccgcca cacgctagtg gaccccgaag gcgtctggga tgcgaacggg  661cctggaacca tagcgtcagg gaggccgggg tccccctggg cctgccagcc ccgggtgcga  721ggaggcgcgg gggcagtgcc agccgaagtc tgccgttgcc caagaggccc aggcgtggcg  781ctgcccctga gccggagcgg acgcccgttg ggcaggggtc ctgggcccac ccgggcagga  841cgcgtggacc gagtgaccgt ggtttctgtg tggtgtcacc tgccagaccc gccgaagaag  901ccacctcttt ggagggtgcg ctctctggca cgcgccactc ccacccatcc gtgggccgcc  961agcaccacgc gggcccccca tccacatcgc ggccaccacg tccctgggac acgccttgtc 1021ccccggtgta cgccgagacc aagcacttcc tctactcctc aggcgacaag gagcagctgc 1081ggccctcctt cctactcagc tctctgaggc ccagcctgac tggcgctcgg aggctcgtgg 1141agaccatctt tctgggttcc aggccctgga tgccagggac tccccgcagg ttgccccgcc 1201tgccccagcg ctactggcaa atgcggcccc tgtttctgga gctgcttggg aaccacgcgc 1261agtgccccta cggggtgctc ctcaagacgc actgcccgct gcgagctgcg gtcaccccag 1321cagccggtgt ctgtgcccgg gagaagcccc agggctctgt ggcggccccc gaggaggagg 1381acacagaccc ccgtcgcctg gtgcagctgc tccgccagca cagcagcccc tggcaggtgt 1441acggcttcgt gcgggcctgc ctgcgccggc tggtgccccc aggcctctgg ggctccaggc 1501acaacgaacg ccgcttcctc aggaacacca agaagttcat ctccctgggg aagcatgcca 1561agctctcgct gcaggagctg acgtggaaga tgagcgtgcg gggctgcgct tggctgcgca 1621ggagcccagg ggttggctgt gttccggccg cagagcaccg tctgcgtgag gagatcctgg 1681ccaagttcct gcactggctg atgagtgtgt acgtcgtcga gctgctcagg tctttctttt 1741atgtcacgga gaccacgttt caaaagaaca ggctcttttt ctaccggaag agtgtctgga 1801gcaagttgca aagcattgga atcagacagc acttgaagag ggtgcagctg cgggagctgt 1861cggaagcaga ggtcaggcag catcgggaag ccaggcccgc cctgctgacg tccagactcc 1921gcttcatccc caagcctgac gggctgcggc cgattgtgaa catggactac gtcgtgggag 1981ccagaacgtt ccgcagagaa aagagggccg agcgtctcac ctcgagggtg aaggcactgt 2041tcagcgtgct caactacgag cgggcgcggc gccccggcct cctgggcgcc tctgtgctgg 2101gcctggacga tatccacagg gcctggcgca ccttcgtgct gcgtgtgcgg gcccaggacc 2161cgccgcctga gctgtacttt gtcaaggtgg atgtgacggg cgcgtacgac accatccccc 2221aggacaggct cacggaggtc atcgccagca tcatcaaacc ccagaacacg tactgcgtgc 2281gtcggtatgc cgtggtccag aaggccgccc atgggcacgt ccgcaaggcc ttcaagagcc 2341acgtctctac cttgacagac ctccagccgt acatgcgaca gttcgtggct cacctgcagg 2401agaccagccc gctgagggat gccgtcgtca tcgagcagag ctcctccctg aatgaggcca 2461gcagtggcct cttcgacgtc ttcctacgct tcatgtgcca ccacgccgtg cgcatcaggg 2521gcaagtccta cgtccagtgc caggggatcc cgcagggctc catcctctcc acgctgctct 2581gcagcctgtg ctacggcgac atggagaaca agctgtttgc ggggattcgg cgggacgggc 2641tgctcctgcg tttggtggat gatttcttgt tggtgacacc tcacctcacc cacgcgaaaa 2701ccttcctcag gaccctggtc cgaggtgtcc ctgagtatgg ctgcgtggtg aacttgcgga 2761agacagtggt gaacttccct gtagaagacg aggccctggg tggcacggct tttgttcaga 2821tgccggccca cggcctattc ccctggtgcg gcctgctgct ggatacccgg accctggagg 2881tgcagagcga ctactccagc tatgcccgga cctccatcag agccagtctc accttcaacc 2941gcggcttcaa ggctgggagg aacatgcgtc gcaaactctt tggggtcttg cggctgaagt 3001gtcacagcct gtttctggat ttgcaggtga acagcctcca gacggtgtgc accaacatct 3061acaagatcct cctgctgcag gcgtacaggt ttcacgcatg tgtgctgcag ctcccatttc 3121atcagcaagt ttggaagaac cccacatttt tcctgcgcgt catctctgac acggcctccc 3181tctgctactc catcctgaaa gccaagaacg cagggatgtc gctgggggcc aagggcgccg 3241ccggccctct gccctccgag gccgtgcagt ggctgtgcca ccaagcattc ctgctcaagc 3301tgactcgaca ccgtgtcacc tacgtgccac tcctggggtc actcaggaca gcccagacgc 3361agctgagtcg gaagctcccg gggacgacgc tgactgccct ggaggccgca gccaacccgg 3421cactgccctc agacttcaag accatcctgg actgatggcc acccgcccac agccaggccg 3481agagcagaca ccagcagccc tgtcacgccg ggctctacgt cccagggagg gaggggcggc 3541ccacacccag gcccgcaccg ctgggagtct gaggcctgag tgagtgtttg gccgaggcct 3601gcatgtccgg ctgaaggctg agtgtccggc tgaggcctga gcgagtgtcc agccaagggc 3661tgagtgtcca gcacacctgc cgtcttcact tccccacagg ctggcgctcg gctccacccc 3721agggccagct tttcctcacc aggagcccgg cttccactcc ccacatagga atagtccatc 3781cccagattcg ccattgttca cccctcgccc tgccctcctt tgccttccac ccccaccatc 3841caggtggaga ccctgagaag gaccctggga gctctgggaa tttggagtga ccaaaggtgt 3901gccctgtaca caggcgagga ccctgcacct ggatgggggt ccctgtgggt caaattgggg 3961ggaggtgctg tgggagtaaa atactgaata tatgagtttt tcagttttga aaaaaaaaaa 4021aaaaaaa

In an embodiment, the hTERT is encoded by a nucleic acid having asequence at least 80%, 85%, 90%, 95%, 96, 97%, 98%, or 99% identical tothe sequence of SEQ ID NO: 1333. In an embodiment, the hTERT is encodedby a nucleic acid of SEQ ID NO: 1333.

Activation and Expansion of Immune Effector Cells (e.g., T Cells)

Immune effector cells such as T cells may be activated and expandedgenerally using methods as described, for example, in U.S. Pat. Nos.6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466;6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843;5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent ApplicationPublication No. 20060121005.

The procedure for ex vivo expansion of hematopoietic stem and progenitorcells is described in U.S. Pat. No. 5,199,942, incorporated herein byreference, can be applied to the cells of the present invention. Othersuitable methods are known in the art, therefore the present inventionis not limited to any particular method of ex vivo expansion of thecells. Briefly, ex vivo culture and expansion of T cells can comprise:(1) collecting CD34+ hematopoietic stem and progenitor cells from amammal from peripheral blood harvest or bone marrow explants; and (2)expanding such cells ex vivo. In addition to the cellular growth factorsdescribed in U.S. Pat. No. 5,199,942, other factors such as flt3-L,IL-1, IL-3 and c-kit ligand, can be used for culturing and expansion ofthe cells.

Generally, a population of immune effector cells may be expanded bycontact with a surface having attached thereto an agent that stimulatesa CD3/TCR complex associated signal and a ligand that stimulates acostimulatory molecule on the surface of the T cells. In particular, Tcell populations may be stimulated as described herein, such as bycontact with an anti-CD3 antibody, or antigen-binding fragment thereof,or an anti-CD2 antibody immobilized on a surface, or by contact with aprotein kinase C activator (e.g., bryostatin) in conjunction with acalcium ionophore. For co-stimulation of an accessory molecule on thesurface of the T cells, a ligand that binds the accessory molecule isused. For example, a population of T cells can be contacted with ananti-CD3 antibody and an anti-CD28 antibody, under conditionsappropriate for stimulating proliferation of the T cells. To stimulateproliferation of either CD4+ T cells or CD8+ T cells, an anti-CD3antibody and an anti-CD28 antibody may be used. Examples of an anti-CD28antibody include 9.3, B-T3, XR-CD28 (Diaclone, Besancon, France) can beused as can other methods commonly known in the art (Berg et al.,Transplant Proc. 30(8):3975-3977, 1998; Haanen et al., J. Exp. Med.190(9):13191328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63,1999).

In some embodiments, immune effector cells (such as PBMCs or T cells)are expanded and stimulated by contacting the cells to one or both of ananti-CD3 antibody and IL-2. In embodiments, the cells are expandedwithout anti-CD3 or anti-CD28 beads.

In certain aspects, the primary stimulatory signal and the costimulatorysignal for the T cell may be provided by different protocols. Forexample, the agents providing each signal may be in solution or coupledto a surface. When coupled to a surface, the agents may be coupled tothe same surface (i.e., in “cis” formation) or to separate surfaces(i.e., in “trans” formation). Alternatively, one agent may be coupled toa surface and the other agent in solution. In one aspect, the agentproviding the costimulatory signal is bound to a cell surface and theagent providing the primary activation signal is in solution or coupledto a surface. In certain aspects, both agents can be in solution. In oneaspect, the agents may be in soluble form, and then cross-linked to asurface, such as a cell expressing Fc receptors or an antibody or otherbinding agent which will bind to the agents. In this regard, see forexample, U.S. Patent Application Publication Nos. 20040101519 and20060034810 for artificial antigen presenting cells (aAPCs) that arecontemplated for use in activating and expanding T cells in the presentinvention.

In one aspect, the two agents are immobilized on beads, either on thesame bead, i.e., “cis,” or to separate beads, i.e., “trans.” By way ofexample, the agent providing the primary activation signal is ananti-CD3 antibody or an antigen-binding fragment thereof and the agentproviding the costimulatory signal is an anti-CD28 antibody orantigen-binding fragment thereof; and both agents are co-immobilized tothe same bead in equivalent molecular amounts. In one aspect, a 1:1ratio of each antibody bound to the beads for CD4+ T cell expansion andT cell growth is used. In certain aspects, a ratio of anti CD3:CD28antibodies bound to the beads is used such that an increase in T cellexpansion is observed as compared to the expansion observed using aratio of 1:1. In one particular aspect an increase of from about 1 toabout 3 fold is observed as compared to the expansion observed using aratio of 1:1. In one aspect, the ratio of CD3:CD28 antibody bound to thebeads ranges from 100:1 to 1:100 and all integer values there between.In one aspect, more anti-CD28 antibody is bound to the particles thananti-CD3 antibody, i.e., the ratio of CD3:CD28 is less than one. Incertain aspects, the ratio of anti CD28 antibody to anti CD3 antibodybound to the beads is greater than 2:1. In one particular aspect, a1:100 CD3:CD28 ratio of antibody bound to beads is used. In one aspect,a 1:75 CD3:CD28 ratio of antibody bound to beads is used. In a furtheraspect, a 1:50 CD3:CD28 ratio of antibody bound to beads is used. In oneaspect, a 1:30 CD3:CD28 ratio of antibody bound to beads is used. In oneaspect, a 1:10 CD3:CD28 ratio of antibody bound to beads is used. In oneaspect, a 1:3 CD3:CD28 ratio of antibody bound to the beads is used. Inyet one aspect, a 3:1 CD3:CD28 ratio of antibody bound to the beads isused.

Ratios of particles to cells from 1:500 to 500:1 and any integer valuesin between may be used to stimulate T cells or other target cells. Asthose of ordinary skill in the art can readily appreciate, the ratio ofparticles to cells may depend on particle size relative to the targetcell. For example, small sized beads could only bind a few cells, whilelarger beads could bind many. In certain aspects the ratio of cells toparticles ranges from 1:100 to 100:1 and any integer values in-betweenand in further aspects the ratio comprises 1:9 to 9:1 and any integervalues in between, can also be used to stimulate T cells. The ratio ofanti-CD3- and anti-CD28-coupled particles to T cells that result in Tcell stimulation can vary as noted above, however certain suitablevalues include 1:100, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6,1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1,and 15:1 with one suitable ratio being at least 1:1 particles per Tcell. In one aspect, a ratio of particles to cells of 1:1 or less isused. In one particular aspect, a suitable particle: cell ratio is 1:5.In further aspects, the ratio of particles to cells can be varieddepending on the day of stimulation. For example, in one aspect, theratio of particles to cells is from 1:1 to 10:1 on the first day andadditional particles are added to the cells every day or every other daythereafter for up to 10 days, at final ratios of from 1:1 to 1:10 (basedon cell counts on the day of addition). In one particular aspect, theratio of particles to cells is 1:1 on the first day of stimulation andadjusted to 1:5 on the third and fifth days of stimulation. In oneaspect, particles are added on a daily or every other day basis to afinal ratio of 1:1 on the first day, and 1:5 on the third and fifth daysof stimulation. In one aspect, the ratio of particles to cells is 2:1 onthe first day of stimulation and adjusted to 1:10 on the third and fifthdays of stimulation. In one aspect, particles are added on a daily orevery other day basis to a final ratio of 1:1 on the first day, and 1:10on the third and fifth days of stimulation. One of skill in the art willappreciate that a variety of other ratios may be suitable for use in thepresent invention. In particular, ratios will vary depending on particlesize and on cell size and type. In one aspect, the most typical ratiosfor use are in the neighborhood of 1:1, 2:1 and 3:1 on the first day.

In further aspects of the present invention, the cells, such as T cells,are combined with agent-coated beads, the beads and the cells aresubsequently separated, and then the cells are cultured. In analternative aspect, prior to culture, the agent-coated beads and cellsare not separated but are cultured together. In a further aspect, thebeads and cells are first concentrated by application of a force, suchas a magnetic force, resulting in increased ligation of cell surfacemarkers, thereby inducing cell stimulation.

By way of example, cell surface proteins may be ligated by allowingparamagnetic beads to which anti-CD3 and anti-CD28 are attached (3×28beads) to contact the T cells. In one aspect the cells (for example, 10⁴to 10⁹ T cells) and beads (for example, DYNABEADS® M-450 CD3/CD28 Tparamagnetic beads at a ratio of 1:1) are combined in a buffer, forexample PBS (without divalent cations such as, calcium and magnesium).Again, those of ordinary skill in the art can readily appreciate anycell concentration may be used. For example, the target cell may be veryrare in the sample and comprise only 0.01% of the sample or the entiresample (i.e., 100%) may comprise the target cell of interest.Accordingly, any cell number is within the context of the presentinvention. In certain aspects, it may be desirable to significantlydecrease the volume in which particles and cells are mixed together(i.e., increase the concentration of cells), to ensure maximum contactof cells and particles. For example, in one aspect, a concentration ofabout 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6billion/ml, or 5 billion/ml or 2 billion cells/ml is used. In oneaspect, greater than 100 million cells/ml is used. In a further aspect,a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50million cells/ml is used. In yet one aspect, a concentration of cellsfrom 75, 80, 85, 90, 95, or 100 million cells/ml is used. In furtheraspects, concentrations of 125 or 150 million cells/ml can be used.Using high concentrations can result in increased cell yield, cellactivation, and cell expansion. Further, use of high cell concentrationsallows more efficient capture of cells that may weakly express targetantigens of interest, such as CD28-negative T cells. Such populations ofcells may have therapeutic value and would be desirable to obtain incertain aspects. For example, using high concentration of cells allowsmore efficient selection of CD8+ T cells that normally have weaker CD28expression.

In one embodiment, cells transduced with a nucleic acid encoding a CAR,e.g., a CAR described herein, are expanded, e.g., by a method describedherein. In one embodiment, the cells are expanded in culture for aperiod of several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 18,21 hours) to about 14 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13 or 14 days). In one embodiment, the cells are expanded for a periodof 4 to 9 days. In one embodiment, the cells are expanded for a periodof 8 days or less, e.g., 7, 6 or 5 days. In one embodiment, the cells,e.g., a CAR cell described herein, are expanded in culture for 5 days,and the resulting cells are more potent than the same cells expanded inculture for 9 days under the same culture conditions. Potency can bedefined, e.g., by various T cell functions, e.g. proliferation, targetcell killing, cytokine production, activation, migration, orcombinations thereof. In one embodiment, the cells, e.g., a CD19 CARcell described herein, expanded for 5 days show at least a one, two,three or four fold increase in cells doublings upon antigen stimulationas compared to the same cells expanded in culture for 9 days under thesame culture conditions. In one embodiment, the cells, e.g., the cellsexpressing a CAR described herein, are expanded in culture for 5 days,and the resulting cells exhibit higher proinflammatory cytokineproduction, e.g., IFN-γ and/or GM-CSF levels, as compared to the samecells expanded in culture for 9 days under the same culture conditions.In one embodiment, the cells, e.g., a CAR cell described herein,expanded for 5 days show at least a one, two, three, four, five, tenfold or more increase in pg/ml of proinflammatory cytokine production,e.g., IFN-γ and/or GM-CSF levels, as compared to the same cells expandedin culture for 9 days under the same culture conditions.

In one aspect of the present invention, the mixture may be cultured forseveral hours (about 3 hours) to about 14 days or any hourly integervalue in between. In one aspect, the mixture may be cultured for 21days. In one aspect of the invention the beads and the T cells arecultured together for about eight days. In one aspect, the beads and Tcells are cultured together for 2-3 days.

Several cycles of stimulation may also be desired such that culture timeof T cells can be 60 days or more. Conditions appropriate for T cellculture include an appropriate media (e.g., Minimal Essential Media orRPMI Media 1640 or, X-vivo 15, (Lonza)) that may contain factorsnecessary for proliferation and viability, including serum (e.g., fetalbovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4,IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFβ, and TNF-α or any otheradditives for the growth of cells known to the skilled artisan. Otheradditives for the growth of cells include, but are not limited to,surfactant, plasmanate, and reducing agents such as N-acetyl-cysteineand 2-mercaptoethanol. Media can include RPMI 1640, AIM-V, DMEM, MEM,α-MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added aminoacids, sodium pyruvate, and vitamins, either serum-free or supplementedwith an appropriate amount of serum (or plasma) or a defined set ofhormones, and/or an amount of cytokine(s) sufficient for the growth andexpansion of T cells. Antibiotics, e.g., penicillin and streptomycin,are included only in experimental cultures, not in cultures of cellsthat are to be infused into a subject. The target cells are maintainedunder conditions necessary to support growth, for example, anappropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5%CO₂).

In one embodiment, the cells are expanded in an appropriate media (e.g.,media described herein) that includes one or more interleukin thatresult in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold,350-fold) increase in cells over a 14 day expansion period, e.g., asmeasured by a method described herein such as flow cytometry. In oneembodiment, the cells are expanded in the presence IL-15 and/or IL-7(e.g., IL-15 and IL-7).

In some embodiments a CAR-expressing cell described herein (e.g., a Tcell such as a CD4+ T cell or a CD8+ T cell) is contacted with acomposition comprising a interleukin-15 (IL-15) polypeptide, ainterleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination ofboth a IL-15 polypeptide and a IL-15Ra polypeptide e.g., hetIL-15,during the manufacturing of the CAR-expressing cell, e.g., ex vivo. Inembodiments, a CAR-expressing cell described herein is contacted with acomposition comprising a IL-15 polypeptide during the manufacturing ofthe CAR-expressing cell, e.g., ex vivo. In embodiments, a CAR-expressingcell described herein is contacted with a composition comprising acombination of both a IL-15 polypeptide and a IL-15 Ra polypeptideduring the manufacturing of the CAR-expressing cell, e.g., ex vivo. Inembodiments, a CAR-expressing cell described herein is contacted with acomposition comprising hetIL-15 during the manufacturing of theCAR-expressing cell, e.g., ex vivo.

In one embodiment the CAR-expressing cell (e.g., a T cell or NK cell)described herein is contacted with a composition comprising hetIL-15during ex vivo expansion. In an embodiment, the CAR-expressing celldescribed herein is contacted with a composition comprising an IL-15polypeptide during ex vivo expansion. In an embodiment, theCAR-expressing cell described herein is contacted with a compositioncomprising both an IL-15 polypeptide and an IL-15Ra polypeptide duringex vivo expansion. In one embodiment the contacting results in thesurvival and proliferation of a lymphocyte subpopulation, e.g., CD8+ Tcells.

In an embodiments, the method of making disclosed herein furthercomprises contacting the population of immune effector cells (e.g., Tcells or NK cells) with a nucleic acid encoding a telomerase subunit,e.g., hTERT. The nucleic acid encoding the telomerase subunit can beDNA.

T cells that have been exposed to varied stimulation times may exhibitdifferent characteristics. For example, typical blood or apheresedperipheral blood mononuclear cell products have a helper T cellpopulation (TH, CD4+) that is greater than the cytotoxic or suppressor Tcell population (TC, CD8+). Ex vivo expansion of T cells by stimulatingCD3 and CD28 receptors produces a population of T cells that prior toabout days 8-9 consists predominately of TH cells, while after aboutdays 8-9, the population of T cells comprises an increasingly greaterpopulation of TC cells. Accordingly, depending on the purpose oftreatment, infusing a subject with a T cell population comprisingpredominately of TH cells may be advantageous. Similarly, if anantigen-specific subset of TC cells has been isolated it may bebeneficial to expand this subset to a greater degree.

Further, in addition to CD4 and CD8 markers, other phenotypic markersvary significantly, but in large part, reproducibly during the course ofthe cell expansion process. Thus, such reproducibility enables theability to tailor an activated T cell product for specific purposes.

Once a CAR, e.g., CD19 CAR is constructed, various assays can be used toevaluate the activity of the molecule, such as but not limited to, theability to expand T cells following antigen stimulation, sustain T cellexpansion in the absence of re-stimulation, and anti-cancer activitiesin appropriate in vitro and animal models. Assays to evaluate theeffects of a CAR, e.g., CD19 CAR are described in further detail below

Western blot analysis of CAR expression in primary T cells can be usedto detect the presence of monomers and dimers, e.g., as described inparagraph 695 of International Application WO2015/142675, filed Mar. 13,2015, which is herein incorporated by reference in its entirety.

In vitro expansion of CAR⁺ T cells following antigen stimulation can bemeasured by flow cytometry. For example, a mixture of CD4⁺ and CD8⁺ Tcells are stimulated with αCD3/αCD28 beads followed by transduction withlentiviral vectors expressing GFP under the control of the promoters tobe analyzed. Exemplary promoters include the CMV IE gene, EF-1α,ubiquitin C, or phosphoglycerokinase (PGK) promoters. GFP fluorescenceis evaluated on day 6 of culture in the CD4⁺ and/or CD8⁺ T cell subsetsby flow cytometry. See, e.g., Milone et al., Molecular Therapy 17(8):1453-1464 (2009). Alternatively, a mixture of CD4⁺ and CD8⁺ T cells arestimulated with αCD3/αCD28 coated magnetic beads on day 0, andtransduced with CAR on day 1 using a bicistronic lentiviral vectorexpressing CAR along with eGFP using a 2A ribosomal skipping sequence.Cultures are re-stimulated with either CD19⁺ K562 cells (K562-CD19),wild-type K562 cells (K562 wild type) or K562 cells expressing hCD32 and4-1BBL in the presence of anti-CD3 and anti-CD28 antibody(K562-BBL-3/28) following washing. Exogenous IL-2 is added to thecultures every other day at 100 IU/ml. GFP⁺ T cells are enumerated byflow cytometry using bead-based counting. See, e.g., Milone et al.,Molecular Therapy 17(8): 1453-1464 (2009).

Sustained CAR⁺ T cell expansion in the absence of re-stimulation canalso be measured. See, e.g., Milone et al., Molecular Therapy 17(8):1453-1464 (2009). Briefly, mean T cell volume (fl) is measured on day 8of culture using a Coulter Multisizer particle counter, a NexcelomCellometer Vision, or Millipore Scepter following stimulation withαCD3/αCD28 coated magnetic beads on day 0, and transduction with theindicated CAR on day 1.

Animal models can also be used to measure a CAR-expressing cellactivity, e.g., as described in paragraph 698 of InternationalApplication WO2015/142675, filed Mar. 13, 2015, which is hereinincorporated by reference in its entirety.

Dose dependent CAR treatment response can be evaluated, e.g., asdescribed in paragraph 699 of International Application WO2015/142675,filed Mar. 13, 2015, which is herein incorporated by reference in itsentirety. Assessment of cell proliferation and cytokine production hasbeen previously described, e.g., as described in paragraph 700 ofInternational Application WO2015/142675, filed Mar. 13, 2015, which isherein incorporated by reference in its entirety. Cytotoxicity can beassessed by a standard ⁵¹Cr-release assay, e.g., as described inparagraph 701 of International Application WO2015/142675, filed Mar. 13,2015, which is herein incorporated by reference in its entirety. Imagingtechnologies can be used to evaluate specific trafficking andproliferation of CARs in tumor-bearing animal models, e.g., as describedin paragraph 702 of International Application WO2015/142675, filed Mar.13, 2015, which is herein incorporated by reference in its entirety.

Other assays, including those described in the Example section herein aswell as those that are known in the art can also be used to evaluate theCARs described herein.

Alternatively, or in combination to the methods disclosed herein,methods and compositions for one or more of detection and/orquantification of CAR-expressing cells (e.g., in vitro or in vivo (e.g.,clinical monitoring)), immune cell expansion and/or activation, and/orCAR-specific selection, that involve the use of a CAR ligand, aredisclosed. In one exemplary embodiment, the CAR ligand is an antibodythat binds to the CAR molecule, e.g., binds to the extracellular antigenbinding domain of CAR (e.g., an antibody that binds to the antigenbinding domain, e.g., an anti-idiotypic antibody; or an antibody thatbinds to a constant region of the extracellular binding domain). Inother embodiments, the CAR ligand is a CAR antigen molecule (e.g., a CARantigen molecule as described herein).

In one aspect, a method for detecting and/or quantifying CAR-expressingcells is disclosed. For example, the CAR ligand can be used to detectand/or quantify CAR-expressing cells in vitro or in vivo (e.g., clinicalmonitoring of CAR-expressing cells in a patient, or dosing a patient).The method includes:

-   -   providing the CAR ligand (optionally, a labelled CAR ligand,        e.g., a CAR ligand that includes a tag, a bead, a radioactive or        fluorescent label);    -   acquiring the CAR-expressing cell (e.g., acquiring a sample        containing CAR-expressing cells, such as a manufacturing sample        or a clinical sample);    -   contacting the CAR-expressing cell with the CAR ligand under        conditions where binding occurs, thereby detecting the level        (e.g., amount) of the CAR-expressing cells present. Binding of        the CAR-expressing cell with the CAR ligand can be detected        using standard techniques such as FACS, ELISA and the like.

In another aspect, a method of expanding and/or activating cells (e.g.,immune effector cells) is disclosed. The method includes:

-   -   providing a CAR-expressing cell (e.g., a first CAR-expressing        cell or a transiently expressing CAR cell);    -   contacting said CAR-expressing cell with a CAR ligand, e.g., a        CAR ligand as described herein), under conditions where immune        cell expansion and/or proliferation occurs, thereby producing        the activated and/or expanded cell population.

In certain embodiments, the CAR ligand is present on (e.g., isimmobilized or attached to a substrate, e.g., a non-naturally occurringsubstrate). In some embodiments, the substrate is a non-cellularsubstrate. The non-cellular substrate can be a solid support chosenfrom, e.g., a plate (e.g., a microtiter plate), a membrane (e.g., anitrocellulose membrane), a matrix, a chip or a bead. In embodiments,the CAR ligand is present in the substrate (e.g., on the substratesurface). The CAR ligand can be immobilized, attached, or associatedcovalently or non-covalently (e.g., cross-linked) to the substrate. Inone embodiment, the CAR ligand is attached (e.g., covalently attached)to a bead. In the aforesaid embodiments, the immune cell population canbe expanded in vitro or ex vivo. The method can further includeculturing the population of immune cells in the presence of the ligandof the CAR molecule, e.g., using any of the methods described herein.

In other embodiments, the method of expanding and/or activating thecells further comprises addition of a second stimulatory molecule, e.g.,CD28. For example, the CAR ligand and the second stimulatory moleculecan be immobilized to a substrate, e.g., one or more beads, therebyproviding increased cell expansion and/or activation.

In other embodiments, a method for selecting or enriching for a CARexpressing cell is provided. The method includes contacting the CARexpressing cell with a CAR ligand as described herein; and selecting thecell on the basis of binding of the CAR ligand.

In yet other embodiments, a method for depleting (e.g., reducing and/orkilling) a CAR expressing cell is provided. The method includescontacting the CAR expressing cell with a CAR ligand as describedherein; and targeting the cell on the basis of binding of the CAR ligandthereby reducing the number, and/or killing, the CAR-expressing cell. Inone embodiment, the CAR ligand is coupled to a toxic agent (e.g., atoxin or a cell ablative drug). In another embodiment, theanti-idiotypic antibody can cause effector cell activity, e.g., ADCC orADC activities.

Exemplary anti-CAR antibodies that can be used in the methods disclosedherein are described, e.g., in WO 2014/190273 and by Jena et al.,“Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to DetectCD19-Specific T cells in Clinical Trials”, PLOS March 2013 8:3 e57838,the contents of which are incorporated by reference. In some aspects andembodiments, the compositions and methods herein are optimized for aspecific subset of T cells, e.g., as described in US Serial No.PCT/US2015/043219 filed Jul. 31, 2015, the contents of which areincorporated herein by reference in their entirety. In some embodiments,the optimized subsets of T cells display an enhanced persistencecompared to a control T cell, e.g., a T cell of a different type (e.g.,CD8+ or CD4+) expressing the same construct.

In some embodiments, a CD4+ T cell comprises a CAR described herein,which CAR comprises an intracellular signaling domain suitable for(e.g., optimized for, e.g., leading to enhanced persistence in) a CD4+ Tcell, e.g., an ICOS domain. In some embodiments, a CD8+ T cell comprisesa CAR described herein, which CAR comprises an intracellular signalingdomain suitable for (e.g., optimized for, e.g., leading to enhancedpersistence of) a CD8+ T cell, e.g., a 4-1BB domain, a CD28 domain, oranother costimulatory domain other than an ICOS domain. In someembodiments, the CAR described herein comprises an antigen bindingdomain described herein, e.g., a CAR comprising an antigen bindingdomain.

In an aspect, described herein is a method of treating a subject, e.g.,a subject having cancer. The method includes administering to saidsubject, an effective amount of:

-   -   1) a CD4+ T cell comprising a CAR (the CARCD4+) comprising:    -   an antigen binding domain, e.g., an antigen binding domain        described herein;    -   a transmembrane domain; and    -   an intracellular signaling domain, e.g., a first costimulatory        domain, e.g., an ICOS domain; and    -   2) a CD8+ T cell comprising a CAR (the CARCD8+) comprising:    -   an antigen binding domain, e.g., an antigen binding domain        described herein;    -   a transmembrane domain; and    -   an intracellular signaling domain, e.g., a second costimulatory        domain, e.g., a 4-1BB domain, a CD28 domain, or another        costimulatory domain other than an ICOS domain;    -   wherein the CARCD4+ and the CARCD8+ differ from one another.

Optionally, the method further includes administering:

-   -   3) a second CD8+ T cell comprising a CAR (the second CARCD8+)        comprising:    -   an antigen binding domain, e.g., an antigen binding domain        described herein;    -   a transmembrane domain; and    -   an intracellular signaling domain, wherein the second CARCD8+        comprises an intracellular signaling domain, e.g., a        costimulatory signaling domain, not present on the CARCD8+, and,        optionally, does not comprise an ICOS signaling domain.

Methods of Manufacture/Production

In some embodiments, the methods disclosed herein further includeadministering a T cell depleting agent after treatment with the cell(e.g., an immune effector cell as described herein, e.g., an immuneeffector cell expressing CAR driven by a truncated PGK1 promoter),thereby reducing (e.g., depleting) the CAR-expressing cells (e.g., theCD19CAR-expressing cells). Such T cell depleting agents can be used toeffectively deplete CAR-expressing cells (e.g., CD19CAR-expressingcells) to mitigate toxicity. In some embodiments, the CAR-expressingcells were manufactured according to a method herein, e.g., assayed(e.g., before or after transfection or transduction) according to amethod herein.

In some embodiments, the T cell depleting agent is administered one,two, three, four, or five weeks after administration of the cell, e.g.,the population of immune effector cells, described herein.

In one embodiment, the T cell depleting agent is an agent that depletesCAR-expressing cells, e.g., by inducing antibody dependent cell-mediatedcytotoxicity (ADCC) and/or complement-induced cell death. For example,CAR-expressing cells described herein may also express an antigen (e.g.,a target antigen) that is recognized by molecules capable of inducingcell death, e.g., ADCC or complement-induced cell death. For example,CAR expressing cells described herein may also express a target protein(e.g., a receptor) capable of being targeted by an antibody or antibodyfragment. Examples of such target proteins include, but are not limitedto, EpCAM, VEGFR, integrins (e.g., integrins αvβ3, α4, αI3/4β3, α4β7,α5β1, αvβ3, αv), members of the TNF receptor superfamily (e.g.,TRAIL-R1, TRAIL-R2), PDGF Receptor, interferon receptor, folatereceptor, GPNMB, ICAM-1, HLA-DR, CEA, CA-125, MUC1, TAG-72, IL-6receptor, 5T4, GD2, GD3, CD2, CD3, CD4, CD5, CD11, CD11a/LFA-1, CD15,CD18/ITGB2, CD19, CD20, CD22, CD23/lgE Receptor, CD25, CD28, CD30, CD33,CD38, CD40, CD41, CD44, CD51, CD52, CD62L, CD74, CD80, CD125,CD147/basigin, CD152/CTLA-4, CD154/CD40L, CD195/CCR5, CD319/SLAMF7, andEGFR, and truncated versions thereof (e.g., versions preserving one ormore extracellular epitopes but lacking one or more regions within thecytoplasmic domain).

In some embodiments, the CAR expressing cell co-expresses the CAR andthe target protein, e.g., naturally expresses the target protein or isengineered to express the target protein. For example, the cell, e.g.,the population of immune effector cells, can include a nucleic acid(e.g., vector) comprising the CAR nucleic acid (e.g., a CAR nucleic acidas described herein) and a nucleic acid encoding the target protein.

In one embodiment, the T cell depleting agent is a CD52 inhibitor, e.g.,an anti-CD52 antibody molecule, e.g., alemtuzumab.

In other embodiments, the cell, e.g., the population of immune effectorcells, expresses a CAR molecule as described herein (e.g., CD19CAR) andthe target protein recognized by the T cell depleting agent. In oneembodiment, the target protein is CD20. In embodiments where the targetprotein is CD20, the T cell depleting agent is an anti-CD20 antibody,e.g., rituximab.

In further embodiments of any of the aforesaid methods, the methodsfurther include transplanting a cell, e.g., a hematopoietic stem cell,or a bone marrow, into the mammal.

In another aspect, the invention features a method of conditioning amammal prior to cell transplantation. The method includes administeringto the mammal an effective amount of the cell comprising a CAR nucleicacid or polypeptide, e.g., a CD19 CAR nucleic acid or polypeptide. Insome embodiments, the cell transplantation is a stem celltransplantation, e.g., a hematopoietic stem cell transplantation, or abone marrow transplantation. In other embodiments, conditioning asubject prior to cell transplantation includes reducing the number oftarget-expressing cells in a subject, e.g., CD19-expressing normal cellsor CD19-expressing cancer cells.

Biopolymer Delivery Methods

In some embodiments, one or more CAR-expressing cells as disclosedherein can be administered or delivered to the subject via a biopolymerscaffold, e.g., a biopolymer implant. Biopolymer scaffolds can supportor enhance the delivery, expansion, and/or dispersion of theCAR-expressing cells described herein. A biopolymer scaffold comprises abiocompatible (e.g., does not substantially induce an inflammatory orimmune response) and/or a biodegradable polymer that can be naturallyoccurring or synthetic. Exemplary biopolymers are described, e.g., inparagraphs 1004-1006 of International Application WO2015/142675, filedMar. 13, 2015, which is herein incorporated by reference in itsentirety.

Therapeutic Applications

CD19 Associated Diseases and/or Disorders

In one aspect, the invention provides methods for treating a diseaseassociated with CD19 expression. In one aspect, the invention providesmethods for treating a disease wherein part of the cancer is negativefor CD19 and part of the cancer is positive for CD19. For example, themethods and compositions of the invention are useful for treatingsubjects that have undergone treatment for a disease associated withexpression of CD19, wherein the subject that has undergone treatmentrelated to CD19 expression, e.g., treatment with a CD19 CAR, exhibits adisease associated with expression of CD19.

In another aspect, the invention provides methods for treating a diseaseassociated with expression of a B-cell antigen, e.g., one or more ofCD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1. In one aspect, theinvention provides methods for treating a disease wherein part of thetumor is negative for the B-cell antigen and part of the tumor ispositive for B-cell antigen. For example, the compositions and methodsof the invention are useful for treating subjects that have undergonetreatment for a disease associated with expression of the B-cellantigen, wherein the subject that has undergone treatment related toexpression of a B-cell antigen, e.g., treatment with a CAR targeting aB-cell antigen, exhibits a disease associated with expression of theB-cell antigen. In a third aspect, the invention provides methods fortreating a disease associated with expression of the B-cell antigen,e.g., associated with the expression of CD19 and one or more otherB-cell antigens.

In one aspect, the invention pertains to a vector comprising CD19 CARoperably linked to promoter for expression in mammalian cells, e.g., Tcells or NK cells. In one aspect, the invention provides a recombinantcell, e.g., a T cell or NK cell, expressing the CD19 CAR for use intreating CD19-expressing cancers, wherein the recombinant T cellexpressing the CD19 CAR is termed a CD19 CART. In one aspect, the CD19CART described herein, is capable of contacting a cancer cell with atleast one CD19 CAR expressed on its surface such that the CART targetsthe cancer cell and growth of the cancer is inhibited.

In one aspect the invention pertains to a CD22 inhibitor which is a CD22CART, e.g., a T cell, expressing the CD22 CAR for use in treatingCD22-expressing tumors in combination with CD19 CARTS, wherein therecombinant T cell expressing the CD22 CAR is termed a CD22 CART. In oneaspect, the CD22 CART described herein, is capable of contacting a tumorcell with at least one CD22 CAR expressed on its surface such that theCD22 CART targets the tumor cell and growth of the tumor is inhibited.

In one aspect, the invention pertains to a method of inhibiting growthof a CD19-expressing cancer cell, comprising contacting the cancer cellwith a CD19 CAR expressing cell, e.g., a CD19 CART cell, described, andone or more other CAR expressing cells, e.g., as described herein, suchthat the CART is activated in response to the antigen and targets thecancer cell, wherein the growth of the cancer is inhibited. The CD19CAR-expressing cell, e.g., T cell, is administered in combination with aB-cell inhibitor, e.g., a B-cell inhibitor described herein.

In some embodiments, the CD19 inhibitor (e.g., one or more cells thatexpress a CAR molecule that binds CD19, e.g., a CAR molecule that bindsCD19 described herein) and the B cell inhibitor (e.g., one or moreinhibitors of CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, or ROR1, e.g.,as described herein) are administered simultaneously. In someembodiments, the CD19 inhibitor and the B cell inhibitor are infusedinto a subject simultaneously, e.g., are admixed in the same infusionvolume. In other embodiments, the simultaneous administration comprisesseparate administration of the CD19 inhibitor and the B cell inhibitor,e.g., administration of each is initiated within a predetermined timeinterval (e.g., within 15, 30, or 45 minutes of each other).

In some embodiments, the start of CD19 inhibitor delivery and the startof B cell inhibitor delivery are within 1, 2, 3, 4, 6, 12, 18, or 24hours of each other, or within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35,40, 60, 80, or 100 days of each other. In some embodiments, the end ofCD19 inhibitor delivery and the end of B cell inhibitor delivery arewithin 1, 2, 3, 4, 6, 12, 18, or 24 hours of each other, or within 1, 2,3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 60, 80, or 100 days of each other.In some embodiments, the overlap in terms of administration between theCD19 inhibitor delivery (e.g., infusion) and the end of B cell inhibitordelivery (e.g., infusion) is at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30,or 45 minutes.

In some embodiments, the B cell inhibitor is administered while the oneor more cells that express a CAR molecule that binds CD19 are present(e.g., undergoing expansion) in the subject. In some embodiments, theCD19 inhibitor is administered while the one or more cells that expressa CAR molecule that binds one or more of CD10, CD20, CD22, CD34, CD123,FLT-3, ROR1, CD79b, CD179b, or CD79a are present (e.g., undergoingexpansion) in the subject.

The invention includes (among other things) a type of cellular therapywhere T cells are genetically modified to express a chimeric antigenreceptor (CAR) and the CAR T cell is infused to a recipient in needthereof. The infused cell is able to kill tumor cells in the recipient.Unlike antibody therapies, CAR-modified T cells are able to replicate invivo resulting in long-term persistence that can lead to sustained tumorcontrol. In various aspects, the T cells administered to the patient, ortheir progeny, persist in the patient for at least four months, fivemonths, six months, seven months, eight months, nine months, ten months,eleven months, twelve months, thirteen months, fourteen month, fifteenmonths, sixteen months, seventeen months, eighteen months, nineteenmonths, twenty months, twenty-one months, twenty-two months,twenty-three months, two years, three years, four years, or five yearsafter administration of the T cell to the patient.

The invention also includes a type of cellular therapy where immuneeffector cells, e.g., NK cells or T cells are modified, e.g., by invitro transcribed RNA, to transiently express a chimeric antigenreceptor (CAR) and the CAR-expressing (e.g., CAR T) cell is infused to arecipient in need thereof. The infused cell is able to kill cancer cellsin the recipient. Thus, in various aspects, the CAR-expressing cells,e.g., T cells, administered to the patient, is present for less than onemonth, e.g., three weeks, two weeks, one week, after administration ofthe CAR-expressing cell, e.g., T cell, to the patient.

Without wishing to be bound by any particular theory, the anti-cancerimmunity response elicited by the CAR-modified T cells may be an activeor a passive immune response, or alternatively may be due to a direct vsindirect immune response. In one aspect, the CAR (e.g., CD19-CAR)transduced T cells exhibit specific proinflammatory cytokine secretionand potent cytolytic activity in response to human cancer cellsexpressing the target antigen (e.g., CD19), resist soluble targetantigen inhibition, mediate bystander killing and mediate regression ofan established human cancer. For example, antigen-less cancer cellswithin a heterogeneous field of target antigen-expressing cancer may besusceptible to indirect destruction by target antigen-redirected T cellsthat has previously reacted against adjacent antigen-positive cancercells.

In one aspect, the CAR-modified cells of the invention, e.g., fullyhuman CAR T cells, may be a type of vaccine for ex vivo immunizationand/or in vivo therapy in a mammal. In one aspect, the mammal is ahuman.

With respect to ex vivo immunization, at least one of the followingoccurs in vitro prior to administering the cell into a mammal: i)expansion of the cells, ii) introducing a nucleic acid encoding a CAR tothe cells or iii) cryopreservation of the cells.

Ex vivo procedures are well known in the art and are discussed morefully below. Briefly, cells are isolated from a mammal (e.g., a human)and genetically modified (i.e., transduced or transfected in vitro) witha vector expressing a CAR disclosed herein. The CAR-modified cell can beadministered to a mammalian recipient to provide a therapeutic benefit.The mammalian recipient may be a human and the CAR-modified cell can beautologous with respect to the recipient. Alternatively, the cells canbe allogeneic, syngeneic or xenogeneic with respect to the recipient.

The procedure for ex vivo expansion of hematopoietic stem and progenitorcells is described in U.S. Pat. No. 5,199,942, incorporated herein byreference, can be applied to the cells of the present invention. Othersuitable methods are known in the art, therefore the present inventionis not limited to any particular method of ex vivo expansion of thecells. Briefly, ex vivo culture and expansion of T cells can comprise:(1) collecting CD34+ hematopoietic stem and progenitor cells from amammal from peripheral blood harvest or bone marrow explants; and (2)expanding such cells ex vivo. In addition to the cellular growth factorsdescribed in U.S. Pat. No. 5,199,942, other factors such as flt3-L,IL-1, IL-3 and c-kit ligand, can be used for culturing and expansion ofthe cells.

In addition to using a cell-based vaccine in terms of ex vivoimmunization, also included in the methods described herein arecompositions and methods for in vivo immunization to elicit an immuneresponse directed against an antigen in a patient.

Generally, the cells activated and expanded as described herein may beutilized in the treatment and prevention of diseases that arise inindividuals who are immunocompromised. In particular, the CAR-expressingcells described herein are used in the treatment of diseases, disordersand conditions associated with expression of one or more B-cell antigen.In certain aspects, the cells are used in the treatment of patients atrisk for developing diseases, disorders and conditions associated withexpression of one or more B-cell antigen. Thus, the present inventionprovides (among other things) methods for the treatment or prevention ofdiseases, disorders and conditions associated with expression of aB-cell antigen comprising administering to a subject in need thereof, atherapeutically effective amount of the CD19 CAR-expressing cellsdescribed herein, in combination with one or more of B-cell inhibitordescribed herein.

The present invention also provides methods for inhibiting theproliferation or reducing a CD19-expressing cell population, the methodscomprising contacting a population of cells comprising a CD19-expressingcell with an anti-CD19 CAR-expressing cell described herein that bindsto the CD19-expressing cell, and contacting the population ofCD19-expressing cells with one or more of a B-cell inhibitor describedherein. In a specific aspect, the present invention provides methods forinhibiting the proliferation or reducing the population of cancer cellsexpressing CD19, the methods comprising contacting the CD19-expressingcancer cell population with an anti-CD19 CAR-expressing cell describedherein that binds to the CD19-expressing cell, and contacting theCD19-expressing cell with one or more B-cell described herein. In oneaspect, the present invention provides methods for inhibiting theproliferation or reducing the population of cancer cells expressingCD19, the methods comprising contacting the CD19-expressing cancer cellpopulation with an anti-CD19 CAR-expressing cell described herein thatbinds to the CD19-expressing cell and contacting the CD19-expressingcell with one or more B-cell described herein. In certain aspects, thecombination of the anti-CD19 CAR-expressing cell described herein andone or more B-cell described herein reduces the quantity, number, amountor percentage of cells and/or cancer cells by at least 25%, at least30%, at least 40%, at least 50%, at least 65%, at least 75%, at least85%, at least 95%, or at least 99% in a subject with or animal model fora hematological cancer or another cancer associated with CD19-expressingcells relative to a negative control. In one aspect, the subject is ahuman.

The present invention also provides methods for inhibiting theproliferation or reducing a cell population comprising CD19-expressingcells and cells expressing a second B-cell antigen. In one aspect, CD19and second B-cell antigen are expressed by the same cells within thepopulation. In another aspect, CD19 and second B-cell antigen areexpressed by distinct subsets of cells within the population. In anotheraspect, CD19 and second B-cell antigen are expressed by overlappingsubsets of cells within the population, such that some cells expressCD19 and second B-cell antigen, some cells express CD19, and some cellsexpress the second B-cell antigen.

The present invention also provides methods for inhibiting theproliferation or reducing a cell population expressing CD19 and a secondB-cell antigen, the methods comprising (i) contacting a population ofcells comprising a CD19-expressing cell with an anti-CD19 CAR-expressingcell described herein that binds to the CD19-expressing cell, and (ii)contacting the second B-cell antigen-expressing cell with a secondCAR-expressing cell described herein that binds to the second B-cellantigen-expressing cell. In a specific aspect, the present inventionprovides methods for inhibiting the proliferation or reducing thepopulation of cancer cells expressing CD19 and a second B-cell antigen,the methods comprising (i) contacting the CD19-expressing cancer cellpopulation with an anti-CD19 CAR-expressing cell described herein thatbinds to the CD19-expressing cell, and (ii) contacting the second B-cellantigen-expressing cell population with a second CAR-expressing celldescribed herein that binds to the cell expressing the second B-cellantigen. In one aspect, the present invention provides methods forinhibiting the proliferation or reducing the population of cancer cellsexpressing CD19 and/or a second B-cell antigen, the methods comprising(i) contacting the CD19-expressing cancer cell population with ananti-CD19 CAR-expressing cell described herein that binds to theCD19-expressing cell and (ii) contacting the second B-cellantigen-expressing cell population with a second CAR-expressing celldescribed herein that binds to the cell expressing the second B-cellantigen. In certain aspects, the combination of the anti-CD19CAR-expressing cell described herein and the second CAR-expressing celldescribed herein, reduces the quantity, number, amount or percentage ofcells and/or cancer cells by at least 25%, at least 30%, at least 40%,at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, orat least 99% in a subject with or animal model for a hematologicalcancer or another cancer associated with CD19 and/or second B-cellantigen-expressing cells relative to a negative control. In one aspect,the subject is a human.

The present invention also provides methods for preventing, treatingand/or managing a disease associated with CD19-expressing cells (e.g., ahematologic cancer or atypical cancer expressing CD19), the methodscomprising administering to a subject in need an anti-CD19CAR-expressing cell that binds to the CD19-expressing cell andadministering one or B-cell inhibitor described herein. In one aspect,the subject is a human. Non-limiting examples of disorders associatedwith CD19-expressing cells include autoimmune disorders (such as lupus),inflammatory disorders (such as allergies and asthma) and cancers (suchas hematological cancers or atypical cancers expressing CD19).

The present invention also provides methods for preventing, treatingand/or managing a disease associated with CD19 and/or a second B-cellantigen-expressing cells (e.g., a hematologic cancer or atypical cancerexpressing CD19 and/or second B-cell antigen), the methods comprisingadministering to a subject in need an anti-CD19 CAR-expressing cell thatbinds to the CD19-expressing cell and a B-cell inhibitor.

The present invention also provides methods for preventing, treatingand/or managing a disease associated with CD19-expressing cells, themethods comprising administering to a subject in need an anti-CD19 CARTcell of the invention that binds to the CD19-expressing cell. In oneaspect, the subject is a human.

The present invention also provides methods for preventing relapse ofcancer associated with CD19-expressing cells, the methods comprisingadministering to a subject in need thereof an anti-CD19 CART cell of theinvention that binds to the CD19-expressing cell. In one aspect, themethods comprise administering to the subject in need thereof aneffective amount of an anti-CD19 CART cell described herein that bindsto the CD19-expressing cell in combination with an effective amount ofanother therapy.

In one aspect, the invention pertains to a method of treating cancer ina subject. The method comprises administering to the subject a CD19CAR-expressing cell, e.g., T cell, described herein, in combination witha B-cell inhibitor, such that the cancer is treated in the subject. Anexample of a cancer that is treatable by the methods described herein isa cancer associated with expression of CD19. In one embodiment, thedisease is a solid or liquid tumor. In one embodiment, the disease is ahematologic cancer, e.g., as described herein.

Non-cancer related indications associated with expression of CD19include, but are not limited to, e.g., autoimmune disease, (e.g.,lupus), inflammatory disorders (allergy and asthma) and transplantation.

In some embodiments, a cancer that can be treated with the combinationdescribed herein is multiple myeloma. Multiple myeloma is a cancer ofthe blood, characterized by accumulation of a plasma cell clone in thebone marrow. Current therapies for multiple myeloma include, but are notlimited to, treatment with lenalidomide, which is an analog ofthalidomide. Lenalidomide has activities which include anti-tumoractivity, angiogenesis inhibition, and immunomodulation. In someembodiments, a CD19 CAR, e.g., as described herein, may be used totarget myeloma cells. In some embodiments, the combination describedherein can be used with one or more additional therapies, e.g.,lenalidomide treatment.

The CAR-expressing cells described herein may be administered eitheralone, or as a pharmaceutical composition in combination with diluentsand/or with other components such as IL-2 or other cytokines or cellpopulations.

Hematologic Cancers

Hematological cancer conditions are the types of cancer such asleukemia, lymphoma and malignant lymphoproliferative conditions thataffect blood, bone marrow and the lymphatic system.

In one embodiment, the hematologic cancer is leukemia. In oneembodiment, the cancer is selected from the group consisting of one ormore acute leukemias including but not limited to B-cell acute lymphoidleukemia (BALL), T-cell acute lymphoid leukemia (TALL), smalllymphocytic leukemia (SLL), acute lymphoid leukemia (ALL); one or morechronic leukemias including but not limited to chronic myelogenousleukemia (CIVIL), chronic lymphocytic leukemia (CLL); additionalhematologic cancers or hematologic conditions including, but not limitedto mantle cell lymphoma (MCL), B cell prolymphocytic leukemia, blasticplasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse largeB cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell-or a large cell-follicular lymphoma, malignant lymphoproliferativeconditions, MALT lymphoma, Marginal zone lymphoma, multiple myeloma,myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma,Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cellneoplasm, Waldenstrom macroglobulinemia, and “preleukemia” which are adiverse collection of hematological conditions united by ineffectiveproduction (or dysplasia) of myeloid blood cells. Diseases associatedwith CD19, CD20, or CD22 expression include, but not limited to atypicaland/or non-classical cancers, malignancies, precancerous conditions orproliferative diseases expressing CD19, CD20, or CD22; and anycombination thereof.

Leukemia can be classified as acute leukemia and chronic leukemia. Acuteleukemia can be further classified as acute myelogenous leukemia (AML)and acute lymphoid leukemia (ALL). Chronic leukemia includes chronicmyelogenous leukemia (CIVIL) and chronic lymphoid leukemia (CLL). Otherrelated conditions include myelodysplastic syndromes (MDS, formerlyknown as “preleukemia”) which are a diverse collection of hematologicalconditions united by ineffective production (or dysplasia) of myeloidblood cells and risk of transformation to AML.

Lymphoma is a group of blood cell tumors that develop from lymphocytes.Exemplary lymphomas include non-Hodgkin lymphoma and Hodgkin lymphoma.

In an aspect, the invention pertains to a method of treating a mammalhaving Hodgkin lymphoma, comprising administering to the mammal aneffective amount of the cells expressing a CD19 CAR molecule, e.g., aCD19 CAR molecule described herein and a B-cell inhibitor.

In one aspect, the compositions and CART cells or CAR expressing NKcells of the present invention are particularly useful for treating Bcell malignancies, such as non-Hodgkin lymphomas, e.g., DLBCL,Follicular lymphoma, or CLL.

Non-Hodgkin lymphoma (NHL) is a group of cancers of lymphocytes, formedfrom either B or T cells. NHLs occur at any age and are oftencharacterized by lymph nodes that are larger than normal, weight loss,and fever. Different types of NHLs are categorized as aggressive(fast-growing) and indolent (slow-growing) types. B-cell non-Hodgkinlymphomas include Burkitt lymphoma, chronic lymphocytic leukemia/smalllymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL),follicular lymphoma, immunoblastic large cell lymphoma, precursorB-lymphoblastic lymphoma, and mantle cell lymphoma. Examples of T-cellnon-Hodgkin lymphomas include mycosis fungoides, anaplastic large celllymphoma, and precursor T-lymphoblastic lymphoma. Lymphomas that occurafter bone marrow or stem cell transplantation are typically B-cellnon-Hodgkin lymphomas. See, e.g., Maloney. NEJM. 366.21(2012):2008-16.

Diffuse large B-cell lymphoma (DLBCL) is a form of NHL that developsfrom B cells. DLBCL is an aggressive lymphoma that can arise in lymphnodes or outside of the lymphatic system, e.g., in the gastrointestinaltract, testes, thyroid, skin, breast, bone, or brain. Three variants ofcellular morphology are commonly observed in DLBCL: centroblastic,immunoblastic, and anaplastic. Centroblastic morphology is most commonand has the appearance of medium-to-large-sized lymphocytes with minimalcytoplasm. There are several subtypes of DLBCL. For example, primarycentral nervous system lymphoma is a type of DLBCL that only affects thebrain is called and is treated differently than DLBCL that affects areasoutside of the brain. Another type of DLBCL is primary mediastinalB-cell lymphoma, which often occurs in younger patients and growsrapidly in the chest. Symptoms of DLBCL include a painless rapidswelling in the neck, armpit, or groin, which is caused by enlargedlymph nodes. For some subjects, the swelling may be painful. Othersymptoms of DLBCL include night sweats, unexplained fevers, and weightloss. Although most patients with DLBCL are adults, this diseasesometimes occurs in children. Treatment for DLBCL includes chemotherapy(e.g., cyclophosphamide, doxorubicin, vincristine, prednisone,etoposide), antibodies (e.g., Rituxan), radiation, or stem celltransplants.

Follicular lymphoma a type of non-Hodgkin lymphoma and is a lymphoma offollicle center B-cells (centrocytes and centroblasts), which has atleast a partially follicular pattern. Follicular lymphoma cells expressthe B-cell markers CD10, CD19, CD20, and CD22. Follicular lymphoma cellsare commonly negative for CD5. Morphologically, a follicular lymphomatumor is made up of follicles containing a mixture of centrocytes (alsocalled cleaved follicle center cells or small cells) and centroblasts(also called large noncleaved follicle center cells or large cells). Thefollicles are surrounded by non-malignant cells, mostly T-cells. Thefollicles contain predominantly centrocytes with a minority ofcentroblasts. The World Health Organization (WHO) morphologically gradesthe disease as follows: grade 1 (<5 centroblasts per high-power field(hpf); grade 2 (6-15 centroblasts/hpf); grade 3 (>15 centroblasts/hpf).Grade 3 is further subdivided into the following grades: grade 3A(centrocytes still present); grade 3B (the follicles consist almostentirely of centroblasts). Treatment of follicular lymphoma includeschemotherapy, e.g., alkyating agents, nucleoside analogs,anthracycline-containing regimens, e.g., a combination therapy calledCHOP—cyclophosphamide, doxorubicin, vincristine,prednisone/prednisolone, antibodies (e.g., rituximab),radioimmunotherapy, and hematopoietic stem cell transplantation.

CLL is a B-cell malignancy characterized by neoplastic cellproliferation and accumulation in bone morrow, blood, lymph nodes, andthe spleen. The median age at time of diagnosis of CLL is about 65years. Current treatments include chemotherapy, radiation therapy,biological therapy, or bone marrow transplantation. Sometimes symptomsare treated surgically (e.g., splenectomy removal of enlarged spleen) orby radiation therapy (e.g., de-bulking swollen lymph nodes).Chemotherapeutic agents to treat CLL include, e.g., fludarabine,2-chlorodeoxyadenosine (cladribine), chlorambucil, vincristine,pentostatin, cyclophosphamide, alemtuzumab (Campath-1H), doxorubicin,and prednisone. Biological therapy for CLL includes antibodies, e.g.,alemtuzumab, rituximab, and ofatumumab; as well as tyrosine kinaseinhibitor therapies. A number of criteria can be used to classify stageof CLL, e.g., the Rai or Binet system. The Rai system describes CLL hashaving five stages: stage 0 where only lymphocytosis is present; stage Iwhere lymphadenopathy is present; stage II where splenomegaly,lymphadenopathy, or both are present; stage III where anemia,organomegaly, or both are present (progression is defined by weightloss, fatigue, fever, massive organomegaly, and a rapidly increasinglymphocyte count); and stage IV where anemia, thrombocytopenia,organomegaly, or a combination thereof are present. Under the Binetstaging system, there are three categories: stage A where lymphocytosisis present and less than three lymph nodes are enlarged (this stage isinclusive of all Rai stage 0 patients, one-half of Rai stage I patients,and one-third of Rai stage II patients); stage B where three or morelymph nodes are involved; and stage C wherein anemia orthrombocytopenia, or both are present. These classification systems canbe combined with measurements of mutation of the immunoglobulin genes toprovide a more accurate characterization of the state of the disease.The presence of mutated immunoglobulin genes correlates to improvedprognosis.

In another embodiment, the CAR expressing cells of the present inventionare used to treat cancers or leukemias, e.g., with leukemia stem cells.For example, the leukemia stem cells are CD34⁺/CD38⁻ leukemia cells.

CD20 and CD22 Associated Diseases and/or Disorders

The present invention provides, among other things, compositions andmethods for treating a disease associated with expression of CD20 orCD22 or condition associated with cells which express CD20 or CD22including, e.g., a proliferative disease such as a cancer or malignancyor a precancerous condition; or a noncancer related indicationassociated with cells which express CD20 or CD22. In one aspect, acancer associated with expression of CD22 is a hematological cancer,e.g., a hematological cancer described herein.

Non-cancer related indications associated with expression of CD20 orCD22 may also be included. Non-cancer related indications associatedwith expression of CD20 or CD22 include, but are not limited to, e.g.,autoimmune disease, (e.g., lupus, rheumatoid arthritis, multiplesclerosis autoimmune hemolytic anemia, pure red cell aplasia, idiopathicthrombocytopenic purpura, Evans syndrome, vasculitis, bullous skindisorders, type 1 diabetes mellitus, Sjogren's syndrome, anti-NMDAreceptor encephalitis and Devic's disease, Graves' ophthalmopathy, andautoimmune pancreatitis), inflammatory disorders (allergy and asthma)and solid-organ or hematopoietic cell transplantation.

Compositions and methods disclosed herein may be used to treathematologic diseases including, but not limited to myelodysplasia,anemia, paroxysmal nocturnal hemoglobinuria, aplastic anemia, acquiredpure red cell anemia, Diamon-Blackfan anemia, Fanconi anemia, cytopenia,amegakaryotic thrombocytopenia, myeloproliferative disorders,polycythemia vera, essential thrombocytosis, myelofibrosis,hemoglobinopathies, sickle cell disease, β thalassemia major, amongothers.

In one aspect, the invention provides methods for treating a diseaseassociated with CD22 expression. In one aspect, the invention providesmethods for treating a disease wherein part of the tumor is negative forCD20 or CD22 and part of the tumor is positive for CD20 or CD22. Forexample, the CAR of the invention is useful for treating subjects thathave undergone treatment for a disease associated with expression ofCD20 or CD22, wherein the subject that has undergone treatment relatedto expression of CD20 or CD22 exhibits a disease associated withexpression of CD20 or CD22.

In one aspect, the invention pertains to a method of inhibiting growthof a CD20 or CD22-expressing tumor cell, comprising contacting the tumorcell with a CD20 or CD22 CAR cell (e.g., T cell or NK cell) of thepresent invention such that the CART is activated in response to theantigen and targets the cancer cell, wherein the growth of the tumor isinhibited.

In one aspect, the invention pertains to a method of treating cancer ina subject. The method comprises administering to the subject a CD20 orCD22 CAR expressing cell (e.g., T cell or NK cell) of the presentinvention such that the cancer is treated in the subject. An example ofa cancer that is treatable by the CD20 or CD22 CAR expressing cell(e.g., T cell or NK cell) of the invention is a cancer associated withexpression of CD20 or CD22. An example of a cancer that is treatable bythe CD20 or CD22 CAR expressing cell (e.g., T cell or NK cell) of theinvention includes but is not limited to a hematological cancerdescribed herein.

The invention includes a type of cellular therapy where cells (e.g., Tcells or NK cells) are genetically modified to express a chimericantigen receptor (CAR) and the CAR expressing cell (e.g., T cell or NKcells) is infused to a recipient in need thereof. The infused cell isable to kill tumor cells in the recipient. Unlike antibody therapies,CAR-modified cells (e.g., T cells or NK cells) are able to replicate invivo resulting in long-term persistence that can lead to sustained tumorcontrol. In various aspects, the cells (e.g., T cells or NK cells)administered to the patient, or their progeny, persist in the patientfor at least four months, five months, six months, seven months, eightmonths, nine months, ten months, eleven months, twelve months, thirteenmonths, fourteen month, fifteen months, sixteen months, seventeenmonths, eighteen months, nineteen months, twenty months, twenty-onemonths, twenty-two months, twenty-three months, two years, three years,four years, or five years after administration of the T cell to thepatient.

The invention also includes a type of cellular therapy where immuneeffector cells, e.g., NK cells or T cells are modified, e.g., by invitro transcribed RNA, to transiently express a chimeric antigenreceptor (CAR) and the CAR-expressing (e.g., CART or CAR expressing NKcell) cell is infused to a recipient in need thereof. The infused cellis able to kill cancer cells in the recipient. Thus, in various aspects,the CAR-expressing cells, e.g., T cells or NK cells, are administered tothe patient, is present for less than one month, e.g., three weeks, twoweeks, one week, after administration of the CAR-expressing cell, e.g.,T cells or NK cell, to the patient.

Without wishing to be bound by any particular theory, the anti-tumorimmunity response elicited by the CAR-modified cells (e.g., T cells orNK cells) may be an active or a passive immune response, oralternatively may be due to a direct vs indirect immune response. In oneaspect, the CAR transduced cells (e.g., T cells or NK cells) exhibitspecific proinflammatory cytokine secretion and potent cytolyticactivity in response to human cancer cells expressing CD20 or CD22,resist soluble CD20 or CD22 inhibition, mediate bystander killing andmediate regression of an established human tumor. For example,antigen-less tumor cells within a heterogeneous field of CD20 orCD22-expressing tumor may be susceptible to indirect destruction by CD20or CD22-redirected T cells that has previously reacted against adjacentantigen-positive cancer cells.

In one aspect, the CAR-modified cells (e.g., T cells or NK cells) of theinvention, e.g., fully human CAR-expressing cells, may be a type ofvaccine for ex vivo immunization and/or in vivo therapy in a mammal. Inone aspect, the mammal is a human.

With respect to ex vivo immunization, at least one of the followingoccurs in vitro prior to administering the cell into a mammal: i)expansion of the cells, ii) introducing a nucleic acid encoding a CAR tothe cells or iii) cryopreservation of the cells.

Ex vivo procedures are well known in the art and are discussed morefully below. Briefly, cells are isolated from a mammal (e.g., a human)and genetically modified (i.e., transduced or transfected in vitro) witha vector expressing a CAR disclosed herein. The CAR-modified cell can beadministered to a mammalian recipient to provide a therapeutic benefit.The mammalian recipient may be a human and the CAR-modified cell can beautologous with respect to the recipient. Alternatively, the cells canbe allogeneic, syngeneic or xenogeneic with respect to the recipient.

The procedure for ex vivo expansion of hematopoietic stem and progenitorcells is described in U.S. Pat. No. 5,199,942, incorporated herein byreference, can be applied to the cells of the present invention. Othersuitable methods are known in the art, therefore the present inventionis not limited to any particular method of ex vivo expansion of thecells. Briefly, ex vivo culture and expansion of T cells comprises: (1)collecting CD34+ hematopoietic stem and progenitor cells from a mammalfrom peripheral blood harvest or bone marrow explants; and (2) expandingsuch cells ex vivo. In addition to the cellular growth factors describedin U.S. Pat. No. 5,199,942, other factors such as flt3-L, IL-1, IL-3 andc-kit ligand, can be used for culturing and expansion of the cells.

In addition to using a cell-based vaccine in terms of ex vivoimmunization, the present invention also provides compositions andmethods for in vivo immunization to elicit an immune response directedagainst an antigen in a patient.

Generally, the cells activated and expanded as described herein may beutilized in the treatment and prevention of diseases that arise inindividuals who are immunocompromised. In particular, the CAR-modifiedcells (e.g., T cells or NK cells) of the invention are used in thetreatment of diseases, disorders and conditions associated withexpression of CD20 or CD22. In certain aspects, the cells of theinvention are used in the treatment of patients at risk for developingdiseases, disorders and conditions associated with expression of CD20 orCD22. Thus, the present invention provides methods for the treatment orprevention of diseases, disorders and conditions associated withexpression of CD20 or CD22 comprising administering to a subject in needthereof, a therapeutically effective amount of the CAR-modified cells(e.g., T cells or NK cells) of the invention.

In one aspect the CAR expressing cells of the inventions may be used totreat a proliferative disease such as a cancer or malignancy or is aprecancerous condition. In one aspect, a cancer associated withexpression of CD20 or CD22 is a hematological cancer preleukemia,hyperproliferative disorder, hyperplasia or a dysplasia, which ischaracterized by abnormal growth of cells.

The CAR-modified cells of the present invention may be administeredeither alone, or as a pharmaceutical composition in combination withdiluents and/or with other components such as IL-2 or other cytokines orcell populations.

The present invention also methods for inhibiting the proliferation orreducing a CD20 or CD22-expressing cell population, the methodscomprising contacting a population of cells comprising a CD20 orCD22-expressing cell with a CD20 or CD22 CAR expressing cell of theinvention that binds to the CD20 or CD22-expressing cell. In a specificaspect, the present invention provides methods for inhibiting theproliferation or reducing the population of cancer cells expressing CD20or CD22, the methods comprising contacting the CD20 or CD22-expressingcancer cell population with a CD20 or CD22 CAR expressing cell of theinvention that binds to the CD20 or CD22-expressing cell. In one aspect,the present invention provides methods for inhibiting the proliferationor reducing the population of cancer cells expressing CD20 or CD22, themethods comprising contacting the CD20 or CD22-expressing cancer cellpopulation with a CD20 or CD22 CART of the invention that binds to theCD20 or CD22-expressing cell. In certain aspects, the CD20 or CD22 CARexpressing cell of the invention reduces the quantity, number, amount orpercentage of cells and/or cancer cells by at least 25%, at least 30%,at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, atleast 95%, or at least 99% in a subject with or animal model for B-cellmalignancy or another cancer associated with CD20 or CD22-expressingcells relative to a negative control. In one aspect, the subject is ahuman.

The present invention provides methods for preventing relapse of cancerassociated with CD20 or CD22-expressing cells, the methods comprisingadministering to a subject in need thereof a CD20 or CD22 CAR expressingcell of the invention that binds to the CD20 or CD22-expressing cell. Inone aspect, the methods comprise administering to the subject in needthereof an effective amount of a CD20 or CD22 CAR expressing celldescribed herein that binds to the CD20 or CD22-expressing cell incombination with an effective amount of another therapy.

In some embodiments, the CD22 expressing cell expresses CD19, CD123,FLT-3, ROR-1, CD79b, CD179b, CD79a, CD10, CD34, and/or CD20. In certainembodiments, the CD22 expressing cell expresses CD19. In someembodiments, the CD22-expressing cell does not express CD19. In someembodiments, the CD20 expressing cell expresses CD19, CD123, FLT-3,ROR-1, CD79b, CD179b, CD79a, CD10, CD34, and/or CD22. In certainembodiments, the CD20 expressing cell expresses CD19. In someembodiments, the CD20-expressing cell does not express CD19.

In some embodiments, the subject is a non-responder to CD19 CAR therapy.In some embodiments, the subject is a partial responder to CD19 CARtherapy. In some embodiments, the subject is a complete responder toCD19 CAR therapy. In some embodiments, the subject is a non-relapser toCD19 CAR therapy. In some embodiments, the subject is a partial relapserto CD19 CAR therapy. In some embodiments, the subject is a completerelapser to CD19 CAR therapy.

In some embodiments, a cancer or other condition that was previouslyresponsive to treatment with CD19 CAR-expressing cells does not expressCD19. In some embodiments, a cancer or other condition that waspreviously responsive to treatment with CD19 CAR-expressing cells has a10%, 20%, 30%, 40%, 50% or more reduction in CD19 expression levelsrelative to when the cancer or other condition was responsive totreatment with CD19 CAR-expressing cells. In some embodiments, a canceror other condition that was previously responsive to treatment with CD19CAR-expressing cells expresses CD20, CD22, CD123, or any combinationthereof.

In some embodiments, the CD20 or CD22 CAR-expressing cell of theinvention is administered post-relapse of a cancer or other conditionpreviously treated with CD19 CAR-expressing cell. In some embodiments, aCD19 CAR-expressing cell and a CD20 or CD22 CAR-expressing cell areadministered concurrently, as described herein.

Bone Marrow Ablation

In one aspect, the present invention provides compositions and methodsfor bone marrow ablation. For example, in one aspect, the inventionprovides compositions and methods for eradication of at least a portionof existing bone marrow in a subject. It is described herein that, incertain instances, the CD19, C20, or CD22 CAR expressing cell comprisinga CAR of the present invention eradicates CD19, C20, or CD22 positivebone marrow myeloid progenitor cells.

In one aspect, the invention provides a method of bone marrow ablationcomprising administering a CD19, C20, or CD22 expressing CAR cell (e.g.,T cell or NK cell) of the invention to a subject in need of bone marrowablation. For example, the present method may be used to eradicate someor all of the existing bone marrow of a subject having a disease ordisorder in which bone marrow transplantation or bone marrowreconditioning is a beneficial treatment strategy. In one aspect, thebone marrow ablation method of the invention, comprising theadministration of a CD19, C20, or CD22 expressing CAR cell (e.g., T cellor NK cell) described elsewhere herein, is performed in a subject priorto bone marrow transplantation. Thus, in one aspect, the method of theinvention provides a cellular conditioning regimen prior to bone marrowor stem cell transplantation. In one aspect, bone marrow transplantationcomprises transplantation of a stem cell. The bone marrowtransplantation may comprise transplantation of autologous or allogeneiccells.

The present invention provides a method of treating a disease ordisorder comprising administering a CD19, C20, or CD22 expressing CARcell (e.g., T cell or NK cell) of the invention to eradicate at least aportion of existing bone marrow. The method may be used as at least aportion of a treatment regimen for treating any disease or disorderwhere bone marrow transplantation is beneficial. That is, the presentmethod may be used in any subject in need of a bone marrow transplant.In one aspect, bone marrow ablation comprising administration of a CD19,C20, or CD22 expressing CAR cell (e.g., T cell or NK cell) is useful inthe treatment of AML. In certain aspects, bone marrow ablation by way ofthe present method is useful in treating a hematological cancer, a solidtumor, a hematologic disease, a metabolic disorder, HIV, HTLV, alysosomal storage disorder, and an immunodeficiency.

Compositions and methods disclosed herein may be used to eradicate atleast a portion of existing bone marrow to treat hematological cancersincluding, but not limited to, cancers described herein, e.g., leukemia,lymphoma, myeloma, ALL, AML, CLL, CIVIL, Hodgkin lymphoma, Non-Hodgkinlymphoma (e.g., DLBCL or follicular lymphoma), and multiple myeloma.

In one aspect, the present invention provides a method of treatingcancer comprising bone marrow conditioning, where at least a portion ofbone marrow of the subject is eradicated by the CD22 CAR cell (e.g., Tcell or NK cell) of the invention. For example, in certain instances,the bone marrow of the subject comprises a malignant precursor cell thatcan be targeted and eliminated by the activity of the C20 or CD22 CARcell (e.g., T cell or NK cell). In one aspect, a bone marrowconditioning therapy comprises administering a bone marrow or stem celltransplant to the subject following the eradication of native bonemarrow. In one aspect, the bone marrow reconditioning therapy iscombined with one or more other anti-cancer therapies, including, butnot limited to anti-tumor CAR therapies, chemotherapy, radiation, andthe like.

In one aspect, eradication of the administered CD19, CD20, or CD22 CARexpressing cells may be required prior to infusion of bone marrow orstem cell transplant. Eradication of the CD19, CD20, or CD22 expressingCAR cell (e.g., T cell or NK cell) may be accomplished using anysuitable strategy or treatment, including, but not limited to, use of asuicide gene, limited CAR persistence using RNA encoded CARs, or anti-Tcell modalities including antibodies or chemotherapy.

Combination Therapies

The combination of a CAR as described herein (e.g., a CD20 CAR, a CD22CAR, or a CD19 CAR-expressing cell described herein e.g., and one ormore B-cell inhibitors, e.g., as described herein) may be used incombination with other known agents and therapies.

A CAR-expressing cell described herein (e.g., a CD20 CAR, a CD22 CAR, ora CD19 CAR-expressing cell), optionally the one or more B-cellinhibitors, and/or the at least one additional therapeutic agent can beadministered simultaneously, in the same or in separate compositions, orsequentially. For sequential administration, the CAR-expressing celldescribed herein (e.g., a CD20 CAR, a CD22 CAR, or a CD19 CAR-expressingcell) can be administered first, and the additional agent can beadministered second, or the order of administration can be reversed.

The CAR therapy and/or other therapeutic agents (such as a second CARtherapy), procedures or modalities can be administered during periods ofactive disorder, or during a period of remission or less active disease.The CAR therapy can be administered before the other treatment,concurrently with the treatment, post-treatment, or during remission ofthe disorder.

For instance, in some embodiments, CAR therapy is administered to asubject having a disease associated with CD19, CD20, or CD22 expression,e.g., a cancer. The subject can be assayed for indicators ofresponsiveness or relapse. In some embodiments, when the subject showsone or more signs of relapse, e.g., a frameshift and/or premature stopcodon in CD19, an additional therapy is administered. In embodiments,the additional therapy is a B-cell inhibitor. The CD19 therapy may becontinued (for instance, when there are still some CD19-expressingcancer cells detectable in the subject) or may be discontinued (forinstance, when a risk-benefit analysis favors discontinuing thetherapy).

When administered in combination, the CAR therapy and the additionalagent (e.g., second or third agent), or all, can be administered in anamount or dose that is higher, lower or the same than the amount ordosage of each agent used individually, e.g., as a monotherapy. Incertain embodiments, the administered amount or dosage of the CARtherapy, the additional agent (e.g., second or third agent), or all, islower (e.g., at least 20%, at least 30%, at least 40%, or at least 50%)than the amount or dosage of each agent used individually, e.g., as amonotherapy. In other embodiments, the amount or dosage of the CARtherapy, the additional agent (e.g., second or third agent), or all,that results in a desired effect (e.g., treatment of cancer) is lower(e.g., at least 20%, at least 30%, at least 40%, or at least 50% lower)than the amount or dosage of each agent used individually, e.g., as amonotherapy, required to achieve the same therapeutic effect.

In embodiments, one or more of the therapeutics in the combinationtherapy is an antibody molecule. Cancer antigens can be targeted withmonoclonal antibody therapy. Monoclonal antibody (mAb) therapy has beenshown to exert powerful antitumor effects by multiple mechanisms,including complement-dependent cytotoxicity (CDC), antibody-dependentcellular cytotoxicity (ADCC) and direct cell inhibition orapoptosis-inducing effects on tumor cells that over-express the targetmolecules.

In further aspects, the combination of the CAR-expressing cell describedherein (e.g., a CD20 CAR, a CD22 CAR, or a CD19 CAR-expressing cell,optionally in combination with one or more B-cell inhibitor) may be usedin a treatment regimen in combination with surgery, chemotherapy,radiation, an mTOR pathway inhibitor, immunosuppressive agents, such ascyclosporin, azathioprine, methotrexate, mycophenolate, and FK506,antibodies, or other immunoablative agents such as CAMPATH, anti-CD3antibodies or other antibody therapies, cytoxin, fludarabine,cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228,cytokines, and irradiation. peptide vaccine, such as that described inIzumoto et al. 2008 J Neurosurg 108:963-971.

In one embodiment, the combination of a CD19, CD20, or CD22CAR-expressing cell described herein (e.g., and one or more B-cellinhibitor) can be used in combination with a chemotherapeutic agent.Exemplary chemotherapeutic agents include an anthracycline (e.g.,doxorubicin (e.g., liposomal doxorubicin)); a vinca alkaloid (e.g.,vinblastine, vincristine, vindesine, vinorelbine); an alkylating agent(e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide,temozolomide); an immune cell antibody (e.g., alemtuzamab, gemtuzumab,rituximab, tositumomab); an antimetabolite (including, e.g., folic acidantagonists, pyrimidine analogs, purine analogs and adenosine deaminaseinhibitors (e.g., fludarabine)); a TNFR glucocorticoid induced TNFRrelated protein (GITR) agonist; a proteasome inhibitor (e.g.,aclacinomycin A, gliotoxin or bortezomib); an immunomodulator such asthalidomide or a thalidomide derivative (e.g., lenalidomide).

General Chemotherapeutic agents considered for use in combinationtherapies include anastrozole (Arimidex®), bicalutamide (Casodex®),bleomycin sulfate (Blenoxane®), busulfan (Myleran®), busulfan injection(Busulfex®), capecitabine (Xeloda®),N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®),carmustine (BiCNU®), chlorambucil (Leukeran®), cisplatin (Platinol®),cladribine (Leustatin®), cyclophosphamide (Cytoxan® or Neosar®),cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposomeinjection (DepoCyt®), dacarbazine (DTIC-Dome®), dactinomycin(Actinomycin D, Cosmegan), daunorubicin hydrochloride (Cerubidine®),daunorubicin citrate liposome injection (DaunoXome®), dexamethasone,docetaxel (Taxotere®), doxorubicin hydrochloride (Adriamycin®, Rubex®),etoposide (Vepesid®), fludarabine phosphate (Fludara®), 5-fluorouracil(Adrucil®, Efudex®), flutamide (Eulexin®), tezacitibine, gemcitabine(difluorodeoxycitidine), hydroxyurea (Hydrea®), Idarubicin (Idamycin®),ifosfamide (IFEX®), irinotecan (Camptosar®), L-asparaginase (ELSPAR®),leucovorin calcium, melphalan (Alkeran®), 6-mercaptopurine(Purinethol®), methotrexate (Folex®), mitoxantrone (Novantrone®),mylotarg, paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), phoenix(Yttrium90/MX-DTPA), pentostatin, polifeprosan 20 with carmustineimplant (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide (Vumon®),6-thioguanine, thiotepa, tirapazamine (Tirazone®), topotecanhydrochloride for injection (Hycamptin®), vinblastine (Velban®),vincristine (Oncovin®), and vinorelbine (Navelbine®).

Treatment with a combination of a chemotherapeutic agent and a cellexpressing a CAR molecule described herein can be used to treat ahematologic cancer described herein, e.g., AML. In embodiments, thecombination of a chemotherapeutic agent and a CAR-expressing cell isuseful for targeting, e.g., killing, cancer stem cells, e.g., leukemicstem cells, e.g., in subjects with AML. In embodiments, the combinationof a chemotherapeutic agent and a CAR-expressing cell is useful fortreating minimal residual disease (MRD). MRD refers to the small numberof cancer cells that remain in a subject during treatment, e.g.,chemotherapy, or after treatment. MRD is often a major cause forrelapse. The present invention provides a method for treating cancer,e.g., MRD, comprising administering a chemotherapeutic agent incombination with a CAR-expressing cell, e.g., as described herein.

In an embodiment, the chemotherapeutic agent is administered prior toadministration of the cell expressing a CAR molecule, e.g., a CARmolecule described herein. In chemotherapeutic regimens where more thanone administration of the chemotherapeutic agent is desired, thechemotherapeutic regimen is initiated or completed prior toadministration of a cell expressing a CAR molecule, e.g., a CAR moleculedescribed herein. In embodiments, the chemotherapeutic agent isadministered at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15days, 20 days, 25 days, or 30 days prior to administration of the cellexpressing the CAR molecule. In embodiments, the chemotherapeuticregimen is initiated or completed at least 1 day, 2 days, 3 days, 4days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days,13 days, 14 days, 15 days, 20 days, 25 days, or 30 days prior toadministration of the cell expressing the CAR molecule. In embodiments,the chemotherapeutic agent is a chemotherapeutic agent that increasesexpression of CD19, CD20, or CD22 on the cancer cells, e.g., the tumorcells, e.g., as compared to expression on normal or non-cancer cells.Expression can be determined, for example, by immunohistochemicalstaining or flow cytometry analysis. For example, the chemotherapeuticagent is cytarabine (Ara-C).

Anti-cancer agents of particular interest for combinations with thecompounds of the present invention include: antimetabolites; drugs thatinhibit either the calcium dependent phosphatase calcineurin or thep70S6 kinase FK506) or inhibit the p70S6 kinase; alkylating agents; mTORinhibitors; immunomodulators; anthracyclines; vinca alkaloids;proteosome inhibitors; GITR agonists; protein tyrosine phosphataseinhibitors; a CDK4 kinase inhibitor; a BTK kinase inhibitor; a MKNkinase inhibitor; a DGK kinase inhibitor; or an oncolytic virus.

Exemplary antimetabolites include, without limitation, folic acidantagonists (also referred to herein as antifolates), pyrimidineanalogs, purine analogs and adenosine deaminase inhibitors):methotrexate (Rheumatrex®, Trexall®), 5-fluorouracil (Adrucil®, Efudex®,Fluoroplex®), floxuridine (FUDF®), cytarabine (Cytosar-U®, TarabinePFS), 6-mercaptopurine (Puri-Nethol®)), 6-thioguanine (ThioguanineTabloid®), fludarabine phosphate (Fludara®), pentostatin (Nipent®),pemetrexed (Alimta®), raltitrexed (Tomudex®), cladribine (Leustatin®),clofarabine (Clofarex®, Clolar®), mercaptopurine (Puri-Nethol®),capecitabine (Xeloda®), nelarabine (Arranon®), azacitidine (Vidaza®) andgemcitabine (Gemzar®). Preferred antimetabolites include, e.g.,5-fluorouracil (Adrucil®, Efudex®, Fluoroplex®), floxuridine (FUDF®),capecitabine (Xeloda®), pemetrexed (Alimta®), raltitrexed (Tomudex®) andgemcitabine (Gemzar®).

Exemplary alkylating agents include, without limitation, nitrogenmustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas andtriazenes): uracil mustard (Aminouracil Mustard®, Chlorethaminacil®,Demethyldopan®, Desmethyldopan®, Haemanthamine®, Nordopan®, Uracilnitrogen Mustard®, Uracillost®, Uracilmostaza®, Uramustin®,Uramustine®), chlormethine (Mustargen®), cyclophosphamide (Cytoxan®,Neosar®, Clafen®, Endoxan®, Procytox®, Revimmune™), ifosfamide(Mitoxana®), melphalan (Alkeran®), Chlorambucil (Leukeran®), pipobroman(Amedel®, Vercyte®), triethylenemelamine (Hemel®, Hexalen®, Hexastat®),triethylenethiophosphoramine, Temozolomide (Temodar®), thiotepa(Thioplex®), busulfan (Busilvex®, Myleran®), carmustine (BiCNU®),lomustine (CeeNU®), streptozocin (Zanosar®), and Dacarbazine(DTIC-Dome®). Additional exemplary alkylating agents include, withoutlimitation, Oxaliplatin (Eloxatin®); Temozolomide (Temodar® andTemodal®); Dactinomycin (also known as actinomycin-D, Cosmegen®);Melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard,Alkeran®); Altretamine (also known as hexamethylmelamine (HMM),Hexalen®); Carmustine (BiCNU®); Bendamustine (Treanda®); Busulfan(Busulfex® and Myleran®); Carboplatin (Paraplatin®); Lomustine (alsoknown as CCNU, CeeNU®); Cisplatin (also known as CDDP, Platinol® andPlatinol®-AQ); Chlorambucil (Leukeran®); Cyclophosphamide (Cytoxan® andNeosar®); Dacarbazine (also known as DTIC, DIC and imidazolecarboxamide, DTIC-Dome®); Altretamine (also known as hexamethylmelamine(HMM), Hexalen®); Ifosfamide (Ifex®); Prednumustine; Procarbazine(Matulane®); Mechlorethamine (also known as nitrogen mustard, mustineand mechloroethamine hydrochloride, Mustargen®); Streptozocin(Zanosar®); Thiotepa (also known as thiophosphoamide, TESPA and TSPA,Thioplex®); Cyclophosphamide (Endoxan®, Cytoxan®, Neosar®, Procytox®,Revimmune®); and Bendamustine HCl (Treanda®).

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with fludarabine, cyclophosphamide, and/orrituximab. In embodiments, a CAR-expressing cell described herein isadministered to a subject in combination with fludarabine,cyclophosphamide, and rituximab (FCR). In embodiments, the subject hasCLL. For example, the subject has a deletion in the short arm ofchromosome 17 (del(17p), e.g., in a leukemic cell). In other examples,the subject does not have a del(17p). In embodiments, the subjectcomprises a leukemic cell comprising a mutation in the immunoglobulinheavy-chain variable-region (IgVH) gene. In other embodiments, thesubject does not comprise a leukemic cell comprising a mutation in theimmunoglobulin heavy-chain variable-region (IgVH) gene. In embodiments,the fludarabine is administered at a dosage of about 10-50 mg/m² (e.g.,about 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, or 45-50 mg/m²),e.g., intravenously. In embodiments, the cyclophosphamide isadministered at a dosage of about 200-300 mg/m² (e.g., about 200-225,225-250, 250-275, or 275-300 mg/m²), e.g., intravenously. Inembodiments, the rituximab is administered at a dosage of about 400-600mg/m2 (e.g., 400-450, 450-500, 500-550, or 550-600 mg/m²), e.g.,intravenously.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with bendamustine and rituximab. Inembodiments, the subject has CLL. For example, the subject has adeletion in the short arm of chromosome 17 (del(17p), e.g., in aleukemic cell). In other examples, the subject does not have a del(17p).In embodiments, the subject comprises a leukemic cell comprising amutation in the immunoglobulin heavy-chain variable-region (IgVH) gene.In other embodiments, the subject does not comprise a leukemic cellcomprising a mutation in the immunoglobulin heavy-chain variable-region(IgVH) gene. In embodiments, the bendamustine is administered at adosage of about 70-110 mg/m2 (e.g., 70-80, 80-90, 90-100, or 100-110mg/m2), e.g., intravenously. In embodiments, the rituximab isadministered at a dosage of about 400-600 mg/m2 (e.g., 400-450, 450-500,500-550, or 550-600 mg/m²), e.g., intravenously.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with rituximab, cyclophosphamide,doxorubicine, vincristine, and/or a corticosteroid (e.g., prednisone).In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with rituximab, cyclophosphamide,doxorubicine, vincristine, and prednisone (R-CHOP). In embodiments, thesubject has diffuse large B-cell lymphoma (DLBCL). In embodiments, thesubject has nonbulky limited-stage DLBCL (e.g., comprises a tumor havinga size/diameter of less than 7 cm). In embodiments, the subject istreated with radiation in combination with the R-CHOP. For example, thesubject is administered R-CHOP (e.g., 1-6 cycles, e.g., 1, 2, 3, 4, 5,or 6 cycles of R-CHOP), followed by radiation. In some cases, thesubject is administered R-CHOP (e.g., 1-6 cycles, e.g., 1, 2, 3, 4, 5,or 6 cycles of R-CHOP) following radiation.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with etoposide, prednisone, vincristine,cyclophosphamide, doxorubicin, and/or rituximab. In embodiments, aCAR-expressing cell described herein is administered to a subject incombination with etoposide, prednisone, vincristine, cyclophosphamide,doxorubicin, and rituximab (EPOCH-R). In embodiments, a CAR-expressingcell described herein is administered to a subject in combination withdose-adjusted EPOCH-R (DA-EPOCH-R). In embodiments, the subject has a Bcell lymphoma, e.g., a Myc-rearranged aggressive B cell lymphoma.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with rituximab and/or lenalidomide.Lenalidomide ((RS)-3-(4-Amino-1-oxo1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione) is animmunomodulator. In embodiments, a CAR-expressing cell described hereinis administered to a subject in combination with rituximab andlenalidomide. In embodiments, the subject has follicular lymphoma (FL)or mantle cell lymphoma (MCL). In embodiments, the subject has FL andhas not previously been treated with a cancer therapy. In embodiments,lenalidomide is administered at a dosage of about 10-20 mg (e.g., 10-15or 15-20 mg), e.g., daily. In embodiments, rituximab is administered ata dosage of about 350-550 mg/m² (e.g., 350-375, 375-400, 400-425,425-450, 450-475, or 475-500 mg/m²), e.g., intravenously.

Exemplary mTOR inhibitors include, e.g., temsirolimus; ridaforolimus(formally known as deforolimus, (1R,2R,4S)-4-[(2R)-2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0^(4.9)]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyldimethylphosphinate, also known as AP23573 and MK8669, and described inPCT Publication No. WO 03/064383); everolimus (Afinitor® or RAD001);rapamycin (AY22989, Sirolimus®); simapimod (CAS 164301-51-3);emsirolimus,(5-{2,4-Bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol(AZD8055);2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one(PF04691502, CAS 1013101-36-4); andN²-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartylL-serine-,inner salt (SF1126, CAS 936487-67-1) (SEQ ID NO: 1316), and XL765.

Exemplary immunomodulators include, e.g., afutuzumab (available fromRoche®); pegfilgrastim (Neulasta®); lenalidomide (CC-5013, Revlimid®);thalidomide (Thalomid®), actimid (CC4047); and IRX-2 (mixture of humancytokines including interleukin 1, interleukin 2, and interferon γ, CAS951209-71-5, available from IRX Therapeutics).

Exemplary anthracyclines include, e.g., doxorubicin (Adriamycin® andRubex®); bleomycin (Lenoxane®); daunorubicin (dauorubicin hydrochloride,daunomycin, and rubidomycin hydrochloride, Cerubidine®); daunorubicinliposomal (daunorubicin citrate liposome, DaunoXome®); mitoxantrone(DHAD, Novantrone®); epirubicin (Ellence™); idarubicin (Idamycin®,Idamycin PFS®); mitomycin C (Mutamycin®); geldanamycin; herbimycin;ravidomycin; and desacetylravidomycin.

Exemplary vinca alkaloids include, e.g., vinorelbine tartrate(Navelbine®), Vincristine (Oncovin®), and Vindesine (Eldisine®));vinblastine (also known as vinblastine sulfate, vincaleukoblastine andVLB, Alkaban-AQ® and Velban®); and vinorelbine (Navelbine®).

Exemplary proteosome inhibitors include bortezomib (Velcade®);carfilzomib (PX-171-007,(S)-4-Methyl-N—((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-pentanamide);marizomib (NPI-0052); ixazomib citrate (MLN-9708); delanzomib(CEP-18770); and0-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-R1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide(ONX-0912).

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with brentuximab. Brentuximab is anantibody-drug conjugate of anti-CD30 antibody and monomethyl auristatinE. In embodiments, the subject has Hodgkin's lymphoma (HL), e.g.,relapsed or refractory HL. In embodiments, the subject comprises CD30+HL. In embodiments, the subject has undergone an autologous stem celltransplant (ASCT). In embodiments, the subject has not undergone anASCT. In embodiments, brentuximab is administered at a dosage of about1-3 mg/kg (e.g., about 1-1.5, 1.5-2, 2-2.5, or 2.5-3 mg/kg), e.g.,intravenously, e.g., every 3 weeks.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with brentuximab and dacarbazine or incombination with brentuximab and bendamustine. Dacarbazine is analkylating agent with a chemical name of5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide. Bendamustine is analkylating agent with a chemical name of4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid.In embodiments, the subject has Hodgkin's lymphoma (HL). In embodiments,the subject has not previously been treated with a cancer therapy. Inembodiments, the subject is at least 60 years of age, e.g., 60, 65, 70,75, 80, 85, or older. In embodiments, dacarbazine is administered at adosage of about 300-450 mg/m² (e.g., about 300-325, 325-350, 350-375,375-400, 400-425, or 425-450 mg/m²), e.g., intravenously. Inembodiments, bendamustine is administered at a dosage of about 75-125mg/m2 (e.g., 75-100 or 100-125 mg/m², e.g., about 90 mg/m²), e.g.,intravenously. In embodiments, brentuximab is administered at a dosageof about 1-3 mg/kg (e.g., about 1-1.5, 1.5-2, 2-2.5, or 2.5-3 mg/kg),e.g., intravenously, e.g., every 3 weeks.

In some embodiments, a CAR-expressing cell described herein isadministered to a subject in combination with a CD20 inhibitor, e.g., ananti-CD20 antibody (e.g., an anti-CD20 mono- or bispecific antibody) ora fragment thereof. Exemplary anti-CD20 antibodies include but are notlimited to rituximab, ofatumumab, ocrelizumab, veltuzumab, obinutuzumab,TRU-015 (Trubion Pharmaceuticals), ocaratuzumab, and Pro131921(Genentech). See, e.g., Lim et al. Haematologica. 95.1(2010):135-43.

In some embodiments, the anti-CD20 antibody comprises rituximab.Rituximab is a chimeric mouse/human monoclonal antibody IgG1 kappa thatbinds to CD20 and causes cytolysis of a CD20 expressing cell, e.g., asdescribed inaccessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Inembodiments, a CAR-expressing cell described herein is administered to asubject in combination with rituximab. In embodiments, the subject hasCLL or SLL.

In some embodiments, rituximab is administered intravenously, e.g., asan intravenous infusion. For example, each infusion provides about500-2000 mg (e.g., about 500-550, 550-600, 600-650, 650-700, 700-750,750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1100, 1100-1200,1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800,1800-1900, or 1900-2000 mg) of rituximab. In some embodiments, rituximabis administered at a dose of 150 mg/m² to 750 mg/m², e.g., about 150-175mg/m², 175-200 mg/m², 200-225 mg/m², 225-250 mg/m², 250-300 mg/m²,300-325 mg/m², 325-350 mg/m², 350-375 mg/m², 375-400 mg/m², 400-425mg/m², 425-450 mg/m², 450-475 mg/m², 475-500 mg/m², 500-525 mg/m²,525-550 mg/m², 550-575 mg/m², 575-600 mg/m², 600-625 mg/m², 625-650mg/m², 650-675 mg/m², or 675-700 mg/m2, where m² indicates the bodysurface area of the subject. In some embodiments, rituximab isadministered at a dosing interval of at least 4 days, e.g., 4, 7, 14,21, 28, 35 days, or more. For example, rituximab is administered at adosing interval of at least 0.5 weeks, e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8weeks, or more. In some embodiments, rituximab is administered at a doseand dosing interval described herein for a period of time, e.g., atleast 2 weeks, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20 weeks, or greater. For example, rituximab isadministered at a dose and dosing interval described herein for a totalof at least 4 doses per treatment cycle (e.g., at least 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, or more doses per treatment cycle).

In some embodiments, the anti-CD20 antibody comprises ofatumumab.Ofatumumab is an anti-CD20 IgG1κ human monoclonal antibody with amolecular weight of approximately 149 kDa. For example, ofatumumab isgenerated using transgenic mouse and hybridoma technology and isexpressed and purified from a recombinant murine cell line (NS0). See,e.g., accessdatafda.gov/drugsatfda_docs/label/2009/125326lbl.pdf; andClinical Trial Identifier number NCT01363128, NCT01515176, NCT01626352,and NCT01397591. In embodiments, a CAR-expressing cell described hereinis administered to a subject in combination with ofatumumab. Inembodiments, the subject has CLL or SLL.

In some embodiments, ofatumumab is administered as an intravenousinfusion. For example, each infusion provides about 150-3000 mg (e.g.,about 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500,500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900,900-950, 950-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800,1800-2000, 2000-2200, 2200-2400, 2400-2600, 2600-2800, or 2800-3000 mg)of ofatumumab. In embodiments, ofatumumab is administered at a startingdosage of about 300 mg, followed by 2000 mg, e.g., for about 11 doses,e.g., for 24 weeks. In some embodiments, ofatumumab is administered at adosing interval of at least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, ormore. For example, ofatumumab is administered at a dosing interval of atleast 1 week, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28,20, 22, 24, 26, 28, 30 weeks, or more. In some embodiments, ofatumumabis administered at a dose and dosing interval described herein for aperiod of time, e.g., at least 1 week, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 40, 50,60 weeks or greater, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months orgreater, or 1, 2, 3, 4, 5 years or greater. For example, ofatumumab isadministered at a dose and dosing interval described herein for a totalof at least 2 doses per treatment cycle (e.g., at least 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, or more doses per treatmentcycle).

In some cases, the anti-CD20 antibody comprises ocrelizumab. Ocrelizumabis a humanized anti-CD20 monoclonal antibody, e.g., as described inClinical Trials Identifier Nos. NCT00077870, NCT01412333, NCT00779220,NCT00673920, NCT01194570, and Kappos et al. Lancet.19.378(2011):1779-87.

In some cases, the anti-CD20 antibody comprises veltuzumab. Veltuzumabis a humanized monoclonal antibody against CD20. See, e.g., ClinicalTrial Identifier No. NCT00547066, NCT00546793, NCT01101581, andGoldenberg et al. Leuk Lymphoma. 51(5)(2010):747-55.

In some cases, the anti-CD20 antibody comprises GA101. GA101 (alsocalled obinutuzumab or R05072759) is a humanized and glyco-engineeredanti-CD20 monoclonal antibody. See, e.g., Robak. Curr. Opin. Investig.Drugs. 10.6(2009):588-96; Clinical Trial Identifier Numbers:NCT01995669, NCT01889797, NCT02229422, and NCT01414205; andaccessdata.fda.gov/drugsatfda_docs/label/2013/125486s000lbl.pdf.

In some cases, the anti-CD20 antibody comprises AME-133v. AME-133v (alsocalled LY2469298 or ocaratuzumab) is a humanized IgG1 monoclonalantibody against CD20 with increased affinity for the FcγRIIIa receptorand an enhanced antibody dependent cellular cytotoxicity (ADCC) activitycompared with rituximab. See, e.g., Robak et al. BioDrugs25.1(2011):13-25; and Forero-Torres et al. Clin Cancer Res.18.5(2012):1395-403.

In some cases, the anti-CD20 antibody comprises PRO131921. PRO131921 isa humanized anti-CD20 monoclonal antibody engineered to have betterbinding to FcγRIIIa and enhanced ADCC compared with rituximab. See,e.g., Robak et al. BioDrugs 25.1(2011):13-25; and Casulo et al. ClinImmunol. 154.1(2014):37-46; and Clinical Trial Identifier No.NCT00452127.

In some cases, the anti-CD20 antibody comprises TRU-015. TRU-015 is ananti-CD20 fusion protein derived from domains of an antibody againstCD20. TRU-015 is smaller than monoclonal antibodies, but retainsFc-mediated effector functions. See, e.g., Robak et al. BioDrugs25.1(2011):13-25. TRU-015 contains an anti-CD20 single-chain variablefragment (scFv) linked to human IgG1 hinge, CH2, and CH3 domains butlacks CH1 and CL domains.

In some embodiments, an anti-CD20 antibody described herein isconjugated or otherwise bound to a therapeutic agent, e.g., achemotherapeutic agent (e.g., cytoxan, fludarabine, histone deacetylaseinhibitor, demethylating agent, peptide vaccine, anti-tumor antibiotic,tyrosine kinase inhibitor, alkylating agent, anti-microtubule oranti-mitotic agent), anti-allergic agent, anti-nausea agent (oranti-emetic), pain reliever, or cytoprotective agent described herein.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with a B-cell lymphoma 2 (BCL-2) inhibitor(e.g., venetoclax, also called ABT-199 or GDC-0199) and/or rituximab. Inembodiments, a CAR-expressing cell described herein is administered to asubject in combination with venetoclax and rituximab. Venetoclax is asmall molecule that inhibits the anti-apoptotic protein, BCL-2. Thestructure of venetoclax(4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide)is shown below.

In embodiments, the subject has CLL. In embodiments, the subject hasrelapsed CLL, e.g., the subject has previously been administered acancer therapy. In embodiments, venetoclax is administered at a dosageof about 15-600 mg (e.g., 15-20, 20-50, 50-75, 75-100, 100-200, 200-300,300-400, 400-500, or 500-600 mg), e.g., daily. In embodiments, rituximabis administered at a dosage of about 350-550 mg/m2 (e.g., 350-375,375-400, 400-425, 425-450, 450-475, or 475-500 mg/m2), e.g.,intravenously, e.g., monthly.

In some embodiments, one or more CAR-expressing cells described hereinis administered in combination with an oncolytic virus. In embodiments,oncolytic viruses are capable of selectively replicating in andtriggering the death of or slowing the growth of a cancer cell. In somecases, oncolytic viruses have no effect or a minimal effect onnon-cancer cells. An oncolytic virus includes but is not limited to anoncolytic adenovirus, oncolytic Herpes Simplex Viruses, oncolyticretrovirus, oncolytic parvovirus, oncolytic vaccinia virus, oncolyticSinbis virus, oncolytic influenza virus, or oncolytic RNA virus (e.g.,oncolytic reovirus, oncolytic Newcastle Disease Virus (NDV), oncolyticmeasles virus, or oncolytic vesicular stomatitis virus (VSV)).

In some embodiments, the oncolytic virus is a virus, e.g., recombinantoncolytic virus, described in US2010/0178684 A1, which is incorporatedherein by reference in its entirety. In some embodiments, a recombinantoncolytic virus comprises a nucleic acid sequence (e.g., heterologousnucleic acid sequence) encoding an inhibitor of an immune orinflammatory response, e.g., as described in US2010/0178684 A1,incorporated herein by reference in its entirety. In embodiments, therecombinant oncolytic virus, e.g., oncolytic NDV, comprises apro-apoptotic protein (e.g., apoptin), a cytokine (e.g., GM-CSF,interferon-gamma, interleukin-2 (IL-2), tumor necrosis factor-alpha), animmunoglobulin (e.g., an antibody against ED-B firbonectin), tumorassociated antigen, a bispecific adapter protein (e.g., bispecificantibody or antibody fragment directed against NDV HN protein and a Tcell co-stimulatory receptor, such as CD3 or CD28; or fusion proteinbetween human IL-2 and single chain antibody directed against NDV HNprotein). See, e.g., Zamarin et al. Future Microbiol. 7.3(2012):347-67,incorporated herein by reference in its entirety. In some embodiments,the oncolytic virus is a chimeric oncolytic NDV described in U.S. Pat.No. 8,591,881 B2, US 2012/0122185 A1, or US 2014/0271677 A1, each ofwhich is incorporated herein by reference in their entireties.

In some embodiments, the oncolytic virus comprises a conditionallyreplicative adenovirus (CRAd), which is designed to replicateexclusively in cancer cells. See, e.g., Alemany et al. NatureBiotechnol. 18(2000):723-27. In some embodiments, an oncolyticadenovirus comprises one described in Table 1 on page 725 of Alemany etal., incorporated herein by reference in its entirety.

Exemplary oncolytic viruses include but are not limited to thefollowing:

-   -   Group B Oncolytic Adenovirus (ColoAd1) (PsiOxus Therapeutics        Ltd.) (see, e.g., Clinical Trial Identifier: NCT02053220);    -   ONCOS-102 (previously called CGTG-102), which is an adenovirus        comprising granulocyte-macrophage colony stimulating factor        (GM-CSF) (Oncos Therapeutics) (see, e.g., Clinical Trial        Identifier: NCT01598129);    -   VCN-01, which is a genetically modified oncolytic human        adenovirus encoding human PH20 hyaluronidase (VCN Biosciences,        S.L.) (see, e.g., Clinical Trial Identifiers: NCT02045602 and        NCT02045589);    -   Conditionally Replicative Adenovirus ICOVIR-5, which is a virus        derived from wild-type human adenovirus serotype 5 (Had5) that        has been modified to selectively replicate in cancer cells with        a deregulated retinoblastoma/E2F pathway (Institut Català        d'Oncologia) (see, e.g., Clinical Trial Identifier:        NCT01864759);    -   Celyvir, which comprises bone marrow-derived autologous        mesenchymal stem cells (MSCs) infected with ICOVIR5, an        oncolytic adenovirus (Hospital Infantil Universitario Nino        Jesús, Madrid, Spain/Ramon Alemany) (see, e.g., Clinical Trial        Identifier: NCT01844661);    -   CG0070, which is a conditionally replicating oncolytic serotype        5 adenovirus (Ad5) in which human E2F-1 promoter drives        expression of the essential Ela viral genes, thereby restricting        viral replication and cytotoxicity to Rb pathway-defective tumor        cells (Cold Genesys, Inc.) (see, e.g., Clinical Trial        Identifier: NCT02143804); or    -   DNX-2401 (formerly named Delta-24-RGD), which is an adenovirus        that has been engineered to replicate selectively in        retinoblastoma (Rb)-pathway deficient cells and to infect cells        that express certain RGD-binding integrins more efficiently        (Clinica Universidad de Navarra, Universidad de Navarra/DNAtrix,        Inc.) (see, e.g., Clinical Trial Identifier: NCT01956734).

In some embodiments, an oncolytic virus described herein isadministering by injection, e.g., subcutaneous, intra-arterial,intravenous, intramuscular, intrathecal, or intraperitoneal injection.In embodiments, an oncolytic virus described herein is administeredintratumorally, transdermally, transmucosally, orally, intranasally, orvia pulmonary administration.

In an embodiment, cells expressing a CAR described herein areadministered to a subject in combination with a molecule that decreasesthe Treg cell population. Methods that decrease the number of (e.g.,deplete) Treg cells are known in the art and include, e.g., CD25depletion, cyclophosphamide administration, modulating GITR function.Without wishing to be bound by theory, it is believed that reducing thenumber of Treg cells in a subject prior to apheresis or prior toadministration of a CAR-expressing cell described herein reduces thenumber of unwanted immune cells (e.g., Tregs) in the tumormicroenvironment and reduces the subject's risk of relapse.

In an embodiment, a CAR-expressing cell described herein is administeredto a subject in combination with a molecule that decreases the Treg cellpopulation. Methods that decrease the number of (e.g., deplete) Tregcells are known in the art and include, e.g., CD25 depletion,cyclophosphamide administration, and modulating GITR function. Withoutwishing to be bound by theory, it is believed that reducing the numberof Treg cells in a subject prior to apheresis or prior to administrationof a CAR-expressing cell described herein reduces the number of unwantedimmune cells (e.g., Tregs) in the tumor microenvironment and reduces thesubject's risk of relapse. In one embodiment, CAR-expressing cellsdescribed herein are administered to a subject in combination with amolecule targeting GITR and/or modulating GITR functions, such as a GITRagonist and/or a GITR antibody that depletes regulatory T cells (Tregs).In one embodiment, CAR-expressing cells described herein areadministered to a subject in combination with cyclophosphamide. In oneembodiment, the GITR binding molecule and/or molecule modulating GITRfunction (e.g., GITR agonist and/or Treg depleting GITR antibodies) isadministered prior to the CAR-expressing cells. For example, in oneembodiment, the GITR agonist can be administered prior to apheresis ofthe cells. In embodiments, cyclophosphamide is administered to thesubject prior to administration (e.g., infusion or re-infusion) of theCAR-expressing cell or prior to apheresis of the cells. In embodiments,cyclophosphamide and an anti-GITR antibody are administered to thesubject prior to administration (e.g., infusion or re-infusion) of theCAR-expressing cell or prior to apheresis of the cells. In oneembodiment, the subject has cancer (e.g., a solid cancer or ahematological cancer such as ALL or CLL). In one embodiment, the subjecthas CLL. In embodiments, the subject has a solid cancer, e.g., a solidcancer described herein.

In one embodiment, the combination of a CD19 CAR expressing celldescribed herein and one or more B-cell inhibitor described herein isadministered to a subject in combination with a GITR agonist, e.g., aGITR agonist described herein. In one embodiment, the GITR agonist isadministered prior to the CAR-expressing cell, e.g., CD19 CAR-expressingcells. For example, in one embodiment, the GITR agonist can beadministered prior to apheresis of the cells. In one embodiment, thesubject has CLL.

In one embodiment, a CAR expressing cell described herein isadministered to a subject in combination with a GITR agonist, e.g., aGITR agonist described herein. In one embodiment, the GITR agonist isadministered prior to the CAR-expressing cell. For example, in oneembodiment, the GITR agonist can be administered prior to apheresis ofthe cells.

Exemplary GITR agonists include, e.g., GITR fusion proteins andanti-GITR antibodies (e.g., bivalent anti-GITR antibodies) such as,e.g., a GITR fusion protein described in U.S. Pat. No. 6,111,090,European Patent No.: 090505B1, U.S. Pat. No. 8,586,023, PCT PublicationNos.: WO 2010/003118 and 2011/090754, or an anti-GITR antibodydescribed, e.g., in U.S. Pat. No. 7,025,962, European Patent No.:1947183B1, U.S. Pat. Nos. 7,812,135, 8,388,967, 8,591,886, EuropeanPatent No.: EP 1866339, PCT Publication No.: WO 2011/028683, PCTPublication No.: WO 2013/039954, PCT Publication No.: WO2005/007190, PCTPublication No.: WO 2007/133822, PCT Publication No.: WO2005/055808, PCTPublication No.: WO 99/40196, PCT Publication No.: WO 2001/03720, PCTPublication No.: WO99/20758, PCT Publication No.: WO2006/083289, PCTPublication No.: WO 2005/115451, U.S. Pat. No. 7,618,632, and PCTPublication No.: WO 2011/051726.

In one embodiment, a CAR expressing cell described herein isadministered to a subject in combination with a protein tyrosinephosphatase inhibitor, e.g., a protein tyrosine phosphatase inhibitordescribed herein. In one embodiment, the protein tyrosine phosphataseinhibitor is an SHP-1 inhibitor, e.g., an SHP-1 inhibitor describedherein, such as, e.g., sodium stibogluconate. In one embodiment, theprotein tyrosine phosphatase inhibitor is an SHP-2 inhibitor, e.g., anSHP-2 inhibitor described herein.

In one embodiment, a CAR-expressing cell described herein optionally incombination with one or more B-cell inhibitor can be used in combinationwith a kinase inhibitor. In one embodiment, the kinase inhibitor is aCDK4 inhibitor, e.g., a CDK4 inhibitor described herein, e.g., a CD4/6inhibitor, such as, e.g.,6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one,hydrochloride (also referred to as palbociclib or PD0332991). In oneembodiment, the kinase inhibitor is a BTK inhibitor, e.g., a BTKinhibitor described herein, such as, e.g., ibrutinib. In one embodiment,the kinase inhibitor is an mTOR inhibitor, e.g., an mTOR inhibitordescribed herein, such as, e.g., rapamycin, a rapamycin analog, OSI-027.The mTOR inhibitor can be, e.g., an mTORC1 inhibitor and/or an mTORC2inhibitor, e.g., an mTORC1 inhibitor and/or mTORC2 inhibitor describedherein. In one embodiment, the kinase inhibitor is a MNK inhibitor,e.g., a MNK inhibitor described herein, such as, e.g.,4-amino-5-(4-fluoroanilino)-pyrazolo[3,4-d] pyrimidine. The MNKinhibitor can be, e.g., a MNK1a, MNK1b, MNK2a and/or MNK2b inhibitor.

In one embodiment, the kinase inhibitor is a CDK4 inhibitor selectedfrom aloisine A; flavopiridol or HMR-1275,2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone;crizotinib (PF-02341066;2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one,hydrochloride (P276-00);1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine(RAF265); indisulam (E7070); roscovitine (CYC202); palbociclib(PD0332991); dinaciclib (SCH727965);N-[5-[[(5-tert-butyloxazol-2-yl)methyl]thio]thiazol-2-yl]piperidine-4-carboxamide(BMS 387032);4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-benzoicacid (MLN8054);5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-pyridinemethanamine(AG-024322); 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acidN-(piperidin-4-yl)amide (AT7519);4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine(AZD5438); and XL281 (BMS908662).

In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g.,palbociclib (PD0332991), and the palbociclib is administered at a doseof about 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 105 mg, 110mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg (e.g., 75 mg, 100 mg or 125mg) daily for a period of time, e.g., daily for 14-21 days of a 28 daycycle, or daily for 7-12 days of a 21 day cycle. In one embodiment, 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of palbociclib areadministered.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with a cyclin-dependent kinase (CDK) 4 or 6inhibitor, e.g., a CDK4 inhibitor or a CDK6 inhibitor described herein.In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with a CDK4/6 inhibitor (e.g., an inhibitorthat targets both CDK4 and CDK6), e.g., a CDK4/6 inhibitor describedherein. In an embodiment, the subject has MCL. MCL is an aggressivecancer that is poorly responsive to currently available therapies, i.e.,essentially incurable. In many cases of MCL, cyclin D1 (a regulator ofCDK4/6) is expressed (e.g., due to chromosomal translocation involvingimmunoglobulin and Cyclin D1 genes) in MCL cells. Thus, without beingbound by theory, it is thought that MCL cells are highly sensitive toCDK4/6 inhibition with high specificity (i.e., minimal effect on normalimmune cells). CDK4/6 inhibitors alone have had some efficacy intreating MCL, but have only achieved partial remission with a highrelapse rate. An exemplary CDK4/6 inhibitor is LEE011 (also calledribociclib), the structure of which is shown below.

Without being bound by theory, it is believed that administration of aCAR-expressing cell described herein with a CDK4/6 inhibitor (e.g.,LEE011 or other CDK4/6 inhibitor described herein) can achieve higherresponsiveness, e.g., with higher remission rates and/or lower relapserates, e.g., compared to a CDK4/6 inhibitor alone.

In one embodiment, the kinase inhibitor is a BTK inhibitor selected fromibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224;CC-292; ONO-4059; CNX-774; and LFM-A13. In an embodiment, the BTKinhibitor does not reduce or inhibit the kinase activity ofinterleukin-2-inducible kinase (ITK), and is selected from GDC-0834;RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; andLFM-A13.

In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g.,ibrutinib (PCI-32765). In embodiments, a CAR-expressing cell describedherein is administered to a subject in combination with a BTK inhibitor(e.g., ibrutinib). In embodiments, a CAR-expressing cell describedherein is administered to a subject in combination with ibrutinib (alsocalled PCI-32765). The structure of ibrutinib(1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one)is shown below.

In embodiments, the subject has CLL, mantle cell lymphoma (MCL), orsmall lymphocytic lymphoma (SLL). For example, the subject has adeletion in the short arm of chromosome 17 (del(17p), e.g., in aleukemic cell). In other examples, the subject does not have a del(17p).In embodiments, the subject has relapsed CLL or SLL, e.g., the subjecthas previously been administered a cancer therapy (e.g., previously beenadministered one, two, three, or four prior cancer therapies). Inembodiments, the subject has refractory CLL or SLL. In otherembodiments, the subject has follicular lymphoma, e.g., relapse orrefractory follicular lymphoma. In one embodiment, the kinase inhibitoris a BTK inhibitor, e.g., ibrutinib (PCI-32765), and the ibrutinib isadministered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg,440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg(e.g., 250 mg, 420 mg or 560 mg) daily for a period of time, e.g., dailyfor 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib areadministered. In some embodiments, ibrutinib is administered incombination with rituximab. See, e.g., Burger et al. (2013) Ibrutinib InCombination With Rituximab (iR) Is Well Tolerated and Induces a HighRate Of Durable Remissions In Patients With High-Risk ChronicLymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In40 Patients, Abstract 675 presented at 55^(th) ASH Annual Meeting andExposition, New Orleans, LA 7-10 December Without being bound by theory,it is thought that the addition of ibrutinib enhances the T cellproliferative response and may shift T cells from a T-helper-2 (Th2) toT-helper-1 (Th1) phenotype. Th1 and Th2 are phenotypes of helper Tcells, with Th1 versus Th2 directing different immune response pathways.A Th1 phenotype is associated with proinflammatory responses, e.g., forkilling cells, such as intracellular pathogens/viruses or cancerouscells, or perpetuating autoimmune responses. A Th2 phenotype isassociated with eosinophil accumulation and anti-inflammatory responses.In some embodiments of the methods, uses, and compositions herein, theBTK inhibitor is a BTK inhibitor described in International ApplicationWO/2015/079417, which is herein incorporated by reference in itsentirety. For instance, in some embodiments, the BTK inhibitor is acompound of formula (I) or a pharmaceutically acceptable salt thereof;

wherein,

-   -   R1 is hydrogen, C1-C6 alkyl optionally substituted by hydroxy;    -   R2 is hydrogen or halogen;    -   R3 is hydrogen or halogen;    -   R4 is hydrogen;    -   R5 is hydrogen or halogen;    -   or R4 and R5 are attached to each other and stand for a bond,        —CH2-, —CH2-CH2-, —CH═CH—, —CH═CH—CH2-; —CH2-CH═CH—; or        —CH2-CH2-CH2-;    -   R6 and R7 stand independently from each other for H, C1-C6 alkyl        optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally        substituted by halogen or hydroxy, or halogen;    -   R8, R9, R, R′, R10 and R11 independently from each other stand        for H, or C1-C6 alkyl optionally substituted by C1-C6 alkoxy; or        any two of R8, R9, R, R′, R10 and R11 together with the carbon        atom to which they are bound may form a 3-6 membered saturated        carbocyclic ring;    -   R12 is hydrogen or C1-C6 alkyl optionally substituted by halogen        or C1-C6 alkoxy;    -   or R12 and any one of R8, R9, R, R′, R10 or R11 together with        the atoms to which they are bound may form a 4, 5, 6 or 7        membered azacyclic ring, which ring may optionally be        substituted by halogen, cyano, hydroxyl, C1-C6 alkyl or C1-C6        alkoxy;    -   n is 0 or 1; and    -   R13 is C2-C₆ alkenyl optionally substituted by C1-C6 alkyl,        C1-C6 alkoxy or N,N-di-C1-C6 alkyl amino; C2-C₆ alkynyl        optionally substituted by C1-C6 alkyl or C1-C6 alkoxy; or C2-C₆        alkylenyl oxide optionally substituted by C1-C6 alkyl.

In some embodiments, the BTK inhibitor of Formula I is chosen from:N-(3-(5-((1-Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(E)-N-(3-(6-Amino-5-((1-(but-2-enoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-((1-propioloylazetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-((1-(but-2-ynoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(5-((1-Acryloylpiperidin-4-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(E)-N-(3-(6-Amino-5-(2-(N-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(2-(N-methylpropiolamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(E)-N-(3-(6-Amino-5-(2-(4-methoxy-N-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(2-(N-methylbut-2-ynamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(2-((4-Amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2-methylphenyl)pyrimidin-5-yl)oxy)ethyl)-N-methyloxirane-2-carboxamide;N-(2-((4-Amino-6-(3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)phenyl)pyrimidin-5-yl)oxy)ethyl)-N-methylacrylamide;N-(3-(5-(2-Acrylamidoethoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(2-(N-ethylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(2-(N-(2-fluoroethyl)acrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(5-((1-Acrylamidocyclopropyl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)-N-(3-(5-(2-Acrylamidopropoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)—N-(3-(6-Amino-5-(2-(but-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)—N-(3-(6-Amino-5-(2-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)—N-(3-(6-Amino-5-(2-(N-methylbut-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(3-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)—N-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)—N-(3-(6-Amino-5-((1-(but-2-ynoyl)pyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)-2-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;N-(2-((4-Amino-6-(3-(6-cyclopropyl-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-5-fluoro-2-(hydroxymethyl)phenyl)pyrimidin-5-yl)oxy)ethyl)-N-methylacrylamide;N-(3-(5-4(2S,4R)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;2-(3-(5-(((2S,4R)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;N-(3-(5-(((2S,4S)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(((2S,4S)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(5-(((2S,4R)-1-Acryloyl-4-fluoropyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-fluoropyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)—N-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)—N-(3-(6-Amino-5-((1-propioloylazetidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(S)-2-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;(R)-N-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;(R)-N-(3-(5-((1-Acryloylpiperidin-3-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(5-(((2R,3S)-1-Acryloyl-3-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;N-(3-(5-(((2S,4R)-1-Acryloyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;orN-(3-(5-(((2S,4S)-1-Acryloyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide.

Unless otherwise provided, the chemical terms used above in describingthe BTK inhibitor of Formula I are used according to their meanings asset out in International Application WO/2015/079417, which is hereinincorporated by reference in its entirety.

In one embodiment, the kinase inhibitor is an mTOR inhibitor selectedfrom temsirolimus; ridaforolimus (1R,2R,4S)-4-[(2R)-2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0^(4.9)]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyldimethylphosphinate, also known as AP23573 and MK8669; everolimus(RAD001); rapamycin (AY22989); simapimod; (542,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol(AZD8055);2-amino-8-[frans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one(PF04691502); andN²-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartylL-serine-,inner salt (SF1126) (SEQ ID NO: 1316); and XL765.

In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g.,rapamycin, and the rapamycin is administered at a dose of about 3 mg, 4mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (e.g., 6 mg) daily for a periodof time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In oneembodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles ofrapamycin are administered. In one embodiment, the kinase inhibitor isan mTOR inhibitor, e.g., everolimus and the everolimus is administeredat a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (e.g., 10 mg) daily for aperiod of time, e.g., daily for 28 day cycle. In one embodiment, 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of everolimus areadministered.

In one embodiment, the kinase inhibitor is an MNK inhibitor selectedfrom CGP052088;4-amino-3-(p-fluorophenylamino)-pyrazolo[3,4-d]pyrimidine (CGP57380);cercosporamide; ETC-1780445-2; and4-amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with a phosphoinositide 3-kinase (PI3K)inhibitor (e.g., a PI3K inhibitor described herein, e.g., idelalisib orduvelisib) and/or rituximab. In embodiments, a CAR-expressing celldescribed herein is administered to a subject in combination withidelalisib and rituximab. In embodiments, a CAR-expressing celldescribed herein is administered to a subject in combination withduvelisib and rituximab. Idelalisib (also called GS-1101 or CAL-101;Gilead) is a small molecule that blocks the delta isoform of PI3K. Thestructure of idelalisib(5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone)is shown below.

Duvelisib (also called IPI-145; Infinity Pharmaceuticals and Abbvie) isa small molecule that blocks PI3K-δ,γ. The structure of duvelisib(8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone)is shown below.

In embodiments, the subject has CLL. In embodiments, the subject hasrelapsed CLL, e.g., the subject has previously been administered acancer therapy (e.g., previously been administered an anti-CD20 antibodyor previously been administered ibrutinib). For example, the subject hasa deletion in the short arm of chromosome 17 (del(17p), e.g., in aleukemic cell). In other examples, the subject does not have a del(17p).In embodiments, the subject comprises a leukemic cell comprising amutation in the immunoglobulin heavy-chain variable-region (IgVH) gene.In other embodiments, the subject does not comprise a leukemic cellcomprising a mutation in the immunoglobulin heavy-chain variable-region(IgVH) gene. In embodiments, the subject has a deletion in the long armof chromosome 11 (del(11q)). In other embodiments, the subject does nothave a del(11q). In embodiments, idelalisib is administered at a dosageof about 100-400 mg (e.g., 100-125, 125-150, 150-175, 175-200, 200-225,225-250, 250-275, 275-300, 325-350, 350-375, or 375-400 mg), e.g., BID.In embodiments, duvelisib is administered at a dosage of about 15-100 mg(e.g., about 15-25, 25-50, 50-75, or 75-100 mg), e.g., twice a day. Inembodiments, rituximab is administered at a dosage of about 350-550mg/m² (e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500mg/m²), e.g., intravenously.

In one embodiment, the kinase inhibitor is a dual phosphatidylinositol3-kinase (PI3K) and mTOR inhibitor selected from2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one(PF-04691502);N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea(PF-05212384, PKI-587);2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile(BEZ-235); apitolisib (GDC-0980, RG7422);2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide(GSK2126458);8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-oneMaleic acid (NVP-BGT226);3-[4-(4-Morpholinylpyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl]phenol103);5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine(VS-5584, SB2343); andN-[2-[(3,5-Dimethoxyphenyl)amino]quinoxalin-3-yl]-4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide(XL765).

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with an anaplastic lymphoma kinase (ALK)inhibitor. Exemplary ALK kinases include but are not limited tocrizotinib (Pfizer), ceritinib (Novartis), alectinib (Chugai),brigatinib (also called AP26113; Ariad), entrectinib (Ignyta),PF-06463922 (Pfizer), TSR-011 (Tesaro) (see, e.g., Clinical TrialIdentifier No. NCT02048488), CEP-37440 (Teva), and X-396 (Xcovery). Insome embodiments, the subject has a solid cancer, e.g., a solid cancerdescribed herein, e.g., lung cancer.

The chemical name of crizotinib is3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine.The chemical name of ceritinib is5-Chloro-N²-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N⁴-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine.The chemical name of alectinib is9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile.The chemical name of brigatinib is5-Chloro-N²-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-N⁴-[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine.The chemical name of entrectinib isN-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide.The chemical name of PF-06463922 is(10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile.The chemical structure of CEP-37440 is(S)-2-((5-chloro-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide.The chemical name of X-396 is(R)-6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide.

In one embodiment, the kinase inhibitor is an ITK inhibitor selectedfrom ibrutinib;N-(5-(5-(4-Acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenylthio)thiazol-2-yl)-4-((3,3-dimethylbutan-2-ylamino)methyl)benzamide(BMS-509744);7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin-4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one (CTA056);R)-3-(1-(1-Acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-methyl-4-(1-methylethyl))benzamide(PF-06465469).

Drugs that inhibit either the calcium dependent phosphatase calcineurin(cyclosporine and FK506) or inhibit the p70S6 kinase that is importantfor growth factor induced signaling (rapamycin). (Liu et al., Cell66:807-815, 1991; Henderson et al., Immun. 73:316-321, 1991; Bierer etal., Curr. Opin. Immun. 5:763-773, 1993) can also be used. In a furtheraspect, the cell compositions of the present invention may beadministered to a patient in conjunction with (e.g., before,simultaneously or following) bone marrow transplantation, T cellablative therapy using chemotherapy agents such as, fludarabine,external-beam radiation therapy (XRT), cyclophosphamide, and/orantibodies such as OKT3 or CAMPATH. In one aspect, the cell compositionsof the present invention are administered following B-cell ablativetherapy such as agents that react with CD20, e.g., Rituxan. For example,in one embodiment, subjects may undergo standard treatment with highdose chemotherapy followed by peripheral blood stem celltransplantation. In certain embodiments, following the transplant,subjects receive an infusion of the expanded immune cells of the presentinvention. In an additional embodiment, expanded cells are administeredbefore or following surgery.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with an indoleamine 2,3-dioxygenase (IDO)inhibitor. IDO is an enzyme that catalyzes the degradation of the aminoacid, L-tryptophan, to kynurenine. Many cancers overexpress IDO, e.g.,prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head, andlung cancer. pDCs, macrophages, and dendritic cells (DCs) can expressIDO. Without being bound by theory, it is thought that a decrease inL-tryptophan (e.g., catalyzed by IDO) results in an immunosuppressivemilieu by inducing T-cell anergy and apoptosis. Thus, without beingbound by theory, it is thought that an IDO inhibitor can enhance theefficacy of a CAR-expressing cell described herein, e.g., by decreasingthe suppression or death of a CAR-expressing immune cell. Inembodiments, the subject has a solid tumor, e.g., a solid tumordescribed herein, e.g., prostatic, colorectal, pancreatic, cervical,gastric, ovarian, head, or lung cancer. Exemplary inhibitors of IDOinclude but are not limited to 1-methyl-tryptophan, indoximod (NewLinkGenetics) (see, e.g., Clinical Trial Identifier Nos. NCT01191216;NCT01792050), and INCB024360 (Incyte Corp.) (see, e.g., Clinical TrialIdentifier Nos. NCT01604889; NCT01685255)

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with a modulator of myeloid-derivedsuppressor cells (MDSCs). MDSCs accumulate in the periphery and at thetumor site of many solid tumors. These cells suppress T cell responses,thereby hindering the efficacy of CAR-expressing cell therapy. Withoutbeing bound by theory, it is thought that administration of a MDSCmodulator enhances the efficacy of a CAR-expressing cell describedherein. In an embodiment, the subject has a solid tumor, e.g., a solidtumor described herein, e.g., glioblastoma. Exemplary modulators ofMDSCs include but are not limited to MCS110 and BLZ945. MCS110 is amonoclonal antibody (mAb) against macrophage colony-stimulating factor(M-CSF). See, e.g., Clinical Trial Identifier No. NCT00757757. BLZ945 isa small molecule inhibitor of colony stimulating factor 1 receptor(CSF1R). See, e.g., Pyonteck et al. Nat. Med. 19(2013):1264-72. Thestructure of BLZ945 is shown below.

In embodiments, a CAR-expressing cell described herein is administeredto a subject in combination with a CD19 CART cell (e.g., CTL019, e.g.,as described in WO2012/079000, incorporated herein by reference). Inembodiments, the subject has acute myeloid leukemia (AML), e.g., a CD19positive AML or a CD19 negative AML. In embodiments, the subject has aCD19+ lymphoma, e.g., a CD19+ Non-Hodgkin's Lymphoma (NHL), a CD19+ FL,or a CD19+ DLBCL. In embodiments, the subject has a relapsed orrefractory CD19+ lymphoma. In embodiments, a lymphodepletingchemotherapy is administered to the subject prior to, concurrently with,or after administration (e.g., infusion) of CD19 CART cells. In anexample, the lymphodepleting chemotherapy is administered to the subjectprior to administration of CD19 CART cells. For example, thelymphodepleting chemotherapy ends 1-4 days (e.g., 1, 2, 3, or 4 days)prior to CD19 CART cell infusion. In embodiments, multiple doses of CD19CART cells are administered, e.g., as described herein. For example, asingle dose comprises about 5×10⁸ CD19 CART cells. In embodiments, alymphodepleting chemotherapy is administered to the subject prior to,concurrently with, or after administration (e.g., infusion) of aCAR-expressing cell described herein, e.g., a non-CD19 CAR-expressingcell. In embodiments, a CD19 CART is administered to the subject priorto, concurrently with, or after administration (e.g., infusion) of anon-CD19 CAR-expressing cell, e.g., a non-CD19 CAR-expressing celldescribed herein.

In some embodiments, a CAR-expressing cell described herein isadministered to a subject in combination with a CD19 CAR-expressingcell, e.g., CTL019, e.g., as described in WO2012/079000, incorporatedherein by reference, for treatment of a disease associated with theexpression of CLL-1, e.g., a cancer described herein. Without beingbound by theory, it is believed that administering a CD19 CAR-expressingcell in combination with a CAR-expressing cell improves the efficacy ofa CAR-expressing cell described herein by targeting early lineage cancercells, e.g., cancer stem cells, modulating the immune response,depleting regulatory B cells, and/or improving the tumormicroenvironment. For example, a CD19 CAR-expressing cell targets cancercells that express early lineage markers, e.g., cancer stem cells andCD19-expressing cells, while the CAR-expressing cell described hereintargets cancer cells that express later lineage markers, e.g., CLL-1.This preconditioning approach can improve the efficacy of theCAR-expressing cell described herein. In such embodiments, the CD19CAR-expressing cell is administered prior to, concurrently with, orafter administration (e.g., infusion) of a CAR-expressing cell describedherein.

In embodiments, a CAR-expressing cell described herein also expresses aCAR targeting CD19, e.g., a CD19 CAR. In an embodiment, the cellexpressing a CAR described herein and a CD19 CAR is administered to asubject for treatment of a cancer described herein, e.g., AML. In anembodiment, the configurations of one or both of the CAR moleculescomprise a primary intracellular signaling domain and a costimulatorysignaling domain. In another embodiment, the configurations of one orboth of the CAR molecules comprise a primary intracellular signalingdomain and two or more, e.g., 2, 3, 4, or 5 or more, costimulatorysignaling domains. In such embodiments, the CAR molecule describedherein and the CD19 CAR may have the same or a different primaryintracellular signaling domain, the same or different costimulatorysignaling domains, or the same number or a different number ofcostimulatory signaling domains. Alternatively, the CAR described hereinand the CD19 CAR are configured as a split CAR, in which one of the CARmolecules comprises an antigen binding domain and a costimulatory domain(e.g., 4-1BB), while the other CAR molecule comprises an antigen bindingdomain and a primary intracellular signaling domain (e.g., CD3 zeta).

In some embodiments, a CAR-expressing cell described herein isadministered to a subject in combination with a interleukin-15 (IL-15)polypeptide, a interleukin-15 receptor alpha (IL-15Ra) polypeptide, or acombination of both a IL-15 polypeptide and a IL-15Ra polypeptide e.g.,hetIL-15 (Admune Therapeutics, LLC). hetIL-15 is a heterodimericnon-covalent complex of IL-15 and IL-15Ra. hetIL-15 is described in,e.g., U.S. Pat. No. 8,124,084, U.S. 2012/0177598, U.S. 2009/0082299,U.S. 2012/0141413, and U.S. 2011/0081311, incorporated herein byreference. In embodiments, het-IL-15 is administered subcutaneously. Inembodiments, the subject has a cancer, e.g., solid cancer, e.g.,melanoma or colon cancer. In embodiments, the subject has a metastaticcancer.

In embodiments, a subject having a disease described herein, e.g., ahematological disorder, e.g., AML or MDS, is administered aCAR-expressing cell described herein in combination with an agent, e.g.,cytotoxic or chemotherapy agent, a biologic therapy (e.g., antibody,e.g., monoclonal antibody, or cellular therapy), or an inhibitor (e.g.,kinase inhibitor). In embodiments, the subject is administered aCAR-expressing cell described herein in combination with a cytotoxicagent, e.g., CPX-351 (Celator Pharmaceuticals), cytarabine,daunorubicin, vosaroxin (Sunesis Pharmaceuticals), sapacitabine(Cyclacel Pharmaceuticals), idarubicin, or mitoxantrone. CPX-351 is aliposomal formulation comprising cytarabine and daunorubicin at a 5:1molar ratio. In embodiments, the subject is administered aCAR-expressing cell described herein in combination with ahypomethylating agent, e.g., a DNA methyltransferase inhibitor, e.g.,azacitidine or decitabine. In embodiments, the subject is administered aCAR-expressing cell described herein in combination with a biologictherapy, e.g., an antibody or cellular therapy, e.g., 225Ac-lintuzumab(Actimab-A; Actinium Pharmaceuticals), IPH2102 (Innate Pharma/BristolMyers Squibb), SGN-CD33A (Seattle Genetics), or gemtuzumab ozogamicin(Mylotarg; Pfizer). SGN-CD33A is an antibody-drug conjugate (ADC)comprising a pyrrolobenzodiazepine dimer that is attached to ananti-CD33 antibody. Actimab-A is an anti-CD33 antibody (lintuzumab)labeled with actinium. IPH2102 is a monoclonal antibody that targetskiller immunoglobulin-like receptors (KIRs). In embodiments, the subjectis administered a CAR-expressing cell described herein in combination aFLT3 inhibitor, e.g., sorafenib (Bayer), midostaurin (Novartis),quizartinib (Daiichi Sankyo), crenolanib (Arog Pharmaceuticals), PLX3397(Daiichi Sankyo), AKN-028 (Akinion Pharmaceuticals), or ASP2215(Astellas). In embodiments, the subject is administered a CAR-expressingcell described herein in combination with an isocitrate dehydrogenase(IDH) inhibitor, e.g., AG-221 (Celgene/Agios) or AG-120 (Agios/Celgene).In embodiments, the subject is administered a CAR-expressing celldescribed herein in combination with a cell cycle regulator, e.g.,inhibitor of polo-like kinase 1 (Plk1), e.g., volasertib (BoehringerIngelheim); or an inhibitor of cyclin-dependent kinase 9 (Cdk9), e.g.,alvocidib (Tolero Pharmaceuticals/Sanofi Aventis). In embodiments, thesubject is administered a CAR-expressing cell described herein incombination with a B cell receptor signaling network inhibitor, e.g., aninhibitor of B-cell lymphoma 2 (Bcl-2), e.g., venetoclax (Abbvie/Roche);or an inhibitor of Bruton's tyrosine kinase (Btk), e.g., ibrutinib(Pharmacyclics/Johnson & Johnson Janssen Pharmaceutical). Inembodiments, the subject is administered a CAR-expressing cell describedherein in combination with an inhibitor of M1 aminopeptidase, e.g.,tosedostat (CTI BioPharma/Vernalis); an inhibitor of histone deacetylase(HDAC), e.g., pracinostat (MEI Pharma); a multi-kinase inhibitor, e.g.,rigosertib (Onconova Therapeutics/Baxter/SymBio); or a peptidic CXCR4inverse agonist, e.g., BL-8040 (BioLineRx).

In another embodiment, the subjects receive an infusion of the CARexpressing cell, e.g., CD19 CAR-expressing cell, compositions of thepresent invention prior to transplantation, e.g., allogeneic stem celltransplant, of cells. In a preferred embodiment, CAR expressing cellstransiently express the CAR, e.g., by electroporation of an mRNA CAR,whereby the expression of the antigen targeted by the CAR, e.g., CD19 isterminated prior to infusion of donor stem cells to avoid engraftmentfailure. In one embodiment, the subject can be administered an agentwhich reduces or ameliorates a side effect associated with theadministration of a CAR-expressing cell. Side effects associated withthe administration of a CAR-expressing cell include, but are not limitedto CRS, and hemophagocytic lymphohistiocytosis (HLH), also termedMacrophage Activation Syndrome (MAS). Symptoms of CRS include highfevers, nausea, transient hypotension, hypoxia, and the like.Accordingly, the methods described herein can comprise administering aCAR-expressing cell described herein to a subject and furtheradministering an agent to manage elevated levels of a soluble factorresulting from treatment with a CAR-expressing cell. In one embodiment,the soluble factor elevated in the subject is one or more of IFN-γ,TNFα, IL-2 and IL-6. Therefore, an agent administered to treat this sideeffect can be an agent that neutralizes one or more of these solublefactors. Examples of such agents include, but are not limited to asteroid (e.g., corticosteroid), an inhibitor of TNFα, and an inhibitorof IL-6. An example of a TNFα inhibitor is an anti-TNFα antibodymolecule such as, infliximab, adalimumab, certolizumab pegol, andgolimumab. Another example of a TNFα inhibitor is a fusion protein suchas entanercept. Small molecule inhibitor of TNFα include, but are notlimited to, xanthine derivatives (e.g. pentoxifylline) and bupropion. Anexample of an IL-6 inhibitor is an anti-IL-6 antibody molecule such astocilizumab (toc), sarilumab, elsilimomab, CNTO 328, ALD518/BMS-945429,CNTO 136, CPSI-2364, CDP6038, VX30, ARGX-109, FE301, and FM101. In oneembodiment, the anti-IL-6 antibody molecule is tocilizumab. An exampleof an IL-1R based inhibitor is anakinra.

In embodiments, lymphodepletion is performed on a subject, e.g., priorto administering one or more cells that express a CAR described herein.In embodiments, the lymphodepletion comprises administering one or moreof melphalan, cytoxan, cyclophosphamide, and fludarabine.

In embodiments, a lymphodepleting chemotherapy is administered to thesubject prior to, concurrently with, or after administration (e.g.,infusion) of CAR cells, e.g., cells described herein. In an example, thelymphodepleting chemotherapy is administered to the subject prior toadministration of CAR cells. For example, the lymphodepletingchemotherapy ends 1-4 days (e.g., 1, 2, 3, or 4 days) prior to CAR cellinfusion. In embodiments, multiple doses of CAR cells are administered,e.g., as described herein. For example, a single dose comprises about5×10⁸ CAR cells. In embodiments, a lymphodepleting chemotherapy isadministered to the subject prior to, concurrently with, or afteradministration (e.g., infusion) of a CAR-expressing cell describedherein.

In some embodiments, CAR-expressing cells described herein areadministered to a subject in combination with a CD19 CAR-expressingcell, e.g., CTL019, e.g., as described in WO2012/079000, incorporatedherein by reference, for treatment of a disease associated with theexpression of cancer antigen, e.g., a cancer described herein. Withoutbeing bound by theory, it is believed that administering a CD19CAR-expressing cell in combination with another CAR-expressing cellimproves the efficacy of a CAR-expressing cell described herein bytargeting early lineage cancer cells, e.g., cancer stem cells,modulating the immune response, depleting regulatory B cells, and/orimproving the tumor microenvironment. For example, a CD19 CAR-expressingcell targets cancer cells that express early lineage markers, e.g.,cancer stem cells and CD19-expressing cells, while some otherCAR-expressing cells described herein target cancer cells that expresslater lineage markers. This preconditioning approach can improve theefficacy of the CAR-expressing cell described herein. In suchembodiments, the CD19 CAR-expressing cell is administered prior to,concurrently with, or after administration (e.g., infusion) of thesecond CAR-expressing cell.

In embodiments, a CAR-expressing cell which expresses a CAR targeting acancer antigen other than CD19 also expresses a CAR targeting CD19,e.g., a CD19 CAR. In an embodiment, the cell expressing a non-CD19 CARand a CD19 CAR is administered to a subject for treatment of a cancerdescribed herein, e.g., AML. In an embodiment, the configurations of oneor both of the CAR molecules comprise a primary intracellular signalingdomain and a costimulatory signaling domain. In another embodiment, theconfigurations of one or both of the CAR molecules comprise a primaryintracellular signaling domain and two or more, e.g., 2, 3, 4, or 5 ormore, costimulatory signaling domains. In such embodiments, the non-CD19CAR molecule and the CD19 CAR may have the same or a different primaryintracellular signaling domain, the same or different costimulatorysignaling domains, or the same number or a different number ofcostimulatory signaling domains. Alternatively, the non-CD19 CAR and theCD19 CAR are configured as a split CAR, in which one of the CARmolecules comprises an antigen binding domain and a costimulatory domain(e.g., 4-1BB), while the other CAR molecule comprises an antigen bindingdomain and a primary intracellular signaling domain (e.g., CD3 zeta).

Inhibitory Molecule Inhibitors/Checkpoint Inhibitors

In one embodiment, the subject can be administered an agent whichenhances the activity of a CAR-expressing cell. For example, in oneembodiment, the agent can be an agent which inhibits an inhibitorymolecule, e.g., the agent is a checkpoint inhibitor. Inhibitory orcheckpoint molecules, e.g., Programmed Death 1 (PD1), can, in someembodiments, decrease the ability of a CAR-expressing cell to mount animmune effector response. Examples of inhibitory molecules include PD1,PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/orCEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD160, 2B4,CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR,A2aR, MHC class I, MHC class II, GALS, adenosine, and TGFR (e.g., TGFRbeta). In embodiments, the CAR-expressing cell described hereincomprises a switch costimulatory receptor, e.g., as described in WO2013/019615, which is incorporated herein by reference in its entirety.

The methods described herein can include administration of aCAR-expressing cell in combination with a checkpoint inhibitor. In oneembodiment, the subject is a complete responder. In another embodiment,the subject is a partial responder or non-responder, and, e.g., in someembodiments, the checkpoint inhibitor is administered prior to theCAR-expressing cell, e.g., two weeks, 12 days, 10 days, 8 days, oneweek, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day beforeadministration of the CAR-expressing cell. In some embodiments, thecheckpoint inhibitor is administered concurrently with theCAR-expressing cell.

Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA,RNA or protein level, can optimize a CAR-expressing cell performance. Inembodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleicacid, e.g., a dsRNA, e.g., an siRNA or shRNA, or a clustered regularlyinterspaced short palindromic repeats (CRISPR), atranscription-activator like effector nuclease (TALEN), or a zinc fingerendonuclease (ZFN), can be used to inhibit expression of an inhibitorymolecule in the CAR-expressing cell. In an embodiment the inhibitor isan shRNA. In an embodiment, the inhibitory molecule is inhibited withina CAR-expressing cell. In these embodiments, a dsRNA molecule thatinhibits expression of the inhibitory molecule is linked to the nucleicacid that encodes a component, e.g., all of the components, of the CAR.

In an embodiment, a nucleic acid molecule that encodes a dsRNA moleculethat inhibits expression of the molecule that modulates or regulates,e.g., inhibits, T-cell function is operably linked to a promoter, e.g.,a H1- or a U6-derived promoter such that the dsRNA molecule thatinhibits expression of the molecule that modulates or regulates, e.g.,inhibits, T-cell function is expressed, e.g., is expressed within aCAR-expressing cell. See e.g., Tiscornia G., “Development of LentiviralVectors Expressing siRNA,” Chapter 3, in Gene Transfer: Delivery andExpression of DNA and RNA (eds. Friedmann and Rossi). Cold Spring HarborLaboratory Press, Cold Spring Harbor, NY, USA, 2007; Brummelkamp T R, etal. (2002) Science 296: 550-553; Miyagishi M, et al. (2002) Nat.Biotechnol. 19: 497-500. In an embodiment the nucleic acid molecule thatencodes a dsRNA molecule that inhibits expression of the molecule thatmodulates or regulates, e.g., inhibits, T-cell function is present onthe same vector, e.g., a lentiviral vector, that comprises a nucleicacid molecule that encodes a component, e.g., all of the components, ofthe CAR. In such an embodiment, the nucleic acid molecule that encodes adsRNA molecule that inhibits expression of the molecule that modulatesor regulates, e.g., inhibits, T-cell function is located on the vector,e.g., the lentiviral vector, 5′- or 3′- to the nucleic acid that encodesa component, e.g., all of the components, of the CAR. The nucleic acidmolecule that encodes a dsRNA molecule that inhibits expression of themolecule that modulates or regulates, e.g., inhibits, T-cell functioncan be transcribed in the same or different direction as the nucleicacid that encodes a component, e.g., all of the components, of the CAR.In an embodiment the nucleic acid molecule that encodes a dsRNA moleculethat inhibits expression of the molecule that modulates or regulates,e.g., inhibits, T-cell function is present on a vector other than thevector that comprises a nucleic acid molecule that encodes a component,e.g., all of the components, of the CAR. In an embodiment, the nucleicacid molecule that encodes a dsRNA molecule that inhibits expression ofthe molecule that modulates or regulates, e.g., inhibits, T-cellfunction it transiently expressed within a CAR-expressing cell. In anembodiment, the nucleic acid molecule that encodes a dsRNA molecule thatinhibits expression of the molecule that modulates or regulates, e.g.,inhibits, T-cell function is stably integrated into the genome of aCAR-expressing cell. In an embodiment, the molecule that modulates orregulates, e.g., inhibits, T-cell function is PD-1.

In one embodiment, the inhibitor of an inhibitory signal can be, e.g.,an antibody or antibody fragment that binds to an inhibitory molecule.For example, the agent can be an antibody or antibody fragment thatbinds to PD1, PD-L1, PD-L2 or CTLA4 (e.g., ipilimumab (also referred toas MDX-010 and MDX-101, and marketed as Yervoy®; Bristol-Myers Squibb;Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerlyknown as ticilimumab, CP-675,206)). In an embodiment, the agent is anantibody or antibody fragment that binds to TIM3. In an embodiment, theagent is an antibody or antibody fragment that binds to LAG3. In anembodiment, the agent is an antibody or antibody fragment that binds toCEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5). In embodiments, theagent that enhances the activity of a CAR-expressing cell, e.g.,inhibitor of an inhibitory molecule, is administered in combination withan allogeneic CAR, e.g., an allogeneic CAR described herein (e.g.,described in the Allogeneic CAR section herein).

PD1 is an inhibitory member of the CD28 family of receptors that alsoincludes CD28, CTLA-4, ICOS, and BTLA. PD1 is expressed on activated Bcells, T cells and myeloid cells (Agata et al. 1996 Int. Immunol8:765-75). Two ligands for PD1, PD-L1 and PD-L2 have been shown todownregulate T cell activation upon binding to PD1 (Freeman et a. 2000 JExp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter etal. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers(Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol.Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094).Immune suppression can be reversed by inhibiting the local interactionof PD1 with PD-L1.

Antibodies, antibody fragments, and other inhibitors of PD1, PD-L1 andPD-L2 are available in the art and may be used combination with a CD19CAR described herein. For example, nivolumab (also referred to asBMS-936558 or MDX1106; Bristol-Myers Squibb) is a fully human IgG4monoclonal antibody which specifically blocks PD1. Nivolumab (clone 5C4)and other human monoclonal antibodies that specifically bind to PD1 aredisclosed in U.S. Pat. No. 8,008,449 and WO2006/121168. Pidilizumab(CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that bindsto PD1. Pidilizumab and other humanized anti-PD1 monoclonal antibodiesare disclosed in WO2009/101611. Pembrolizumab (formerly known aslambrolizumab, and also referred to as Keytruda, MK03475; Merck) is ahumanized IgG4 monoclonal antibody that binds to PD1. Pembrolizumab andother humanized anti-PD1 antibodies are disclosed in U.S. Pat. No.8,354,509 and WO2009/114335. MEDI4736 (Medimmune) is a human monoclonalantibody that binds to PDL1, and inhibits interaction of the ligand withPD1. MDPL3280A (Genentech/Roche) is a human Fc optimized IgG1 monoclonalantibody that binds to PD-L1. MDPL3280A and other human monoclonalantibodies to PD-L1 are disclosed in U.S. Pat. No. 7,943,743 and U.SPublication No.: 20120039906. Other anti-PD-L1 binding agents includeYW243.55.S70 (heavy and light chain variable regions are shown in SEQ IDNOs 20 and 21 in WO2010/077634) and MDX-1 105 (also referred to asBMS-936559, and, e.g., anti-PD-L1 binding agents disclosed inWO2007/005874). AMP-224 (B7-DCIg; Amplimmune; e.g., disclosed inWO2010/027827 and WO2011/066342), is a PD-L2 Fc fusion soluble receptorthat blocks the interaction between PD1 and B7-H1. Other anti-PD1antibodies include AMP 514 (Amplimmune), among others, e.g., anti-PD1antibodies disclosed in U.S. Pat. No. 8,609,089, US 2010028330, and/orUS 20120114649.

In some embodiments, a PD1 inhibitor described herein (e.g., a PD1antibody, e.g., a PD1 antibody described herein) is used combinationwith a CD19 CAR described herein to treat a disease associated withexpression of CD19. In some embodiments, a PD-L1 inhibitor describedherein (e.g., a PD-L1 antibody, e.g., a PD-L1 antibody described herein)is used combination with a CD19 CAR described herein to treat a diseaseassociated with expression of CD19. The disease may be, e.g., a lymphomasuch as DLBCL including primary DLBCL or secondary DLBCL. In someembodiments, the subject has, or is identified as having, at least 5%,6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of cancercells, e.g., DLBCL cells, which are CD3+/PD1+. In some embodiments, thesubject has, or is identified as having, substantially non-overlappingpopulations of CD19+ cells and PD-L1+ cells in a cancer, e.g., thecancer microenvironment. For instance, in some embodiments, less than20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of cells in the cancer,e.g., cancer microenvironment, are double positive for CD19 and PD-L1.

In some embodiments, the subject is treated with a combination of a CD19CAR, a PD1 inhibitor, and a PD-L1 inhibitor. In some embodiments, thesubject is treated with a combination of a CD19 CAR, a PD1 inhibitor,and a CD3 inhibitor. In some embodiments, the subject is treated with acombination of a CD19 CAR, a PD1 inhibitor, a PD-L1 inhibitor, and a CD3inhibitor.

In some embodiments, the methods herein include a step of assaying cellsin a biological sample, e.g., a sample comprising DLBCL cells, for CD3and/or PD-1 (e.g., CD3 and/or PD-1 expression). In some embodiments, themethods include a step of assaying cells in a biological sample, e.g., asample comprising DLBCL cells, for CD19 and/or PD-L1 (e.g., CD19 and/orPD-L1 expression). In some embodiments, the methods include, e.g.,providing a sample comprising cancer cells and performing a detectionstep, e.g., by immunohistochemistry, for one or more of CD3, PD-1, CD19,or PD-L1. The methods may comprise a further step of recommending oradministering a treatment, e.g., a treatment comprising a CD19 CAR.

In one embodiment, the anti-PD-1 antibody or fragment thereof is ananti-PD-1 antibody molecule as described in US 2015/0210769, entitled“Antibody Molecules to PD-1 and Uses Thereof,” incorporated by referencein its entirety. In one embodiment, the anti-PD-1 antibody moleculeincludes at least one, two, three, four, five or six CDRs (orcollectively all of the CDRs) from a heavy and light chain variableregion from an antibody chosen from any of BAP049-hum01, BAP049-hum02,BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07,BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11, BAP049-hum12,BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-Clone-A,BAP049-Clone-B, BAP049-Clone-C, BAP049-Clone-D, or BAP049-Clone-E; or asdescribed in Table 1 of US 2015/0210769, or encoded by the nucleotidesequence in Table 1, or a sequence substantially identical (e.g., atleast 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to anyof the aforesaid sequences; or closely related CDRs, e.g., CDRs whichare identical or which have at least one amino acid alteration, but notmore than two, three or four alterations (e.g., substitutions,deletions, or insertions, e.g., conservative substitutions).

In yet another embodiment, the anti-PD-1 antibody molecule comprises atleast one, two, three or four variable regions from an antibodydescribed herein, e.g., an antibody chosen from any of BAP049-hum01,BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06,BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11,BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16,BAP049-Clone-A, BAP049-Clone-B, BAP049-Clone-C, BAP049-Clone-D, orBAP049-Clone-E; or as described in Table 1 of US 2015/0210769, orencoded by the nucleotide sequence in Table 1; or a sequencesubstantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%,98%, 99% or higher identical) to any of the aforesaid sequences.

TIM3 (T cell immunoglobulin-3) also negatively regulates T cellfunction, particularly in IFN-g-secreting CD4+ T helper 1 and CD8+ Tcytotoxic 1 cells, and plays a critical role in T cell exhaustion.Inhibition of the interaction between TIM3 and its ligands, e.g.,galectin-9 (Ga19), phosphatidylserine (PS), and HMGB1, can increaseimmune response. Antibodies, antibody fragments, and other inhibitors ofTIM3 and its ligands are available in the art and may be usedcombination with a CD19 CAR described herein. For example, antibodies,antibody fragments, small molecules, or peptide inhibitors that targetTIM3 binds to the IgV domain of TIM3 to inhibit interaction with itsligands. Antibodies and peptides that inhibit TIM3 are disclosed inWO2013/006490 and US20100247521. Other anti-TIM3 antibodies includehumanized versions of RMT3-23 (disclosed in Ngiow et al., 2011, CancerRes, 71:3540-3551), and clone 8B.2C12 (disclosed in Monney et al., 2002,Nature, 415:536-541). Bi-specific antibodies that inhibit TIM3 and PD-1are disclosed in US20130156774.

In one embodiment, the anti-TIM3 antibody or fragment thereof is ananti-TIM3 antibody molecule as described in US 2015/0218274, entitled“Antibody Molecules to TIM3 and Uses Thereof,” incorporated by referencein its entirety. In one embodiment, the anti-TIM3 antibody moleculeincludes at least one, two, three, four, five or six CDRs (orcollectively all of the CDRs) from a heavy and light chain variableregion from an antibody chosen from any of ABTIM3, ABTIM3-hum01,ABTIM3-hum02, ABTIM3-hum03, ABTIM3-hum04, ABTIM3-hum05, ABTIM3-hum06,ABTIM3-hum07, ABTIM3-hum08, ABTIM3-hum09, ABTIM3-hum10, ABTIM3-hum11,ABTIM3-hum12, ABTIM3-hum13, ABTIM3-hum14, ABTIM3-hum15, ABTIM3-hum16,ABTIM3-hum17, ABTIM3-hum18, ABTIM3-hum19, ABTIM3-hum20, ABTIM3-hum21,ABTIM3-hum22, ABTIM3-hum23; or as described in Tables 1-4 of US2015/0218274; or encoded by the nucleotide sequence in Tables 1-4; or asequence substantially identical (e.g., at least 80%, 85%, 90%, 92%,95%, 97%, 98%, 99% or higher identical) to any of the aforesaidsequences, or closely related CDRs, e.g., CDRs which are identical orwhich have at least one amino acid alteration, but not more than two,three or four alterations (e.g., substitutions, deletions, orinsertions, e.g., conservative substitutions).

In yet another embodiment, the anti-TIM3 antibody molecule comprises atleast one, two, three or four variable regions from an antibodydescribed herein, e.g., an antibody chosen from any of ABTIM3,ABTIM3-hum01, ABTIM3-hum02, ABTIM3-hum03, ABTIM3-hum04, ABTIM3-hum05,ABTIM3-hum06, ABTIM3-hum07, ABTIM3-hum08, ABTIM3-hum09, ABTIM3-hum10,ABTIM3-hum11, ABTIM3-hum12, ABTIM3-hum13, ABTIM3-hum14, ABTIM3-hum15,ABTIM3-hum16, ABTIM3-hum17, ABTIM3-hum18, ABTIM3-hum19, ABTIM3-hum20,ABTIM3-hum21, ABTIM3-hum22, ABTIM3-hum23; or as described in Tables 1-4of US 2015/0218274; or encoded by the nucleotide sequence in Tables 1-4;or a sequence substantially identical (e.g., at least 80%, 85%, 90%,92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaidsequences.

In other embodiments, the agent which enhances the activity of aCAR-expressing cell is a CEACAM inhibitor (e.g., CEACAM-1, CEACAM-3,and/or CEACAM-5 inhibitor). In one embodiment, the inhibitor of CEACAMis an anti-CEACAM antibody molecule. Exemplary anti-CEACAM-1 antibodiesare described in WO 2010/125571, WO 2013/082366 WO 2014/059251 and WO2014/022332, e.g., a monoclonal antibody 34B1, 26H7, and 5F4; or arecombinant form thereof, as described in, e.g., US 2004/0047858, U.S.Pat. No. 7,132,255 and WO 99/052552. In other embodiments, theanti-CEACAM antibody binds to CEACAM-5 as described in, e.g., Zheng etal. PLoS One. 2010 Sep. 2; 5(9). pii: e12529(DOI:10:1371/journal.pone.0021146), or crossreacts with CEACAM-1 andCEACAM-5 as described in, e.g., WO 2013/054331 and US 2014/0271618.

Without wishing to be bound by theory, carcinoembryonic antigen celladhesion molecules (CEACAM), such as CEACAM-1 and CEACAM-5, are believedto mediate, at least in part, inhibition of an anti-tumor immuneresponse (see e.g., Markel et al. J Immunol. 2002 Mar. 15;168(6):2803-10; Markel et al. J Immunol. 2006 Nov. 1; 177(9):6062-71;Markel et al. Immunology. 2009 February; 126(2):186-200; Markel et al.Cancer Immunol Immunother. 2010 February; 59(2):215-30; Ortenberg et al.Mol Cancer Ther. 2012 June; 11(6):1300-10; Stern et al. J Immunol. 2005Jun. 1; 174(11):6692-701; Zheng et al. PLoS One. 2010 Sep. 2; 5(9). pii:e12529). For example, CEACAM-1 has been described as a heterophilicligand for TIM-3 and as playing a role in TIM-3-mediated T celltolerance and exhaustion (see e.g., WO 2014/022332; Huang, et al. (2014)Nature doi:10.1038/nature13848). In embodiments, co-blockade of CEACAM-1and TIM-3 has been shown to enhance an anti-tumor immune response inxenograft colorectal cancer models (see e.g., WO 2014/022332; Huang, etal. (2014), supra). In other embodiments, co-blockade of CEACAM-1 andPD-1 reduce T cell tolerance as described, e.g., in WO 2014/059251.Thus, CEACAM inhibitors can be used with the other immunomodulatorsdescribed herein (e.g., anti-PD-1 and/or anti-TIM-3 inhibitors) toenhance an immune response against a cancer, e.g., a melanoma, a lungcancer (e.g., NSCLC), a bladder cancer, a colon cancer, an ovariancancer, and other cancers as described herein.

LAG3 (lymphocyte activation gene-3 or CD223) is a cell surface moleculeexpressed on activated T cells and B cells that has been shown to play arole in CD8+ T cell exhaustion. Antibodies, antibody fragments, andother inhibitors of LAG3 and its ligands are available in the art andmay be used combination with a CD19 CAR described herein. For example,BMS-986016 (Bristol-Myers Squib) is a monoclonal antibody that targetsLAG3. IMP701 (Immutep) is an antagonist LAG3 antibody and IMP731(Immutep and GlaxoSmithKline) is a depleting LAG3 antibody. Other LAG3inhibitors include IMP321 (Immutep), which is a recombinant fusionprotein of a soluble portion of LAG3 and Ig that binds to WIC class IImolecules and activates antigen presenting cells (APC). Other antibodiesare disclosed, e.g., in WO2010/019570.

In one embodiment, the anti-LAG3 antibody or fragment thereof is ananti-LAG3 antibody molecule as described in US 2015/0259420, entitled“Antibody Molecules to LAG3 and Uses Thereof,” incorporated by referencein its entirety. In one embodiment, the anti-LAG3 antibody moleculeincludes at least one, two, three, four, five or six CDRs (orcollectively all of the CDRs) from a heavy and light chain variableregion from an antibody chosen from any of BAP050-hum01, BAP050-hum02,BAP050-hum03, BAP050-hum04, BAP050-hum05, BAP050-hum06, BAP050-hum07,BAP050-hum08, BAP050-hum09, BAP050-hum10, BAP050-hum11, BAP050-hum12,BAP050-hum13, BAP050-hum14, BAP050-hum15, BAP050-hum16, BAP050-hum17,BAP050-hum18, BAP050-hum19, BAP050-hum20, huBAP050(Ser) (e.g.,BAP050-hum01-Ser, BAP050-hum02-Ser, BAP050-hum03-Ser, BAP050-hum04-Ser,BAP050-hum05-Ser, BAP050-hum06-Ser, BAP050-hum07-Ser, BAP050-hum08-Ser,BAP050-hum09-Ser, BAP050-hum10-Ser, BAP050-hum11-Ser, BAP050-hum12-Ser,BAP050-hum13-Ser, BAP050-hum14-Ser, BAP050-hum15-Ser, BAP050-hum18-Ser,BAP050-hum19-Ser, or BAP050-hum20-Ser), BAP050-Clone-F, BAP050-Clone-G,BAP050-Clone-H, BAP050-Clone-I, or BAP050-Clone-J; or as described inTable 1 of US 2015/0259420; or encoded by the nucleotide sequence inTable 1; or a sequence substantially identical (e.g., at least 80%, 85%,90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of theaforesaid sequences, or closely related CDRs, e.g., CDRs which areidentical or which have at least one amino acid alteration, but not morethan two, three or four alterations (e.g., substitutions, deletions, orinsertions, e.g., conservative substitutions).

In yet another embodiment, the anti-LAG3 antibody molecule comprises atleast one, two, three or four variable regions from an antibodydescribed herein, e.g., an antibody chosen from any of BAP050-hum01,BAP050-hum02, BAP050-hum03, BAP050-hum04, BAP050-hum05, BAP050-hum06,BAP050-hum07, BAP050-hum08, BAP050-hum09, BAP050-hum10, BAP050-hum11,BAP050-hum12, BAP050-hum13, BAP050-hum14, BAP050-hum15, BAP050-hum16,BAP050-hum17, BAP050-hum18, BAP050-hum19, BAP050-hum20, huBAP050(Ser)(e.g., BAP050-hum01-Ser, BAP050-hum02-Ser, BAP050-hum03-Ser,BAP050-hum04-Ser, BAP050-hum05-Ser, BAP050-hum06-Ser, BAP050-hum07-Ser,BAP050-hum08-Ser, BAP050-hum09-Ser, BAP050-hum10-Ser, BAP050-hum11-Ser,BAP050-hum12-Ser, BAP050-hum13-Ser, BAP050-hum14-Ser, BAP050-hum15-Ser,BAP050-hum18-Ser, BAP050-hum19-Ser, or BAP050-hum20-Ser),BAP050-Clone-F, BAP050-Clone-G, BAP050-Clone-H, BAP050-Clone-I, orBAP050-Clone-J; or as described in Table 1 of US 2015/0259420; orencoded by the nucleotide sequence in Tables 1; or a sequencesubstantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%,98%, 99% or higher identical) to any of the aforesaid sequences.

While not wishing to be bound by theory, in some embodiments, a tumormicroenvironment is not conducive to CART cells attacking cancer cells,due to direct or indirect inhibitory effects exerted by the presence ofPD-L1+ expressing cells or PD1+ T cells within the tumormicroenvironment. More specifically, a tumor microenvironment cancomprise tumor cells (which are generally CD19+), immune effector cells(which can be CD3+ T cells and can be PD1+ or PD1−, and which can beendogenous cells or CAR-expressing cells), and activated myeloid cells(which are generally PD-L1+). PD1+ T cells can create a “barrier” aroundthe tumor microenvironment by preventing entry of CART cells the tumor.According to the non-limiting theory herein, pre-administration of a PD1inhibitor and/or PD-L1 inhibitor makes the tumor microenvironment morefavorable to entry of CAR-expressing cells into the tumormicroenvironment and effectively clear the target positive cancer cells.Data supporting this model is provided herein, e.g., in Examples 20 and21.

Accordingly, in certain aspects, the present disclosure provides methodsof combination therapy comprising administering to a subject a cell thatexpresses a CAR molecule that binds CD19, e.g., a CD19 CAR, incombination with a PD1 inhibitor, a PD-L1 inhibitor, or both. In someembodiments, the PD1 inhibitor and/or PD-L1 inhibitor is administeredbefore the CAR therapy. In other embodiments, the PD1 inhibitor and/orPD-L1 inhibitor is administered concurrently with or after the CARtherapy. In some aspects, the subject is a subject having a diseaseassociated with expression of CD19, e.g., a hematologic malignancy,e.g., a leukemia or lymphoma, e.g., DLBCL, e.g. primary DLBCL. In someembodiments, the patient has, or is identified as having, elevatedlevels of PD1, PDL1, or CD3, or any combination thereof. In someembodiments, the patient has, or is identified as having, or at least5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% ofDLBCL cells which are positive for CD3 and PD1.

Also provided herein are methods for monitoring the efficacy of a CARtherapy, e.g., a CD19 CAR therapy. CAR-expressing cells can beadministered to a patient's bloodstream with the intent that the cellshome to a tumor cell, e.g., infiltrate a tumor. Accordingly, in someembodiments, the method comprises assaying a tumor sample for thepresence of CAR-expressing cells. In embodiments, the method comprisesdetecting a tumor marker, e.g., CD19. In embodiments, the methodcomprises detecting a marker of a CAR-expressing cell, e.g., a CARconstruct or nucleic acid encoding the CAR construct. In embodiments,the method further comprises detecting a T cell marker, e.g., CD3. Insome aspects, the subject is a subject having a disease associated withexpression of CD19, e.g., a hematologic malignancy, e.g., a leukemia orlymphoma, e.g., DLBCL, e.g. primary DLBCL. In some embodiments, if theCAR-expressing cells show poor infiltration of the tumor, the subject isidentified as at an elevated risk of relapse compared to a subject withgood infiltration of the tumor. In some embodiments, if theCAR-expressing cells show poor infiltration of the tumor, the subject isadministered a PD1 inhibitor and/or PD-L1 inhibitor, e.g., incombination with a second dose of CAR-expressing cells.

In some embodiments, the agent which enhances the activity of aCAR-expressing cell can be, e.g., a fusion protein comprising a firstdomain and a second domain, wherein the first domain is an inhibitorymolecule, or fragment thereof, and the second domain is a polypeptidethat is associated with a positive signal, e.g., a polypeptidecomprising an intracellular signaling domain as described herein. Insome embodiments, the polypeptide that is associated with a positivesignal can include a costimulatory domain of CD28, CD27, ICOS, e.g., anintracellular signaling domain of CD28, CD27 and/or ICOS, and/or aprimary signaling domain, e.g., of CD3 zeta, e.g., described herein. Inone embodiment, the fusion protein is expressed by the same cell thatexpressed the CAR. In another embodiment, the fusion protein isexpressed by a cell, e.g., a T cell that does not express an anti-CD19CAR.

In one embodiment, the agent which enhances activity of a CAR-expressingcell described herein is miR-17-92.

In one embodiment, the agent which enhances activity of a CAR-describedherein is a cytokine. Cytokines have important functions related to Tcell expansion, differentiation, survival, and homeostasis. Cytokinesthat can be administered to the subject receiving a CAR-expressing celldescribed herein include: IL-2, IL-4, IL-7, IL-9, IL-15, IL-18, andIL-21, or a combination thereof. In embodiments, the cytokineadministered is IL-7, IL-15, or IL-21, or a combination thereof. Thecytokine can be administered once a day or more than once a day, e.g.,twice a day, three times a day, or four times a day. The cytokine can beadministered for more than one day, e.g. the cytokine is administeredfor 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or4 weeks. For example, the cytokine is administered once a day for 7days.

In embodiments, the cytokine is administered in combination withCAR-expressing cells. The cytokine can be administered simultaneously orconcurrently with the CAR-expressing cells, e.g., administered on thesame day. The cytokine may be prepared in the same pharmaceuticalcomposition as the CAR-expressing cells, or may be prepared in aseparate pharmaceutical composition. Alternatively, the cytokine can beadministered shortly after administration of the CAR-expressing T cells,e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days afteradministration of the CAR-expressing cells. In embodiments where thecytokine is administered in a dosing regimen that occurs over more thanone day, the first day of the cytokine dosing regimen can be on the sameday as administration with the CAR-expressing cells, or the first day ofthe cytokine dosing regimen can be 1 day, 2 days, 3 days, 4 days, 5days, 6 days, or 7 days after administration of the CAR-expressing Tcells. In one embodiment, on the first day, the CAR-expressing cells areadministered to the subject, and on the second day, a cytokine isadministered once a day for the next 7 days. In an embodiment, thecytokine to be administered in combination with the CAR-expressing cellsis IL-7, IL-15, and/or IL-21.

In other embodiments, the cytokine is administered a sufficient periodof time after administration of the CAR-expressing cells, e.g., at least2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 4months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11months, or 1 year or more after administration of CAR-expressing cells.In one embodiment, the cytokine is administered after assessment of thesubject's response to the CAR-expressing cells. For example, the subjectis administered CAR-expressing cells according to the dosage andregimens described herein. The response of the subject to CART therapyis assessed at 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10months, 11 months, or 1 year or more after administration ofCAR-expressing cells, using any of the methods described herein,including inhibition of tumor growth, reduction of circulating tumorcells, or tumor regression. Subjects that do not exhibit a sufficientresponse to CART therapy can be administered a cytokine. Administrationof the cytokine to the subject that has sub-optimal response to the CARTtherapy improves CART efficacy and/or anti-tumor activity. In anembodiment, the cytokine administered after administration ofCAR-expressing cells is IL-7.

Further combination therapies may include anti-allergenic agents,anti-emetics, analgesics, adjunct therapies,

Some patients may experience allergic reactions to the therapeuticsdescribed herein and/or other anti-cancer agent(s) during or afteradministration; therefore, anti-allergic agents are often administeredto minimize the risk of an allergic reaction. Suitable anti-allergicagents include corticosteroids, such as dexamethasone (e.g., Decadron®),beclomethasone (e.g., Beclovent®), hydrocortisone (also known ascortisone, hydrocortisone sodium succinate, hydrocortisone sodiumphosphate, and sold under the tradenames Ala-Cort®, hydrocortisonephosphate, Solu-Cortef®, Hydrocort Acetate® and Lanacort®), prednisolone(sold under the tradenames Delta-Cortel®, Orapred®, Pediapred® andPrelone®), prednisone (sold under the tradenames Deltasone®, LiquidRed®, Meticorten® and Orasone®), methylprednisolone (also known as6-methylprednisolone, methylprednisolone acetate, methylprednisolonesodium succinate, sold under the tradenames Duralone®, Medralone®,Medrol®, M-Prednisol® and Solu-Medrol®); antihistamines, such asdiphenhydramine (e.g., Benadryl®), hydroxyzine, and cyproheptadine; andbronchodilators, such as the beta-adrenergic receptor agonists,albuterol (e.g., Proventil®), and terbutaline (Brethine®).

Some patients may experience nausea during and after administration ofthe therapeutics described herein and/or other anti-cancer agent(s);therefore, anti-emetics are used in preventing nausea (upper stomach)and vomiting. Suitable anti-emetics include aprepitant (Emend®),ondansetron (Zofran®), granisetron HCl (Kytril®), lorazepam (Ativan®.dexamethasone (Decadron®), prochlorperazine (Compazine®), casopitant(Rezonic® and Zunrisa®), and combinations thereof.

Medication to alleviate the pain experienced during the treatment periodis often prescribed to make the patient more comfortable. Commonover-the-counter analgesics, such Tylenol®, are often used. However,opioid analgesic drugs such as hydrocodone/paracetamol orhydrocodone/acetaminophen (e.g., Vicodin®), morphine (e.g., Astramorph®or Avinza®), oxycodone (e.g., OxyContin® or Percocet®), oxymorphonehydrochloride (Opana®), and fentanyl (e.g., Duragesic®) are also usefulfor moderate or severe pain.

In an effort to protect normal cells from treatment toxicity and tolimit organ toxicities, cytoprotective agents (such as neuroprotectants,free-radical scavengers, cardioprotectors, anthracycline extravasationneutralizers, nutrients and the like) may be used as an adjunct therapy.Suitable cytoprotective agents include Amifostine (Ethyol®), glutamine,dimesna (Tavocept®), mesna (Mesnex®), dexrazoxane (Zinecard® orTotect®), xaliproden (Xaprila®), and leucovorin (also known as calciumleucovorin, citrovorum factor and folinic acid).

The structure of the active compounds identified by code numbers,generic or trade names may be taken from the actual edition of thestandard compendium “The Merck Index” or from databases, e.g. PatentsInternational (e.g. IMS World Publications).

The above-mentioned compounds, which can be used in combination with acompound of the present invention, can be prepared and administered asdescribed in the art, such as in the documents cited above.

In one embodiment, the present invention provides pharmaceuticalcompositions comprising at least one compound of the present invention(e.g., a compound of the present invention) or a pharmaceuticallyacceptable salt thereof together with a pharmaceutically acceptablecarrier suitable for administration to a human or animal subject, eitheralone or together with other anti-cancer agents.

In one embodiment, the present invention provides methods of treatinghuman or animal subjects suffering from a cellular proliferativedisease, such as cancer. The present invention provides methods oftreating a human or animal subject in need of such treatment, comprisingadministering to the subject a therapeutically effective amount of acompound of the present invention (e.g., a compound of the presentinvention) or a pharmaceutically acceptable salt thereof, either aloneor in combination with other anti-cancer agents.

In particular, compositions will either be formulated together as acombination therapeutic or administered separately.

In combination therapy, the compound of the present invention and otheranti-cancer agent(s) may be administered either simultaneously,concurrently or sequentially with no specific time limits, wherein suchadministration provides therapeutically effective levels of the twocompounds in the body of the patient.

In a preferred embodiment, the compound of the present invention and theother anti-cancer agent(s) is generally administered sequentially in anyorder by infusion or orally. The dosing regimen may vary depending uponthe stage of the disease, physical fitness of the patient, safetyprofiles of the individual drugs, and tolerance of the individual drugs,as well as other criteria well-known to the attending physician andmedical practitioner(s) administering the combination. The compound ofthe present invention and other anti-cancer agent(s) may be administeredwithin minutes of each other, hours, days, or even weeks apart dependingupon the particular cycle being used for treatment. In addition, thecycle could include administration of one drug more often than the otherduring the treatment cycle and at different doses per administration ofthe drug.

In another aspect of the present invention, kits that include one ormore compound of the present invention and a combination partner asdisclosed herein are provided. Representative kits include (a) acompound of the present invention or a pharmaceutically acceptable saltthereof, (b) at least one combination partner, e.g., as indicated above,whereby such kit may comprise a package insert or other labelingincluding directions for administration.

A compound of the present invention may also be used to advantage incombination with known therapeutic processes, for example, theadministration of hormones or especially radiation. A compound of thepresent invention may in particular be used as a radiosensitizer,especially for the treatment of tumors which exhibit poor sensitivity toradiotherapy.

Combination with a Low, Immune-Enhancing Dose of an mTOR Inhibitor

In one embodiment, the cells expressing a CAR molecule, e.g., a CARmolecule described herein, are administered in combination with a low,immune enhancing dose of an mTOR inhibitor. For instance, in anembodiment, the combination therapy includes: CD19 CAR expressing cells,a B-cell inhibitor (inhibitor of one or more of CD10, CD20, CD22, CD34,CD123, FLT-3, or ROR1, e.g., a CAR-expressing cell targeting one or moreof CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1), and an mTORinhibitor. Methods described herein use low, immune enhancing, doses ofmTOR inhibitors, e.g., allosteric mTOR inhibitors, including rapalogssuch as RAD001. Administration of a low, immune enhancing, dose of anmTOR inhibitor (e.g., a dose that is insufficient to completely suppressthe immune system, but sufficient to improve immune function) canoptimize the performance of immune effector cells, e.g., T cells orCAR-expressing cells, in the subject. Methods for measuring mTORinhibition, dosages, treatment regimens, and suitable pharmaceuticalcompositions are described in U.S. Patent Application No. 2015/01240036,hereby incorporated by reference.

In an embodiment, administration of a low, immune enhancing, dose of anmTOR inhibitor can result in one or more of the following:

-   -   i) a decrease in the number of PD-1 positive immune effector        cells;    -   ii) an increase in the number of PD-1 negative immune effector        cells;    -   iii) an increase in the ratio of PD-1 negative immune effector        cells/PD-1 positive immune effector cells;    -   iv) an increase in the number of naive T cells;    -   v) an increase in the expression of one or more of the following        markers: CD62L^(high), CD127^(high), CD27⁺, and BCL2, e.g., on        memory T cells, e.g., memory T cell precursors;    -   vi) a decrease in the expression of KLRG1, e.g., on memory T        cells, e.g., memory T cell precursors; or    -   vii) an increase in the number of memory T cell precursors,        e.g., cells with any one or combination of the following        characteristics: increased CD62L^(high), increased CD127^(high),        increased CD27⁺, decreased KLRG1, and increased BCL2;    -   and wherein any of the foregoing, e.g., i), ii), iii), iv), v),        vi), or vii), occurs e.g., at least transiently, e.g., as        compared to a non-treated subject.

In another embodiment, administration of a low, immune enhancing, doseof an mTOR inhibitor results in increased or prolonged proliferation orpersistence of CAR-expressing cells, e.g., in culture or in a subject,e.g., as compared to non-treated CAR-expressing cells or a non-treatedsubject. In embodiments, increased proliferation or persistence isassociated with in an increase in the number of CAR-expressing cells.Methods for measuring increased or prolonged proliferation are describedin Examples 18 and 19. In another embodiment, administration of a low,immune enhancing, dose of an mTOR inhibitor results in increased killingof cancer cells by CAR-expressing cells, e.g., in culture or in asubject, e.g., as compared to non-treated CAR-expressing cells or anon-treated subject. In embodiments, increased killing of cancer cellsis associated with in a decrease in tumor volume.

In one embodiment, the cells expressing a CAR molecule, e.g., a CARmolecule described herein, are administered in combination with a low,immune enhancing dose of an mTOR inhibitor, e.g., an allosteric mTORinhibitor, e.g., RAD001, or a catalytic mTOR inhibitor. For example,administration of the low, immune enhancing, dose of the mTOR inhibitorcan be initiated prior to administration of a CAR-expressing celldescribed herein; completed prior to administration of a CAR-expressingcell described herein; initiated at the same time as administration of aCAR-expressing cell described herein; overlapping with administration ofa CAR-expressing cell described herein; or continuing afteradministration of a CAR-expressing cell described herein.

Alternatively or in addition, administration of a low, immune enhancing,dose of an mTOR inhibitor can optimize immune effector cells to beengineered to express a CAR molecule described herein. In suchembodiments, administration of a low, immune enhancing, dose of an mTORinhibitor, e.g., an allosteric inhibitor, e.g., RAD001, or a catalyticinhibitor, is initiated or completed prior to harvest of immune effectorcells, e.g., T cells or NK cells, to be engineered to express a CARmolecule described herein, from a subject.

In another embodiment, immune effector cells, e.g., T cells or NK cells,to be engineered to express a CAR molecule described herein, e.g., afterharvest from a subject, or CAR-expressing immune effector cells, e.g., Tcells or NK cells, e.g., prior to administration to a subject, can becultured in the presence of a low, immune enhancing, dose of an mTORinhibitor.

In an embodiment, administering to the subject a low, immune enhancing,dose of an mTOR inhibitor comprises administering, e.g., once per week,e.g., in an immediate release dosage form, 0.1 to 20, 0.5 to 10, 2.5 to7.5, 3 to 6, or about 5, mgs of RAD001, or a bioequivalent dose thereof.In an embodiment, administering to the subject a low, immune enhancing,dose of an mTOR inhibitor comprises administering, e.g., once per week,e.g., in a sustained release dosage form, 0.3 to 60, 1.5 to 30, 7.5 to22.5, 9 to 18, or about 15 mgs of RAD001, or a bioequivalent dosethereof.

In an embodiment, a dose of an mTOR inhibitor is associated with, orprovides, mTOR inhibition of at least 5 but no more than 90%, at least10 but no more than 90%, at least 15, but no more than 90%, at least 20but no more than 90%, at least 30 but no more than 90%, at least but nomore than 90%, at least 50 but no more than 90%, at least 60 but no morethan 90%, at least 70 but no more than 90%, at least 5 but no more than80%, at least 10 but no more than 80%, at least 15, but no more than80%, at least 20 but no more than 80%, at least 30 but no more than 80%,at least 40 but no more than 80%, at least 50 but no more than 80%, atleast 60 but no more than 80%, at least 5 but no more than 70%, at least10 but no more than 70%, at least 15, but no more than 70%, at least 20but no more than 70%, at least 30 but no more than 70%, at least 40 butno more than 70%, at least 50 but no more than 70%, at least 5 but nomore than 60%, at least 10 but no more than 60%, at least 15, but nomore than 60%, at least 20 but no more than 60%, at least 30 but no morethan 60%, at least 40 but no more than 60%, at least but no more than50%, at least 10 but no more than 50%, at least 15, but no more than50%, at least 20 but no more than 50%, at least 30 but no more than 50%,at least 40 but no more than 50%, at least 5 but no more than 40%, atleast 10 but no more than 40%, at least 15, but no more than 40%, atleast 20 but no more than 40%, at least 30 but no more than 40%, atleast 35 but no more than 40%, at least 5 but no more than 30%, at least10 but no more than 30%, at least 15, but no more than 30%, at least 20but no more than 30%, or at least 25 but no more than 30%.

The extent of mTOR inhibition can be conveyed as, or corresponds to, theextent of P70 S6 kinase inhibition, e.g., the extent of mTOR inhibitioncan be determined by the level of decrease in P70 S6 kinase activity,e.g., by the decrease in phosphorylation of a P70 S6 kinase substrate.The level of mTOR inhibition can be evaluated by various methods, suchas measuring P70 S6 kinase activity by the Boulay assay, as described inU.S. Patent Application No. 2015/01240036, hereby incorporated byreference, or as described in U.S. Pat. No. 7,727,950, herebyincorporated by reference; measuring the level of phosphorylated S6 bywestern blot; or evaluating a change in the ratio of PD1 negative immuneeffector cells to PD1 positive immune effector cells.

As used herein, the term “mTOR inhibitor” refers to a compound orligand, or a pharmaceutically acceptable salt thereof, which inhibitsthe mTOR kinase in a cell. In an embodiment, an mTOR inhibitor is anallosteric inhibitor. Allosteric mTOR inhibitors include the neutraltricyclic compound rapamycin (sirolimus), rapamycin-related compounds,that is compounds having structural and functional similarity torapamycin including, e.g., rapamycin derivatives, rapamycin analogs(also referred to as rapalogs) and other macrolide compounds thatinhibit mTOR activity. In an embodiment, an mTOR inhibitor is acatalytic inhibitor.

Rapamycin is a known macrolide antibiotic produced by Streptomyceshygroscopicus having the structure shown in Formula A.

See, e.g., McAlpine, J. B., et al., J. Antibiotics (1991) 44: 688;Schreiber, S. L., et al., J. Am. Chem. Soc. (1991) 113: 7433; U.S. Pat.No. 3,929,992. There are various numbering schemes proposed forrapamycin. To avoid confusion, when specific rapamycin analogs are namedherein, the names are given with reference to rapamycin using thenumbering scheme of formula A.

Rapamycin analogs useful in the invention are, for example,O-substituted analogs in which the hydroxyl group on the cyclohexyl ringof rapamycin is replaced by OR₁ in which R₁ is hydroxyalkyl,hydroxyalkoxyalkyl, acylaminoalkyl, or aminoalkyl; e.g. RAD001, alsoknown as everolimus, as described in U.S. Pat. No. 5,665,772 andWO94/09010, the contents of each are incorporated by reference.

Other suitable rapamycin analogs include those substituted at the 26- or28-position. The rapamycin analog may be an epimer of an analogmentioned above, particularly an epimer of an analog substituted inposition 40, 28 or 26, and may optionally be further hydrogenated, e.g.as described in U.S. Pat. No. 6,015,815, WO95/14023 and WO99/15530 thecontents of which are incorporated by reference, e.g. ABT578 also knownas zotarolimus or a rapamycin analog described in U.S. Pat. No.7,091,213, WO98/02441 and WO01/14387 the contents of which areincorporated by reference, e.g. AP23573 also known as ridaforolimus.

Examples of rapamycin analogs suitable for use in the present inventionfrom U.S. Pat. No. 5,665,772 include, but are not limited to,40-O-benzyl-rapamycin, 40-O-(4′-hydroxymethyl)benzyl-rapamycin,40-O-[4′-(1,2-dihydroxyethyl)]benzyl-rapamycin, 40-O-allyl-rapamycin,40-O-[3′-(2,2-dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin,(2′E,4′S)-40-O-(4′,5′-dihydroxypent-2′-en-1′-yl)-rapamycin,40-O-(2-hydroxy)ethoxycarbonylmethyl-rapamycin,40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin,40-O-(6-hydroxy)hexyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin,40-O-[(3S)-2,2-dimethyldioxolan-3-yl]methyl-rapamycin,40-O-[(2S)-2,3-dihydroxyprop-1-yl]-rapamycin,40-O-(2-acetoxy)ethyl-rapamycin, 40-O-(2-nicotinoyloxy)ethyl-rapamycin,40-O-[2-(N-morpholino)acetoxy]ethyl-rapamycin,40-O-(2-(N-imidazolylacetoxy)ethyl-rapamycin,40-O-[2-(N-methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin,39-O-desmethyl-39,40-O,O-ethylene-rapamycin,(26R)-26-dihydro-40-O-(2-hydroxy)ethyl-rapamycin,40-O-(2-aminoethyl)-rapamycin, 40-O-(2-acetaminoethyl)-rapamycin,40-O-(2-nicotinamidoethyl)-rapamycin,40-O-(2-(N-methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin,40-O-(2-ethoxycarbonylaminoethyl)-rapamycin,40-O-(2-tolylsulfonamidoethyl)-rapamycin and40-O-[2-(4′,5′-dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin.

Other rapamycin analogs useful in the present invention are analogswhere the hydroxyl group on the cyclohexyl ring of rapamycin and/or thehydroxy group at the 28 position is replaced with an hydroxyester groupare known, for example, rapamycin analogs found in U.S. RE44,768, e.g.temsirolimus.

Other rapamycin analogs useful in the preset invention include thosewherein the methoxy group at the 16 position is replaced with anothersubstituent, e.g., (optionally hydroxy-substituted) alkynyloxy, benzyl,orthomethoxybenzyl or chlorobenzyl and/or wherein the mexthoxy group atthe 39 position is deleted together with the 39 carbon so that thecyclohexyl ring of rapamycin becomes a cyclopentyl ring lacking the 39position methyoxy group; e.g. as described in WO95/16691 and WO96/41807,the contents of which are incorporated by reference. The analogs can befurther modified such that the hydroxy at the 40-position of rapamycinis alkylated and/or the 32-carbonyl is reduced.

Rapamycin analogs from WO95/16691 include, but are not limited to,16-demethoxy-16-(pent-2-ynyl)oxy-rapamycin,16-demthoxy-16-(but-2-ynyl)oxy-rapamycin,16-demthoxy-16-(propargyl)oxy-rapamycin,16-demethoxy-16-(4-hydroxy-but-2-ynyl)oxy-rapamycin,16-demthoxy-16-benzyloxy-40-O-(2-hydroxyethyl)-rapamycin,16-demethoxy-16-benzyloxy-rapamycin,16-demethoxy-16-ortho-methoxybenzyl-rapamycin,16-demethoxy-40-O-(2-methoxyethyl)-16-pent-2-ynyl)oxy-rapamycin,39-demethoxy-40-desoxy-39-formyl-42-nor-rapamycin,39-demethoxy-40-desoxy-39-hydroxymethyl-42-nor-rapamycin,39-demethoxy-40-desoxy-39-carboxy-42-nor-rapamycin,39-demethoxy-40-desoxy-39-(4-methyl-piperazin-1-yl)carbonyl-42-nor-rapamycin,39-demethoxy-40-desoxy-39-(morpholin-4-yl)carbonyl-42-nor-rapamycin,39-demethoxy-40-desoxy-39-[N-methyl,N-(2-pyridin-2-yl-ethyl)]carbamoyl-42-nor-rapamycin and39-demethoxy-40-desoxy-39-(p-toluenesulfonylhydrazonomethyl)-42-nor-rapamycin.

Rapamycin analogs from WO96/41807 include, but are not limited to,32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-rapamycin,16-O-pent-2-ynyl-32-deoxo-40-O-(2-hydroxy-ethyl)-rapamycin,16-O-pent-2-ynyl-32-(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin,32(S)-dihydro-40-O-(2-methoxy)ethyl-rapamycin and32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin.

Another suitable rapamycin analog is umirolimus as described inUS2005/0101624 the contents of which are incorporated by reference.

RAD001, otherwise known as everolimus (Afinitor®), has the chemical name(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone,as described in U.S. Pat. No. 5,665,772 and WO94/09010, the contents ofeach are incorporated by reference.

Further examples of allosteric mTOR inhibitors include sirolimus(rapamycin, AY-22989),40-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin (alsocalled temsirolimus or CCI-779) and ridaforolimus (AP-23573/MK-8669).Other examples of allosteric mTor inhibitors include zotarolimus(ABT578) and umirolimus.

Alternatively or additionally, catalytic, ATP-competitive mTORinhibitors have been found to target the mTOR kinase domain directly andtarget both mTORC1 and mTORC2. These are also more effective inhibitorsof mTORC1 than such allosteric mTOR inhibitors as rapamycin, becausethey modulate rapamycin-resistant mTORC1 outputs such as 4EBP1-T37/46phosphorylation and cap-dependent translation.

Catalytic inhibitors include: BEZ235 or2-methyl-244-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile,or the monotosylate salt form (the synthesis of BEZ235 is described inWO2006/122806); CCG168 (otherwise known as AZD-8055, Chresta, C. M., etal., Cancer Res, 2010, 70(1), 288-298) which has the chemical name{5-[2,4-bis-((S)-3-methyl-morpholin-4-yl)-pyrido[2,3d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol;3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide(WO09104019);3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine(WO10051043 and WO2013023184); AN-(3-(N-(3-((3,5-dimethoxyphenyl)amino)quinoxaline-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide(WO07044729 and WO12006552); PKI-587 (Venkatesan, A. M., J. Med. Chem.,2010, 53, 2636-2645) which has the chemical name1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyflurea;GSK-2126458 (ACS Med. Chem. Lett., 2010, 1, 39-43) which has thechemical name2,4-difluoro-N-{2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide;5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine(WO10114484); and(E)-N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide(WO12007926).

Further examples of catalytic mTOR inhibitors include8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one(WO2006/122806) and Ku-0063794 (Garcia-Martinez J M, et al., Biochem J.,2009, 421(1), 29-42. Ku-0063794 is a specific inhibitor of the mammaliantarget of rapamycin (mTOR).) WYE-354 is another example of a catalyticmTOR inhibitor (Yu K, et al. (2009). Biochemical, Cellular, and In vivoActivity of Novel ATP-Competitive and Selective Inhibitors of theMammalian Target of Rapamycin. Cancer Res. 69(15): 6232-6240).

mTOR inhibitors useful according to the present invention also includeprodrugs, derivatives, pharmaceutically acceptable salts, or analogsthereof of any of the foregoing. mTOR inhibitors, such as RAD001, may beformulated for delivery based on well-established methods in the artbased on the particular dosages described herein. In particular, U.S.Pat. No. 6,004,973 (incorporated herein by reference) provides examplesof formulations useable with the mTOR inhibitors described herein.

Methods and Biomarkers for Evaluating CAR-Effectiveness or SampleSuitability

The present disclosure provides, among other things, gene signaturesthat indicate whether a cancer patient treated with a CAR therapy islikely to relapse, or has relapsed. Without wishing to be bound bytheory, an experimental basis for this gene signature is set out inExample 12.

In an embodiment, novel transcriptional gene signatures described herein(e.g., in Table 29 in Example 12) are used to enable manufacturedproduct improvements, thereby reducing the likelihood of patientrelapse. In an embodiment, gene signatures described herein are used tomodify therapeutic application of manufactured product, thereby reducingthe likelihood of patient relapse.

In an embodiment, gene signatures described herein (e.g., in Table 29 inExample 12) are identified in a subject prior to treatment with aCAR-expressing cell, e.g., CART treatment (e.g., a CART19 treatment,e.g., CTL019 therapy) that predict relapse to CAR treatment. In anembodiment, gene signatures described herein are identified in anapheresis sample or bone marrow sample. In an embodiment, genesignatures described herein are identified in a manufacturedCAR-expressing cell product, e.g., CART product (e.g., a CART19 product,e.g., CTL019) prior to infusion.

This disclosure also provides evidence, for instance in Example 12, that(without wishing to be bound by theory) decreasing the T_(REG) signaturein the patient prior to apheresis or during manufacturing of the CARTproduct reduces the risk of patient relapse.

In an embodiment, a patient is pre-treated with one or more therapiesthat reduce T_(REG) cells prior to collection of cells for CAR productmanufacturing, e.g., CART product manufacturing, thereby reducing therisk of patient relapse to CAR-expressing cell treatment (e.g., CTL019treatment). Methods of decreasing T_(REG) cells include, but are notlimited to, cyclophosphamide, anti-GITR antibody, CD25-depletion, andcombinations thereof.

In an embodiment, a patient is pre-treated with cyclophosphamide or ananti-GITR antibody prior to collection of cells for CAR-expressing cellproduct manufacturing, thereby reducing the risk of patient relapse toCAR-expressing cell treatment (e.g., CTL019 treatment).

In an embodiment, the CAR-expressing cell manufacturing process ismodified to deplete T_(REG) cells prior to manufacturing of theCAR-expressing cell product (e.g., a CTL019 product). In an embodiment,CD25-depletion is used to deplete T_(REG) cells prior to manufacturingof the CAR-expressing cell product (e.g., a CTL019 product).

In an embodiment, after treating a patient or a CAR-expressing cellproduct with a treatment that reduces T_(REG) cells, the patient istreated with a combination therapy. The combination therapy maycomprise, e.g., a CD19 inhibitor such as a CD19 CAR-expressing cell, andone or more B-cell inhibitors, e.g., B-cell inhibitors as describedherein.

In an embodiment, a patient is assayed for the level of T_(REG) cells ina patient sample, e.g., a sample comprising cancer cells and/or a samplerepresenting a tumor microenvironment. In an embodiment, thisinformation is used to determine a course of treatment for the patient.For instance, in an embodiment, if the patient is identified as havingelevated levels of T_(REG) cells compared to a control, the therapycomprises administering a treatment other than a CAR-expressing cell.For instance, the therapy may comprise administration of an antibodymolecule, administration of a small molecule therapeutic, surgery, orradiation therapy, or any combination thereof. This therapy may targetone or more B-cell antigens.

In an embodiment, a relapser is a patient having, or who is identifiedas having, an increased level of expression (e.g., increase in RNAlevels) of one or more of (e.g., 2, 3, 4, or all of) the followinggenes, compared to non relapsers: MIR199A1, MIR1203, uc021ovp, ITM2C,and HLA-DQB1 and/or a decreased levels of expression (e.g., decrease inRNA levels) of one or more of (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, orall of) the following genes, compared to non relapsers: PPIAL4D, TTTY10,TXLNG2P, MIR4650-1, KDM5D, USP9Y, PRKY, RPS4Y2, RPS4Y1, NCRNA00185,SULT1E1, and EIF1AY.

In another aspect, the invention features a method of evaluating ormonitoring the effectiveness of a CAR-expressing cell therapy, in asubject (e.g., a subject having a cancer), or the suitability of asample (e.g., an apheresis sample) for a CAR therapy, e.g., therapyincluding administration of a low, immune-enhancing dose of an mTORinhibitor. The method includes acquiring a value of effectiveness to theCAR therapy, or sample suitability, wherein said value is indicative ofthe effectiveness or suitability of the CAR-expressing cell therapy.

In embodiments, the value of effectiveness to the CAR therapy, or samplesuitability, comprises a measure of one, two, three, four, five, six ormore (all) of the following:

-   -   (i) the level or activity of one, two, three, or more (e.g.,        all) of resting T_(EFF) cells, resting T_(REG) cells, younger T        cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells),        or early memory T cells, or a combination thereof, in a sample        (e.g., an apheresis sample or a manufactured CAR-expressing cell        product sample);    -   (ii) the level or activity of one, two, three, or more (e.g.,        all) of activated T_(EFF) cells, activated T_(REG) cells, older        T cells (e.g., older CD4 or CD8 cells), or late memory T cells,        or a combination thereof, in a sample (e.g., an apheresis sample        or a manufactured CAR-expressing cell product sample);    -   (iii) the level or activity of an immune cell exhaustion marker,        e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1,        PD-L1, TIM-3 and/or LAG-3) in a sample (e.g., an apheresis        sample or a manufactured CAR-expressing cell product sample). In        one embodiment, an immune cell has an exhausted phenotype, e.g.,        co-expresses at least two exhaustion markers, e.g., co-expresses        PD-1 and TIM-3. In other embodiments, an immune cell has an        exhausted phenotype, e.g., co-expresses at least two exhaustion        markers, e.g., co-expresses PD-1 and LAG-3;    -   (iv) the level or activity of CD27 and/or CD45RO− (e.g.,        CD27+CD45RO−) immune effector cells, e.g., in a CD4+ or a CD8+ T        cell population, in a sample (e.g., an apheresis sample or a        manufactured CAR-expressing cell product sample);    -   (v) the level or activity of one, two, three, four, five, ten,        twelve or more of the biomarkers chosen from CCL20, IL-17a        and/or IL-6, PD-1, PD-L1, LAG-3, TIM-3, CD57, CD27, CD122,        CD62L, KLRG1;    -   (vi) a cytokine level or activity (e.g., quality of cytokine        repertoire) in a CAR-expressing cell product sample; or    -   (vii) a transduction efficiency of a CAR-expressing cell in a        manufactured CAR-expressing cell product sample.

In some embodiments of any of the methods disclosed herein, theCAR-expressing cell therapy comprises a plurality (e.g., a population)of CAR-expressing immune effector cells, e.g., a plurality (e.g., apopulation) of T cells or NK cells, or a combination thereof. In oneembodiment, the CAR-expressing cell therapy includes administration of alow, immune-enhancing dose of an mTOR inhibitor.

In some embodiments of any of the methods disclosed herein, the measureof one or more of (i)-(vii) is obtained from an apheresis sampleacquired from the subject. The apheresis sample can be evaluated priorto infusion or re-infusion.

In some embodiments of any of the methods disclosed herein, the measureof one or more of (i)-(vii) is obtained from a manufacturedCAR-expressing cell product sample. The manufactured CAR-expressing cellproduct can be evaluated prior to infusion or re-infusion.

In some embodiments of any of the methods disclosed herein, the subjectis evaluated prior to receiving, during, or after receiving, theCAR-expressing cell therapy.

In some embodiments of any of the methods disclosed herein, the measureof one or more of (i)-(vii) evaluates a profile for one or more of geneexpression, flow cytometry or protein expression.

In some embodiments of any of the methods disclosed herein, the methodfurther comprises identifying the subject as a responder, anon-responder, a relapser or a non-relapser, based on a measure of oneor more of (i)-(vii).

In some embodiments of any of the methods disclosed herein, a responder(e.g., a complete responder) has, or is identified as having, a greaterlevel or activity of one, two, or more (all) of GZMK, PPF1BP2, or naïveT cells as compared to a non-responder.

In some embodiments of any of the methods disclosed herein, anon-responder has, or is identified as having, a greater level oractivity of one, two, three, four, five, six, seven, or more (e.g., all)of IL22, IL-2RA, IL-21, IRF8, IL8, CCL17, CCL22, effector T cells, orregulatory T cells, as compared to a responder.

In an embodiment, a relapser is a patient having, or who is identifiedas having, an increased level of expression of one or more of (e.g., 2,3, 4, or all of) the following genes, compared to non relapsers:MIR199A1, MIR1203, uc021ovp, ITM2C, and HLA-DQB1 and/or a decreasedlevels of expression of one or more of (e.g., 2, 3, 4, 5, 6, 7, 8, 9,10, 11, or all of) the following genes, compared to non relapsers:PPIAL4D, TTTY10, TXLNG2P, MIR4650-1, KDM5D, USP9Y, PRKY, RPS4Y2, RPS4Y1,NCRNA00185, SULT1E1, and EIF1AY.

In some embodiments of any of the methods disclosed herein, a completeresponder has, or is identified as having, a greater, e.g., astatistically significant greater, percentage of CD8+ T cells comparedto a reference value, e.g., a non-responder percentage of CD8+ T cells.

In some embodiments of any of the methods disclosed herein, a completeresponder has, or is identified as having, a greater percentage ofCD27+CD45RO− immune effector cells, e.g., in the CD8+ population,compared to a reference value, e.g., a non-responder number ofCD27+CD45RO− immune effector cells.

In some embodiments of any of the methods disclosed herein, a completeresponder or a partial responder has, or is identified as having, agreater, e.g., a statistically significant greater, percentage of CD4+ Tcells compared to a reference value, e.g., a non-responder percentage ofCD4+ T cells.

In some embodiments of any of the methods disclosed herein, a completeresponder has, or is identified as having, a greater percentage of one,two, three, or more (e.g., all) of resting T_(EFF) cells, restingT_(REG) cells, younger T cells (e.g., younger CD4 or CD8 cells, orgamma/delta T cells), or early memory T cells, or a combination thereof,compared to a reference value, e.g., a non-responder number of restingT_(EFF) cells, resting T_(REG) cells, younger T cells (e.g., younger CD4or CD8 cells), or early memory T cells.

In some embodiments of any of the methods disclosed herein, anon-responder has, or is identified as having, a greater percentage ofone, two, three, or more (e.g., all) of activated T_(EFF) cells,activated T_(REG) cells, older T cells (e.g., older CD4 or CD8 cells),or late memory T cells, or a combination thereof, compared to areference value, e.g., a responder number of activated T_(EFF) cells,activated T_(REG) cells, older T cells (e.g., older CD4 or CD8 cells),or late memory T cells.

In some embodiments of any of the methods disclosed herein, anon-responder has, or is identified as having, a greater percentage ofan immune cell exhaustion marker, e.g., one, two or more immunecheckpoint inhibitors (e.g., PD-1, PD-L1, TIM-3 and/or LAG-3). In oneembodiment, a non-responder has, or is identified as having, a greaterpercentage of PD-1, PD-L1, or LAG-3 expressing immune effector cells(e.g., CD4+ T cells and/or CD8+ T cells) (e.g., CAR-expressing CD4+cells and/or CD8+ T cells) compared to the percentage of PD-1 or LAG-3expressing immune effector cells from a responder.

In one embodiment, a non-responder has, or is identified as having, agreater percentage of immune cells having an exhausted phenotype, e.g.,immune cells that co-express at least two exhaustion markers, e.g.,co-expresses PD-1, PD-L1 and/or TIM-3. In other embodiments, anon-responder has, or is identified as having, a greater percentage ofimmune cells having an exhausted phenotype, e.g., immune cells thatco-express at least two exhaustion markers, e.g., co-expresses PD-1 andLAG-3.

In some embodiments of any of the methods disclosed herein, anon-responder has, or is identified as having, a greater percentage ofPD-1/PD-L1+/LAG-3+ cells in the CAR-expressing cell population comparedto a responder (e.g., a complete responder) to the CAR-expressing celltherapy.

In some embodiments of any of the methods disclosed herein, a partialresponder has, or is identified as having, a higher percentages ofPD-1/PD-L1+/LAG-3+ cells, than a responder, in the CAR-expressing cellpopulation.

In some embodiments of any of the methods disclosed herein, anon-responder has, or is identified as having, an exhausted phenotype ofPD1/PD-L1+ CAR+ and co-expression of LAG3 in the CAR-expressing cellpopulation.

In some embodiments of any of the methods disclosed herein, anon-responder has, or is identified as having, a greater percentage ofPD-1/PD-L1+/TIM-3+ cells in the CAR-expressing cell population comparedto the responder (e.g., a complete responder).

In some embodiments of any of the methods disclosed herein, a partialresponders has, or is identified as having, a higher percentage ofPD-1/PD-L1+/TIM-3+ cells, than responders, in the CAR-expressing cellpopulation.

In some embodiments of any of the methods disclosed herein, the presenceof CD8+CD27+CD45RO− T cells in an apheresis sample is a positivepredictor of the subject response to a CAR-expressing cell therapy.

In some embodiments of any of the methods disclosed herein, a highpercentage of PD1+ CAR+ and LAG3+ or TIM3+ T cells in an apheresissample is a poor prognostic predictor of the subject response to aCAR-expressing cell therapy.

In some embodiments of any of the methods disclosed herein, theresponder (e.g., the complete or partial responder) has one, two, threeor more (or all) of the following profile:

-   -   (i) has a greater number of CD27+ immune effector cells compared        to a reference value, e.g., a non-responder number of CD27+        immune effector cells;    -   (ii) has a greater number of CD8+ T cells compared to a        reference value, e.g., a non-responder number of CD8+ T cells;    -   (iii) has a lower number of immune cells expressing one or more        checkpoint inhibitors, e.g., a checkpoint inhibitor chosen from        PD-1, PD-L1, LAG-3, TIM-3, or KLRG-1, or a combination, compared        to a reference value, e.g., a non-responder number of cells        expressing one or more checkpoint inhibitors; or    -   (iv) has a greater number of one, two, three, four or more (all)        of resting TEFF cells, resting T_(REG) cells, naïve CD4 cells,        unstimulated memory cells or early memory T cells, or a        combination thereof, compared to a reference value, e.g., a        non-responder number of resting T_(EFF) cells, resting T_(REG)        cells, naïve CD4 cells, unstimulated memory cells or early        memory T cells.

In some embodiments of any of the methods disclosed herein, the cytokinelevel or activity of (vi) is chosen from one, two, three, four, five,six, seven, eight, or more (or all) of cytokine CCL20/MIP3a, IL17A, IL6,GM-CSF, IFNγ, IL10, IL13, IL2, IL21, IL4, IL5, IL9 or TNFα, or acombination thereof. The cytokine can be chosen from one, two, three,four or more (all) of IL-17a, CCL20, IL2, IL6, or TNFa. In oneembodiment, an increased level or activity of a cytokine is chosen fromone or both of IL-17a and CCL20, is indicative of increasedresponsiveness or decreased relapse.

In some embodiments of any of the methods disclosed herein, atransduction efficiency of 15% or higher in (vii) is indicative ofincreased responsiveness or decreased relapse.

In some embodiments of any of the methods disclosed herein, atransduction efficiency of less than 15% in (vii) is indicative ofdecreased responsiveness or increased relapse.

In embodiments, the responder, a non-responder, a relapser or anon-relapser identified by the methods herein can be further evaluatedaccording to clinical criteria. For example, a complete responder has,or is identified as, a subject having a disease, e.g., a cancer, whoexhibits a complete response, e.g., a complete remission, to atreatment. A complete response may be identified, e.g., using the NCCNGuidelines® (which are incorporated by reference herein in theirentireties), as described herein. A partial responder has, or isidentified as, a subject having a disease, e.g., a cancer, who exhibitsa partial response, e.g., a partial remission, to a treatment. A partialresponse may be identified, e.g., using the NCCN Guidelines®, asdescribed herein. A non-responder has, or is identified as, a subjecthaving a disease, e.g., a cancer, who does not exhibit a response to atreatment, e.g., the patient has stable disease or progressive disease.A non-responder may be identified, e.g., using the NCCN Guidelines®, asdescribed herein.

Alternatively, or in combination with the methods disclosed herein,responsive to said value, performing one, two, three, four or more of:

-   -   administering e.g., to a responder or a non-relapser, a        CAR-expressing cell therapy;    -   administered an altered dosing of a CAR-expressing cell therapy;    -   altering the schedule or time course of a CAR-expressing cell        therapy;    -   administering, e.g., to a non-responder or a partial responder,        an additional agent in combination with a CAR-expressing cell        therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint        inhibitor described herein;    -   administering to a non-responder or partial responder a therapy        that increases the number of younger T cells in the subject        prior to treatment with a CAR-expressing cell therapy;    -   modifying a manufacturing process of a CAR-expressing cell        therapy, e.g., enriching for younger T cells prior to        introducing a nucleic acid encoding a CAR, or increasing the        transduction efficiency, e.g., for a subject identified as a        non-responder or a partial responder;    -   administering an alternative therapy, e.g., for a non-responder        or partial responder or relapser; or if the subject is, or is        identified as, a non-responder or a relapser, decreasing the        T_(REG) cell population and/or T_(REG) gene signature, e.g., by        one or more of CD25 depletion, administration of        cyclophosphamide, anti-GITR antibody, or a combination thereof.

In certain embodiments, the subject is pre-treated with an anti-GITRantibody. In certain embodiment, the subject is treated with ananti-GITR antibody prior to infusion or re-infusion.

In some embodiments of the methods described herein, imaging withFDG-PET/CT (PET/CT) is performed on a subject who has been treated witha CAR therapy. This measurement can predict response to the therapy. Forinstance, in embodiments, metabolically active tumor volume (MTV) and/or[11F]-2-fluoro-2-deoxy-D-glucose (FDG) uptake are measured. Inembodiments, a decrease in MTV is indicative of response, e.g., CR(complete response) or PR (partial response), e.g., a post-treatment MTVvalue of about 0 is indicative of CR, while an increase in MTV isindicative of PD (progressive disease). In embodiments, a decrease inFDG uptake is indicative of response, e.g., CR or PR, while an increasein FDG uptake is indicative of PD. In embodiments, the imaging isperformed after administration of the CAR therapy, e.g., about 1 week, 2weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5months, or 6 months after administration of the CAR therapy. Inembodiments, the imaging is performed on a subject who does not havesymptoms of CRS (cytokine release syndrome), e.g., a patient whosuffered from CRS and whose symptoms resolved prior to imaging. Inembodiments, the imaging is performed on a subject who has symptoms ofCRS. In embodiments, imaging is performed prior to CAR therapy, and thepre-therapy image is compared to a post-therapy image. In embodiments,the subject has a cancer, e.g., lymphoma, e.g., diffuse large B-celllymphoma (DLBCL) or follicular lymphoma (FL). In some embodiments, theCAR therapy comprises a CAR19-expressing cell, e.g., CTL019. In someembodiments, the CAR therapy comprises a CAR therapy described herein,e.g., a CAR20-expressing cell, a CAR22-expressing cell, or aCAR19-expressing cell, optionally in combination with a B-cell therapy.

Personalized Medicine (Theranostics)

CD19 Characteristics, e.g. Mutations

Without wishing to be bound by theory, some cancer patients show aninitial response to a CD19 inhibitor such as a CD19 CAR-expressing cell,and then relapse. In some embodiments, the relapse is caused (at leastin part) by a frameshift and/or premature stop codon in CD19 in thecancer cells, or other change in the expression (including expressionlevels) of CD19 which reduces the ability of a CD19 CAR-expressing cellto target the cancer cells. Such a mutation can reduce the effectivenessof the CD19 therapy and contribute to the patient's relapse.Accordingly, in some embodiments, it can be beneficial when a CD19therapy is supplemented or replaced with a therapy directed to a second,different target, e.g., a target expressed in B-cells, e.g., one or moreof CD10, CD20, CD22, CD34, CD123, FLT-3, or ROR1. Various exemplarycombination therapies of this type are disclosed herein.

This application discloses, among other things, methods for treating asubject having cancer comprising one or more of: (1) determining if asubject has a difference, e.g., statistically significant difference, ina characteristic of CD19 relative to a reference characteristic, and (2)if there is a difference between the determined characteristic andreference characteristic, administering to the subject a therapeuticallyeffective dose of a CAR therapy, e.g., CART, thereby treating thesubject. The patient may be, e.g., a patient who has relapsed aftertreatment with a CD19 inhibitor, e.g., a CD19 CAR expressing cell. Thepatient may be a patient who has received or is receiving a CD19 CARtherapy and is at risk of relapse. The patient may be a non-responder toa CD19 CAR therapy.

The characteristic can be, e.g., a CD19 sequence, e.g., protein ornucleic acid sequence. The sequence can be determined, e.g., asdescribed in the Examples, by high throughput nucleic acid sequencing,or by mass spectrometry of proteins. As described in the Example herein,a patient may relapse after CD19 CART therapy because of mutations inCD19, e.g., in exon 2 of CD19, e.g., a mutation that causes a frameshiftand a premature stop codon in CD19. In embodiments, the insertion ordeletion does not cause one or both of a frameshift and a premature stopcodon. The mutation may be, e.g., an insertion, a deletion, asubstitution, a translocation, or a combination of any of the foregoing.The insertion, deletion, or substitution may involve, e.g., at least 1,2, 3, 4, 5, 10, 15, 20, 20, or 50 nucleotides. The insertion, deletion,or substitution may involve, e.g., at most 2, 3, 4, 5, 10, 15, 20, 20,50, or 100 nucleotides. In some cases, a population of cells willcomprise more than one mutation. In such cases, the mutations can be inoverlapping or non-overlapping sub-populations of cells.

In some cases a patient is identified as having a CD19 characteristicthat reduces CD19's ability to engage with a CD19 inhibitor such as aCD19 CAR expressing cell. Such a characteristic may be, e.g., aframeshift mutation, a premature stop codon, an alteration in nucleicacid sequence or an alteration in the structure of the primary mRNAtranscript. The characteristic may be, e.g., a departure from normalproduction of CD19 that occurs earlier than splicing. The characteristicmay be, e.g., a characteristic other than exon skipping. Such patientsmay be treated with an inhibitor of another target, e.g., a B-cellinhibitor, for example a CAR expressing cell directed against anotherepitope, e.g., an epitope within one or more of CD10, CD20, CD22, CD34,CD123, FLT-3, or ROR1.

In some cases, a patient is identified as having a CD19 characteristicthat reduces CD19's ability to engage with a CD19 inhibitor, such as aCD19 CAR expressing cell, but does not reduce or abrogate CD19's abilityto engage with a second CD19 inhibitor, such as a CD19 inhibitor thatbinds to a different region on CD19. Such a characteristic may be, e.g.,a mutation that does not cause one or both of a frameshift mutation or apremature stop codon. Such a characteristic may be, e.g., an alterationin nucleic acid sequence or an alteration in the structure of theprimary mRNA transcript, a departure from normal production of CD19 thatoccurs earlier than splicing, or a characteristic other than exonskipping. Such patients may be treated with an inhibitor of CD19, e.g.,a B-cell inhibitor directed against an intact region of CD19, e.g., awild-type portion of CD19. For instance, if a mutation is present inexon 2, the second CD19 inhibitor may bind to an exon other than exon 2,or a part of exon 2 that lacks the mutation. The second CD19 inhibitormay be, e.g., a CD19 inhibitor described herein.

T_(EFF) AND T_(REG) Signatures

Methods herein can include steps of determining a T_(REG) signature ordetermining the levels of T_(EFF) cells or T_(REG) cells, e.g., in apatient or in a population of cells e.g., immune cells. Methods hereincan also include steps of reducing the level of T_(REG) cells, ordecreasing a T_(REG) signature, in a patient or in a population ofcells. In some embodiments, a T_(EFF) is a cell with upregulatedexpression of one or more (e.g., at least 10, 20, 30, 40, 50, 60, 70,80, or all) of the following genes: AIM2, ALAS1, B4GALT5, BATF, C3orf26,C4orf43, CCL3, CCL4, CCT3, CCT7, CD40LG, CHAC2, CSF2, CTNNA1, EBNA1BP2,EDARADD, EEF1E1, EIF2B3, EIF2S1, FABP5, FAM40B, FKBP4, FOSL1, GFOD1,GLRX2, HSPD1, HSPE1, IFNG, IL15RA, IL21, IL2RA, IL3, KCNK5, KIAA0020,LARP4, LRP8, LTA, MANF, MIR1182, MIR155, MIR155HG, MTCH2, MYOF, NDUFAF1,NLN, NME1, NME1-NME2, OTUD7B, PAM, PDIA6, PEA15, PFKM, PGAM1, PGAM4,PPIL1, PRDX4, PRSS23, PSMD1, PSMD11, PSMD14, PTRH2, PUS7, RBBP8, RPF2,RPP25, SFXN1, SLC27A2, SLC39A14, SLC43A3, SORD, SPR, SRXN1, STIP1,STT3A, TBX21, TMCC2, TMEM165, TNFRSF9, TXN, TXNDC5, UCK2, VDR, WDR12,YWHAG, and ZDHHC16. In some embodiments, a T_(REG) cell is a cell withupregulated expression of one or more (e.g., at least 10, 20, 30, 40,50, 60, 70, or all) of the following genes: AIM2, ALAS1, BATF, C5orf32,CCL17, CD40LG, CHAC2, CSF1, CTSL1, EBNA1BP2, EDARADD, EMP1, EPAS1,FABP5, FAM40B, FKBP4, FOSL1, GCLM, GK, GPR56, HMOX1, HSPD1, HSPE1,IKBIP, IL10, IL13, IL15RA, IL1RN, IL2RA, IL3, IL4, IL5, IL9, KCNK5, LTA,MANF, MIR1182, MIR155, MIR155HG, MYOF, NDUFAF1, NLN, NME1, NME1-NME2,PANX2, PDIA6, PGAM4, PPIL1, PPPDE2, PRDX4, PRKAR1B, PSMD1, PSMD11, PUS7,RBBP8, SLC27A2, SLC39A14, SLC43A3, SRXN1, STIP1, STT3A, TBX21,TNFRSF11A, TNFRSF1B, TNFRSF8, TNFRSF9, TXN, UCK2, VDR, VTRNA1-3, WDR12,YWHAG, ZDHHC16, and ZNF282. The upregulated expression may be, e.g.,measured 16 hours after stimulation. The upregulated expression may bedetermined, e.g., by measuring RNA levels for the indicated genes.

Pharmaceutical Compositions and Treatments

Pharmaceutical compositions of the present invention may comprise, insome aspects, a CAR-expressing cell, e.g., a plurality of CAR-expressingcells, as described herein, in combination with one or morepharmaceutically or physiologically acceptable carriers, diluents orexcipients. Such compositions may comprise buffers such as neutralbuffered saline, phosphate buffered saline and the like; carbohydratessuch as glucose, mannose, sucrose or dextrans, mannitol; proteins;polypeptides or amino acids such as glycine; antioxidants; chelatingagents such as EDTA or glutathione; adjuvants (e.g., aluminumhydroxide); and preservatives. Compositions of the present invention arein one aspect formulated for intravenous administration.

Pharmaceutical compositions of the present invention may be administeredin a manner appropriate to the disease to be treated (or prevented). Thequantity and frequency of administration will be determined by suchfactors as the condition of the patient, and the type and severity ofthe patient's disease, although appropriate dosages may be determined byclinical trials.

In one embodiment, the pharmaceutical composition is substantially freeof, e.g., there are no detectable levels of a contaminant, e.g.,selected from the group consisting of endotoxin, mycoplasma, replicationcompetent lentivirus (RCL), p24, VSV-G nucleic acid, HIV gag, residualanti-CD3/anti-CD28 coated beads, mouse antibodies, pooled human serum,bovine serum albumin, bovine serum, culture media components, vectorpackaging cell or plasmid components, a bacterium and a fungus. In oneembodiment, the bacterium is at least one selected from the groupconsisting of Alcaligenes faecalis, Candida albicans, Escherichia coli,Haemophilus influenza, Neisseria meningitides, Pseudomonas aeruginosa,Staphylococcus aureus, Streptococcus pneumonia, and Streptococcuspyogenes group A.

When “an immunologically effective amount,” “an anti-tumor effectiveamount,” “a tumor-inhibiting effective amount,” or “therapeutic amount”is indicated, the precise amount of the compositions of the presentinvention to be administered can be determined by a physician withconsideration of individual differences in age, weight, tumor size,extent of infection or metastasis, and condition of the patient(subject). In some embodiments, a pharmaceutical composition comprisingthe cells, e.g., T cells described herein may be administered at adosage of 10⁴ to 10⁹ cells/kg body weight, in some instances 10⁵ to 10⁶cells/kg body weight, including all integer values within those ranges.In some embodiments, the cells, e.g., T cells described herein may beadministered at 3×10⁴, 1×10⁶, 3×10⁶, or 1×10⁷ cells/kg body weight. Thecell compositions may also be administered multiple times at thesedosages. The cells can be administered by using infusion techniques thatare commonly known in immunotherapy (see, e.g., Rosenberg et al., NewEng. J. of Med. 319:1676, 1988).

In some embodiments, a dose of CAR cells (e.g., CD10, CD19, CD20, CD22,CD34, CD123, FLT-3, or ROR1 CAR cells) comprises about 1×10⁵, 2×10⁵,5×10⁵, 1×10⁶, 1.1×10⁶, 2×10⁶, 3.6×10⁶, 5×10⁶, 1×10⁷, 1.8×10⁷, 2×10⁷,5×10⁷, 1×10⁸, 2×10⁸, or 5×10⁸ cells/kg. In some embodiments, a dose ofCAR cells (e.g., CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, or ROR1 CARcells) comprises at least about 1×10⁵, 2×10⁵, 5×10⁵, 1×10⁶, 1.1×10⁶,2×10⁶, 3.6×10⁶, 5×10⁶, 1×10⁷, 1.8×10⁷, 2×10⁷, 5×10⁷, 1×10⁸, 2×10⁸, or5×10⁸ cells/kg. In some embodiments, a dose of CAR cells (e.g., CD10,CD19, CD20, CD22, CD34, CD123, FLT-3, or ROR1 CAR cells) comprises up toabout 1×10⁵, 2×10⁵, 5×10⁵, 1×10⁶, 1.1×10⁶, 2×10⁶, 3.6×10⁶, 5×10⁶, 1×10⁷,1.8×10⁷, 2×10⁷, 5×10⁷, 1×10⁸, 2×10⁸, or 5×10⁸ cells/kg. In someembodiments, a dose of CAR cells (e.g., CD10, CD19, CD20, CD22, CD34,CD123, FLT-3, or ROR1 CAR cells) comprises about 1.1×10⁶-1.8×10⁷cells/kg or about 8×10⁵-1.5×10⁶ cells/kg. In some embodiments, a dose ofCAR cells (e.g., CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, or ROR1 CARcells) comprises about 1×10⁷, 2×10⁷, 5×10⁷, 1×10⁸, 2×10⁸, 5×10⁸, 1×10⁹,2×10⁹, or 5×10⁹ cells. In some embodiments, a dose of CAR cells (e.g.,CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, or ROR1 CAR cells) comprisesat least about 1×10⁷, 2×10⁷, 5×10⁷, 1×10⁸, 2×10⁸, 5×10⁸, 1×10⁹, 2×10⁹,or 5×10⁹ cells. In some embodiments, a dose of CAR cells (e.g., CD10,CD19, CD20, CD22, CD34, CD123, FLT-3, or ROR1 CAR cells) comprises up toabout 1×10⁷, 2×10⁷, 5×10⁷, 1×10⁸, 2×10⁸, 5×10⁸, 1×10⁹, 2×10⁹, or 5×10⁹cells.

In certain aspects, it may be desired to administer activated cells,e.g., T cells or NK cells, to a subject and then subsequently redrawblood (or have an apheresis performed), activate the cells therefromaccording to the present invention, and reinfuse the patient with theseactivated and expanded cells. This process can be carried out multipletimes every few weeks. In certain aspects, cells, e.g., T cells or NKcells, can be activated from blood draws of from 10 cc to 400 cc. Incertain aspects, cells, e.g., T cells or NK cells, are activated fromblood draws of 20 cc, 30 cc, 40 cc, 50 cc, 60 cc, 70 cc, 80 cc, 90 cc,or 100 cc.

The administration of the subject compositions may be carried out in anyconvenient manner, including by aerosol inhalation, injection,ingestion, transfusion, implantation or transplantation. Thecompositions described herein may be administered to a patient transarterially, subcutaneously, intradermally, intratumorally, intranodally,intramedullary, intramuscularly, by intravenous (i.v.) injection, orintraperitoneally. In one aspect, the cell compositions, e.g., T cell orNK cell compositions, of the present invention are administered to apatient by intradermal or subcutaneous injection. In one aspect, thecell compositions e.g., T cell or NK cell compositions, of the presentinvention are administered by i.v. injection. The compositions of cellse.g., T cell or NK cell compositions, may be injected directly into atumor, lymph node, or site of infection.

In a particular exemplary aspect, subjects may undergo leukapheresis,wherein leukocytes are collected, enriched, or depleted ex vivo toselect and/or isolate the cells of interest, e.g., T cells. These cellisolates, e.g., T cell or NK cell isolates, may be expanded by methodsknown in the art and treated such that one or more CAR constructs of theinvention may be introduced, thereby creating a CAR-expressing cell,e.g., CAR T cell of the invention. Subjects in need thereof maysubsequently undergo standard treatment with high dose chemotherapyfollowed by peripheral blood stem cell transplantation. In certainaspects, following or concurrent with the transplant, subjects receivean infusion of the expanded CAR-expressing cells of the presentinvention. In an additional aspect, expanded cells are administeredbefore or following surgery.

The dosage of the above treatments to be administered to a patient willvary with the precise nature of the condition being treated and therecipient of the treatment. The scaling of dosages for humanadministration can be performed according to art-accepted practices. Thedose for a therapeutic, e.g., an antibody, e.g., CAMPATH, for example,may be, e.g., in the range 1 to about 100 mg for an adult patient, e.g.,administered daily for a period between 1 and 30 days. A suitable dailydose is 1 to 10 mg per day although in some instances larger doses of upto 40 mg per day may be used (described in U.S. Pat. No. 6,120,766).

In one embodiment, the CAR is introduced into cells, e.g., T cells or NKcells, e.g., using in vitro transcription, and the subject (e.g., human)receives an initial administration of CAR-expressing cells, e.g., CAR Tcells of the invention, and one or more subsequent administrations ofthe CAR-expressing cells, e.g., CAR T cells of the invention, whereinthe one or more subsequent administrations are administered less than 15days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after theprevious administration. In one embodiment, more than one administrationof the CAR-expressing cells, e.g., CAR T cells of the invention areadministered to the subject (e.g., human) per week, e.g., 2, 3, or 4administrations of the CAR-expressing cells, e.g., CAR T cells of theinvention are administered per week. In one embodiment, the subject(e.g., human subject) receives more than one administration of theCAR-expressing cells, e.g., CAR T cells per week (e.g., 2, 3 or 4administrations per week) (also referred to herein as a cycle), followedby a week of no CAR-expressing cells, e.g., CAR T cells administrations,and then one or more additional administration of the CAR-expressingcells, e.g., CAR T cells (e.g., more than one administration of theCAR-expressing cells, e.g., CAR T cells per week) is administered to thesubject. In another embodiment, the subject (e.g., human subject)receives more than one cycle of CAR-expressing cells, e.g., CART cells,and the time between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3days. In one embodiment, the CAR-expressing cells, e.g., CAR T cells areadministered every other day for 3 administrations per week. In oneembodiment, the CAR-expressing cells, e.g., CAR T cells of the inventionare administered for at least two, three, four, five, six, seven, eightor more weeks.

In some embodiments, subjects may be adult subjects (i.e., 18 years ofage and older). In certain embodiments, subjects may be between 1 and 30years of age. In some embodiments, the subjects are 16 years of age orolder. In certain embodiments, the subjects are between 16 and 30 yearsof age. In some embodiments, the subjects are child subjects (i.e.,between 1 and 18 years of age).

In one aspect, CAR-expressing cells, e.g., CARTs are generated usinglentiviral viral vectors, such as lentivirus. CAR-expressing cells,e.g., CARTs generated that way will have stable CAR expression.

In one aspect, CAR-expressing cells, e.g., CARTs, are generated using aviral vector such as a gammaretroviral vector, e.g., a gammaretroviralvector described herein. CARTs generated using these vectors can havestable CAR expression.

In one aspect, CAR-expressing cells, e.g., CARTs transiently express CARvectors for 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days aftertransduction. Transient expression of CARs can be effected by RNA CARvector delivery. In one aspect, the CAR RNA is transduced into the cell,e.g., NK cell or T cell, by electroporation.

A potential issue that can arise in patients being treated usingtransiently expressing CAR T cells (particularly with murine scFvbearing CARTs) is anaphylaxis after multiple treatments.

Without being bound by this theory, it is believed that such ananaphylactic response might be caused by a patient developing humoralanti-CAR response, i.e., anti-CAR antibodies having an anti-IgE isotype.It is thought that a patient's antibody producing cells undergo a classswitch from IgG isotype (that does not cause anaphylaxis) to IgE isotypewhen there is a ten to fourteen day break in exposure to antigen.

If a patient is at high risk of generating an anti-CAR antibody responseduring the course of transient CAR therapy (such as those generated byRNA transductions), CART infusion breaks should not last more than tento fourteen days.

CD19 Antibodies and CARs Humanization of Murine Anti-CD19 Antibody

Humanization of murine CD19 antibody is desired for the clinicalsetting, where the mouse-specific residues may induce a human-anti-mouseantigen (HAMA) response in patients who receive CART19 treatment, i.e.,treatment with T cells transduced with the CAR19 construct. Theproduction, characterization, and efficacy of humanized CD19 CARsequences is described in International Application WO2014/153270 whichis herein incorporated by reference in its entirety, including Examples1-5 (p. 115-159), for instance Tables 3, 4, and 5 (p. 125-147).

CAR Constructs, e.g., CD19 CAR Constructs

Of the CD19 CAR constructs described in International ApplicationWO2014/153270, certain sequences are reproduced herein. It is understoodthat the sequences in this section can also be used in the context ofother CARs, e.g., CD10 CARs, CD20 CARs, CD22 CARs, CD34 CARs, CD123CARs, FLT-3 CARs, ROR1 CARs, CD79b CARs, CD179b CARs, or CD79a CARs.

The sequences of the humanized scFv fragments (SEQ ID NOS: 1-12) areprovided below in Table 2. Full CAR constructs were generated using SEQID NOs: 1-12 with additional sequences, SEQ ID NOs: 13-17, shown below,to generate full CAR constructs with SEQ ID NOs: 31-42.

leader (amino acid sequence) (SEQ ID NO: 13) MALPVTALLLPLALLLHAARPleader (nucleic acid sequence) (SEQ ID NO: 54)ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCA TGCCGCTAGACCCCD8 hinge (amino acid sequence) (SEQ ID NO: 14)TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDCD8 hinge (nucleic acid sequence) (SEQ ID NO: 55)ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATCD8 transmembrane (amino acid sequence) (SEQ ID NO: 15)IYIWAPLAGTCGVLLLSLVITLYC transmembrane (nucleic acid sequence)(SEQ ID NO: 56) ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC 4-1BB Intracellular domain (amino acid sequence)(SEQ ID NO: 16) KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL4-1BB Intracellular domain (nucleic acid sequence) (SEQ ID NO: 60)AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG CD3 zeta domain (amino acid sequence)(SEQ ID NO: 17) RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPRCD3 zeta (nucleic acid sequence) (SEQ ID NO: 101)AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCCD3 zeta domain (amino acid sequence; NCBIReference Sequence NM_000734.3) (SEQ ID NO: 43)RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPRCD3 zeta (nucleic acid sequence; NCBI Reference Sequence NM_000734.3);(SEQ ID NO: 44) AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC CD28 domain(amino acid sequence, SEQ ID NO: 1317)RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS CD28 domain(nucleotide sequence, SEQ ID NO: 1318)AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCC Wild-type ICOS domain(amino acid sequence, SEQ ID NO: 1319)TKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL Wild-type ICOS domain(nucleotide sequence, SEQ ID NO: 1320)ACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTG ACCCTAY to F mutant ICOS domain (amino acid sequence, SEQ ID NO: 1321)TKKKYSSSVHDPNGEFMFMRAVNTAKKSRLTDVTL IgG4 Hinge (amino acid sequence)(SEQ ID NO: 102) ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKM IgG4 Hinge (nucleotide sequence)(SEQ ID NO: 103) GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATG

These clones all contained a Q/K residue change in the signal domain ofthe co-stimulatory domain derived from 4-1BB.

TABLE 2 Humanized CD19 CAR Constructs Name SEQ ID Sequence CAR1CAR1 scFv 1 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHT domainSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS 103101 61atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR1tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Solubleagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattgg scFv-nttatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactactcttcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagccaccaccatcatcaccatcaccat 103101 73 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlscrasqdiskylnw CAR1yqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqg Solublentlpytfgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltctvs scFv-aagvslpdygvswirqppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss hhhhhhhh 104875 85atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR1-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Full-ntagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactactcttcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctc gg 104875 31MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc rasqdiskylnw CAR1-yqqkpgqaprlliy htsrlhs giparfsgsgsgtdytltisslqpedfavyfc qqg Full-aantlpyt fgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltctvs gvslp dygvswirqppgkglewig viwgsettyyssslks rvtiskdnsknqvslk lssvtaadtavyycakhyyyggsyamdy wgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR2 CAR2 scFv 2eivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhs domaingiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgsettyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss 103102 62atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR2-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Solubleagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattgg scFv-nttatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactaccaatcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagccaccaccatcatcaccatcaccat 103102 74 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlscrasqdiskylnw CAR2-yqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqg Solublentlpytfgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltctvs scFv-aagvslpdygvswirqppgkglewigviwgsettyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss hhhhhhhh 104876 86atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR2-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Full-ntagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactaccaatcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctc gg 104876 32MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc rasqdiskyln w CAR2-yqqkpgqaprlliy htsrlhs giparfsgsgsgtdytltisslqpedfavyfc qqq Full-aantlpyt fgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltctvs gvslp dygvswirqppgkglewig viwgsettyyqsslks rvtiskdnsknqvslk lssvtaadtavyycakhyyyggsyamdy wgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR3 CAR3 scFv 3qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgset domaintyyssslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggseivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik 103104 63atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR3-tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Solublectctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagc scFv-nttggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactattcatcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaacatcaccaccatcatcaccatcac 103104 75 MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslpdygvs CAR3-wirqppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaadta Solublevyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggseivmtqspatls scFv-aalspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik hhhhhhhh 104877 87atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR3-tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Full-ntctctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagctggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactattcatcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaaggccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctc gg 104877 33MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp dygvs CAR3-wirqppgkglewig viwgsettyyssslks rvtiskdnsknqvslklssvtaadta Full-aavyycak hyyyggsyamdy wgqgtlvtvssggggsggggsggggseivmtqspatls lspgeratlscrasqdiskyln wyqqkpgqaprlliy htsrlhs giparfsgsgsg tdytltisslqpedfavyfcqqgntlpyt fgqgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR4 CAR4 scFv 4qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgset domaintyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggseivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik 103106 64atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR4-tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Solublectctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagc scFv-nttggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactatcaatcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaacatcaccaccatcatcaccatcac 103106 76 MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslpdygvs CAR4-wirqppgkglewigviwgsettyyqsslksrvtiskdnsknqvslklssvtaadta Solublevyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggseivmtqspatls scFv-aalspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik hhhhhhhh 104878 88atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR4-tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Full-ntctctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagctggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactatcaatcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaaggccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctc gg 104878 34MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp dygvs CAR4-wirqppgkglewig viwgsettyyqsslks rvtiskdnsknqvslklssvtaadta Full-aavyycak hyyyggsyamdy wgqgtlvtvssggggsggggsggggseivmtqspatls lspgeratlscrasqdiskyln wyqqkpgqaprlliy htsrlhs giparfsgsgsg tdytltisslqpedfavyfcqqgntlpyt fgqgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR5 CAR5 scFv 5eivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhs domaingiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss 99789 65atggccctcccagtgaccgctctgctgctgcctctcgcacttcttctccatgccgc CAR5-tcggcctgagatcgtcatgacccaaagccccgctaccctgtccctgtcacccggcg Solubleagagggcaaccctttcatgcagggccagccaggacatttctaagtacctcaactgg scFv-nttatcagcagaagccagggcaggctcctcgcctgctgatctaccacaccagccgcctccacagcggtatccccgccagattttccgggagcgggtctggaaccgactacaccctcaccatctcttctctgcagcccgaggatttcgccgtctatttctgccagcaggggaatactctgccgtacaccttcggtcaaggtaccaagctggaaatcaagggaggcggaggatcaggcggtggcggaagcggaggaggtggctccggaggaggaggttcccaagtgcagcttcaagaatcaggacccggacttgtgaagccatcagaaaccctctccctgacttgtaccgtgtccggtgtgagcctccccgactacggagtctcttggattcgccagcctccggggaagggtcttgaatggattggggtgatttggggatcagagactacttactactcttcatcacttaagtcacgggtcaccatcagcaaagataatagcaagaaccaagtgtcacttaagctgtcatctgtgaccgccgctgacaccgccgtgtactattgtgccaaacattactattacggagggtcttatgctatggactactggggacaggggaccctggtgactgtctctagccatcaccatcaccaccatcatcac 99789 77MALPVTALLLPLALLLHAARP eivmtqspatlslspgeratlscrasqdiskylnw CAR5-yqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqg Solublentlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsl scFv-aatctvsgvslpdygvswirqppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss hhhhhhhh 104879 89atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR5-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Full-ntagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggcggaggcgggagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactactcttcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 104879 35 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlscrasqdiskyln w CAR5- yqqkpgqaprlliy htsrlhsgiparfsgsgsgtdytltisslqpedfavyfc qqg Full-aa ntlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsl tctvsgvslp dygvswirqppgkglewig viwgsettyyssslks rvtiskdnskn qvslklssvtaadtavyycakhyyyggsyamdy wgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR6 CAR6 6eivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhs scFvgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggggs domainggggsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgsettyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss 99790 66atggccctcccagtgaccgctctgctgctgcctctcgcacttcttctccatgccgc CAR6-tcggcctgagatcgtcatgacccaaagccccgctaccctgtccctgtcacccggcg Solubleagagggcaaccctttcatgcagggccagccaggacatttctaagtacctcaactgg scFv-nttatcagcagaagccagggcaggctcctcgcctgctgatctaccacaccagccgcctccacagcggtatccccgccagattttccgggagcgggtctggaaccgactacaccctcaccatctcttctctgcagcccgaggatttcgccgtctatttctgccagcaggggaatactctgccgtacaccttcggtcaaggtaccaagctggaaatcaagggaggcggaggatcaggcggtggcggaagcggaggaggtggctccggaggaggaggttcccaagtgcagcttcaagaatcaggacccggacttgtgaagccatcagaaaccctctccctgacttgtaccgtgtccggtgtgagcctccccgactacggagtctcttggattcgccagcctccggggaagggtcttgaatggattggggtgatttggggatcagagactacttactaccagtcatcacttaagtcacgggtcaccatcagcaaagataatagcaagaaccaagtgtcacttaagctgtcatctgtgaccgccgctgacaccgccgtgtactattgtgccaaacattactattacggagggtcttatgctatggactactggggacaggggaccctggtgactgtctctagccatcaccatcaccaccatcatcac 99790 78MALPVTALLLPLALLLHAARP eivmtqspatlslspgeratlscrasqdiskylnw CAR6-yqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqg Solublentlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsl scFv-aatctvsgvslpdygvswirqppgkglewigviwgsettyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss hhhhhhhh 104880 90atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR6-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Full-ntagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggaggcggagggagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactaccaatcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 104880 36 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlscrasqdiskylnw CAR6- yqqkpgqaprlliy htsrlhsgiparfsgsgsgtdytltisslqpedfavyfc qqg Full-aa ntlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsl tctvsgvslp dygvswirqppgkglewig viwgsettyyqsslks rvtiskdnskn qvslklssvtaadtavyycakhyyyggsyamdy wgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR7 CAR7 scFv 7qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgset domaintyyssslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik 100796 67atggcactgcctgtcactgccctcctgctgcctctggccctccttctgcatgccgc CAR7-caggccccaagtccagctgcaagagtcaggacccggactggtgaagccgtctgaga Solublectctctcactgacttgtaccgtcagcggcgtgtccctccccgactacggagtgtca scFv-nttggatccgccaacctcccgggaaagggcttgaatggattggtgtcatctggggttctgaaaccacctactactcatcttccctgaagtccagggtgaccatcagcaaggataattccaagaaccaggtcagccttaagctgtcatctgtgaccgctgctgacaccgccgtgtattactgcgccaagcactactattacggaggaagctacgctatggactattggggacagggcactctcgtgactgtgagcagcggcggtggagggtctggaggtggaggatccggtggtggtgggtcaggcggaggagggagcgagattgtgatgactcagtcaccagccaccctttctctttcacccggcgagagagcaaccctgagctgtagagccagccaggacatttctaagtacctcaactggtatcagcaaaaaccggggcaggcccctcgcctcctgatctaccatacctcacgccttcactctggtatccccgctcggtttagcggatcaggatctggtaccgactacactctgaccatttccagcctgcagccagaagatttcgcagtgtatttctgccagcagggcaatacccttccttacaccttcggtcagggaaccaagctcgaaatcaagcaccatcaccatcatcaccaccat 100796 79MALPVTALLLPLALLLHAARP qvqlqesgpglvkpsetlsltctvsgvslpdygvs CAR7-wirqppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaadta Solublevyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggsggggseivmtqs scFv-aapatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik hhhhhhhh 104881 91atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR7tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Full-ntctctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagctggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactattcatcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccggaggtggcggaagcgaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaaggccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 104881 37MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp dygvs CAR7wirqppgkglewig viwgsettyyssslks rvtiskdnsknqvslklssvtaadta Full-aavyycak hyyyggsyamdy wgqgtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlsc rasqdiskyln wyqqkpgqaprlliy htsrlhs giparfsgsgsgtdytltisslqpedfavyfc qqgntlpyt fgqgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR8 CAR8 scFv 8qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgset domaintyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik 100798 68atggcactgcctgtcactgccctcctgctgcctctggccctccttctgcatgccgc CAR8-caggccccaagtccagctgcaagagtcaggacccggactggtgaagccgtctgaga Solublectctctcactgacttgtaccgtcagcggcgtgtccctccccgactacggagtgtca scFv-nttggatccgccaacctcccgggaaagggcttgaatggattggtgtcatctggggttctgaaaccacctactaccagtcttccctgaagtccagggtgaccatcagcaaggataattccaagaaccaggtcagccttaagctgtcatctgtgaccgctgctgacaccgccgtgtattactgcgccaagcactactattacggaggaagctacgctatggactattggggacagggcactctcgtgactgtgagcagcggcggtggagggtctggaggtggaggatccggtggtggtgggtcaggcggaggagggagcgagattgtgatgactcagtcaccagccaccctttctctttcacccggcgagagagcaaccctgagctgtagagccagccaggacatttctaagtacctcaactggtatcagcaaaaaccggggcaggcccctcgcctcctgatctaccatacctcacgccttcactctggtatccccgctcggtttagcggatcaggatctggtaccgactacactctgaccatttccagcctgcagccagaagatttcgcagtgtatttctgccagcagggcaatacccttccttacaccttcggtcagggaaccaagctcgaaatcaagcaccatcaccatcatcatcaccac 100798 80MALPVTALLLPLALLLHAARP qvqlqesgpglvkpsetlsltctvsgvslpdygvs CAR8-wirqppgkglewigviwgsettyyqsslksrvtiskdnsknqvslklssvtaadta Solublevyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggsggggseivmtqs scFv-aapatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik hhhhhhhh 104882 92atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR8-tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Full-ntctctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagctggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactatcaatcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccggaggcggtgggtcagaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaaggccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 104882 38MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp dygvs CAR8-wirqppgkglewig viwgsettyyqsslks rvtiskdnsknqvslklssvtaadta Full-aavyycak hyyyggsyamdy wgqgtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlsc rasqdiskyln wyqqkpgqaprlliy htsrlhs giparfsgsgsgtdytltisslqpedfavyfc qqgntlpyt fgqgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR9 CAR9 scFv 9eivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhs domaingiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss 99789 69atggccctcccagtgaccgctctgctgctgcctctcgcacttcttctccatgccgc CAR9-tcggcctgagatcgtcatgacccaaagccccgctaccctgtccctgtcacccggcg Solubleagagggcaaccctttcatgcagggccagccaggacatttctaagtacctcaactgg scFv-nttatcagcagaagccagggcaggctcctcgcctgctgatctaccacaccagccgcctccacagcggtatccccgccagattttccgggagcgggtctggaaccgactacaccctcaccatctcttctctgcagcccgaggatttcgccgtctatttctgccagcaggggaatactctgccgtacaccttcggtcaaggtaccaagctggaaatcaagggaggcggaggatcaggcggtggcggaagcggaggaggtggctccggaggaggaggttcccaagtgcagcttcaagaatcaggacccggacttgtgaagccatcagaaaccctctccctgacttgtaccgtgtccggtgtgagcctccccgactacggagtctcttggattcgccagcctccggggaagggtcttgaatggattggggtgatttggggatcagagactacttactacaattcatcacttaagtcacgggtcaccatcagcaaagataatagcaagaaccaagtgtcacttaagctgtcatctgtgaccgccgctgacaccgccgtgtactattgtgccaaacattactattacggagggtcttatgctatggactactggggacaggggaccctggtgactgtctctagccatcaccatcaccaccatcatcac 99789 81MALPVTALLLPLALLLHAARP eivmtqspatlslspgeratlscrasqdiskylnw CAR9-yqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqg Solublentlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsl scFv-aatctvsgvslpdygvswirqppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss hhhhhhhh 105974 93atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR9-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Full-ntagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggaggcggtgggagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactacaactcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 105974 39 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlscrasqdiskyln w CAR9- yqqkpgqaprlliy htsrlhsgiparfsgsgsgtdytltisslqpedfavyfc qqg Full-aa ntlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpsetlsl tctvsgvslp dygvswirqppgkglewig viwgsettyynsslks rvtiskdnskn qvslklssvtaadtavyycakhyyyggsyamdy wgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR10 CAR10 10qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgset scFvtyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgq domaingtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik 100796 70atggcactgcctgtcactgccctcctgctgcctctggccctccttctgcatgccgc CAR10-caggccccaagtccagctgcaagagtcaggacccggactggtgaagccgtctgaga Solublectctctcactgacttgtaccgtcagcggcgtgtccctccccgactacggagtgtca scFv-nttggatccgccaacctcccgggaaagggcttgaatggattggtgtcatctggggttctgaaaccacctactacaactcttccctgaagtccagggtgaccatcagcaaggataattccaagaaccaggtcagccttaagctgtcatctgtgaccgctgctgacaccgccgtgtattactgcgccaagcactactattacggaggaagctacgctatggactattggggacagggcactctcgtgactgtgagcagcggcggtggagggtctggaggtggaggatccggtggtggtgggtcaggcggaggagggagcgagattgtgatgactcagtcaccagccaccctttctctttcacccggcgagagagcaaccctgagctgtagagccagccaggacatttctaagtacctcaactggtatcagcaaaaaccggggcaggcccctcgcctcctgatctaccatacctcacgccttcactctggtatccccgctcggtttagcggatcaggatctggtaccgactacactctgaccatttccagcctgcagccagaagatttcgcagtgtatttctgccagcagggcaatacccttccttacaccttcggtcagggaaccaagctcgaaatcaagcaccatcaccatcatcaccaccat 100796 82MALPVTALLLPLALLLHAARP qvqlqesgpglvkpsetlsltctvsgvslpdygvs CAR10-wirqppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadta Solublevyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggsggggseivmtqs scFv-aapatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik hhhhhhhh 105975 94atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR10tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Full-ntagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggaggcggtgggagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactacaactcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 105975 40 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLN W CAR10 YQQKPGQAPRLLIY HTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFC QQG Full-aa NTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSL TCTVSGVSLP DYGVSWIRQPPGKGLEWIG VIWGSETTYYNSSLKS RVTISKDNSKN QVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDY WGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CAR11 CAR11 11eivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhs scFvgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggggs domainggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss 103101 71Atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR11-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Solubleagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattgg scFv-nttatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactacaattcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagccaccaccatcatcaccatcaccat 103101 83 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlscrasqdiskylnw CAR11-yqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqg Solublentlpytfgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltctvs scFv-aagvslpdygvswirqppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss hhhhhhhh 105976 95atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR11tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Full-ntctctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagctggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactataactcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccggaggtggcggaagcgaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaaggccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 105976 41MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGVSLP DYGVS CAR11WIRQPPGKGLEWIG VIWGSETTYYNSSLKS RVTISKDNSKNQVSLKLSSVTAADTA Full-aaVYYCAK HYYYGGSYAMDY WGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSC RASQDISKYLN WYQQKPGQAPRLLIY HTSRLHS GIPARFSGSGSGTDYTLTISSLQPEDFAVYFC QQGNTLPYT FGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CAR12 CAR12 12qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgset scFvtyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdywgq domaingtlvtvssggggsggggsggggseivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik 103104 72atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccgc CAR12-tcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctgaga Solublectctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtgagc scFv-nttggattagacagcctcccggaaagggactggagtggatcggagtgatttggggtagcgaaaccacttactataactcttccctgaagtcacgggtcaccatttcaaaggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgacaccgccgtgtattactgtgccaagcattactactatggagggtcctacgccatggactactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcggaggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccagggcaccaagcttgagatcaaacatcaccaccatcatcaccatcac 103104 84 MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslpdygvs CAR12-wirqppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadta Solublevyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggseivmtqspatls scFv-aalspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik hhhhhhhh 105977 96atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc CAR12-tcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccggtg Full-ntagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaaggtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctctgagactacttactacaactcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggattactggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctc gg 105977 42MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSC RASQDISKYLN W CAR12-YQQKPGQAPRLLIY HTSRLHS GIPARFSGSGSGTDYTLTISSLQPEDFAVYFC QQG Full-aaNTLPYT FGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVS GVSLP DYGVSWIRQPPGKGLEWIG VIWGSETTYYNSSLKS RVTISKDNSKNQVSLK LSSVTAADTAVYYCAKHYYYGGSYAMDY WGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR

TABLE 3 Murine CD19 CAR Constructs CTL019 CTL019-  97Atggccctgcccgtcaccgctctgctgctgccccttgctctgcttcttcatgcagc Solubleaaggccggacatccagatgacccaaaccacctcatccctctctgcctctcttggag scFv-Histag-acagggtgaccatttcttgtcgcgccagccaggacatcagcaagtatctgaactgg nttatcagcagaagccggacggaaccgtgaagctcctgatctaccatacctctcgcctgcatagcggcgtgccctcacgcttctctggaagcggatcaggaaccgattattctctcactatttcaaatcttgagcaggaagatattgccacctatttctgccagcagggtaataccctgccctacaccttcggaggagggaccaagctcgaaatcaccggtggaggaggcagcggcggtggagggtctggtggaggtggttctgaggtgaagctgcaagaatcaggccctggacttgtggccccttcacagtccctgagcgtgacttgcaccgtgtccggagtctccctgcccgactacggagtgtcatggatcagacaacctccacggaaaggactggaatggctcggtgtcatctggggtagcgaaactacttactacaattcagccctcaaaagcaggctgactattatcaaggacaacagcaagtcccaagtctttcttaagatgaactcactccagactgacgacaccgcaatctactattgtgctaagcactactactacggaggatcctacgctatggattactggggacaaggtacttccgtcactgtctcttcacaccatcatcaccatcaccatcac CTL019-  98 MALPVTALLLPLALLLHAARPdiqmtqttsslsaslgdrvtiscrasqdiskylnw Solubleyqqkpdgtvklliyhtsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqg scFv-Histag-ntlpytfgggtkleitggggsggggsggggsevklqesgpglvapsqslsvtctvs aagvslpdygvswirqpprkglewlgviwgsettyynsalksrltiikdnsksqvflkmnslqtddtaiyycakhyyyggsyamdywgqgtsvtvss hhhhhhhh CTL019  99atggccttaccagtgaccgccttgctcctgccgctggccttgctgctccacgccgc Full-ntcaggccggacatccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagggcaagtcaggacattagtaaatatttaaattggtatcagcagaaaccagatggaactgttaaactcctgatctaccatacatcaagattacactcaggagtcccatcaaggttcagtggcagtgggtctggaacagattattctctcaccattagcaacctggagcaagaagatattgccacttacttttgccaacagggtaatacgcttccgtacacgttcggaggggggaccaagctggagatcacaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctgaggtgaaactgcaggagtcaggacctggcctggtggcgccctcacagagcctgtccgtcacatgcactgtctcaggggtctcattacccgactatggtgtaagctggattcgccagcctccacgaaagggtctggagtggctgggagtaatatggggtagtgaaaccacatactataattcagctctcaaatccagactgaccatcatcaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgatgacacagccatttactactgtgccaaacattattactacggtggtagctatgctatggactactggggccaaggaacctcagtcaccgtctcctcaaccacgacgccagcgccgcgaccaccaacaccggcgcccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcggcggggggcgcagtgcacacgagggggctggacttcgcctgtgatatctacatctgggcgcccttggccgggacttgtggggtccttctcctgtcactggttatcaccctttactgcaaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagctgccgatttccagaagaagaagaaggaggatgtgaactgagagtgaagttcagcaggagcgcagacgcccccgcgtacaagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctc gc CTL019  58MALPVTALLLPLALLLHAARPdiqmtqttsslsaslgdrvtiscrasqdiskylnw Full-aayqqkpdgtvklliyhtsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlpytfgggtkleitggggsggggsggggsevklqesgpglvapsqslsvtctvsgvslpdygvswirqpprkglewlgviwgsettyynsalksrltiikdnsksqvflkmnslqtddtaiyycakhyyyggsyamdywgqgtsvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CTL019  59Diqmtqttsslsaslgdrvtiscrasqdiskylnwyqqkpdgtvklliyhtsrlhs scFvgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlpytfgggtkleitggggs domainggggsggggsevklqesgpglvapsqslsvtctvsgvslpdygvswirqpprkglewlgviwgsettyynsalksrltiikdnsksqvflkmnslqtddtaiyycakhyyyggsyamdywgqgtsvtvss mCAR1 109QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGDG scFvDTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFDYWGQGTTVTGGGSGGGSGGGSGGGSELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLADYFCQYNRYPYTSFFFTKLEIKRRS mCAR1 110QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGDG Full-aaDTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFDYWGQGTTVTGGGSGGGSGGGSGGGSELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLADYFCQYNRYPYTSFFFTKLEIKRRSKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR mCAR2 111DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS scFvGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSE mCAR2 112DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS CAR-aaGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSESKYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRL mCAR2 113DIQMTQTT   SSLSASLGDR VTISCRASQD ISKYLNWYQQ KPDGTVKLLI Full-aaYHTSRLHSGV PSRFSGSGSG TDYSLTISNL EQEDIATYFC QQGNTLPYTFGGGTKLEITG STSGSGKPGS GEGSTKGEVK LQESGPGLVA PSQSLSVTCTVSGVSLPDYG VSWIRQPPRK GLEWLGVIWG SETTYYNSAL KSRLTIIKDNSKSQVFLKMN SLQTDDTAIY YCAKHYYYGG SYAMDYWGQG TSVTVSSESKYGPPCPPCPM            FWVLVVVGGV            LACYSLLVTVAFIIFWVKRG RKKLLYIFKQ PFMRPVQTTQ EEDGCSCRFE EEEGGCELRVKFSRSADAPA YQQGQNQLYN ELNLGRREEY DVLDKRRGRD PEMGGKPRRKNPQEGLYNEL QKDKMAEAYS EIGMKGERRR GKGHDGLYQG LSTATKDTYDALHMQALPPR LEGGGEGRGS LLTCGDVEEN PGPRMLLLVT SLLLCELPHPAFLLIPRKVC NGIGIGEFKD SLSINATNIK HFKNCTSISG DLHILPVAFRGDSFTHTPPL DPQELDILKT VKEITGFLLI QAWPENRTDL HAFENLEIIRGRTKQHGQFS LAVVSLNITS LGLRSLKEIS DGDVIISGNK NLCYANTINWKKLFGTSGQK TKIISNRGEN SCKATGQVCH ALCSPEGCWG PEPRDCVSCRNVSRGRECVD KCNLLEGEPR EFVENSECIQ CHPECLPQAM NITCTGRGPDNCIQCAHYID GPHCVKTCPA GVMGENNTLV WKYADAGHVC HLCHPNCTYGCTGPGLEGCP TNGPKIPSIA TGMVGALLLL LVVALGIGLF M mCAR3 114DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS scFvGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS mCAR3 115DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHS Full-aaGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR

In some embodiments, the antigen binding domain comprises a HC CDR1, aHC CDR2, and a HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 2. In embodiments, the antigen binding domainfurther comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments,the antigen binding domain comprises a LC CDR1, a LC CDR2, and a LC CDR3of any light chain binding domain amino acid sequences listed in Table2.

In some embodiments, the antigen binding domain comprises one, two orall of LC CDR1, LC CDR2, and LC CDR3 of any light chain binding domainamino acid sequences listed in Table 2, and one, two or all of HC CDR1,HC CDR2, and HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 2.

In some embodiments, the CDRs are defined according to the Kabatnumbering scheme, the Chothia numbering scheme, or a combinationthereof.

The sequences of humanized CDR sequences of the scFv domains are shownin Table 4 for the heavy chain variable domains and in Table 5 for thelight chain variable domains. “ID” stands for the respective SEQ ID NOfor each CDR.

TABLE 4 Heavy Chain Variable Domain CDRs (Kabat) Candidate FW HCDR1 IDHCDR2 ID HCDR3 ID murine_CART19 GVSLPDYGVS 19 VIWGSETTYYNSALKS 20HYYYGGSYAMDY 24 humanized_CART19 a VH4 GVSLPDYGVS 19 VIWGSETTYYSSSLKS 21HYYYGGSYAMDY 24 humanized_CART19 b VH4 GVSLPDYGVS 19 VIWGSETTYYQSSLKS 22HYYYGGSYAMDY 24 humanized_CART19 c VH4 GVSLPDYGVS 19 VIWGSETTYYNSSLKS 23HYYYGGSYAMDY 24

TABLE 5 Light Chain Variable Domain CDRs Candidate FW LCDR1 ID LCDR2 IDLCDR3 ID murine_CART19 RASQDISKYLN 25 HTSRLHS 26 QQGNTLPYT 27humanized_CART19 a VK3 RASQDISKYLN 25 HTSRLHS 26 QQGNTLPYT 27humanized_CART19 b VK3 RASQDISKYLN 25 HTSRLHS 26 QQGNTLPYT 27humanized_CART19 c VK3 RASQDISKYLN 25 HTSRLHS 26 QQGNTLPYT 27

The CAR scFv fragments were then cloned into lentiviral vectors tocreate a full length CAR construct in a single coding frame, and usingthe EF1 alpha promoter for expression (SEQ ID NO: 100).

EF1 alpha promoter (SEQ ID NO: 100)CGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGA.

CAR22 Constructs: Design and Function

Fully human anti-CD22 single chain variable fragments were isolated.Anti-CD22 ScFvs were cloned into lentiviral CAR expression vectors withthe CD3zeta chain and the 4-1BB costimulatory molecule. CAR-containingplasmids were amplified by bacterial transformation in STBL3 cells,followed by Maxiprep using endotoxin-free Qiagen Plasmid Maki kit.Lentiviral supernatant was produced in 293T cells using standardtechniques.

The sequences of the human CARs are provided below in Table 6A and 6B.

These clones all contained a Q/K residue change in the signal domain ofthe co-stimulatory domain derived from CD3zeta chain.

TABLE 6A Human CD22 CAR Constructs Name SEQ ID Sequence m971 NT 200gtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggaagcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgcttccggctcgtatgttgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagcgcgcaattaaccctcactaaagggaacaaaagctggagctgcaagcttaatgtagtcttatgcaatactcttgtagtcttgcaacatggtaacgatgagttagcaacatgccttacaaggagagaaaaagcaccgtgcatgccgattggtggaagtaaggtggtacgatcgtgccttattaggaaggcaacagacgggtctgacatggattggacgaaccactgaattgccgcattgcagagatattgtatttaagtgcctagctcgatacataaacgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcagggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacaggatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttagacaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacgctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttggggttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctggatggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggaggcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaaccccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatctcgacggtatcgattagactgtagcccaggaatatggcagctagattgtacacatttagaaggaaaagttatcttggtagcagttcatgtagccagtggatatatagaagcagaagtaattccagcagagacagggcaagaaacagcatacttcctcttaaaattagcaggaagatggccagtaaaaacagtacatacagacaatggcagcaatttcaccagtactacagttaaggccgcctgttggtgggcggggatcaagcaggaatttggcattccctacaatccccaaagtcaaggagtaatagaatctatgaataaagaattaaagaaaattataggacaggtaagagatcaggctgaacatcttaagacagcagtacaaatggcagtattcatccacaattttaaaagaaaaggggggattgggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacagggacagcagagatccagtttggctgcatacgcgtcgtgaggctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgaaccggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccagaacacaggtaagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggcccttgcgtgccttgaattacttccacctggctgcagtacgtgattcttgatcccgagcttcgggttggaagtgggtgggagagttcgaggccttgcgcttaaggagccccttcgcctcgtgcttgagttgaggcctggcctgggcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcctgtctcgctgctttcgataagtctctagccatttaaaatttttgatgacctgctgcgacgctttttttctggcaagatagtcttgtaaatgcgggccaagatctgcacactggtatttcggtttttggggccgcgggcggcgacggggcccgtgcgtcccagcgcacatgttcggcgaggcggggcctgcgagcgcggccaccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcctcgcgccgccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgcgtgagcggaaagatggccgcttcccggccctgctgcagggagctcaaaatggaggacgcggcgctcgggagagcgggcgggtgagtcacccacacaaaggaaaagggcctttccgtcctcagccgtcgcttcatgtgactccactgagtaccgggcgccgtccaggcacctcgattagttctcgtgcttttggagtacgtcgtctttaggttggggggaggggttttatgcgatggagtttccccacactgagtgggtggagactgaagttaggccagcttggcacttgatgtaattctccttggaatttgccctttttgagtttggatcttggttcattctcaagcctcagacagtggttcaaagtttttttcttccatttcaggtgtcgtgagctagctctagagccaccatggccctgcctgtgacagccctgctgctgcctctggctctgctgctgcatgccgctagacccggatcccaggtgcagctgcagcagtctggacccggcctcgtgaagcctagccagaccctgtctctgacctgcgccatcagcggcgatagcgtgtccagcaatagcgccgcctggaactggatcagacagagccctagcagaggcctggaatggctgggccggacctactaccggtccaagtggtacaacgactacgccgtgtccgtgaagtcccggatcaccatcaaccccgacaccagcaagaaccagttctccctgcagctgaacagcgtgacccccgaggataccgccgtgtactactgcgccagagaagtgaccggcgacctggaagatgccttcgacatctggggccagggcacaatggtcaccgtgtctagcggaggcggaggatctggcggcggaggaagtggcggagggggatctgggggaggcggaagcgatatccagatgacccagagccccagctccctgtctgccagcgtgggcgacagagtgaccatcacctgtagggccagccagaccatctggtcctacctgaactggtatcagcagcggcctggcaaggcccccaacctgctgatctatgccgccagctctctgcagtccggcgtgcccagcagattttccggcagaggctccggcaccgacttcaccctgacaatcagttccctgcaggccgaggacttcgccacctactactgccagcagagctacagcatcccccagaccttcggccaggggaccaagctggaaatcaagtccggaaccacgacgccagcgccgcgaccaccaacaccggcgcccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcggcggggggcgcagtgcacacgagggggctggacttcgcctgtgatatctacatctgggcgcccttggccgggacttgtggggtccttctcctgtcactggttatcaccctttactgcaaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagctgccgatttccagaagaagaagaaggaggatgtgaactgagagtgaagttcagcaggagcgcagacgcccccgcgtacaagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgctaagtcgacaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaagctgacgtcctttccatggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcctggaattcgagctcggtacctttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtagtagttcatgtcatcttattattcagtatttataacttgcaaagaaatgaatatcagagagtgagaggaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggctctagctatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcgtcgagacgtacccaattcgccctatagtgagtcgtattacgcgcgctcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgg m971 VH 201qvqlqqsgpg lvkpsqtlsl tcaisgdsvs snsaawnwir qspsrglewl grtyyrskwyndyavsvksr itinpdtskn qfslqlnsvt pedtavyyca revtgdleda fdiwgqgtmvtvssastkgp svfplapssk stsggtaalg clvkdyfpep vtvswnsgal tsgvhtfpavlqssglysls svvtvpsssl gtqtyicnvs hkpsntkvdk kvepkscdkt sgqag m971 VL 202diqmtqspss lsasvgdrvt itcrasqtiw sylnwyqqrp gkapnlliya asslqsgvpsrfsgrgsgtd ftltisslqa edfatyycqq sysipqtfgq gtkleikrtv aapsvfifppsdeqlksgta svvcllnnfy preakvqwkv dnalqsgnsq esvteqdskd styslsstltlskadyekhk vyacevthqg lsspvtksfn rgec CAR22-1 203qvqlvqsgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgr scFvftisrdnskntlylqmnslraedtavyycasqstpydssgyysgdafdiwgqgtmvtvssggggsg AAgggsggggssyvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgyvfgtgtkltvl CAR22-1 204caagtgcaactcgtccaatccggcggcggactgattcaaccaggaggttcccttagactctcatgtscFv NTgccgctagcggattcactgtgtcctcaaactacatgagctgggtccgccaggcgcccggaaagggcctggaatgggtgtccgtgatctactcgggcggatcaacctactacgccgattccgtgaaggggcggttcaccatctcgcgggataactccaagaacaccctgtacttgcaaatgaactcactgagggccgaagataccgccgtctactactgcgcgagccagtccactccctacgactcgagcgggtactactccggggacgccttcgacatctggggacagggaactatggtcacggtgtcgtcgggaggagggggcagcggcggcggaggaagcgggggagggggttcgtcctatgtgctgacccagccgccgagcgcctccgggactccgggccagcgcgtgaccatttcctgctccggctcctcatccaacatcggttcgaattatgtgtactggtaccagcagctgcctggtactgcccctaagcttctcatctaccggaacaaccagcgcccgtctggcgtgcccgaccggttctccggctcgaagtccggcaccagcgcctccctggctatctccgggctgagatccgaggatgaggccgactactattgcgcagcgtgggacgacagcctgtcgggatacgtgtttggaaccggaaccaagctcaccgtgctg CAR22-1 205atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcaactcgtccaatccggcggcggactgattcaaccaggaggttcccttagactctcatgtgccscFV NTgctagcggattcactgtgtcctcaaactacatgagctgggtccgccaggcgcccggaaagggcctggaatgggtgtccgtgatctactcgggcggatcaacctactacgccgattccgtgaaggggcggttcaccatctcgcgggataactccaagaacaccctgtacttgcaaatgaactcactgagggccgaagataccgccgtctactactgcgcgagccagtccactccctacgactcgagcgggtactactccggggacgccttcgacatctggggacagggaactatggtcacggtgtcgtcgggaggagggggcagcggcggcggaggaagcgggggagggggttcgtcctatgtgctgacccagccgccgagcgcctccgggactccgggccagcgcgtgaccatttcctgctccggctcctcatccaacatcggttcgaattatgtgtactggtaccagcagctgcctggtactgcccctaagcttctcatctaccggaacaaccagcgcccgtctggcgtgcccgaccggttctccggctcgaagtccggcaccagcgcctccctggctatctccgggctgagatccgaggatgaggccgactactattgcgcagcgtgggacgacagcctgtcgggatacgtgtttggaaccggaaccaagctcaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-1 206malpvtalllplalllhaarpqvqlvqsgggliqpggslrlscaasgftvssnymswvrqapgkglsolubleewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycasqstpydssgyysgdscFV AAafdiwgqgtmvtvssggggsggggsggggssyvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgyvfgtgtkltvlgshhhhhhhh CAR22-1 207malpvtalllplalllhaarpqvqlvqsgggliqpggslrlscaasgftvssnymswvrqapgkglFull AAewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycasqstpydssgyysgdafdiwgqgtmvtvssggggsggggsggggssyvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgyvfgtgtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-1 208atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcaactcgtccaatccggcggcggactgattcaaccaggaggttcccttagactctcatgtgcclentivirusgctagcggattcactgtgtcctcaaactacatgagctgggtccgccaggcgcccggaaagggcctggaatgggtgtccgtgatctactcgggcggatcaacctactacgccgattccgtgaaggggcggttcaccatctcgcgggataactccaagaacaccctgtacttgcaaatgaactcactgagggccgaagataccgccgtctactactgcgcgagccagtccactccctacgactcgagcgggtactactccggggacgccttcgacatctggggacagggaactatggtcacggtgtcgtcgggaggagggggcagcggcggcggaggaagcgggggagggggttcgtcctatgtgctgacccagccgccgagcgcctccgggactccgggccagcgcgtgaccatttcctgctccggctcctcatccaacatcggttcgaattatgtgtactggtaccagcagctgcctggtactgcccctaagcttctcatctaccggaacaaccagcgcccgtctggcgtgcccgaccggttctccggctcgaagtccggcaccagcgcctccctggctatctccgggctgagatccgaggatgaggccgactactattgcgcagcgtgggacgacagcctgtcgggatacgtgtttggaaccggaaccaagctcaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-2 209evqlqqsgpglvkpsqtlsltcaisgdsvssnsaawnwirqspsrglewlgrtyyrskwyndyavs scFvvksritinpdtsknqfslqlnsvtpedtavyycardlgwiavagtfdywgqgtlvtvssggggsgg AAggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssslnhvfgtgtkvtvl CAR22-2 210gaagtgcaactccaacagagcggacccggacttgtgaaaccatcccagactctcagcctgacgtgtscFv NTgcgatcagcggggactctgtgtcctccaactccgccgcctggaactggattaggcagtcgccgtcgagagggctggagtggttgggtagaacctactaccggtccaagtggtacaatgactacgccgtgtccgtgaagtcccggatcactattaacccggatacctcaaagaaccagttctccctgcaactgaactcggtgacccctgaggacaccgcagtgtactactgcgcccgggatctgggttggatcgctgtcgccggcaccttcgactattggggacagggcactctcgtgaccgtgtcgtcgggtggaggagggagcggagggggcggaagcggtggcggcggttcccagtccgcgctgacccagcctgctagcgtgtccgggtcgcccggacagtcaatcaccatctcctgcactgggactagcagcgacgtgggcggctacaactacgtgtcatggtaccagcagcacccgggaaaggcgcccaagctgatgatctacgacgtgtccaagcgcccttcgggagtctccaaccgctttagcggctccaagtcgggcaacactgcctccctgaccattagcggactgcaggccgaagatgaggccgactattactgctcatcctacacctcctcctcactgaaccatgtgttcggcaccggaaccaaggtcacagtcctc CAR22-2 211atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaactccaacagagcggacccggacttgtgaaaccatcccagactctcagcctgacgtgtgcgscFV NTatcagcggggactctgtgtcctccaactccgccgcctggaactggattaggcagtcgccgtcgagagggctggagtggttgggtagaacctactaccggtccaagtggtacaatgactacgccgtgtccgtgaagtcccggatcactattaacccggatacctcaaagaaccagttctccctgcaactgaactcggtgacccctgaggacaccgcagtgtactactgcgcccgggatctgggttggatcgctgtcgccggcaccttcgactattggggacagggcactctcgtgaccgtgtcgtcgggtggaggagggagcggagggggcggaagcggtggcggcggttcccagtccgcgctgacccagcctgctagcgtgtccgggtcgcccggacagtcaatcaccatctcctgcactgggactagcagcgacgtgggcggctacaactacgtgtcatggtaccagcagcacccgggaaaggcgcccaagctgatgatctacgacgtgtccaagcgcccttcgggagtctccaaccgctttagcggctccaagtcgggcaacactgcctccctgaccattagcggactgcaggccgaagatgaggccgactattactgctcatcctacacctcctcctcactgaaccatgtgttcggcaccggaaccaaggtcacagtcctcggatcgcaccaccatcaccatcatcatcac CAR22-2 212MalpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvssnsaawnwirqspsrsolubleglewlgrtyyrskwyndyavsvksritinpdtsknqfslqlnsvtpedtavyycardlgwiavagtscFV AAfdywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssslnhvfgtgtkvtvlgshhhhhhhh CAR22-2 213malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvssnsaawnwirqspsrFull AAglewlgrtyyrskwyndyavsvksritinpdtsknqfslqlnsvtpedtavyycardlgwiavagtfdywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssslnhvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-2 214atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaactccaacagagcggacccggacttgtgaaaccatcccagactctcagcctgacgtgtgcglentivirusatcagcggggactctgtgtcctccaactccgccgcctggaactggattaggcagtcgccgtcgagagggctggagtggttgggtagaacctactaccggtccaagtggtacaatgactacgccgtgtccgtgaagtcccggatcactattaacccggatacctcaaagaaccagttctccctgcaactgaactcggtgacccctgaggacaccgcagtgtactactgcgcccgggatctgggttggatcgctgtcgccggcaccttcgactattggggacagggcactctcgtgaccgtgtcgtcgggtggaggagggagcggagggggcggaagcggtggcggcggttcccagtccgcgctgacccagcctgctagcgtgtccgggtcgcccggacagtcaatcaccatctcctgcactgggactagcagcgacgtgggcggctacaactacgtgtcatggtaccagcagcacccgggaaaggcgcccaagctgatgatctacgacgtgtccaagcgcccttcgggagtctccaaccgctttagcggctccaagtcgggcaacactgcctccctgaccattagcggactgcaggccgaagatgaggccgactattactgctcatcctacacctcctcctcactgaaccatgtgttcggcaccggaaccaaggtcacagtcctcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-3 215evqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrglewlgrtyhrstwyddyass scFvvrgrvsinvdtsknqyslqlnavtpedtgayycardrlqdgnswsdafdvwgqgtmvtvssggggs AAggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtqltvl CAR22-3 216gaagtgcaactccaacagagcggacccggacttgtgaaaccttcccaaactctctccctgacctgtscFv NTgcgatctctggggattcggtgctgtcgaatagcgacacctggaactggatcagacagtcaccctcccggggcctggagtggctcgggagaacttaccaccggtccacttggtacgacgactatgccagctcagtgcgcggaagggtgtccattaacgtggacacctccaagaaccagtacagcctgcagttgaacgctgtgaccccggaagataccggagcctactactgcgcccgcgaccggctgcaggacggaaactcctggtccgatgccttcgacgtctggggccagggaaccatggtcactgtgtcatccggcggtggcggttcgggcggtggtggcagcggtggaggcggctcccagtcggcactgactcagccagcttcagtctccggctcgccgggacagtccatcaccatttcctgcactggaaccagctccgatgtcggggggtataactacgtgtcgtggtaccagcaacatcctggaaaggcccccaagctcatgatctacgacgtgtccaatcgccctagcggagtgtcaaaccggttttccggctccaagtccgggaacaccgcgtccctgacaatcagcggactgcaggccgaggacgaagccgactactactgctcgagctacaccagctcgtccacgccgtacgtgttcggaactgggacccagctgaccgtgctg CAR22-3 217atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaactccaacagagcggacccggacttgtgaaaccttcccaaactctctccctgacctgtgcgscFV NTatctctggggattcggtgctgtcgaatagcgacacctggaactggatcagacagtcaccctcccggggcctggagtggctcgggagaacttaccaccggtccacttggtacgacgactatgccagctcagtgcgcggaagggtgtccattaacgtggacacctccaagaaccagtacagcctgcagttgaacgctgtgaccccggaagataccggagcctactactgcgcccgcgaccggctgcaggacggaaactcctggtccgatgccttcgacgtctggggccagggaaccatggtcactgtgtcatccggcggtggcggttcgggcggtggtggcagcggtggaggcggctcccagtcggcactgactcagccagcttcagtctccggctcgccgggacagtccatcaccatttcctgcactggaaccagctccgatgtcggggggtataactacgtgtcgtggtaccagcaacatcctggaaaggcccccaagctcatgatctacgacgtgtccaatcgccctagcggagtgtcaaaccggttttccggctccaagtccgggaacaccgcgtccctgacaatcagcggactgcaggccgaggacgaagccgactactactgctcgagctacaccagctcgtccacgccgtacgtgttcggaactgggacccagctgaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-3 218malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrsolubleglewlgrtyhrstwyddyassvrgrvsinvdtsknqyslqlnavtpedtgayycardrlqdgnswsscFV AAdafdvwgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtqltvlgshhhhhhhh CAR22-3 219malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrFull AAglewlgrtyhrstwyddyassvrgrvsinvdtsknqyslqlnavtpedtgayycardrlqdgnswsdafdvwgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtqltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-3 220atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaactccaacagagcggacccggacttgtgaaaccttcccaaactctctccctgacctgtgcglentivirusatctctggggattcggtgctgtcgaatagcgacacctggaactggatcagacagtcaccctcccggggcctggagtggctcgggagaacttaccaccggtccacttggtacgacgactatgccagctcagtgcgcggaagggtgtccattaacgtggacacctccaagaaccagtacagcctgcagttgaacgctgtgaccccggaagataccggagcctactactgcgcccgcgaccggctgcaggacggaaactcctggtccgatgccttcgacgtctggggccagggaaccatggtcactgtgtcatccggcggtggcggttcgggcggtggtggcagcggtggaggcggctcccagtcggcactgactcagccagcttcagtctccggctcgccgggacagtccatcaccatttcctgcactggaaccagctccgatgtcggggggtataactacgtgtcgtggtaccagcaacatcctggaaaggcccccaagctcatgatctacgacgtgtccaatcgccctagcggagtgtcaaaccggttttccggctccaagtccgggaacaccgcgtccctgacaatcagcggactgcaggccgaggacgaagccgactactactgctcgagctacaccagctcgtccacgccgtacgtgttcggaactgggacccagctgaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-4 221evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkg scFvrftisrdnaknslylqmnslraedtalyycakglsswhfhdaldiwgqgtmvtvssggggsggggs AAggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhlwvfgggtkltvl CAR22-4 222gaagtgcagttggtggaatcaggaggaggacttgtgcaacctggaagatctctcagactctcgtgtscFv NTgcggcctccggtttcaccttcgacgactacgccatgcattgggtcagacaggccccgggaaagggcctggagtgggtgtcaggcatctcatggaacagcggctccattggctacgccgactcggtcaagggaaggttcactatctcccgggacaacgccaagaactccctgtacctccaaatgaacagcctgcgcgccgaggatactgccctgtactactgcgccaaggggctgtccagctggcactttcacgacgcacttgatatctggggacagggtaccatggtcaccgtgtcctccggtggcggaggctcagggggaggaggaagcgggggcggtggttcctcctccgaactgacccaggacccggccgtgtccgtggcgctgggacaaaccgtgcgcattacttgccagggcgacagcttgcggtcgtactacgcctcgtggtaccagcagaagcccggccaggctcccgtgctggtcatctatggcaaaaacaaccgcccgagcggaattccagaccggttctccgggagctcgtccgggaacaccgcttcgctcaccatcacgggggcccaggcggaggacgaagcagattactactgcaactcgcgggattccagcggcaatcacctctgggtgttcgggggcggaaccaagctgactgtgctg CAR22-4 223atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcagttggtggaatcaggaggaggacttgtgcaacctggaagatctctcagactctcgtgtgcgscFV NTgcctccggtttcaccttcgacgactacgccatgcattgggtcagacaggccccgggaaagggcctggagtgggtgtcaggcatctcatggaacagcggctccattggctacgccgactcggtcaagggaaggttcactatctcccgggacaacgccaagaactccctgtacctccaaatgaacagcctgcgcgccgaggatactgccctgtactactgcgccaaggggctgtccagctggcactttcacgacgcacttgatatctggggacagggtaccatggtcaccgtgtcctccggtggcggaggctcagggggaggaggaagcgggggcggtggttcctcctccgaactgacccaggacccggccgtgtccgtggcgctgggacaaaccgtgcgcattacttgccagggcgacagcttgcggtcgtactacgcctcgtggtaccagcagaagcccggccaggctcccgtgctggtcatctatggcaaaaacaaccgcccgagcggaattccagaccggttctccgggagctcgtccgggaacaccgcttcgctcaccatcacgggggcccaggcggaggacgaagcagattactactgcaactcgcgggattccagcggcaatcacctctgggtgttcgggggcggaaccaagctgactgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-4 224malpvtalllplalllhaarpevqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglsolubleewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakglsswhfhdaldiscFV AAwgqgtmvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhlwvfgggtkltvlgshhhhhhhh CAR22-4 225malpvtalllplalllhaarpevqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglFull AAewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakglsswhfhdaldiwgqgtmvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhlwvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-4 226atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagttggtggaatcaggaggaggacttgtgcaacctggaagatctctcagactctcgtgtgcglentivirusgcctccggtttcaccttcgacgactacgccatgcattgggtcagacaggccccgggaaagggcctggagtgggtgtcaggcatctcatggaacagcggctccattggctacgccgactcggtcaagggaaggttcactatctcccgggacaacgccaagaactccctgtacctccaaatgaacagcctgcgcgccgaggatactgccctgtactactgcgccaaggggctgtccagctggcactttcacgacgcacttgatatctggggacagggtaccatggtcaccgtgtcctccggtggcggaggctcagggggaggaggaagcgggggcggtggttcctcctccgaactgacccaggacccggccgtgtccgtggcgctgggacaaaccgtgcgcattacttgccagggcgacagcttgcggtcgtactacgcctcgtggtaccagcagaagcccggccaggctcccgtgctggtcatctatggcaaaaacaaccgcccgagcggaattccagaccggttctccgggagctcgtccgggaacaccgcttcgctcaccatcacgggggcccaggcggaggacgaagcagattactactgcaactcgcgggattccagcggcaatcacctctgggtgttcgggggcggaaccaagctgactgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-5 227evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkg scFvrftisrdnaknslylqmnslraedtalyycakdkgggyydfwsgsdywgqgtlvtvssggggsggg AAgsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgwvfgggtkltvl CAR22-5 116gaagtgcaacttgtggaatctggtggaggacttgtgcaacctggaagatcactgagactgtcatgtscFv NTgcagcctcggggtttaccttcgacgactacgccatgcactgggtgcgccaggctccggggaagggcctcgaatgggtgtcgggcatcagctggaactccggttccattggctatgcggactccgtgaaaggacgcttcacaatttcccgggataacgccaagaacagcctgtacttgcagatgaactccctgcgggccgaggataccgccctgtactactgcgctaaggacaagggcggtggatactacgacttctggagcggaagcgactactggggacagggaactctggtcaccgtgtcctccggcggagggggctccggcggcggtggtagcgggggtggagggtcgtcgtcggagctgacccaggaccccgcagtgtccgtcgccctggggcagactgtgcggatcacttgccaaggagacagcctgcggtcctactacgcgtcctggtatcagcagaagccggggcaggccccagtcctcgtcatctacggaaagaacaataggcccagcggaatccctgaccgcttctcgggctcatcctccggcaacaccgcctccctgaccatcacgggcgcgcaggccgaggacgaagccgattactactgcaactcacgggattccagcggatgggtgttcggaggaggaaccaagctcactgtgctc CAR22-5 228atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaacttgtggaatctggtggaggacttgtgcaacctggaagatcactgagactgtcatgtgcascFV NTgcctcggggtttaccttcgacgactacgccatgcactgggtgcgccaggctccggggaagggcctcgaatgggtgtcgggcatcagctggaactccggttccattggctatgcggactccgtgaaaggacgcttcacaatttcccgggataacgccaagaacagcctgtacttgcagatgaactccctgcgggccgaggataccgccctgtactactgcgctaaggacaagggcggtggatactacgacttctggagcggaagcgactactggggacagggaactctggtcaccgtgtcctccggcggagggggctccggcggcggtggtagcgggggtggagggtcgtcgtcggagctgacccaggaccccgcagtgtccgtcgccctggggcagactgtgcggatcacttgccaaggagacagcctgcggtcctactacgcgtcctggtatcagcagaagccggggcaggccccagtcctcgtcatctacggaaagaacaataggcccagcggaatccctgaccgcttctcgggctcatcctccggcaacaccgcctccctgaccatcacgggcgcgcaggccgaggacgaagccgattactactgcaactcacgggattccagcggatgggtgttcggaggaggaaccaagctcactgtgctcggatcgcaccaccatcaccatcatcatcac CAR22-5 229malpvtalllplalllhaarpevqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglsolubleewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdkgggyydfwsgsscFV AAdywgqgtlvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgwvfgggtkltvlgshhhhhhhh CAR22-5 230malpvtalllplalllhaarpevqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglFull AAewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdkgggyydfwsgsdywgqgtlvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgwvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-5 231atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaacttgtggaatctggtggaggacttgtgcaacctggaagatcactgagactgtcatgtgcalentivirusgcctcggggtttaccttcgacgactacgccatgcactgggtgcgccaggctccggggaagggcctcgaatgggtgtcgggcatcagctggaactccggttccattggctatgcggactccgtgaaaggacgcttcacaatttcccgggataacgccaagaacagcctgtacttgcagatgaactccctgcgggccgaggataccgccctgtactactgcgctaaggacaagggcggtggatactacgacttctggagcggaagcgactactggggacagggaactctggtcaccgtgtcctccggcggagggggctccggcggcggtggtagcgggggtggagggtcgtcgtcggagctgacccaggaccccgcagtgtccgtcgccctggggcagactgtgcggatcacttgccaaggagacagcctgcggtcctactacgcgtcctggtatcagcagaagccggggcaggccccagtcctcgtcatctacggaaagaacaataggcccagcggaatccctgaccgcttctcgggctcatcctccggcaacaccgcctccctgaccatcacgggcgcgcaggccgaggacgaagccgattactactgcaactcacgggattccagcggatgggtgttcggaggaggaaccaagctcactgtgctcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-6 232evqlqqsgpglvkpsltlsltcaisgdsvssnsatwtwirqspsrglewlgrtyyrstwyndyavs scFvvksritinpdtsknqfslqlnsvtpedtavyycaregsgsyyaywgqgtlvtvssggggsggggsg AAgggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl CAR22-6 233gaagtgcaactccaacaatcaggtccaggactcgtcaaaccctcgcttactctgtcgctgacttgtscFv NTgctatctcgggagactccgtgagctccaacagcgccacctggacttggattagacagtccccgtcacggggcctcgaatggctgggaaggacctactaccggagcacctggtacaacgactatgctgtgtccgtgaagtcccgcatcaccatcaaccccgatacctccaagaaccagttcagcttgcaactgaactccgtgacccctgaggatacggccgtctattactgcgcccgcgaggggtccggttcctactacgcctactggggacagggtactctggtcaccgtgtcgagcggagggggggggtccggcggaggaggatctggtggcggaggctcccagtccgcgctgacccagcctgcgtccgtgtccggctcaccgggccagtctatcaccattagctgcaccggcactagctcagacgtgggagggtacaactacgtgtcgtggtaccagcagcaccctggaaaggccccgaagctgatgatctacgacgtgtccaaccggcccagcggggtgtcgaatcgcttctccggctcaaagtccggcaacacagccagcctgaccattagcggactgcaggccgaggatgaagcagactactactgctcgtcctacacctcctcctcgactctctacgtgtttggcaccggaactaaggtcaccgtgctg CAR22-6 234atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaactccaacaatcaggtccaggactcgtcaaaccctcgcttactctgtcgctgacttgtgctscFV NTatctcgggagactccgtgagctccaacagcgccacctggacttggattagacagtccccgtcacggggcctcgaatggctgggaaggacctactaccggagcacctggtacaacgactatgctgtgtccgtgaagtcccgcatcaccatcaaccccgatacctccaagaaccagttcagcttgcaactgaactccgtgacccctgaggatacggccgtctattactgcgcccgcgaggggtccggttcctactacgcctactggggacagggtactctggtcaccgtgtcgagcggagggggggggtccggcggaggaggatctggtggcggaggctcccagtccgcgctgacccagcctgcgtccgtgtccggctcaccgggccagtctatcaccattagctgcaccggcactagctcagacgtgggagggtacaactacgtgtcgtggtaccagcagcaccctggaaaggccccgaagctgatgatctacgacgtgtccaaccggcccagcggggtgtcgaatcgcttctccggctcaaagtccggcaacacagccagcctgaccattagcggactgcaggccgaggatgaagcagactactactgctcgtcctacacctcctcctcgactctctacgtgtttggcaccggaactaaggtcaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-6 235malpvtalllplalllhaarpevqlqqsgpglvkpsltlsltcaisgdsvssnsatwtwirqspsrsolubleglewlgrtyyrstwyndyavsvksritinpdtsknqfslqlnsvtpedtavyycaregsgsyyaywscFV AAgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvlgshhhhhhhhh CAR22-6 236malpvtalllplalllhaarpevqlqqsgpglvkpsltlsltcaisgdsvssnsatwtwirqspsrFull AAglewlgrtyyrstwyndyavsvksritinpdtsknqfslqlnsvtpedtavyycaregsgsyyaywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-6 237atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaactccaacaatcaggtccaggactcgtcaaaccctcgcttactctgtcgctgacttgtgctlentivirusatctcgggagactccgtgagctccaacagcgccacctggacttggattagacagtccccgtcacggggcctcgaatggctgggaaggacctactaccggagcacctggtacaacgactatgctgtgtccgtgaagtcccgcatcaccatcaaccccgatacctccaagaaccagttcagcttgcaactgaactccgtgacccctgaggatacggccgtctattactgcgcccgcgaggggtccggttcctactacgcctactggggacagggtactctggtcaccgtgtcgagcggagggggggggtccggcggaggaggatctggtggcggaggctcccagtccgcgctgacccagcctgcgtccgtgtccggctcaccgggccagtctatcaccattagctgcaccggcactagctcagacgtgggagggtacaactacgtgtcgtggtaccagcagcaccctggaaaggccccgaagctgatgatctacgacgtgtccaaccggcccagcggggtgtcgaatcgcttctccggctcaaagtccggcaacacagccagcctgaccattagcggactgcaggccgaggatgaagcagactactactgctcgtcctacacctcctcctcgactctctacgtgtttggcaccggaactaaggtcaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-7 238qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqg scFvrvtmtrdtsistaymelsrlrsddtavyycardywgyygsgtldywgqgtlvtvssggggsggggs AAggggsqsaltqpgsvsgspgqsitisctgtssdvggynyvswyqqhpgkapkliiydvssrpsgvsnrfsgsqsgntasltisglqaedeadyscssyagsntlvfgtgtkvtvl CAR22-7 239caagtccaactcgtccagtccggtgcagaagtcaagaagccaggagcgtccgtgaaagtgtcctgcscFv NTaaagcctcgggctacaccttcaccggatactacatgcactgggtgcgccaggctcccggacaaggattggagtggatgggttggatcaacccgaactccggcggaaccaactacgcccagaagttccagggacgcgtgactatgactcgggacacgtccatcagcactgcctacatggaactgagccggcttagatcagacgacaccgccgtgtactactgcgcccgcgattactggggctactacggaagcggaaccctcgactactggggacagggaactctcgtgactgtgtcgagcggtggaggcggctccggcggagggggttccggtggtggaggctcccagtccgcgctgacccagcctgggtcggtgtccggctcacctggccaatccatcaccatttcctgcaccggcacttcctccgacgtgggagggtacaactacgtgtcgtggtaccagcagcatccgggaaaggcccccaagctgatcatctacgatgtgtcgtcccggccgagcggagtgtcaaacaggtttagcgggagccagtccgggaatactgcctcgctgacaattagcgggctgcaggctgaggacgaggccgattattcgtgttcctcatatgcgggctctaacaccctggtgttcggcaccgggaccaaggtcaccgtgctg CAR22-7 240atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtccaactcgtccagtccggtgcagaagtcaagaagccaggagcgtccgtgaaagtgtcctgcaaascFV NTgcctcgggctacaccttcaccggatactacatgcactgggtgcgccaggctcccggacaaggattggagtggatgggttggatcaacccgaactccggcggaaccaactacgcccagaagttccagggacgcgtgactatgactcgggacacgtccatcagcactgcctacatggaactgagccggcttagatcagacgacaccgccgtgtactactgcgcccgcgattactggggctactacggaagcggaaccctcgactactggggacagggaactctcgtgactgtgtcgagcggtggaggcggctccggcggagggggttccggtggtggaggctcccagtccgcgctgacccagcctgggtcggtgtccggctcacctggccaatccatcaccatttcctgcaccggcacttcctccgacgtgggagggtacaactacgtgtcgtggtaccagcagcatccgggaaaggcccccaagctgatcatctacgatgtgtcgtcccggccgagcggagtgtcaaacaggtttagcgggagccagtccgggaatactgcctcgctgacaattagcgggctgcaggctgaggacgaggccgattattcgtgttcctcatatgcgggctctaacaccctggtgttcggcaccgggaccaaggtcaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-7 241malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglsolubleewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardywgyygsgtldyscFV AAwgqgtlvtvssggggsggggsggggsqsaltqpgsvsgspgqsitisctgtssdvggynyvswyqqhpgkapkliiydvssrpsgvsnrfsgsqsgntasltisglqaedeadyscssyagsntlvfgtgtkvtvlgshhhhhhhhh CAR22-7 242malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglFull AAewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardywgyygsgtldywgqgtlvtvssggggsggggsggggsqsaltqpgsvsgspgqsitisctgtssdvggynyvswyqqhpgkapkliiydvssrpsgvsnrfsgsqsgntasltisglqaedeadyscssyagsntlvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-7 243atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccagtccggtgcagaagtcaagaagccaggagcgtccgtgaaagtgtcctgcaaalentivirusgcctcgggctacaccttcaccggatactacatgcactgggtgcgccaggctcccggacaaggattggagtggatgggttggatcaacccgaactccggcggaaccaactacgcccagaagttccagggacgcgtgactatgactcgggacacgtccatcagcactgcctacatggaactgagccggcttagatcagacgacaccgccgtgtactactgcgcccgcgattactggggctactacggaagcggaaccctcgactactggggacagggaactctcgtgactgtgtcgagcggtggaggcggctccggcggagggggttccggtggtggaggctcccagtccgcgctgacccagcctgggtcggtgtccggctcacctggccaatccatcaccatttcctgcaccggcacttcctccgacgtgggagggtacaactacgtgtcgtggtaccagcagcatccgggaaaggcccccaagctgatcatctacgatgtgtcgtcccggccgagcggagtgtcaaacaggtttagcgggagccagtccgggaatactgcctcgctgacaattagcgggctgcaggctgaggacgaggccgattattcgtgttcctcatatgcgggctctaacaccctggtgttcggcaccgggaccaaggtcaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-8 244qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqg scFvrvtmttdtststaymelrslrsddtavyycaraglalysnyvpyyyygmdvwgqgttvtvssgggg AAsggggsggggsnfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnpwvfgggtkltvl CAR22-8 245caagtccaactggtgcagtcgggagccgaagtcaagaagccgggggcctccgtcaaagtgtcctgcscFv NTaaagccagcggctacactttcacctcctatgggatctcatgggtcagacaggctcccggccaaggactggaatggatgggttggatctccgcctacaacggcaacactaactacgcccagaagctgcaggggagagtgaccatgacaactgacacctcgacctcaaccgcgtacatggaactgcgcagccttaggtccgacgatacggcggtgtactattgtgcacgggccggcttggccctctactcgaactacgtgccctactactactacggaatggacgtctggggacagggaaccactgtgaccgtgtcctccgggggtggaggctcaggcggaggaggaagcggcgggggtggaagcaactttatgctgacccagcctcactcggtgtcggagagccctggaaagactgtgaccatctcctgcactcggagctcgggctccattgcgtcaaactacgtgcagtggtaccagcagcgccccggttcctcgccaaccaccgtgatctacgaggacaaccaacgcccgtccggggtgcctgaccggttctccggctccatcgattcctcttccaactccgcttccctgaccattagcggcctcaagaccgaggatgaagccgactactactgccagtcctacgactcaagcaatccgtgggtgttcggtggaggaactaagctgaccgtgctc CAR22-8 246atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtccaactggtgcagtcgggagccgaagtcaagaagccgggggcctccgtcaaagtgtcctgcaaascFV NTgccagcggctacactttcacctcctatgggatctcatgggtcagacaggctcccggccaaggactggaatggatgggttggatctccgcctacaacggcaacactaactacgcccagaagctgcaggggagagtgaccatgacaactgacacctcgacctcaaccgcgtacatggaactgcgcagccttaggtccgacgatacggcggtgtactattgtgcacgggccggcttggccctctactcgaactacgtgccctactactactacggaatggacgtctggggacagggaaccactgtgaccgtgtcctccgggggtggaggctcaggcggaggaggaagcggcgggggtggaagcaactttatgctgacccagcctcactcggtgtcggagagccctggaaagactgtgaccatctcctgcactcggagctcgggctccattgcgtcaaactacgtgcagtggtaccagcagcgccccggttcctcgccaaccaccgtgatctacgaggacaaccaacgcccgtccggggtgcctgaccggttctccggctccatcgattcctcttccaactccgcttccctgaccattagcggcctcaagaccgaggatgaagccgactactactgccagtcctacgactcaagcaatccgtgggtgttcggtggaggaactaagctgaccgtgctcggatcgcaccaccatcaccatcatcatcac CAR22-8247 malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglsolubleewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaraglalysnyvpyyscFV AAyygmdvwgqgttvtvssggggsggggsggggsnfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnpwvfgggtkltvlgshhhhhhhh CAR22-8 248malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglFull AAewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaraglalysnyvpyyyygmdvwgqgttvtvssggggsggggsggggsnfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnpwvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-8 249atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactggtgcagtcgggagccgaagtcaagaagccgggggcctccgtcaaagtgtcctgcaaalentivirusgccagcggctacactttcacctcctatgggatctcatgggtcagacaggctcccggccaaggactggaatggatgggttggatctccgcctacaacggcaacactaactacgcccagaagctgcaggggagagtgaccatgacaactgacacctcgacctcaaccgcgtacatggaactgcgcagccttaggtccgacgatacggcggtgtactattgtgcacgggccggcttggccctctactcgaactacgtgccctactactactacggaatggacgtctggggacagggaaccactgtgaccgtgtcctccgggggtggaggctcaggcggaggaggaagcggcgggggtggaagcaactttatgctgacccagcctcactcggtgtcggagagccctggaaagactgtgaccatctcctgcactcggagctcgggctccattgcgtcaaactacgtgcagtggtaccagcagcgccccggttcctcgccaaccaccgtgatctacgaggacaaccaacgcccgtccggggtgcctgaccggttctccggctccatcgattcctcttccaactccgcttccctgaccattagcggcctcaagaccgaggatgaagccgactactactgccagtcctacgactcaagcaatccgtgggtgttcggtggaggaactaagctgaccgtgctcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-9 250evqlvesggglvkpggslrlscvasgftfsnawmnwvrqapgkglewvgriksktdggtadyaapv scFvkgrftisrddskntmylqmnslktedtgvyycitgatdvwgqgttvtvssggggsggggsggggss AAyvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl CAR22-9 251gaagtgcagctcgtggaatcgggcggtggactggtcaagccaggaggttccctgcggctgtcctgcscFv NTgtggcctccggtttcacattctccaacgcgtggatgaattgggtgcgccaagcccctggaaagggacttgaatgggtcggacggatcaagagcaaaaccgacggaggaactgccgattacgccgcacccgtgaagggcagattcaccatttcgcgggatgactcgaagaacaccatgtacctccagatgaactcgctcaagaccgaggataccggcgtctactactgcatcaccggcgctactgacgtctggggacagggaactaccgtgactgtgtcctccggcggaggcggaagcggaggagggggcagcgggggcgggggatcatcctacgtgctcactcagccgccttcagcctccggtaccccgggccagcgcgtgaccatttcatgctcgggctcctcctcaaacatcgggagcaactacgtgtactggtaccagcagctgcccggtactgcccccaagctgctgatctaccggaacaaccaacgcccgagcggagtgccggacagattctccgggtccaagtctgggacctccgctagcctggcgatctccggtctgaggagcgaggacgaggcagactactattgtgcggcctgggacgattccctgtcggggcctgtgtttggaggcggcacgaagttgaccgtgctg CAR22-9252 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcagctcgtggaatcgggcggtggactggtcaagccaggaggttccctgcggctgtcctgcgtgscFV NTgcctccggtttcacattctccaacgcgtggatgaattgggtgcgccaagcccctggaaagggacttgaatgggtcggacggatcaagagcaaaaccgacggaggaactgccgattacgccgcacccgtgaagggcagattcaccatttcgcgggatgactcgaagaacaccatgtacctccagatgaactcgctcaagaccgaggataccggcgtctactactgcatcaccggcgctactgacgtctggggacagggaactaccgtgactgtgtcctccggcggaggcggaagcggaggagggggcagcgggggcgggggatcatcctacgtgctcactcagccgccttcagcctccggtaccccgggccagcgcgtgaccatttcatgctcgggctcctcctcaaacatcgggagcaactacgtgtactggtaccagcagctgcccggtactgcccccaagctgctgatctaccggaacaaccaacgcccgagcggagtgccggacagattctccgggtccaagtctgggacctccgctagcctggcgatctccggtctgaggagcgaggacgaggcagactactattgtgcggcctgggacgattccctgtcggggcctgtgtttggaggcggcacgaagttgaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-9 253malpvtalllplalllhaarpevqlvesggglvkpggslrlscvasgftfsnawmnwvrqapgkglsolubleewvgriksktdggtadyaapvkgrftisrddskntmylqmnslktedtgvyycitgatdvwgqgttscFV AAvtvssggggsggggsggggssyvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvlgshhhhhhhh CAR22-9 254malpvtalllplalllhaarpevqlvesggglvkpggslrlscvasgftfsnawmnwvrqapgkglFull AAewvgriksktdggtadyaapvkgrftisrddskntmylqmnslktedtgvyycitgatdvwgqgttvtvssggggsggggsggggssyvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-9 255atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagctcgtggaatcgggcggtggactggtcaagccaggaggttccctgcggctgtcctgcgtglentivirusgcctccggtttcacattctccaacgcgtggatgaattgggtgcgccaagcccctggaaagggacttgaatgggtcggacggatcaagagcaaaaccgacggaggaactgccgattacgccgcacccgtgaagggcagattcaccatttcgcgggatgactcgaagaacaccatgtacctccagatgaactcgctcaagaccgaggataccggcgtctactactgcatcaccggcgctactgacgtctggggacagggaactaccgtgactgtgtcctccggcggaggcggaagcggaggagggggcagcgggggcgggggatcatcctacgtgctcactcagccgccttcagcctccggtaccccgggccagcgcgtgaccatttcatgctcgggctcctcctcaaacatcgggagcaactacgtgtactggtaccagcagctgcccggtactgcccccaagctgctgatctaccggaacaaccaacgcccgagcggagtgccggacagattctccgggtccaagtctgggacctccgctagcctggcgatctccggtctgaggagcgaggacgaggcagactactattgtgcggcctgggacgattccctgtcggggcctgtgtttggaggcggcacgaagttgaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcct cggCAR22-10 256evqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrglewlgrtyhrstwyddyass scFvvrgrvsinvdtsknqyslqlnavtpedtgvyycardrlqdgnswsdafdvwgqgtmvtvssggggs AAggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvyvfgtgtkvtvl CAR22-10 257gaagtgcagcttcagcagtctggtcccgggcttgtcaaaccatcgcagaccctgtccctgacttgcscFv NTgcgatcagcggcgatagcgtgctgtcaaactcggacacctggaactggatcaggcagtccccttcccgcggactggaatggttgggccggacgtaccatcgctccacttggtacgacgactatgccagctccgtgagaggccgggtgtcgatcaacgtggatacttcaaagaaccagtactccctccaactcaatgctgtgaccccggaggacaccggagtgtactactgtgcccgggatagactgcaggacggaaactcatggagcgacgccttcgacgtgtggggacagggcaccatggtcaccgtgtccagcggtggaggaggctccggcggtggaggttcggggggaggagggagccaatcggctctgacccaaccggcctcagtcagcggttcgcccggacagtccattactattagctgcaccggaacctccagcgacgtgggcggctacaactatgtgtcgtggtaccagcagcacccggggaaggcccctaagctgatgatctacgacgtgtccaatcggccctccggggtgtccaaccgcttctccggctcgaagtccggcaacactgcatcactgacaatcagcggactgcaagccgaggacgaagcggattactactgctcctcctacacctcctcctccactctcgtctacgtgtttggaaccgggaccaaggtcaccgtgctg CAR22-10 258atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcagcttcagcagtctggtcccgggcttgtcaaaccatcgcagaccctgtccctgacttgcgcgscFV NTatcagcggcgatagcgtgctgtcaaactcggacacctggaactggatcaggcagtccccttcccgcggactggaatggttgggccggacgtaccatcgctccacttggtacgacgactatgccagctccgtgagaggccgggtgtcgatcaacgtggatacttcaaagaaccagtactccctccaactcaatgctgtgaccccggaggacaccggagtgtactactgtgcccgggatagactgcaggacggaaactcatggagcgacgccttcgacgtgtggggacagggcaccatggtcaccgtgtccagcggtggaggaggctccggcggtggaggttcggggggaggagggagccaatcggctctgacccaaccggcctcagtcagcggttcgcccggacagtccattactattagctgcaccggaacctccagcgacgtgggcggctacaactatgtgtcgtggtaccagcagcacccggggaaggcccctaagctgatgatctacgacgtgtccaatcggccctccggggtgtccaaccgcttctccggctcgaagtccggcaacactgcatcactgacaatcagcggactgcaagccgaggacgaagcggattactactgctcctcctacacctcctcctccactctcgtctacgtgtttggaaccgggaccaaggtcaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-10259 malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrsolubleglewlgrtyhrstwyddyassvrgrvsinvdtsknqyslqlnavtpedtgvyycardrlqdgnswsscFV AAdafdvwgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvyvfgtgtkvtvlgshhhhhhhh CAR22-10 260malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrFull AAglewlgrtyhrstwyddyassvrgrvsinvdtsknqyslqlnavtpedtgvyycardrlqdgnswsdafdvwgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvyvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-10 261atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagcttcagcagtctggtcccgggcttgtcaaaccatcgcagaccctgtccctgacttgcgcglentivirusatcagcggcgatagcgtgctgtcaaactcggacacctggaactggatcaggcagtccccttcccgcggactggaatggttgggccggacgtaccatcgctccacttggtacgacgactatgccagctccgtgagaggccgggtgtcgatcaacgtggatacttcaaagaaccagtactccctccaactcaatgctgtgaccccggaggacaccggagtgtactactgtgcccgggatagactgcaggacggaaactcatggagcgacgccttcgacgtgtggggacagggcaccatggtcaccgtgtccagcggtggaggaggctccggcggtggaggttcggggggaggagggagccaatcggctctgacccaaccggcctcagtcagcggttcgcccggacagtccattactattagctgcaccggaacctccagcgacgtgggcggctacaactatgtgtcgtggtaccagcagcacccggggaaggcccctaagctgatgatctacgacgtgtccaatcggccctccggggtgtccaaccgcttctccggctcgaagtccggcaacactgcatcactgacaatcagcggactgcaagccgaggacgaagcggattactactgctcctcctacacctcctcctccactctcgtctacgtgtttggaaccgggaccaaggtcaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-11 262evqlqqsgpglvkpsqtlsltcaisgdsvssnsaawnwirqspsrglewlgrtyyrskwyndyavs scFvvksritinpdtsknqfslqlnsvtpedtavyycareesssgwyegnwfdpwgqgtlvtvssggggs AAggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknhrpsgipdrfsgsssgdtdsltitgaqaedeadyychsrdssgnhlfgggtkltvl CAR22-11 263gaagtgcaacttcagcagtccggtcctggcttggtcaagccgtcacagaccctgtcgctgacttgtscFv NTgctattagcggggactctgtgtcctcaaactccgccgcatggaactggattagacagtcgccctcccggggactggagtggctgggccgcacctactaccggtccaagtggtacaatgactacgccgtgtccgtgaagtcccgcattactatcaaccccgacacttcgaagaaccagttttcgctgcaactcaactccgtcacccctgaggataccgccgtgtactattgcgcccgggaagaatcctccagcggttggtacgaaggaaactggttcgacccatggggccagggcaccctggtcactgtgtcctcgggaggagggggcagcggtggcggaggaagcggaggaggaggctccagctccgagctcacccaggacccggcggtgtcagtggccctgggccaaacggtccgcatcacatgccagggggattccctgaggtcatactacgcgagctggtatcagcagaaacccggacaagcccctgtgctcgtgatctacgggaagaaccacaggccgagcggaatcccggatagattctccgggtcctcatcgggagacactgacagcctcaccatcaccggcgcgcaggccgaggacgaagctgattactactgccattcccgggactcgagcgggaaccaccttttcggtggcggaaccaagctgaccgtgctg CAR22-11 264atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaacttcagcagtccggtcctggcttggtcaagccgtcacagaccctgtcgctgacttgtgctscFV NTattagcggggactctgtgtcctcaaactccgccgcatggaactggattagacagtcgccctcccggggactggagtggctgggccgcacctactaccggtccaagtggtacaatgactacgccgtgtccgtgaagtcccgcattactatcaaccccgacacttcgaagaaccagttttcgctgcaactcaactccgtcacccctgaggataccgccgtgtactattgcgcccgggaagaatcctccagcggttggtacgaaggaaactggttcgacccatggggccagggcaccctggtcactgtgtcctcgggaggagggggcagcggtggcggaggaagcggaggaggaggctccagctccgagctcacccaggacccggcggtgtcagtggccctgggccaaacggtccgcatcacatgccagggggattccctgaggtcatactacgcgagctggtatcagcagaaacccggacaagcccctgtgctcgtgatctacgggaagaaccacaggccgagcggaatcccggatagattctccgggtcctcatcgggagacactgacagcctcaccatcaccggcgcgcaggccgaggacgaagctgattactactgccattcccgggactcgagcgggaaccaccttttcggtggcggaaccaagctgaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-11 265malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvssnsaawnwirqspsrsolubleglewlgrtyyrskwyndyavsvksritinpdtsknqfslqlnsvtpedtavyycareesssgwyegscFV AAnwfdpwgqgtlvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknhrpsgipdrfsgsssgdtdsltitgaqaedeadyychsrdssgnhlfgggtkltvlgshhhhhhhh CAR22-11 266malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvssnsaawnwirqspsrFull AAglewlgrtyyrskwyndyavsvksritinpdtsknqfslqlnsvtpedtavyycareesssgwyegnwfdpwgqgtlvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknhrpsgipdrfsgsssgdtdsltitgaqaedeadyychsrdssgnhlfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-11 267atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaacttcagcagtccggtcctggcttggtcaagccgtcacagaccctgtcgctgacttgtgctlentivirusattagcggggactctgtgtcctcaaactccgccgcatggaactggattagacagtcgccctcccggggactggagtggctgggccgcacctactaccggtccaagtggtacaatgactacgccgtgtccgtgaagtcccgcattactatcaaccccgacacttcgaagaaccagttttcgctgcaactcaactccgtcacccctgaggataccgccgtgtactattgcgcccgggaagaatcctccagcggttggtacgaaggaaactggttcgacccatggggccagggcaccctggtcactgtgtcctcgggaggagggggcagcggtggcggaggaagcggaggaggaggctccagctccgagctcacccaggacccggcggtgtcagtggccctgggccaaacggtccgcatcacatgccagggggattccctgaggtcatactacgcgagctggtatcagcagaaacccggacaagcccctgtgctcgtgatctacgggaagaaccacaggccgagcggaatcccggatagattctccgggtcctcatcgggagacactgacagcctcaccatcaccggcgcgcaggccgaggacgaagctgattactactgccattcccgggactcgagcgggaaccaccttttcggtggcggaaccaagctgaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-12 268evqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrglewlgrtyhrstwyddyass scFvvrgrvsinvdtsknqyslqlnavtpedtgvyycardrlqdgnswsdafdvwgqgtmvtvssggggs AAggggsggggsqsaltqpasasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtqltvl CAR22-12 269gaagtgcagctgcagcagagcggaccgggcctggtcaaaccctcccaaaccctgtccctcacttgcscFv NTgcgatctccggggactccgtgctctcgaactccgacacctggaactggattcggcagagcccatcgaggggcctggaatggctgggaagaacctaccaccggtccacttggtacgatgactacgcgagctcagtgcgcggacgcgtgtcgattaacgtggacacctccaagaaccagtacagcttgcaactgaacgccgtgacccctgaggacaccggagtgtactattgcgcccgggatagacttcaggacggaaacagctggtccgacgcctttgacgtctggggacagggcaccatggtcactgtgtcctcgggtggcggggggtccggtggaggaggttcaggcggaggcggctcacagtcagcactgacgcagccggcttccgcttccgggagccctggacagagcgtgaccatctcgtgtaccgggacttccagcgatgtcggcgggtacaactacgtgtcttggtaccaacagcatccgggaaaggcccccaagctcatgatctacgacgtgtcaaaccggcccagcggagtgtccaatcgcttctccggctccaagtcgggcaatactgcctcgctgactatcagcggtctgcaagccgaagatgaggccgactattactgctcctcctacacctcgtcctccacactctacgtgttcggaaccggtactcagctgaccgtgctt CAR22-12 270atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcagctgcagcagagcggaccgggcctggtcaaaccctcccaaaccctgtccctcacttgcgcgscFV NTatctccggggactccgtgctctcgaactccgacacctggaactggattcggcagagcccatcgaggggcctggaatggctgggaagaacctaccaccggtccacttggtacgatgactacgcgagctcagtgcgcggacgcgtgtcgattaacgtggacacctccaagaaccagtacagcttgcaactgaacgccgtgacccctgaggacaccggagtgtactattgcgcccgggatagacttcaggacggaaacagctggtccgacgcctttgacgtctggggacagggcaccatggtcactgtgtcctcgggtggcggggggtccggtggaggaggttcaggcggaggcggctcacagtcagcactgacgcagccggcttccgcttccgggagccctggacagagcgtgaccatctcgtgtaccgggacttccagcgatgtcggcgggtacaactacgtgtcttggtaccaacagcatccgggaaaggcccccaagctcatgatctacgacgtgtcaaaccggcccagcggagtgtccaatcgcttctccggctccaagtcgggcaatactgcctcgctgactatcagcggtctgcaagccgaagatgaggccgactattactgctcctcctacacctcgtcctccacactctacgtgttcggaaccggtactcagctgaccgtgcttggatcgcaccaccatcaccatcatcatcac CAR22-12271 malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrsolubleglewlgrtyhrstwyddyassvrgrvsinvdtsknqyslqlnavtpedtgvyycardrlqdgnswsscFV AAdafdvwgqgtmvtvssggggsggggsggggsqsaltqpasasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtqltvlgshhhhhhhh CAR22-12 272malpvtalllplalllhaarpevqlqqsgpglvkpsqtlsltcaisgdsvlsnsdtwnwirqspsrFull AAglewlgrtyhrstwyddyassvrgrvsinvdtsknqyslqlnavtpedtgvyycardrlqdgnswsdafdvwgqgtmvtvssggggsggggsggggsqsaltqpasasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtqltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-12 273atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagctgcagcagagcggaccgggcctggtcaaaccctcccaaaccctgtccctcacttgcgcglentivirusatctccggggactccgtgctctcgaactccgacacctggaactggattcggcagagcccatcgaggggcctggaatggctgggaagaacctaccaccggtccacttggtacgatgactacgcgagctcagtgcgcggacgcgtgtcgattaacgtggacacctccaagaaccagtacagcttgcaactgaacgccgtgacccctgaggacaccggagtgtactattgcgcccgggatagacttcaggacggaaacagctggtccgacgcctttgacgtctggggacagggcaccatggtcactgtgtcctcgggtggcggggggtccggtggaggaggttcaggcggaggcggctcacagtcagcactgacgcagccggcttccgcttccgggagccctggacagagcgtgaccatctcgtgtaccgggacttccagcgatgtcggcgggtacaactacgtgtcttggtaccaacagcatccgggaaaggcccccaagctcatgatctacgacgtgtcaaaccggcccagcggagtgtccaatcgcttctccggctccaagtcgggcaatactgcctcgctgactatcagcggtctgcaagccgaagatgaggccgactattactgctcctcctacacctcgtcctccacactctacgtgttcggaaccggtactcagctgaccgtgcttaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-13 274qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslk scFvsrvtisvdtsknqfslklssvtaadtavyycargrmdtamaqiwgqgtmvtvssgdggsggggsgg AAggsnfmltqphsvsespgktvtipctgssgsfassyvqwyqqrpgsapatviyednqrpsgvpdrfsgsvdsssnsasltisglktedeavyycqsydgatwvfgggtkltvl CAR22-13 275caagtgcagctccaagaatcaggtcccggcctcgtgaagccttccgaaaccctctcccttacttgtscFv NTaccgtgtccgggggaagcatctcgagcagctcctattactggggatggatcaggcagcctcccggaaagggactggagtggattggctccatctactactcggggtccacctactacaacccgtcactgaagtcccgcgtgaccatctcggtggatacctccaagaaccagttcagcctgaagctgtcctccgtgactgccgccgacactgccgtgtactactgcgcgcggggtcggatggacacagcgatggctcagatttggggacagggcaccatggtcactgtgtcctccggggatggaggctccgggggcggaggatctggtggcggggggtcgaacttcatgttgacccagccacactccgtgtcggaaagcccaggaaagaccgtcaccatcccttgcactggaagcagcggttcgttcgcatcaagctacgtgcagtggtaccagcaaagacccggcagcgctccggccaccgtcatctatgaggacaatcagcggccgtccggcgtgccggaccgcttcagcggatcggtggactcatcctcaaactccgcctccctgacgatttccggtctgaaaaccgaggacgaagccgtctactactgccagtcgtacgatggcgccacttgggtgtttggaggaggcaccaagctgaccgtgctg CAR22-13 276atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcagctccaagaatcaggtcccggcctcgtgaagccttccgaaaccctctcccttacttgtaccscFV NTgtgtccgggggaagcatctcgagcagctcctattactggggatggatcaggcagcctcccggaaagggactggagtggattggctccatctactactcggggtccacctactacaacccgtcactgaagtcccgcgtgaccatctcggtggatacctccaagaaccagttcagcctgaagctgtcctccgtgactgccgccgacactgccgtgtactactgcgcgcggggtcggatggacacagcgatggctcagatttggggacagggcaccatggtcactgtgtcctccggggatggaggctccgggggcggaggatctggtggcggggggtcgaacttcatgttgacccagccacactccgtgtcggaaagcccaggaaagaccgtcaccatcccttgcactggaagcagcggttcgttcgcatcaagctacgtgcagtggtaccagcaaagacccggcagcgctccggccaccgtcatctatgaggacaatcagcggccgtccggcgtgccggaccgcttcagcggatcggtggactcatcctcaaactccgcctccctgacgatttccggtctgaaaaccgaggacgaagccgtctactactgccagtcgtacgatggcgccacttgggtgtttggaggaggcaccaagctgaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-13 277malpvtalllplalllhaarpqvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgksolubleglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargrmdtamaqiwgscFV AAqgtmvtvssgdggsggggsggggsnfmltqphsvsespgktvtipctgssgsfassyvqwyqqrpgsapatviyednqrpsgvpdrfsgsvdsssnsasltisglktedeavyycqsydgatwvfgggtkltvlgshhhhhhhh CAR22-13 278malpvtalllplalllhaarpqvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkFull AAglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargrmdtamaqiwgqgtmvtvssgdggsggggsggggsnfmltqphsvsespgktvtipctgssgsfassyvqwyqqrpgsapatviyednqrpsgvpdrfsgsvdsssnsasltisglktedeavyycqsydgatwvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-13 279atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcagctccaagaatcaggtcccggcctcgtgaagccttccgaaaccctctcccttacttgtaccgtgtccgggggaagcatctcgagcagctcctattactggggatggatcaggcagcctcccggaaagggactggagtggattggctccatctactactcggggtccacctactacaacccgtcactgaagtcccgcgtgaccatctcggtggatacctccaagaaccagttcagcctgaagctgtcctccgtgactgccgccgacactgccgtgtactactgcgcgcggggtcggatggacacagcgatggctcagatttggggacagggcaccatggtcactgtgtcctccggggatggaggctccgggggcggaggatctggtggcggggggtcgaacttcatgttgacccagccacactccgtgtcggaaagcccaggaaagaccgtcaccatcccttgcactggaagcagcggttcgttcgcatcaagctacgtgcagtggtaccagcaaagacccggcagcgctccggccaccgtcatctatgaggacaatcagcggccgtccggcgtgccggaccgcttcagcggatcggtggactcatcctcaaactccgcctccctgacgatttccggtctgaaaaccgaggacgaagccgtctactactgccagtcgtacgatggcgccacttgggtgtttggaggaggcaccaagctgaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-14 280qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtststvymelsslrsedtavyycardldvsldiwgqgtmvtvssggggsggggsggggs AAqsaltqpasvsgspgqsitiscsgtssdvggynsvswyqqypgkapklmiydvnnrpsgvssrfsgsksgntasltisglqaedeadyycssytssstlffgagtkvtvl CAR22-14 281caagtgcaacttgtccagagcggagcagaagtcaagaaaccaggagcaagcgtgaaggtgtcctgcscFv NTaaagcgtcaggctacactttcacctcctactatatgcactgggtccgccaggcccctggacaaggcctggaatggatgggtatcatcaacccgtccggtggaagcaccagctacgcccagaagtttcagggaagagtgaccatgactcgggacacttcaacctcgacggtgtacatggagctgtcctccctgcggtcggaggacaccgccgtgtactactgcgcgagggatctcgatgtgtccctggacatttggggacagggcaccatggtcaccgtgtcctccggggggggcggatcaggcggcggaggttcagggggcgggggctcccagtccgcgctgactcagccggctagcgtgtccggctcgccgggacagagcattaccatctcgtgctcgggtaccagctccgacgtgggaggctataactccgtgtcctggtaccagcagtaccccggaaaggcccccaagctgatgatctacgacgtgaacaatcgcccttctggggtgtcctctcggttctccgggtcaaagagcggaaacaccgcctccctgaccatctcgggactccaagctgaggatgaagccgactactactgttcgagctacacctcctcctccactctcttcttcggtgccggaactaaggtcacagtgttgCAR22-14 282atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcaacttgtccagagcggagcagaagtcaagaaaccaggagcaagcgtgaaggtgtcctgcaaascFV NTgcgtcaggctacactttcacctcctactatatgcactgggtccgccaggcccctggacaaggcctggaatggatgggtatcatcaacccgtccggtggaagcaccagctacgcccagaagtttcagggaagagtgaccatgactcgggacacttcaacctcgacggtgtacatggagctgtcctccctgcggtcggaggacaccgccgtgtactactgcgcgagggatctcgatgtgtccctggacatttggggacagggcaccatggtcaccgtgtcctccggggggggcggatcaggcggcggaggttcagggggcgggggctcccagtccgcgctgactcagccggctagcgtgtccggctcgccgggacagagcattaccatctcgtgctcgggtaccagctccgacgtgggaggctataactccgtgtcctggtaccagcagtaccccggaaaggcccccaagctgatgatctacgacgtgaacaatcgcccttctggggtgtcctctcggttctccgggtcaaagagcggaaacaccgcctccctgaccatctcgggactccaagctgaggatgaagccgactactactgttcgagctacacctcctcctccactctcttcttcggtgccggaactaaggtcacagtgttgggatcgcaccaccatcaccatcatcatcac CAR22-14 283malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardldvsldiwgqgtscFV AAmvtvssggggsggggsggggsqsaltqpasvsgspgqsitiscsgtssdvggynsvswyqqypgkapklmiydvnnrpsgvssrfsgsksgntasltisglqaedeadyycssytssstlffgagtkvtvlgshhhhhhhh CAR22-14 284malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardldvsldiwgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitiscsgtssdvggynsvswyqqypgkapklmiydvnnrpsgvssrfsgsksgntasltisglqaedeadyycssytssstlffgagtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-14 285atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcaacttgtccagagcggagcagaagtcaagaaaccaggagcaagcgtgaaggtgtcctgcaaagcgtcaggctacactttcacctcctactatatgcactgggtccgccaggcccctggacaaggcctggaatggatgggtatcatcaacccgtccggtggaagcaccagctacgcccagaagtttcagggaagagtgaccatgactcgggacacttcaacctcgacggtgtacatggagctgtcctccctgcggtcggaggacaccgccgtgtactactgcgcgagggatctcgatgtgtccctggacatttggggacagggcaccatggtcaccgtgtcctccggggggggcggatcaggcggcggaggttcagggggcgggggctcccagtccgcgctgactcagccggctagcgtgtccggctcgccgggacagagcattaccatctcgtgctcgggtaccagctccgacgtgggaggctataactccgtgtcctggtaccagcagtaccccggaaaggcccccaagctgatgatctacgacgtgaacaatcgcccttctggggtgtcctctcggttctccgggtcaaagagcggaaacaccgcctccctgaccatctcgggactccaagctgaggatgaagccgactactactgttcgagctacacctcctcctccactctcttcttcggtgccggaactaaggtcacagtgttgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-15 286evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkgleyvsaissnggstyyansvkd scFvrftisrdnskntlylqmgslraedmavyycarvhssgyyhpgpndywgqgtlvtvssggggsgggg AAsggggssseltqdpavsvalgqtvritcqgdslrtyyatwyqqkpgqapvlvfydennrpsgipdrfsgsssgntasltitgtqaedeadyycssrdssgnpscvfgggtkltvl CAR22-15 287gaagtgcagttggtggagagcggtggaggacttgtgcaacctggaggatcattgagactgtcgtgtscFv NTgcggcctccggctttaccttctcgtcctacgctatgcattgggtccgccaggcccccgggaaaggactcgaatacgtcagcgccatctcctcaaacgggggatcaacctactacgccaattccgtgaaggatcggttcaccatctcccgggataacagcaagaacaccctgtatctgcaaatggggtccctgagggcagaggacatggccgtctactactgcgcgcgcgtgcacagctctggatactaccaccctggaccgaacgattactggggccagggcactctcgtgaccgtgtcctcggggggtggtggaagcggcggcggaggatcggggggaggcggctcctcgagcgaactgacacaggaccctgccgtgtccgtggctctgggtcagactgtgcgcattacgtgtcaaggagactccctgagaacttattacgcgacctggtaccagcagaagccgggacaggcaccggtgctggtgttctacgacgaaaacaaccggccatccgggattcccgaccggttctccggctcatcgagcggcaacactgcctccctgaccatcaccgggacccaggccgaggacgaggccgattactactgctcctcgcgggactcctccggcaacccctcctgcgtgttcggcggtggaaccaagctgactgtcctc CAR22-15 288atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcagttggtggagagcggtggaggacttgtgcaacctggaggatcattgagactgtcgtgtgcgscFV NTgcctccggctttaccttctcgtcctacgctatgcattgggtccgccaggcccccgggaaaggactcgaatacgtcagcgccatctcctcaaacgggggatcaacctactacgccaattccgtgaaggatcggttcaccatctcccgggataacagcaagaacaccctgtatctgcaaatggggtccctgagggcagaggacatggccgtctactactgcgcgcgcgtgcacagctctggatactaccaccctggaccgaacgattactggggccagggcactctcgtgaccgtgtcctcggggggtggtggaagcggcggcggaggatcggggggaggcggctcctcgagcgaactgacacaggaccctgccgtgtccgtggctctgggtcagactgtgcgcattacgtgtcaaggagactccctgagaacttattacgcgacctggtaccagcagaagccgggacaggcaccggtgctggtgttctacgacgaaaacaaccggccatccgggattcccgaccggttctccggctcatcgagcggcaacactgcctccctgaccatcaccgggacccaggccgaggacgaggccgattactactgctcctcgcgggactcctccggcaacccctcctgcgtgttcggcggtggaaccaagctgactgtcctcggatcgcaccaccatcaccatcatcatcac CAR22-15 289malpvtalllplalllhaarpevqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglsolubleeyvsaissnggstyyansvkdrftisrdnskntlylqmgslraedmavyycarvhssgyyhpgpndscFV AAywgqgtlvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrtyyatwyqqkpgqapvlvfydennrpsgipdrfsgsssgntasltitgtqaedeadyycssrdssgnpscvfgggtkltvlgshhhhhhhh CAR22-15 290malpvtalllplalllhaarpevqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglFull AAeyvsaissnggstyyansvkdrftisrdnskntlylqmgslraedmavyycarvhssgyyhpgpndywgqgtlvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrtyyatwyqqkpgqapvlvfydennrpsgipdrfsgsssgntasltitgtqaedeadyycssrdssgnpscvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-15 291atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagttggtggagagcggtggaggacttgtgcaacctggaggatcattgagactgtcgtgtgcggcctccggctttaccttctcgtcctacgctatgcattgggtccgccaggcccccgggaaaggactcgaatacgtcagcgccatctcctcaaacgggggatcaacctactacgccaattccgtgaaggatcggttcaccatctcccgggataacagcaagaacaccctgtatctgcaaatggggtccctgagggcagaggacatggccgtctactactgcgcgcgcgtgcacagctctggatactaccaccctggaccgaacgattactggggccagggcactctcgtgaccgtgtcctcggggggtggtggaagcggcggcggaggatcggggggaggcggctcctcgagcgaactgacacaggaccctgccgtgtccgtggctctgggtcagactgtgcgcattacgtgtcaaggagactccctgagaacttattacgcgacctggtaccagcagaagccgggacaggcaccggtgctggtgttctacgacgaaaacaaccggccatccgggattcccgaccggttctccggctcatcgagcggcaacactgcctccctgaccatcaccgggacccaggccgaggacgaggccgattactactgctcctcgcgggactcctccggcaacccctcctgcgtgttcggcggtggaaccaagctgactgtcctcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-16 292evqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtststaymelsslrsedtavyycareagvvavdywgqgtlvtvssggggsggggsgggg AAsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl CAR22-16 293gaagtgcaactcgtcgaatctggagcggaagtcaagaagcctggagcaagcgtgaaagtgtcctgtscFv NTaaagcgtccggttacaccttcacttcgtattacatgcactgggtccgccaagctccgggacagggactggaatggatgggcatcatcaaccctagcggaggatcgacctcctacgcccaaaagttccagggcagagtgaccatgacccgggacaccagcacatcaactgcctacatggagctgtcatcactgaggtccgaggataccgccgtgtactattgcgcccgcgaggccggcgtggtggccgtcgactactggggacagggcactctcgtgaccgtgtcatcgggaggcggcggttccggggggggagggtcggggggcggaggctcccagtccgcactgacgcagccggcttccgtgtctggttcgcccggacagtccatcaccatttcctgcactggaaccagcagcgacgtgggcggttacaactacgtgtcatggtaccagcagcatcccggaaaggccccaaagcttatgatctacgacgtgtccaatcggccgtcgggcgtcagcaaccggttctccggctccaagtccgggaacactgccagcctgaccattagcgggctgcaggccgaggacgaagcggattactactgctcctcctacacttcctcctcgacctgggtgtttggtggaggcaccaagttgactgtg ctgCAR22-16 294atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaactcgtcgaatctggagcggaagtcaagaagcctggagcaagcgtgaaagtgtcctgtaaascFV NTgcgtccggttacaccttcacttcgtattacatgcactgggtccgccaagctccgggacagggactggaatggatgggcatcatcaaccctagcggaggatcgacctcctacgcccaaaagttccagggcagagtgaccatgacccgggacaccagcacatcaactgcctacatggagctgtcatcactgaggtccgaggataccgccgtgtactattgcgcccgcgaggccggcgtggtggccgtcgactactggggacagggcactctcgtgaccgtgtcatcgggaggcggcggttccggggggggagggtcggggggcggaggctcccagtccgcactgacgcagccggcttccgtgtctggttcgcccggacagtccatcaccatttcctgcactggaaccagcagcgacgtgggcggttacaactacgtgtcatggtaccagcagcatcccggaaaggccccaaagcttatgatctacgacgtgtccaatcggccgtcgggcgtcagcaaccggttctccggctccaagtccgggaacactgccagcctgaccattagcgggctgcaggccgaggacgaagcggattactactgctcctcctacacttcctcctcgacctgggtgtttggtggaggcaccaagttgactgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-16 295malpvtalllplalllhaarpevqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtststaymelsslrsedtavyycareagvvavdywgqgscFV AAtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvlgshhhhhhhh CAR22-16 296malpvtalllplalllhaarpevqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststaymelsslrsedtavyycareagvvavdywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-16 297atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaactcgtcgaatctggagcggaagtcaagaagcctggagcaagcgtgaaagtgtcctgtaaagcgtccggttacaccttcacttcgtattacatgcactgggtccgccaagctccgggacagggactggaatggatgggcatcatcaaccctagcggaggatcgacctcctacgcccaaaagttccagggcagagtgaccatgacccgggacaccagcacatcaactgcctacatggagctgtcatcactgaggtccgaggataccgccgtgtactattgcgcccgcgaggccggcgtggtggccgtcgactactggggacagggcactctcgtgaccgtgtcatcgggaggcggcggttccggggggggagggtcggggggcggaggctcccagtccgcactgacgcagccggcttccgtgtctggttcgcccggacagtccatcaccatttcctgcactggaaccagcagcgacgtgggcggttacaactacgtgtcatggtaccagcagcatcccggaaaggccccaaagcttatgatctacgacgtgtccaatcggccgtcgggcgtcagcaaccggttctccggctccaagtccgggaacactgccagcctgaccattagcgggctgcaggccgaggacgaagcggattactactgctcctcctacacttcctcctcgacctgggtgtttggtggaggcaccaagttgactgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-17 298qvqlvqsgggvvqpgrslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkg scFvrftisrdnskntlylqmnslraedtavyycakeplfgvveedvdywgqgtlvtvssggggsggggs AAggggsdvvmtqsplslpvtpgepasiscrssqsllagnghnyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqnpltfgggtkleikr CAR22-17 299caagtgcagttggtccagagcggaggaggagtggtgcaacccggaagatcattgaggctctcatgtscFv NTgctgcaagcggattcaccttctcgagctacgcaatgtcctgggtgcgccaggcccctggaaagggactggaatgggtgtccgccatctcgggctccggcggatcaacgtactacgccgactccgtgaagggccgctttactatttcaagagacaactccaagaacactctgtacctccaaatgaactctctgcgggccgaggacaccgccgtgtactactgcgcgaaggagccgctgttcggcgtggtggaggaagatgtggactactggggccagggcactctcgtcaccgtgtcctccggcggtggaggatcgggaggcggaggcagcgggggtggtggctccgacgtcgtgatgacccagtcgcccctgtccctgcccgtgacccctggggaaccggcctccatttcctgccggtccagccagtcgctgctggctggaaacggacacaattaccttgattggtatctgcaaaagcctgggcagtcaccgcagctgctgatctacctcggaagcaaccgggcgtccggggtgccggaccggttctccggttccgggagcggcaccgacttcaccctgaaaatctcgagggtggaggccgaagatgtcggagtgtactattgcatgcaggcgcttcagaacccactcactttcgggggcggtactaagctggaaatcaagcgc CAR22-17 300atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcagttggtccagagcggaggaggagtggtgcaacccggaagatcattgaggctctcatgtgctscFV NTgcaagcggattcaccttctcgagctacgcaatgtcctgggtgcgccaggcccctggaaagggactggaatgggtgtccgccatctcgggctccggcggatcaacgtactacgccgactccgtgaagggccgctttactatttcaagagacaactccaagaacactctgtacctccaaatgaactctctgcgggccgaggacaccgccgtgtactactgcgcgaaggagccgctgttcggcgtggtggaggaagatgtggactactggggccagggcactctcgtcaccgtgtcctccggcggtggaggatcgggaggcggaggcagcgggggtggtggctccgacgtcgtgatgacccagtcgcccctgtccctgcccgtgacccctggggaaccggcctccatttcctgccggtccagccagtcgctgctggctggaaacggacacaattaccttgattggtatctgcaaaagcctgggcagtcaccgcagctgctgatctacctcggaagcaaccgggcgtccggggtgccggaccggttctccggttccgggagcggcaccgacttcaccctgaaaatctcgagggtggaggccgaagatgtcggagtgtactattgcatgcaggcgcttcagaacccactcactttcgggggcggtactaagctggaaatcaagcgcggatcgcaccaccatcaccatcatcatcac CAR22-17 301malpvtalllplalllhaarpqvqlvqsgggvvqpgrslrlscaasgftfssyamswvrqapgkglsolubleewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakeplfgvveedvdyscFV AAwgqgtlvtvssggggsggggsggggsdvvmtqsplslpvtpgepasiscrssqsllagnghnyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqnpltfgggtkleikrgshhhhhhhh CAR22-17 302malpvtalllplalllhaarpqvqlvqsgggvvqpgrslrlscaasgftfssyamswvrqapgkglFull AAewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakeplfgvveedvdywgqgtlvtvssggggsggggsggggsdvvmtqsplslpvtpgepasiscrssqsllagnghnyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqnpltfgggtkleikrtttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-17 303atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcagttggtccagagcggaggaggagtggtgcaacccggaagatcattgaggctctcatgtgctgcaagcggattcaccttctcgagctacgcaatgtcctgggtgcgccaggcccctggaaagggactggaatgggtgtccgccatctcgggctccggcggatcaacgtactacgccgactccgtgaagggccgctttactatttcaagagacaactccaagaacactctgtacctccaaatgaactctctgcgggccgaggacaccgccgtgtactactgcgcgaaggagccgctgttcggcgtggtggaggaagatgtggactactggggccagggcactctcgtcaccgtgtcctccggcggtggaggatcgggaggcggaggcagcgggggtggtggctccgacgtcgtgatgacccagtcgcccctgtccctgcccgtgacccctggggaaccggcctccatttcctgccggtccagccagtcgctgctggctggaaacggacacaattaccttgattggtatctgcaaaagcctgggcagtcaccgcagctgctgatctacctcggaagcaaccgggcgtccggggtgccggaccggttctccggttccgggagcggcaccgacttcaccctgaaaatctcgagggtggaggccgaagatgtcggagtgtactattgcatgcaggcgcttcagaacccactcactttcgggggcggtactaagctggaaatcaagcgcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-18 304qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtststvymelsslrsedtavyycargsgslgdafdiwgqgtmvtvssggggsggggsgg AAggsqsaltqpasvsgspgqsitisctgsssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtkvtvl CAR22-18 305caagtccaactcgtccaaagcggagctgaagtcaagaagcctggagcgtcagtgaaagtgtcctgcscFv NTaaggcctccggctacacgtttacttcctactacatgcattgggtgcggcaggccccaggtcaaggactggaatggatgggcatcattaacccttccggggggtccacctcgtatgcgcagaagttccagggcagagtgaccatgacccgcgacacctccacctccactgtgtacatggaactgtccagcctgaggtctgaggacactgccgtgtactactgtgcgcgcggtagcggatcactgggcgatgccttcgacatctggggccagggaactatggtcaccgtgtcctccgggggagggggctcgggtggaggaggttcaggcggaggaggctcccagagcgcattgacacagcccgcttcggtgtccggctccccgggacagtccattaccatctcgtgcaccggaagctcaagcgatgtcggagggtacaactacgtgtcgtggtatcagcagcacccgggaaaggcccccaagctcatgatctacgaagtgtccaatcggccgtccggggtgtcgaaccggttcagcggttccaagtcgggcaacactgccagcctgaccatcagcgggctgcaggccgaggacgaggccgactactactgctcctcgtacacctcctcctcaaccctggtgttcggcactggaactaaggtcaccgtgctt CAR22-18 306atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtccaactcgtccaaagcggagctgaagtcaagaagcctggagcgtcagtgaaagtgtcctgcaagscFV NTgcctccggctacacgtttacttcctactacatgcattgggtgcggcaggccccaggtcaaggactggaatggatgggcatcattaacccttccggggggtccacctcgtatgcgcagaagttccagggcagagtgaccatgacccgcgacacctccacctccactgtgtacatggaactgtccagcctgaggtctgaggacactgccgtgtactactgtgcgcgcggtagcggatcactgggcgatgccttcgacatctggggccagggaactatggtcaccgtgtcctccgggggagggggctcgggtggaggaggttcaggcggaggaggctcccagagcgcattgacacagcccgcttcggtgtccggctccccgggacagtccattaccatctcgtgcaccggaagctcaagcgatgtcggagggtacaactacgtgtcgtggtatcagcagcacccgggaaaggcccccaagctcatgatctacgaagtgtccaatcggccgtccggggtgtcgaaccggttcagcggttccaagtcgggcaacactgccagcctgaccatcagcgggctgcaggccgaggacgaggccgactactactgctcctcgtacacctcctcctcaaccctggtgttcggcactggaactaaggtcaccgtgcttggatcgcaccaccatcaccatcatcatcac CAR22-18 307malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargsgslgdafdiwgscFV AAqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgsssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtkvtvlgshhhhhhhh CAR22-18 308malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargsgslgdafdiwgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgsssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-18 309atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccaaagcggagctgaagtcaagaagcctggagcgtcagtgaaagtgtcctgcaaggcctccggctacacgtttacttcctactacatgcattgggtgcggcaggccccaggtcaaggactggaatggatgggcatcattaacccttccggggggtccacctcgtatgcgcagaagttccagggcagagtgaccatgacccgcgacacctccacctccactgtgtacatggaactgtccagcctgaggtctgaggacactgccgtgtactactgtgcgcgcggtagcggatcactgggcgatgccttcgacatctggggccagggaactatggtcaccgtgtcctccgggggagggggctcgggtggaggaggttcaggcggaggaggctcccagagcgcattgacacagcccgcttcggtgtccggctccccgggacagtccattaccatctcgtgcaccggaagctcaagcgatgtcggagggtacaactacgtgtcgtggtatcagcagcacccgggaaaggcccccaagctcatgatctacgaagtgtccaatcggccgtccggggtgtcgaaccggttcagcggttccaagtcgggcaacactgccagcctgaccatcagcgggctgcaggccgaggacgaggccgactactactgctcctcgtacacctcctcctcaaccctggtgttcggcactggaactaaggtcaccgtgcttaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-19 310qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtststvymelsslrsedtavyycardgfgelsgafdiwgqgtmvtvssggggsggggsg AAgggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssyassstlvfgggtkvtvl CAR22-19 311caagtgcaactcgtccagtccggtgcagaagtcaagaaacccggagcctccgtgaaagtgtcctgcscFv NTaaggcctccggctacacgttcacttcatactacatgcactgggtccgccaggcgcccggacagggactggagtggatgggcatcatcaacccttccggcggctcgacctcctacgcccaaaagttccagggaagagtgacaatgaccagggatacttcaaccagcactgtctacatggaactgtctagcttgcggtccgaggacactgccgtgtactattgcgctcgggacggtttcggggagctgtccggggcctttgacatctggggccaggggactatggtgaccgtgtcctcgggcggaggcggcagcggaggaggaggttcgggaggcggaggaagccagtcagcactgacccagccagcctcggtgtccgggagcccgggccagagcatcactatttcctgtaccgggacctcctccgacgtgggagggtacaattacgtgtcatggtatcaacagcatccgggaaaggcgccgaagctgatgatctacgacgtgtcgaaccgccctagcggagtgtccaaccggttctccggttcgaagtccgggaacaccgcgagcctgaccattagcggactccaggccgaggatgaagccgactactactgctcctcctacgcttcatcgtccaccctggtgttcggtggtggcaccaaggtcaccgtgctt CAR22-19 312atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcaactcgtccagtccggtgcagaagtcaagaaacccggagcctccgtgaaagtgtcctgcaagscFV NTgcctccggctacacgttcacttcatactacatgcactgggtccgccaggcgcccggacagggactggagtggatgggcatcatcaacccttccggcggctcgacctcctacgcccaaaagttccagggaagagtgacaatgaccagggatacttcaaccagcactgtctacatggaactgtctagcttgcggtccgaggacactgccgtgtactattgcgctcgggacggtttcggggagctgtccggggcctttgacatctggggccaggggactatggtgaccgtgtcctcgggcggaggcggcagcggaggaggaggttcgggaggcggaggaagccagtcagcactgacccagccagcctcggtgtccgggagcccgggccagagcatcactatttcctgtaccgggacctcctccgacgtgggagggtacaattacgtgtcatggtatcaacagcatccgggaaaggcgccgaagctgatgatctacgacgtgtcgaaccgccctagcggagtgtccaaccggttctccggttcgaagtccgggaacaccgcgagcctgaccattagcggactccaggccgaggatgaagccgactactactgctcctcctacgcttcatcgtccaccctggtgttcggtggtggcaccaaggtcaccgtgcttggatcgcaccaccatcaccatcatcatcac CAR22-19 313malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardgfgelsgafdiwscFV AAgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssyassstlvfgggtkvtvlgshhhhhhhh CAR22-19 314malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardgfgelsgafdiwgqgtmvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssyassstlvfgggtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-19 315atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcaactcgtccagtccggtgcagaagtcaagaaacccggagcctccgtgaaagtgtcctgcaaggcctccggctacacgttcacttcatactacatgcactgggtccgccaggcgcccggacagggactggagtggatgggcatcatcaacccttccggcggctcgacctcctacgcccaaaagttccagggaagagtgacaatgaccagggatacttcaaccagcactgtctacatggaactgtctagcttgcggtccgaggacactgccgtgtactattgcgctcgggacggtttcggggagctgtccggggcctttgacatctggggccaggggactatggtgaccgtgtcctcgggcggaggcggcagcggaggaggaggttcgggaggcggaggaagccagtcagcactgacccagccagcctcggtgtccgggagcccgggccagagcatcactatttcctgtaccgggacctcctccgacgtgggagggtacaattacgtgtcatggtatcaacagcatccgggaaaggcgccgaagctgatgatctacgacgtgtcgaaccgccctagcggagtgtccaaccggttctccggttcgaagtccgggaacaccgcgagcctgaccattagcggactccaggccgaggatgaagccgactactactgctcctcctacgcttcatcgtccaccctggtgttcggtggtggcaccaaggtcaccgtgcttaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-20 316evqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtststvymelsslrsedtavyycargpigcsggscldywgqgtlvtvssggggsggggs AAggggsqsaltqpayvsgspgqsitisctgtnsdvgrynyvswyqqhpgkapklmiyevsyrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstldfgtgtkvtvl CAR22-20 317gaagtgcaactcgtcgaatcaggagcagaagtcaagaaaccaggagcctccgtgaaagtcagctgcscFv NTaaggcctcgggctacactttcacttcctactacatgcattgggtgcgccaggccccgggccagggactggaatggatgggcatcatcaatccctcgggaggttccactagctacgcgcagaagttccagggaagagtgaccatgaccagagacacctcgacttcgacggtgtacatggagctgagctccctgaggagcgaggacactgccgtgtactactgcgcccggggcccgatcggatgcagcggggggtcctgtctcgattactggggccagggcacactcgtgaccgtgtccagcgggggcggtggtagcggaggagggggatcgggcggtggaggatcgcagtccgccctgacccaaccggcgtacgtgtctggatcacccggacagtccattaccatctcctgcaccggaaccaactcggacgtgggccgctacaactacgtgtcatggtaccagcagcaccccgggaaggctcctaagctgatgatctacgaggtgtcctatcggcctagcggtgtcagcaaccggttctccggctccaagtccggcaacactgcttcccttaccatttccgggttgcaagccgaggacgaggccgattactactgttcctcctataccacttcatccaccctggactttggaaccggcaccaaggtcaccgtgctg CAR22-20 318atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaactcgtcgaatcaggagcagaagtcaagaaaccaggagcctccgtgaaagtcagctgcaagscFV NTgcctcgggctacactttcacttcctactacatgcattgggtgcgccaggccccgggccagggactggaatggatgggcatcatcaatccctcgggaggttccactagctacgcgcagaagttccagggaagagtgaccatgaccagagacacctcgacttcgacggtgtacatggagctgagctccctgaggagcgaggacactgccgtgtactactgcgcccggggcccgatcggatgcagcggggggtcctgtctcgattactggggccagggcacactcgtgaccgtgtccagcgggggcggtggtagcggaggagggggatcgggcggtggaggatcgcagtccgccctgacccaaccggcgtacgtgtctggatcacccggacagtccattaccatctcctgcaccggaaccaactcggacgtgggccgctacaactacgtgtcatggtaccagcagcaccccgggaaggctcctaagctgatgatctacgaggtgtcctatcggcctagcggtgtcagcaaccggttctccggctccaagtccggcaacactgcttcccttaccatttccgggttgcaagccgaggacgaggccgattactactgttcctcctataccacttcatccaccctggactttggaaccggcaccaaggtcaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-20 319malpvtalllplalllhaarpevqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargpigcsggscldyscFV AAwgqgtlvtvssggggsggggsggggsqsaltqpayvsgspgqsitisctgtnsdvgrynyvswyqqhpgkapklmiyevsyrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstldfgtgtkvtvlgshhhhhhhh CAR22-20 320malpvtalllplalllhaarpevqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargpigcsggscldywgqgtlvtvssggggsggggsggggsqsaltqpayvsgspgqsitisctgtnsdvgrynyvswyqqhpgkapklmiyevsyrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstldfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-20 321atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaactcgtcgaatcaggagcagaagtcaagaaaccaggagcctccgtgaaagtcagctgcaaggcctcgggctacactttcacttcctactacatgcattgggtgcgccaggccccgggccagggactggaatggatgggcatcatcaatccctcgggaggttccactagctacgcgcagaagttccagggaagagtgaccatgaccagagacacctcgacttcgacggtgtacatggagctgagctccctgaggagcgaggacactgccgtgtactactgcgcccggggcccgatcggatgcagcggggggtcctgtctcgattactggggccagggcacactcgtgaccgtgtccagcgggggcggtggtagcggaggagggggatcgggcggtggaggatcgcagtccgccctgacccaaccggcgtacgtgtctggatcacccggacagtccattaccatctcctgcaccggaaccaactcggacgtgggccgctacaactacgtgtcatggtaccagcagcaccccgggaaggctcctaagctgatgatctacgaggtgtcctatcggcctagcggtgtcagcaaccggttctccggctccaagtccggcaacactgcttcccttaccatttccgggttgcaagccgaggacgaggccgattactactgttcctcctataccacttcatccaccctggactttggaaccggcaccaaggtcaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-21 322qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtststvymelsslrsedtavyycargsygdygdafdiwgqgttvtvssggggsggggsg AAsggsqsaltqpasvsgspgqsitisctgtssdvggykyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgggtkltvl CAR22-21 323caagtgcaactcgtccagtccggtgcagaagtcaagaaacccggagcctccgtgaaagtgtcctgcscFv NTaaggcctcgggctacaccttcacctcctactacatgcactgggtgcgccaggcgccgggccagggacttgagtggatgggtatcatcaacccgtccggcggaagcacctcgtacgcccaaaagtttcaggggagagtgaccatgaccagggacacttcaaccagcaccgtgtacatggaactgtcaagcttgcgctccgaggatactgccgtctactactgcgcccggggatcgtacggagactacggcgacgctttcgatatctggggacagggcacaaccgtgaccgtgtcctccggcggagggggctcgggcggaggaggctcaggttccggcgggagccagtccgcactgactcagccagcgtccgtgagcggtagccctgggcagtctatcacgatttcgtgcactggcacctcctccgacgtgggaggctataagtacgtcagctggtaccaacagcatccgggaaaggcgcctaagctgatgatctatgacgtcagcaaccggccctccggggtgtcaaaccggttcagcggttccaagtcgggaaataccgcctccctgaccattagcgggctgcaggccgaagatgaggctgactactactgttcctcctacacttcatcgtccactctcgtgttcgggggaggaactaagctcaccgtgctg CAR22-21 324atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcaactcgtccagtccggtgcagaagtcaagaaacccggagcctccgtgaaagtgtcctgcaagscFV NTgcctcgggctacaccttcacctcctactacatgcactgggtgcgccaggcgccgggccagggacttgagtggatgggtatcatcaacccgtccggcggaagcacctcgtacgcccaaaagtttcaggggagagtgaccatgaccagggacacttcaaccagcaccgtgtacatggaactgtcaagcttgcgctccgaggatactgccgtctactactgcgcccggggatcgtacggagactacggcgacgctttcgatatctggggacagggcacaaccgtgaccgtgtcctccggcggagggggctcgggcggaggaggctcaggttccggcgggagccagtccgcactgactcagccagcgtccgtgagcggtagccctgggcagtctatcacgatttcgtgcactggcacctcctccgacgtgggaggctataagtacgtcagctggtaccaacagcatccgggaaaggcgcctaagctgatgatctatgacgtcagcaaccggccctccggggtgtcaaaccggttcagcggttccaagtcgggaaataccgcctccctgaccattagcgggctgcaggccgaagatgaggctgactactactgttcctcctacacttcatcgtccactctcgtgttcgggggaggaactaagctcaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-21 325malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargsygdygdafdiwscFV AAgqgttvtvssggggsggggsgsggsqsaltqpasvsgspgqsitisctgtssdvggykyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgggtkltvlgshhhhhhhh CAR22-21 326malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargsygdygdafdiwgqgttvtvssggggsggggsgsggsqsaltqpasvsgspgqsitisctgtssdvggykyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-21 327atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcaactcgtccagtccggtgcagaagtcaagaaacccggagcctccgtgaaagtgtcctgcaaggcctcgggctacaccttcacctcctactacatgcactgggtgcgccaggcgccgggccagggacttgagtggatgggtatcatcaacccgtccggcggaagcacctcgtacgcccaaaagtttcaggggagagtgaccatgaccagggacacttcaaccagcaccgtgtacatggaactgtcaagcttgcgctccgaggatactgccgtctactactgcgcccggggatcgtacggagactacggcgacgctttcgatatctggggacagggcacaaccgtgaccgtgtcctccggcggagggggctcgggcggaggaggctcaggttccggcgggagccagtccgcactgactcagccagcgtccgtgagcggtagccctgggcagtctatcacgatttcgtgcactggcacctcctccgacgtgggaggctataagtacgtcagctggtaccaacagcatccgggaaaggcgcctaagctgatgatctatgacgtcagcaaccggccctccggggtgtcaaaccggttcagcggttccaagtcgggaaataccgcctccctgaccattagcgggctgcaggccgaagatgaggctgactactactgttcctcctacacttcatcgtccactctcgtgttcgggggaggaactaagctcaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-22 328evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqg scFvrvtitadeststaymelsslrsedtavyycardhkvvrfgywgqgtlvtvssggggsggggsgggg AAshviltqppsasaslgasvkltctlssghssyaiawhqqqpekgprylmkvnsdgslskgdgipdrfsgstsgaeryltisslqsedeadyycqtwgsgmaifgggtkltvl CAR22-22 329gaagtgcaattggtggaatcaggcgcagaagtcaagaaacccggaagcagcgtgaaagtgtcctgcscFv NTaaggcctcaggaggcaccttctcgtcctatgccatttcctgggtccgccaggccccgggacagggcctggaatggatgggcggaattatccctatcttcggaaccgcgaactacgcccagaagtttcagggacgcgtgaccatcactgccgatgaatcaacctccactgcgtacatggaactgtcctccctgcggagcgaggacaccgccgtgtactactgcgcaagggatcataaggtcgtgcggttcggatactggggacagggaacccttgtgaccgtgtcctccggcggcggggggtccggcggagggggttccgggggaggcggatcgcacgtgatcctgactcaaccaccctcagcctccgcctctctgggagccagcgtgaagctcacctgtactctgagctcgggacactcgtcgtacgccatcgcttggcaccagcagcagccggagaaggggcctagatacctgatgaaggtcaactccgacggttcgctgagcaagggcgacggcatcccggatcggttcagcggttccacgtccggcgcggagagatacctcacaatctcctcgctccaatccgaggacgaggctgactactactgccagacctggggtagcggcatggcgattttcgggggtggaactaagctgaccgtgctg CAR22-22 330atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaattggtggaatcaggcgcagaagtcaagaaacccggaagcagcgtgaaagtgtcctgcaagscFV NTgcctcaggaggcaccttctcgtcctatgccatttcctgggtccgccaggccccgggacagggcctggaatggatgggcggaattatccctatcttcggaaccgcgaactacgcccagaagtttcagggacgcgtgaccatcactgccgatgaatcaacctccactgcgtacatggaactgtcctccctgcggagcgaggacaccgccgtgtactactgcgcaagggatcataaggtcgtgcggttcggatactggggacagggaacccttgtgaccgtgtcctccggcggcggggggtccggcggagggggttccgggggaggcggatcgcacgtgatcctgactcaaccaccctcagcctccgcctctctgggagccagcgtgaagctcacctgtactctgagctcgggacactcgtcgtacgccatcgcttggcaccagcagcagccggagaaggggcctagatacctgatgaaggtcaactccgacggttcgctgagcaagggcgacggcatcccggatcggttcagcggttccacgtccggcgcggagagatacctcacaatctcctcgctccaatccgaggacgaggctgactactactgccagacctggggtagcggcatggcgattttcgggggtggaactaagctgaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-22 331malpvtalllplalllhaarpevqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglsolubleewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardhkvvrfgywgqgscFV AAtlvtvssggggsggggsggggshviltqppsasaslgasvkltctlssghssyaiawhqqqpekgprylmkvnsdgslskgdgipdrfsgstsgaeryltisslqsedeadyycqtwgsgmaifgggtkltvlgshhhhhhhh CAR22-22 332malpvtalllplalllhaarpevqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglFull AAewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardhkvvrfgywgqgtlvtvssggggsggggsggggshviltqppsasaslgasvkltctlssghssyaiawhqqqpekgprylmkvnsdgslskgdgipdrfsgstsgaeryltisslqsedeadyycqtwgsgmaifgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-22 333atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaattggtggaatcaggcgcagaagtcaagaaacccggaagcagcgtgaaagtgtcctgcaaggcctcaggaggcaccttctcgtcctatgccatttcctgggtccgccaggccccgggacagggcctggaatggatgggcggaattatccctatcttcggaaccgcgaactacgcccagaagtttcagggacgcgtgaccatcactgccgatgaatcaacctccactgcgtacatggaactgtcctccctgcggagcgaggacaccgccgtgtactactgcgcaagggatcataaggtcgtgcggttcggatactggggacagggaacccttgtgaccgtgtcctccggcggcggggggtccggcggagggggttccgggggaggcggatcgcacgtgatcctgactcaaccaccctcagcctccgcctctctgggagccagcgtgaagctcacctgtactctgagctcgggacactcgtcgtacgccatcgcttggcaccagcagcagccggagaaggggcctagatacctgatgaaggtcaactccgacggttcgctgagcaagggcgacggcatcccggatcggttcagcggttccacgtccggcgcggagagatacctcacaatctcctcgctccaatccgaggacgaggctgactactactgccagacctggggtagcggcatggcgattttcgggggtggaactaagctgaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-23 334qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtststvymelsslrsedtavyycargdyymdvwgkgttvtvssggggsggggsggggsq AAsaltqpasasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltisglqaedeadyycssytssgtlvfgggtkltvl CAR22-23 335caagtgcaactcgtccagtccggtgcagaagtcaagaaacccggtgcttccgtgaaagtgtcctgcscFv NTaaggcctcaggttacaccttcacctcctactacatgcattgggtccgccaagcccccggacaaggcctggagtggatgggaattatcaacccgtccggcggcagcacaagctacgcccagaagttccagggacgcgtgactatgaccagagatacctccacctccaccgtgtacatggaactgtcctcactccggtcggaagataccgccgtgtactactgtgcccggggagactactatatggacgtctggggaaagggcaccaccgtgactgtgtcgtcgggcggcgggggttcgggaggaggaggaagcggtggcgggggaagccagtccgcactgactcagcccgcgtcggccagcgggagccctggccagagcgtgaccatttcgtgcaccggaacttcctctgacgtcggcggatacaactacgtgtcctggtaccagcagcaccctggaaaggccccgaagctgatgatctacgaggtgtccaagaggccatccggcgtgccggaccggttttcgggatcaaagtccgggaacacggccagcctgaccatcagcgggcttcaggctgaggacgaagcggattactactgctcctcctatacttcatccggcaccttggtgttcggcggagggactaagctgactgtgctc CAR22-23336 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcaactcgtccagtccggtgcagaagtcaagaaacccggtgcttccgtgaaagtgtcctgcaagscFV NTgcctcaggttacaccttcacctcctactacatgcattgggtccgccaagcccccggacaaggcctggagtggatgggaattatcaacccgtccggcggcagcacaagctacgcccagaagttccagggacgcgtgactatgaccagagatacctccacctccaccgtgtacatggaactgtcctcactccggtcggaagataccgccgtgtactactgtgcccggggagactactatatggacgtctggggaaagggcaccaccgtgactgtgtcgtcgggcggcgggggttcgggaggaggaggaagcggtggcgggggaagccagtccgcactgactcagcccgcgtcggccagcgggagccctggccagagcgtgaccatttcgtgcaccggaacttcctctgacgtcggcggatacaactacgtgtcctggtaccagcagcaccctggaaaggccccgaagctgatgatctacgaggtgtccaagaggccatccggcgtgccggaccggttttcgggatcaaagtccgggaacacggccagcctgaccatcagcgggcttcaggctgaggacgaagcggattactactgctcctcctatacttcatccggcaccttggtgttcggcggagggactaagctgactgtgctcggatcgcaccaccatcaccatcatcatcac CAR22-23 337malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargdyymdvwgkgttscFV AAvtvssggggsggggsggggsqsaltqpasasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltisglqaedeadyycssytssgtlvfgggtkltvlgshhhhhhhh CAR22-23 338malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargdyymdvwgkgttvtvssggggsggggsggggsqsaltqpasasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltisglqaedeadyycssytssgtlvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-23 339atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcaactcgtccagtccggtgcagaagtcaagaaacccggtgcttccgtgaaagtgtcctgcaaggcctcaggttacaccttcacctcctactacatgcattgggtccgccaagcccccggacaaggcctggagtggatgggaattatcaacccgtccggcggcagcacaagctacgcccagaagttccagggacgcgtgactatgaccagagatacctccacctccaccgtgtacatggaactgtcctcactccggtcggaagataccgccgtgtactactgtgcccggggagactactatatggacgtctggggaaagggcaccaccgtgactgtgtcgtcgggcggcgggggttcgggaggaggaggaagcggtggcgggggaagccagtccgcactgactcagcccgcgtcggccagcgggagccctggccagagcgtgaccatttcgtgcaccggaacttcctctgacgtcggcggatacaactacgtgtcctggtaccagcagcaccctggaaaggccccgaagctgatgatctacgaggtgtccaagaggccatccggcgtgccggaccggttttcgggatcaaagtccgggaacacggccagcctgaccatcagcgggcttcaggctgaggacgaagcggattactactgctcctcctatacttcatccggcaccttggtgttcggcggagggactaagctgactgtgctcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcct cggCAR22-24 340evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsyissssstiyyadsvkg scFvrftisrdnaknslylqmnslraedtavyycardgpiryfdhskafdiwgqgtmvtvssggggsggg AAgsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyyrnsrdssgnpyvfgtgtkvtvl CAR22-24 341gaagtgcaattggtggaatcaggaggaggacttgtgcaacctggaggatctctgagactgtcatgcscFv NTgccgcgtcgggattcactttctcctcctacgcaatgtcgtgggtcagacaggcccccggaaagggcctggaatgggtgtcatacatcagctcctcctcctccacgatctactacgccgactctgtgaaggggcggttcaccattagccgggacaacgcaaagaactccctgtatctgcaaatgaacagcctcagggcggaagataccgccgtgtactactgtgcgcgcgatggtccgattcgctatttcgaccactccaaggccttcgatatctggggccagggaaccatggtcaccgtgtcgtccggtggaggcggcagcggggggggcggaagcggcggcgggggttcatcctcggagctgactcaggaccccgccgtgtccgtggctctgggacagaccgtgcgcatcacatgccagggagattccctgcggtcgtactacgcctcctggtaccagcagaaaccgggccaggcccccgtcctcgtgatctacggaaagaacaacaggccttcgggtatcccagaccggttcagcggcagctccagcggaaacaccgcaagcctcactattaccggggcccaggctgaggacgaggccgactactaccggaactcccgcgactcctcgggcaatccgtacgtctttggtactgggaccaaggtcaccgtgctg CAR22-24 342atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcaattggtggaatcaggaggaggacttgtgcaacctggaggatctctgagactgtcatgcgccscFV NTgcgtcgggattcactttctcctcctacgcaatgtcgtgggtcagacaggcccccggaaagggcctggaatgggtgtcatacatcagctcctcctcctccacgatctactacgccgactctgtgaaggggcggttcaccattagccgggacaacgcaaagaactccctgtatctgcaaatgaacagcctcagggcggaagataccgccgtgtactactgtgcgcgcgatggtccgattcgctatttcgaccactccaaggccttcgatatctggggccagggaaccatggtcaccgtgtcgtccggtggaggcggcagcggggggggcggaagcggcggcgggggttcatcctcggagctgactcaggaccccgccgtgtccgtggctctgggacagaccgtgcgcatcacatgccagggagattccctgcggtcgtactacgcctcctggtaccagcagaaaccgggccaggcccccgtcctcgtgatctacggaaagaacaacaggccttcgggtatcccagaccggttcagcggcagctccagcggaaacaccgcaagcctcactattaccggggcccaggctgaggacgaggccgactactaccggaactcccgcgactcctcgggcaatccgtacgtctttggtactgggaccaaggtcaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-24 343malpvtalllplalllhaarpevqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglsolubleewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardgpiryfdhskafscFV AAdiwgqgtmvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyyrnsrdssgnpyvfgtgtkvtvlgshhhhhhhh CAR22-24 344malpvtalllplalllhaarpevqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglFull AAewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardgpiryfdhskafdiwgqgtmvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyyrnsrdssgnpyvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-24 345atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcaattggtggaatcaggaggaggacttgtgcaacctggaggatctctgagactgtcatgcgccgcgtcgggattcactttctcctcctacgcaatgtcgtgggtcagacaggcccccggaaagggcctggaatgggtgtcatacatcagctcctcctcctccacgatctactacgccgactctgtgaaggggcggttcaccattagccgggacaacgcaaagaactccctgtatctgcaaatgaacagcctcagggcggaagataccgccgtgtactactgtgcgcgcgatggtccgattcgctatttcgaccactccaaggccttcgatatctggggccagggaaccatggtcaccgtgtcgtccggtggaggcggcagcggggggggcggaagcggcggcgggggttcatcctcggagctgactcaggaccccgccgtgtccgtggctctgggacagaccgtgcgcatcacatgccagggagattccctgcggtcgtactacgcctcctggtaccagcagaaaccgggccaggcccccgtcctcgtgatctacggaaagaacaacaggccttcgggtatcccagaccggttcagcggcagctccagcggaaacaccgcaagcctcactattaccggggcccaggctgaggacgaggccgactactaccggaactcccgcgactcctcgggcaatccgtacgtctttggtactgggaccaaggtcaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-25 346qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqg scFvrvtmtrdtsistaymelsrlrsddtavyycaremddssgpdywgqgtlvtvssggggsggggsggg AAgsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtkltvl CAR22-25 347caagtgcagctcgtccagtccggtgcagaagtcaagaaacccggtgcttccgtgaaagtgtcctgcscFv NTaaggcatccggctacacgttcacctcctactacatgcattgggtccgccaagcccccggccaaggcctggagtggatggggatcattaacccaagcggaggaagcactagctacgcgcagaagtttcagggccgcgtgaccatgaccagggatacttccatctccaccgcttacatggaactgtcgcggctgagaagcgacgacacagccgtgtactactgtgcccgggaaatggacgactcctccgggcctgattactggggacaggggactctggtcaccgtgtcgtccggtggaggcggatcggggggcggaggttccggcggagggggctcacagtccgcgctgacccagccggccagcgtgtcaggatcaccgggccagagcatcaccatttcctgcaccggaacctcatcggacgtcggcggatataactacgtgtcgtggtaccagcagcaccctggaaaggccccgaagctcatgatctacgaggtgtccaatagacccagcggagtgtcgaaccggttcagcgggtccaagtcgggaaacaccgccagcttgaccatctctggactgcaagccgaggacgaagccgattactactgctcctcgtatacttcctcctcaacccttgtgttcggaactggcactaagctgaccgtgctc CAR22-25 348atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcagctcgtccagtccggtgcagaagtcaagaaacccggtgcttccgtgaaagtgtcctgcaagscFV NTgcatccggctacacgttcacctcctactacatgcattgggtccgccaagcccccggccaaggcctggagtggatggggatcattaacccaagcggaggaagcactagctacgcgcagaagtttcagggccgcgtgaccatgaccagggatacttccatctccaccgcttacatggaactgtcgcggctgagaagcgacgacacagccgtgtactactgtgcccgggaaatggacgactcctccgggcctgattactggggacaggggactctggtcaccgtgtcgtccggtggaggcggatcggggggcggaggttccggcggagggggctcacagtccgcgctgacccagccggccagcgtgtcaggatcaccgggccagagcatcaccatttcctgcaccggaacctcatcggacgtcggcggatataactacgtgtcgtggtaccagcagcaccctggaaaggccccgaagctcatgatctacgaggtgtccaatagacccagcggagtgtcgaaccggttcagcgggtccaagtcgggaaacaccgccagcttgaccatctctggactgcaagccgaggacgaagccgattactactgctcctcgtatacttcctcctcaacccttgtgttcggaactggcactaagctgaccgtgctcggatcgcaccaccatcaccatcatcatcac CAR22-25 349malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsolubleewmgiinpsggstsyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaremddssgpdywgqscFV AAgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtkltvlgshhhhhhhh CAR22-25 350malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaremddssgpdywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-25 351atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcagctcgtccagtccggtgcagaagtcaagaaacccggtgcttccgtgaaagtgtcctgcaaggcatccggctacacgttcacctcctactacatgcattgggtccgccaagcccccggccaaggcctggagtggatggggatcattaacccaagcggaggaagcactagctacgcgcagaagtttcagggccgcgtgaccatgaccagggatacttccatctccaccgcttacatggaactgtcgcggctgagaagcgacgacacagccgtgtactactgtgcccgggaaatggacgactcctccgggcctgattactggggacaggggactctggtcaccgtgtcgtccggtggaggcggatcggggggcggaggttccggcggagggggctcacagtccgcgctgacccagccggccagcgtgtcaggatcaccgggccagagcatcaccatttcctgcaccggaacctcatcggacgtcggcggatataactacgtgtcgtggtaccagcagcaccctggaaaggccccgaagctcatgatctacgaggtgtccaatagacccagcggagtgtcgaaccggttcagcgggtccaagtcgggaaacaccgccagcttgaccatctctggactgcaagccgaggacgaagccgattactactgctcctcgtatacttcctcctcaacccttgtgttcggaactggcactaagctgaccgtgctcaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-26 352evqlvesgaevkkpgeslkisckgsgysftgswigwgrqmpgkglewmgiiypgdsdtryspsfqg scFvqvtisadksistaylqwsslkasdtamyycargflrggdccgaldiwgqgtmvtvssggggsgggg AAsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtppwtfgqgtkleikr CAR22-26 353gaagtgcagttggtggaatcaggagcagaagtcaagaaacccggagaaagcctgaagatctcgtgcscFv NTaaagggagcggatactcgttcaccggatcatggattggatggggccgccagatgcctggaaagggtctggaatggatgggaatcatctacccgggggactccgatactcggtactccccgagctttcagggccaggtcaccatctccgccgacaagtccatctccactgcgtatttgcagtggagctcactgaaggcctcggacaccgctatgtactactgcgcccgcggtttcctgaggggcggagattgttgcggcgcccttgatatctggggccaggggaccatggtgaccgtgtcctccggtggtggcggctccggcggaggagggtccgggggaggaggctccgacattgtgatgacccagagccccctgtccctgcccgtgactcctggggagccagcctcgatcagctgccggtcgtcccagtcccttctgcactccaacggctacaactatctcgattggtacctccagaagcctggtcaaagcccgcagctgctgatctacctcggttcaaacagagcttccggggtgccggacagattcagcggatctggatcgggcacagacttcacgctcaagatttcccgcgtggaggccgaggacgtcggcgtgtactactgtatgcaagcgctgcagaccccgccctggactttcggacaaggaaccaagctggagattaagcgg CAR22-26 354atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcagttggtggaatcaggagcagaagtcaagaaacccggagaaagcctgaagatctcgtgcaaascFV NTgggagcggatactcgttcaccggatcatggattggatggggccgccagatgcctggaaagggtctggaatggatgggaatcatctacccgggggactccgatactcggtactccccgagctttcagggccaggtcaccatctccgccgacaagtccatctccactgcgtatttgcagtggagctcactgaaggcctcggacaccgctatgtactactgcgcccgcggtttcctgaggggcggagattgttgcggcgcccttgatatctggggccaggggaccatggtgaccgtgtcctccggtggtggcggctccggcggaggagggtccgggggaggaggctccgacattgtgatgacccagagccccctgtccctgcccgtgactcctggggagccagcctcgatcagctgccggtcgtcccagtcccttctgcactccaacggctacaactatctcgattggtacctccagaagcctggtcaaagcccgcagctgctgatctacctcggttcaaacagagcttccggggtgccggacagattcagcggatctggatcgggcacagacttcacgctcaagatttcccgcgtggaggccgaggacgtcggcgtgtactactgtatgcaagcgctgcagaccccgccctggactttcggacaaggaaccaagctggagattaagcggggatcgcaccaccatcaccatcatcatcac CAR22-26 355malpvtalllplalllhaarpevqlvesgaevkkpgeslkisckgsgysftgswigwgrqmpgkglsolubleewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargflrggdccgaldscFV AAiwgqgtmvtvssggggsggggsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtppwtfgqgtkleikrgshhhhhhhh CAR22-26 356malpvtalllplalllhaarpevqlvesgaevkkpgeslkisckgsgysftgswigwgrqmpgkglFull AAewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargflrggdccgaldiwgqgtmvtvssggggsggggsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtppwtfgqgtkleikrtttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-26 357atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagttggtggaatcaggagcagaagtcaagaaacccggagaaagcctgaagatctcgtgcaaagggagcggatactcgttcaccggatcatggattggatggggccgccagatgcctggaaagggtctggaatggatgggaatcatctacccgggggactccgatactcggtactccccgagctttcagggccaggtcaccatctccgccgacaagtccatctccactgcgtatttgcagtggagctcactgaaggcctcggacaccgctatgtactactgcgcccgcggtttcctgaggggcggagattgttgcggcgcccttgatatctggggccaggggaccatggtgaccgtgtcctccggtggtggcggctccggcggaggagggtccgggggaggaggctccgacattgtgatgacccagagccccctgtccctgcccgtgactcctggggagccagcctcgatcagctgccggtcgtcccagtcccttctgcactccaacggctacaactatctcgattggtacctccagaagcctggtcaaagcccgcagctgctgatctacctcggttcaaacagagcttccggggtgccggacagattcagcggatctggatcgggcacagacttcacgctcaagatttcccgcgtggaggccgaggacgtcggcgtgtactactgtatgcaagcgctgcagaccccgccctggactttcggacaaggaaccaagctggagattaagcggaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-27 358qvqlqesgpglvkpsetlsltcsvsggsinsyywswirqapgkglewiaftshsgnvkynpsltgr scFvvtiavdtsknqfylevtsvtaadtavyfcargldplfaydafeiwglgtmvtvssggggsggggsg AAgggseivltqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlqtppltfgggtkvdikr CAR22-27 359caagtgcaacttcaggaatcaggccccggacttgtgaaaccatcagaaactctctccctcacttgcscFv NTtccgtgagcggggggtccatcaactcctactactggtcgtggattagacaggcccctggaaaggggctggagtggatcgcgttcacttcgcactccggcaacgtcaagtacaacccgtccctgaccggaagagtgaccattgccgtggatacctccaagaaccagttctacctggaagtcacgtcggtgaccgctgctgacaccgccgtgtacttctgcgcacgggggctggacccattgtttgcctacgatgcgttcgaaatctgggggctcggaaccatggtcactgtgtcctccggcggaggcggcagcggtggaggaggcagcggaggaggaggttccgagatcgtgctgacccagagccccctgtccctccccgtgacccctggagaaccggccagcatttcctgccggtcgagccagtccctgttgcattcaaatggctacaactacctggattggtatctgcagaagcccggccagtcaccgcaactgctcatctacctgggaagcaaccgcgcctcgggtgtcccggaccgcttctccggctcggggtctggcactgacttcacactgaagatctccagggtggaggccgaggacgtgggagtgtattactgtatgcaagtgctgcagaccccgcctctgaccttcggcggtggaactaaggtcgacatcaagcgg CAR22-27 360atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasolublegtgcaacttcaggaatcaggccccggacttgtgaaaccatcagaaactctctccctcacttgctccscFV NTgtgagcggggggtccatcaactcctactactggtcgtggattagacaggcccctggaaaggggctggagtggatcgcgttcacttcgcactccggcaacgtcaagtacaacccgtccctgaccggaagagtgaccattgccgtggatacctccaagaaccagttctacctggaagtcacgtcggtgaccgctgctgacaccgccgtgtacttctgcgcacgggggctggacccattgtttgcctacgatgcgttcgaaatctgggggctcggaaccatggtcactgtgtcctccggcggaggcggcagcggtggaggaggcagcggaggaggaggttccgagatcgtgctgacccagagccccctgtccctccccgtgacccctggagaaccggccagcatttcctgccggtcgagccagtccctgttgcattcaaatggctacaactacctggattggtatctgcagaagcccggccagtcaccgcaactgctcatctacctgggaagcaaccgcgcctcgggtgtcccggaccgcttctccggctcggggtctggcactgacttcacactgaagatctccagggtggaggccgaggacgtgggagtgtattactgtatgcaagtgctgcagaccccgcctctgaccttcggcggtggaactaaggtcgacatcaagcggggatcgcaccaccatcaccatcatcatcac CAR22-27 361malpvtalllplalllhaarpqvqlqesgpglvkpsetlsltcsvsggsinsyywswirqapgkglsolubleewiaftshsgnvkynpsltgrvtiavdtsknqfylevtsvtaadtavyfcargldplfaydafeiwscFV AAglgtmvtvssggggsggggsggggseivltqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlqtppltfgggtkvdikrgshhhhhhhh CAR22-27 362malpvtalllplalllhaarpqvqlqesgpglvkpsetlsltcsvsggsinsyywswirqapgkglFull AAewiaftshsgnvkynpsltgrvtiavdtsknqfylevtsvtaadtavyfcargldplfaydafeiwglgtmvtvssggggsggggsggggseivltqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlqtppltfgggtkvdikrtttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-27 363atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcaacttcaggaatcaggccccggacttgtgaaaccatcagaaactctctccctcacttgctccgtgagcggggggtccatcaactcctactactggtcgtggattagacaggcccctggaaaggggctggagtggatcgcgttcacttcgcactccggcaacgtcaagtacaacccgtccctgaccggaagagtgaccattgccgtggatacctccaagaaccagttctacctggaagtcacgtcggtgaccgctgctgacaccgccgtgtacttctgcgcacgggggctggacccattgtttgcctacgatgcgttcgaaatctgggggctcggaaccatggtcactgtgtcctccggcggaggcggcagcggtggaggaggcagcggaggaggaggttccgagatcgtgctgacccagagccccctgtccctccccgtgacccctggagaaccggccagcatttcctgccggtcgagccagtccctgttgcattcaaatggctacaactacctggattggtatctgcagaagcccggccagtcaccgcaactgctcatctacctgggaagcaaccgcgcctcgggtgtcccggaccgcttctccggctcggggtctggcactgacttcacactgaagatctccagggtggaggccgaggacgtgggagtgtattactgtatgcaagtgctgcagaccccgcctctgaccttcggcggtggaactaaggtcgacatcaagcggaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-28 364evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgscFv AArftisrdnaknslylqmnslraedtavyycarddfwsgsvdywgqgtlvtvssggggsggggsggggsggggssyvltqppsvsvapgktatitcggtnigsknvhwyqqkpgqapvlaiyydsdrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhwvfgggtkltvl CAR22-28 365gaagtgcagttggtggaatctggtggtggactcgtgaaacctggaggaagcttgcgcctgtcttgcscFv NTgcggcctccggcttcactttctcggattactacatgtcctggattagacaggctccggggaagggactcgaatgggtgtcctacatttcatcaagcggcagcaccatctactatgcggactccgtgaaggggcggttcactatttcccgggataacgcaaagaacagcctgtaccttcaaatgaattcactgcgcgccgaggacaccgccgtgtactattgcgcccgggatgacttctggtcggggtccgtggactactggggccaggggaccctggtcaccgtgtcctcgggaggaggaggaagcgggggaggcggttccgggggcggcggctcgggcggcggtggctccagctacgtgctcacccagccgccctccgtgtccgtggccccgggaaagaccgccaccatcacctgtggaggaacgaacatcggctccaagaacgtccattggtaccagcagaagcccggacaggcccccgtgctggcaatctactacgactccgaccgcccaagcggtatccctgaaaggttctccggctccaacagcggaaacactgcgactctgaccatctcaagagtggaggctggcgatgaggccgactacttctgccaagtctgggactcgtcctcggaccactgggtgtttgggggaggcaccaagctgactgtcctg CAR22-28 366atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasolublegtgcagttggtggaatctggtggtggactcgtgaaacctggaggaagcttgcgcctgtcttgcgcgscFV NTgcctccggcttcactttctcggattactacatgtcctggattagacaggctccggggaagggactcgaatgggtgtcctacatttcatcaagcggcagcaccatctactatgcggactccgtgaaggggcggttcactatttcccgggataacgcaaagaacagcctgtaccttcaaatgaattcactgcgcgccgaggacaccgccgtgtactattgcgcccgggatgacttctggtcggggtccgtggactactggggccaggggaccctggtcaccgtgtcctcgggaggaggaggaagcgggggaggcggttccgggggcggcggctcgggcggcggtggctccagctacgtgctcacccagccgccctccgtgtccgtggccccgggaaagaccgccaccatcacctgtggaggaacgaacatcggctccaagaacgtccattggtaccagcagaagcccggacaggcccccgtgctggcaatctactacgactccgaccgcccaagcggtatccctgaaaggttctccggctccaacagcggaaacactgcgactctgaccatctcaagagtggaggctggcgatgaggccgactacttctgccaagtctgggactcgtcctcggaccactgggtgtttgggggaggcaccaagctgactgtcctgggatcgcaccaccatcaccatcatcatcac CAR22-28 367malpvtalllplalllhaarpevqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglsolubleewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarddfwsgsvdywgqscFV NTgtlvtvssggggsggggsggggsggggssyvltqppsvsvapgktatitcggtnigsknvhwyqqkpgqapvlaiyydsdrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhwvfgggtkltvlgshhhhhhhh CAR22-28 368malpvtalllplalllhaarpevqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglFull AAewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarddfwsgsvdywgqgtlvtvssggggsggggsggggsggggssyvltqppsvsvapgktatitcggtnigsknvhwyqqkpgqapvlaiyydsdrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhwvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-28 369atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagttggtggaatctggtggtggactcgtgaaacctggaggaagcttgcgcctgtcttgcgcggcctccggcttcactttctcggattactacatgtcctggattagacaggctccggggaagggactcgaatgggtgtcctacatttcatcaagcggcagcaccatctactatgcggactccgtgaaggggcggttcactatttcccgggataacgcaaagaacagcctgtaccttcaaatgaattcactgcgcgccgaggacaccgccgtgtactattgcgcccgggatgacttctggtcggggtccgtggactactggggccaggggaccctggtcaccgtgtcctcgggaggaggaggaagcgggggaggcggttccgggggcggcggctcgggcggcggtggctccagctacgtgctcacccagccgccctccgtgtccgtggccccgggaaagaccgccaccatcacctgtggaggaacgaacatcggctccaagaacgtccattggtaccagcagaagcccggacaggcccccgtgctggcaatctactacgactccgaccgcccaagcggtatccctgaaaggttctccggctccaacagcggaaacactgcgactctgaccatctcaagagtggaggctggcgatgaggccgactacttctgccaagtctgggactcgtcctcggaccactgggtgtttgggggaggcaccaagctgactgtcctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-29 370qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgscFv AArvtmtrdtststvymelsslrsedtavyycareddssgytspfdywgqgtlvtvssggggsggggsggggsgggrssyeltqppsvsvapgetasiacgghnirsknvhwyqqkpgqapvlvisydgdrpsgiperfsgsnlgstatltisrveagdeadyycqvwdsdsdhyvfgtgtkvtvl CAR22-29 371caagtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcscFv NTaaggcctcggggtacacattcacctcctactacatgcactgggtgcgccaggccccgggccagggactggaatggatgggaatcattaacccgtccggcggatcgaccagctacgcccagaagtttcagggacgcgtgaccatgacccgggacactagcaccagcactgtgtacatggaactgagctcactgcggtccgaggacactgcggtgtactattgcgcccgggaggacgattcctccgggtacacttcgcccttcgactattggggacagggaaccttggtcaccgtgtcatcgggtggtggaggaagcggaggaggcggctccggcggcgggggttcaggcggtggcagaagctcctacgaactgacccagcctccgtccgtgtccgtggcccccggcgaaaccgcctcgatcgcgtgtggagggcacaatattcggagcaagaacgtgcattggtaccagcagaagccgggacaggcaccagtgctcgtgatctcctacgatggggacaggccttctggcatccctgagagattcagcgggtccaacctgggctccactgctaccctgaccatctcgcgcgtggaagccggggatgaggccgactactactgccaagtctgggactccgacagcgatcactacgtgttcggaactggaaccaaggtcacggtgctt CAR22-29 372atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaSoluble scFv-gtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcaag ntgcctcggggtacacattcacctcctactacatgcactgggtgcgccaggccccgggccagggactggaatggatgggaatcattaacccgtccggcggatcgaccagctacgcccagaagtttcagggacgcgtgaccatgacccgggacactagcaccagcactgtgtacatggaactgagctcactgcggtccgaggacactgcggtgtactattgcgcccgggaggacgattcctccgggtacacttcgcccttcgactattggggacagggaaccttggtcaccgtgtcatcgggtggtggaggaagcggaggaggcggctccggcggcgggggttcaggcggtggcagaagctcctacgaactgacccagcctccgtccgtgtccgtggcccccggcgaaaccgcctcgatcgcgtgtggagggcacaatattcggagcaagaacgtgcattggtaccagcagaagccgggacaggcaccagtgctcgtgatctcctacgatggggacaggccttctggcatccctgagagattcagcgggtccaacctgggctccactgctaccctgaccatctcgcgcgtggaagccggggatgaggccgactactactgccaagtctgggactccgacagcgatcactacgtgttcggaactggaaccaaggtcacggtgcttggatcgcaccaccatcaccatcatcatcac CAR22-29 373malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsoluble scFvewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycareddssgytspfdy AAwgqgtlvtvssggggsggggsggggsgggrssyeltqppsvsvapgetasiacgghnirsknvhwyqqkpgqapvlvisydgdrpsgiperfsgsnlgstatltisrveagdeadyycqvwdsdsdhyvfgtgtkvtvlgshhhhhhhh CAR22-29 374malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycareddssgytspfdywgqgtlvtvssggggsggggsggggsgggrssyeltqppsvsvapgetasiacgghnirsknvhwyqqkpgqapvlvisydgdrpsgiperfsgsnlgstatltisrveagdeadyycqvwdsdsdhyvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-29 375atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcaaggcctcggggtacacattcacctcctactacatgcactgggtgcgccaggccccgggccagggactggaatggatgggaatcattaacccgtccggcggatcgaccagctacgcccagaagtttcagggacgcgtgaccatgacccgggacactagcaccagcactgtgtacatggaactgagctcactgcggtccgaggacactgcggtgtactattgcgcccgggaggacgattcctccgggtacacttcgcccttcgactattggggacagggaaccttggtcaccgtgtcatcgggtggtggaggaagcggaggaggcggctccggcggcgggggttcaggcggtggcagaagctcctacgaactgacccagcctccgtccgtgtccgtggcccccggcgaaaccgcctcgatcgcgtgtggagggcacaatattcggagcaagaacgtgcattggtaccagcagaagccgggacaggcaccagtgctcgtgatctcctacgatggggacaggccttctggcatccctgagagattcagcgggtccaacctgggctccactgctaccctgaccatctcgcgcgtggaagccggggatgaggccgactactactgccaagtctgggactccgacagcgatcactacgtgttcggaactggaaccaaggtcacggtgcttaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-30 376evqlvesgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgscFv AArvtmtrdtsistaymelsrlrsddtavyycarepassswygyyyymdvwgkgtlvtvssggggsggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsintylnwyqqkpgkppklliyaasnlqsgvpsrfsgsgsgthftltisslqpddfatyycqqsysslltfgggtkleik CAR22-30 377gaagtgcagttggtggaatcaggagcagaagtcaagaaacccggagcatcagtcaaagtgtcctgcscFv NTaaggcctccgggtacactttcactggttactacatgcattgggtgcgccaggcgcccggacaaggactcgagtggatgggctggattaaccccaactccggcggaaccaactacgcccagaagttccagggtagagtgacgatgactcgggacaccagcatctccaccgcgtacatggagctgtcgagactgaggtccgacgataccgccgtgtactactgcgcccgggaaccggcttcctcgtcttggtacggatattactattacatggatgtctggggaaagggaacacttgtcactgtgtccagcggtggcggaggcagcggcggtggagggtccggcggcggcggatcgggagggggaggcagcgacatccagatgactcagtccccatcctcgctgtcggctagcgtgggcgaccgcgtgaccattacctgtcgggccagccaatccatcaacacctacctgaactggtaccagcagaagccggggaagcctccaaagctgctcatctacgcggcctcaaatctgcaatccggggtgccttcccggttctccggttccggttcggggacccacttcactctgaccattagctcactgcaaccggacgactttgccacctactactgccagcagagctactcctccctcctgaccttcggcggaggaaccaagctcgagatcaag CAR22-30 378atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaasoluble scFvgtgcagttggtggaatcaggagcagaagtcaagaaacccggagcatcagtcaaagtgtcctgcaag NTgcctccgggtacactttcactggttactacatgcattgggtgcgccaggcgcccggacaaggactcgagtggatgggctggattaaccccaactccggcggaaccaactacgcccagaagttccagggtagagtgacgatgactcgggacaccagcatctccaccgcgtacatggagctgtcgagactgaggtccgacgataccgccgtgtactactgcgcccgggaaccggcttcctcgtcttggtacggatattactattacatggatgtctggggaaagggaacacttgtcactgtgtccagcggtggcggaggcagcggcggtggagggtccggcggcggcggatcgggagggggaggcagcgacatccagatgactcagtccccatcctcgctgtcggctagcgtgggcgaccgcgtgaccattacctgtcgggccagccaatccatcaacacctacctgaactggtaccagcagaagccggggaagcctccaaagctgctcatctacgcggcctcaaatctgcaatccggggtgccttcccggttctccggttccggttcggggacccacttcactctgaccattagctcactgcaaccggacgactttgccacctactactgccagcagagctactcctccctcctgaccttcggcggaggaaccaagctcgagatcaagggatcgcaccaccatcaccatcatcatcac CAR22-30 379malpvtalllplalllhaarpevqlvesgaevkkpgasvkvsckasgytftgyymhwvrqapgqglsoluble scFvewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarepassswygyyyy AAmdvwgkgtlvtvssggggsggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsintylnwyqqkpgkppklliyaasnlqsgvpsrfsgsgsgthftltisslqpddfatyycqqsysslltfgggtkleikgshhhhhhhh CAR22-30 380malpvtalllplalllhaarpevqlvesgaevkkpgasvkvsckasgytftgyymhwvrqapgqglFull AAewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarepassswygyyyymdvwgkgtlvtvssggggsggggsggggsggggsdiqmtqspsslsasvgdrvtitcrasqsintylnwyqqkpgkppklliyaasnlqsgvpsrfsgsgsgthftltisslqpddfatyycqqsysslltfgggtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-30 381atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgaaFull NTgtgcagttggtggaatcaggagcagaagtcaagaaacccggagcatcagtcaaagtgtcctgcaaggcctccgggtacactttcactggttactacatgcattgggtgcgccaggcgcccggacaaggactcgagtggatgggctggattaaccccaactccggcggaaccaactacgcccagaagttccagggtagagtgacgatgactcgggacaccagcatctccaccgcgtacatggagctgtcgagactgaggtccgacgataccgccgtgtactactgcgcccgggaaccggcttcctcgtcttggtacggatattactattacatggatgtctggggaaagggaacacttgtcactgtgtccagcggtggcggaggcagcggcggtggagggtccggcggcggcggatcgggagggggaggcagcgacatccagatgactcagtccccatcctcgctgtcggctagcgtgggcgaccgcgtgaccattacctgtcgggccagccaatccatcaacacctacctgaactggtaccagcagaagccggggaagcctccaaagctgctcatctacgcggcctcaaatctgcaatccggggtgccttcccggttctccggttccggttcggggacccacttcactctgaccattagctcactgcaaccggacgactttgccacctactactgccagcagagctactcctccctcctgaccttcggcggaggaaccaagctcgagatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-31 382QvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgscFv AArvtmtrntsistaymelsslrsedtavyycargdsnywsyygmdvwgqgtlvtvssggggsggggsggggsggggsqsvltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgeapkliiydadkrpsgisnrfssgksgntasltisglqvedeadyyccsyaggstwvfgggtkvtvl CAR22-31 383CaagtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcscFv NTaaggcctcgggttacaccttcacctcctacgacattaactgggtgcgccaggccactgggcagggactggaatggatgggctggatgaaccctaactcgggcaacaccggctatgcccagaagtttcagggacgcgtgacgatgacccggaatacctccatctcaaccgcctacatggaactgagcagcctgaggtccgaggatactgcagtgtactactgcgctcggggagactccaactattggtcctactacggaatggacgtgtggggccagggaaccctcgtcactgtgtcgagcgggggaggcggttcagggggcggcggaagcggaggcggagggtccggcggaggaggttctcagagcgtgctgactcaaccgagatccgtgtccgggagcccgggccagtcagtgactatctcgtgcaccgggaccagctccgacgtgggagggtacaactacgtgtcgtggtaccagcagcaccccggagaggcgccaaagttgattatctacgacgccgataagcgcccttcgggaatctccaaccggttctcctccgggaagtccggcaacactgcctccctgaccatcagcggacttcaagtggaggacgaagcggattactactgctgttcatacgccggcggatcgacctgggtgttcggcggtggtaccaaggtcacagtgctg CAR22-31 384atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcaag NTgcctcgggttacaccttcacctcctacgacattaactgggtgcgccaggccactgggcagggactggaatggatgggctggatgaaccctaactcgggcaacaccggctatgcccagaagtttcagggacgcgtgacgatgacccggaatacctccatctcaaccgcctacatggaactgagcagcctgaggtccgaggatactgcagtgtactactgcgctcggggagactccaactattggtcctactacggaatggacgtgtggggccagggaaccctcgtcactgtgtcgagcgggggaggcggttcagggggcggcggaagcggaggcggagggtccggcggaggaggttctcagagcgtgctgactcaaccgagatccgtgtccgggagcccgggccagtcagtgactatctcgtgcaccgggaccagctccgacgtgggagggtacaactacgtgtcgtggtaccagcagcaccccggagaggcgccaaagttgattatctacgacgccgataagcgcccttcgggaatctccaaccggttctcctccgggaagtccggcaacactgcctccctgaccatcagcggacttcaagtggaggacgaagcggattactactgctgttcatacgccggcggatcgacctgggtgttcggcggtggtaccaaggtcacagtgctgggatcgcaccaccatcaccatcatcatcac CAR22-31 385malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglsoluble scFvewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycargdsnywsyygmdv AAwgqgtlvtvssggggsggggsggggsggggsqsvltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgeapkliiydadkrpsgisnrfssgksgntasltisglqvedeadyyccsyaggstwvfgggtkvtvlgshhhhhhhh CAR22-31 386malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglFull AAewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycargdsnywsyygmdvwgqgtlvtvssggggsggggsggggsggggsqsvltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgeapkliiydadkrpsgisnrfssgksgntasltisglqvedeadyyccsyaggstwvfgggtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-31 387atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcaaggcctcgggttacaccttcacctcctacgacattaactgggtgcgccaggccactgggcagggactggaatggatgggctggatgaaccctaactcgggcaacaccggctatgcccagaagtttcagggacgcgtgacgatgacccggaatacctccatctcaaccgcctacatggaactgagcagcctgaggtccgaggatactgcagtgtactactgcgctcggggagactccaactattggtcctactacggaatggacgtgtggggccagggaaccctcgtcactgtgtcgagcgggggaggcggttcagggggcggcggaagcggaggcggagggtccggcggaggaggttctcagagcgtgctgactcaaccgagatccgtgtccgggagcccgggccagtcagtgactatctcgtgcaccgggaccagctccgacgtgggagggtacaactacgtgtcgtggtaccagcagcaccccggagaggcgccaaagttgattatctacgacgccgataagcgcccttcgggaatctccaaccggttctcctccgggaagtccggcaacactgcctccctgaccatcagcggacttcaagtggaggacgaagcggattactactgctgttcatacgccggcggatcgacctgggtgttcggcggtggtaccaaggtcacagtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-32 388qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgscFv AArvtmttdtststaymelrslrsddtavyycasfsssdsydywgqgtlvtvssggggsggggsggggsggggseivltqspatlsvspgeratlscrasqsvtsnlawyqqkpgqaprlliyaastratgiparfsgsgsgteftltissmqsedfavyfcqqyhtwppltfgggtkveikt CAR22-32 389caagtccaactcgtccagtccggtgcagaagtcaagaaaccaggagcttcagtgaaagtgtcgtgcscFv NTaaggcctccgggtataccttcacttcctacggcattagctgggtgcggcaggcccccggccaagggctggagtggatgggctggatcagcgcctacaacggaaacaccaactacgcccagaagctgcagggacgcgtgaccatgaccactgacacctccacttcgaccgcgtacatggagctcagatcactgcgctccgacgataccgccgtgtactactgcgcctccttctcctcctccgactcctacgactactggggacaggggactctggtcactgtgtcgtccggcggcggcggaagcggtggcggaggcagcggtggaggcggttcgggaggaggagggtccgaaatcgtgctgacccagtcccccgctaccctttccgtgagcccgggggaacgggccaccctgtcttgccgcgcgtcacaaagcgtgacttcgaacctggcctggtaccagcagaagccggggcaggccccgagattgctcatctatgccgcgagcaccagggcaaccggaattcctgcccggttttccggttccgggtcgggcactgagttcaccctgacaatcagctcaatgcagtccgaggatttcgctgtgtacttctgtcaacagtaccacacctggcctcccctgacgttcggaggcggaaccaaggtcgaaatcaagacc CAR22-32 390atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtccaactcgtccagtccggtgcagaagtcaagaaaccaggagcttcagtgaaagtgtcgtgcaag NTgcctccgggtataccttcacttcctacggcattagctgggtgcggcaggcccccggccaagggctggagtggatgggctggatcagcgcctacaacggaaacaccaactacgcccagaagctgcagggacgcgtgaccatgaccactgacacctccacttcgaccgcgtacatggagctcagatcactgcgctccgacgataccgccgtgtactactgcgcctccttctcctcctccgactcctacgactactggggacaggggactctggtcactgtgtcgtccggcggcggcggaagcggtggcggaggcagcggtggaggcggttcgggaggaggagggtccgaaatcgtgctgacccagtcccccgctaccctttccgtgagcccgggggaacgggccaccctgtcttgccgcgcgtcacaaagcgtgacttcgaacctggcctggtaccagcagaagccggggcaggccccgagattgctcatctatgccgcgagcaccagggcaaccggaattcctgcccggttttccggttccgggtcgggcactgagttcaccctgacaatcagctcaatgcagtccgaggatttcgctgtgtacttctgtcaacagtaccacacctggcctcccctgacgttcggaggcggaaccaaggtcgaaatcaagaccggatcgcaccaccatcaccatcatcatcac CAR22-32 391Malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglsoluble scFvewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycasfsssdsydywgqg AAtlvtvssggggsggggsggggsggggseivltqspatlsvspgeratlscrasqsvtsnlawyqqkpgqaprlliyaastratgiparfsgsgsgteftltissmqsedfavyfcqqyhtwppltfgggtkveiktgshhhhhhhh CAR22-32 392malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglFull AAewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycasfsssdsydywgqgtlvtvssggggsggggsggggsggggseivltqspatlsvspgeratlscrasqsvtsnlawyqqkpgqaprlliyaastratgiparfsgsgsgteftltissmqsedfavyfcqqyhtwppltfgggtkveiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-32 393atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccagtccggtgcagaagtcaagaaaccaggagcttcagtgaaagtgtcgtgcaaggcctccgggtataccttcacttcctacggcattagctgggtgcggcaggcccccggccaagggctggagtggatgggctggatcagcgcctacaacggaaacaccaactacgcccagaagctgcagggacgcgtgaccatgaccactgacacctccacttcgaccgcgtacatggagctcagatcactgcgctccgacgataccgccgtgtactactgcgcctccttctcctcctccgactcctacgactactggggacaggggactctggtcactgtgtcgtccggcggcggcggaagcggtggcggaggcagcggtggaggcggttcgggaggaggagggtccgaaatcgtgctgacccagtcccccgctaccctttccgtgagcccgggggaacgggccaccctgtcttgccgcgcgtcacaaagcgtgacttcgaacctggcctggtaccagcagaagccggggcaggccccgagattgctcatctatgccgcgagcaccagggcaaccggaattcctgcccggttttccggttccgggtcgggcactgagttcaccctgacaatcagctcaatgcagtccgaggatttcgctgtgtacttctgtcaacagtaccacacctggcctcccctgacgttcggaggcggaaccaaggtcgaaatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-33 394qvnlresgpalvkptqtltltctfsgfslntfgmsvswirqppgkalewlalidwdddkyystslrscFv AAtrltiskdtaknqvvlrmtnmdpmdtatyycariyggdrtntqapyffdlwgqgtlvtvssggggsggggsggggsdvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpwtfgqgtkleik CAR22-33 395caagtcaacctcagagaatcaggtcctgccctcgtcaaacctacccagaccctcaccttgacctgtscFv NTaccttctccgggttctcgctgaacaccttcgggatgtccgtgagctggattaggcagcccccgggaaaggccctggagtggctggccctgatcgattgggatgacgacaagtactactccacctcactccgcactcgcctgaccatctcaaaggacactgccaagaaccaagtggtgctgcggatgactaacatggacccgatggacaccgccacctattactgcgcccggatctacggaggcgacagaaccaacactcaggccccctacttcttcgatctgtggggacagggcactcttgtgaccgtgtcctcgggcggaggaggctccggtggagggggatcaggaggaggcggcagcgacgtcgtgatgactcaatccccgctgtccttgcctgtgacccctggcgaacccgcgtccattagctgccggagcagccagtccctcctgcactcgaacggatacaactacctggattggtatctgcagaagcccggccagtccccacaactcctgatctacctgggctctaatcgggcatccggggtcccggatcgcttcagcggttcgggctcgggtaccgacttcacgctgaagatttccagggtggaagctgaggacgtgggagtgtactactgcatgcaggcgcttcagactccatggacatttggacaggggaccaagctggagatcaag CAR22-33- 396atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtcaacctcagagaatcaggtcctgccctcgtcaaacctacccagaccctcaccttgacctgtacc NTttctccgggttctcgctgaacaccttcgggatgtccgtgagctggattaggcagcccccgggaaaggccctggagtggctggccctgatcgattgggatgacgacaagtactactccacctcactccgcactcgcctgaccatctcaaaggacactgccaagaaccaagtggtgctgcggatgactaacatggacccgatggacaccgccacctattactgcgcccggatctacggaggcgacagaaccaacactcaggccccctacttcttcgatctgtggggacagggcactcttgtgaccgtgtcctcgggcggaggaggctccggtggagggggatcaggaggaggcggcagcgacgtcgtgatgactcaatccccgctgtccttgcctgtgacccctggcgaacccgcgtccattagctgccggagcagccagtccctcctgcactcgaacggatacaactacctggattggtatctgcagaagcccggccagtccccacaactcctgatctacctgggctctaatcgggcatccggggtcccggatcgcttcagcggttcgggctcgggtaccgacttcacgctgaagatttccagggtggaagctgaggacgtgggagtgtactactgcatgcaggcgcttcagactccatggacatttggacaggggaccaagctggagatcaagggatcgcaccaccatcaccatcatcatcac CAR22-33397 malpvtalllplalllhaarpqvnlresgpalvkptqtltltctfsgfslntfgmsvswirqppgksoluble scFvalewlalidwdddkyystslrtrltiskdtaknqvvlrmtnmdpmdtatyycariyggdrtntqap AAyffdlwgqgtlvtvssggggsggggsggggsdvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpwtfgqgtkleikgshhhhhhhh CAR22-33 398malpvtalllplalllhaarpqvnlresgpalvkptqtltltctfsgfslntfgmsvswirqppgkFull AAalewlalidwdddkyystslrtrltiskdtaknqvvlrmtnmdpmdtatyycariyggdrtntqapyffdlwgqgtlvtvssggggsggggsggggsdvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpwtfgqgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-33 399atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtcaacctcagagaatcaggtcctgccctcgtcaaacctacccagaccctcaccttgacctgtaccttctccgggttctcgctgaacaccttcgggatgtccgtgagctggattaggcagcccccgggaaaggccctggagtggctggccctgatcgattgggatgacgacaagtactactccacctcactccgcactcgcctgaccatctcaaaggacactgccaagaaccaagtggtgctgcggatgactaacatggacccgatggacaccgccacctattactgcgcccggatctacggaggcgacagaaccaacactcaggccccctacttcttcgatctgtggggacagggcactcttgtgaccgtgtcctcgggcggaggaggctccggtggagggggatcaggaggaggcggcagcgacgtcgtgatgactcaatccccgctgtccttgcctgtgacccctggcgaacccgcgtccattagctgccggagcagccagtccctcctgcactcgaacggatacaactacctggattggtatctgcagaagcccggccagtccccacaactcctgatctacctgggctctaatcgggcatccggggtcccggatcgcttcagcggttcgggctcgggtaccgacttcacgctgaagatttccagggtggaagctgaggacgtgggagtgtactactgcatgcaggcgcttcagactccatggacatttggacaggggaccaagctggagatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-34 400qvqlqesgpglvkpsgtlsltcavsgasitsrhwwnwvrhspgkglewigqiyhsgtttynpslgsscFv AArvtisvdksknqislelrsvtaadtatyycvrdylelatyygmdvwgqgttvtvssggggsggggsggggseivltqsplslpvtpgepasiscrssqsllysdgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlqisgvetedvgvyycmqalqtqsfgqgtkleik CAR22-34 401caagtgcagcttcaagaatcaggacctggcctcgtcaaaccctccggtaccctctccctcacctgtscFv NTgccgtgtccggggcatctatcacctcccgccactggtggaactgggtcagacactccccgggaaagggattggagtggattggccagatctaccattccggcaccactacttacaacccgtccctgggctcccgcgtcactatctccgtggacaagtccaagaatcagattagcctggagctgcggtccgtgaccgctgccgataccgcgacctattactgcgtgcgggactacctggagctcgccacgtactacggaatggacgtctggggccagggcactaccgtgaccgtgtcaagcggggggggcggatcgggtggtggaggatcgggaggaggagggtcggaaatcgtgctgactcagtcccccctgtcgctgcctgtgactcctggggaaccagcctcaattagctgccgctcgagccagtccctgctgtattccgacggatacaactacctggattggtaccttcaaaagcccggccagagcccgcagctgctgatctacctgggttcaaacagggcctccggcgtgccggatcggttctcgggaagcggtagcgggacagacttcaccctgcaaatcagcggagtggaaactgaggacgtgggcgtgtactactgcatgcaggcgttgcagacccagtcctttggacaaggcaccaagctcgaaatcaag CAR22-34 402atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtgcagcttcaagaatcaggacctggcctcgtcaaaccctccggtaccctctccctcacctgtgcc NTgtgtccggggcatctatcacctcccgccactggtggaactgggtcagacactccccgggaaagggattggagtggattggccagatctaccattccggcaccactacttacaacccgtccctgggctcccgcgtcactatctccgtggacaagtccaagaatcagattagcctggagctgcggtccgtgaccgctgccgataccgcgacctattactgcgtgcgggactacctggagctcgccacgtactacggaatggacgtctggggccagggcactaccgtgaccgtgtcaagcggggggggcggatcgggtggtggaggatcgggaggaggagggtcggaaatcgtgctgactcagtcccccctgtcgctgcctgtgactcctggggaaccagcctcaattagctgccgctcgagccagtccctgctgtattccgacggatacaactacctggattggtaccttcaaaagcccggccagagcccgcagctgctgatctacctgggttcaaacagggcctccggcgtgccggatcggttctcgggaagcggtagcgggacagacttcaccctgcaaatcagcggagtggaaactgaggacgtgggcgtgtactactgcatgcaggcgttgcagacccagtcctttggacaaggcaccaagctcgaaatcaagggatcgcaccaccatcaccatcatcatcac CAR22-34 403Malpvtalllplalllhaarpqvqlqesgpglvkpsgtlsltcavsgasitsrhwwnwvrhspgkgsoluble scFvlewigqiyhsgtttynpslgsrvtisvdksknqislelrsvtaadtatyycvrdylelatyygmdv AAwgqgttvtvssggggsggggsggggseivltqsplslpvtpgepasiscrssqsllysdgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlqisgvetedvgvyycmqalqtqsfgqgtkleikgshhhhhhhh CAR22-34 404malpvtalllplalllhaarpqvqlqesgpglvkpsgtlsltcavsgasitsrhwwnwvrhspgkgFull AAlewigqiyhsgtttynpslgsrvtisvdksknqislelrsvtaadtatyycvrdylelatyygmdvwgqgttvtvssggggsggggsggggseivltqsplslpvtpgepasiscrssqsllysdgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlqisgvetedvgvyycmqalqtqsfgqgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-34 405atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtgcagcttcaagaatcaggacctggcctcgtcaaaccctccggtaccctctccctcacctgtgccgtgtccggggcatctatcacctcccgccactggtggaactgggtcagacactccccgggaaagggattggagtggattggccagatctaccattccggcaccactacttacaacccgtccctgggctcccgcgtcactatctccgtggacaagtccaagaatcagattagcctggagctgcggtccgtgaccgctgccgataccgcgacctattactgcgtgcgggactacctggagctcgccacgtactacggaatggacgtctggggccagggcactaccgtgaccgtgtcaagcggggggggcggatcgggtggtggaggatcgggaggaggagggtcggaaatcgtgctgactcagtcccccctgtcgctgcctgtgactcctggggaaccagcctcaattagctgccgctcgagccagtccctgctgtattccgacggatacaactacctggattggtaccttcaaaagcccggccagagcccgcagctgctgatctacctgggttcaaacagggcctccggcgtgccggatcggttctcgggaagcggtagcgggacagacttcaccctgcaaatcagcggagtggaaactgaggacgtgggcgtgtactactgcatgcaggcgttgcagacccagtcctttggacaaggcaccaagctcgaaatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-35 406qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgscFv AArvtmtrdtststvymelsslrsedtavyycardlaaagnyyyygmdvwgqgttvtvssggggsggggsggggssseltqdpavsvalgqtaritcqgdslrsyftswyhqkpgqapvlviygnnnrpsgipdrfsgsssgntasltitgaqaedegdyycdsrdssgdhlvfgggtkltvl CAR22-35 407caagtccaactcgtccagtccggtgcagaagtcaagaaaccaggagcttcagtgaaagtgtcgtgcscFv NTaaggcctccggctataccttcacctcctactacatgcactgggtgcgccaggccccgggccagggactggagtggatgggaattatcaacccttcgggcggctccactagctacgcccaaaagtttcaggggagagtgaccatgactcgggacacctcaacctcgaccgtgtacatggaactgtcgtcactgcggtccgaggacaccgccgtgtactactgcgcgcgcgacttggccgccgcggggaattactactactacggaatggatgtctggggacagggaaccactgtgactgtgtcgtctggtggtggtggaagcgggggaggaggttcgggcggcggcggaagctcctccgaactgacccaggaccctgcggtgtccgtggccctgggacagaccgcaaggatcacgtgtcagggagacagcctccgctcctacttcacatcctggtatcatcagaagcccggccaggctccggtgctggtcatctacggaaacaacaacagaccgtccgggattcccgaccggttcagcggctcctcatccggcaacaccgcctccctgaccatcaccggcgcccaggccgaggacgagggagattactactgcgactcccgggatagcagcggcgatcacctcgtgttcgggggagggactaagcttactgtgctg CAR22-35 408atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtccaactcgtccagtccggtgcagaagtcaagaaaccaggagcttcagtgaaagtgtcgtgcaag NTgcctccggctataccttcacctcctactacatgcactgggtgcgccaggccccgggccagggactggagtggatgggaattatcaacccttcgggcggctccactagctacgcccaaaagtttcaggggagagtgaccatgactcgggacacctcaacctcgaccgtgtacatggaactgtcgtcactgcggtccgaggacaccgccgtgtactactgcgcgcgcgacttggccgccgcggggaattactactactacggaatggatgtctggggacagggaaccactgtgactgtgtcgtctggtggtggtggaagcgggggaggaggttcgggcggcggcggaagctcctccgaactgacccaggaccctgcggtgtccgtggccctgggacagaccgcaaggatcacgtgtcagggagacagcctccgctcctacttcacatcctggtatcatcagaagcccggccaggctccggtgctggtcatctacggaaacaacaacagaccgtccgggattcccgaccggttcagcggctcctcatccggcaacaccgcctccctgaccatcaccggcgcccaggccgaggacgagggagattactactgcgactcccgggatagcagcggcgatcacctcgtgttcgggggagggactaagcttactgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-35 409malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsoluble scFvewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardlaaagnyyyygm AAdvwgqgttvtvssggggsggggsggggssseltqdpavsvalgqtaritcqgdslrsyftswyhqkpgqapvlviygnnnrpsgipdrfsgsssgntasltitgaqaedegdyycdsrdssgdhlvfgggtkltvlgshhhhhhhh CAR22-35 410malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardlaaagnyyyygmdvwgqgttvtvssggggsggggsggggssseltqdpavsvalgqtaritcqgdslrsyftswyhqkpgqapvlviygnnnrpsgipdrfsgsssgntasltitgaqaedegdyycdsrdssgdhlvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-35 411atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccagtccggtgcagaagtcaagaaaccaggagcttcagtgaaagtgtcgtgcaaggcctccggctataccttcacctcctactacatgcactgggtgcgccaggccccgggccagggactggagtggatgggaattatcaacccttcgggcggctccactagctacgcccaaaagtttcaggggagagtgaccatgactcgggacacctcaacctcgaccgtgtacatggaactgtcgtcactgcggtccgaggacaccgccgtgtactactgcgcgcgcgacttggccgccgcggggaattactactactacggaatggatgtctggggacagggaaccactgtgactgtgtcgtctggtggtggtggaagcgggggaggaggttcgggcggcggcggaagctcctccgaactgacccaggaccctgcggtgtccgtggccctgggacagaccgcaaggatcacgtgtcagggagacagcctccgctcctacttcacatcctggtatcatcagaagcccggccaggctccggtgctggtcatctacggaaacaacaacagaccgtccgggattcccgaccggttcagcggctcctcatccggcaacaccgcctccctgaccatcaccggcgcccaggccgaggacgagggagattactactgcgactcccgggatagcagcggcgatcacctcgtgttcgggggagggactaagcttactgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-36 412QvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgscFv AArvtmtrdtststvymelsslrsedtavyycardddfwsgsgafdiwgqgttvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhpvvfgggtkltvl CAR22-36 413caagtccaactcgtccaatccggtgcagaagtcaagaaacctggagcttccgtgaaagtgtcctgcscFv NTaaggcgtcaggctacacctttacgtcctactacatgcactgggtccgccaggccccgggccagggcttggagtggatgggaatcattaaccccagcggcggcagcactagctatgcccagaagttccagggtcgggtcaccatgactagagacacatccacctccaccgtgtacatggaactgagctccctgcggtccgaggataccgcggtgtactactgcgcccgcgatgacgacttctggtccggctcgggggcattcgacatctggggacagggcaccaccgtgactgtgtcctccggcggtggaggatcgggtggcggaggaagcggtggaggcggatcttcgtccgaactgactcaggaccctgccgtgtcggtggccctgggacagactgtgcgcatcacctgtcaaggagatagcctgaggtcgtactatgcctcctggtaccagcagaagcccggacaggccccggtgcttgtgatctacgggaagaacaacagaccgtcagggattccagaccggttcagcgggtcatccagcgggaataccgcttccctcactatcaccggagcccaggcggaggacgaggccgattactactgcaactcgcgggactcatccggcaaccatcccgtggtgttcggagggggcactaagctgaccgtgctg CAR22-36 414atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtccaactcgtccaatccggtgcagaagtcaagaaacctggagcttccgtgaaagtgtcctgcaag NTgcgtcaggctacacctttacgtcctactacatgcactgggtccgccaggccccgggccagggcttggagtggatgggaatcattaaccccagcggcggcagcactagctatgcccagaagttccagggtcgggtcaccatgactagagacacatccacctccaccgtgtacatggaactgagctccctgcggtccgaggataccgcggtgtactactgcgcccgcgatgacgacttctggtccggctcgggggcattcgacatctggggacagggcaccaccgtgactgtgtcctccggcggtggaggatcgggtggcggaggaagcggtggaggcggatcttcgtccgaactgactcaggaccctgccgtgtcggtggccctgggacagactgtgcgcatcacctgtcaaggagatagcctgaggtcgtactatgcctcctggtaccagcagaagcccggacaggccccggtgcttgtgatctacgggaagaacaacagaccgtcagggattccagaccggttcagcgggtcatccagcgggaataccgcttccctcactatcaccggagcccaggcggaggacgaggccgattactactgcaactcgcgggactcatccggcaaccatcccgtggtgttcggagggggcactaagctgaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-36- 415malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsoluble scFvewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardddfwsgsgafdi AAwgqgttvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhpvvfgggtkltvlgshhhhhhhh CAR22-36 416malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardddfwsgsgafdiwgqgttvtvssggggsggggsggggssseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhpvvfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-36 417atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccaatccggtgcagaagtcaagaaacctggagcttccgtgaaagtgtcctgcaaggcgtcaggctacacctttacgtcctactacatgcactgggtccgccaggccccgggccagggcttggagtggatgggaatcattaaccccagcggcggcagcactagctatgcccagaagttccagggtcgggtcaccatgactagagacacatccacctccaccgtgtacatggaactgagctccctgcggtccgaggataccgcggtgtactactgcgcccgcgatgacgacttctggtccggctcgggggcattcgacatctggggacagggcaccaccgtgactgtgtcctccggcggtggaggatcgggtggcggaggaagcggtggaggcggatcttcgtccgaactgactcaggaccctgccgtgtcggtggccctgggacagactgtgcgcatcacctgtcaaggagatagcctgaggtcgtactatgcctcctggtaccagcagaagcccggacaggccccggtgcttgtgatctacgggaagaacaacagaccgtcagggattccagaccggttcagcgggtcatccagcgggaataccgcttccctcactatcaccggagcccaggcggaggacgaggccgattactactgcaactcgcgggactcatccggcaaccatcccgtggtgttcggagggggcactaagctgaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-37 418qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgscFv AArvtmtrdtststvymelsslrsedtavyycarpegvsyydssvldywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggykhvswyqhhpgkapklmiydvsnrpsgvsnrfsgsksgntasltvsglqaedeahyycvsyrnfnslvfgtgtkvtvl CAR22-37 117caagtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcscFv NTaaggcctcggggtataccttcacttcctactacatgcactgggtccggcaggcgccgggacagggactggaatggatgggtatcatcaacccctcgggcggttccactagctacgcccagaagttccagggaagagtgaccatgacccgggacacttccacttcgaccgtgtacatggaactgagcagcctgaggagcgaggacaccgccgtgtactactgtgcccggcccgagggagtgtcctactacgattcctccgtgctggattactggggacagggaacacttgtgaccgtgtcctcgggaggaggcggaagcgggggcggagggtctgggggaggcggctcccagtccgctctgacgcagcctgcgtccgtgtccgggagccctggccagagcattactatttcatgcaccggtaccagctccgacgtgggcggatataagcacgtgtcatggtaccagcatcacccgggaaaggccccaaagctgatgatctacgacgtgtcgaacagaccgagcggggtgtcaaatcgcttttccggttcaaagtcgggcaacactgcctcactcaccgtgtcgggcctccaagcggaggacgaagcccactactactgcgtgtcctaccgcaacttcaactccttggtgttcggcaccggcaccaaggtcaccgtcctg CAR22-37 419atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcaag NTgcctcggggtataccttcacttcctactacatgcactgggtccggcaggcgccgggacagggactggaatggatgggtatcatcaacccctcgggcggttccactagctacgcccagaagttccagggaagagtgaccatgacccgggacacttccacttcgaccgtgtacatggaactgagcagcctgaggagcgaggacaccgccgtgtactactgtgcccggcccgagggagtgtcctactacgattcctccgtgctggattactggggacagggaacacttgtgaccgtgtcctcgggaggaggcggaagcgggggcggagggtctgggggaggcggctcccagtccgctctgacgcagcctgcgtccgtgtccgggagccctggccagagcattactatttcatgcaccggtaccagctccgacgtgggcggatataagcacgtgtcatggtaccagcatcacccgggaaaggccccaaagctgatgatctacgacgtgtcgaacagaccgagcggggtgtcaaatcgcttttccggttcaaagtcgggcaacactgcctcactcaccgtgtcgggcctccaagcggaggacgaagcccactactactgcgtgtcctaccgcaacttcaactccttggtgttcggcaccggcaccaaggtcaccgtcctgggatcgcaccaccatcaccatcatcatcac CAR22-37 420Malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsoluble scFvewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpegvsyydssvld AAywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggykhvswyqhhpgkapklmiydvsnrpsgvsnrfsgsksgntasltvsglqaedeahyycvsyrnfnslvfgtgtkvtvlgshhhhhhhh CAR22-37 421malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpegvsyydssvldywgqgtlvtvssggggsggggsggggsqsaltqpasvsgspgqsitisctgtssdvggykhvswyqhhpgkapklmiydvsnrpsgvsnrfsgsksgntasltvsglqaedeahyycvsyrnfnslvfgtgtkvtvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-37 422atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccagtccggtgcagaagtcaagaaacccggagcttccgtgaaagtgtcctgcaaggcctcggggtataccttcacttcctactacatgcactgggtccggcaggcgccgggacagggactggaatggatgggtatcatcaacccctcgggcggttccactagctacgcccagaagttccagggaagagtgaccatgacccgggacacttccacttcgaccgtgtacatggaactgagcagcctgaggagcgaggacaccgccgtgtactactgtgcccggcccgagggagtgtcctactacgattcctccgtgctggattactggggacagggaacacttgtgaccgtgtcctcgggaggaggcggaagcgggggcggagggtctgggggaggcggctcccagtccgctctgacgcagcctgcgtccgtgtccgggagccctggccagagcattactatttcatgcaccggtaccagctccgacgtgggcggatataagcacgtgtcatggtaccagcatcacccgggaaaggccccaaagctgatgatctacgacgtgtcgaacagaccgagcggggtgtcaaatcgcttttccggttcaaagtcgggcaacactgcctcactcaccgtgtcgggcctccaagcggaggacgaagcccactactactgcgtgtcctaccgcaacttcaactccttggtgttcggcaccggcaccaaggtcaccgtcctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR22-38 423qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgscFv AArvtmtrdtststvymelsslraedtavyycarggygdyldafdiwgqgttvtvssggggsggggsgsggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtqltvl CAR22-38 424caagtccaactcgtccaatccggtgcagaagtcaagaaacctggagcatccgtgaaagtgtcctgcscFv NTaaggcgtccgggtatacgttcacctcctactacatgcactgggtgcgccaggccccgggacagggactggaatggatgggaatcatcaatcctagcggcggcagcaccagctacgcccagaagtttcagggccgcgtgaccatgaccagggacactagcacctccaccgtgtacatggaattgtccagcctgagagccgaggatactgctgtgtactactgcgcccggggcggatacggagattatctggacgccttcgacatttggggacagggcactactgtgaccgtgtcctcggggggaggcggctcggggggcggcggatcaggatcaggcggttcccagtccgcgctgacacagcccgcttccgtgagcggttcgcccgggcagtccatcaccatttcgtgtaccggaacttcctccgacgtcggtggctacaactacgtgtcgtggtaccagcaacatccgggaaaggccccaaagctcatgatctacgaggtgtccaaccggccgtccggggtgtcaaaccggttcagcggctcaaagagcggaaacaccgcctccctcaccatctcgggactgcaggccgaggatgaagcggactactactgctcgagctacacttcctcatctaccctggtgttcgggactggtacccagcttaccgtgctg CAR22-38 425atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaasoluble scFvgtccaactcgtccaatccggtgcagaagtcaagaaacctggagcatccgtgaaagtgtcctgcaag NTgcgtccgggtatacgttcacctcctactacatgcactgggtgcgccaggccccgggacagggactggaatggatgggaatcatcaatcctagcggcggcagcaccagctacgcccagaagtttcagggccgcgtgaccatgaccagggacactagcacctccaccgtgtacatggaattgtccagcctgagagccgaggatactgctgtgtactactgcgcccggggcggatacggagattatctggacgccttcgacatttggggacagggcactactgtgaccgtgtcctcggggggaggcggctcggggggcggcggatcaggatcaggcggttcccagtccgcgctgacacagcccgcttccgtgagcggttcgcccgggcagtccatcaccatttcgtgtaccggaacttcctccgacgtcggtggctacaactacgtgtcgtggtaccagcaacatccgggaaaggccccaaagctcatgatctacgaggtgtccaaccggccgtccggggtgtcaaaccggttcagcggctcaaagagcggaaacaccgcctccctcaccatctcgggactgcaggccgaggatgaagcggactactactgctcgagctacacttcctcatctaccctggtgttcgggactggtacccagcttaccgtgctgggatcgcaccaccatcaccatcatcatcac CAR22-38 426malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglsoluble scFvewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslraedtavyycarggygdyldafdiw AAgqgttvtvssggggsggggsgsggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtqltvlgshhhhhhhh CAR22-38 427malpvtalllplalllhaarpqvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglFull AAewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslraedtavyycarggygdyldafdiwgqgttvtvssggggsggggsgsggsqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgtgtqltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR22-38 428atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccaaFull NTgtccaactcgtccaatccggtgcagaagtcaagaaacctggagcatccgtgaaagtgtcctgcaaggcgtccgggtatacgttcacctcctactacatgcactgggtgcgccaggccccgggacagggactggaatggatgggaatcatcaatcctagcggcggcagcaccagctacgcccagaagtttcagggccgcgtgaccatgaccagggacactagcacctccaccgtgtacatggaattgtccagcctgagagccgaggatactgctgtgtactactgcgcccggggcggatacggagattatctggacgccttcgacatttggggacagggcactactgtgaccgtgtcctcggggggaggcggctcggggggcggcggatcaggatcaggcggttcccagtccgcgctgacacagcccgcttccgtgagcggttcgcccgggcagtccatcaccatttcgtgtaccggaacttcctccgacgtcggtggctacaactacgtgtcgtggtaccagcaacatccgggaaaggccccaaagctcatgatctacgaggtgtccaaccggccgtccggggtgtcaaaccggttcagcggctcaaagagcggaaacaccgcctccctcaccatctcgggactgcaggccgaggatgaagcggactactactgctcgagctacacttcctcatctaccctggtgttcgggactggtacccagcttaccgtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg

Several additional CD22 scFv sequences were generated and are describedin Table 6B below. Clones CD22-64 and CD22-65 were based on affinitymaturation of clone CD22-12 above. In some embodiments, the affinity ofan affinity-matured binding domain for CD22 is stronger than that ofCD22-12 for CD22. In some embodiments, the on-rate of anaffinity-matured binding domain for CD22 is faster than that of CD22-12for CD22.

TABLE 6B Human CD22 scFv sequences Name SEQ ID Sequence CAR22-53  131EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYSDYAVSscFv domainVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDPYDFWSGYPDAFDIWGQGTMVTVSSGGGGS AAGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKVIISEVNNRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYFCSSYTSGRTLYVFGTGSKVTVLG CAR22-53 1108GAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTscFv NTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAGTGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGATCCTTACGATTTTTGGAGTGGTTATCCTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGGTGGTGGTGGCAGCGGCGGCGGCGGCTCTGGTGGTGGTGGATCCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTACAACTATGTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCCAAGGTCATAATTTCTGAGGTCAATAATCGGCCCTCAGGGGTTTCTCATCGCTTCTCTGGGTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTTCTGCAGCTCATATACAAGTGGCAGGACTCTTTATGTCTTCGGAACTGGGAGCAAGGTCACCGTCCTAGGT CAR22-53 1109MALPVTALLLPLALLLHAARPEVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRFull AAGLEWLGRTYYRSKWYSDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDPYDFWSGYPDAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKVIISEVNNRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYFCSSYTSGRTLYVFGTGSKVTVLGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CAR22-53 1110ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCCCGAGFull NTGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCC(CD22-53ATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAscFv +GGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAGTGATTATGCAGTATCTGTGhumanCD8AAAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAACTCTGTGalpha + 41-ACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGATCCTTACGATTTTTGGAGTGGTTATCCT BB +GATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGGTGGTGGTGGCAGCGGCCD3zeta)GGCGGCGGCTCTGGTGGTGGTGGATCCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTACAACTATGTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCCAAGGTCATAATTTCTGAGGTCAATAATCGGCCCTCAGGGGTTTCTCATCGCTTCTCTGGGTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTTCTGCAGCTCATATACAAGTGGCAGGACTCTTTATGTCTTCGGAACTGGGAGCAAGGTCACCGTCCTAGGTACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG CAR 22-57  132EVQLQQSGPGLVKPSQTLSLTCAISGDSVSNNNAAWNWIRQSPSRGLEWLGRTYHRSTWYNDYVGSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARETDYGDYGAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGSRNDIGAYESVSWYQQHPGNAPKLIIHGVNNRPSGVFDRFSVSQSGNTASLTISGLQAEDEADYYCSSHTTTSTLYVFGTGTKVTVLG CAR22-58  133EVQLQQSGPGLVNPSQTLSITCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTFYRSKWYNDYAVSVKGRITISPDTSKNQFSLQLNSVTPEDTAVYYCAGGDYYYGLDVWGQGTTVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGSSSDVGGYNSVSWYQQHPGKAPKLMIYEVINRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTYVFGTGTKVTVLG CAR22-59  134EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWGQGTMVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGSSSDIGGFNYVSWYQQHAGEAPKLMIYEVTNRPSGVSDRFSGSKSDNTASLTISGLQAEDEADYYCSSYASGSPLYVFGTGTKVTVLG CAR22-60  135EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWGQGTMVTVSSGGGGSGGGGSGSGGSQSALTQPASVSGSPGQSITFSCTGTSSDIGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGTKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKLTVLG CAR22-61  136QVQLQESGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWGQGTMVTVSSGGGGSGGGGSGSGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKVTVLG CAR22-62  137EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWGQGTMVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKVTVLG CAR22-63  138EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWGQGTMVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYIFGTGTKVTVLG CAR22-64  139EVQLQQSGPGLVKPSQTLPLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARVRLQDGNSWSDAFDVWGQGTMVTVSSGGGGSGGGGSGGGGPQSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTQLTVL CAR22-65  140EVQLQQSGPGLVKPSQTLSLTCAISGDSMLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARVRLQDGNSWSDAFDVWGQGTMVTVSSGGGGSGGGGSGGGGSQSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTQLTVL

In some embodiments, the antigen binding domain comprises a HC CDR1, aHC CDR2, and a HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 6A or 6B. In embodiments, the antigen bindingdomain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. Inembodiments, the antigen binding domain comprises a LC CDR1, a LC CDR2,and a LC CDR3 of any light chain binding domain amino acid sequenceslisted in Table 6A or 6B.

In some embodiments, the antigen binding domain comprises one, two orall of LC CDR1, LC CDR2, and LC CDR3 of any light chain binding domainamino acid sequences listed in Table 6A or 6B, and one, two or all of HCCDR1, HC CDR2, and HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 6A or 6B.

In some embodiments, the CDRs are defined according to the Kabatnumbering scheme, the Chothia numbering scheme, or a combinationthereof.

CD22-64 and CD22-65 were based on affinity maturation of clone CD22-12.All three constructs were tested and found to have activity (see Example25 herein). Based on these observations, a structural genus was designedto encompass the working examples. Thus, in some embodiments, a CD22binding domain described herein comprises a HCDR3 having a sequence:XRLQDGNSWSDAFDV (SEQ ID NO: 141). In some embodiments, X is any aminoacid, any canonical amino acid, a nonpolar amino acid (e.g., G, A, V, L,I, P, M, F, or W), a nonpolar amino acid without an aromatic ring (e.g.,G, A, V, L, I, P, or M), or an acidic amino acid (e.g., D or E).

Furthermore, CAR22-53 and CAR22-57 through CAR22-65 have structuralsimilarities in their CDRs. A structural genus was designed to encompassthese working examples. Thus, in some embodiments, a CD22 binding domaindescribed herein comprises a LCDR1 having a sequence:TGX₁X₂X₃DX₄GX₅X₆X₇X₈VS (SEQ ID NO: 1334). In some embodiments, X₁, X₂,X₃, X₄, X₅, X₆, X₇, or X₈, or any combination thereof, is eachindependently any amino acid, e.g., any canonical amino acid. In someembodiments, X₄ or X₅ or both are each independently a nonpolar aminoacid (e.g., G, A, V, L, I, P, M, F, or W) or a nonpolar amino acidwithout an aromatic ring (e.g., G, A, V, L, I, P, or M). In someembodiments, X₆ is an aromatic amino acid (e.g., F, Y, or W). In someembodiments, X₁ is S or T; X₂ is R or S; X₃ is N or S, X₄ is V or I, X₅is A or G; X₆ is Y or F; X₇ is E or N; or X₈ is S or Y, or anycombination thereof. In some embodiments, X₁ is S or T; X₂ is R or S; X₃is N or S, X₄ is V or I, X₅ is A or G; X₆ is Y or F; X₇ is E or N; andX₈ is S or Y.

Similarly, in some embodiments, a CD22 binding domain described hereincomprises a LCDR2 having a sequence: X₁VX₂NRPS (SEQ ID NO: 1335). Insome embodiments, X₁ or X₂ or both is each independently any amino acid,e.g., any canonical amino acid. In some embodiments, X₁ is an acidicamino acid (e.g., D or E), a nonpolar amino acid (e.g., G, A, V, L, I,P, M, F, or W), or a nonpolar amino acid without an aromatic ring (e.g.,G, A, V, L, I, P, or M). In embodiments, X₂ is a nonpolar amino acid(e.g., G, A, V, L, I, P, M, F, or W), a nonpolar amino acid without anaromatic ring (e.g., G, A, V, L, I, P, or M), or a polar uncharged aminoacid (e.g., S, T, N, or Q). In some embodiments, X₁ is E, G, or D and/orX₂ is N, I, S, or T.

Similarly, in some embodiments, a CD22 binding domain described hereincomprises a LCDR3 having a sequence: SSX₁X₂X₃X₄X₅X₆X₇X₈X₉ (SEQ ID NO:1336). In some embodiments, X₁, X₂, X₃, X₄, X₅, X₆, X₇, or X₈, or anycombination thereof, is each independently any amino acid, e.g., anycanonical amino acid. In some embodiments, X₁ is an aromatic amino acid(e.g., F, Y, or W) or a positively charged amino acid (e.g., K, R, orH). In some embodiments, X₂ is a nonpolar amino acid (e.g., G, A, V, L,I, P, M, F, or W), a nonpolar amino acid without an aromatic ring (e.g.,G, A, V, L, I, P, or M), or a polar uncharged amino acid (e.g., S, T, N,or Q). In some embodiments, X₃ is a polar uncharged amino acid (e.g., S,T, N, or Q). In some embodiments, X₄ is a nonpolar amino acid (e.g., G,A, V, L, I, P, M, F, or W), a nonpolar amino acid without an aromaticring (e.g., G, A, V, L, I, P, or M), or a polar uncharged amino acid(e.g., S, T, N, or Q). In some embodiments, X₅ is a positively chargedamino acid (e.g., K, R, or H) or a polar uncharged amino acid (e.g., S,T, N, or Q). In some embodiments, X₆ is a polar uncharged amino acid(e.g., S, T, N, or Q), a nonpolar amino acid (e.g., G, A, V, L, I, P, M,F, or W), a nonpolar amino acid without an aromatic ring (e.g., G, A, V,L, I, P, or M). In some embodiments, X₇ is a nonpolar amino acid (e.g.,G, A, V, L, I, P, M, F, or W), a nonpolar amino acid without an aromaticring (e.g., G, A, V, L, I, P, or M) or an aromatic amino acid (e.g., F,Y, or W). In some embodiments, X₈ is absent or an aromatic amino acid(e.g., F, Y, or W). In some embodiments, X₉ is a nonpolar amino acid(e.g., G, A, V, L, I, P, M, F, or W), a nonpolar amino acid without anaromatic ring (e.g., G, A, V, L, I, P, or M). In some embodiments, X₁ isY or H, X₂ is A or T, X₃ is S or T; X₄ is G, T, or S, X₅ is R or S, X₆is T or P, X₇ is L or Y, X₈ is Y or absent, or X₉ is V or I, or anycombination thereof. In some embodiments, X₁ is Y or H, X₂ is A or T, X₃is S or T; X₄ is G, T, or S, X₅ is R or S, X₆ is T or P, X₇ is L or Y,X₈ is Y or absent, and X₉ is V or I. The sequences of human CDRsequences of the scFv domains are shown in Table 7A, 7B, or 7C for theheavy chain variable domains and in Table 8A or 8B for the light chainvariable domains. “ID” stands for the respective SEQ ID NO for each CDR.

TABLE 7A Heavy Chain Variable Domain CDRs of CD22 CARs.CDRs are identified according to the “combined” definition. SEQ SEQ SEQID ID ID Candidate HCDR1 NO: HCDR2 NO: HCDR3 NO: m971 GDSVSSNSAAWN 142RTYYRSKWYNDYAVSVKS 181 EVTGDLEDAFDI 449 CAR22-1 GFTVSSNYMS 143VIYSGGSTYYADSVKG 182 QSTPYDSSGYYSGDAFDI 450 CAR22-2 GDSVSSNSAAWN 144RTYYRSKWYNDYAVSVKS 183 DLGWIAVAGTFDY 451 CAR22-3 GDSVLSNSDTWN 145RTYHRSTWYDDYASSVRG 184 DRLQDGNSWSDAFDV 452 CAR22-4 GFTFDDYAMH 146GISWNSGSIGYADSVKG 185 GLSSWHFHDALDI 453 CAR22-5 GFTFDDYAMH 147GISWNSGSIGYADSVKG 186 DKGGGYYDFWSGSDY 454 CAR22-6 GDSVSSNSATWT 148RTYYRSTWYNDYAVSVKS 187 EGSGSYYAY 455 CAR22-7 GYTFTGYYMH 149WINPNSGGTNYAQKFQG 188 DYWGYYGSGTLDY 456 CAR22-8 GYTFTSYGIS 150WISAYNGNTNYAQKLQG 189 AGLALYSNYVPYYYYGMDV 457 CAR22-9 GFTFSNAWMN 151RIKSKTDGGTADYAAPVKG 190 GATDV 458 CAR22-10 GDSVLSNSDTWN 152RTYHRSTWYDDYASSVRG 191 DRLQDGNSWSDAFDV 459 CAR22-11 GDSVSSNSAAWN 153RTYYRSKWYNDYAVSVKS 192 EESSSGWYEGNWFDP 460 CAR22-12 GDSVLSNSDTWN 154RTYHRSTWYDDYASSVRG 193 DRLQDGNSWSDAFDV 461 CAR22-13 GGSISSSSYYWG 155SIYYSGSTYYNPSLKS 194 GRMDTAMAQI 462 CAR22-14 GYTFTSYYMH 156IINPSGGSTSYAQKFQG 195 DLDVSLDI 463 CAR22-15 GFTFSSYAMH 157AISSNGGSTYYANSVKD 196 VHSSGYYHPGPNDY 464 CAR22-16 GYTFTSYYMH 158IINPSGGSTSYAQKFQG 197 EAGVVAVDY 465 CAR22-17 GFTFSSYAMS 159AISGSGGSTYYADSVKG 198 EPLFGVVEEDVDY 466 CAR22-18 GYTFTSYYMH 160IINPSGGSTSYAQKFQG 199 GSGSLGDAFDI 467 CAR22-19 GYTFTSYYMH 161IINPSGGSTSYAQKFQG 429 DGFGELSGAFDI 468 CAR22-20 GYTFTSYYMH 162IINPSGGSTSYAQKFQG 430 GPIGCSGGSCLDY 469 CAR22-21 GYTFTSYYMH 163IINPSGGSTSYAQKFQG 431 GSYGDYGDAFDI 470 CAR22-22 GGTFSSYAIS 164GIIPIFGTANYAQKFQG 432 DHKVVRFGY 471 CAR22-23 GYTFTSYYMH 165IINPSGGSTSYAQKFQG 433 GDYYMDV 472 CAR22-24 GFTFSSYAMS 166YISSSSSTIYYADSVKG 434 DGPIRYFDHSKAFDI 473 CAR22-25 GYTFTSYYMH 167IINPSGGSTSYAQKFQG 435 EMDDSSGPDY 474 CAR22-26 GYSFTGSWIG 168IIYPGDSDTRYSPSFQG 436 GFLRGGDCCGALDI 475 CAR22-27 GGSINSYYWS 169FTSHSGNVKYNPSLTG 437 GLDPLFAYDAFEI 476 CAR22-28 GFTFSDYYMS 170YISSSGSTIYYADSVKG 438 DDFWSGSVDY 477 CAR22-29 GYTFTSYYMH 171IINPSGGSTSYAQKFQG 439 EDDSSGYTSPFDY 478 CAR22-30 GYTFTGYYMH 172WINPNSGGTNYAQKFQG 440 EPASSSWYGYYYYMDV 479 CAR22-31 GYTFTSYDIN 173WMNPNSGNTGYAQKFQG 441 GDSNYWSYYGMDV 480 CAR22-32 GYTFTSYGIS 174WISAYNGNTNYAQKLQG 442 FSSSDSYDY 481 CAR22-33 GFSLNTFGMSVS 175LIDWDDDKYYSTSLRT 443 IYGGDRTNTQAPYFFDL 482 CAR22-34 GASITSRHWWN 176QIYHSGTTTYNPSLGS 444 DYLELATYYGMDV 483 CAR22-35 GYTFTSYYMH 177IINPSGGSTSYAQKFQG 445 DLAAAGNYYYYGMDV 484 CAR22-36 GYTFTSYYMH 178IINPSGGSTSYAQKFQG 446 DDDFWSGSGAFDI 485 CAR22-37 GYTFTSYYMH 179IINPSGGSTSYAQKFQG 447 PEGVSYYDSSVLDY 486 CAR22-38 GYTFTSYYMH 180IINPSGGSTSYAQKFQG 448 GGYGDYLDAFDI 487

TABLE 7B Heavy Chain Variable Domain CDRs of CD22 CARs SEQ SEQ SEQ ID IDID Candidate HCDR1 NO: HCDR2 NO: HCDR3 NO: CAR22-53 SNSAAWN 488RTYYRSKWYSDYAVSVKS 499 DPYDFWSGYPDAFDI 510 Kabat CAR22-53 GDSVSSNSA 489YYRSKWY 500 DPYDFWSGYPDAFDI 511 Chothia CAR22-53 GDSVSSNSAAWN 1111RTYYRSKWYSDYAVSVKS 1113 DPYDFWSGYPDAFDI 1115 Combined Kabat/ChothiaCAR22-53 GDSVSSNSAA 1112 TYYRSKWYS 1114 ARDPYDFWSGYPDAFDI 1116 IMGTCAR22-57 GDSVSNNNAAWN 490 RTYHRSTWYNDYVGSVKS 501 ETDYGDYGAFDI 512Combined CAR22-57 NNNAAWN 1337 RTYHRSTWYNDYVGSVKS 1346 ETDYGDYGAFDI 1355Kabat CAR22-58 GDSVSSNSAAWN 491 RTFYRSKWYNDYAVSVKG 502 GDYYYGLDV 513Combined CAR22-58 SNSAAWN 1338 RTFYRSKWYNDYAVSVKG 1347 GDYYYGLDV 1356Kabat CAR22-59 GDSVLSNSDTWN 492 RTYHRSTWYDDYASSVRG 503 DRLQDGNSWSDAFDV514 Combined CAR22-59 SNSDTWN 1339 RTYHRSTWYDDYASSVRG 1348DRLQDGNSWSDAFDV 1357 Kabat CAR22-60 GDSVLSNSDTWN 493 RTYHRSTWYDDYASSVRG504 DRLQDGNSWSDAFDV 515 Combined CAR22-60 SNSDTWN 1340RTYHRSTWYDDYASSVRG 1349 DRLQDGNSWSDAFDV 1358 Kabat CAR22-61 GDSVLSNSDTWN494 RTYHRSTWYDDYASSVRG 505 DRLQDGNSWSDAFDV 516 Combined CAR22-61 SNSDTWN1341 RTYHRSTWYDDYASSVRG 1350 DRLQDGNSWSDAFDV 1359 Kabat CAR22-62GDSVLSNSDTWN 495 RTYHRSTWYDDYASSVRG 506 DRLQDGNSWSDAFDV 517 CombinedCAR22-62 SNSDTWN 1342 RTYHRSTWYDDYASSVRG 1351 DRLQDGNSWSDAFDV 1360 KabatCAR22-63 GDSVLSNSDTWN 496 RTYHRSTWYDDYASSVRG 507 DRLQDGNSWSDAFDV 518Combined CAR22-63 SNSDTWN 1343 RTYHRSTWYDDYASSVRG 1352 DRLQDGNSWSDAFDV1361 Kabat CAR22-64 GDSVLSNSDTWN 497 RTYHRSTWYDDYASSVRG 508VRLQDGNSWSDAFDV 519 Combined CAR22-64 SNSDTWN 1344 RTYHRSTWYDDYASSVRG1353 VRLQDGNSWSDAFDV 1362 Kabat CAR22-65 GDSMLSNSDTWN 498RTYHRSTWYDDYASSVRG 509 VRLQDGNSWSDAFDV 520 Combined CAR22-65 SNSDTWN1345 RTYHRSTWYDDYASSVRG 1354 VRLQDGNSWSDAFDV 1363 Kabat

TABLE 7C Heavy Chain Variable Domain CDRs of CD22 CARs. CDRs areidentified according to Kabat. SEQ SEQ SEQ ID ID ID Candidate HCDR1 NO:HCDR2 NO: HCDR3 NO: m971 SNSAAWN 1364 RTYYRSKWYNDYAVSVKS 1403EVTGDLEDAFDI 1442 CAR22-1 SNYMS 1365 VIYSGGSTYYADSVKG 1404QSTPYDSSGYYSGDAFDI 1443 CAR22-2 SNSAAWN 1366 RTYYRSKWYNDYAVSVKS 1405DLGWIAVAGTFDY 1444 CAR22-3 SNSDTWN 1367 RTYHRSTWYDDYASSVRG 1406DRLQDGNSWSDAFDV 1445 CAR22-4 DYAMH 1368 GISWNSGSIGYADSVKG 1407GLSSWHFHDALDI 1446 CAR22-5 DYAMH 1369 GISWNSGSIGYADSVKG 1408DKGGGYYDFWSGSDY 1447 CAR22-6 SNSATWT 1370 RTYYRSTWYNDYAVSVKS 1409EGSGSYYAY 1448 CAR22-7 GYYMH 1371 WINPNSGGTNYAQKFQG 1410 DYWGYYGSGTLDY1449 CAR22-8 SYGIS 1372 WISAYNGNTNYAQKLQG 1411 AGLALYSNYVPYYYYGMDV 1450CAR22-9 NAWMN 1373 RIKSKTDGGTADYAAPVKG 1412 GATDV 1451 CAR22-10 SNSDTWN1374 RTYHRSTWYDDYASSVRG 1413 DRLQDGNSWSDAFDV 1452 CAR22-11 SNSAAWN 1375RTYYRSKWYNDYAVSVKS 1414 EESSSGWYEGNWFDP 1453 CAR22-12 SNSDTWN 1376RTYHRSTWYDDYASSVRG 1415 DRLQDGNSWSDAFDV 1454 CAR22-13 SSSYYWG 1377SIYYSGSTYYNPSLKS 1416 GRMDTAMAQI 1455 CAR22-14 SYYMH 1378IINPSGGSTSYAQKFQG 1417 DLDVSLDI 1456 CAR22-15 SYAMH 1379AISSNGGSTYYANSVKD 1418 VHSSGYYHPGPNDY 1457 CAR22-16 SYYMH 1380IINPSGGSTSYAQKFQG 1419 EAGVVAVDY 1458 CAR22-17 SYAMS 1381AISGSGGSTYYADSVKG 1420 EPLFGVVEEDVDY 1459 CAR22-18 SYYMH 1382IINPSGGSTSYAQKFQG 1421 GSGSLGDAFDI 1460 CAR22-19 SYYMH 1383IINPSGGSTSYAQKFQG 1422 DGFGELSGAFDI 1461 CAR22-20 SYYMH 1384IINPSGGSTSYAQKFQG 1423 GPIGCSGGSCLDY 1462 CAR22-21 SYYMH 1385IINPSGGSTSYAQKFQG 1424 GSYGDYGDAFDI 1463 CAR22-22 SYAIS 1386GIIPIFGTANYAQKFQG 1425 DHKVVRFGY 1464 CAR22-23 SYYMH 1387IINPSGGSTSYAQKFQG 1426 GDYYMDV 1465 CAR22-24 SYAMS 1388YISSSSSTIYYADSVKG 1427 DGPIRYFDHSKAFDI 1466 CAR22-25 SYYMH 1389IINPSGGSTSYAQKFQG 1428 EMDDSSGPDY 1467 CAR22-26 GSWIG 1390IIYPGDSDTRYSPSFQG 1429 GFLRGGDCCGALDI 1468 CAR22-27 SYYWS 1391FTSHSGNVKYNPSLTG 1430 GLDPLFAYDAFEI 1469 CAR22-28 DYYMS 1392YISSSGSTIYYADSVKG 1431 DDFWSGSVDY 1470 CAR22-29 SYYMH 1393IINPSGGSTSYAQKFQG 1432 EDDSSGYTSPFDY 1471 CAR22-30 GYYMH 1394WINPNSGGTNYAQKFQG 1433 EPASSSWYGYYYYMDV 1472 CAR22-31 SYDIN 1395WMNPNSGNTGYAQKFQG 1434 GDSNYWSYYGMDV 1473 CAR22-32 SYGIS 1396WISAYNGNTNYAQKLQG 1435 FSSSDSYDY 1474 CAR22-33 TFGMSVS 1397LIDWDDDKYYSTSLRT 1436 IYGGDRTNTQAPYFFDL 1475 CAR22-34 TSRHWWN 1398QIYHSGTTTYNPSLGS 1437 DYLELATYYGMDV 1476 CAR22-35 SYYMH 1399IINPSGGSTSYAQKFQG 1438 DLAAAGNYYYYGMDV 1477 CAR22-36 SYYMH 1400IINPSGGSTSYAQKFQG 1439 DDDFWSGSGAFDI 1478 CAR22-37 SYYMH 1401IINPSGGSTSYAQKFQG 1440 PEGVSYYDSSVLDY 1479 CAR22-38 SYYMH 1402IINPSGGSTSYAQKFQG 1441 GGYGDYLDAFDI 1480

TABLE 8A Light Chain Variable Domain CDRs of CD22 CARs.The LC CDR sequences in this table have the samesequence under the Kabat or combined definitions. SEQ SEQ SEQ ID ID IDCandidate LCDR1 NO: LCDR2 NO: LCDR3 NO: m971 RASQTIWSYLN 521 AASSLQS 560QQSYSIPQT 599 CAR22-1 SGSSSNIGSNYVY 522 RNNQRPS 561 AAWDDSLSGYV 600CAR22-2 TGTSSDVGGYNYVS 523 DVSKRPS 562 SSYTSSSLNHV 601 CAR22-3TGTSSDVGGYNYVS 524 DVSNRPS 563 SSYTSSSTPYV 602 CAR22-4 QGDSLRSYYAS 525GKNNRPS 564 NSRDSSGNHLWV 603 CAR22-5 QGDSLRSYYAS 526 GKNNRPS 565NSRDSSGWV 604 CAR22-6 TGTSSDVGGYNYVS 527 DVSNRPS 566 SSYTSSSTLYV 605CAR22-7 TGTSSDVGGYNYVS 528 DVSSRPS 567 SSYAGSNTLV 606 CAR22-8TRSSGSIASNYVQ 529 EDNQRPS 568 QSYDSSNPWV 607 CAR22-9 SGSSSNIGSNYVY 530RNNQRPS 569 AAWDDSLSGPV 608 CAR22-10 TGTSSDVGGYNYVS 531 DVSNRPS 570SSYTSSSTLVYV 609 CAR22-11 QGDSLRSYYAS 532 GKNHRPS 571 HSRDSSGNHL 610CAR22-12 TGTSSDVGGYNYVS 533 DVSNRPS 572 SSYTSSSTLYV 611 CAR22-13TGSSGSFASSYVQ 534 EDNQRPS 573 QSYDGATWV 612 CAR22-14 SGTSSDVGGYNSVS 535DVNNRPS 574 SSYTSSSTLF 613 CAR22-15 QGDSLRTYYAT 536 DENNRPS 575SSRDSSGNPSCV 614 CAR22-16 TGTSSDVGGYNYVS 537 DVSNRPS 576 SSYTSSSTWV 615CAR22-17 RSSQSLLAGNGHNYLD 538 LGSNRAS 577 MQALQNPLT 616 CAR22-18TGSSSDVGGYNYVS 539 EVSNRPS 578 SSYTSSSTLV 617 CAR22-19 TGTSSDVGGYNYVS540 DVSNRPS 579 SSYASSSTLV 618 CAR22-20 TGTNSDVGRYNYVS 541 EVSYRPS 580SSYTTSSTLD 619 CAR22-21 TGTSSDVGGYKYVS 542 DVSNRPS 581 SSYTSSSTLV 620CAR22-22 TLSSGHSSYAIA 543 VNSDGSLSKGD 582 QTWGSGMAI 621 CAR22-23TGTSSDVGGYNYVS 544 EVSKRPS 583 SSYTSSGTLV 622 CAR22-24 QGDSLRSYYAS 545GKNNRPS 584 NSRDSSGNPYV 623 CAR22-25 TGTSSDVGGYNYVS 546 EVSNRPS 585SSYTSSSTLV 624 CAR22-26 RSSQSLLHSNGYNYLD 547 LGSNRAS 586 MQALQTPPWT 625CAR22-27 RSSQSLLHSNGYNYLD 548 LGSNRAS 587 MQVLQTPPLT 626 CAR22-28GGTNIGSKNVH 549 YDSDRPS 588 QVWDSSSDHWV 627 CAR22-29 GGHNIRSKNVH 550YDGDRPS 589 QVWDSDSDHYV 628 CAR22-30 RASQSINTYLN 551 AASNLQS 590QQSYSSLLT 629 CAR22-31 TGTSSDVGGYNYVS 552 DADKRPS 591 CSYAGGSTWV 630CAR22-32 RASQSVTSNLA 553 AASTRAT 592 QQYHTWPPLT 631 CAR22-33RSSQSLLHSNGYNYLD 554 LGSNRAS 593 MQALQTPWT 632 CAR22-34 RSSQSLLYSDGYNYLD555 LGSNRAS 594 MQALQTQS 633 CAR22-35 QGDSLRSYFTS 556 GNNNRPS 595DSRDSSGDHLV 634 CAR22-36 QGDSLRSYYAS 557 GKNNRPS 596 NSRDSSGNHPVV 635CAR22-37 TGTSSDVGGYKHVS 558 DVSNRPS 597 VSYRNFNSLV 636 CAR22-38TGTSSDVGGYNYVS 559 EVSNRPS 598 SSYTSSSTLV 637

TABLE 8B Light Chain Variable Domain CDRs of CD22 CARs.The LC CDR sequences in this table have the samesequence under the Kabat or combined definitions. SEQ SEQ SEQ ID IDCandidate LCDR1 ID NO: LCDR2 NO: LCDR3 NO: CAR22-53 TGTSSDVGGYNYVS 638EVNNRPS 649 SSYTSGRTLYV 660 Kabat CAR22-53 TSSDVGGYNY 639 EVN 650YTSGRTLY 661 Chothia CAR22-53 TGTSSDVGGYNYVS 1117 EVNNRPS 1119SSYTSGRTLYV 1121 Combined CAR22-53 SSDVGGYNY 1118 EVN 1120 SSYTSGRTLYV1122 IMGT CAR22-57 TGSRNDIGAYESVS 640 GVNNRPS 651 SSHTTTSTLYV 662Combined CAR22-58 TGSSSDVGGYNSVS 641 EVINRPS 652 SSYTSSSTYV 663 CombinedCAR22-59 TGSSSDIGGFNYVS 642 EVTNRPS 653 SSYASGSPLYV 664 CombinedCAR22-60 TGTSSDIGGYNYVS 643 EVSNRPS 654 SSYTSSSTLYV 665 CombinedCAR22-61 TGTSSDVGGYNYVS 644 EVSNRPS 655 SSYTSSSTLYV 666 CombinedCAR22-62 TGTSSDVGGYNYVS 645 DVSNRPS 656 SSYTSSSTLYV 667 CombinedCAR22-63 TGTSSDVGGYNYVS 646 EVSNRPS 657 SSYTSSSTLYI 668 CombinedCAR22-64 TGTSSDVGGYNYVS 647 DVSNRPS 658 SSYTSSSTLYV 669 CombinedCAR22-65 TGTSSDVGGYNYVS 648 DVSNRPS 659 SSYTSSSTLYV 670 Combined

TABLE 9A Heavy Chain Variable Regions of CD22 antibody moleculesCandidate ID Heavy Chain Variable region m971 700QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIWGQGTM VTV CAR22-1701 QVQLVQSGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASQSTPYDSSGYYSGDAFDIWGQ GTMVTVCAR22-2 702 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDLGWIAVAGTFDYWGQG TLVTVCAR22-3 703 EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGAYYCARDRLQDGNSWSDAFDVWG QGTMVTVCAR22-4 704 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGLSSWHFHDALDIWGQGTM VTV CAR22-5705 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDKGGGYYDFWSGSDYWGQ GTLVTV CAR22-6706 EVQLQQSGPGLVKPSLTLSLTCAISGDSVSSNSATWTWIRQSPSRGLEWLGRTYYRSTWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREGSGSYYAYWGQGTLVTV CAR22-7 707QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINP-NSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYWGYYGSGTLDY WGQGTLVTVCAR22-8 708 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARAGLALYSNYVPYYYYGM DVWGQGTTVTVCAR22-9 709 EVQLVESGGGLVKPGGSLRLSCVASGFTFSNAWMNWVRQAPGKGLEWVGRIKSKTDGGTADYAAPVKGRFTISRDDSKNTMYLQMNSLKTEDTGVYYCITGATDVWGQGTTVTV CAR22-10 710EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWG QGTMVTVCAR22-11 711 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREESSSGWYEGNWFDPWG QGTLVTVCAR22-12 712EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWG QGTMVTVCAR22-13 713QVQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRMDTAMAQIWGQGTMVTV CAR22-14 714QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDLDVSLDIWGQGTMVTV CAR22-15 715EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEYVSAISSNGGSTYYANSVKDRFTISRDNSKNTLYLQMGSLRAEDMAVYYCARVHSSGYYHPGPNDYWGQGT LVTV CAR22-16716 EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTAYMELSSLRSEDTAVYYCAREAGVVAVDYWGQGTLVTV CAR22-17 717QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEPLFGVVEEDVDYWGQGTL VTV CAR22-18718 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGSGSLGDAFDIWGQGTMVTV CAR22-19719 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDGFGELSGAFDIWGQGTMV TV CAR22-20720 EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGPIGCSGGSCLDYWGQGTLV TV CAR22-21721 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGSYGDYGDAFDIWGQGTT VTV CAR22-22722 EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDHKVVRFGYWGQGTLVTV CAR22-23 723QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGDYYMDVWGKGTTVTV CAR22-24 724EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGPIRYFDHSKAFDIWGQGTM VTV CAR22-25725 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREMDDSSGPDYWGQGTLVTV CAR22-26 726EVQLVESGAEVKKPGESLKISCKGSGYSFTGSWIGWGRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGFLRGGDCCGALDIWGQGTM VTV CAR22-27727 QVQLQESGPGLVKPSETLSLTCSVSGGSINSYYWSWIRQAPGKGLEWIAFTSHSGNVKYNPSLTGRVTIAVDTSKNQFYLEVTSVTAADTAVYFCARGLDPLFAYDAFEIWGLGTMVTV CAR22-28 728EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDDFWSGSVDYWGQGTLVTV CAR22-29 729QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREDDSSGYTSPFDYWGQGTL VTV CAR22-30730 EVQLVESGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPASSSWYGYYYYMDVW GKGTLVTVCAR22-31 731 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARG- DSNYWSYYGMDVWGQGTLVTVCAR22-32 732 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCASFSSSDSYDYWGQGTLVTV CAR22-33 733QVNLRESGPALVKPTQTLTLTCTFSGFSLNTFGMSVSWIRQPPGKALEWLALIDWDDDKYYSTSLRTRLTISKDTAKNQVVLRMTNMDPMDTATYYCARIYGGDRTNTQAPYFFDLWG QGTLVTVCAR22-34 734 QVQLQESGPGLVKPSGTLSLTCAVSGASITSRHWWNWVRHSPGKGLEWIGQIYHSGTTTYNPSLGSRVTISVDKSKNQISLELRSVTAADTATYYCVRDYLELATYYGMDVWGQGTTV TV CAR22-35735 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDLAAAGNYYYYGMDVWG QGTTVTVCAR22-36 736 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDDDFWSGSGAFDIWGQGTT VTV CAR22-37737 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPEGVSYYDSSVLDYWGQG TLVTVCAR22-38 738 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRAEDTAVYYCARGGYGDYLDAFDIWGQGTT VTV

TABLE 9B Heavy Chain Variable Regions of CD22 antibody molecules SEQ IDCandidate NO: Heavy Chain Variable region CAR22-53 671EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYSDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDPYDFWSGYPDAFDIWGQ GTMVTVSSCAR22-57 672 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSNNNAAWNWIRQSPSRGLEWLGRTYHRSTWYNDYVGSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARETDYGDYGAFDIWGQGTT VTVSSCAR22-58 673EVQLQQSGPGLVNPSQTLSITCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTFYRSKWYNDYAVSVKGRITISPDTSKNQFSLQLNSVTPEDTAVYYCAGGDYYYGLDVWGQGTTVTV SS CAR22-59674 EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWG QGTMVTVSSCAR22-60 675EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWG QGTMVTVSSCAR22-61 676QVQLQESGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWG QGTMVTVSSCAR22-62 677EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWG QGTMVTVSSCAR22-63 678EVQLQQSGPGLVKPSQTLSLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARDRLQDGNSWSDAFDVWG QGTMVTVSSCAR22-64 679EVQLQQSGPGLVKPSQTLPLTCAISGDSVLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARVRLQDGNSWSDAFDVWG QGTMVTVSSCAR22-65 680 EVQLQQSGPGLVKPSQTLSLTCAISGDSMLSNSDTWNWIRQSPSRGLEWLGRTYHRSTWYDDYASSVRGRVSINVDTSKNQYSLQLNAVTPEDTGVYYCARVRLQDGNSWSDAFDVW GQGTMVTVSS

TABLE 10A Light Chain Variable Regions of CD22 antibody moleculesCandidate ID Light Chain Variable region m971 739DIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQGTKLEIK CAR22-1 740SYVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGYVFGTGTKLTVL CAR22-2 741QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSLNHVFGTGTKVTVL CAR22-3 742QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPYVFGTGTQLTVL CAR22-4 743SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHLWVFGGGTKLTVL CAR22-5 744SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGWVFGGGTKLTVL CAR22-6 745QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKVTVL CAR22-7 746QSALTQPGSVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLIIYDVSSRPSGVSNRFSGSQSGNTASLTISGLQAEDEADYSCSSYAGSNTLVFGTGTKVTVL CAR22-8 747NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNPWVFGGGTKLTVL CAR22-9 748SYVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGPVFGGGTKLTVL CAR22-10 749QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVYVFGTGTKVTVL CAR22-11 750SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNHRPSGIPDRFSGSSSGDTDSLTITGAQAEDEADYYCHSRDSSGNHLFGGGTKLTVL CAR22-12 751QSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTQLTVL CAR22-13 752NFMLTQPHSVSESPGKTVTIPCTGSSGSFASSYVQWYQQRPGSAPATVIYEDNQRPSGVPDRFSGSVDSSSNSASLTISGLKTEDEAVYYCQSYDGATWVFGGGTKLTVL CAR22-14 753QSALTQPASVSGSPGQSITISCSGTSSDVGGYNSVSWYQQYPGKAPKLMIYDVNNRPSGVSSRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLFFGAGTKVTVL CAR22-15 754SSELTQDPAVSVALGQTVRITCQGDSLRTYYATWYQQKPGQAPVLVFYDENNRPSGIPDRFSGSSSGNTASLTITGTQAEDEADYYCSSRDSSGNPSCVFGGGTKLTVL CAR22-16 755QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL CAR22-17 756DVVMTQSPLSLPVTPGEPASISCRSSQSLLAGNGHNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQNPLTFGGGTKLEIKR CAR22-18 757QSALTQPASVSGSPGQSITISCTGSSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGTGTKVTVL CAR22-19 758QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYASSSTLVFGGGTKVTVL CAR22-20 759QSALTQPAYVSGSPGQSITISCTGTNSDVGRYNYVSWYQQHPGKAPKLMIYEVSYRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSTLDFGTGTKVTVL CAR22-21 760QSALTQPASVSGSPGQSITISCTGTSSDVGGYKYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL CAR22-22 761HVILTQPPSASASLGASVKLTCTLSSGHSSYAIAWHQQQPEKGPRYLMKVNSDGSLSKGDGIPDRFSGSTSGAERYLTISSLQSEDEADYYCQTWGSGMAIFGGGTKLTVL CAR22-23 762QSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSGTLVFGGGTKLTVL CAR22-24 763SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYRNSRDSSGNPYVFGTGTKVTVL CAR22-25 764QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGTGTKLTVL CAR22-26 765DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPPWTFGQGTKLEIKR CAR22-27 766EIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQVLQTPPLTFGGGTKVDIKR CAR22-28 767SYVLTQPPSVSVAPGKTATITCGGTNIGSKNVHWYQQKPGQAPVLAIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYFCQVWDSSSDH-WVFGGGTKLTVL CAR22-29 768SYELTQPPSVSVAPGETASIACGGHNIRSKNVHWYQQKPGQAPVLVISYDGDRPSGIPERFSGSNLGSTATLTISRVEAGDEADYYCQVWDSDSDH-YVFGTGTKVTVL CAR22-30 769DIQMTQSPSSLSASVGDRVTITCRASQSINTYLNWYQQKPGKPPKLLIYAASNLQSGVPSRFSGSGSGTHFTLTISSLQPDDFATYYCQQSYSSLLTFGGGTKLEIK CAR22-31 770QSVLTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGEAPKLIIYDADKRPSGISNRFSSGKSGNTASLTISGLQVEDEADYYCCSYAGGSTWVFGGGTKVTVL CAR22-32 771EIVLTQSPATLSVSPGERATLSCRASQSVTSNLAWYQQKPGQAPRLLIYAASTRATGIPARFSGSGSGTEFTLTISSMQSEDFAVYFCQQYHTWPPLTFGGGTKVEIKT CAR22-33 772DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPWTFGQGTKLEIK CAR22-34 773EIVLTQSPLSLPVTPGEPASISCRSSQSLLYSDGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLQISGVETEDVGVYYCMQALQTQSFGQGTKLEIK CAR22-35 774SSELTQDPAVSVALGQTARITCQGDSLRSYFTSWYHQKPGQAPVLVIYGNNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEGDYYCDSRDSSGDHLVFGGGTKLTVL CAR22-36 775SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHPVVFGGGTKLTVL CAR22-37 776QSALTQPASVSGSPGQSITISCTGTSSDVGGYKHVSWYQHHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTVSGLQAEDEAHYYCVSYRNFNSLVFGTGTKVTVL CAR22-38 777QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGTGTQLTVL

TABLE 10B Light Chain Variable Regions of CD22 antibody moleculesCandidate ID Light Chain Variable region CAR22-53 681QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKVIISEVNNRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYFCSSYTSGRTLYVFGTGSKVTVLG CAR22-57 682QSALTQPASVSGSPGQSITISCTGSRNDIGAYESVSWYQQHPGNAPKLIIHGVNNRPSGVFDRFSVSQSGNTASLTISGLQAEDEADYYCSSHTTTSTLYVFGTGTKVTVLG CAR22-58 683QSALTQPASVSGSPGQSITISCTGSSSDVGGYNSVSWYQQHPGKAPKLMIYEVINRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTYVFGTGTKVTVLG CAR22-59 684QSALTQPASVSGSPGQSITISCTGSSSDIGGFNYVSWYQQHAGEAPKLMIYEVTNRPSGVSDRFSGSKSDNTASLTISGLQAEDEADYYCSSYASGSPLYVFGTGTKVTVLG CAR22-60 685QSALTQPASVSGSPGQSITFSCTGTSSDIGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGTKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKLTVLG CAR22-61 686QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKVTVLG CAR22-62 687QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKVTVLG CAR22-63 688QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYIFGTGTKVTVLG CAR22-64 689QSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTQLTVL CAR22-65 690QSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTQLTVL

In some embodiments, the antigen binding domain comprises a HC CDR1, aHC CDR2, and a HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 9A or 9B. In embodiments, the antigen bindingdomain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. Inembodiments, the antigen binding domain comprises a LC CDR1, a LC CDR2,and a LC CDR3 of any light chain binding domain amino acid sequenceslisted in Table 10A or 10B.

In some embodiments, the antigen binding domain comprises one, two orall of LC CDR1, LC CDR2, and LC CDR3 of any light chain binding domainamino acid sequences listed in Table 10A or 10B, and one, two or all ofHC CDR1, HC CDR2, and HC CDR3 of any heavy chain binding domain aminoacid sequences listed in Table 9A or 9B.

In some embodiments, the CDRs are defined according to the Kabatnumbering scheme, the Chothia numbering scheme, or a combinationthereof.

The order in which the VL and VH domains appear in the scFv can bevaried (i.e., VL-VH, or VH-VL orientation), and where either three orfour copies of the “G4S” (SEQ ID NO:18) subunit, in which each subunitcomprises the sequence GGGGS (SEQ ID NO:18) (e.g., (G4S)₃ (SEQ IDNO:107) or (G4S)₄ (SEQ ID NO:106)), can connect the variable domains tocreate the entirety of the scFv domain. Alternatively, the CAR constructcan include, for example, a linker including the sequenceGSTSGSGKPGSGEGSTKG (SEQ ID NO: 1322).

These clones all contained a Q/K residue change in the signal domain ofthe co-stimulatory domain derived from CD3zeta chain.

CAR20 Constructs

Anti-CD20 single chain variable fragments were isolated. See Table 11Aand 11B. Anti-CD20 scFvs were cloned into lentiviral CAR expressionvectors with the CD3zeta chain and the 4-1BB costimulatory molecule.CAR-containing plasmids were amplified by bacterial transformation inSTBL3 cells, followed by Maxiprep using endotoxin-free Qiagen PlasmidMaki kit. Lentiviral supernatant was produced in 293T cells usingstandard techniques.

The sequences of the CARs are provided below in Tables 11A and 11B.Additional components of CARs (e.g., leader, hinge, transmembrane, andsignalling domains) are described herein.

TABLE 11A Rat CD20 CAR Constructs SEQ ID Name NO: Sequence CAR20-1 800qiqlvqsgpelkkpgesvkiscktseytftdyafhwvkqapgkglkwmgwintysgkpt scFvyaddfkgrfvfsledsartanlqisnlknedtatyfcargayygyrdwftywgqgtlvtvssg domaingggsggggsggggsggggsdivmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspklliywastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfppwtfgggtklelk CAR20-1 801caaattcaactggtccagtccggccctgagctgaagaagccgggagaatccgtgaagatctc scFvctgcaagacctcggagtacaccttcactgactacgccttccactgggtcaagcaggcacctggdomain nt gaaaggcctgaagtggatgggctggatcaacacttactcggggaagccaacctacgccgatgatttcaagggaagattcgtgtttagcctggaggactccgcccggacagctaacctccaaatctccaaccttaagaacgaggacactgcgacctacttctgcgcgcggggagcctattacggttatcgcgactggttcacctactggggacagggcaccctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgatattgtgatgacccagaccccgtcgagccaggcagtgtccgctggagaaaaggtcaccatgtcctgcaagagctcacagtccctgttgtactccgaaaacaagaagaattacctggcctggtaccagcagaagcccggacagtcccctaaactgctgatctactgggcctcgactagggaatctggcgtgcccgaccgctttatcggaagcggttcagggactgacttcaccctgaccattagcagcgtgcaggccgaggacctggcggtgtactactgtcaacagtactacaacttcccgccctggactttcggcggtggaacgaagctcgaactcaag CAR20-1 802atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Solubleaaattcaactggtccagtccggccctgagctgaagaagccgggagaatccgtgaagatctcct scFv-ntgcaagacctcggagtacaccttcactgactacgccttccactgggtcaagcaggcacctgggaaaggcctgaagtggatgggctggatcaacacttactcggggaagccaacctacgccgatgatttcaagggaagattcgtgtttagcctggaggactccgcccggacagctaacctccaaatctccaaccttaagaacgaggacactgcgacctacttctgcgcgcggggagcctattacggttatcgcgactggttcacctactggggacagggcaccctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgatattgtgatgacccagaccccgtcgagccaggcagtgtccgctggagaaaaggtcaccatgtcctgcaagagctcacagtccctgttgtactccgaaaacaagaagaattacctggcctggtaccagcagaagcccggacagtcccctaaactgctgatctactgggcctcgactagggaatctggcgtgcccgaccgctttatcggaagcggttcagggactgacttcaccctgaccattagcagcgtgcaggccgaggacctggcggtgtactactgtcaacagtactacaacttcccgccctggactttcggcggtggaacgaagctcgaactcaagggatcgcaccaccatcaccatcatcatcac CAR20-1 803malpvtalllplalllhaarpqiqlvqsgpelkkpgesvkiscktseytftdyafhwvkqapg Solublekglkwmgwintysgkptyaddfkgrfvfsledsartanlqisnlknedtatyfcargayyg scFv-aayrdwftywgqgtlvtvssggggsggggsggggsggggsdivmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspklliywastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfppwtfgggtklelkgshhhhhhhh CAR20-1 804atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Full-ntaaattcaactggtccagtccggccctgagctgaagaagccgggagaatccgtgaagatctcctlentivirusgcaagacctcggagtacaccttcactgactacgccttccactgggtcaagcaggcacctgggaaaggcctgaagtggatgggctggatcaacacttactcggggaagccaacctacgccgatgatttcaagggaagattcgtgtttagcctggaggactccgcccggacagctaacctccaaatctccaaccttaagaacgaggacactgcgacctacttctgcgcgcggggagcctattacggttatcgcgactggttcacctactggggacagggcaccctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgatattgtgatgacccagaccccgtcgagccaggcagtgtccgctggagaaaaggtcaccatgtcctgcaagagctcacagtccctgttgtactccgaaaacaagaagaattacctggcctggtaccagcagaagcccggacagtcccctaaactgctgatctactgggcctcgactagggaatctggcgtgcccgaccgctttatcggaagcggttcagggactgacttcaccctgaccattagcagcgtgcaggccgaggacctggcggtgtactactgtcaacagtactacaacttcccgccctggactttcggcggtggaacgaagctcgaactcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccg cctcggCAR20-1- 805malpvtalllplalllhaarpqiqlvqsgpelkkpgesvkiscktseytftdyafhwvkqapg Full-aakglkwmgwintysgkptyaddfkgrfvfsledsartanlqisnlknedtatyfcargayygyrdwftywgqgtlvtvssggggsggggsggggsggggsdivmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspklliywastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfppwtfgggtklelktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydal hmqalpprCAR20-2 806evqlvesggglvqpgrslklsclasgftfskygmnwirqapgkglewvasisstsiyiyyad scFvtvkgrftisrenakntlylqmtslrsedtalyycarhdyssysywgqgvmvtvssggggsg domaingggsggggsggggsqvvltqpksvstslestvklsckinsgnigsyfihwyqqhegrspttmiyrddkrphgvpdrfsgsidsssnsafltinnvqtedeaiyfchsydsginivfgggtkltvl CAR20-2807 gaggtgcagctcgtcgaatccggtggaggactggtgcagccaggaagatccctgaagctgt scFvcctgtctcgcctcgggcttcactttctccaaatacggcatgaattggattcgccaggcacccggdomain-ntaaaggggctggaatgggtggccagcatcagctcgactagcatctacatctactatgccgataccgtcaagggccgcttcactatctcccgcgagaacgctaagaacaccctttacttgcaaatgacctccctgaggtccgaagataccgccctgtactattgcgcccggcacgactactcatcctactcctactggggacagggagtcatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcgtgctgacgcaacccaagtccgtgagcaccagcctggagagcaccgtgaagctcagctgcaagattaactcgggcaacattgggtcctacttcatccattggtaccagcagcacgaaggacggtcccctaccactatgatctaccgggacgacaagcggccgcacggagtgccggacagattctcgggttcaatcgattcctcatctaactcggcgtttctcaccatcaacaacgtgcagaccgaggacgaagcgatctacttctgccactcctacgactcgggtattaacattgtgttcggcggcgggactaagctgacagtgctg CAR20-2- 808atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Solubleaggtgcagctcgtcgaatccggtggaggactggtgcagccaggaagatccctgaagctgtcc scFv-nttgtctcgcctcgggcttcactttctccaaatacggcatgaattggattcgccaggcacccggaaaggggctggaatgggtggccagcatcagctcgactagcatctacatctactatgccgataccgtcaagggccgcttcactatctcccgcgagaacgctaagaacaccctttacttgcaaatgacctccctgaggtccgaagataccgccctgtactattgcgcccggcacgactactcatcctactcctactggggacagggagtcatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcgtgctgacgcaacccaagtccgtgagcaccagcctggagagcaccgtgaagctcagctgcaagattaactcgggcaacattgggtcctacttcatccattggtaccagcagcacgaaggacggtcccctaccactatgatctaccgggacgacaagcggccgcacggagtgccggacagattctcgggttcaatcgattcctcatctaactcggcgtttctcaccatcaacaacgtgcagaccgaggacgaagcgatctacttctgccactcctacgactcgggtattaacattgtgttcggcggcgggactaagctgacagtgctgggatcgcaccaccatcaccatcatcatcac CAR20-2- 809malpvtalllplalllhaarpevqlvesggglvqpgrslklsclasgftfskygmnwirqapg Solublekglewvasisstsiyiyyadtvkgrftisrenakntlylqmtslrsedtalyycarhdyssysy scFv-aawgqgvmvtvssggggsggggsggggsggggsqvvltqpksvstslestvklsckinsgnigsyfihwyqqhegrspttmiyrddkrphgvpdrfsgsidsssnsafltinnvqtedeaiyfchsydsginivfgggtkltvlgshhhhhhhh CAR20-2- 810atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Full-ntaggtgcagctcgtcgaatccggtggaggactggtgcagccaggaagatccctgaagctgtcctgtctcgcctcgggcttcactttctccaaatacggcatgaattggattcgccaggcacccggaaaggggctggaatgggtggccagcatcagctcgactagcatctacatctactatgccgataccgtcaagggccgcttcactatctcccgcgagaacgctaagaacaccctttacttgcaaatgacctccctgaggtccgaagataccgccctgtactattgcgcccggcacgactactcatcctactcctactggggacagggagtcatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcgtgctgacgcaacccaagtccgtgagcaccagcctggagagcaccgtgaagctcagctgcaagattaactcgggcaacattgggtcctacttcatccattggtaccagcagcacgaaggacggtcccctaccactatgatctaccgggacgacaagcggccgcacggagtgccggacagattctcgggttcaatcgattcctcatctaactcggcgtttctcaccatcaacaacgtgcagaccgaggacgaagcgatctacttctgccactcctacgactcgggtattaacattgtgttcggcggcgggactaagctgacagtgctgaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-2- 811malpvtalllplalllhaarpevqlvesggglvqpgrslklsclasgftfskygmnwirqapg Full-aakglewvasisstsiyiyyadtvkgrftisrenakntlylqmtslrsedtalyycarhdyssysywgqgvmvtvssggggsggggsggggsggggsqvvltqpksvstslestvklsckinsgnigsyfihwyqqhegrspttmiyrddkrphgvpdrfsgsidsssnsafltinnvqtedeaiyfchsydsginivfgggtkltvltttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-3 812evqlvesggglvqpgrslklscaasgftfrdyymawvrqapkkglewvasisyegnpyy scFvgdsvkgrftisrnnakstlylqmnslrsedtatyycarhdhnnvdwfaywgqgtlvtvssg domaingggsggggsggggsggggsdivmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspkllifwastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfptfgsgtkleik CAR20-3 813gaagtgcagcttgtggagtctggcggcggtctggtgcagccgggaagatccctgaagctgtc scFvatgcgccgcgtccgggtttaccttccgcgattactacatggcctgggtcagacaggcacctaadomain nt gaaggggctggaatgggtggcatccatctcatatgaaggaaacccgtactacggagactcggtgaaaggccgcttcactatctcacggaacaacgctaagagcacgctgtacttgcaaatgaactccctccggtcggaggacacagccacttactactgtgcccggcacgaccataacaacgtcgattggttcgcctactggggtcaaggaaccctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatcgtgatgactcagactccaagcagccaggccgtgtccgccggagagaaagtcaccatgtcgtgcaagagctcccagtccctgctgtactccgaaaacaagaagaattatctcgcctggtaccagcagaagcctggacagtccccgaagctcctgatcttttgggcgtcgaccagggaatccggcgtgcccgatcgcttcattggctccggttccggcaccgacttcaccctgaccattagcagcgtccaggcggaggacctggctgtgtactactgccaacagtactacaacttccccactttcggatcggggaccaagctgga gatcaagCAR20-3- 814atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Solubleaagtgcagcttgtggagtctggcggcggtctggtgcagccgggaagatccctgaagctgtca scFv-nttgcgccgcgtccgggtttaccttccgcgattactacatggcctgggtcagacaggcacctaagaaggggctggaatgggtggcatccatctcatatgaaggaaacccgtactacggagactcggtgaaaggccgcttcactatctcacggaacaacgctaagagcacgctgtacttgcaaatgaactccctccggtcggaggacacagccacttactactgtgcccggcacgaccataacaacgtcgattggttcgcctactggggtcaaggaaccctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatcgtgatgactcagactccaagcagccaggccgtgtccgccggagagaaagtcaccatgtcgtgcaagagctcccagtccctgctgtactccgaaaacaagaagaattatctcgcctggtaccagcagaagcctggacagtccccgaagctcctgatcttttgggcgtcgaccagggaatccggcgtgcccgatcgcttcattggctccggttccggcaccgacttcaccctgaccattagcagcgtccaggcggaggacctggctgtgtactactgccaacagtactacaacttccccactttcggatcggggaccaagctggagatcaagggatcgcaccaccatcaccatcatcatcac CAR20-3- 815malpvtalllplalllhaarpevqlvesggglvqpgrslklscaasgftfrdyymawvrqap Solublekkglewvasisyegnpyygdsvkgrftisrnnakstlylqmnslrsedtatyycarhdhnn scFv-aavdwfaywgqgtlvtvssggggsggggsggggsggggsdivmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspkllifwastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfptfgsgtkleikgshhhhhhhh CAR20-3- 816atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Full-ntaagtgcagcttgtggagtctggcggcggtctggtgcagccgggaagatccctgaagctgtcatgcgccgcgtccgggtttaccttccgcgattactacatggcctgggtcagacaggcacctaagaaggggctggaatgggtggcatccatctcatatgaaggaaacccgtactacggagactcggtgaaaggccgcttcactatctcacggaacaacgctaagagcacgctgtacttgcaaatgaactccctccggtcggaggacacagccacttactactgtgcccggcacgaccataacaacgtcgattggttcgcctactggggtcaaggaaccctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatcgtgatgactcagactccaagcagccaggccgtgtccgccggagagaaagtcaccatgtcgtgcaagagctcccagtccctgctgtactccgaaaacaagaagaattatctcgcctggtaccagcagaagcctggacagtccccgaagctcctgatcttttgggcgtcgaccagggaatccggcgtgcccgatcgcttcattggctccggttccggcaccgacttcaccctgaccattagcagcgtccaggcggaggacctggctgtgtactactgccaacagtactacaacttccccactttcggatcggggaccaagctggagatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-3- 817malpvtalllplalllhaarpevqlvesggglvqpgrslklscaasgftfrdyymawvrqap Full-aakkglewvasisyegnpyygdsvkgrftisrnnakstlylqmnslrsedtatyycarhdhnnvdwfaywgqgtlvtvssggggsggggsggggsggggsdivmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspkllifwastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfptfgsgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhm qalpprCAR20-4 818qvtlkesgpgilqpsqtlsltctftrfslstygmsvgwirqpsgkglewladiwwdddkhyn scFvpslknrltiskdtsknqaflkitnvdtadtatyycarssttdgivtyvmdvwgqgasvtvssg domaingggsggggsggggsggggsdvqmtqspsllsasvgdavtinckasqninrylnwyqqklgegprlliysanslqtgipsrfsgsgsgadftltitspqpedvatyfclqhnswpltfgsgtkleikCAR20-4 819caagtcacgctgaaggaatcgggccctggaattctgcagccaagccagaccctctcgcttact scFvtgcaccttcacccgcttctcactgtccacttacggaatgtccgtgggatggattcggcagcccadomain nt gcggaaagggtttggagtggctggccgacatttggtgggatgacgacaagcattacaaccctagcctgaagaatcggctcaccatcagcaaagacacctccaagaaccaggcgttcctgaagatcaccaacgtggataccgccgacactgcaacatactattgtgcccgctcctcaaccaccgatgggatcgtgacctacgtgatggacgtctggggccagggagcttccgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacgtgcagatgactcagtccccgtcgctcctgtccgcctccgtcggcgacgccgtgactattaactgcaaggcgtcccagaacatcaatcggtacctgaactggtaccagcaaaaactgggagaagggccgagacttctcatctactccgccaactccctgcaaactggcatcccgtcgaggttcagcggatcaggctctggtgccgacttcactttgaccatcacgagccctcagcccgaagatgtggccacctacttctgcctccaacacaactcctggcccctgacctttggttcgggcaccaagctggagat caagCAR20-4- 820atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Solubleaagtcacgctgaaggaatcgggccctggaattctgcagccaagccagaccctctcgcttactt scFv-ntgcaccttcacccgcttctcactgtccacttacggaatgtccgtgggatggattcggcagcccagcggaaagggtttggagtggctggccgacatttggtgggatgacgacaagcattacaaccctagcctgaagaatcggctcaccatcagcaaagacacctccaagaaccaggcgttcctgaagatcaccaacgtggataccgccgacactgcaacatactattgtgcccgctcctcaaccaccgatgggatcgtgacctacgtgatggacgtctggggccagggagcttccgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacgtgcagatgactcagtccccgtcgctcctgtccgcctccgtcggcgacgccgtgactattaactgcaaggcgtcccagaacatcaatcggtacctgaactggtaccagcaaaaactgggagaagggccgagacttctcatctactccgccaactccctgcaaactggcatcccgtcgaggttcagcggatcaggctctggtgccgacttcactttgaccatcacgagccctcagcccgaagatgtggccacctacttctgcctccaacacaactcctggcccctgacctttggttcgggcaccaagctggagatcaagggatcgcaccaccatcaccatcatcatcac CAR20-4- 821malpvtalllplalllhaarpqvtlkesgpgilqpsqtlsltctftrfslstygmsvgwirqpsgkSoluble glewladiwwdddkhynpslknrltiskdtsknqaflkitnvdtadtatyycarssttdgivtscFv-aa yvmdvwgqgasvtvssggggsggggsggggsggggsdvqmtqspsllsasvgdavtinckasqninrylnwyqqklgegprlliysanslqtgipsrfsgsgsgadftltitspqpedvatyfclqhnswpltfgsgtkleikgshhhhhhhh CAR20-4- 822atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Full-ntaagtcacgctgaaggaatcgggccctggaattctgcagccaagccagaccctctcgcttacttgcaccttcacccgcttctcactgtccacttacggaatgtccgtgggatggattcggcagcccagcggaaagggtttggagtggctggccgacatttggtgggatgacgacaagcattacaaccctagcctgaagaatcggctcaccatcagcaaagacacctccaagaaccaggcgttcctgaagatcaccaacgtggataccgccgacactgcaacatactattgtgcccgctcctcaaccaccgatgggatcgtgacctacgtgatggacgtctggggccagggagcttccgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacgtgcagatgactcagtccccgtcgctcctgtccgcctccgtcggcgacgccgtgactattaactgcaaggcgtcccagaacatcaatcggtacctgaactggtaccagcaaaaactgggagaagggccgagacttctcatctactccgccaactccctgcaaactggcatcccgtcgaggttcagcggatcaggctctggtgccgacttcactttgaccatcacgagccctcagcccgaagatgtggccacctacttctgcctccaacacaactcctggcccctgacctttggttcgggcaccaagctggagatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-4- 823malpvtalllplalllhaarpqvtlkesgpgilqpsqtlsltctftrfslstygmsvgwirqpsgkFull-aa glewladiwwdddkhynpslknrltiskdtsknqaflkitnvdtadtatyycarssttdgivtyvmdvwgqgasvtvssggggsggggsggggsggggsdvqmtqspsllsasvgdavtinckasqninrylnwyqqklgegprlliysanslqtgipsrfsgsgsgadftltitspqpedvatyfclqhnswpltfgsgtkleiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-5 824evqlvesggglvqpgtslklscvasgftfsssgmqwirqapkkglewisgiyydsykksy scFvadsvkgrftisrdnskntlylemnslrsedtatyycaksayygykdyfdywgqgvmvtvs domainsggggsggggsggggsggggsdiqmtqsppslsaslgdkvtitcqasqninkyiawyqqkpgkaprllirytstlesgtpsrfsgsgsgrdysfsisnvesgdvasyyclqyddlpytfgpgt klelkCAR20-5 825gaggtccagcttgtggaatcaggaggcggactcgtccagccgggtactagcctgaagctcag scFvctgtgtggccagcggttttaccttctcgtcctccgggatgcagtggattcggcaggctcccaagdomain ntaagggactggaatggatctcgggcatctactacgactcgtacaagaagtcctacgccgattccgtgaaaggtcgcttcaccatctcccgggacaacagcaagaacactctgtacctcgagatgaactccttgcgctccgaggataccgcaacctattactgcgccaagtcggcctactacggctacaaggactacttcgactattggggccagggagtgatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatccaaatgacacagtcacccccttctctttccgcgagcctgggagataaggtcaccattacgtgccaagcgtcccagaacatcaacaagtacatcgcctggtaccagcagaaaccgggaaaggccccgcggctgctgattagatacacctcgactctggaatccggcactccatcaagattcagcggctccggcagcgggagggactactcgttctccatctccaatgtggagtccggggacgtggccagctactattgcctgcaatacgacgatctgccctacaccttcggacctggaaccaagctggaactcaag CAR20-5- 826atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Solubleaggtccagcttgtggaatcaggaggcggactcgtccagccgggtactagcctgaagctcagc scFv-nttgtgtggccagcggttttaccttctcgtcctccgggatgcagtggattcggcaggctcccaagaagggactggaatggatctcgggcatctactacgactcgtacaagaagtcctacgccgattccgtgaaaggtcgcttcaccatctcccgggacaacagcaagaacactctgtacctcgagatgaactccttgcgctccgaggataccgcaacctattactgcgccaagtcggcctactacggctacaaggactacttcgactattggggccagggagtgatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatccaaatgacacagtcacccccttctctttccgcgagcctgggagataaggtcaccattacgtgccaagcgtcccagaacatcaacaagtacatcgcctggtaccagcagaaaccgggaaaggccccgcggctgctgattagatacacctcgactctggaatccggcactccatcaagattcagcggctccggcagcgggagggactactcgttctccatctccaatgtggagtccggggacgtggccagctactattgcctgcaatacgacgatctgccctacaccttcggacctggaaccaagctggaactcaagggatcgcaccaccatcaccatcatcatcac CAR20-5- 827malpvtalllplalllhaarpevqlvesggglvqpgtslklscvasgftfsssgmqwirqapk Solublekglewisgiyydsykksyadsvkgrftisrdnskntlylemnslrsedtatyycaksayygy scFv-aakdyfdywgqgvmvtvssggggsggggsggggsggggsdiqmtqsppslsaslgdkvtitcqasqninkyiawyqqkpgkaprllirytstlesgtpsrfsgsgsgrdysfsisnvesgdvasyyclqyddlpytfgpgtklelkgshhhhhhhh CAR20-5- 828atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Full-ntaggtccagcttgtggaatcaggaggcggactcgtccagccgggtactagcctgaagctcagctgtgtggccagcggttttaccttctcgtcctccgggatgcagtggattcggcaggctcccaagaagggactggaatggatctcgggcatctactacgactcgtacaagaagtcctacgccgattccgtgaaaggtcgcttcaccatctcccgggacaacagcaagaacactctgtacctcgagatgaactccttgcgctccgaggataccgcaacctattactgcgccaagtcggcctactacggctacaaggactacttcgactattggggccagggagtgatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatccaaatgacacagtcacccccttctctttccgcgagcctgggagataaggtcaccattacgtgccaagcgtcccagaacatcaacaagtacatcgcctggtaccagcagaaaccgggaaaggccccgcggctgctgattagatacacctcgactctggaatccggcactccatcaagattcagcggctccggcagcgggagggactactcgttctccatctccaatgtggagtccggggacgtggccagctactattgcctgcaatacgacgatctgccctacaccttcggacctggaaccaagctggaactcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-5- 829malpvtalllplalllhaarpevqlvesggglvqpgtslklscvasgftfsssgmqwirqapk Full-aakglewisgiyydsykksyadsvkgrftisrdnskntlylemnslrsedtatyycaksayygykdyfdywgqgvmvtvssggggsggggsggggsggggsdiqmtqsppslsaslgdkvtitcqasqninkyiawyqqkpgkaprllirytstlesgtpsrfsgsgsgrdysfsisnvesgdvasyyclqyddlpytfgpgtklelktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-6 830qvtlkesgpgllqpsqtlsltctfagfslnthgmgvgwirqpsgkglewlaniwwdddky scFvynpslknrltmskdtsnnqaflkitnvdtadtatyycariegspvvttvfdywgqgvmvtv domainssggggsggggsggggsggggsdiqmtqspsflsasvgdrvtinckasqninrylnwyqqklgeapklliynanslqtgipsrfsgsgsgtdftltisslqpadvatyfclqhnsrpltfgsgtil eikCAR20-6 831caagtcactcttaaggaatccgggccaggactgttgcagccgagccagaccctgtccctcact scFvtgtaccttcgccggcttttcactgaacacccacggaatgggcgtgggatggattaggcagcccdomain nt tcgggaaagggactggagtggctggccaacatttggtgggacgacgacaagtattacaacccgagcctcaagaaccgcctgactatgtccaaggatacctccaacaaccaggccttcctgaaaatcactaacgtggataccgctgacaccgcaacgtactactgcgcccggatcgaaggttcccccgtcgtgacaactgtgttcgactactggggacagggcgtgatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatccaaatgacccagtcacctagctttctgtcggcctcggtcggcgacagagtgaccattaactgcaaagcgtcccagaacatcaaccgctacctgaattggtaccagcagaagctgggggaagccccgaagctgctgatctacaacgcgaacagcctccagactggtattccttcccggttctccgggagcggctcgggtaccgatttcaccctcaccatctcctcccttcaacccgctgacgtggccacctacttctgcttgcaacataattctcggcctctgaccttcggaagcggcactatcctcgagatcaagCAR20-6- 832atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Solubleaagtcactcttaaggaatccgggccaggactgttgcagccgagccagaccctgtccctcactt scFv-ntgtaccttcgccggcttttcactgaacacccacggaatgggcgtgggatggattaggcagccctcgggaaagggactggagtggctggccaacatttggtgggacgacgacaagtattacaacccgagcctcaagaaccgcctgactatgtccaaggatacctccaacaaccaggccttcctgaaaatcactaacgtggataccgctgacaccgcaacgtactactgcgcccggatcgaaggttcccccgtcgtgacaactgtgttcgactactggggacagggcgtgatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatccaaatgacccagtcacctagctttctgtcggcctcggtcggcgacagagtgaccattaactgcaaagcgtcccagaacatcaaccgctacctgaattggtaccagcagaagctgggggaagccccgaagctgctgatctacaacgcgaacagcctccagactggtattccttcccggttctccgggagcggctcgggtaccgatttcaccctcaccatctcctcccttcaacccgctgacgtggccacctacttctgcttgcaacataattctcggcctctgaccttcggaagcggcactatcctcgagatcaagggatcgcaccaccatcaccatcatcatcac CAR20-6- 833malpvtalllplalllhaarpqvtlkesgpgllqpsqtlsltctfagfslnthgmgvgwirqpsgSoluble kglewlaniwwdddkyynpslknrltmskdtsnnqaflkitnvdtadtatyycariegspvscFv-aa vttvfdywgqgvmvtvssggggsggggsggggsggggsdiqmtqspsflsasvgdrvtinckasqninrylnwyqqklgeapklliynanslqtgipsrfsgsgsgtdftltisslqpadvatyfclqhnsrpltfgsgtileikgshhhhhhhh CAR20-6- 834atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Full-ntaagtcactcttaaggaatccgggccaggactgttgcagccgagccagaccctgtccctcacttgtaccttcgccggcttttcactgaacacccacggaatgggcgtgggatggattaggcagccctcgggaaagggactggagtggctggccaacatttggtgggacgacgacaagtattacaacccgagcctcaagaaccgcctgactatgtccaaggatacctccaacaaccaggccttcctgaaaatcactaacgtggataccgctgacaccgcaacgtactactgcgcccggatcgaaggttcccccgtcgtgacaactgtgttcgactactggggacagggcgtgatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgacatccaaatgacccagtcacctagctttctgtcggcctcggtcggcgacagagtgaccattaactgcaaagcgtcccagaacatcaaccgctacctgaattggtaccagcagaagctgggggaagccccgaagctgctgatctacaacgcgaacagcctccagactggtattccttcccggttctccgggagcggctcgggtaccgatttcaccctcaccatctcctcccttcaacccgctgacgtggccacctacttctgcttgcaacataattctcggcctctgaccttcggaagcggcactatcctcgagatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-6- 835malpvtalllplalllhaarpqvtlkesgpgllqpsqtlsltctfagfslnthgmgvgwirqpsgFull-aa kglewlaniwwdddkyynpslknrltmskdtsnnqaflkitnvdtadtatyycariegspvvttvfdywgqgvmvtvssggggsggggsggggsggggsdiqmtqspsflsasvgdrvtinckasqninrylnwyqqklgeapklliynanslqtgipsrfsgsgsgtdftltisslqpadvatyfclqhnsrpltfgsgtileiktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-7 836qvtlkesgpgmlqpsktlsltcsfsgfslstsgmvvswirqpsgkslewlaaiawdgdkyy scFvnpslksrvtvskdtsntqvflritsvdiadtatyyctrrdydvgyyyfdfwgqgvmvtvssg domaingggsggggsggggsggggskivltqsptitaaspgekvtitclassrvsniywyqqksgaspklliystsslasgvpyrfsgsgsgtsysltintmeaedaatyychqwssnpwtfgggtklelk CAR20-7837 caagtcaccctgaaagaatcgggtcccggaatgctgcagccatccaagacgctgtcccttaca scFvtgctccttctccgggttcagcctctcaacttccgggatggtggtgtcatggatcagacagccgadomain nt gcggaaagtccctggagtggctggcggccatcgcatgggatggcgataagtactacaacccgagcctgaagtcaagggtcactgtgtccaaggacacctccaacacccaagtgttccttcggatcacctccgtggacattgctgacaccgccacctattactgcactcgccgggactacgacgtgggctactactacttcgatttctggggacagggtgtcatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccaagattgtgctgacccagagccccactattaccgccgcctccccgggggaaaaggtcaccatcacttgtctggcgtcctcacgcgtgtcgaatatctactggtatcagcagaagtccggcgccagccccaagctgctgatctactcgacctcctccctcgcgtcgggagtgccttaccggttttctggctcgggaagcggaaccagctactccttgaccatcaacaccatggaagccgaggacgctgccacttactactgccaccagtggtcgagcaacccttggactttcggtggaggcaccaaactcgagctcaag CAR20-7- 838atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Solubleaagtcaccctgaaagaatcgggtcccggaatgctgcagccatccaagacgctgtcccttacat scFv-ntgctccttctccgggttcagcctctcaacttccgggatggtggtgtcatggatcagacagccgagcggaaagtccctggagtggctggcggccatcgcatgggatggcgataagtactacaacccgagcctgaagtcaagggtcactgtgtccaaggacacctccaacacccaagtgttccttcggatcacctccgtggacattgctgacaccgccacctattactgcactcgccgggactacgacgtgggctactactacttcgatttctggggacagggtgtcatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccaagattgtgctgacccagagccccactattaccgccgcctccccgggggaaaaggtcaccatcacttgtctggcgtcctcacgcgtgtcgaatatctactggtatcagcagaagtccggcgccagccccaagctgctgatctactcgacctcctccctcgcgtcgggagtgccttaccggttttctggctcgggaagcggaaccagctactccttgaccatcaacaccatggaagccgaggacgctgccacttactactgccaccagtggtcgagcaacccttggactttcggtggaggcaccaaactcgagctcaagggatcgcaccaccatcaccatcatcatcac CAR20-7- 839malpvtalllplalllhaarpqvtlkesgpgmlqpsktlsltcsfsgfslstsgmvvswirqps Solublegkslewlaaiawdgdkyynpslksrvtvskdtsntqvflritsvdiadtatyyctrrdydvgy scFv-aayyfdfwgqgvmvtvssggggsggggsggggsggggskivltqsptitaaspgekvtitclassrvsniywyqqksgaspklliystsslasgvpyrfsgsgsgtsysltintmeaedaatyychqwssnpwtfgggtklelkgshhhhhhhh CAR20-7 840atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Full-ntaagtcaccctgaaagaatcgggtcccggaatgctgcagccatccaagacgctgtcccttacatgctccttctccgggttcagcctctcaacttccgggatggtggtgtcatggatcagacagccgagcggaaagtccctggagtggctggcggccatcgcatgggatggcgataagtactacaacccgagcctgaagtcaagggtcactgtgtccaaggacacctccaacacccaagtgttccttcggatcacctccgtggacattgctgacaccgccacctattactgcactcgccgggactacgacgtgggctactactacttcgatttctggggacagggtgtcatggtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccaagattgtgctgacccagagccccactattaccgccgcctccccgggggaaaaggtcaccatcacttgtctggcgtcctcacgcgtgtcgaatatctactggtatcagcagaagtccggcgccagccccaagctgctgatctactcgacctcctccctcgcgtcgggagtgccttaccggttttctggctcgggaagcggaaccagctactccttgaccatcaacaccatggaagccgaggacgctgccacttactactgccaccagtggtcgagcaacccttggactttcggtggaggcaccaaactcgagctcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-7 841malpvtalllplalllhaarpqvtlkesgpgmlqpsktlsltcsfsgfslstsgmvvswirqps Full-aagkslewlaaiawdgdkyynpslksrvtvskdtsntqvflritsvdiadtatyyctrrdydvgyyyfdfwgqgvmvtvssggggsggggsggggsggggskivltqsptitaaspgekvtitclassrvsniywyqqksgaspklliystsslasgvpyrfsgsgsgtsysltintmeaedaatyychqwssnpwtfgggtklelktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-8 842qiqlvqsgpelkkpgesvkisckasgntvtgyamhwvrqapgkglkwmgwintysgk scFvptyaddfkgrcvfsleasastahlqisnlknedtatyfcarstyygykdwfaywgqgtlvtv domainssggggsggggsggggsggggsniqltqspsrlsasvgdrvtlsckgsqninnylawyqqklgeapklliyntnnlqtgipsrfsgsgsgtdytftisglqpedvatyfccqynngntfgagtkl elkCAR20-8 843caaattcagttggtgcagtccggcccggagctgaagaagcctggagaatccgtgaagatctc scFvgtgcaaagcttccgggaacaccgtgaccggatacgcaatgcactgggtccgccaggcaccg domain ntggaaagggactgaagtggatggggtggatcaacacctacagcggaaagccgacttacgccgatgactttaagggacgctgtgtgttctccctggaagcgtccgcctcgactgcccatcttcaaatctccaacctgaagaatgaggacaccgccacttacttctgcgcccggagcacctattacggctacaaggactggttcgcgtattggggccagggcactctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccaacatccaactgactcagagccccagccggctgtccgcctccgtgggggacagggtcacactgagctgcaagggttctcagaacatcaacaactacctcgcgtggtaccagcagaagctgggagaggcccccaagctgctcatctacaacaccaacaatctgcaaactggcattccatcgagattctcaggatcagggtccggtaccgactacaccttcacgatttcgggacttcagcctgaggatgtggccacctacttctgctgtcagtacaacaacggcaacaccttcggtgctggcaccaagctggaactcaaa CAR20-8-844 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccSoluble aaattcagttggtgcagtccggcccggagctgaagaagcctggagaatccgtgaagatctcgtscFv-nt gcaaagcttccgggaacaccgtgaccggatacgcaatgcactgggtccgccaggcaccgggaaagggactgaagtggatggggtggatcaacacctacagcggaaagccgacttacgccgatgactttaagggacgctgtgtgttctccctggaagcgtccgcctcgactgcccatcttcaaatctccaacctgaagaatgaggacaccgccacttacttctgcgcccggagcacctattacggctacaaggactggttcgcgtattggggccagggcactctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccaacatccaactgactcagagccccagccggctgtccgcctccgtgggggacagggtcacactgagctgcaagggttctcagaacatcaacaactacctcgcgtggtaccagcagaagctgggagaggcccccaagctgctcatctacaacaccaacaatctgcaaactggcattccatcgagattctcaggatcagggtccggtaccgactacaccttcacgatttcgggacttcagcctgaggatgtggccacctacttctgctgtcagtacaacaacggcaacaccttcggtgctggcaccaagctggaactcaaaggatcgcaccaccatcaccatcatcatcac CAR20-8- 845malpvtalllplalllhaarpqiqlvqsgpelkkpgesvkisckasgntvtgyamhwvrqa Solublepgkglkwmgwintysgkptyaddfkgrcvfsleasastahlqisnlknedtatyfcarsty scFv-aaygykdwfaywgqgtlvtvssggggsggggsggggsggggsniqltqspsrlsasvgdrvtlsckgsqninnylawyqqklgeapklliyntnnlqtgipsrfsgsgsgtdytftisglqpedvatyfccqynngntfgagtklelkgshhhhhhhh CAR20-8- 846atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Full-ntaaattcagttggtgcagtccggcccggagctgaagaagcctggagaatccgtgaagatctcgtgcaaagcttccgggaacaccgtgaccggatacgcaatgcactgggtccgccaggcaccgggaaagggactgaagtggatggggtggatcaacacctacagcggaaagccgacttacgccgatgactttaagggacgctgtgtgttctccctggaagcgtccgcctcgactgcccatcttcaaatctccaacctgaagaatgaggacaccgccacttacttctgcgcccggagcacctattacggctacaaggactggttcgcgtattggggccagggcactctcgtgaccgtgtcctccggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccaacatccaactgactcagagccccagccggctgtccgcctccgtgggggacagggtcacactgagctgcaagggttctcagaacatcaacaactacctcgcgtggtaccagcagaagctgggagaggcccccaagctgctcatctacaacaccaacaatctgcaaactggcattccatcgagattctcaggatcagggtccggtaccgactacaccttcacgatttcgggacttcagcctgaggatgtggccacctacttctgctgtcagtacaacaacggcaacaccttcggtgctggcaccaagctggaactcaaaaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-8- 847malpvtalllplalllhaarpqiqlvqsgpelkkpgesvkisckasgntvtgyamhwvrqa Full-aapgkglkwmgwintysgkptyaddfkgrcvfsleasastahlqisnlknedtatyfcarstyygykdwfaywgqgtlvtvssggggsggggsggggsggggsniqltqspsrlsasvgdrvtlsckgsqninnylawyqqklgeapklliyntnnlqtgipsrfsgsgsgtdytftisglqpedvatyfccqynngntfgagtklelktttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-9 848divmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspkllifwastr scFvesgvpdrfigsgsgtdftltissvqaedlavyycqqyynfptfgsgtkleikggggsggggs domainggggsggggsevqlvesggglvqpgrslklscaasgftfrdyymawvrqapkkglewvasisyegnpyygdsvkgrftisrnnakstlylqmnslrsedtatyycarhdhnnvdwfayw gqgtlvtvssCAR20-9 849gacatcgtgatgactcagactccaagcagccaggccgtgtccgccggagagaaagtcacca scFvtgtcgtgcaagagctcccagtccctgctgtactccgaaaacaagaagaattatctcgcctggtadomain nt ccagcagaagcctggacagtccccgaagctcctgatcttttgggcgtcgaccagggaatccggcgtgcccgatcgcttcattggctccggttccggcaccgacttcaccctgaccattagcagcgtccaggcggaggacctggctgtgtactactgccaacagtactacaacttccccactttcggatcggggaccaagctggagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaagtgcagcttgtggagtctggcggcggtctggtgcagccgggaagatccctgaagctgtcatgcgccgcgtccgggtttaccttccgcgattactacatggcctgggtcagacaggcacctaagaaggggctggaatgggtggcatccatctcatatgaaggaaacccgtactacggagactcggtgaaaggccgcttcactatctcacggaacaacgctaagagcacgctgtacttgcaaatgaactccctccggtcggaggacacagccacttactactgtgcccggcacgaccataacaacgtcgattggttcgcctactggggtcaaggaaccctcgtgaccgtgt cctccCAR20-9- 850atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Solubleacatcgtgatgactcagactccaagcagccaggccgtgtccgccggagagaaagtcaccat scFv-ntgtcgtgcaagagctcccagtccctgctgtactccgaaaacaagaagaattatctcgcctggtaccagcagaagcctggacagtccccgaagctcctgatcttttgggcgtcgaccagggaatccggcgtgcccgatcgcttcattggctccggttccggcaccgacttcaccctgaccattagcagcgtccaggcggaggacctggctgtgtactactgccaacagtactacaacttccccactttcggatcggggaccaagctggagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaagtgcagcttgtggagtctggcggcggtctggtgcagccgggaagatccctgaagctgtcatgcgccgcgtccgggtttaccttccgcgattactacatggcctgggtcagacaggcacctaagaaggggctggaatgggtggcatccatctcatatgaaggaaacccgtactacggagactcggtgaaaggccgcttcactatctcacggaacaacgctaagagcacgctgtacttgcaaatgaactccctccggtcggaggacacagccacttactactgtgcccggcacgaccataacaacgtcgattggttcgcctactggggtcaaggaaccctcgtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-9- 851malpvtalllplalllhaarpdivmtqtpssqavsagekvtmsckssqsllysenkknylaw Solubleyqqkpgqspkllifwastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfptfg scFv-aasgtkleikggggsggggsggggsggggsevqlvesggglvqpgrslklscaasgftfrdyymawvrqapkkglewvasisyegnpyygdsvkgrftisrnnakstlylqmnslrsedtatyycarhdhnnvdwfaywgqgtlvtvssgshhhhhhhh CAR20-9- 852atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Full-ntacatcgtgatgactcagactccaagcagccaggccgtgtccgccggagagaaagtcaccatgtcgtgcaagagctcccagtccctgctgtactccgaaaacaagaagaattatctcgcctggtaccagcagaagcctggacagtccccgaagctcctgatcttttgggcgtcgaccagggaatccggcgtgcccgatcgcttcattggctccggttccggcaccgacttcaccctgaccattagcagcgtccaggcggaggacctggctgtgtactactgccaacagtactacaacttccccactttcggatcggggaccaagctggagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaagtgcagcttgtggagtctggcggcggtctggtgcagccgggaagatccctgaagctgtcatgcgccgcgtccgggtttaccttccgcgattactacatggcctgggtcagacaggcacctaagaaggggctggaatgggtggcatccatctcatatgaaggaaacccgtactacggagactcggtgaaaggccgcttcactatctcacggaacaacgctaagagcacgctgtacttgcaaatgaactccctccggtcggaggacacagccacttactactgtgcccggcacgaccataacaacgtcgattggttcgcctactggggtcaaggaaccctcgtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-9- 853malpvtalllplalllhaarpdivmtqtpssqavsagekvtmsckssqsllysenkknylaw Full-aayqqkpgqspkllifwastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfptfgsgtkleikggggsggggsggggsggggsevqlvesggglvqpgrslklscaasgftfrdyymawvrqapkkglewvasisyegnpyygdsvkgrftisrnnakstlylqmnslrsedtatyycarhdhnnvdwfaywgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqa lpprCAR20-10 854diqmtqsppslsaslgdkvtitcqasqninkyiawyqqkpgkaprllirytstlesgtpsrfsg scFvsgsgrdysfsisnvesgdvasyyclqyddlpytfgpgtklelkggggsggggsggggsgg domainggsevqlvesggglvqpgtslklscvasgftfsssgmqwirqapkkglewisgiyydsykksyadsvkgrftisrdnskntlylemnslrsedtatyycaksayygykdyfdywgqgvm vtvssCAR20-10 855gacatccaaatgacacagtcacccccttctctttccgcgagcctgggagataaggtcaccatta scFvcgtgccaagcgtcccagaacatcaacaagtacatcgcctggtaccagcagaaaccgggaaa domain ntggccccgcggctgctgattagatacacctcgactctggaatccggcactccatcaagattcagcggctccggcagcgggagggactactcgttctccatctccaatgtggagtccggggacgtggccagctactattgcctgcaatacgacgatctgccctacaccttcggacctggaaccaagctggaactcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaggtccagcttgtggaatcaggaggcggactcgtccagccgggtactagcctgaagctcagctgtgtggccagcggttttaccttctcgtcctccgggatgcagtggattcggcaggctcccaagaagggactggaatggatctcgggcatctactacgactcgtacaagaagtcctacgccgattccgtgaaaggtcgcttcaccatctcccgggacaacagcaagaacactctgtacctcgagatgaactccttgcgctccgaggataccgcaacctattactgcgccaagtcggcctactacggctacaaggactacttcgactattggggccagggagtgatggtgaccgtgtcctcc CAR20-10- 856atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Solubleacatccaaatgacacagtcacccccttctctttccgcgagcctgggagataaggtcaccattac scFv-ntgtgccaagcgtcccagaacatcaacaagtacatcgcctggtaccagcagaaaccgggaaaggccccgcggctgctgattagatacacctcgactctggaatccggcactccatcaagattcagcggctccggcagcgggagggactactcgttctccatctccaatgtggagtccggggacgtggccagctactattgcctgcaatacgacgatctgccctacaccttcggacctggaaccaagctggaactcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaggtccagcttgtggaatcaggaggcggactcgtccagccgggtactagcctgaagctcagctgtgtggccagcggttttaccttctcgtcctccgggatgcagtggattcggcaggctcccaagaagggactggaatggatctcgggcatctactacgactcgtacaagaagtcctacgccgattccgtgaaaggtcgcttcaccatctcccgggacaacagcaagaacactctgtacctcgagatgaactccttgcgctccgaggataccgcaacctattactgcgccaagtcggcctactacggctacaaggactacttcgactattggggccagggagtgatggtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-10- 857malpvtalllplalllhaarpdiqmtqsppslsaslgdkvtitcqasqninkyiawyqqkpg SolublekaprllirytstlesgtpsrfsgsgsgrdysfsisnvesgdvasyyclqyddlpytfgpgtklelscFv-aa kggggsggggsggggsggggsevqlvesggglvqpgtslklscvasgftfsssgmqwirqapkkglewisgiyydsykksyadsvkgrftisrdnskntlylemnslrsedtatyycaksayygykdyfdywgqgvmvtvssgshhhhhhhh 194181 858atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgCAR20-10-acatccaaatgacacagtcacccccttctctttccgcgagcctgggagataaggtcaccattac Full-ntgtgccaagcgtcccagaacatcaacaagtacatcgcctggtaccagcagaaaccgggaaaggccccgcggctgctgattagatacacctcgactctggaatccggcactccatcaagattcagcggctccggcagcgggagggactactcgttctccatctccaatgtggagtccggggacgtggccagctactattgcctgcaatacgacgatctgccctacaccttcggacctggaaccaagctggaactcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaggtccagcttgtggaatcaggaggcggactcgtccagccgggtactagcctgaagctcagctgtgtggccagcggttttaccttctcgtcctccgggatgcagtggattcggcaggctcccaagaagggactggaatggatctcgggcatctactacgactcgtacaagaagtcctacgccgattccgtgaaaggtcgcttcaccatctcccgggacaacagcaagaacactctgtacctcgagatgaactccttgcgctccgaggataccgcaacctattactgcgccaagtcggcctactacggctacaaggactacttcgactattggggccagggagtgatggtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg 194181 859malpvtalllplalllhaarpdiqmtqsppslsaslgdkvtitcqasqninkyiawyqqkpg CAR20-10-kaprllirytstlesgtpsrfsgsgsgrdysfsisnvesgdvasyyclqyddlpytfgpgtklelFull-aa kggggsggggsggggsggggsevqlvesggglvqpgtslklscvasgftfsssgmqwirqapkkglewisgiyydsykksyadsvkgrftisrdnskntlylemnslrsedtatyycaksayygykdyfdywgqgvmvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-11 860divmtqtpssqavsagekvtmsckssqsllysenkknylawyqqkpgqspklliywastr scFvesgvpdrfigsgsgtdftltissvqaedlavyycqqyynfppwtfgggtklelkggggsggg domaingsggggsggggsqiqlvqsgpelkkpgesvkiscktseytftdyafhwvkqapgkglkwmgwintysgkptyaddfkgrfvfsledsartanlqisnlknedtatyfcargayygyrdwftywgqgtlvtvss CAR20-11 861gatattgtgatgacccagaccccgtcgagccaggcagtgtccgctggagaaaaggtcaccat scFvgtcctgcaagagctcacagtccctgttgtactccgaaaacaagaagaattacctggcctggtacdomain nt cagcagaagcccggacagtcccctaaactgctgatctactgggcctcgactagggaatctggcgtgcccgaccgctttatcggaagcggttcagggactgacttcaccctgaccattagcagcgtgcaggccgaggacctggcggtgtactactgtcaacagtactacaacttcccgccctggactttcggcggtggaacgaagctcgaactcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaaattcaactggtccagtccggccctgagctgaagaagccgggagaatccgtgaagatctcctgcaagacctcggagtacaccttcactgactacgccttccactgggtcaagcaggcacctgggaaaggcctgaagtggatgggctggatcaacacttactcggggaagccaacctacgccgatgatttcaagggaagattcgtgtttagcctggaggactccgcccggacagctaacctccaaatctccaaccttaagaacgaggacactgcgacctacttctgcgcgcggggagcctattacggttatcgcgactggttcacctactggggacagggcaccctcgtgaccgtgtcctcc CAR20-11- 862atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Solubleatattgtgatgacccagaccccgtcgagccaggcagtgtccgctggagaaaaggtcaccatg scFv-nttcctgcaagagctcacagtccctgttgtactccgaaaacaagaagaattacctggcctggtaccagcagaagcccggacagtcccctaaactgctgatctactgggcctcgactagggaatctggcgtgcccgaccgctttatcggaagcggttcagggactgacttcaccctgaccattagcagcgtgcaggccgaggacctggcggtgtactactgtcaacagtactacaacttcccgccctggactttcggcggtggaacgaagctcgaactcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaaattcaactggtccagtccggccctgagctgaagaagccgggagaatccgtgaagatctcctgcaagacctcggagtacaccttcactgactacgccttccactgggtcaagcaggcacctgggaaaggcctgaagtggatgggctggatcaacacttactcggggaagccaacctacgccgatgatttcaagggaagattcgtgtttagcctggaggactccgcccggacagctaacctccaaatctccaaccttaagaacgaggacactgcgacctacttctgcgcgcggggagcctattacggttatcgcgactggttcacctactggggacagggcaccctcgtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-11- 863malpvtalllplalllhaarpdivmtqtpssqavsagekvtmsckssqsllysenkknylaw Solubleyqqkpgqspklliywastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfpp scFv-aawtfgggtklelkggggsggggsggggsggggsqiqlvqsgpelkkpgesvkiscktseytftdyafhwvkqapgkglkwmgwintysgkptyaddfkgrfvfsledsartanlqisnlknedtatyfcargayygyrdwftywgqgtlvtvssgshhhhhhhh CAR20-11- 864atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Full-ntatattgtgatgacccagaccccgtcgagccaggcagtgtccgctggagaaaaggtcaccatgtcctgcaagagctcacagtccctgttgtactccgaaaacaagaagaattacctggcctggtaccagcagaagcccggacagtcccctaaactgctgatctactgggcctcgactagggaatctggcgtgcccgaccgctttatcggaagcggttcagggactgacttcaccctgaccattagcagcgtgcaggccgaggacctggcggtgtactactgtcaacagtactacaacttcccgccctggactttcggcggtggaacgaagctcgaactcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaaattcaactggtccagtccggccctgagctgaagaagccgggagaatccgtgaagatctcctgcaagacctcggagtacaccttcactgactacgccttccactgggtcaagcaggcacctgggaaaggcctgaagtggatgggctggatcaacacttactcggggaagccaacctacgccgatgatttcaagggaagattcgtgtttagcctggaggactccgcccggacagctaacctccaaatctccaaccttaagaacgaggacactgcgacctacttctgcgcgcggggagcctattacggttatcgcgactggttcacctactggggacagggcaccctcgtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgc cgcctcggCAR20-11- 865malpvtalllplalllhaarpdivmtqtpssqavsagekvtmsckssqsllysenkknylaw Full-aayqqkpgqspklliywastresgvpdrfigsgsgtdftltissvqaedlavyycqqyynfppwtfgggtklelkggggsggggsggggsggggsqiqlvqsgpelkkpgesvkiscktseytftdyafhwvkqapgkglkwmgwintysgkptyaddfkgrfvfsledsartanlqisnlknedtatyfcargayygyrdwftywgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtyd alhmqalpprCAR20-12 866qvvltqpksvstslestvklsckinsgnigsyfihwyqqhegrspttmiyrddkrphgvpdr scFvfsgsidsssnsafltinnvqtedeaiyfchsydsginivfgggtkltvlggggsggggsgggg domainsggggsevqlvesggglvqpgrslklsclasgftfskygmnwirqapgkglewvasisstsiyiyyadtvkgrftisrenakntlylqmtslrsedtalyycarhdyssysywgqgvmvtvss CAR20-12867 caagtcgtgctgacgcaacccaagtccgtgagcaccagcctggagagcaccgtgaagctca scFvgctgcaagattaactcgggcaacattgggtcctacttcatccattggtaccagcagcacgaagdomain nt gacggtcccctaccactatgatctaccgggacgacaagcggccgcacggagtgccggacagattctcgggttcaatcgattcctcatctaactcggcgtttctcaccatcaacaacgtgcagaccgaggacgaagcgatctacttctgccactcctacgactcgggtattaacattgtgttcggcggcgggactaagctgacagtgctgggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaggtgcagctcgtcgaatccggtggaggactggtgcagccaggaagatccctgaagctgtcctgtctcgcctcgggcttcactttctccaaatacggcatgaattggattcgccaggcacccggaaaggggctggaatgggtggccagcatcagctcgactagcatctacatctactatgccgataccgtcaagggccgcttcactatctcccgcgagaacgctaagaacaccctttacttgcaaatgacctccctgaggtccgaagataccgccctgtactattgcgcccggcacgactactcatcctactcctactggggacagggagtcatggtgaccgtgtcctcc CAR20-12-868 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccccSoluble aagtcgtgctgacgcaacccaagtccgtgagcaccagcctggagagcaccgtgaagctcagscFv-nt ctgcaagattaactcgggcaacattgggtcctacttcatccattggtaccagcagcacgaaggacggtcccctaccactatgatctaccgggacgacaagcggccgcacggagtgccggacagattctcgggttcaatcgattcctcatctaactcggcgtttctcaccatcaacaacgtgcagaccgaggacgaagcgatctacttctgccactcctacgactcgggtattaacattgtgttcggcggcgggactaagctgacagtgctgggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaggtgcagctcgtcgaatccggtggaggactggtgcagccaggaagatccctgaagctgtcctgtctcgcctcgggcttcactttctccaaatacggcatgaattggattcgccaggcacccggaaaggggctggaatgggtggccagcatcagctcgactagcatctacatctactatgccgataccgtcaagggccgcttcactatctcccgcgagaacgctaagaacaccctttacttgcaaatgacctccctgaggtccgaagataccgccctgtactattgcgcccggcacgactactcatcctactcctactggggacagggagtcatggtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-12- 869malpvtalllplalllhaarpqvvltqpksvstslestvklsckinsgnigsyfihwyqqhegr Solublespttmiyrddkrphgvpdrfsgsidsssnsafltinnvqtedeaiyfchsydsginivfgggt scFv-aakltvlggggsggggsggggsggggsevqlvesggglvqpgrslklsclasgftfskygmnwirqapgkglewvasisstsiyiyyadtvkgrftisrenakntlylqmtslrsedtalyycarhdyssysywgqgvmvtvssgshhhhhhhh CAR20-12- 870atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccc Full-ntaagtcgtgctgacgcaacccaagtccgtgagcaccagcctggagagcaccgtgaagctcagctgcaagattaactcgggcaacattgggtcctacttcatccattggtaccagcagcacgaaggacggtcccctaccactatgatctaccgggacgacaagcggccgcacggagtgccggacagattctcgggttcaatcgattcctcatctaactcggcgtttctcaccatcaacaacgtgcagaccgaggacgaagcgatctacttctgccactcctacgactcgggtattaacattgtgttcggcggcgggactaagctgacagtgctgggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctccgaggtgcagctcgtcgaatccggtggaggactggtgcagccaggaagatccctgaagctgtcctgtctcgcctcgggcttcactttctccaaatacggcatgaattggattcgccaggcacccggaaaggggctggaatgggtggccagcatcagctcgactagcatctacatctactatgccgataccgtcaagggccgcttcactatctcccgcgagaacgctaagaacaccctttacttgcaaatgacctccctgaggtccgaagataccgccctgtactattgcgcccggcacgactactcatcctactcctactggggacagggagtcatggtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-12- 871malpvtalllplalllhaarpqvvltqpksvstslestvklsckinsgnigsyfihwyqqhegr Full-aaspttmiyrddkrphgvpdrfsgsidsssnsafltinnvqtedeaiyfchsydsginivfgggtkltvlggggsggggsggggsggggsevqlvesggglvqpgrslklsclasgftfskygmnwirqapgkglewvasisstsiyiyyadtvkgrftisrenakntlylqmtslrsedtalyycarhdyssysywgqgvmvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-13 872dvqmtqspsllsasvgdavtinckasqninrylnwyqqklgegprlliysanslqtgipsrfs scFvgsgsgadftltitspqpedvatyfclqhnswpltfgsgtkleikggggsggggsggggsggg domaingsqvtlkesgpgilqpsqtlsltctftrfslstygmsvgwirqpsgkglewladiwwdddkhynpslknrltiskdtsknqaflkitnvdtadtatyycarssttdgivtyvmdvwgqgasvtvssCAR20-13 873gacgtgcagatgactcagtccccgtcgctcctgtccgcctccgtcggcgacgccgtgactatt scFvaactgcaaggcgtcccagaacatcaatcggtacctgaactggtaccagcaaaaactgggaga domain ntagggccgagacttctcatctactccgccaactccctgcaaactggcatcccgtcgaggttcagcggatcaggctctggtgccgacttcactttgaccatcacgagccctcagcccgaagatgtggccacctacttctgcctccaacacaactcctggcccctgacctttggttcgggcaccaagctggagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcacgctgaaggaatcgggccctggaattctgcagccaagccagaccctctcgcttacttgcaccttcacccgcttctcactgtccacttacggaatgtccgtgggatggattcggcagcccagcggaaagggtttggagtggctggccgacatttggtgggatgacgacaagcattacaaccctagcctgaagaatcggctcaccatcagcaaagacacctccaagaaccaggcgttcctgaagatcaccaacgtggataccgccgacactgcaacatactattgtgcccgctcctcaaccaccgatgggatcgtgacctacgtgatggacgtctggggccagggagcttccgtgaccgtgtc ctccCAR20-13- 874atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Solubleacgtgcagatgactcagtccccgtcgctcctgtccgcctccgtcggcgacgccgtgactatta scFv-ntactgcaaggcgtcccagaacatcaatcggtacctgaactggtaccagcaaaaactgggagaagggccgagacttctcatctactccgccaactccctgcaaactggcatcccgtcgaggttcagcggatcaggctctggtgccgacttcactttgaccatcacgagccctcagcccgaagatgtggccacctacttctgcctccaacacaactcctggcccctgacctttggttcgggcaccaagctggagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcacgctgaaggaatcgggccctggaattctgcagccaagccagaccctctcgcttacttgcaccttcacccgcttctcactgtccacttacggaatgtccgtgggatggattcggcagcccagcggaaagggtttggagtggctggccgacatttggtgggatgacgacaagcattacaaccctagcctgaagaatcggctcaccatcagcaaagacacctccaagaaccaggcgttcctgaagatcaccaacgtggataccgccgacactgcaacatactattgtgcccgctcctcaaccaccgatgggatcgtgacctacgtgatggacgtctggggccagggagcttccgtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-13- 875malpvtalllplalllhaarpdvqmtqspsllsasvgdavtinckasqninrylnwyqqklg SolubleegprlliysanslqtgipsrfsgsgsgadftltitspqpedvatyfclqhnswpltfgsgtkleikscFv-aa ggggsggggsggggsggggsqvtlkesgpgilqpsqtlsltctftrfslstygmsvgwirqpsgkglewladiwwdddkhynpslknrltiskdtsknqaflkitnvdtadtatyycarssttdgivtyvmdvwgqgasvtvssgshhhhhhhh CAR20-13- 876atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Full ntacgtgcagatgactcagtccccgtcgctcctgtccgcctccgtcggcgacgccgtgactattaactgcaaggcgtcccagaacatcaatcggtacctgaactggtaccagcaaaaactgggagaagggccgagacttctcatctactccgccaactccctgcaaactggcatcccgtcgaggttcagcggatcaggctctggtgccgacttcactttgaccatcacgagccctcagcccgaagatgtggccacctacttctgcctccaacacaactcctggcccctgacctttggttcgggcaccaagctggagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcacgctgaaggaatcgggccctggaattctgcagccaagccagaccctctcgcttacttgcaccttcacccgcttctcactgtccacttacggaatgtccgtgggatggattcggcagcccagcggaaagggtttggagtggctggccgacatttggtgggatgacgacaagcattacaaccctagcctgaagaatcggctcaccatcagcaaagacacctccaagaaccaggcgttcctgaagatcaccaacgtggataccgccgacactgcaacatactattgtgcccgctcctcaaccaccgatgggatcgtgacctacgtgatggacgtctggggccagggagcttccgtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-13- 877malpvtalllplalllhaarpdvqmtqspsllsasvgdavtinckasqninrylnwyqqklg Full aaegprlliysanslqtgipsrfsgsgsgadftltitspqpedvatyfclqhnswpltfgsgtkleikggggsggggsggggsggggsqvtlkesgpgilqpsqtlsltctftrfslstygmsvgwirqpsgkglewladiwwdddkhynpslknrltiskdtsknqaflkitnvdtadtatyycarssttdgivtyvmdvwgqgasvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-14 878diqmtqspsflsasvgdrvtinckasqninrylnwyqqklgeapklliynanslqtgipsrfs scFvgsgsgtdftltisslqpadvatyfclqhnsrpltfgsgtileikggggsggggsggggsggggs domainqvtlkesgpgllqpsqtlsltctfagfslnthgmgvgwirqpsgkglewlaniwwdddkyynpslknrltmskdtsnnqaflkitnvdtadtatyycariegspvvttvfdywgqgvmvtv ssCAR20-14 879gacatccaaatgacccagtcacctagctttctgtcggcctcggtcggcgacagagtgaccatta scFvactgcaaagcgtcccagaacatcaaccgctacctgaattggtaccagcagaagctgggggaa domain ntgccccgaagctgctgatctacaacgcgaacagcctccagactggtattccttcccggttctccgggagcggctcgggtaccgatttcaccctcaccatctcctcccttcaacccgctgacgtggccacctacttctgcttgcaacataattctcggcctctgaccttcggaagcggcactatcctcgagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcactcttaaggaatccgggccaggactgttgcagccgagccagaccctgtccctcacttgtaccttcgccggcttttcactgaacacccacggaatgggcgtgggatggattaggcagccctcgggaaagggactggagtggctggccaacatttggtgggacgacgacaagtattacaacccgagcctcaagaaccgcctgactatgtccaaggatacctccaacaaccaggccttcctgaaaatcactaacgtggataccgctgacaccgcaacgtactactgcgcccggatcgaaggttcccccgtcgtgacaactgtgttcgactactggggacagggcgtgatggtgaccgtgtcctcc CAR20-14-880 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccgSoluble acatccaaatgacccagtcacctagctttctgtcggcctcggtcggcgacagagtgaccattaascFv-nt ctgcaaagcgtcccagaacatcaaccgctacctgaattggtaccagcagaagctgggggaagccccgaagctgctgatctacaacgcgaacagcctccagactggtattccttcccggttctccgggagcggctcgggtaccgatttcaccctcaccatctcctcccttcaacccgctgacgtggccacctacttctgcttgcaacataattctcggcctctgaccttcggaagcggcactatcctcgagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcactcttaaggaatccgggccaggactgttgcagccgagccagaccctgtccctcacttgtaccttcgccggcttttcactgaacacccacggaatgggcgtgggatggattaggcagccctcgggaaagggactggagtggctggccaacatttggtgggacgacgacaagtattacaacccgagcctcaagaaccgcctgactatgtccaaggatacctccaacaaccaggccttcctgaaaatcactaacgtggataccgctgacaccgcaacgtactactgcgcccggatcgaaggttcccccgtcgtgacaactgtgttcgactactggggacagggcgtgatggtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-14- 881malpvtalllplalllhaarpdiqmtqspsflsasvgdrvtinckasqninrylnwyqqklge SolubleapklliynanslqtgipsrfsgsgsgtdftltisslqpadvatyfclqhnsrpltfgsgtileikggscFv-aa ggsggggsggggsggggsqvtlkesgpgllqpsqtlsltctfagfslnthgmgvgwirqpsgkglewlaniwwdddkyynpslknrltmskdtsnnqaflkitnvdtadtatyycariegspvvttvfdywgqgvmvtvssgshhhhhhhh CAR20-14- 882atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcccg Full ntacatccaaatgacccagtcacctagctttctgtcggcctcggtcggcgacagagtgaccattaactgcaaagcgtcccagaacatcaaccgctacctgaattggtaccagcagaagctgggggaagccccgaagctgctgatctacaacgcgaacagcctccagactggtattccttcccggttctccgggagcggctcgggtaccgatttcaccctcaccatctcctcccttcaacccgctgacgtggccacctacttctgcttgcaacataattctcggcctctgaccttcggaagcggcactatcctcgagatcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcactcttaaggaatccgggccaggactgttgcagccgagccagaccctgtccctcacttgtaccttcgccggcttttcactgaacacccacggaatgggcgtgggatggattaggcagccctcgggaaagggactggagtggctggccaacatttggtgggacgacgacaagtattacaacccgagcctcaagaaccgcctgactatgtccaaggatacctccaacaaccaggccttcctgaaaatcactaacgtggataccgctgacaccgcaacgtactactgcgcccggatcgaaggttcccccgtcgtgacaactgtgttcgactactggggacagggcgtgatggtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-14- 883malpvtalllplalllhaarpdiqmtqspsflsasvgdrvtinckasqninrylnwyqqklge Full aaapklliynanslqtgipsrfsgsgsgtdftltisslqpadvatyfclqhnsrpltfgsgtileikggggsggggsggggsggggsqvtlkesgpgllqpsqtlsltctfagfslnthgmgvgwirqpsgkglewlaniwwdddkyynpslknrltmskdtsnnqaflkitnvdtadtatyycariegspvvttvfdywgqgvmvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-15 884kivltqsptitaaspgekvtitclassrvsniywyqqksgaspklliystsslasgvpyrfsgsg scFvsgtsysltintmeaedaatyychqwssnpwtfgggtklelkggggsggggsggggsggg domaingsqvtlkesgpgmlqpsktlsltcsfsgfslstsgmvvswirqpsgkslewlaaiawdgdkyynpslksrvtvskdtsntqvflritsvdiadtatyyctrrdydvgyyyfdfwgqgvmvtvss CAR20-15885 aagattgtgctgacccagagccccactattaccgccgcctccccgggggaaaaggtcaccat scFvcacttgtctggcgtcctcacgcgtgtcgaatatctactggtatcagcagaagtccggcgccagcdomain ntcccaagctgctgatctactcgacctcctccctcgcgtcgggagtgccttaccggttttctggctcgggaagcggaaccagctactccttgaccatcaacaccatggaagccgaggacgctgccacttactactgccaccagtggtcgagcaacccttggactttcggtggaggcaccaaactcgagctcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcaccctgaaagaatcgggtcccggaatgctgcagccatccaagacgctgtcccttacatgctccttctccgggttcagcctctcaacttccgggatggtggtgtcatggatcagacagccgagcggaaagtccctggagtggctggcggccatcgcatgggatggcgataagtactacaacccgagcctgaagtcaagggtcactgtgtccaaggacacctccaacacccaagtgttccttcggatcacctccgtggacattgctgacaccgccacctattactgcactcgccgggactacgacgtgggctactactacttcgatttctggggacagggtgtcatggtgaccgtgtcctcc CAR20-15- 886atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccca Solubleagattgtgctgacccagagccccactattaccgccgcctccccgggggaaaaggtcaccatc scFv-ntacttgtctggcgtcctcacgcgtgtcgaatatctactggtatcagcagaagtccggcgccagccccaagctgctgatctactcgacctcctccctcgcgtcgggagtgccttaccggttttctggctcgggaagcggaaccagctactccttgaccatcaacaccatggaagccgaggacgctgccacttactactgccaccagtggtcgagcaacccttggactttcggtggaggcaccaaactcgagctcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcaccctgaaagaatcgggtcccggaatgctgcagccatccaagacgctgtcccttacatgctccttctccgggttcagcctctcaacttccgggatggtggtgtcatggatcagacagccgagcggaaagtccctggagtggctggcggccatcgcatgggatggcgataagtactacaacccgagcctgaagtcaagggtcactgtgtccaaggacacctccaacacccaagtgttccttcggatcacctccgtggacattgctgacaccgccacctattactgcactcgccgggactacgacgtgggctactactacttcgatttctggggacagggtgtcatggtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-15- 887malpvtalllplalllhaarpkivltqsptitaaspgekvtitclassrvsniywyqqksgaspkSoluble lliystsslasgvpyrfsgsgsgtsysltintmeaedaatyychqwssnpwtfgggtklelkgscFv-aa gggsggggsggggsggggsqvtlkesgpgmlqpsktlsltcsfsgfslstsgmvvswirqpsgkslewlaaiawdgdkyynpslksrvtvskdtsntqvflritsvdiadtatyyctrrdydvgyyyfdfwgqgvmvtvssgshhhhhhhh CAR20-15- 888atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccca Full ntagattgtgctgacccagagccccactattaccgccgcctccccgggggaaaaggtcaccatcacttgtctggcgtcctcacgcgtgtcgaatatctactggtatcagcagaagtccggcgccagccccaagctgctgatctactcgacctcctccctcgcgtcgggagtgccttaccggttttctggctcgggaagcggaaccagctactccttgaccatcaacaccatggaagccgaggacgctgccacttactactgccaccagtggtcgagcaacccttggactttcggtggaggcaccaaactcgagctcaagggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaagtcaccctgaaagaatcgggtcccggaatgctgcagccatccaagacgctgtcccttacatgctccttctccgggttcagcctctcaacttccgggatggtggtgtcatggatcagacagccgagcggaaagtccctggagtggctggcggccatcgcatgggatggcgataagtactacaacccgagcctgaagtcaagggtcactgtgtccaaggacacctccaacacccaagtgttccttcggatcacctccgtggacattgctgacaccgccacctattactgcactcgccgggactacgacgtgggctactactacttcgatttctggggacagggtgtcatggtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-15- 889malpvtalllplalllhaarpkivltqsptitaaspgekvtitclassrvsniywyqqksgaspkFull aa lliystsslasgvpyrfsgsgsgtsysltintmeaedaatyychqwssnpwtfgggtklelkggggsggggsggggsggggsqvtlkesgpgmlqpsktlsltcsfsgfslstsgmvvswirqpsgkslewlaaiawdgdkyynpslksrvtvskdtsntqvflritsvdiadtatyyctrrdydvgyyyfdfwgqgvmvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr CAR20-16 890niqltqspsrlsasvgdrvtlsckgsqninnylawyqqklgeapklliyntnnlqtgipsrfsg scFvsgsgtdytftisglqpedvatyfccqynngntfgagtklelkggggsggggsggggsgggg domainsqiqlvqsgpelkkpgesvkisckasgntvtgyamhwvrqapgkglkwmgwintysgkptyaddfkgrcvfsleasastahlqisnlknedtatyfcarstyygykdwfaywgqgtlvt vssCAR20-16 891aacatccaactgactcagagccccagccggctgtccgcctccgtgggggacagggtcacac scFvtgagctgcaagggttctcagaacatcaacaactacctcgcgtggtaccagcagaagctggga domain ntgaggcccccaagctgctcatctacaacaccaacaatctgcaaactggcattccatcgagattctcaggatcagggtccggtaccgactacaccttcacgatttcgggacttcagcctgaggatgtggccacctacttctgctgtcagtacaacaacggcaacaccttcggtgctggcaccaagctggaactcaaaggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaaattcagttggtgcagtccggcccggagctgaagaagcctggagaatccgtgaagatctcgtgcaaagcttccgggaacaccgtgaccggatacgcaatgcactgggtccgccaggcaccgggaaagggactgaagtggatggggtggatcaacacctacagcggaaagccgacttacgccgatgactttaagggacgctgtgtgttctccctggaagcgtccgcctcgactgcccatcttcaaatctccaacctgaagaatgaggacaccgccacttacttctgcgcccggagcacctattacggctacaaggactggttcgcgtattggggccagggcactctcgtgaccgtgtcctcc CAR20-16- 892atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccca Solubleacatccaactgactcagagccccagccggctgtccgcctccgtgggggacagggtcacact scFv-ntgagctgcaagggttctcagaacatcaacaactacctcgcgtggtaccagcagaagctgggagaggcccccaagctgctcatctacaacaccaacaatctgcaaactggcattccatcgagattctcaggatcagggtccggtaccgactacaccttcacgatttcgggacttcagcctgaggatgtggccacctacttctgctgtcagtacaacaacggcaacaccttcggtgctggcaccaagctggaactcaaaggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaaattcagttggtgcagtccggcccggagctgaagaagcctggagaatccgtgaagatctcgtgcaaagcttccgggaacaccgtgaccggatacgcaatgcactgggtccgccaggcaccgggaaagggactgaagtggatggggtggatcaacacctacagcggaaagccgacttacgccgatgactttaagggacgctgtgtgttctccctggaagcgtccgcctcgactgcccatcttcaaatctccaacctgaagaatgaggacaccgccacttacttctgcgcccggagcacctattacggctacaaggactggttcgcgtattggggccagggcactctcgtgaccgtgtcctccggatcgcaccaccatcaccatcatcatcac CAR20-16- 893malpvtalllplalllhaarpniqltqspsrlsasvgdrvtlsckgsqninnylawyqqklgea Solublepklliyntnnlqtgipsrfsgsgsgtdytftisglqpedvatyfccqynngntfgagtklelkg scFv-aagggsggggsggggsggggsqiqlvqsgpelkkpgesvkisckasgntvtgyamhwvrqapgkglkwmgwintysgkptyaddfkgrcvfsleasastahlqisnlknedtatyfcarstyygykdwfaywgqgtlvtvssgshhhhhhhh CAR20-16- 894atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccca Full ntacatccaactgactcagagccccagccggctgtccgcctccgtgggggacagggtcacactgagctgcaagggttctcagaacatcaacaactacctcgcgtggtaccagcagaagctgggagaggcccccaagctgctcatctacaacaccaacaatctgcaaactggcattccatcgagattctcaggatcagggtccggtaccgactacaccttcacgatttcgggacttcagcctgaggatgtggccacctacttctgctgtcagtacaacaacggcaacaccttcggtgctggcaccaagctggaactcaaaggcggtggaggctcaggggggggcggctcgggagggggtggaagcggaggaggaggctcccaaattcagttggtgcagtccggcccggagctgaagaagcctggagaatccgtgaagatctcgtgcaaagcttccgggaacaccgtgaccggatacgcaatgcactgggtccgccaggcaccgggaaagggactgaagtggatggggtggatcaacacctacagcggaaagccgacttacgccgatgactttaagggacgctgtgtgttctccctggaagcgtccgcctcgactgcccatcttcaaatctccaacctgaagaatgaggacaccgccacttacttctgcgcccggagcacctattacggctacaaggactggttcgcgtattggggccagggcactctcgtgaccgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR20-16- 895malpvtalllplalllhaarpniqltqspsrlsasvgdrvtlsckgsqninnylawyqqklgea Full aapklliyntnnlqtgipsrfsgsgsgtdytftisglqpedvatyfccqynngntfgagtklelkggggsggggsggggsggggsqiqlvqsgpelkkpgesvkisckasgntvtgyamhwvrqapgkglkwmgwintysgkptyaddfkgrcvfsleasastahlqisnlknedtatyfcarstyygykdwfaywgqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr

TABLE 11B Humanized CD20 CAR Constructs SEQ  ID Name NO: SequenceCD20-3m 691 QVQLVESGGGVVQPGRSLRLSCAASGFTFRDYYMAWVRQAPGKGL scFvEWVASISYEGNPYYGDSVKGRFTISRDNAKSTLYLQMSSLRAEDTAVYYCARHDHNNVDWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIVMTQTPLSLSVTPGQPVSMSCKSSQSLLYSENKKNYLAWYLQKPGQSPQLLIFWASTRESGVPDRFSGSGSGTDFTLKISRVEAEDVGV YYCQQYYNFPTFGQGTKLEIKCD20-3J 692 QVQLVQSGAEVKKPGASVKVSCKASGFTFRDYYMAWVRQAPGQRL scFvEWMGSISYEGNPYYGDSVKGRVTITRDNSASTLYMELSSLRSEDTAVYYCARHDHNNVDWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCKSSQSLLYSENKKNYLAWYQQKPGKVPKLLIFWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDVATY YCQQYYNFPTFGQGTKLEIKCD20- 693 EVQLVQSGAEVKKPGESLKISCKGSGFTFRDYYMAWVRQMPGKGL 3H5k3 scFvEWMGSISYEGNPYYGDSVKGQVTISRDNSISTLYLQWSSLKASDTAMYYCARHDHNNVDWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCKSSQSLLYSENKKNYLAWYQQKPGQAPRLLIFWASTRESGIPARFSGSGSGTDFTLTISSLQPEDLAV YYCQQYYNFPTFGQGTKLEIKCD20- 694 EVQLVQSGAEVKKPGESLKISCKGSGFTFRDYYMAWVRQMPGKGL 3H5k1 scFvEWMGSISYEGNPYYGDSVKGQVTISRDNSISTLYLQWSSLKASDTAMYYCARHDHNNVDWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCKSSQSLLYSENKKNYLAWYQQKPGKVPKLLIFWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYYNFPTFGQGTKLEIKCD20- 695 QVQLVQSGAEVKKPGASVKVSCKASGFTFRDYYMAWVRQAPGQG 3H1k3 scFvLEWMGSISYEGNPYYGDSVKGRVTMTRDNSTSTLYMELSSLRSEDTAVYYCARHDHNNVDWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCKSSQSLLYSENKKNYLAWYQQKPGQAPRLLIFWASTRESGIPARFSGSGSGTDFTLTISSLQPEDLAV YYCQQYYNFPTFGQGTKLEIKCD20- 696 QVQLVQSGAEVKKPGASVKVSCKASGFTFRDYYMAWVRQAPGQG 3H1k1 scFvLEWMGSISYEGNPYYGDSVKGRVTMTRDNSTSTLYMELSSLRSEDTAVYYCARHDHNNVDWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCKSSQSLLYSENKKNYLAWYQQKPGKVPKLLIFWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDVA TYYCQQYYNFPTFGQGTKLEIK

In some embodiments, the antigen binding domain comprises a HC CDR1, aHC CDR2, and a HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 11A and 11B. In embodiments, the antigenbinding domain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. Inembodiments, the antigen binding domain comprises a LC CDR1, a LC CDR2,and a LC CDR3 of any light chain binding domain amino acid sequenceslisted in Table 11A and 11B.

In some embodiments, the antigen binding domain comprises one, two orall of LC CDR1, LC CDR2, and LC CDR3 of any light chain binding domainamino acid sequences listed in Table 11A and 11B, and one, two or all ofHC CDR1, HC CDR2, and HC CDR3 of any heavy chain binding domain aminoacid sequences listed in Table 11A and 11B.

In some embodiments, the CDRs are defined according to the Kabatnumbering scheme, the Chothia numbering scheme, or a combinationthereof.

The sequences of human CDR sequences of the scFv domains are shown inTable 12A or 12B for the heavy chain variable domains and in Table 13for the light chain variable domains. “ID” stands for the respective SEQID NO for each CDR.

TABLE 12A Heavy Chain Variable Domain CDRs of CD20 CARs. CDRs areidentified according to the “combined” definition. SEQ SEQ SEQ Candi- IDID ID date HCDR1 NO: HCDR2 NO: HCDR3 NO: CAR20-1 EYTFTDYAFH 697WINTYSGKPTYADDFKG 791 DWFTY 903 CAR20-2 GFTFSKYGMN 698 SISSTSIYIYYADTVKG792 HDYSSYSY 904 CAR20-3 GFTFRDYYMA 699 SISYEGNPYYGDSVKG 793 HDHNNVDWFAY905 CAR20-4 RFSLSTYGMSVG 778 DIWWDDDKHYNPSLKN 794 SSTTDGIVTYVMDV 906CAR20-5 GFTFSSSGMQ 779 GIYYDSYKKSYADSVKG 795 SAYYGYKDYFDY 907 CAR20-6GFSLNTHGMGVG 780 NIWWDDDKYYNPSLKN 796 IEGSPVVTTVFDY 908 CAR20-7GFSLSTSGMVVS 781 AIAWDGDKYYNPSLKS 797 RDYDVGYYYFDF 909 CAR20-8GNTVTGYAMH 782 WINTYSGKPTYADDFKG 798 DWFAY 910 CAR20-9 GFTFRDYYMA 783SISYEGNPYYGDSVKG 799 HDHNNVDWFAY 911 CAR20-10 GFTFSSSGMQ 784GIYYDSYKKSYADSVKG 896 SAYYGYKDYFDY 912 CAR20-11 EYTFTDYAFH 785WINTYSGKPTYADDFKG 897 GAYYGYRDWFTY 913 CAR20-12 GFTFSKYGMN 786SISSTSIYIYYADTVKG 898 HDYSSYSY 914 CAR20-13 RFSLSTYGMSVG 787DIWWDDDKHYNPSLKN 899 SSTTDGIVTYVMDV 915 CAR20-14 GFSLNTHGMGVG 788NIWWDDDKYYNPSLKN 900 IEGSPVVTTVFDY 916 CAR20-15 GFSLSTSGMVVS 789AIAWDGDKYYNPSLKS 901 RDYDVGYYYFDF 917 CAR20-16 GNTVTGYAMH 790WINTYSGKPTYADDFKG 902 STYYGYKDWFAY 918

TABLE 12B Heavy Chain Variable Domain CDRs of CD20 CARs.CDRs are identified according to Kabat. SEQ SEQ SEQ Candi- ID ID ID dateHCDR1 NO: HCDR2 NO: HCDR3 NO: CAR20-1 DYAFH 1481 WINTYSGKPTYADDFKG 1497GAYYGYRDWFTY 1513 CAR20-2 KYGMN 1482 SISSTSIYIYYADTVKG 1498 HDYSSYSY1514 CAR20-3 DYYMA 1483 SISYEGNPYYGDSVKG 1499 HDHNNVDWFAY 1515 CAR20-4TYGMSVG 1484 DIWWDDDKHYNPSLKN 1500 SSTTDGIVTYVMDV 1516 CAR20-5 SSGMQ1485 GIYYDSYKKSYADSVKG 1501 SAYYGYKDYFDY 1517 CAR20-6 THGMGVG 1486NIWWDDDKYYNPSLKN 1502 IEGSPVVTTVFDY 1518 CAR20-7 TSGMVVS 1487AIAWDGDKYYNPSLKS 1503 RDYDVGYYYFDF 1519 CAR20-8 GYAMH 1488WINTYSGKPTYADDFKG 1504 STYYGYKDWFAY 1520 CAR20-9 DYYMA 1489SISYEGNPYYGDSVKG 1505 HDHNNVDWFAY 1521 CAR20-10 SSGMQ 1490GIYYDSYKKSYADSVKG 1506 SAYYGYKDYFDY 1522 CAR20-11 DYAFH 1491WINTYSGKPTYADDFKG 1507 GAYYGYRDWFTY 1523 CAR20-12 KYGMN 1492SISSTSIYIYYADTVKG 1508 HDYSSYSY 1524 CAR20-13 TYGMSVG 1493DIWWDDDKHYNPSLKN 1509 SSTTDGIVTYVMDV 1525 CAR20-14 THGMGVG 1494NIWWDDDKYYNPSLKN 1510 IEGSPVVTTVFDY 1526 CAR20-15 TSGMVVS 1495AIAWDGDKYYNPSLKS 1511 RDYDVGYYYFDF 1527 CAR20-16 GYAMH 1496WINTYSGKPTYADDFKG 1512 STYYGYKDWFAY 1528

TABLE 13 Light Chain Variable Domain CDRs of CD20 CARs.The LC CDR sequences in this table have the samesequence under the Kabat or combined definitions. SEQ SEQ SEQ ID ID IDCandidate LCDR1 NO: LCDR2 NO: LCDR3 NO: CAR20-1 KSSQSLLYSENKKNYLA 919WASTRES 935 QQYYNFPPWT 951 CAR20-2 KINSGNIGSYFIH 920 RDDKRPH 936HSYDSGINIV 952 CAR20-3 KSSQSLLYSENKKNYLA 921 WASTRES 937 QQYYNFPT 953CAR20-4 KASQNINRYLN 922 SANSLQT 938 LQHNSWPLT 954 CAR20-5 QASQNINKYIA923 YTSTLES 939 LQYDDLPYT 955 CAR20-6 KASQNINRYLN 924 NANSLQT 940LQHNSRPLT 956 CAR20-7 LASSRVSNIY 925 STSSLAS 941 HQWSSNPWT 957 CAR20-8KGSQNINNYLA 926 NTNNLQT 942 CQYNNGNT 958 CAR20-9 KSSQSLLYSENKKNYLA 927WASTRES 943 QQYYNFPT 959 CAR20-10 QASQNINKYIA 928 YTSTLES 944 LQYDDLPYT960 CAR20-11 KSSQSLLYSENKKNYLA 929 WASTRES 945 QQYYNFPPWT 961 CAR20-12KINSGNIGSYFIH 930 RDDKRPH 946 HSYDSGINIV 962 CAR20-13 KASQNINRYLN 931SANSLQT 947 LQHNSWPLT 963 CAR20-14 KASQNINRYLN 932 NANSLQT 948 LQHNSRPLT964 CAR20-15 LASSRVSNIY 933 STSSLAS 949 HQWSSNPWT 965 CAR20-16KGSQNINNYLA 934 NTNNLQT 950 CQYNNGNT 966

TABLE 14A Heavy Chain Variable Regions of CD20 antibody molecules Candi-SEQ ID date NO: Heavy Chain Variable region CAR-1 967QIQLVQSGPELKKPGESVKISCKTSEYTFTDYAFHWVKQAPGKGLKWMGWINTYSGKPTYADDFKGRFVFSLEDSARTANLQISNLKNEDTATYFCARGAYYGYRDWFTYWGQGTLVTV CAR20-2 968EVQLVESGGGLVQPGRSLKLSCLASGFTFSKYGMNWIRQAPGKGLEWVASISSTSIYIYYADTVKGRFTISRENAKNTLYLQMTSLRSEDTALY YCARHDYSSYSYWGQGVMVTVCAR20-3 969 EVQLVESGGGLVQPGRSLKLSCAASGFTFRDYYMAWVRQAPKKGLEWVASISYEGNPYYGDSVKGRFTISRNNAKSTLYLQMNSLRSEDTATYYCARHDHNNVDWFAYWGQGTLVTV CAR20-4 970QVTLKESGPGILQPSQTLSLTCTFTRFSLSTYGMSVGWIRQPSGKGLEWLADIWWDDDKHYNPSLKNRLTISKDTSKNQAFLKITNVDTADTATYYCARSSTTDGIVTYVMDVWGQGASVTV CAR20-5 971EVQLVESGGGLVQPGTSLKLSCVASGFTFSSSGMQWIRQAPKKGLEWISGIYYDSYKKSYADSVKGRFTISRDNSKNTLYLEMNSLRSEDTATYYCAKSAYYGYKDYFDYWGQGVMVTV CAR20-6 972QVTLKESGPGLLQPSQTLSLTCTFAGFSLNTHGMGVGWIRQPSGKGLEWLANIWWDDDKYYNPSLKNRLTMSKDTSNNQAFLKITNVDTADTATYYCARIEGSPVVTTVFDYWGQGVMVTV CAR20-7 973QVTLKESGPGMLQPSKTLSLTCSFSGFSLSTSGMVVSWIRQPSGKSLEWLAAIAWDGDKYYNPSLKSRVTVSKDTSNTQVFLRITSVDIADTATYYCTRRDYDVGYYYFDFWGQGVMVTV CAR20-8 974QIQLVQSGPELKKPGESVKISCKASGNTVTGYAMHWVRQAPGKGLKWMGWINTYSGKPTYADDFKGRCVFSLEASASTAHLQISNLKNEDTATYFCARSTYYGYKDWFAYWGQGTLVTV CAR20-9 975EVQLVESGGGLVQPGRSLKLSCAASGFTFRDYYMAWVRQAPKKGLEWVASISYEGNPYYGDSVKGRFTISRNNAKSTLYLQMNSLRSEDTATYYCARHDHNNVDWFAYWGQGTLVTV CAR20-10 976EVQLVESGGGLVQPGTSLKLSCVASGFTFSSSGMQWIRQAPKKGLEWISGIYYDSYKKSYADSVKGRFTISRDNSKNTLYLEMNSLRSEDTATYYCAKSAYYGYKDYFDYWGQGVMVTV CAR20-11 977QIQLVQSGPELKKPGESVKISCKTSEYTFTDYAFHWVKQAPGKGLKWMGWINTYSGKPTYADDFKGRFVFSLEDSARTANLQISNLKNEDTATYFCARGAYYGYRDWFTYWGQGTLVTV CAR20-12 978EVQLVESGGGLVQPGRSLKLSCLASGFTFSKYGMNWIRQAPGKGLEWVASISSTSIYIYYADTVKGRFTISRENAKNTLYLQMTSLRSEDTALY YCARHDYSSYSYWGQGVMVTVCAR20-13 979 QVTLKESGPGILQPSQTLSLTCTFTRFSLSTYGMSVGWIRQPSGKGLEWLADIWWDDDKHYNPSLKNRLTISKDTSKNQAFLKITNVDTADTATYYCARSSTTDGIVTYVMDVWGQGASVTV CAR20-14 980QVTLKESGPGLLQPSQTLSLTCTFAGFSLNTHGMGVGWIRQPSGKGLEWLANIWWDDDKYYNPSLKNRLTMSKDTSNNQAFLKITNVDTADTATYYCARIEGSPVVTTVFDYWGQGVMVTV CAR20-15 981QVTLKESGPGMLQPSKTLSLTCSFSGFSLSTSGMVVSWIRQPSGKSLEWLAAIAWDGDKYYNPSLKSRVTVSKDTSNTQVFLRITSVDIADTATYYCTRRDYDVGYYYFDFWGQGVMVTV CAR20-16 982QIQLVQSGPELKKPGESVKISCKASGNTVTGYAMHWVRQAPGKGLKWMGWINTYSGKPTYADDFKGRCVFSLEASASTAHLQISNLKNEDTATYFCARSTYYGYKDWFAYWGQGTLVTV

TABLE 14B Heavy Chain Variable Regions of HumanizedCD20 antibody molecules SEQ ID Candidate NO: Heavy Chain Variable regionCD20- 983 QVQLVQSGAEVKKPGASVKVSCKASGFTFRDYYMAWVRQAPGQG 3_VH1_1-46LEWMGSISYEGNPYYGDSVKGRVTMTRDNSTSTLYMELSSLRSEDTAVYYCARHDHNNVDWFAYWGQGTLVTVSS CD20- 984EVQLVQSGAEVKKPGESLKISCKGSGFTFRDYYMAWVRQMPGKG 3_VH5_5-51LEWMGSISYEGNPYYGDSVKGQVTISRDNSISTLYLQWSSLKASDTAMYYCARHDHNNVDWFAYWGQGTLVTVSS CD20-3_VH  985QVQLVESGGGVVQPGRSLRLSCAASGFTFRDYYMAWVRQAPGKG MLEWVASISYEGNPYYGDSVKGRFTISRDNAKSTLYLQMSSLRAEDTAVYYCARHDHNNVDWFAYWGQGTLVTVSS CD20-3_VH  986QVQLVQSGAEVKKPGASVKVSCKASGFTFRDYYMAWVRQAPGQR JLEWMGSISYEGNPYYGDSVKGRVTITRDNSASTLYMELSSLRSEDTAVYYCARHDHNNVDWFAYWGQGTLVTVSS

TABLE 15A Light Chain Variable Regions of CD20 antibody molecules Candi-SEQ ID date NO: Light Chain Variable region CAR20-1  987DIVMTQTPSSQAVSAGEKVTMSCKSSQSLLYSENKKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQ YYNFPPWTFGGGTKLELKCAR20-2  988 QVVLTQPKSVSTSLESTVKLSCKINSGNIGSYFIHWYQQHEGRSPTTMIYRDDKRPHGVPDRFSGSIDSSSNSAFLTINNVQTEDEAIYFCHSYDSGIN IVFGGGTKLTVL CAR20-3 989 DIVMTQTPSSQAVSAGEKVTMSCKSSQSLLYSENKKNYLAWYQQKPGQSPKLLIFWASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQ YYNFPTFGSGTKLEIKCAR20-4  990 DVQMTQSPSLLSASVGDAVTINCKASQNINRYLNWYQQKLGEGPRLLIYSANSLQTGIPSRFSGSGSGADFTLTITSPQPEDVATYFCLQHNSWPLTF GSGTKLEIK CAR20-5 991 DIQMTQSPPSLSASLGDKVTITCQASQNINKYIAWYQQKPGKAPRLLIRYTSTLESGTPSRFSGSGSGRDYSFSISNVESGDVASYYCLQYDDLPYTF GPGTKLELK CAR20-6  992DIQMTQSPSFLSASVGDRVTINCKASQNINRYLNWYQQKLGEAPKLLIYNANSLQTGIPSRFSGSGSGTDFTLTISSLQPADVATYFCLQHNSRPLTF GSGTILEIK CAR20-7 993 KIVLTQSPTITAASPGEKVTITCLASSRVSNIYWYQQKSGASPKLLIYSTSSLASGVPYRFSGSGSGTSYSLTINTMEAEDAATYYCHQWSSNPWTFGG GTKLELK CAR20-8  994NIQLTQSPSRLSASVGDRVTLSCKGSQNINNYLAWYQQKLGEAPKLLIYNTNNLQTGIPSRFSGSGSGTDYTFTISGLQPEDVATYFCCQYNNGNTF GAGTKLELK CAR20-9  995DIVMTQTPSSQAVSAGEKVTMSCKSSQSLLYSENKKNYLAWYQQKPGQSPKLLIFWASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQ YYNFPTFGSGTKLEIKCAR20-10  996 DIQMTQSPPSLSASLGDKVTITCQASQNINKYIAWYQQKPGKAPRLLIRYTSTLESGTPSRFSGSGSGRDYSFSISNVESGDVASYYCLQYDDLPYTF GPGTKLELK CAR20-11 997 DIVMTQTPSSQAVSAGEKVTMSCKSSQSLLYSENKKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQ YYNFPPWTFGGGTKLELKCAR20-12  998 QVVLTQPKSVSTSLESTVKLSCKINSGNIGSYFIHWYQQHEGRSPTTMIYRDDKRPHGVPDRFSGSIDSSSNSAFLTINNVQTEDEAIYFCHSYDSGIN IVFGGGTKLTVL CAR20-13 999 DVQMTQSPSLLSASVGDAVTINCKASQNINRYLNWYQQKLGEGPRLLIYSANSLQTGIPSRFSGSGSGADFTLTITSPQPEDVATYFCLQHNSWPLTF GSGTKLEIK CAR20-141000 DIQMTQSPSFLSASVGDRVTINCKASQNINRYLNWYQQKLGEAPKLLIYNANSLQTGIPSRFSGSGSGTDFTLTISSLQPADVATYFCLQHNSRPLTF GSGTILEIK CAR20-151001 KIVLTQSPTITAASPGEKVTITCLASSRVSNIYWYQQKSGASPKLLIYSTSSLASGVPYRFSGSGSGTSYSLTINTMEAEDAATYYCHQWSSNPWTFGG GTKLELK CAR20-16 1002NIQLTQSPSRLSASVGDRVTLSCKGSQNINNYLAWYQQKLGEAPKLLIYNTNNLQTGIPSRFSGSGSGTDYTFTISGLQPEDVATYFCCQYNNGNTF GAGTKLELK

TABLE 15B Light Chain Variable Regions of HumanizedCD20 antibody molecules SEQ  ID Candidate NO:Light Chain Variable region CD20- 1003DIQMTQSPSSLSASVGDRVTITCKSSQSLLYSENKKNYLAWYQQK 3_VK1_A20PGKVPKLLIFWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDVATY YCQQYYNFPTFGQGTKLEIKCD20- 1004 EIVMTQSPATLSLSPGERATLSCKSSQSLLYSENKKNYLAWYQQK 3_VK3_L25PGQAPRLLIFWASTRESGIPARFSGSGSGTDFTLTISSLQPEDLAVY YCQQYYNFPTFGQGTKLEIKCD20-3_VL M 1005 DIVMTQTPLSLSVTPGQPVSMSCKSSQSLLYSENKKNYLAWYLQK and CD20-PGQSPQLLIFWASTRESGVPDRFSGSGSGTDFTLKISRVEAEDVGV 3_VL JYYCQQYYNFPTFGQGTKLEIK

In some embodiments, the antigen binding domain comprises a HC CDR1, aHC CDR2, and a HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 14A or 14B. In embodiments, the antigenbinding domain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. Inembodiments, the antigen binding domain comprises a LC CDR1, a LC CDR2,and a LC CDR3 of any light chain binding domain amino acid sequenceslisted in Table 15A or 15B.

In some embodiments, the antigen binding domain comprises one, two orall of LC CDR1, LC CDR2, and LC CDR3 of any light chain binding domainamino acid sequences listed in Table 15A or 15B, and one, two or all ofHC CDR1, HC CDR2, and HC CDR3 of any heavy chain binding domain aminoacid sequences listed in Table 14A or 14B.

In some embodiments, the CDRs are defined according to the Kabatnumbering scheme, the Chothia numbering scheme, or a combinationthereof.

CAR123 Constructs

Anti-CD123 single chain variable fragments were isolated. Anti-CD123scFvs were cloned into lentiviral CAR expression vectors with theCD3zeta chain and the 4-1BB costimulatory molecule. CAR-containingplasmids were amplified by bacterial transformation in STBL3 cells,followed by Maxiprep using endotoxin-free Qiagen Plasmid Maki kit.Lentiviral supernatant was produced in 293T cells using standardtechniques.

The sequences of the CARs are provided below in Table 16. Additionalcomponents of CARs (e.g., leader, hinge, transmembrane, and signallingdomains) are described herein.

The order in which the VL and VH domains appear in the scFv was varied(i.e., VL-VH, or VH-VL orientation), and where either three or fourcopies of the “G4S” (SEQ ID NO:18) subunit, in which each subunitcomprises the sequence GGGGS (SEQ ID NO:18) (e.g., (G4S)₃ (SEQ IDNO:107) or (G4S)₄ (SEQ ID NO:10⁶)), connect the variable domains tocreate the entirety of the scFv domain.

The sequences of the human CARs are provided below in Table 16.

These clones all contained a Q/K residue change in the signal domain ofthe co-stimulatory domain derived from CD3zeta chain.

TABLE 16 Human CD123 CAR Constructs SEQ Name  ID Sequence CAR123-1 1123atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc NTtcggccccaagtccaactcgtccagtcaggagcggaagtcaagaagcccggagcgtcagtcaaagtgtcatgcaaagcctcgggctacactttcactgggtactacatgcactgggtgcgccaggctccaggacagggactggaatggatgggatggatcaacccgaactccggtggcaccaattacgcccagaagttccaggggagggtgaccatgactcgcgacacgtcgatcagcaccgcatacatggagctgtcaagactccggtccgacgatactgccgtgtactactgcgcacgggacatgaacattctggccaccgtgccttttgacatctggggtcagggaactatggttaccgtgtcctctggtggaggcggctccggcggggggggaagcggaggcggtggaagcgacattcagatgacccagtcgccttcatccctttcggcgagcgtgggagatcgcgtcactatcacttgtcgggcctcgcagtccatctccacctacctcaattggtaccagcagaagccaggaaaagcaccgaatctgctgatctacgccgcgttttccttgcaatcgggagtgccaagcagattcagcggatcgggatcaggcactgatttcaccctcaccatcaactcgctgcaaccggaggatttcgctacgtactattgccaacaaggagacagcgtgccgctcaccttcggcggagggactaagctggaaatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgc ctcgg CAR123-11124 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAP AAGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPNLLIYAAFSLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQGDSVPLTFGGGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CAR123-1 1125MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAP scFvGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPNLLIYAAFSLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQGDSVPLTFGGGTKLEIK CAR123-1 1126QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQ VHKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSS CAR123-11127 DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPNLLIYAAFSLQSGVPSRF VLSGSGSGTDFTLTINSLQPEDFATYYCQQGDSVPLTFGGGTKLEIK CAR123-2 1128atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcc NTccaagtgcaactcgtccaaagcggagcggaagtcaagaaacccggagcgagcgtgaaagtgtcctgcaaagcctccggctacacctttacgggctactacatgcactgggtgcgccaggcaccaggacagggtcttgaatggatgggatggatcaaccctaattcgggcggaactaactacgcacagaagttccaggggagagtgactctgactcgggatacctccatctcaactgtctacatggaactctcccgcttgcggtcagatgatacggcagtgtactactgcgcccgcgacatgaatatcctggctaccgtgccgttcgacatctggggacaggggactatggttactgtctcatcgggcggtggaggttcaggaggaggcggctcgggaggcggaggttcggacattcagatgacccagtccccatcctctctgtcggccagcgtcggagatagggtgaccattacctgtcgggcctcgcaaagcatctcctcgtacctcaactggtatcagcaaaagccgggaaaggcgcctaagctgctgatctacgccgcttcgagcttgcaaagcggggtgccatccagattctcgggatcaggctcaggaaccgacttcaccctgaccgtgaacagcctccagccggaggactttgccacttactactgccagcagggagactccgtgccgcttactttcggggggggtacccgcctggagatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR123-2 1129MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAP AAGQGLEWMGWINPNSGGTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTRLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CAR123-2 1130MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAP scFvGQGLEWMGWINPNSGGTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTRLEIK CAR123-2 1131QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQ VHKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSS CAR123-21132 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRF VLSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTRLEIK CAR123-3 1133atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggcc NTccaagtccaactcgttcaatccggcgcagaagtcaagaagccaggagcatcagtgaaagtgtcctgcaaagcctcaggctacatcttcacgggatactacatccactgggtgcgccaggctccgggccagggccttgagtggatgggctggatcaaccctaactctgggggaaccaactacgctcagaagttccaggggagggtcactatgactcgcgatacctccatctccactgcgtacatggaactctcgggactgagatccgacgatcctgccgtgtactactgcgcccgggacatgaacatcttggcgaccgtgccgtttgacatttggggacagggcaccctcgtcactgtgtcgagcggtggaggaggctcggggggtggcggatcaggagggggaggaagcgacatccagctgactcagagcccatcgtcgttgtccgcgtcggtgggggatagagtgaccattacttgccgcgccagccagagcatctcatcatatctgaattggtaccagcagaagcccggaaaggccccaaaactgctgatctacgctgcaagcagcctccaatcgggagtgccgtcacggttctccgggtccggttcgggaactgactttaccctgaccgtgaattcgctgcaaccggaggatttcgccacgtactactgtcagcaaggagactccgtgccgctgaccttcggtggaggcaccaaggtcgaaatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg CAR123-3 1134MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYIHWVRQAP AAGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSGLRSDDPAVYYCARDMNILATVPFDIWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR CAR123-3 1135MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYIHWVRQAP scFvGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSGLRSDDPAVYYCARDMNILATVPFDIWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTKVEIK CAR123-3 1136QVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYIHWVRQAPGQGLEWMGWINPNSGGTNYAQ VHKFQGRVTMTRDTSISTAYMELSGLRSDDPAVYYCARDMNILATVPFDIWGQGTLVTVSS CAR123-31137 DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRF VLSGSGSGTDFTLTVNSLQPEDFATYYCQQGDSVPLTFGGGTKVEIK CAR123-4 1138atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgc NTtcggccccaagtccaactccaacagtcaggcgcagaagtgaaaaagagcggtgcatcggtgaaagtgtcatgcaaagcctcgggctacaccttcactgactactatatgcactggctgcggcaggcaccgggacagggacttgagtggatgggatggatcaacccgaattcaggggacactaactacgcgcagaagttccaggggagagtgaccctgacgagggacacctcaatttcgaccgtctacatggaattgtcgcgcctgagatcggacgatactgctgtgtactactgtgcccgcgacatgaacatcctcgcgactgtgccttttgatatctggggacaggggactatggtcaccgtttcctccgcttccggtggcggaggctcgggaggccgggcctccggtggaggaggcagcgacatccagatgactcagagcccttcctcgctgagcgcctcagtgggagatcgcgtgaccatcacttgccgggccagccagtccatttcgtcctacctcaattggtaccagcagaagccgggaaaggcgcccaagctcttgatctacgctgcgagctccctgcaaagcggggtgccgagccgattctcgggttccggctcgggaaccgacttcactctgaccatctcatccctgcaaccagaggactttgccacctactactgccaacaaggagattctgtcccactgacgttcggcggaggaaccaaggtcgaaatcaagaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccc tgccgcctcggCAR123-4 1139MALPVTALLLPLALLLHAARPQVQLQQSGAEVKKSGASVKVSCKASGYTFTDYYMHWLRQAP AAGQGLEWMGWINPNSGDTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSASGGGGSGGRASGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSVPLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCK CAR123-4 1140MALPVTALLLPLALLLHAARPQVQLQQSGAEVKKSGASVKVSCKASGYTFTDYYMHWLRQAP scFvGQGLEWMGWINPNSGDTNYAQKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSSASGGGGSGGRASGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDSVPLTFGGGTKVEIK CAR123-4 1141QVQLQQSGAEVKKSGASVKVSCKASGYTFTDYYMHWLRQAPGQGLEWMGWINPNSGDTNYAQ VHKFQGRVTLTRDTSISTVYMELSRLRSDDTAVYYCARDMNILATVPFDIWGQGTMVTVSS CAR123-41142 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRF VLSGSGSGTDFTLTISSLQPEDFATYYCQQGDSVPLTFGGGTKVEIK

In some embodiments, the antigen binding domain comprises a HC CDR1, aHC CDR2, and a HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 16. In embodiments, the antigen binding domainfurther comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments,the antigen binding domain comprises a LC CDR1, a LC CDR2, and a LC CDR3of any light chain binding domain amino acid sequences listed in Table16.

In some embodiments, the antigen binding domain comprises one, two orall of LC CDR1, LC CDR2, and LC CDR3 of any light chain binding domainamino acid sequences listed in Table 16, and one, two or all of HC CDR1,HC CDR2, and HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 16.

In some embodiments, the CDRs are defined according to the Kabatnumbering scheme, the Chothia numbering scheme, or a combinationthereof.

The sequences of human CDR sequences of the scFv domains are shown inTable 17 for the heavy chain variable domains and in Table 18 for thelight chain variable domains. “ID” stands for the respective SEQ ID NOfor each CDR.

TABLE 17 Heavy Chain Variable Domain CDRs SEQ SEQ SEQ ID ID ID CandidateHCDR1 NO: HCDR2 NO: HCDR3 NO: CAR123-1 GYTFTDYYMH 1006 WINPNSGDTNYAQKFQG1010 DMNILATVPFDI 1014 CAR123-2 GYTFTGYYMH 1007 WINPNSGGTNYAQKFQG 1011DMNILATVPFDI 1015 CAR123-3 GYTFTGYYMH 1008 WINPNSGGTNYAQKFQG 1012DMNILATVPFDI 1016 CAR123-4 GYIFTGYYIH 1009 WINPNSGGTNYAQKFQG 1013DMNILATVPFDI 1017

TABLE 18 Light Chain Variable Domain CDRs SEQ ID SEQ ID SEQ ID CandidateLCDR1 NO: LCDR2 NO: LCDR3 NO: CAR123-1 RASQSISSYLN 1018 AASSLQS 1022QQGDSVPLT 1026 CAR123-2 RASQSISTYLN 1019 AAFSLQS 1023 QQGDSVPLT 1027CAR123-3 RASQSISSYLN 1020 AASSLQS 1024 QQGDSVPLT 1028 CAR123-4RASQSISSYLN 1021 AASSLQS 1025 QQGDSVPLT 1029

In an embodiment, the B-cell inhibitor comprises a CD123 CAR whichcomprises an antibody or antibody fragment which includes a CD123binding domain, wherein said CD123 binding domain comprises one or moreof light chain complementarity determining region 1 (LC CDR1), lightchain complementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) amino acid sequencelisted in Table 18, and one or more of heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3) of any CD123 heavy chain binding domain amino acid sequencelisted in Table 17.

Additional CD123 CDR sequences of the scFv domains are shown in Tables19, 21, and 23 for the heavy chain variable domains and in Tables 20,22, and 24 for the light chain variable domains. “ID” stands for therespective SEQ ID NO for each CDR.

The CDRs provided in Tables 19 and 20 are according to a combination ofthe Kabat and Chothia numbering scheme.

TABLE 19 Heavy Chain Variable Domain CDRs SEQ SEQ SEQ ID ID ID CandidateHCDR1 NO: HCDR2 NO: HCDR3 NO: CAR123-1 GYTFTDYYMH 1030 WINPNSGDTNYAQKFQG1034 DMNILATVPFDI 1038 CAR123-2 GYTFTGYYMH 1031 WINPNSGGTNYAQKFQG 1035DMNILATVPFDI 1039 CAR123-3 GYIFTGYYIH 1032 WINPNSGGTNYAQKFQG 1036DMNILATVPFDI 1040 CAR123-4 GYTFTGYYMH 1033 WINPNSGGTNYAQKFQG 1037DMNILATVPFDI 1041

TABLE 20 Light Chain Variable Domain CDRs SEQ ID SEQ ID SEQ ID CandidateLCDR1 NO: LCDR2 NO: LCDR3 NO: CAR123-1 RASQSISTYLN 1042 AASSLQS 1046QQGDSVPLT 1050 CAR123-2 RASQSISSYLN 1043 AAFSLQS 1047 QQGDSVPLT 1051CAR123-3 RASQSISSYLN 1044 AASSLQS 1048 QQGDSVPLT 1052 CAR123-4RASQSISSYLN 1045 AASSLQS 1049 QQGDSVPLT 1053

In an embodiment, the B-cell inhibitor comprises a CD123 CAR whichcomprises an antibody or antibody fragment which includes a CD123binding domain, wherein said CD123 binding domain comprises one or moreof light chain complementarity determining region 1 (LC CDR1), lightchain complementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) amino acid sequencelisted in Table 20, and one or more of heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3) of any CD123 heavy chain binding domain amino acid sequencelisted in Table 19.

TABLE 21 Heavy Chain Variable Domain CDRs according to the Kabatnumbering scheme (Kabat et al. (1991), “Sequences ofProteins of Immunological Interest” 5th Ed. PublicHealth Service, National Institutes of Health, Bethesda, MD) SEQ SEQ SEQID ID ID Candidate HCDR1 NO: HCDR2 NO: HCDR3 NO: CAR123-1 GYYMH 1054WINPNSGGTNYAQKFQG 1058 DMNILATVPFDI 1062 CAR123-2 GYYMH 1055WINPNSGGTNYAQKFQG 1059 DMNILATVPFDI 1063 CAR123-3 GYYIH 1056WINPNSGGTNYAQKFQG 1060 DMNILATVPFDI 1064 CAR123-4 DYYMH 1057WINPNSGDTNYAQKFQG 1061 DMNILATVPFDI 1065

TABLE 22 Light Chain Variable Domain CDRs according tothe Kabat numbering scheme (Kabat et al. (1991),“Sequences of Proteins of Immunological Interest” 5th Ed. Public Health Service, NationalInstitutes of Health, Bethesda, MD) SEQ ID SEQ ID SEQ ID Candidate LCDR1NO: LCDR2 NO: LCDR3 NO: CAR123-1 RASQSISTYLN 1066 AAFSLQS 1070 QQGDSVPLT1074 CAR123-2 RASQSISSYLN 1067 AASSLQS 1071 QQGDSVPLT 1075 CAR123-3RASQSISSYLN 1068 AASSLQS 1072 QQGDSVPLT 1076 CAR123-4 RASQSISSYLN 1069AASSLQS 1073 QQGDSVPLT 1077

In an embodiment, the B-cell inhibitor comprises a CD123 CAR whichcomprises an antibody or antibody fragment which includes a CD123binding domain, wherein said CD123 binding domain comprises one or moreof light chain complementarity determining region 1 (LC CDR1), lightchain complementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) amino acid sequencelisted in Table 22, and one or more of heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3) of any CD123 heavy chain binding domain amino acid sequencelisted in Table 21.

TABLE 23 Heavy Chain Variable Domain CDRs according tothe Chothia numbering scheme (Al-Lazikani etal., (1997) JMB 273, 927-948) SEQ SEQ SEQ Can- ID ID ID didate HCDR1 NO:HCDR2 NO: HCDR3 NO: CAR123-1 GYTFTGY 1078 NPNSGG 1082 DMNILATVPFDI 1086CAR123-2 GYTFTGY 1079 NPNSGG 1083 DMNILATVPFDI 1087 CAR123-3 GYIFTGY1080 NPNSGG 1084 DMNILATVPFDI 1088 CAR123-4 GYTFTDY 1081 NPNSGD 1085DMNILATVPFDI 1089

TABLE 24 Light Chain Variable Domain CDRs accordingto the Chothia numbering scheme (Al-Lazikaniet al., (1997) JMB 273, 927-948) SEQ SEQ SEQ ID ID ID Candidate LCDR1NO: LCDR2 NO: LCDR3 NO: CAR123-1 SQSISTY 1090 AAF 1094 GDSVPL 1098CAR123-2 SQSISSY 1091 AAS 1095 GDSVPL 1099 CAR123-3 SQSISSY 1092 AAS1096 GDSVPL 1100 CAR123-4 SQSISSY 1093 AAS 1097 GDSVPL 1101

In an embodiment, the B-cell inhibitor comprises a CD123 CAR whichcomprises an antibody or antibody fragment which includes a CD123binding domain, wherein said CD123 binding domain comprises one or moreof light chain complementarity determining region 1 (LC CDR1), lightchain complementarity determining region 2 (LC CDR2), and light chaincomplementarity determining region 3 (LC CDR3) amino acid sequencelisted in Table 24, and one or more of heavy chain complementaritydetermining region 1 (HC CDR1), heavy chain complementarity determiningregion 2 (HC CDR2), and heavy chain complementarity determining region 3(HC CDR3) of any CD123 heavy chain binding domain amino acid sequencelisted in Table 23.

Additional description of these CD123 CARs is provided, for instance, inPCT/CN2014/090508, which application incorporated by reference herein inits entirety.

Human anti-CD123 CAR constructs were evaluated for activity using aJurkat cell line containing the luciferase reporter driven by the NFATpromoter (termed JNL cells). CD123 CAR activity was measured for fourhuman CAR constructs described herein (CD123 CAR1-4) and murine CD123CAR constructs 1172 and 1176. CAR activity was measured as activation ofthis NFAT-driven reporter. Lentiviral supernatants containing the CARTconstructs were added to JNL cells for transduction. 4-6 days aftertransduction, JNL cells were either evaluated for CAR expression by FACSas described below or mixed with target-positive (MOLM3, K562 cellsengineered to express CD123 (CD123-K562)) or target-negative (K562) celllines at an effector (JNL) to target cell line (E:T) ratio of 3:1 totrigger activation (FIG. 41 ). After 20 hours of co-incubation,luciferase signal was measured using the Bright-Glo™ Luciferase Assay onthe EnVision instrument as shown in FIGS. 42A, 42B and 42C.

Optimal anti-CD123 CAR constructs were selected based on the quantityand quality of the effector T cell responses of CD123 CAR transduced Tcells (“CART-CD123” or “CART-CD123 T cells”) in response to CD123expressing (“CD123+”) targets. Effector T cell responses include, butare not limited to, cellular expansion, proliferation, doubling,cytokine production and target cell killing or cytolytic activity(degranulation).

Generation of CART-CD123

The human scFv encoding lentiviral transfer vectors were used to producethe genomic material packaged into the VSVg pseudotyped lentiviralparticles. Lentiviral transfer vector DNA was mixed with the threepackaging components of VSVg, gag/pol and rev in combination withlipofectamine reagent to transfect them together in to Lenti-X 293Tcells (Clontech).

After 30 hours, the media was collected, filtered and stored at −80 C.The therapeutic CART-CD123 were generated by starting with the bloodfrom a normal apheresed donor whose naïve T cells were obtained bynegative selection for T cells, CD4+ and CD8+ lymphocytes. These cellswere activated by CD3×28 beads (Dynabeads® Human T-Expander CD3/CD28,Invitrogen) at a ratio of 1:3 in RPMI 1640, 10% heat-inactivated fetalcalf serum (FCS), 2 mM L-glutamine, 1× Penicillin/Streptomycin, 100 μMnon-essential amino acids, 1 mM NaPyruvate, 10 mM Hepes, and 55 μM2-mercaptoethanol at 37° C., 5% CO₂. T cells were cultured at 1×10⁶ Tcells in 0.5 mL medium per well of a 24-well plate. After 24 hours, theT cells was blasting and 0.5 mL of viral supernatant was added. The Tcells then began to divide in a logarithmic growth pattern, which wasmonitored by measuring the cell counts per mL, and T cells were dilutedin fresh medium every two days. As the T cells began to rest down afterapproximately 10 days, the logarithmic growth waned. The combination ofslowing growth rate and T cell size approaching ˜300 fl determined thestate for T cells to be cryopreserved for later analysis.

Before cryopreserving, percentage of cells transduced (expressing theanti-CD123 CAR on the cell surface) and their relative fluorescenceintensity of expression were determined by flow cytometric analysis on aBD LSRFortessa or BD-FACSCanto using Protein L as a detection reagent.Gating histogram plots of relative fluorescent intensity from that FACSfor signal above unstained cells demonstrated the percentage oftransduced T cells. Transduction resulted in a range of CART positivecells from 12-42% as shown in FIGS. 42A, 42B and 42C.

Evaluating Cytolytic Activity of CART-CD123 Redirected T Cells.

To evaluate the functional abilities of CART-CD123 T cells to killtarget expressing cells, the cells were thawed and allowed to recoverovernight.

T cell killing was directed towards CD123-expressing MOLM13 acutemyelogenous leukemia cell lines stably expressing luciferase.Untransduced T cells were used to determine non-specific backgroundkilling levels. The cytolytic activities of CART-CD123 were measured asa titration of effector:target cell ratios of 4:1 and 2-fold downwarddilutions of T cells where effectors were defined as T cells expressingthe anti-CD123 chimeric receptor. Assays were initiated by mixing anappropriate number of T cells with a constant number of targets cells.After 20 hours luciferase signal was measured using the Bright-Glo™Luciferase Assay on the EnVision instrument. As the proportion ofCD123-CART-expressing cells to untransduced T cells was increased,killing of CD123 cells was similarly increased. The data presentedherein suggest that those cells expressing CD123 are destroyed only byCD123-CART-expressing cells and not by untransduced T cells. FIGS. 43Aand 43B.

T Cell Transduction

Human anti-human CD123 clones NVS 2 (expressing CAR123-2), NVS 3(expressing CAR123-3), NVS 4 (expressing CAR123-4) were selected forfurther study. These clones were all cross-reactive against cynomolgusCD123. Their activity was compared against mouse clones 1172 and 1176,comprising the VH and VL domains in a light-to-heavy orientation with aCD8 hinge domain, CD8 transmembrane domain, and 41BB-costimulatorydomain. 1176 is also cross-reactive against cynomolgus CD123. 1172 isnot.

Plasmids were transformed into competent cells, grown in 500 cc broth,isolated by maxiprep, and transduced using standard methods into 293Tcells. Lentiviral supernatant was collected at 24 and 48 hours,concentrated using ultracentrifugation, and frozen.

The lentivirus was titered on SupT1 cells and the appropriate amount ofvirus was determined for a transduction of primary T cells at a MOI of3. Primary normal donor CD4+CD8 cells were stimulated usinganti-CD3/CD28 beads (Dynal, Invitrogen) and interleukin-2 100 U/ml for 6days, followed by debeading and were and frozen once. The T cellcellular volume decreased to <300 fL (after approximately 10-12 days).

T cell transduction efficiency was virtually 100% for all clones (FIGS.44A and 44B). CD4:CD8 ratios were approximately 1:1 in the NVS clones,and 3:2 in the 1172 and 1176 clones (FIG. 45 ).

Degranulation

To assess degranulation, CART cells (NVS 2-4, 1172 and 1176 clones) werethawed, rested overnight at a concentration of 2e⁶ cells/ml in T cellmedia. Cells were then counted and resuspended at 1e⁶ cells/ml thefollowing day. Tumor target cells (TCM, PMA/iono, MOLM14 or JURKAT) wereresuspended at 5e⁶ cells/ml. Cells were plated at a ratio of 1e⁵ Tcell:5e⁵ tumor cell in 48 well plates and incubated for 2 hours in thepresence of anti-CD107a PECy7, anti-CD49d purified, and anti-CD28purified antibodies. Cells were then harvested, stained with anti-CD3APC and acquired using BD LSR Fortessa (FIGS. 46A, 46B and 46C).

T cell degranulation is indicated in the upper right quadrant of eachplot of FIGS. 46A, 46B and 46C. The results presented herein demonstratesimilar T cell recognition of CD123+ targets, manifested by similardegranulation during a 2-hr in vitro assay. C1176 had inferiordegranulation of 65% compared with approximately 80% in the otherclones.

Cytotoxicity

To assess cytotoxicity, CART cells (NVS 2-4, 1172 and 1176 clones) werethawed and rested overnight at 2e⁶ cells/ml in T cell media. Cells werecounted and resuspended at 1e⁶ cells/ml the following day. Tumor targetcells (MOLM14) were resuspended at 1e⁶ cells/ml. Cells were plated in ablack, flat-bottom 96 well plate at decreasing E:T ratios as indicated(FIG. 47 ), in duplicate. After 20 hours of incubation, luciferin wasadded and the plate was imaged to determine photon flux as a measure ofresidual live cells. Killing of MOLM14 cells was equivalent between allclones at most effector:target ratios at 20 hours.

In Vivo Mouse Model

NSG mice were injected iv with 1e⁶ luciferase expressing MOLM14 cells onDO. On D6 mice were imaged (IVIS Spectrum) for tumor burden andrandomized into treatment groups. Mice with the lowest tumor burden wereassigned to the control group (untransduced T cells, UTD). CART cells(NVS 2-4, 1172 and 1176 clones) or control T cells (1e⁶) were injectedi.v. on D7. Data from imaging on performed D13 is shown in FIG. 48 . Sixdays after injection, all anti-CD123 constructs provided equalanti-tumor effect, consistent with in vitro data.

Humanized anti-CD123 single chain variable fragments (scFv) based onmurine 1176 which is cross-reactive against cynomolgus CD123 aregenerated and cloned into a lentiviral expression vector with theintracellular CD3zeta chain and the intracellular co-stimulatory domainof 4-1BB.

The order in which the VL and VH domains appear in the scFv was varied(i.e., VL-VH, or VH-VL orientation), and where either three or fourcopies of the “G4S” (SEQ ID NO:18) subunit, in which each subunitcomprises the sequence GGGGS (SEQ ID NO:18) (e.g., (G4S)₃ (SEQ IDNO:107) or (G4S)₄ (SEQ ID NO:106)), connect the variable domains tocreate the entirety of the scFv domain, as shown in Table 25.

The sequences of the humanized CARs are provided below in Table 25.

These clones all contained a Q/K residue change in the signal domain ofthe co-stimulatory domain derived from CD3zeta chain.

TABLE 25 Humanized CD123 CAR Constructs SEQ Name ID Sequence hzCAR123-11143 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGC NTTCGGCCCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctc gg hzCAR123-11144 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMN AAWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR hzCAR123-1 1145MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAP scFvGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-1 1146QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-1 1147DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-2 1148ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGC NTTCGGCCCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctc gg hzCAR123-21149 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQ AAAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-2 1150MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQ scFvAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-2 1151QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-2 1152EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-3 1153ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-3 1154MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQ AAAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-3 1155MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQ scFvAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-3 1156QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-3 1157DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-4 1158ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-4 1159MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQ AAAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-4 1160MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQ scFvAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-4 1161QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-4 1162DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-5 1163ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-5 1164MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK AAPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-5 1165MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK scFvPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-5 1166QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-5 1167DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-6 1168ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-6 1169MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK AAPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-6 1170MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK scFvPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-6 1171QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-6 1172EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-7 1173ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-7 1174MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK AAPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-7 1175MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK scFvPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-7 1176QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-7 1177DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-8 1178ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTCCAGTCGGGAGCCGAAGTCAAGAAGCCCGGCGCTAGCGTGAAAGTGTCCTGCAAAGCCTCCGGGTACACATTCACCTCCTACTGGATGAATTGGGTCAGACAGGCGCCCGGCCAGGGACTCGAGTGGATGGGAAGGATTGATCCTTACGACTCCGAAACCCATTACAACCAGAAGTTCAAGGACCGCGTGACCATGACTGTGGATAAGTCCACTTCCACCGCTTACATGGAGCTGTCCAGCCTGCGCTCCGAGGATACCGCAGTGTACTACTGCGCCCGGGGAAACTGGGACGACTATTGGGGACAGGGAACTACCGTGACCGTGTCAAGCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-8 1179MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK AAPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-8 1180MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK scFvPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-8 1181QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-8 1182DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-9 1183ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-9 1184MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ AAAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-9 1185MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ scFvAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-9 1186QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-10 1187DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-10 1188ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-10 1189MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ AAAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-10 1190MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ scFvAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-10 1191QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-10 1192EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-11 1193ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-11 1194MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ AAAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-11 1195MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ scFvAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-11 1196QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-11 1197DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-12 1198ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-12 1199MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ AAAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-12 1200MALPVTALLLPLALLLHAARPQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQ scFvAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-12 1201QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-12 1202DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-13 1203ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-13 1204MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK AAPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-13 1205MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK scFvPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-13 1206QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-13 1207DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-14 1208ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-14 1209MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK AAPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-14 1210MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK scFvPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-14 1211QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-14 1212EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-15 1213ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-15 1214MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK AAPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-15 1215MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK scFvPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-15 1216QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-15 1217DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-16 1218ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCCAAGTGCAGCTGGTGCAGTCAGGCAGCGAACTGAAGAAGCCCGGAGCCTCCGTCAAAGTGTCCTGCAAAGCCTCGGGATACACCTTCACCTCCTACTGGATGAACTGGGTCCGCCAGGCACCTGGACAGGGGCTGGAGTGGATGGGAAGGATCGATCCCTACGATTCCGAAACCCATTACAATCAGAAGTTCAAGGACCGGTTTGTGTTCTCCGTGGACAAGTCCGTGTCCACCGCCTACCTCCAAATTAGCAGCCTGAAGGCGGAGGATACAGCTGTCTACTACTGCGCTCGCGGAAACTGGGATGACTATTGGGGCCAGGGAACTACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-16 1219MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK AAPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-16 1220MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK scFvPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSQVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-16 1221QVQLVQSGSELKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYNQ VHKFKDRFVFSVDKSVSTAYLQISSLKAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-16 1222DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-17 1223ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-17 1224MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ AAMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-17 1225MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ scFvMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-17 1226EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-17 1227DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-18 1228ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-18 1229MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ AAMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-18 1230MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ scFvMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-18 1231EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-18 1232EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-19 1233ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-19 1234MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ AAMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-19 1235MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ scFvMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-19 1236EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-19 1237DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-20 1238ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-20 1239MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ AAMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-20 1240MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQ scFvMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-20 1241EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-20 1242DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-21 1243ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-21 1244MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK AAPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-21 1245MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK scFvPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-21 1246EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-21 1247DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-22 1248ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-22 1249MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK AAPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-22 1250MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK scFvPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-22 1251EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-22 1252EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-23 1253ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-23 1254MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK AAPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-23 1255MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK scFvPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-23 1256EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-23 1257DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-24 1258ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTCAAGAAGCCTGGAGAATCCCTGAGGATCAGCTGCAAAGGCAGCGGGTATACCTTCACCTCCTACTGGATGAATTGGGTCCGCCAGATGCCCGGAAAAGGCCTGGAGTGGATGGGACGGATTGACCCCTACGACTCGGAAACCCATTACAACCAGAAGTTCAAGGATCACGTGACCATCTCCGTGGACAAGTCCATTTCCACTGCGTACCTCCAGTGGTCAAGCCTGAAGGCCTCCGACACTGCTATGTACTACTGCGCACGCGGAAACTGGGATGATTACTGGGGACAGGGAACAACCGTGACTGTGTCCTCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-24 1259MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK AAPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-24 1260MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK scFvPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-24 1261EVQLVQSGAEVKKPGESLRISCKGSGYTFTSYWMNWVRQMPGKGLEWMGRIDPYDSETHYNQ VHKFKDHVTISVDKSISTAYLQWSSLKASDTAMYYCARGNWDDYWGQGTTVTVSS hzCAR123-24 1262DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-25 1263ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-25 1264MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ AAAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-25 1265MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ scFvAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-25 1266EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-25 1267DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-26 1268ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-26 1269MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ AAAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-26 1270MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ scFvAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-26 1271EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-26 1272EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-27 1273ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-27 1274MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ AAAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-27 1275MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ scFvAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-27 1276EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-27 1277DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-28 1278ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-28 1279MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ AAAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-28 1280MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQ scFvAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-28 1281EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-28 1282DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-29 1283ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGCAGCTCACCCAGTCGCCCTCATTTCTGTCGGCCTCAGTGGGAGACAGAGTGACCATTACTTGTCGGGCCTCCAAGAGCATCTCCAAGGACCTGGCCTGGTATCAGCAGAAGCCAGGAAAGGCGCCTAAGTTGCTCATCTACTCGGGGTCGACCCTGCAATCTGGCGTGCCGTCCCGGTTCTCCGGTTCGGGAAGCGGTACCGAATTCACCCTTACTATCTCCTCCCTGCAACCGGAGGACTTCGCCACCTACTACTGCCAACAGCACAACAAGTACCCGTACACTTTCGGGGGTGGCACGAAGGTCGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-29 1284MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK AAPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-29 1285MALPVTALLLPLALLLHAARPDVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQK scFvPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-29 1286EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-29 1287DVQLTQSPSFLSASVGDRVTITCRASKSISKDLAWYQQKPGKAPKLLIYSGSTLQSGVPSRF VLSGSGSGTEFTLTISSLQPEDFATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-30 1288ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGAAGTGGTGCTGACCCAGTCGCCCGCAACCCTCTCTCTGTCGCCGGGAGAACGCGCCACTCTTTCCTGTCGGGCGTCCAAGAGCATCTCAAAGGACCTCGCCTGGTACCAGCAGAAGCCTGGTCAAGCCCCGCGGCTGCTGATCTACTCCGGCTCCACGCTGCAATCAGGAATCCCAGCCAGATTTTCCGGTTCGGGGTCGGGGACTGACTTCACCTTGACCATTAGCTCGCTGGAACCTGAGGACTTCGCCGTGTATTACTGCCAGCAGCACAACAAGTACCCGTACACCTTCGGAGGCGGTACTAAGGTCGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-30 1289MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK AAPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-30 1290MALPVTALLLPLALLLHAARPEVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQK scFvPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-30 1291EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-30 1292EVVLTQSPATLSLSPGERATLSCRASKSISKDLAWYQQKPGQAPRLLIYSGSTLQSGIPARF VLSGSGSGTDFTLTISSLEPEDFAVYYCQQHNKYPYTFGGGTKVEIK hzCAR123-31 1293ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTCGTGATGACCCAGTCACCGGCATTCCTGTCCGTGACTCCCGGAGAAAAGGTCACGATTACTTGCCGGGCGTCCAAGAGCATCTCCAAGGACCTCGCCTGGTACCAACAGAAGCCGGACCAGGCCCCTAAGCTGTTGATCTACTCGGGGTCCACCCTTCAATCGGGAGTGCCATCGCGGTTTAGCGGTTCGGGTTCTGGGACCGACTTCACTTTCACCATCTCCTCACTGGAAGCCGAGGATGCCGCCACTTACTACTGTCAGCAGCACAACAAGTATCCGTACACCTTCGGAGGCGGTACCAAAGTGGAGATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-31 1294MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK AAPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-31 1295MALPVTALLLPLALLLHAARPDVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQK scFvPDQAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-31 1296EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-31 1297DVVMTQSPAFLSVTPGEKVTITCRASKSISKDLAWYQQKPDQAPKLLIYSGSTLQSGVPSRF VLSGSGSGTDFTFTISSLEAEDAATYYCQQHNKYPYTFGGGTKVEIK hzCAR123-32 1298ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGCCGCTCGGCC NTCGACGTGGTCATGACTCAGTCCCCGGACTCACTCGCGGTGTCGCTTGGAGAGAGAGCGACCATCAACTGTCGGGCCTCAAAGAGCATCAGCAAGGACCTGGCCTGGTACCAGCAGAAGCCGGGACAGCCGCCAAAGCTGCTGATCTACTCCGGGTCCACCTTGCAATCTGGTGTCCCTGACCGGTTCTCCGGTTCCGGGTCGGGTACCGACTTCACGCTCACTATTTCGTCGCTGCAAGCCGAAGATGTGGCCGTGTACTATTGCCAACAGCACAACAAGTACCCCTACACTTTTGGCGGAGGCACCAAGGTGGAAATCAAGGGGGGTGGCGGTAGCGGAGGAGGGGGCTCCGGCGGCGGCGGCTCAGGGGGCGGAGGAAGCGAAGTGCAGCTCGTCGAGAGCGGAGGGGGACTGGTGCAGCCCGGAGGAAGCCTGAGGCTGTCCTGCGCTGCCTCCGGCTACACCTTCACCTCCTACTGGATGAACTGGGTCAGACAGGCACCTGGAAAGGGACTGGTCTGGGTGTCGCGCATTGACCCCTACGACTCCGAAACCCATTACAATCAGAAATTCAAGGACCGCTTCACCATCTCCGTGGACAAAGCCAAGAGCACCGCGTACCTCCAAATGAACTCCCTGCGCGCTGAGGATACAGCAGTGTACTATTGCGCCCGGGGAAACTGGGATGATTACTGGGGCCAGGGAACTACTGTGACTGTGTCATCCACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccgcctcgg hzCAR123-32 1299MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK AAPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPRhzCAR123-32 1300MALPVTALLLPLALLLHAARPDVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQK scFvPGQPPKLLIYSGSTLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-32 1301EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMNWVRQAPGKGLVWVSRIDPYDSETHYNQ VHKFKDRFTISVDKAKSTAYLQMNSLRAEDTAVYYCARGNWDDYWGQGTTVTVSS hzCAR123-32 1302DVVMTQSPDSLAVSLGERATINCRASKSISKDLAWYQQKPGQPPKLLIYSGSTLQSGVPDRF VLSGSGSGTDFTLTISSLQAEDVAVYYCQQHNKYPYTFGGGTKVEIK

The sequences of humanized CDR sequences of the scFv domains of hzCD123CAR 1-32 are shown in Table 26 for the heavy chain variable domains andin Table 27 for the light chain variable domains. “ID” stands for therespective SEQ ID NO for each CDR.

TABLE 26 Heavy Chain Variable Domain CDR SEQ SEQ SEQ ID ID ID HCDR1 NO:HCDR2 NO: HCDR3 NO: hzCAR123 GYTFTSYWMN 1102 RIDPYDSETHYNQKFKD 1103GNWDDY 1104

TABLE 27 Light Chain Variable Domain CDR SEQ SEQ SEQ ID ID ID LCDR1 NO:LCDR2 NO: LCDR3 NO: hzCAR123 RASKSISKD 1105 SGSTLQS 1106 QQHNKYPYT 1107LA

In some embodiments, the CAR123 has a HCDR3 having the sequenceYCARGNWDDY (SEQ ID NO: 1529).

The CAR scFv fragments were then cloned into lentiviral vectors tocreate a full length CAR construct in a single coding frame, and usingthe EF1 alpha promoter for expression.

Bispecific CAR19/CAR22 Constructs and Function Thereof

This section describes the production and function of bispecificCAR19/CAR22 constructs. Two bispecific scFv tandem fusions weredesigned: antiCD22 (HL)4G4S-antiCD19 (LH) and antiCD19-4G4S-antiCD22.The designation (HL) indicates that the heavy chain variable region isupstream of the light chain region within the indicated scFv, and thedesignation (LH) indicates that the light chain variable region isupstream of the heavy chain region within the indicated scFv. Theanti-CD22 base molecule is hCD22-2, and uses the HL orientation. Theanti-CD19 base molecule is a humanized anti-CD19 sequence, providedherein as construct ID 104876 of Table 2, which uses the LH orientation.The constructs are illustrated schematically in FIG. 13 .

The nucleotide and amino acid sequences of both bispecific constructs,as well as the scFv portions thereof, are given below in Table 28.

TABLE 28 Bispecific CAR19/CAR22 constructs SEQ Name  ID NO SequenceantiCD22- 1303 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEW 4G4S-LGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYY antiCD19CARDLGWIAVAGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSQSALTQP scFv aminoASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKR acid sequencePSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSLNHVFGTGTKVTVLTGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS antiCD22- 1304EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEW CD19 CARLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYY amino acidCARDLGWIAVAGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSQSALTQP sequenceASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSLNHVFGTGTKVTVLTGGGGSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP PR antiCD22- 1305gaagtgcagctccaacagtcaggaccaggactcgtcaaaccctcccaaa 4G4S-ccctcagccttacttgtgccatttccggggattccgtgtcgagcaattc antiCD19cgccgcctggaactggatcaggcagtccccgtcgcgcgggctcgaatgg scFv nucleicctgggacgcacttactaccggtccaagtggtacaacgactacgccgtca sequencegcgtgaagtcgcggatcaccattaaccccgacacctccaagaaccagttcagcctccaactgaactccgtgacccctgaggataccgcggtctactattgtgcccgggacctgggttggattgccgtggccgggaccttcgattactggggccagggaactctcgtcaccgtgtcctcgggagggggtggctcagggggtggtggatcgggtggtggcggctcccagtccgctctgactcagcccgcgtccgtgtccggttccccgggacagtcgatcacaatcagctgcactggcacctcctccgacgtcggcgggtacaactacgtgtcgtggtaccaacagcaccctggaaaagccccgaagctgatgatctacgacgtgtccaagaggccaagcggagtgtcaaatcgcttttccggctcgaagtcgggaaacaccgccagcctgactatctcgggactgcaggccgaggacgaggccgactactactgctcgtcttacacctcctcatccttgaaccacgtgttcggaaccggaaccaaggtcaccgtgctgactggagggggaggctccggtggcggcggctctggaggaggagggtccggcggaggaggatcggaaatcgtgatgacccagtcccccgcaaccctgtccctgagcccgggcgaaagagctaccctgtcgtgccgggcgtcgcaggacatctccaagtacctgaactggtaccagcagaagcccggccaggcaccgagactgctgatctaccacactagccgcctgcattccggtatccccgcacggttcagcggcagcgggagcggaaccgattacacgctcactatttcctcactgcaacccgaggatttcgctgtgtacttctgccaacaaggaaacaccctgccttataccttcggacagggtacaaagctggagattaagggaggagggggctccggcggcgggggcagcgggggcggcggaagccaggtccagctgcaggaatccggtccgggactcgtgaagccctccgaaactctctcccttacgtgcaccgtgtcaggggtgtccctgccggactacggagtgtcctggattcggcaacctccggggaagggactggagtggatcggagtgatctggggctccgaaactacctactaccagtcatcattgaagtcaagagtgaccatttcgaaggacaacagcaagaaccaggtgtcccttaaactgtccagcgtgaccgcggcggatactgccgtctactactgcgccaagcactattactacggcggaagctatgcgatggactactggggacagggcaccttggtcactgtgtcctcc antiCD22- 1306gaagtgcagctccaacagtcaggaccaggactcgtcaaaccctcccaaa CD19 CARccctcagccttacttgtgccatttccggggattccgtgtcgagcaattc nucleic acidcgccgcctggaactggatcaggcagtccccgtcgcgcgggctcgaatgg sequencectgggacgcacttactaccggtccaagtggtacaacgactacgccgtcagcgtgaagtcgcggatcaccattaaccccgacacctccaagaaccagttcagcctccaactgaactccgtgacccctgaggataccgcggtctactattgtgcccgggacctgggttggattgccgtggccgggaccttcgattactggggccagggaactctcgtcaccgtgtcctcgggagggggtggctcagggggtggtggatcgggtggtggcggctcccagtccgctctgactcagcccgcgtccgtgtccggttccccgggacagtcgatcacaatcagctgcactggcacctcctccgacgtcggcgggtacaactacgtgtcgtggtaccaacagcaccctggaaaagccccgaagctgatgatctacgacgtgtccaagaggccaagcggagtgtcaaatcgcttttccggctcgaagtcgggaaacaccgccagcctgactatctcgggactgcaggccgaggacgaggccgactactactgctcgtcttacacctcctcatccttgaaccacgtgttcggaaccggaaccaaggtcaccgtgctgactggagggggaggctccggtggcggcggctctggaggaggagggtccggcggaggaggatcggaaatcgtgatgacccagtcccccgcaaccctgtccctgagcccgggcgaaagagctaccctgtcgtgccgggcgtcgcaggacatctccaagtacctgaactggtaccagcagaagcccggccaggcaccgagactgctgatctaccacactagccgcctgcattccggtatccccgcacggttcagcggcagcgggagcggaaccgattacacgctcactatttcctcactgcaacccgaggatttcgctgtgtacttctgccaacaaggaaacaccctgccttataccttcggacagggtacaaagctggagattaagggaggagggggctccggcggcgggggcagcgggggcggcggaagccaggtccagctgcaggaatccggtccgggactcgtgaagccctccgaaactctctcccttacgtgcaccgtgtcaggggtgtccctgccggactacggagtgtcctggattcggcaacctccggggaagggactggagtggatcggagtgatctggggctccgaaactacctactaccagtcatcattgaagtcaagagtgaccatttcgaaggacaacagcaagaaccaggtgtcccttaaactgtccagcgtgaccgcggcggatactgccgtctactactgcgccaagcactattactacggcggaagctatgcgatggactactggggacagggcaccttggtcactgtgtcctccaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccg cctcgg antiCD19- 1307EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIY 4G4S-HTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTF antiCD22GQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVS scFv aminoGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNS acid sequenceKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDLGWIAVAGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSLNHVFGTGTKVTVLT antiCD19- 1308EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIY 4G4S-HTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTF antiCD22GQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVS CAR aminoGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNS acid sequenceKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDLGWIAVAGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSLNHVFGTGTKVTVLTTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP PR antiCD19- 1309gaaatcgtgatgacccagtcccccgcaaccctgtccctgagcccgggcg 4G4S-aaagagctaccctgtcgtgccgggcgtcgcaggacatctccaagtacct antiCD22gaactggtaccagcagaagcccggccaggcaccgagactgctgatctac scFv nucleiccacactagccgcctgcattccggtatccccgcacggttcagcggcagcg acid sequenceggagcggaaccgattacacgctcactatttcctcactgcaacccgaggatttcgctgtgtacttctgccaacaaggaaacaccctgccttataccttcggacagggtacaaagctggagattaagggaggagggggctccggcggcgggggcagcgggggcggcggaagccaggtccagctgcaggaatccggtccgggactcgtgaagccctccgaaactctctcccttacgtgcaccgtgtcaggggtgtccctgccggactacggagtgtcctggattcggcaacctccggggaagggactggagtggatcggagtgatctggggctccgaaactacctactaccagtcatcattgaagtcaagagtgaccatttcgaaggacaacagcaagaaccaggtgtcccttaaactgtccagcgtgaccgcggcggatactgccgtctactactgcgccaagcactattactacggcggaagctatgcgatggactactggggacagggcaccttggtcactgtgtcctccggagggggaggctccggtggcggcggctctggaggaggagggtccggcggaggaggatcggaagtgcagctccaacagtcaggaccaggactcgtcaaaccctcccaaaccctcagccttacttgtgccatttccggggattccgtgtcgagcaattccgccgcctggaactggatcaggcagtccccgtcgcgcgggctcgaatggctgggacgcacttactaccggtccaagtggtacaacgactacgccgtcagcgtgaagtcgcggatcaccattaaccccgacacctccaagaaccagttcagcctccaactgaactccgtgacccctgaggataccgcggtctactattgtgcccgggacctgggttggattgccgtggccgggaccttcgattactggggccagggaactctcgtcaccgtgtcctcgggagggggtggctcagggggtggtggatcgggtggtggcggctcccagtccgctctgactcagcccgcgtccgtgtccggttccccgggacagtcgatcacaatcagctgcactggcacctcctccgacgtcggcgggtacaactacgtgtcgtggtaccaacagcaccctggaaaagccccgaagctgatgatctacgacgtgtccaagaggccaagcggagtgtcaaatcgcttttccggctcgaagtcgggaaacaccgccagcctgactatctcgggactgcaggccgaggacgaggccgactactactgctcgtcttacacctcctcatccttgaaccacgtgttcggaaccggaaccaaggtcaccgtgctgact antiCD19- 1310gaaatcgtgatgacccagtcccccgcaaccctgtccctgagcccgggcg 4G4S-aaagagctaccctgtcgtgccgggcgtcgcaggacatctccaagtacct antiCD22gaactggtaccagcagaagcccggccaggcaccgagactgctgatctac CAR nucleiccacactagccgcctgcattccggtatccccgcacggttcagcggcagcg acid sequenceggagcggaaccgattacacgctcactatttcctcactgcaacccgaggatttcgctgtgtacttctgccaacaaggaaacaccctgccttataccttcggacagggtacaaagctggagattaagggaggagggggctccggcggcgggggcagcgggggcggcggaagccaggtccagctgcaggaatccggtccgggactcgtgaagccctccgaaactctctcccttacgtgcaccgtgtcaggggtgtccctgccggactacggagtgtcctggattcggcaacctccggggaagggactggagtggatcggagtgatctggggctccgaaactacctactaccagtcatcattgaagtcaagagtgaccatttcgaaggacaacagcaagaaccaggtgtcccttaaactgtccagcgtgaccgcggcggatactgccgtctactactgcgccaagcactattactacggcggaagctatgcgatggactactggggacagggcaccttggtcactgtgtcctccggagggggaggctccggtggcggcggctctggaggaggagggtccggcggaggaggatcggaagtgcagctccaacagtcaggaccaggactcgtcaaaccctcccaaaccctcagccttacttgtgccatttccggggattccgtgtcgagcaattccgccgcctggaactggatcaggcagtccccgtcgcgcgggctcgaatggctgggacgcacttactaccggtccaagtggtacaacgactacgccgtcagcgtgaagtcgcggatcaccattaaccccgacacctccaagaaccagttcagcctccaactgaactccgtgacccctgaggataccgcggtctactattgtgcccgggacctgggttggattgccgtggccgggaccttcgattactggggccagggaactctcgtcaccgtgtcctcgggagggggtggctcagggggtggtggatcgggtggtggcggctcccagtccgctctgactcagcccgcgtccgtgtccggttccccgggacagtcgatcacaatcagctgcactggcacctcctccgacgtcggcgggtacaactacgtgtcgtggtaccaacagcaccctggaaaagccccgaagctgatgatctacgacgtgtccaagaggccaagcggagtgtcaaatcgcttttccggctcgaagtcgggaaacaccgccagcctgactatctcgggactgcaggccgaggacgaggccgactactactgctcgtcttacacctcctcatccttgaaccacgtgttcggaaccggaaccaaggtcaccgtgctgactaccactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctcttcacatgcaggccctgccg cctcgg

In some embodiments, the antigen binding domain comprises a HC CDR1, aHC CDR2, and a HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 28. In embodiments, the antigen binding domainfurther comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments,the antigen binding domain comprises a LC CDR1, a LC CDR2, and a LC CDR3of any light chain binding domain amino acid sequences listed in Table28.

In some embodiments, the antigen binding domain comprises one, two orall of LC CDR1, LC CDR2, and LC CDR3 of any light chain binding domainamino acid sequences listed in Table 28, and one, two or all of HC CDR1,HC CDR2, and HC CDR3 of any heavy chain binding domain amino acidsequences listed in Table 28.

In some embodiments, the CDRs are defined according to the Kabatnumbering scheme, the Chothia numbering scheme, or a combinationthereof.

The bispecific CD19-CD22 and CD22-CD19 constructs described above weretested in an NFAT assay, as described in the Examples below. Ascontrols, an anti-CD19 alone CAR and an anti-CD22 alone CAR were used.The results of this assay are shown in FIG. 14 . The data indicated thatboth anti-CD19 and anti-CD22 scFvs are active against their targets.

EXAMPLES

The invention is further described in detail by reference to thefollowing experimental examples. These examples are provided forpurposes of illustration only, and are not intended to be limitingunless otherwise specified. Thus, the invention should in no way beconstrued as being limited to the following examples, but rather, shouldbe construed to encompass any and all variations which become evident asa result of the teaching provided herein.

Without further description, it is believed that one of ordinary skillin the art can, using the preceding description and the followingillustrative examples, make and utilize the compounds of the presentinvention and practice the claimed methods. The following workingexamples specifically point out various aspects of the presentinvention, and are not to be construed as limiting in any way theremainder of the disclosure.

Example 1: CD19 CAR T Cells for Use in Treating Multiple Myeloma

Even with current regimens of chemotherapy, targeted therapies, andautologous stem cell transplant, myeloma is considered an incurabledisease. The present example describes treating multiple myeloma (MM)with autologous T cells directed to CD19 with a chimeric antigenreceptor (lentivirus/CD19:4-1BB:CD3zeta; also known as “CART19” orCTL019). This example demonstrates that CD19-directed CAR therapies havethe potential to establish deep, long-term durable remissions based ontargeting the myeloma stem cell and/or tumor cells that express very low(undetectable by most methods) levels of CD19.

In treating a patient with an aggressive secondary plasma cell leukemia,we found that CART19 administered two days after a salvage autologousstem cell transplant resulted in rapid clearance of plasma cell leukemiaand a very good partial response in a patient who had progressed throughmultiple lines of chemotherapy. This patient was transfusion-dependentfor months prior to the treatment; at two months after the treatment,she has recovered her blood counts (with normal-range platelet countsand white blood cell counts) and has not required transfusions since shewas discharged from the hospital from her treatment.

Because myeloma cells do not naturally express CD19, the finding thatCART19 treatment induced a rapid and significant tumor response in thistumor was surprising. Without wishing to be bound by a particulartheory, it was reasoned that CART19 could be used to treat myelomabecause: (1) while myeloma cells are traditionally thought to benegative for CD19 expression by flow cytometry, there are dataindicating that myeloma cells may express very low levels of CD19, suchthat expression is detectable by RNA but not by flow cytometry orimmunohistochemistry; and (2) the concept of targeting the clonotypic Bcell, which is thought to be the cancerous stem cell that gives rise tomultiple myeloma, and is particularly resistant to chemotherapy. Thereis a clonal relationship between B cells and myeloma tumor cells, buttraditional myeloma therapy is aimed at the malignant plasma cellsrather than B cells. CART19 for treating myeloma therefore targets adifferent cell population than most myeloma therapies.

In our single patient experience, the patient had circulating plasmacells, and we were able to test her tumor cells for the expression ofCD19. Approximately 1-2% of her tumor cells expressed the CD19 antigen.Thus, it was reasoned that CART19 may have a direct effect on a verysmall population of her tumor cells; a very good partial response,though would not have been predicted based on targeting only the verysmall population of CD19+ tumor cells.

In this case, CART19 was administered following autologous stem celltransplant rescue after high-dose melphalan. Although this is a standardtherapy in myeloma, it is not curative. Furthermore, this patient hadpreviously undergone tandem autologous stem cell transplants andrelapsed early (<6 months) after transplant. Without wishing to be boundby a particular theory, use of CART19 cells as described in the presentexample may have a non-overlapping mechanism in the treatment of myelomawhen combined with a salvage autologous stem cell transplant.

Ten additional multiple myeloma patients will be treated with CART19 ina Phase I trial, and at least three patients have been treated to date.

Dose Rationale and Risks/Benefits

We have chosen to use flat dosing via the intravenous route ofadministration for this protocol. The primary objective of this protocolwas to test the safety and feasibility of administering CART-19 cells topatients with multiple myeloma. The primary toxicities that wereanticipated are (I) cytokine release when the CARs encounter theirsurrogate CD 19 antigen on malignant or normal B cells; (2) depletion ofnormal B cells, similar to rituximab therapy; (3) steroid-responsiveskin and gastrointestinal syndromes resembling graft-versus-host diseaseas has been seen previously when expanded/costimulated autologousT-cells have been coupled with ASCT for MM. A theoretical concern waswhether transformation or uncontrolled proliferation of the CART-19 Tcells might occur in response to high levels of CD 19. This was less aconcern in this application compared to another study of CLL patients,as the burden of clonotypic B-cells in MM is expected to be far lowerthan the burden of malignant B-cells in the refractory CLL patientstreated on that study.

Dose Rationale

With the first 3 patients, we have observed clinical activity at dosesranging from 1.4×10⁷ to 1.1×10⁹ CART-19 cells. This observationdemonstrates, at least in the first 3 patients treated, that there isnot an obvious dose response relationship. A complete response wasobserved in patients administered with two log fold difference in dose.Thus, unlike standard drugs that are metabolized, CAR T cells can have awide dose response range. This is most likely because the CAR T cellsare able to proliferate extensively in the patients. We therefore set adose range of 1-5×10⁸ CART-19 cells for infusion. In this single-patientstudy offered on a compassionate use basis, the patient was offered upto 5×10⁸ CART19 cells, with no lower dose limit. For the ten patienttrial, patients will be offered 1-5×10⁷ CART-19 cells.

General Design

This was single patient-study offered on a compassionate use basis; itwas modeled after a Phase I study to determine if the infusion ofautologous T cells transduced to express CART-19 is safe. The primarygoals of the study were to determine the safety, tolerability andengraftment potential of CART-19 T cells in patients undergoing salvageASCT after early relapse following first ASCT. The protocol consists ofan open label pilot study.

At entry subjects will undergo a bone marrow biopsy and routinelaboratory and imaging assessment of their MM. Eligible subjects willundergo steady-state apheresis to obtain large numbers of peripheralblood mononuclear cells (PBMC) for CART-19 manufacturing. The T cellswill be purified from the PBMC, transduced with TCRζ/4-1BB lentiviralvector, expanded in vitro and then frozen for future administration. Thenumber of patients who have inadequate T cell collections, expansion ormanufacturing compared to the number of patients who have T cellssuccessfully manufactured will be recorded; feasibility of productmanufacturing is not expected to be problematic in this patientpopulation.

Subjects will generally have had adequate peripheral blood stem cellsremaining stored from the mobilization/collection performed inpreparation for their first ASCT to conduct two additional ASCT. Thosewho do not will undergo a second mobilization/collection procedureeither before or after their steady-state apheresis with a regimenaccording to the treating physician's preference. Approximately twoweeks after the initial leukapheresis, subjects will be admitted to thehospital and receive high-dose melphalan (day −2) followed by infusionof autologous stem cells two days later (day 0), and all subjects willreceive infusion of CART-19 cells twelve to fourteen days later (day+12-14). Up to 10 patients will be enrolled.

All subjects will have blood tests to assess safety, and engraftment andpersistence of the CART-19 cells at regular intervals through week 4 ofthe study. At day +42 and day +100, subjects will undergo bone marrowaspirates/biopsies to assess the bone marrow plasma cell burden andtrafficking of CART-19 cells to the bone marrow. A formal responseassessment will be made at day 100 according to International MyelomaWorking Group (IMWG) criteria136, and TTP will be monitored according toroutine clinical practice for patients with multiple myeloma. The mainefficacy outcome measured in this study will be a comparison of TTPafter a patient's initial ASCT to TTP after the ASCT on this study.

As the primary endpoint of this study is safety and feasibility ofinfusion of CART-19 cells with ASCT, the study will employ an earlystopping rule. Briefly, if less than 2 severe, unexpected adverse eventsoccur among the first five subjects treated, the study will then accruean additional five subjects towards a target enrollment of 10. We willobserve treated subjects for 40 days after CART-19 infusion (i.e.,through the first official response assessment at day 42) beforeenrolling a subsequent subject until five subjects have been enrolledand so observed. For treatment of the second group of five patients, nowaiting period will be required between subjects.

Following the 6 months of intensive follow-up, subjects will beevaluated at least quarterly for two years with a medical history,physical examination, and blood tests. Following this evaluation,subjects will enter a roll-over study for annual follow-up by phone andquestionnaire for up to additional thirteen years to assess for thediagnosis of long-term health problems, such as development of newmalignancy.

Primary Study Endpoints

This pilot trial is designed to test the safety and feasibility of theautologous T cells transduced with the CD19 TCRζ/4-1BB in patientsundergoing salvage ASCT for MM following early relapse after first ASCT.

Primary safety and feasibility endpoints include:

Occurrence of study-related adverse events, defined as NCJ CTC 2: grade3 signs/symptoms, laboratory toxicities and clinical events that arepossibly, likely or definitely related to study treatment at any timefrom the infusion until week 24. This will include infusional toxicityand any toxicity possibly related to the CART-19 cells including but notlimited to:

-   -   a. Fevers    -   b. Rash    -   c. Neutropenia, thrombocytopenia, anemia, marrow aplasia    -   d. Hepatic dysfunction    -   e. Pulmonary infiltrates or other pulmonary toxicity    -   f. GVHD-like syndromes affecting gastrointestinal tract or skin.

Feasibility to manufacture CART-19 cells from patient apheresisproducts. The number of manufactured products that do not meet releasecriteria for vector transduction efficiency, T cell purity, viability,sterility and tumor contamination will be determined.

The depth and duration of response following autologous stem celltransplant with CART19 will be compared to the depth and duration ofresponse that each patient initially achieved following standardautologous stem cell transplant.

Subject Selection and Withdrawal Inclusion Criteria

Subjects must have undergone a prior ASCT for MM and have progressedwithin 365 days of stem cell infusion. Subjects who have undergone twoprior ASCTs as part of a planned tandem ASCT consolidation regimen areeligible. Progression will be defined according to IMWG criteria forprogressive disease or, for patients who attained CR or sCR afterinitial ASCT, criteria for relapse from CR (Durie et al. Leukemia 2006;20(9):1467-1473). N.B.: There is no requirement that patients mustenroll within 365 days of prior ASCT, and patients may be treated withother agents, including experimental agents, followingrelapse/progression after prior ASCT before enrollment on this study.

Subjects must have signed written, informed consent.

Subjects must have adequate vital organ function to receive high-dosemelphalan as defined by the following criteria, measured within 12 weeksprior to the date of melphalan infusion: a. Serum creatinine ≤2.5 orestimated creatinine clearance ≥30 ml/min and not dialysis-dependent. b.SGOT≤3× the upper limit of normal and total bilirubin ≤2.0 mg/dl (exceptfor patients in whom hyperbilirubinemia is attributed to Gilbert'ssyndrome). c. Left ventricular ejection fraction (LVEF)≥45% or, if LVEFis <45%, a formal evaluation by a cardiologist identifying no clinicallysignificant cardiovascular function impairment. LVEF assessment musthave been performed within six weeks of enrollment. d. Adequatepulmonary function with FEV1, FVC, TLC, DLCO (after appropriateadjustment for lung volume and hemoglobin concentration)≥40% ofpredicted values. Pulmonary function testing must have been performedwithin six weeks of enrollment.

Subjects must have an ECOG performance status of 0-2, unless a higherperformance status is due solely to bone pain.

Exclusion Criteria

Subjects must not:

-   -   Have any active and uncontrolled infection.    -   Have active hepatitis B, hepatitis C, or HIV infection.

Any uncontrolled medical disorder that would preclude participation asoutlined.

Treatment Regimen

Therapy for Relapsed/Progressive Multiple Myeloma

Patients may receive, prior to enrollment, therapy forrelapsed/progressive multiple myeloma according to the preference oftheir treating physicians. Therapy may continue upon enrollment.

Patients must stop all therapy for two weeks prior to apheresis and fortwo weeks prior to high-dose melphalan. If more than two weeks areexpected to lapse between apheresis and high-dose melphalan, patientsmay resume therapy after apheresis at the discretion of their treatingphysicians.

High-Dose Melphalan (Day −2)

Patients will be admitted to the hospital on day −3 or −2 and willundergo examination by the attending physician and routine laboratorytests, which will include monitoring parameters for tumor lysissyndrome, prior to commencement of the treatment protocol. Blood for MMmonitoring laboratory tests (SPEP, quantitative immunoglobulins, andserum free light chain analysis), will be drawn prior to initiation oftherapy if such tests had not been drawn within 7 days of admission.

High-dose therapy will consist of melphalan at a dose of 200 mg/m²administered intravenously over approximately 20 minutes on day −2. Thedose of melphalan will be reduced to 140 mg/m² for patients >70 years ofage or for patients of any age whom, at the discretion of the treatingphysician, may not tolerate a dose of 200 mg/m² All patients willreceive standard anti-emetic prophylaxis, which may includedexamethasone, and standard antibiotic prophylaxis.

Stem-Cell Re-Infusion (Day 0)

Stem cell infusion will take place on day 0, at least 18 hours after theadministration of the high-dose melphalan. Stem cells will be infusedintravenously over approximately 20-60 minutes following premedicationaccording to standard institutional practice. At least 2×10⁶ CD34+progenitors/kg body weight should be infused. In addition, at least1×10⁶ CD34+ progenitors/kg body weight should be available as a back-upstem-cell product to be infused in the event of delayed engraftment orlate graft failure. G-CSF should be administered SQ beginning on day +5,dosed according to standard institutional practice. Other supportivecare measures such as transfusion support will be done in accordancewith standard institutional guidelines.

CART19 Cell Infusion (Day +12-14)

A single dose of CART-19 transduced T cells will be given consisting ofup to 5×10⁷ CART-19 cells. The minimal acceptable dose for infusion ofcells transduced with the CD19 TCRζ4-1BB vector in this single-patientprotocol is 1×10⁷. CART-19 cells will be given as a single dose by rapidi.v. infusion on day +12-14 after stem cell infusion. If patient failsto meet any of the inclusion criteria described herein in the 12-14 daywindow, the CART-19 infusion may be delayed beyond day +12-14 until thecriteria is satisfied.

Maintenance Lenalidomide

Subjects who received and tolerated maintenance lenalidomide after theirfirst ASCT will re-initiate lenalidomide maintenance therapy atapproximately day +100, assuming there are no contraindications in thejudgment of the treating physician. The starting dose will be 10 mgdaily unless prior experience dictates an alternative starting dose fora particular patient. Maintenance therapy will continue until diseaseprogression or intolerance.

Preparation and Administration of Study Drug

The CART-19 T cells are prepared in the CVPF and are not released fromthe CVPF until FDA approved release criteria for the infused cells(e.g., cell dose, cell purity, sterility, average copy number ofvectors/cell, etc.) are met. Upon release, the cells are taken to thebedside for administration.

Cell thawing. The frozen cells will be transported in dry ice to thesubject's bedside. The cells will be thawed at the bedside using a waterbath maintained at 36° C. to 38° C. The bag will be gently massageduntil the cells have just thawed. There should be no frozen clumps leftin the container. If the CART-19 cell product appears to have a damagedor the bag to be leaking, or otherwise appears to be compromised, itshould not be infused and should be returned to the CVPF as specifiedbelow.

Premedication. Side effects following T cell infusions include transientfever, chills, and/or nausea; see Cruz et al. for review (Cytotherapy2010; 12(6):743-749). It is recommended that the subject bepre-medicated with acetaminophen and diphenhydramine hydrochloride priorto the infusion of CART-19 cells. These medications may be repeatedevery six hours as needed. A course of non-steroidal anti-inflammatorymedication may be prescribed if the patient continues to have fever notrelieved by acetaminophen. It is recommended that patients not receivesystemic corticosteroids such as hydrocortisone, prednisone,methylprednisolone or dexamethasone at any time, except in the case of alife-threatening emergency, since this may have an adverse effect on Tcells.

Febrile reaction. In the unlikely event that the subject develops sepsisor systemic bacteremia following CAR T cell infusion, appropriatecultures and medical management should be initiated. If a contaminatedCART-19 T cell product is suspected, the product can be retested forsterility using archived samples that are stored in the CVPF.

Administration. The infusion will take place in an isolated room inRhoads, using precautions for immunosuppressed patients. The transducedT cells will be administered by rapid intravenous infusion at a flowrate of approximately 10 mL to 20 ml per minute through an 18-gaugelatex free Y-type blood set with a 3-way stopcock. The duration of theinfusion will be based on the total volume to be infused and therecommended infusion rate. Each infusion bag will have affixed to it alabel containing the following: “FOR AUTOLOGOUS USE ONLY.” In additionthe label will have at least two unique identifiers such as thesubject's initials, birth date, and study number. Prior to the infusion,two individuals will independently verify all this information in thepresence of the subject and so confirm that the information is correctlymatched to the participant.

Emergency medical equipment (i.e., emergency trolley) will be availableduring the infusion in case the subject has an allergic response, orsevere hypotensive crisis, or any other reaction to the infusion. Vitalsigns (temperature, respiration rate, pulse, and blood pressure) will betaken before and after infusion, then every 15 minutes for at least onehour and until these signs are satisfactory and stable. The subject willbe asked not to leave until the physician considers it is safe for himor her to do so.

Packaging

Infusion will be comprised of a single dose of 1-5×10⁷ CART19-transduced cells, with a minimal acceptable dose of 1×10⁷ CART-19cells for infusion. Each bag will contain an aliquot (volume dependentupon dose) of cryomedia containing the following infusible gradereagents (% v/v): 31.25% plasmalyte-A, 31.25% dextrose (5%), 0.45% NaCl,up to 7.5% DMSO, 1% dextran 40, 5% human serum albumin.

Apheresis

A large volume (12-15 liters or 4-6 blood volumes) apheresis procedureis carried out at the apheresis center. PBMC are obtained for CART-19during this procedure. From a single leukapheresis, the intention is toharvest at least 5×10⁹ white blood cells to manufacture CART-19 T cells.Baseline blood leukocytes for FDA look-back requirements and forresearch are also obtained and cryopreserved. The cell product isexpected to be ready for release approximately 2-4 weeks later. Flowcytometry lymphocyte subset quantitation, including CD19 and CD20 B celldetermination. Baseline assessment is made for human anti-VSV-G andanti-murine antibody (HAMA). If a subject has previously had an adequateapheresis collection banked according to current Good ManufacturingPractices at the Clinical Cell and Vaccine Production Facility thesecells may be used as the source of cells for CART-19 manufacturing.Using a banked apheresis product would avert the expense, time, and riskto the subject of undergoing an additional apheresis collection.

Cytoreductive Chemotherapy

The lymphodepleting chemotherapy will be high-dose melphalan asdescribed herein.

CART-19 Infusion

Infusion will begin on day +12-14 after stem-cell reinfusion.

On day +12-14 prior to the first infusion, patients will have a CBC withdifferential, and assessment of CD3, CD4 and CD8 counts sincechemotherapy is given in part to induce lymphopenia.

The first dose will be administered using a single dose. The cells arethawed at the patient's bedside. The thawed cells will be given at asrapid an infusion rate as tolerated such that the duration of theinfusion will be approximately 10-15 minutes. In order to facilitatemixing, the cells will be administered simultaneously using a Y-adapter.Subjects will be infused and premedicated as described herein. Subjects'vital signs will be assessed and pulse oxymetry done prior to dosing, atthe end of the infusion, and every 15 minutes thereafter for 1 hour anduntil these are stable and satisfactory. A blood sample fordetermination of a baseline CART-19 level is obtained any time prior tothe first infusion and 20 minutes to 4 hours after each infusion (andsent to TCSL).

Patients experiencing toxicities related to high-dose melphalan willhave their infusion schedule delayed until these toxicities haveresolved. The specific toxicities warranting delay of T cell infusionsinclude: 1) Pulmonary: Requirement for supplemental oxygen to keepsaturation greater than 95% or presence of radiographic abnormalities onchest x-ray that are progressive; 2) Cardiac: New cardiac arrhythmia notcontrolled with medical management 3) Hypotension requiring vasopressorsupport. 4) Active Infection: Positive blood cultures for bacteria,fungus, or virus within 48-hours of T cell infusion.

Management of Toxicity

Uncontrolled T cell proliferation. Toxicity associated with allogeneicor autologous T cell infusions has been managed with a course ofpharmacologic immunosuppression. T body associated toxicity has beenreported to respond to systemic corticosteroids. If uncontrolled T cellproliferation occurs (grade 3 or 4 toxicity related to CART-19 cells),subjects may be treated with corticosteroids. Subjects will be treatedwith pulse methylprednisolone (2 mg/kg i.v. divided q8 hr×2 days),followed by a rapid taper.

In addition, based on the observations of subjects treated on anotherprotocol, there is some concern for macrophage activation syndrome(MAS), though the CD 19+ tumor burden is expected to be much lower inpatients with myeloma than in patients with CLL. Treatment and timing oftreatment of this toxicity will be at the discretion of the patient'sphysician and the study investigator. Suggested management mightinclude: if the subject has a fever greater than 101° F. that lasts morethan 2 consecutive days and there is no evidence of infection (negativeblood cultures, CXR or other source), tocilizumab 4 mg/kg can beconsidered. The addition of corticosteroids and anti-TNF therapy can beconsidered at the physician's discretion.

B cell depletion. It is possible that B cell depletion andhypogammaglobulinemia will occur. This is common with anti-CD20 directedtherapies. In the event of clinically significant hypogammaglobulinemia(i.e. systemic infections), subjects will be given intravenousimmunoglobulin (IVIG) by established clinical dosing guidelines torestore normal levels of serum immunoglobulin levels, as has been donewith Rituximab.

Primary graft failure. Primary graft failure (i.e., non-engraftment) maybe more common after second ASCT compared to first ASCT. Eligibilitycriteria stipulate that sufficient stem cells must be available forrescue reinfusion at the discretion of the treating physician in theevent of primary graft failure.

Results

Three treatment-refractory, advanced multiple myeloma patients have nowbeen treated with CTL019 in this ongoing trial. Results for two of thesepatients show that both have had substantial anti-tumor effects from theCTL019 therapy based on the primary efficacy assessment at thethree-month time-point. The third patient has not yet reached thethree-month time point. The results for the two patients are describedin more detail below.

The first myeloma patient has completed her +100 day response assessmentand she had a very good response to the CART19 therapy. The followingtests were performed with the following results:

-   -   SPEP/immunofixation: negative    -   urine immunofixation: faint unmeasurable kappa light chain band        on her immunofixation (also present at day 38, so not new)        Otherwise, the patient meets the criteria for stringent complete        remission including:    -   serum free light chain ratio: normal    -   bone marrow biopsy: negative    -   IgA immunophenotyping: IgA is below the limit of detection

Other than the faint unmeasurable kappa light chain result from urineimmunofixation, the patient met all criteria for “stringent completeremission”. The summary of the plasma cell immunophenotyping at 3 timepoints (day −2, day +38, day +103) is shown in FIG. 8 , and demonstratesthat the patient's IgA is below the limit of detection. The summaryshows heavy myeloma burden at day −2 and none detectable at day +38 and+103, which classifies the patient as “MRD negative” by flow analysis.At day +103, the summary shows recovery of normal, polyclonal, CD19+plasma cells and B cells. The patient had no symptoms of disease ortherapy and is functioning like a normal person.

The second patient treated has not yet reached the +100 day time point.However, at this time point, she is doing well but it is too early todetermine the effect of the CTL019 infusion.

Example 2: CAR19 T Cell Therapy for Hodgkin Lymphoma

CAR19 T cell therapy can also be used to treat Hodgkin lymphoma (HL).Hodgkin lymphoma is characterized by the presence of malignant HodgkinReed-Sternberg (HRS) cells that are derived from clonal germinal centerB cells. There are several factors that indicate the therapeuticefficacy of CAR19 T cell therapy for HL. CD19 staining of HL tumorsshows CD19-expressing (CD19⁺) cells within the tumor and tumormicroenvironment (FIG. 2 ). A study has shown that a clonal B cellpopulation (CD20⁺CD27⁺ ALDH⁺) that expresses CD19 is responsible for thegeneration and maintenance of Hodgkin lymphoma cell lines, and alsocirculates in the blood of most HL patients (Jones et al., Blood, 2009,113(23):5920-5926). This clonal B cell population has also beensuggested to give rise to or contribute to the generation of themalignant HRS cells. Thus, CART19 therapy would deplete this B cellpopulation that contributes to tumorigenesis or maintenance of tumorcells. Another study showed that B cell depletion retards solid tumorgrowth in multiple murine models (Kim et al., J Immunotherapy, 2008,31(5):446-57). In support of the idea that depletion of B cells in theHL tumor microenvironment results in some anti-tumor effect, currenttherapies, such as rituxan, are being clinically tested for targetingand depletion of tumoral B cells in HL (Younes et al., Blood, 2012,119(18):4123-8). De novo carcinogenesis related to chronic inflammationhas also been shown to be B-cell dependent (de Visser, et al., CancerCell, 2005, 7(5):411-23). The results from these studies indicate thattargeting of the B cell population, particularly in the HL tumormicroenvironment, would be useful for treating HL, by reducing orinhibiting disease progression or tumor growth.

In addition, normal CD19-expressing B cells also infiltrate the tumormicroenvironment in HL. Previous studies with CART19 therapy in CLL andALL (e.g., described in Examples 4 and 5) show that CART19 exposure toCD19+ targets leads to cytokine production and macrophage production.Thus, modulation of the HL tumor microenvironment from a pro-tumormicroenvironment to an anti-tumor microenvironment can be achieved byinfusing CART19 to interact with normal CD19+ B cells present in the HL.For example, CART19 exposure to CD19-expressing targets causes cytokineproduction, e.g., inflammatory cytokines, that promote anti-tumoractivity through the expansion of cytotoxic T cells, activation ofmacrophages, and recruitment of other immune effector cells with variousfunctions that inhibit tumor growth, such as leukocytes, macrophages,and antigen-presenting cells. Because the target CD19+ B cells may notbe malignant (e.g., normally circulating B cells), a transient ratherthan protracted CART19 effect may be preferred for modulation of thetumor microenvironment.

A study to examine the therapeutic efficacy of CART19 therapy in HLpatients can be performed as described below (FIG. 3 ). The study willalso assess the safety and tolerability of CART19 in HL subjects, anddetermine the effect of CART19 cells on the HL tumor microenvironment.

8 patients with classical HL are treated in this study. Patients are ofall ages, though separate protocols for drug delivery can be establishedfor pediatric and adult patients. Patients in this study have noavailable potentially curative treatment options (such as autologous(ASCT) or allogeneic stem cell transplantation), or are not suitable forsuch curative treatment options. For example, patients can be any of thefollowing: PET+ after salvage chemotherapy, PET+ after treatment withbrentuximab, or PET+ after ASCT with or without prior brentuximabexposure. The patients will have a limited prognosis (several months toless than or equal to 2 year expected survival) with currently availabletherapies. And finally, the patients will not have received anti-CD20antibody therapy. Patients are excluded due to lack of feasibility,e.g., if the patient has insufficient numbers of T cells for 6 infusionsof CART19.

An mRNA CAR19 is produced by in vitro transcription. The CAR19 mRNA iselectroporated into donor T cells, and the resulting cells are expandedand stimulated by incubation with CD3/CD28 beads. Dosages containing1×10⁸-5×10⁸ RNA-electroporated CAR19 T cells are delivered to thepatient three times a week for two weeks (e.g., at day 0, 2, 4, 7, 9 and11). The overall response rate will be assessed by clinical, CT, and PETscanning at 1 month after treatment. Response and survival will bemonitored monthly for the first 6 months, then every 3 months until 2years after the first CART19 infusion (day 0). Monitoring techniquesinclude biopsy of the tumor or lymph node (e.g., for immunohistochemicalanalysis and/or RNA for gene expression profiling) and PET scanningbefore and after CART19 treatment. For example, the effect of the CART19cells on the HL tumor microenvironment are analyzed by comparing theresults of gene expression profiling performed on accessible lymph nodebiopsies from selected patients before treatment and approximately oneweek after treatment (or the appropriate time after treatment to allowfor alteration of cellular phenotype). To assess the safety andtolerability of CART19 treatment, the frequency and severity of adverseevents are reported, including the frequency of cytokine releasesyndrome (CRS) and macrophage activation syndrome (MAS).

Chemotherapy may be administered concurrently with CART19 treatment. Thefirst dose of CART19 can be preceded by lymphodepleting chemotherapy,e.g., cytoxan.

Example 3: Non-Responder Subset of CLL Patients Exhibit IncreasedExpression of Immune Checkpoint Inhibitor Molecules

In this study, CART19 cells from clinical manufacture from 34 CLLpatients were assessed for expression of immune checkpoint inhibitormolecules, such as PD-1, LAG3, and TIM3. The response of this cohort toCART19 was known and hence a correlation between response and biomarkerexpression patterns could be assessed.

Manufactured CART19 cells from CLL patients with different responses toCART therapy were analyzed by flow cytometry to determine the expressionof CAR and the immune checkpoint inhibitor molecules PD-1, LAG3, andTIM3. The CART19 cells were from: healthy donors (HD) (n=2); CLLpatients that responded to CART therapy (CR) (n=5); CLL patients thatpartially responded to CART therapy (PR) (n=8); CLL patients that didnot respond to CART therapy (NR) (n=21). Cells were stained withfluorescently labeled antibodies that specifically recognize CD3, CD4,CD8, CD27, CD45RO, the CAR19 molecule, and immune checkpoint moleculesPD-1, LAG3, and TIM3, according to standard methods for flow cytometryanalysis known in the art. Expression of each marker, e.g., CD4+, CD8+,etc., was determined by flow cytometry analysis software, andsubpopulations (e.g., CD4+ T cells, CD8+ T cells, or CAR19-expressing Tcells) were further analyzed for the expression of immune checkpointmolecules PD-1, LAG3, and TIM3.

An example of the flow cytometry profiles analysis used to determinesurface marker expression is shown in FIGS. 4A and 4B. T cellsexpressing CD4 were determined using flow cytometry, and were furtheranalyzed for CAR19 and PD-1 expression, such that the x-axis of theprofiles indicate CAR19 expression (the top left (Q5) and bottom left(Q8) quadrants show the CAR19-negative CD4+ cells, while the top right(Q6) and bottom right (Q7) quadrants show the CAR19-expressing CD4+cells) and the y-axis shows PD-1 expression (the bottom left (Q8) andright (Q7) quadrants show the PD-1 negative CD4+ cells and the top left(Q5) and right (Q6) quadrants show the PD-1-expressing CD4+ cells). Inthe CD4+ population from a CART responder, 44.7% of the CD4+ cellsoverall expressed PD-1, and about 22.3% of the CAR19-expressing cellswere PD-1 positive, while 27.2% of CAR19-expressing cells were PD-1negative (FIG. 4A). In contrast, in the CD4+ population from anon-responder, there was a significant decrease in CAR19-expressingcells overall (about 15.3% compared to the 49.5% in CR), with 14.7% ofthe CAR19-expressing cells being PD-1 positive while only 0.64% werePD-1 negative (FIG. 4B). Comparison between the profiles in FIG. 4A andFIG. 4B shows that a much higher percentage of the CD4+ cells from anon-responder express PD-1 (about 92.9%) compared to the CART responder(about 44.7%).

Using the methods and analysis described above, the percentage of PD-1expressing (PD-1+) cells of the CD4+ population and the CD8+ populationwas determined for each patient in each response group. Non-responderswere shown to have a greater percentage of PD-1+ cells in both the CD4+(FIG. 4C) and CD8+ (FIG. 4D) populations compared to those thatresponded to CAR therapy (CR); the increase of average PD-1 percentagewas statistically significant for both CD4+ and CD8+ populations.Partial responders (PR) exhibited higher percentages of PD-1+ cells thanresponders (CR) in both CD4+ (FIG. 4C) and CD8+ (FIG. 4D) populations.

Next, the percentage of PD-1 expressing (PD-1+) cells of theCAR19-expressing CD4+ population and the CAR19-expressing CD8+population was determined for each patient in each response group.Similar analysis was performed as above, with the additional step ofanalyzing the CD4+ and CD8+ cells for CAR19-expression, and afteridentification of the CAR19-expressing cells, determining the percentageof cells with PD-1 expression from the populations of CAR19-expressingcells. A similar trend as that observed in the CD4+ and CD8+ overallpopulations was observed for the CAR19 expressing CD4+ and CD8+populations: non-responders were shown to have a greater percentage ofPD-1+ cells in both the CD4+ (FIG. 5A) and CD8+ (FIG. 5B) populationscompared to those that responded to CAR therapy (CR); the increase ofaverage PD-1 percentage was statistically significant for both CD4+ andCD8+ populations. Partial responders (PR) exhibited higher percentagesof PD-1+ cells than responders (CR) in both CD4+ (FIG. 5A) and CD8+(FIG. 5B) populations.

Further analysis was performed to determine the distribution of cellsexpressing PD-1, LAG3, and TIM3 from patients with different responsesto CAR therapy. Representative cell profile analysis for PD-1, LAG3, andTIM3 expression in the CD4+ population is shown in FIG. 6 . The cellpopulations were first analyzed for CD4+ and CD8+ expression. The CD4+population (or CD8+ population, not shown) was then analyzed for PD-1and CAR19 expression (FIG. 6 , left profiles). As described previously,non-responders (NR) had a significantly increased percentage of cellsthat were PD-1+ overall compared to CART responders (CR) (about 92.9%PD-1 positive for NR compared to 44.7% PD-1 positive for CR). Moreover,in non-responders, CAR19-expressing cells were mostly PD-1 positive(14.7% PD-1 positive and CAR+ compared to 0.64% PD-1 negative and CAR+).Then the populations were analyzed for PD-1 and LAG3 co-expression (FIG.6 , middle profiles). Cells that expressed both PD-1 and LAG3 are shownin the top right quadrant (Q2). Non-responders had a significantlyincreased percentage of cells that expressed both immune checkpointinhibitors, PD-1 and LAG3, compared to CART responders (67.3% comparedto 7.31%). PD-1 expression was also analyzed with TIM3 expression. InFIG. 6 , right profiles, the box indicates the cells that express bothPD-1 and TIM3. Similar to the results obtained with PD-1 and LAG3, thenon-responders had a significantly higher percentage of cells thatexpressed both immune checkpoint inhibitors, PD-1 and TIM3, compared toCART responders (83.3% compared to 28.5%). The percentage of PD-1expressing cells (PD1+), PD-1 and LAG3-expressing cells (PD1+LAG3+), andPD-1 and TIM3-expressing cells (PD1+ TIM3+) was determined for eachpatient in each response group using the flow cytometry analysis asdescribed above. Non-responders were shown to have an increasedpercentage of PD1+LAG3+ cells (FIG. 7A) and PD1+ TIM3+ cells (FIG. 7B)compared to CART responders that was statistically significant for bothcell populations. Partial responders also showed an increased percentageof both cell populations compared to CART responders, with the averagesbeing decreased compared to the non-responders.

These results indicate that patients that do not respond to CAR therapyexhibit increased expression of immune checkpoint inhibitors (e.g.,PD-1, LAG3, and TIM3) compared to patients that respond or partiallyrespond to CAR therapy. Thus, these results show that agents thatinhibit or decrease expression of immune checkpoint inhibitors, e.g.,PD-1, LAG3, or TIM3, may be useful for administration to patientsreceiving CAR therapy to prevent immune suppression through immunecheckpoint pathways (e.g., mediated by PD-1, LAG3, or TIM3), therebyincreasing the efficacy of the CAR-expressing cells.

Example 4: Effects of mTOR Inhibition on Immunosenescence in the Elderly

The efficacy of mTOR inhibition on immunosenescence is described, e.g.,in Example 1 of International Application WO/2015/073644, and theentirety of the application is herein incorporated by reference.

Example 5: Enhancement of Immune Response to Vaccine in Elderly Subjects

The efficacy of mTOR inhibition on enhancing an immune response isdescribed, e.g., in Example 2 of International ApplicationWO/2015/073644, and the entirety of the application is hereinincorporated by reference.

Example 6: Low Dose mTOR Inhibition Increases Energy and Exercise

The effect of mTOR inhibition on energy and exercise is described, e.g.,in Example 3 of International Application WO/2015/073644, and theentirety of the application is herein incorporated by reference.

Example 7: P70 S6 Kinase Inhibition with RAD001

The effect of mTOR inhibition on P70 S6 kinase inhibition is described,e.g., in Example 4 of International Application WO/2015/073644, and theentirety of the application is herein incorporated by reference.

Example 8: Exogenous IL-7 Enhances the Function of CAR T Cells

After adoptive transfer of CAR T cells, some patients experience limitedpersistence of the CAR T cells, which can result in suboptimal levels ofanti-tumor activity. In this example, the effects of administration ofexogenous human IL-7 is assessed in mouse xenograft models where aninitial suboptimal response to CAR T cells has been observed.

Expression of the IL-7 receptor CD127 was first assessed in differentcancer cell lines and in CAR-expressing cells. Two mantle cell lymphomacell lines (RL and Jeko-1) and one B-ALL cell line (Nalm-6) wereanalyzed by flow cytometry for CD127 expression. As shown in FIG. 9A,out of the three cancer cell lines tested, RL was shown to have thehighest expression of CD127, followed by Jeko-1 and Nalm-6. CART19 cellswere infused into NSG mice and CD127 expression was assessed on thecirculating CART19 cells by flow cytometry. As shown in FIG. 9B, CD127is uniformly expressed on all circulating CART19 cells.

Next, the effect of exogenous IL-7 treatment on anti-tumor activity ofCART19 cells was assessed in a lymphoma animal model. NSG mice wereengrafted with a luciferase-expressing mantle cell line (RL luc) on Day0 (DO), followed by treatment of CART19 cells on Day 6. The NSG micewere divided into groups, where one group received no CART19 cells, asecond group received 0.5×10⁶ CART19 cells, a third group received 1×10⁶CART19 cells, and a fourth group received 2×10⁶ CART19 cells. Tumor sizewas monitored by measuring the mean bioluminescence of the engraftedtumors over more than 80 days. Only mice receiving 2×10⁶ CART19 cellsdemonstrated rejection of the tumor and inhibition of tumor growth (FIG.10A). Mice from the two groups receiving 0.5×10⁶ CART19 cells or 1×10⁶CART19 cells were shown to s a suboptimal anti-tumor response. Mice fromthese two groups were then randomized, where three mice (mouse #3827 and#3829 which received 0.5×10⁶ CART19 cells, and mouse #3815 whichreceived 1×10⁶ CART19 cells) received exogenous recombinant human IL-7at a dosage of 200 ng/mouse by intraperitoneal injection three timesweekly starting at Day 85, and two mice did not. The tumor burden ofmice receiving exogenous IL-7 from Day 85-125, as detected by meanbioluminescence, is shown in FIG. 10B. All mice receiving IL-7 showed adramatic response of 1-3 log reduction in tumor burden. Mice thatoriginally received a higher dose of CART19 cells (mouse #3815 whichreceived 1×10⁶ CART19 cells) showed a more profound response. Whencomparing the tumor burden of mice that received IL-7 treatment tocontrol, before and after IL-7 treatment, tumor reduction in tumorburden was only seen in the mice that had received IL-7 treatment (FIG.10C).

T cell dynamics following IL-7 treatment in the lymphoma animal modelwas also examined. Human CART19 cells were not detectable in the bloodprior to IL-7 treatment. Upon treatment of IL-7, there was rapid, butvariable increase in the numbers of T cells in the treated mice (FIG.11A). The extent of T cell expansion observed in mice receiving the IL-7also correlated with tumor response. The mouse with the highest numberof T cells detected in the blood at peak expansion during IL-7 treatment(mouse #3815) had the most robust reduction in tumor burden (see FIG.10B). Moreover, the time of peak expansion correlated with the T celldose injected as baseline. The number/level CD3-expressing cells in theblood were also measured before and after IL-7 treatment. In controlmice, very few CD3-expressing cells were detected, while IL-7-treatedmice showed a significant increase in CD3+ cells after IL-7 treatment(FIG. 11B).

Together, the results in this example demonstrate that exogenous IL-7treatment increases T cell proliferation and anti-tumor activity invivo, indicating that use of IL-7 in patients with suboptimal resultsafter CAR therapy can improve anti-tumor response in these patients.

Example 9: Evaluation of CD22 CAR

Automated Jurkat-NFAT-Luciferase (JNL) Cell Assay

An automated assay was performed to determine reactivity of specificCD22 CART clones. 3e⁴ lentivirally-transduced Jurkat cell line cellsstably expressing luciferase from an NFAT promoter (JNL cells) wereplated in a 96 well plate with CD22-expressing target cell lines (Daudi,Raji) and a non-CD22 expressing cell line (K562) as a negative control.The next day, luciferin substrate was added to each well of the 96 wellplate and relative luminescence of the luciferase reporter wasdetermined. In this assay, CD22 CAR constructs were compared to a CD19CAR construct and a CD22 (m971-derived) CAR construct (m971-HL) thatserved as positive controls. A m971-LH CAR construct, which contains theVH and VL chains of m971-HL but in reverse orientation (L-H instead ofH-L), contained a CAR but was unable to bind target due to lack ofspecificity and served as a negative control. Untransduced T-cellscontaining no CAR (Neg cnt) also served as a negative control.Luciferase activity from Jurkat T-cell activation was graphed. Theresults presented herein demonstrate that several of the CD-22transduced JNL clones showed specific reactivity towards theCD22-expressing cell lines that increased in a dose-dependent manner(FIGS. 18A-18C).

Expression of CD22 CAR in Primary Human T-Cells

Primary human T-cells were activated with anti-CD3/antiCD28 stimulatorybeads on day 0, followed by lentiviral transduction of specified CARconstructs on day 1. Cells were expanded in vitro until day, 10 at whichpoint they were analyzed by flow cytometry for surface expression ofCAR. Two different approaches were utilized to determine surfaceexpression of CAR: Protein-L-biotin followed by streptavidin-PE, andrecombinant human CD22-Fc followed by anti-Fc-alexafluor 488. Theresults are shown in FIGS. 19A, 19B, 19C, and 19D. The results presentedherein demonstrate that CD22 CAR clone 2 (hCD22-2), clone (hCD22-5),clone 7 (hCD22-7), clone 8 (hCD22-8), clone 10 (hCD22-10), clone 12(hCD22-12), clone 30 (hCD22-30), and clone 31 (hCD22-31) showed positivesurface expression. CD22 CAR m971 served as a positive control forbinding both Protein-L and hrCD22-Fc, and Isotype CAR with nospecificity (anti-gH) served as a positive control for Protein-L. Tcells expressing no CAR were used as a negative control.

Primary T-Cell Tumor Target Killing Assay

Primary T-cells activated and transduced as described above were mixedwith target cell lines stably expressing luciferase at the ratiosindicated (FIG. 20A-20F). Target cell lines Raji, SEM, K562-hCD22,Daudi, and Nalm6 all expressed CD22 target, whereas the K562 cell linedid not express CD22 and served as a negative control (FIG. 20A-20F).The results presented herein demonstrate that several CD22 CAR clones(e.g., CD22 CAR clones 2, 5, 7, 8, 10, 12, 30, and 31) and positivecontrol CD22 m971-HL CAR exhibited dose-dependent target cell killing,with extent of killing varying depending on target cell type.Untransduced T-cells (UTD) lacked the ability to kill target cell lines.

Primary T-Cell Cytokine Bead Array

The ability of CD22-expressing cell lines to induce release ofproinflammatory cytokines from CD22-expressing CART cells wasinvestigated. Proinflammatory cytokine concentration was determinedusing a cytokine bead array kit on samples taken from the primary T-cellkilling assay. Interferon-g (IFN-g), Tumor necrosis factor alpha (TNFa),and interleukin 2 (IL-2) were all measured on samples from 2.5:1 E:T and10:1 E:T ratios. The results are shown in FIG. 21A-21F. The resultspresented herein demonstrate that multiple CD22 CAR clones inducedsignificantly more IFN-g, TNFa and IL-2 than the m971-LH CAR (negativecontrol) or untransduced T-cells (UTD), with cytokine induction levelsvarying by target cell type.

Example 10: Dose Escalation Study of CD22 CART Treatment

A phase 1 clinical trial is performed to determine the optimal dose ofCD22 CART with or without CD19 CART in ALL subjects who have and havenot previously received CART therapy. The purpose of this study is todetermine the feasibility of producing anti-CD22 CAR engineered T cellsmeeting the established release criteria and to assess the safety ofadministering escalating doses of autologous anti-CD22 CAR engineered Tcells in children and young adults with B cell malignancies following acyclophosphamide/fludarabine lymphodepletion regimen.

Subjects are between 1 and 30 years of age and weighing at least 15 kgwith CD22+ ALL. Disease activity is measurable by bone marrow analysisor FDG-PET. Subjects with minimal residual disease activity are allowed.Subjects with a central nervous system (CNS) status of 1 or 2 areallowed. Subjects must have adequate organ function and adequate CD3count.

A phase 1 dose escalation study with an expansion cohort is performed.Subjects are stratified according to whether they have or have notpreviously received CART therapy. Subjects are given one of four doselevels of four doses of autologous anti-CD22 CAR engineered T cells:3×10⁵ cells/kg body weight, 1×10⁶ cells/kg body weight, 3×10⁶ cells/kgbody weight and 1×10⁷ cells/kg body weight. A subset of the subjectsreceiving the 3×10⁶ cells/kg body weight dose are also given anti-CD19CAR engineered T cells. The first 2 patients at each dose level are 16years of age or older.

After eligibility is determined, apheresis is performed to isolate Tcells. Subjects then undergo preparative chemotherapy. Subjects aretreated with 25 mg/m² fludarabine daily for three days and given asingle dose of 900 mg/m² of cyclophosphamide. Anti-CD22 CAR engineered Tcells are then administered and 28 days later response and toxicity areevaluated.

Example 11: Utilization of CD20-Targeting Chimeric Antigen Receptors(CARS) for the Treatment of B-Cell Malignancies

A Jurkat-NFAT-Luciferase (JNL) cell assay was performed to determinereactivity of specific CD20 CART clones. Jurkat cells stably expressingluciferase from an NFAT promoter (JNL cells) were lentivirallytransduced with CAR constructs shown in FIG. 15A-15C. CAR-expressing JNLcells (3e4) were mixed with CD20 expressing target cell lines Daudi(FIG. 15A) and Raji (FIG. 15B), and a non CD20 expressing negativecontrol K562 (FIG. 15C) at effector cell:target cell (E:T) ratios of0.5:1, 1:1, 2:1, and 4:1. Lentivirally transduced JNL cells were platedin a 96 well plate with CD20-expressing target cell lines (Daudi, Raji)and a non-CD20 expressing cell line (K562) as a negative control. Thenext day, luciferin substrate was added to each well of the 96 wellplate, and relative luminescence of the luciferase reporter (from JurkatT-cell activation) was determined. In this assay, CD20 CAR constructswere compared to a CD19 CAR construct and a CD22 (m971-derived) CARconstruct described in Haso et al., Blood, 14 Feb. 2013, Vol. 121, No. 7that served as positive controls. Isotype CAR, which contained a CAR butwas unable to bind target due to lack of specificity, and untransducedT-cells containing no CAR (Neg cnt) served as negative controls. Theresults are shown in FIG. 15A-15C. Several of the CD20 transduced JNLclones showed specific reactivity towards the CD20-expressing cell linesthat increased in a dose-dependent manner.

Example 12: Identification of Factors that Predict Subject Relapse toCD19CART Therapy in B-Cell Acute Lymphocytic Leukemia (B-ALL)

The present Example describes, among other things, the identification ofnovel transcriptional gene signatures that predict patient relapse toCD19CART therapy (e.g., CTL019 therapy) in B cell Acute LymphocyticLeukemia (B-ALL), for use in accordance with the present invention.

Among other things, the present Example describes novel gene signaturesbased on mRNA expression levels of selected genes in the patient priorto CD19CART treatment (e.g., CTL019) (apheresis or bone marrow) or inmanufactured CD19CART product samples (e.g., CTL019) prior tore-infusion. In an embodiment, the present example describes novel genesignatures that discriminate relapsers to CTL019 therapy in B-ALL fromnon-relapsers to CTL019 therapy in B-ALL.

The present Example describes methods of unbiased feature selection todiscover novel gene signatures that predict subject relapse to CD19CARTtherapy (e.g., CTL019) in B-ALL, for use in accordance with the presentinvention.

The present Example also describes methods of Gene Set Analysis todiscover novel gene signatures, for use in accordance with the presentinvention.

Novel gene signatures based on mRNA expression levels in manufacturedCD19CART product samples prior to re-infusion were identified thatpredict subject relapse to CD19CART therapy in B cell Acute LymphocyticLeukemia (B-ALL). The identified signatures were discovered in a wholegenome RNAseq study of manufactured product samples which included 7B-ALL subject samples. B-ALL subject samples (7 total) were stratifiedas follows: biological samples were taken from 4 subjects who did notrelapse (“non-relapsers”) following CTL019 therapy, and 3 subjects whodid relapse (“relapsers”) following CTL019 therapy. Several genesignatures discriminating responders from non-responders, and relapsersfrom non-relapsers, in manufactured product samples were discovered andare described further in detail below.

Novel gene signatures were then discovered using various data analyticalapproaches: 1) unbiased feature selection; 2) gene set analysis; and 3)differential expression analysis of selected genes of interest.

Novel gene signatures derived from unbiased feature selection werediscovered by determining which genes were differentially expressedbetween the 2-group comparison of relapsers and non-relapsers whichcompared the 3 relapsers to the 4 non-relapsers. Genes were defined asdifferentially expressed if their differential expression wasstatistically significant in the 2-group comparison with a FDR p-valuecutoff of 0.25. The gene list for the relapser versus non-relapsercomparison (N=17) is tabulated in Table 29. 2-group statistical modelswere applied to determine whether the meta-gene was statisticallydifferent between the groups and an exemplary schematic illustrating theapproach is illustrated in FIGS. 32A and 32B. FIGS. 32A and 32B depictan exemplary heat map of genes upregulated in activated T_(EFF) versusresting T_(EFF) cells for complete responders (CR), partial responders(PR), and non-responders (NR) with CLL.

Without wishing to be bound by a particular theory, these data indicatethat the differentiation state of T cells in CD19CART product (e.g.,CTL019) correlate with subject response (i.e., CR, PR, or NR) andpredict subject relapse to CD19CART therapy (e.g., CTL019 therapy) inB-ALL. Complete responders gene signatures are more like resting T_(REG)and T_(EFF) cells. Among other things, gene signatures for relapsers(e.g., a complete responder that relapses to CTL019 therapy) containgenes upregulated in T_(REG) versus T_(EFF) cells at resting. Withoutwishing to be bound by a particular theory, these data indicate thatrelapsers to CART therapy (e.g., CTL019) in B-ALL have higher levels ofT_(REG) compared to non-relapsers to CART therapy (e.g., CTL019). FIG.17 depicts exemplary results illustrating that T_(REG) aredifferentially enriched in relapsers (R) versus non-relapsers, e.g.,relapsers express high levels of T_(REG) genes compared to completeresponders (CR) (e.g., non-relapsers).

TABLE 29 Exemplary Genes that Predict Patient Relapse to CTL019 TherapyGene miRBase Unigene Accession No. FDR MIR199A1 MI0000242 NR_029586.12.11E−05 PPIAL4D Hs.730589 NM_001164261.1 3.94E−05 MIR1203 MI0006335NR_031607.1 4.63E−03 uc021ovp 6.73E−03 ITM2C Hs.111577 NM_001012514.21.17E−01 NM_001012516.2 NM_001287240.1 NM_001287241.1 NM_030926.5HLA-DQB1 Hs.409934 NM_001243961.1 1.17E−01 Hs.534322 NM_001243962.1NM_002123.4 TTTY10 Hs.461175 NR_001542.1 1.25E−01 TXLNG2P Hs.522863NR_045128.1 2.27E−01 NR_045129.1 MIR4650-1 MI0017277 NR_039793.12.27E−01 KDM5D Hs.80358 NM_001146705.1 2.27E−01 NM_001146706.1NM_004653.4 USP9Y Hs.598540 NM_004654.3 2.27E−01 PRKY Hs.584730NR_028062.1 2.27E−01 RPS4Y2 Hs.367761 NM_001039567.2 2.27E−01 RPS4Y1Hs.282376 NM_001008.3 2.27E−01 NCRNA00185 Hs.138453 NR_001543.3 2.28E−01Hs.729534 NR_125733.1 Hs.734681 NR_125734.1 NR_125735.1 NR_125736.1NR_125737.1 SULT1E1 Hs.479898 NM_005420.2 2.33E−01 EIF1AY Hs.461178NM_001278612.1 2.38E−01 NM_004681.3

The following genes showed increased levels in relapsers and decreasedlevels in non relapsers: MIR199A1, MIR1203, uc021ovp, ITM2C, andHLA-DQB1. The following genes showed decreased levels in relapsers andincreased levels in non relapsers: PPIAL4D, TTTY10, TXLNG2P, MIR4650-1,KDM5D, USP9Y, PRKY, RPS4Y2, RPS4Y1, NCRNA00185, SULT1E1, and EIF1AY.

Gene set analysis yielded a number of gene signatures predictive ofsubject relapse to CTL019 therapy in B-ALL.

Among other things, the present Example describes novel gene signaturesbased on Gene Set Analysis, that are predictive of patent relapse toCD19CART therapy (e.g., CTL019) in B-ALL. Gene set analysis wasperformed on three gene sets i.e., gene sets were sourced from (1)additional experiments were based on unpublished experiments by Szabo etal., (described below); (2) gene sets published by Abbas et al. inGenome Research 2005; and (3) gene sets published by Gattinoni et al. inNature Medicine 2011. The gene sets defined by Szabo, Abbs, andGattinoni and considered in this analysis described in Example 1 of U.S.Provisional Patent App. 62/061,553.

The Szabo core gene set includes the following genes which areupregulated in Teff cells (16 h v 0 h): AIM2, ALAS1, B4GALT5, BATF,C3orf26, C4orf43, CCL3, CCL4, CCT3, CCT7, CD40LG, CHAC2, CSF2, CTNNA1,EBNA1BP2, EDARADD, EEF1E1, EIF2B3, EIF2S1, FABP5, FAM40B, FKBP4, FOSL1,GFOD1, GLRX2, HSPD1, HSPE1, IFNG, IL15RA, IL21, IL2RA, IL3, KCNK5,KIAA0020, LARP4, LRP8, LTA, MANF, MIR1182, MIR155, MIR155HG, MTCH2,MYOF, NDUFAF1, NLN, NME1, NME1-NME2, OTUD7B, PAM, PDIA6, PEA15, PFKM,PGAM1, PGAM4, PPIL1, PRDX4, PRSS23, PSMD1, PSMD11, PSMD14, PTRH2, PUS7,RBBP8, RPF2, RPP25, SFXN1, SLC27A2, SLC39A14, SLC43A3, SORD, SPR, SRXN1,STIP1, STT3A, TBX21, TMCC2, TMEM165, TNFRSF9, TXN, TXNDC5, UCK2, VDR,WDR12, YWHAG, and ZDHHC16. The Szabo core gene set also includes thefollowing genes which are upregulated in Treg cells (16 h v 0 h): AIM2,ALAS1, BATF, C5orf32, CCL17, CD40LG, CHAC2, CSF1, CTSL1, EBNA1BP2,EDARADD, EMP1, EPAS1, FABP5, FAM40B, FKBP4, FOSL1, GCLM, GK, GPR56,HMOX1, HSPD1, HSPE1, IKBIP, IL10, IL13, IL15RA, IL1RN, IL2RA, IL3, IL4,IL5, IL9, KCNK5, LTA, MANF, MIR1182, MIR155, MIR155HG, MYOF, NDUFAF1,NLN, NME1, NME1-NME2, PANX2, PDIA6, PGAM4, PPIL1, PPPDE2, PRDX4,PRKAR1B, PSMD1, PSMD11, PUS7, RBBP8, SLC27A2, SLC39A14, SLC43A3, SRXN1,STIP1, STT3A, TBX21, TNFRSF11A, TNFRSF1B, TNFRSF8, TNFRSF9, TXN, UCK2,VDR, VTRNA1-3, WDR12, YWHAG, ZDHHC16, and ZNF282.

Each gene set (e.g., Szabo gene sets, Abbas gene sets, and Gattinonigene sets) was evaluated to determine its association with subjectresponse (i.e., relapser or non-relapser) in the following manner: ameta-gene was calculated for each subject, where the meta-gene score forsubject j was defined as

$m_{j} = {{\sum_{i = G}^{1}x_{ij}} - {{\mu\left( x_{.j} \right)}/{\sigma\left( x_{.j} \right)}}}$

where x_(ij) is the expression value of gene i in subject j for a givengene set n=1, . . . , G; μ(x_(.j)) is the mean of genes 1, . . . , G insubject j; and σ(x_(.j)) is the standard deviation of genes 1, . . . , Gin subject j.

A 2-group statistical model was applied to each gene set to determinewhether the meta-gene was statistically different between themanufactured CTL019 product of relapsers and non-relapsers. A schematicillustrating this approach is given in FIG. 16 . Of the Szabo, Abbas,and Gattinoni gene sets, there was one gene set that was significantlydifferentially enriched between relapsers and non-relapsers. This geneset was from the Szabo collection and contains genes upregulated inT_(REG) versus T_(EFF) cells at resting, and correlated with patientrelapse to CTL019 therapy. Specifically, this gene set was found to beenriched in relapsers, indicating that relapsers have higher levels ofT_(REGS) compared to non-relapsers. For example, the meta-gene score forthe gene set comprised of genes upregulated in T_(REG) in comparison toT_(EFF) cells is found to be correlated with patient relapse in productsamples (see FIG. 17 ). FIG. 17 depicts exemplary results (p=0.000215)illustrating that T_(REG) genes have high expression levels in relapsers(R) compared to non-relapser, complete responders (CR). The x-axis issamples by response group where CR=complete responder and R=relapser.The y-axis is normalized meta-gene expression scores.

Without wishing to be bound by a particular theory, these data indicatethat decreasing the T_(REG) signature in the patient prior to apheresisor during manufacturing of the CART product significantly reduces therisk of patient relapse.

Example 13: Insertion Mutations are a Mechanism of Resistance to CTL019Therapy in B Cell Acute Lymphoid Leukemia (B-ALL)

Several resistance mechanisms have been discovered by comparing the mRNAsequencing data from B-ALL patient samples taken at baseline and afterrelapse. Certain resistance mechanisms are referred to as “CD19−relapse”, i.e. the patient's tumor cells are characterized as CD19−since they do not bind to the FMC63 epitope used in CTL019 as measuredby flow cytometry. Several resistance mechanisms have been discoveredand are described in detail in this Example.

mRNA sequencing (RNAseq) was performed to compare the transcriptionalprofiles of B-ALL patients before CTL019 treatment and after relapse.Three patients were considered: one patient (Patient #29), who was CD19−at the time of relapse, and two patients (Patients #104 and #10⁵), whowere CD19+ at relapse. See Table 30 below for a list of patients, theirclassification, and percentage of leukemia at both time points.

TABLE 30 % Leukemia in BM, % Leukemia in BM, Sample Type of relapsebaseline relapse Patient #29 CD19− N/A N/A Patient # 104 CD19+ 33% 98.5%Patient # 105 CD19+ 46% pre-CART  65%

Analysis of the RNAseq data for the CD19 gene revealed severalnoteworthy observations.

Three insertions were found in exon 2 of CD19. The insertions were onlyfound in the relapse sample for patient #29. No reads supporting any ofthe three insertions, or any other insertion in exon 2 of CD19, wereobserved in the other two patients and at baseline for patient #29. Thegenomic locations and actual insertions are tabulated in Table 31 below.

TABLE 31 Insertion Location Wild Type Inserted Sequence 1 28943706 C C--> CA 2 28943707 A A --> AT 3 28943811 T T --> TTTGG

The lengths of the three insertions are 1, 1, and 4 bases longrespectively and are likely all frameshift insertions. All three of theinsertions result in premature stop codons within exon 2 (for insertions1 and 2 a new stop codon occurs at ch16:28943752 and for insertion 3 atch16:28943887). Table 32 below lists the number of reads supporting theinsertion and the wild type as well as associated percentages. The mostprevalent insertion is “insertion 3” which is a 4 base insertion andoccurs −30%. Moreover, out of the 15 paired reads which span more thanone insertion, none of the paired reads contained more than oneinsertion, suggesting the insertions are mutually exclusive.

TABLE 32 Sample Ins1 (Ins, wt) Ins2 (Ins, wt) Ins3 (Ins, wt)  29B 0, 620, 62  0, 50  29R 21, 308 4, 327 67, 151 104B 0, 69 0, 69  0, 79 104R 0, 392 0, 398  0, 413 105B 0, 42 0, 42  0, 63 105R  0, 184 0, 185  0,212

In the Table, “Sample” lists the patient number followed by “B” forbaseline sample or “R” for a sample taken upon relapse. The columnlabeled Ins1 indicates the number of reads showing Ins1 (left number)versus the wild-type sequence at that position (right number); thecolumn labeled Ins2 indicates the number of reads showing Ins2 (leftnumber) versus the wild-type sequence at that position (right number);and labeled Ins3 indicates the number of reads showing Ins3 (leftnumber) versus the wild-type sequence at that position (right number).The Table indicates that only patient 29 showed these three insertions,and the insertions were only observed upon relapse. These resultssuggest that insertions in exon 2 of CD19 lead to resistance in somepatients.

This work identified resistance mechanisms to CTL019 therapy in B-ALL,namely insertions in exon 2 of CD19 by which the tumor cells becomeCD19− and resistant to CTL019 therapy. This observation provides supportfor a CTL019 combination strategy with CARs against targets other thanCD19, e.g., CD20, CD22, and ROR1.

Example 14: Expression of B-Cell Antigens in Relapsed ALL CancerPatients

Expression of various B-cell antigens was determined in relapsed acutelymphoblastic leukemia (ALL) cancer patients who had previously beentreated with a cancer therapy other than a CAR therapy, i.e., had notbeen treated with any CAR therapy.

Methods

Samples were obtained as de-identified primary human ALL bone marrow(BM) and peripheral blood (PB) specimens. Anti-human antibodies werepurchased from Abcam, Biolegend, Invitrogen, eBioscience, or BectonDickinson. Mononuclear cells were isolated by Ficoll separation, washedonce in PBS supplemented with 2% fetal calf serum, and stained for 15minutes at room temperature. For cell number quantitation, Countbright(Invitrogen) beads were used according to the manufacturer'sinstructions. In all analyses, the population of interest was gatedbased on forward vs. side scatter characteristics followed by singletgating, and live cells were gated using Live Dead Aqua (Invitrogen).Time gating was included for quality control. For animal studies themurine anti-CD45 antibody (Biolegend) was added to gate out murineleukocytes. Surface expression of CD22 was detected by staining withanti-CD22 monoclonal antibody from clone HIB22 (Biolegend). Surfaceexpression of CD123 was detected by staining with anti-CD123 monoclonalantibody from clone 6H6 (ebioscience). Surface expression of FLT3 wasdetected by staining with anti-FLT3monoclonal antibody from cloneIM2234U (Beckman Coulter). Surface expression of ROR1 was detected bystaining with anti-ROR1 monoclonal antibody from clone 2H6 (Abcam).Surface expression of CD79b was detected by staining with anti-CD79bmonoclonal antibody from clone CB3-1 (Biolegend). Surface expression ofCD79a was detected by staining with anti-CD79a monoclonal antibody fromclone HM47 (R&D Systems). Surface expression of CD10 was detected bystaining with anti-CD10 monoclonal antibody from clone eBioCV-CALLA(ebioscience). Surface expression of CD34 was detected by staining withanti-CD34 monoclonal antibody from clone 561 (Biolegend). Surfaceexpression of CD20 was detected by staining with anti-CD20 monoclonalantibody from clone L27 (BD Biosciences). Quantitation of cellularantigen expression in Antibody Binding Capacity (ABC) units wasperformed using Quantum™ Simply Cellular® (Bangs Lab., Inc) according tostandard procedure (static.abdserotec.com/uploads/ifu/fcsc815b.pdf).Flow cytometry was performed on a four-laser Fortessa-LSR cytometer(Becton-Dickinson) and analyzed with FlowJo X 10.0.7r2 (Tree Star).

Results

In the relapsed ALL patients, several B-cell antigens were expressed,including CD19, CD22, CD123, FLT-3, CD10, and CD34. See FIG. 22 .

In order to identify potential additional B-cell acute lymphoblasticleukemia (B-ALL) targets, samples from 16 r/r patients were screened bymultiparametric flow cytometry for the following markers: CD19 (16 pts),CD22 (16 pts), CD123 (16 pts), FLT-3 (9 pts), ROR-1 (3 pts), CD79b (15pts), CD179b (8 pts), CD79a (16 pts), CD10 (16 pts), CD34 (16 pts), andCD20 (16 pts). CD22 and CD123 were highly (>60%) and homogeneouslyexpressed in the blasts of r/r ALL patients (bar indicates median %expression, respectively 99.50%, 98.80%, 95.70%, 72.00%, 47.00%, 15.00%,13.45%, 4.200%, 98.00%, 87.65%, and 7.00%). (FIG. 22 ).

Example 15: Expression of B-Cell Antigens in Relapsed CD19-NegativeCancer Patients

Expression of various B-cell antigens was determined in patients who hadpreviously been treated with a CD19 CAR and who have relapsed withCD19-negative tumors. Flow cytometry was used according to the methodsin Example 14 to determine expression of the antigens, with a gatingstrategy depicted in FIG. 23 .

Expression of CD22 and CD123 was analyzed in BM and PB samples from 6patients relapsing with CD19-negative leukemia, both before CART19treatment (baseline) and after (CD19-negative relapse). In all analyses,the population of interest was gated based on forward vs. side scattercharacteristics followed by singlet gating, and live cells were gatedusing Live Dead Aqua (Invitrogen). Time gating was included for qualitycontrol. The gating strategy included: time gating→SSClow→singlets→live→CD45dim→CD10+.

Results

Almost all patients who became CD19-negative remained both CD22-positiveand CD-123-positive. See FIG. 24 and FIG. 25 . The results aresummarized in FIG. 26 , and demonstrate that while CD19 CART treatmentresults in a loss of CD19 expression (as measured by flow cytometry),CD22 and CD123 expression remains high.

Example 16: Expanded Access Treatment with Autologous CD22 RedirectedCART Cells in Refractory B-Cell Malignancies

Relapsing/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) isassociated with a poor prognosis in both pediatric and adult patients.Novel therapies targeting CD19 on leukemic blasts, such as anti-CD19Chimeric Antigen Receptor T cells (CART19, CTL019) or bi-specificanti-CD19/CD3 antibodies (blinatumomab) induce significant responses inthis population. However, CD19-negative relapses have been reported in5-10% of patients following CART19 or blinatumomab therapies.

Methods Cell Line and Primary Samples

Cells of the ALL cell line, NALM-6, were maintained in culture with RPMImedia supplemented with 10% fetal calf serum, penicillin, andstreptomycin. For some experiments, NALM-6 cells were transduced withluciferase/GFP+ and then sorted to obtain a >99% positive population.The acute myeloid leukemia cell lines MOLM-14 or K562 and the T-ALL cellline JURKAT were used as CD22-negative controls.

De-identified primary human ALL bone marrow (BM) and peripheral blood(PB) specimens and BM and PB samples from two patients relapsing afterCART-19 therapy were obtained. ALL blasts from patient treated withCART-19 and relapsed with CD19-negative leukemia were collected atbaseline (IR82, prior to CART19 therapy) and relapse (IR243). Primaryblasts from these 2 time points were expanded in vivo in NSG mice andtransduced with luciferase/GFP after several passages (Barrett, D et al.(2011) Blood 118(15):e112-117). For all functional studies, ALL cellswere thawed at least 12 hours before analysis and rested at 37° C.

Generation of CAR Constructs and CAR T Cells

A chimeric antigen receptor (CAR) against CD22 was generated using theanti-CD22 single-chain variable fragment light (L) and heavy (H) chainsequences described in U.S. Patent Application No. 2011/0020344 A1,which describes generation of an anti-CD22 fully human monoclonalantibody m971 (Xiao, X et al. (2009) MAbs. 1(3):297-303). The sequenceswere codon-optimized and two different CAR constructs were generatedusing two different variable chain orientations (H to L and L to H).These two anti-CD22 scFvs were then cloned into a murine CAR19 backbone(CD8 hinge, 41BB costimulatory domain and CD3 zeta signaling domain) andsubsequently in the pTRPE lentiviral vector. Murine CAR19 was generatedas previously described (Milone, M et al. (2009) Molecular therapy: thejournal of the American Society of Gene Therapy 17(8):1453-1464).

Production of CAR-positive T-cells was performed as previously described(Gill, S et al. (2014) Blood 123(15):2343-2354). Normal donorCD4-positive and CD8-positive T cells were plated at the concentrationof 1e6/ml, with a CD4:CD8 ratio of 1:1 and expanded in X-vivo 15 media(Lonza, 04-418Q), human serum AB 5% (Gemini, 100-512),penicillin/streptomycin (Gibco, 15070063) and Glutamax (Gibco, 35050061)using anti-CD3/CD28 Dynabeads (Life Technologies, 11161D) added on theday 1 of culture and removed on day 6. T-cells were transduced withlentivirus carrying either CAR22, CAR19 or mock transfected on day 2.T-cells were expanded in culture for 10-15 days and harvested when themedian cell volume was below 300 fl. T-cells were then cryopreserved inFBS 10% DMSO for future experiments. Prior to all experiments, T-cellswere thawed and rested overnight at 37° C.

Multiparametric Flow Cytometry Analysis

Anti-human antibodies were purchased from Biolegend, eBioscience, orBecton Dickinson. Cells were isolated from in vitro culture or fromanimals, washed once in PBS supplemented with 2% fetal calf serum, andstained for 15 minutes at room temperature. For cell numberquantitation, Countbright (Invitrogen) beads were used according to themanufacturer's instructions. In all analyses, the population of interestwas gated based on forward vs. side scatter characteristics followed bysinglet gating, and live cells were gated using Live Dead Aqua(Invitrogen). Time gating was included for quality control. For animalstudies the murine anti-CD45 antibody (Biolegend) was added to gate outmurine leukocytes. Surface expression of anti-CD22 CAR was detected bystaining with CD22-His protein (11958-H08H-50) and anti-His-APCmonoclonal antibody (IC050A). CAR19 was detected as previously described(Kalos, M et al. (2011) Science translational medicine 3(95):95ra73).Quantitation of CD19 and CD22 cellular antigen expression in AntibodyBinding Capacity (ABC) units was performed on NALM-6 and controls usingQuantum™ Simply Cellular® (Bangs Lab., Inc) according to standardprocedure (static.abdserotec.com/uploads/ifu/fcsc815b.pdf). Flowcytometry was performed on a four-laser Fortessa-LSR cytometer(Becton-Dickinson) and analyzed with FlowJo X 10.0.7r2 (Tree Star).

Degranulation Assay

Degranulation assays were performed as previously described. T-cellswere incubated with target cells at a 1:5 ratio in T cell media.Anti-CD107a-PECY7 (Biolengend), anti-CD28 (BD Biosciences), anti-CD49d(BD Biosciences) antibodies and monensin (BD Biosciences) were added toco-culture 30 minutes after starting time. After 4 hours, cells wereharvested and stained for CAR expression, CD3, CD8 and Live Dead aquastaining (Invitrogen). Cells were fixed and permeabilized (InvitrogenFix/Perm buffers) and intracellular staining was then performed todetect multiple cytokines (IFN, TNFa, IL-2, GM-CSF, MIP1b).

Proliferation Assay

T cells were washed and resuspended at 1×107/ml in 100 μl of PBS andstained with 100 μl of CFSE 2.5 μM (Invitrogen) for 5 minutes at 37° C.The reaction was then quenched with cold media, and cells were washedthree times. Targets were irradiated at a dose of 100 Gy. T-cells wereincubated at a 1:1 ratio with irradiated target cells for 120 hours,adding media at 24 hours. Cells were then harvested, stained for CD3,CAR and Live Dead aqua (Invitrogen), and Countbright beads (Invitrogen)were added prior to flow cytometric analysis for absolutequantification.

Cytotoxicity Assays

Luciferase/GFP+ NALM-6 cells or primary ALL samples were used forcytotoxicity assay as previously described. 4 Targets were incubated atthe indicated ratios with effector T-cells for 4 or 16 hours. Killingwas calculated either by bioluminescence imaging on a Xenogen IVIS-200Spectrum camera or by flow cytometry. For the latter, cells wereharvested and Countbright beads and 7-AAD (Invitrogen) were added priorto analysis. Residual live target cells were CFSE-positive7-AAD-negative.

Cytokine Measurements

Effector and target cells were co-incubated at a 1:1 ratio in T-cellmedia for 24 hours. Supernatant was harvested and analyzed by 30-plexLuminex array (Luminex Corp, FLEXMAP 3D) according to the manufacturer'sprotocol (Invitrogen) (Kalos, M et al. (2011)).

In Vivo Experiments

NOD-SCID-γ chain−/− (NSG) mice were obtained. All experiments wereperformed on protocols approved by the Institutional Animal Care and UseCommittee (IACUC) of the University of Pennsylvania. Schemas of theutilized xenograft models are discussed in details in the resultssection. Cells (NALM-6 or T cells) were injected in 200 ul of PBS at theindicated concentration into the tail veins of mice. Bioluminescentimaging was performed using a Xenogen IVIS-200 Spectrum camera andanalyzed with LivingImage software v. 4.3.1 (Caliper LifeSciences).Animals were euthanized at the end of the experiment or when neededaccording to IACUC policies.

Immunohistochemistry

Tissue microarrays (TMA) of 28 human normal tissues (adipose, adrenal,appendix, cerebellum, cervix, colon, endometrium, esophagus, fat, heart,kidney, liver, lymph node, lung, muscle, ovary, pancreas, parathyroid,placenta, prostate, salivary, spinal, spleen, stomach, testis, thymus,thyroid, tonsil) were performed in order to evaluate off-tumorexpression of CD22 (triplicates). Immuno-histochemical (IHC) staining offormalin fixed paraffin embedded tissues was performed on a LeicaBond-III instrument using the Bond Polymer Refine Detection System.Antibodies against CD22 (Clone FPC1; Leica PA0249) were used undiluted.Heat-induced epitope retrieval was done for 20 minutes with ER2 solution(Leica Microsystems AR9640). Images were digitally acquired using theAperio ScanScope™.

Gene Expression Profiling.

Publicly accessible RNA-expression database (GeneAtlas U133A, gc) wasanalyzed using BioGPS.org website for CD22 expression. Median CD22 RNAexpression was reported for 75 different human normal cell types and 7tumor cell lines (see FIGS. 39A, 39B, 39C and 39D).

51-Chromium-Release Assay

In order to evaluate to possible off-tumor CART22 toxicity,Chromium-release assay was performed, using as a target normal humantissues (CD34+, human neurons, human neuronal progenitors,keratinocytes) and K562 or NALM-6 as controls. Target cells wereincubated with 51Cr 50 μCi/0.5e6 cells for 1-2 hrs at 37° C. Cells werewashed and plated in triplicate with effectors cells at different E:Tratios. After 4 hour-incubation, an aliquot from each well was put in areader plate and dried overnight. The next day chromium release wasquantified using 1450 Microbeta Plus Liquid Scintillation Counter.

Results

TABLE 33 Summary of the donors and the respective experiments performedfor CART22 evaluation. Expan- Degran. + i.c. Prolif. + Kill- In ToxDonors sion cytokines Luminex ing vivo Screen 1 ✓ ✓ X2 ✓ X2 ✓ X2 ✓ 2 ✓ ✓3 ✓ ✓ ✓ 4 ✓ 5 ✓ ✓

In order to identify potential B-ALL targets, samples from 16 r/rpatients and 4 patients relapsing with CD19-negative disease aftertreatment with CART19 therapy were screened by multiparametric flowcytometry for the B cell marker, CD22. CD22 was highly (>60%) andhomogeneously expressed in the blasts of 11/15 r/r ALL patients (FIG.27A). CD22 was also positive in 4/4 patients relapsing withCD19-negative leukemia, both before CART19 treatment (baseline) andafter (CD19-neg relapse) (2 pts shown) (FIG. 27B). (Gating strategy: SSClow→singlets→live→CD45dim).

The schema of the CAR22 constructs that were generated using differentchain orientations (H to L and L to H) is shown in FIG. 28A. Theanti-CD22 scFv (m971) was codon optimized and cloned in the murine CAR19vector containing CD8 hinge, 41-BB costimulatory and CD3 zeta signalingdomains. The expression of CD19, CD22 and isotype control on NALM6 ALLcell line is shown as mean fluorescence intensity (MFI) (FIG. 28B) andantibody-binding capacity (ABC) (FIG. 28C). The results presented hereindemonstrate that in NALM-6 cells, the expression of CD19 is higher thanCD22. However, in most primary ALL samples, the CD19 and CD22expressions are similar (see FIG. 28A).

Normal donor T-cell expansions for generating CART22 and CART19(together with untransduced cells (UTD)) were carried out. Populationdoubling times and T-cell volume were measured relative to days inculture. At the end of the expansion (day 11 in culture) CART22 andcontrol T-cells reached around 4.5 population doublings (PD), with nosignificant difference in comparison to CART19 or UTD cells (FIG. 29A).At day 6 in culture the peak volume was around 450 fl, while in thefollowing days the volume decreased down to 300 fl when the cells wereharvested and frozen (FIG. 29B). No significant different was observedversus CART19 or UTD. CAR expression on CD4-positive and CD8-positive Tcells was observed at day 11 of expansion by flow cytometry (FIG. 29C).Gating for CAR expression is based on UTD. (Gating strategy: FSS vs SSClymphocytes→singlets→live→CD3+).

CD107a degranulation assay with intra-cytoplasmic cytokine productionwas carried out. CART19, CART22 HtoL and LtoH were co-cultured withdifferent targets (alone, PMA/IONOMYCIN, MOLM-14 and NALM-6). CART19 andCART22 HtoL showed high levels of CD107a degranulation, IL-2, IFNg andTNFa production when co-cultured with the ALL cell line (NALM-6) but notwhen co-cultured with negative controls (FIG. 30 ). UTD and CART22 LtoHdo not show degranulation nor cytokine productions (FIG. 30 ). (Gatingstrategy: FSS vs SSC lymphocytes→singlets→live→CD3+).

In a luciferase-based killing assay, CART22 and CART19 HtoL but not UTDwere able to lyse NALM-6 cells when co-cultured for 24 hours (FIG. 31 ).A direct correlation between cytotoxic activity and E:T ratios wasobserved, with better anti-leukemia effect at 2:1 E:T ratio (78% and 75%killing for CART19 and CART22).

In a CF SE-based proliferation assay, co-culture for 5 days of CART22and CART19 with the ALL cell line NALM-6 led to significant T cellproliferation (94% and 92.9% respectively). Controls are also shown(TCM=media alone, P-I=PMA/Ionomycin, MOLM-14) (FIG. 32A) Histogramsshowing the dynamics of CFSE dilution in CART19 and CART22 demonstratethat most T-cells underwent multiple proliferative cycles (FIG. 32B).(Gating strategy: FSS vs SSC lymphocytes→singlets→live→CD3+)

CART22, CART19 and UTD cells were incubated for 24 hours with differentirradiated targets (alone, PMA/Ionomycin, MOLM-14 and NALM-6). Whenco-cultured with the ALL cell line NALM-6, only CART22 and CART19 HtoLwere able to release multiple cytokines (here shown IFNg, IL-2, GM-CSF,TNFa and MIP1b) (FIG. 33 ).

CART22, CART19 and UTD cells were co-incubated for 4 hours with blastsderived from an ALL patient (CHP-959-101) at baseline and after CART19treatment when the patient relapsed with a CD19-negative disease.Degranulation was measured. Both CART19 and CART22 were able todegranulate at baseline (when blasts are CD19+ and CD22+) but at relapseonly CART22 was degranulating (when the disease is CD19-negative) (FIG.34A). CD107a degranulation was measured in CD8-positive and CD8-negativeCART19 and CART22 effector after incubation with CHP101 sample atrelapse. Only CART22 showed degranulation in both CD8 and CD4 T-cells(FIG. 34B). (Gating strategy: FSS vs SSClymphocytes→singlets→live→CD3+).

In vivo CART22 efficacy against NALM-6 was assessed as follows: 1million NALM-6 luciferase+ cells/mouse were injected i.v. in NSG mice.After 6 days tumor engraftment was assessed by bioluminescence. Micewere then randomized to receive untransduced T-cells or different dosesof CART22 (from 1.25 to 5 million total cells/mouse, with 75% CARexpression). Mice were then monitored for tumor burden, PB T cellexpansion, and survival (FIG. 35A). Tumor burden by bioluminescence(BLI) was measured and dose-related anti leukemia response was observed.Mice receiving 5e6 CART22 cells showed better tumor control (FIG. 35B).CART22 treated mice showed a statistically significant better overallsurvival (OS) in comparison to UTD treated mice. Also for OS there was asignificant correlation between higher dose of CART22 and better OS(FIG. 35C). T-cell in vivo expansion was monitored weekly byretro-orbital bleedings. One week after T cell infusion mice receivingthe higher dose of CART22 showed the better CART expansion (median of 12T cells/μl) (FIG. 35D).

In vivo comparison between CART22 and CART19 against NALM-6 was assessedas follows: 1 million NALM-6 luciferase+ cells/mouse were injected i.v.in NSG mice. After 6 days tumor engraftment was assessed bybioluminescence. Mice were then randomized to receive untransducedT-cells, CART19 or CART22 (5 million total cells, with 75% CARexpression). Mice were then monitored for tumor burden, PB T-cellexpansion, and survival (FIG. 36A). Tumor burden by bioluminescence(BLI) was measured and anti-leukemia response was observed in bothCART22 and CART19 treated mice, while UTD mice rapidly progressed (FIG.36B). CART19 treated mice showed better overall survival (OS) incomparison to CART22, possibly due to the different target expression inNALM-6 (CD19>>CD22) (FIG. 36C).

CART22 and CART19 were compared in vivo in a model of primary ALL. Theblasts of a primary ALL patient (JH331) were passaged in vivo andtransduced with luciferase to follow tumor burden. 1 million JH331luciferase+ cells/mouse were injected i.v. in NSG mice. After 14 daystumor engraftment was assessed by bioluminescence. Mice were thenrandomized to receive untransduced T-cells, CART19 or CART22 (5 milliontotal cells, with 75% CAR expression). Mice were then monitored fortumor burden, PB T-cell expansion, and survival (FIG. 37A). Tumor burdenby bioluminescence (BLI) was measured and anti-leukemia response wasobserved in both CART22 and CART19 treated mice, while mice treated withUTD cells rapidly progressed (FIG. 37B).

Tissue microarrays for CD22 expression were performed on 28 human normaltissues by immunohistochemistry staining. Lymphoid organs resultedpositive for CD22 expression (tonsil, lymph node, spleen and thymus)(FIG. 38A). All non-lymphoid organs showed no expression of CD22 (FIG.38B). CD22-positive resident B-cells were observed in multiple tissues(FIG. 38C).

CD22 RNA expression was observed at high level in B-cells, tonsil andlymph nodes, as shown in expression data from GeneAtlas U133A.B-lymphoblast and leukemia/lymphoma cell lines were also highly positive(FIGS. 39A, 39B, 39C and 39D).

Both CART22 and CART19 but not UTD cells triggered the lysis of the ALLcell line NALM-6 in a 51-Chromium-release assay for CART22 toxicity(FIG. 40 ). No cytotoxic effect of CART22 was observed in any normaltissue (CD34+, human neuronal progenitors or neurons and keratinocytes)or control (K562 cell line).

Example 17: Combination of Anti-CD123 and Anti-CD19 CAR T Cells for theTreatment and Prevention of Antigen-Loss Relapse

Chemo-refractory or relapsing (r/r) B-cell acute lymphoblastic leukemia(B-ALL) is associated with a poor prognosis but, as demonstratedrecently, remains exquisitely sensitive to the immune system. Inparticular, anti-CD19 chimeric antigen receptor T cells (CART19, CTL019)and bi-specific anti-CD19/CD3 antibodies (blinatumomab) generateunprecedented complete response rates of 45-90% in this patientpopulation. Both approaches re-direct autologous T cells to recognizeCD19-expressing cells. Blinatumomab uses a continuous long-term infusionof a bispecific construct that combines an anti-CD19 single chainvariable fragment (scFv) with an anti-CD3 scFv; in the case of CART19 Tcells are genetically modified to express an anti-CD19 scFv fused to theT cell receptor signaling with built-in co-stimulatory domains. A recentstudy showed that 90% of patients with r/r B-ALL treated with CTL019reach complete remission (CR) with an overall survival (OS) of 78% at 6months. Encouraging results with CART19 were also obtained in patientswith other B-cell neoplasms, such as chronic lymphocytic leukemia andnon-Hodgkin lymphoma.

However, a subset of patients treated with CART19 or blinatumomabdevelops relapse and a significant portion of these relapses arecharacterized by the loss of CD19. In B-ALL, CD19-negative relapses havebeen reported in 10-20% of patients following CART19 or blinatumomabtherapies and it has not been described in the setting of othertreatments; overall about 30% of relapses after blinatumomab and up to50% after CART19 are CD19-negative. CD19 is a prototypic B-cell markerthat is expressed from the very earliest stages of B cell development tothe mature B-cell. CD19 plays an important role in B cell biology asCD19-deficient B cells exhibit selective growth disadvantage. Thus theabsence of CD19 is a very unusual finding in B-ALL and it is has beenreported in only rare patients prior to the era of potent CD19-directedimmunotherapies. The possible mechanism of antigen loss is currentlyunder investigation and is most likely caused by selective pressure onleukemia sub-clones by these powerful anti-CD19 agents. Because of therecent approval by the FDA of blinatumomab and the breakthrough statusaccorded to CTL019, it is likely that increasing numbers of patientswith r/r B-ALL will be treated with these agents. Hence, novel effectivestrategies are needed in order to be able to treat those patients thatwill relapse with CD19-negative blasts after CART19 or blinatumomab.Ideally a new approach would not only treat patients with activeantigen-loss relapse but if employed upfront could potentially preventtheir occurrence.

The interleukin-3 receptor alpha (or CD123) is involved in hematopoiesisand has been shown to be expressed in several hematologic neoplasms,including acute myeloid leukemia (AML), acute lymphoid leukemia (ALL),plasmacytoid dendritic cell neoplasm, hairy cell leukemia, and Hodgkinlymphoma. Unlike lineage-associated surface antigens such as CD33(myeloid) or CD19 (B-lymphoid), CD123 is hierarchically expressed onhematopoietic progenitor cells and in AML CD123 is expressed on leukemicstem cells that are involved in resistance to chemotherapy and relapseafter initial treatment. Due to these characteristics, CD123 hasgenerated great interest for targeted therapy, and multiple agents arebeing developed such as the IL3-diphtheria toxin fusion protein (SL-401,DT3881L3), naked anti-CD123 monoclonal antibodies (CSL-360, CSL-362),antibody-drug conjugates, bi-specific antibodies or CD3Fv-IL3 fusionconstructs, and more recently, anti-CD123 chimeric antigen receptor Tcells. Some of these approaches are currently being validated inclinical trials and many more will be tested in the clinic in the nextfew years. Targeting CD123 with chimeric antigen receptor T cells(CART123) can lead to deep and long-term responses in human primary AMLxenografts and can establish an anti-leukemia T cell memory. Here, CD123is expressed in CD19-negative B-ALL relapses occurring afterCD19-directed therapies and that CAR-123 T cells combined with CART19(CTL019) is an effective therapy for the treatment and for theprevention of antigen-loss relapses in B-ALL xenografts.

Materials and Methods

Cell lines and primary samples. Cell lines were originally obtained fromATCC (Manassas, VA) (K-562) or DSMZ (Braunschweig, Germany) (MOLM-14 andNALM-6). All cell lines were tested for the presence of mycoplasmacontamination (MycoAlert™ Mycoplasma Detection Kit, LT07-318, Lonza,Basel, Switzerland). For some experiments, cell lines were transducedwith firefly luciferase/eGFP and then sorted to obtain a >99% positivepopulation. The luciferase positive K-562 cell line was also transducedwith truncated CD19 or truncated CD123 to obtain cell lines expressingneither of them, only CD19 or only CD123. MOLM-14 and K562 were used ascontrols as indicated in the relevant figures. The cell lines weremaintained in culture with RPMI media 1640 (Gibco, 11875-085,LifeTechnologies, Grand Island, NY) supplemented with 10% fetal bovineserum (FBS, Gemini, 100-106, West Sacramento, CA), and 50 UI/mlpenicillin/streptomycin (Gibco, LifeTechnologies, 15070-063).De-identified primary human ALL bone marrow (BM) and peripheral blood(PB) specimens were obtained from the clinical practices of Universityof Pennsylvania/Children's Hospital of Philadelphia under anInstitutional Review Board (IRB)-protocol, purchased from the Stem Cellsand Xenograft Core of the University of Pennsylvania or from researchsamples of the current CTL019 clinical trials (Translation andCorrelative Study Laboratory, at the University of Pennsylvania). Forall functional studies, primary cells were thawed at least 12 hoursbefore experiment and rested at 37° C.In vivo expansion of primary B-ALL blasts. Methods disclosed in D. M.Barrett, A. E. Seif, C. Carpenito, D. T. Teachey, J. D. Fish, C. H.June, S. A. Grupp, G. S. Reid, Noninvasive bioluminescent imaging ofprimary patient acute lymphoblastic leukemia: a strategy for preclinicalmodeling. Blood 118, e112-117 (2011).Fluorescence in situ hybridization (FISH) and immunohistochemistry. TheFISH analysis and immunohistochemistry were performed according to thestandard method and as described. (M. A. Belaud-Rotureau, M. Parrens, P.Dubus, J. C. Garroste, A. de Mascarel, J. P. Merlio, A comparativeanalysis of FISH, RT-PCR, PCR, and immunohistochemistry for thediagnosis of mantle cell lymphomas. Modern pathology: an officialjournal of the United States and Canadian Academy of Pathology, Inc 15,517-525 (2002)). The FISH analysis was performed according to thestandard method. In brief, harvested ALL cells were suspended infixative (acetic acid and methanol), deposited on the slides, and leftto dry. The dual color gene fusion probe BCR/ABL (Abbott Molecular), wasapplied in the hybridization buffer solution. The slides werecover-slipped, sealed, and left inside the HYBrite chamber at 37 C for 6hr. After removal of the sealant and the coverslip, the slides werewashed twice, blotted, dried, and counterstained with DAPI. The slideswere examined under fluorescent microscope, with a minimum of 200 nucleievaluated in each specimen.Generation of CAR constructs and CART cells. The murine anti-CD19chimeric antigen receptor (CD8 hinge, 4-1BB co-stimulatory domain andCD3 zeta signaling domain) was generated as previously described.(Milone, et al., Molecular therapy: the journal of the American Societyof Gene Therapy 17, 1453-1464 (2009) and Imai, et al., Leukemia 18,676-684 (2004)). This is the same construct currently used in the CTL019clinical trials at the University of Pennsylvania. For CAR123 scFvanti-CD123 (1172 construct (SEQ ID NO: 707, and as described inPCT/US2014/017328) was used and the same backbone construct of CAR19.Production of CAR-expressing T cells was performed as previouslydescribed. (Gill, et al., Blood 123, 2343-2354 (2014)). Normal donor CD4and CD8 T cells or PB mononuclear cells (PBMC) were obtained from theHuman Immunology Core of the University of Pennsylvania. T cells wereplated at 1×10⁶/ml with a CD4:CD8 ratio of 1:1 and expanded in X-vivo 15media (Lonza, 04-418Q), supplemented with human AB serum 5% (Gemini,100-512), penicillin/streptomycin (Gibco, 15070063) and Glutamax (Gibco,35050061) using anti-CD3/CD28 Dynabeads (Life Technologies, 11161D)added on the day 1 of culture and removed on day 6. T cells weretransduced with lentivirus on day 2. T cells were expanded in culturefor 8-15 days and harvested when the median cell volume was below 300fl. T cells were then cryopreserved in FBS with 10% DMSO for futureexperiments. Prior to all experiments, T cells were thawed and restedovernight at 37° C.Multiparametric flow cytometry. Flow cytometry was performed aspreviously described (Kenderian, et al., Leukemia, (2015)). Anti-humanantibodies were purchased from Biolegend, eBioscience, or BectonDickinson. Cells were isolated from in vitro culture or from animals,washed once in PBS supplemented with 2% fetal calf serum, and stainedfor 15 minutes at room temperature. For cell number quantitation,Countbright (Invitrogen) beads were used according to the manufacturer'sinstructions. In all analyses, the population of interest was gatedbased on forward vs. side scatter characteristics followed by singletgating, and live cells were gated using Live Dead Fixable Aqua(Invitrogen). Time gating was included for quality control. Surfaceexpression of CAR19 was detected as previously described, using ananti-idiotype antibody. Detection of CAR123 was performed usinggoat-anti-mouse antibody (Jackson Laboratories) or CD123-Fc/His (SinoBiologicals) and anti-His-APC (R&D) or PE (AbCam). Flow cytometry wasperformed on a four-laser Fortessa-LSR II cytometer (Becton-Dickinson)and analyzed with FlowJo X 10.0.7r2 (Tree Star).In vitro T-cell effector function assays. Degranulation, CFSEproliferation, cytotoxicity assays and cytokine measurements wereperformed as previously described. (Gill, et al., Blood 123, 2343-2354(2014) and Kalos, et al., Science translational medicine 3, 95ra73(2011)).Degranulation assay. Briefly, T cells were incubated with target cellsat a 1:5 ratio in T cell media. Anti-CD107a-PECY7 (Biolegend), anti-CD28(BD Biosciences), anti-CD49d (BD Biosciences) antibodies and monensin(BD Biosciences) were added to the co-culture. After 4 hours, cells wereharvested and stained for CAR expression, CD3, CD8 and Live Dead aquastaining (Invitrogen). Cells were fixed and permeabilized (InvitrogenFix/Perm buffers) and intracellular staining was then performed todetect multiple cytokines (IFN, TNFα, IL-2, GM-CSF, MIP1β).Proliferation assay. T cells were washed and resuspended at 1×10⁷/ml in100 ul of PBS and stained with 100 ul of CFSE 2.5 uM (Invitrogen) for 5minutes at 37° C. The reaction was then quenched with cold media, andcells were washed three times. Targets were irradiated at a dose of 100Gy. T cells were incubated at a 1:1 ratio with irradiated target cellsfor 120 hours, adding media at 24 hours. Cells were then harvested,stained for CD3, CAR and Live Dead aqua (Invitrogen), and Countbrightbeads (Invitrogen) were added prior to flow cytometric analysis forabsolute quantification.Cytotoxicity assays. Luciferase/eGFP+ cell lines were used forcytotoxicity assay as previously described. In brief, targets wereincubated at the indicated ratios with effector T cells for 24 hours.Killing was calculated by bioluminescence imaging on a Xenogen IVIS-200Spectrum camera.Cytokine measurements. Effector and target cells were co-incubated at a1:1 ratio in T cell media for 24. Supernatant was harvested and analyzedby 30-plex Luminex array (Luminex Corp, FLEXMAP 3D) according to themanufacturer's protocol (Invitrogen).Animal experiments. In vivo experiments were performed as previouslydescribed. (Kenderian, et al., Leukemia, (2015)). Schemas of theutilized xenograft models are discussed in detailed in the relevantfigures, result. NOD-SCID-γ chain−/− (NSG) originally obtained fromJackson Laboratories were purchased from the Stem Cell and XenograftCore of the University of Pennsylvania. All experiments were performedaccording a protocol (#803230) approved by the Institutional Animal Careand Use Committee (IACUC) that adheres to the NIH Guide for the Care andUse of Laboratory Animals. Cells (leukemia cell lines or T cells) wereinjected in 200 ul of PBS at the indicated concentration into the tailveins of mice. Bioluminescent imaging was performed using a XenogenIVIS-200 Spectrum camera and analyzed with LivingImage software v. 4.3.1(Caliper LifeSciences). Animals were euthanized at the end of theexperiment or when they met pre-specified endpoints according to theIACUC protocols.Multiphoton microscopy. Mice were anaesthetized and maintained at coretemperature of 37° C. Bone marrow was imaged after removing the scalpand immobilizing the skull. Imaging was performed using a Leica SP52-photon microscope system (Leica Microsystems) equipped with apicosecond laser (Coherent). Each imaging acquisition lasted 20 minfollowed by an assessment of mouse sedation. CellTrace Violet, GFP, andCellTrace Orange (or TRITC) were excited using laser light of 850 nm.Images were obtained using a 20× water-dipping lens. The resultingimages were analyzed with Volocity software (PerkinElmer).Statistical Analysis. All statistics were performed as indicated usingGraphPad Prism 6 for Windows, version 6.04 (La Jolla, CA). Student'st-test was used to compare two groups; in analysis where multiple groupswere compared, one-way analysis of variance (ANOVA) was performed withHolm-Sida correction for multiple comparisons. When multiple groups atmultiple time points/ratios were compared, the Student's t-test or ANOVAfor each time points/ratios was used. Survival curves were comparedusing the log-rank test. In the figures asterisks are used to representp-values (*=<0.05, **=<0.01, ***=<0.001, ****=<0.0001) and “ns” means“not significant” (p>0.05). Further details of the statistics for eachexperiment are listed in figure legends.

Results CD123 is Expressed in B-ALL, in the Leukemia Stem Cells and inCD19-Negative Relapses

In order to evaluate the expression of CD123 in B-cell acutelymphoblastic leukemia, 42 samples from adult and pediatric ALL patientswere analyzed, including 14 subjects enrolled in our current CTL019clinical trials. As shown in FIGS. 49A, 49B and 49A, CD123 is highly andhomogeneously expressed on the surface of most ALL blasts, representingan ideal candidate for targeted therapy. Moreover, CD123 is also foundto be expressed in the putative leukemia stem cells (LSC), identified asCD34+ CD38− (FIG. 49C). Small subsets of CD19-negative blasts can beidentified in some B-ALL patients and these cells could contribute toantigen-loss relapses, if they contained cells with a malignantphenotype. In order to evaluate the presence of disease in CD19-negativesubsets, CD19− CD123+ cells from a Philadelphia chromosome positiveB-ALL bulk population were sorted (CD45dim, gating strategy shown FIG.56B). It was found that these cells were clonal for the BCR-ABLtranslocation, albeit at a lower frequency than the CD19+ blasts (FIG.49D). This finding indicates that targeting CD19 alone could, in somecases, lead to a subclonal relapse derived from CD19−CD123+ cells.Furthermore, this finding suggests that targeting CD123 could lead todeeper responses through the elimination of the LSC and possiblyCD19-neg leukemia clones.

Finally the expression of CD123 was also evaluated in the samples ofB-ALL patients relapsing after CTL019 with loss of CD19. Importantly, incontrast to the complete loss of CD19, the majority of patientsmaintained CD123 expression at relapse (FIGS. 49E, 49F and 56C). Thesefindings indicate that CD123 represents an ideal marker to targetCD19-neg ALL blasts occurring after CART19 or blinatumomab.

Anti-CD123 Chimeric Antigen Receptor T Cells are Active Against HumanB-ALL In Vitro and In Vivo

Anti-CD123 chimeric antigen receptor T cells (CART123) were generatedthat were lentivirally transduced and expanded with anti-CD3/CD28magnetic beads. The in vitro and in vivo activity of CART123 againstB-acute lymphoblastic leukemia were evaluated as described herein.

The B-ALL cell line NALM-6 that is CD19++ and CD123+ (FIGS. 50A and 57A)and primary B-ALL samples were used. A head-to-head in vitro comparisonbetween CART123 and CART19 revealed similar rates of CD107adegranulation when T cells were co-cultured with NALM-6 or primary ALL(FIG. 50B). CART123 were also able to kill NALM-6 cells with similarefficacy as CART19 in a dose-dependent manner (FIG. 50C). At morelong-term experiments, CART123 proliferated (FIGS. 50D and 50E) andproduced multiple cytokines (FIG. 50F) when co-cultured with NALM-6 orprimary ALL for 3-5 days. These results indicate that CART123 exhibitequivalent potency to CART-19 against multiple B-ALL targets.

In order to confirm these data in an in vivo model, a primary ALL modelwas utilized. In this model, primary blasts obtained from B-ALL patientswere passaged in NOD-SCID-γ chain knock-out (NSG) mice and transducedwith a reporter construct containing eGFP and click beetle luciferase(GFP/Luc). NSG mice were injected with GFP/Luc+ primary ALL blasts i.v.(JH331, CD19+, CD123+, add phenotype) and after engraftment, mice wererandomized to receive CART19, CART123 or control untransduced T cells(UTD). Mice treated with control T cells succumbed quickly to disease,while mice treated with either CART19 or CART123 showed tumoreradication and long term survival (FIGS. 51A and 51B). CAR123 T cellssignificantly expanded in the peripheral blood (PB) of the mice comparedto control T cells and expressed high levels of CAR123 (FIG. 51C). Theanti-leukemia activity of CART123 was specific and based on therecognition of CD123 in the surface of the blasts as when we engraftedmice with a CD123− CD19+ leukemia (AV576), only CART19 showanti-leukemia activity, while CART123 had no effect as compared tocontrols UTD (FIGS. 57B and 57C).

In order to detect a possible correlation of CART123 dose and anti-tumoractivity, an in vivo model of high leukemia burden bearing mice (usingthe NALM-6 cell line) was developed. In this model standard doses ofCART123 (2 million CAR+ cells) are not able to clear the tumor. Thesemice were injected with different doses of CART123 (1.25, 2 and 5million CAR+ cells) and observed a dose-related anti-leukemia activity(FIG. 57D).

CART123 but not CART19 are Highly Active in a Novel Preclinical Model ofAntigen-Loss Relapse

In order to test new strategies to target CD19-negative relapses a novelin vivo model of antigen-loss relapse was developed. B cell blastsobtained from a patient (CHP101) enrolled in one of our CTL019 clinicaltrials were collected at baseline (before CTL019 therapy), when thedisease was CD19++ and CD123+, and at relapse after CTL019 when thepatient developed a CD19-negative disease (CD123 still expressed, FIG.58A). Blasts were then expanded in NSG mice and transduced withclick-beetle green luciferase (CBG) for baseline disease (CD19+) orclick-beetle red luciferase (CBR) for relapse (CD19−) (see Methodssection). Importantly, during in vivo expansion, the blasts retainedmarkers of B cell identity other than CD19 (data not shown). In a firstexperiment NSG mice were engrafted with either the baseline diseaseCD19+ (CBG, green) or the CD19-neg (CBR, red) leukemia. Both groups wererandomized to receive CART19 or control T cells (UTD) (FIG. 52A). Asshown in FIG. 52B, in both groups mice treated with UTD showed rapidprogression of both the baseline and relapse disease, independently bythe expression of CD19. Conversely, in the group of mice treated withCART19, only mice engrafted with the baseline disease (CD19-positive)responded to CART19 treatment while mice engrafted with the relapseddisease (CD19-negative) showed refractoriness as expected. This was alsoreproduced in vitro in a CD107a degranulation assay (FIG. 58B). In orderto simulate in vivo the presence of different clones expressing CD19 orlacking it, NSG mice were engrafted with a 1:1 mixture of baseline andrelapse disease; at day 8 mice were randomized to receive CART19 orcontrol T cells. Tumor burden was monitored with bioluminescence imagingthat could discriminate between CD19+ (CBG, green)/CD19− (CBR, red)leukemia relative growth in vivo. As shown in FIG. 52C, in micereceiving UTD both CD19+ (green) and CD19− (red) leukemia present at day6 was similarly increased at day 11, while in mice treated with CART19the baseline disease (green) was completely cleared while the relapseddisease (red) showed progression.

This unique xenograft model of primary CD19-negative B-ALL and CART19failure was used to evaluate the role of CART123 in the treatment ofantigen-loss relapses. Primary CD19-negative blasts (CBR positive) wereinjected into NSG mice (FIG. 52D) and mice were randomized to receiveCART19, CART123 or control T cells. CART19 and control T cells showedcomplete lack of anti-tumor activity, while CART123 lead to completeeradication of the disease and long term survival in these mice (FIGS.52E and 52F). Indeed in a pre-clinical model of primary B-ALL refractoryto CART19, the novel CART123 are able to eradicate the disease andconfer long-term survival.

In order to understand the differential behavior of CART19 and CART123in this in vivo model at a single cell level, a series of experimentswas performed by injecting a mixture of differentially labelled CART19(CellTrace Violet, blue) and CART123 (CellTracker Orange or TRITC, red)to mice bearing CD19-positive primary blasts (GFP) or CD19-negativerelapsed blasts (GFP) and tracked their behavior using intravital2-photon microscopy of calvarial marrow approximately 24 hours afterinjection (experiment schema, FIG. 53A). These studies showed thatCART19 and CART123 trafficked to marrow spaces containing leukemia andthat CART cell recognition of cognate antigen correlate with motilityarrest. Specifically, in mice engrafted with the baseline CD19+CD123+leukemia, 62.9%+/−3.8 of CART19 and 81.1%+/−1.2 of CART123 were found tobe stalled with a rounded morphology adjacent to blasts, whereas in miceengrafted with the relapsed CD19−CD123+ leukemia, only CART123 cellsarrested next to tumor cells (CART123 80.9%+/−5.1 vs CART19 12.4%+/−2.2)(FIGS. 53B and 53C). These findings indicate that in CD19-negativerelapsed ALL only CART123 were able to establish productive synapseswith the leukemia cells (GFP) and thus reduced their motility, whereasCART19 cells continued sampling and moving in the environment withoutrecognizing the leukemia blasts.

The Combination of CART123 and CART19 is Able to Prevent CD19-NegativeRelapses

CART123 proved to be effective in the treatment of CD19-negativerelapses occurring after CD19-directed therapies in a preclinical modelof CART19 resistance. However, a combinatorial approach could treatactive CD19-positive disease while simultaneously preventingantigen-loss relapses. In order to test this hypothesis the emergingclinical problem of B-ALL with a potential for CD19-negative escape wasmodeled by injecting primary CD19- and CD19+ disease together into NSGmice. Mice were then randomized to receive control T cells (UTD), CART19or the combination of CART19 and CART123, with the same total dose of Tcells (FIG. 54A). As shown in FIG. 54B, mice treated with control Tcells had progression of both leukemia clones and CART19 showed rapidprogression mostly of the CD19-neg disease (red). On the contrary micetreated with the combination of CART123 and CART19 showed clearance ofthe disease and improved overall survival, as shown in FIG. 54C.Analysis of mice sacrificed at the end of the experiment showed noevidence of residual leukemia in the pooled CAR T cell group. Incontrast, mice with progressive disease after CART19 monotherapyretained the expected CD19 negative phenotype (FIG. 54D).

Lastly, T cells were transduced with 2 lentiviruses, one carrying CAR19and the other CAR123 in order to develop a CART able to be activated byboth CD19 and/or CD123. As shown in FIG. 55A, four differentlytransduced T cell subsets were detected: CAR19 and CAR123 doublenegative, CAR19 single positive, CAR123 single positive and doublepositive CAR19/CAR123 T cells. These four subsets were sorted and theirfunctionality and specificity was tested against K562-WT, K562 CD19+ orK562 CD123+. FIG. 55B shows the results of a CD107a degranulation assaywhere the single positive subsets respond to their specific target whileonly the double positive population is able to degranulate in thepresence of both CD19 and CD123 expressing K562. In addition,dually-stimulated CART cells exhibited more potent cytotoxicity againsta double-positive target in comparison with an equivalent number ofsingle-stimulated CART cells, suggesting a potential increment inefficacy by using a CAR that is triggered by two different antigens(FIG. 55C).

Discussion

CD19 directed immunotherapies are changing the paradigm of treatment ofrelapsing and refractory acute lymphoblastic leukemia. Patients with apreviously dismal outcome now have a realistic potential to achieve acomplete response and long-term disease remission. However, as shownunder some circumstances for leukemia treated with other forms of potenttargeted therapy, leukemia cells are able to develop antigen-lossmutations that lead to resistance and relapse. In the case of CART19,two main patterns of relapses have been observed. Patients with earlyloss of CART19 through failure of persistence are at risk for relapse ofthe original clone; indeed, minimal residual disease analyses indicatethat between 1-6 months of sustained CART activity may be required tocompletely eradicate malignancy. In contrast, around 50% of relapsesoccur despite CART19 persistence and are characterized by the occurrenceof aCD19-negative leukemia. The latter observation implicates potentselective pressure by CART19. Notably, CD19-negative relapses have alsooccurred after blinatumomab therapy although these represent theminority of relapse occurrences after this arguably less potent therapy.There are multiple potential mechanisms for the development ofCD19-negative disease. One of these is the selection and relativesurvival advantage of CD19-negative clones that were present at baselinein very low frequency, and this was initially considered the most likelyfactor leading to CD19-negative relapses. More recently othermechanisms, such the dysregulation of the splicing of CD19 have alsobeen considered important. Here it is shown for the first time that rareCD19-ve blasts in B-ALL can contain the hallmark cytogeneticabnormalities found in the more common CD19-positive leukemia blasts,confirming this as a potential mechanism of CD19-negative relapse. Weconfirmed these findings by demonstrating that CD123+CD19-ve blasts canengraft in immunodeficient mice, indicating that CD123 may be a markerof leukemic stem cells in B-ALL as it is in AML.

The goal of this study was to define novel strategies to treat patientsrelapsing with antigen loss after CD19-directed therapies. CD123 washighly expressed in the majority of B-ALL, and in particular CD123remains expressed in those relapsing with CD19-negative disease. It wasdemonstrated the presence of clonal leukemic cells in the CD19− CD123+population indicating that targeting CD123 in combination with CART19can increase the likelihood of eradicating sub-clones that couldproliferate due to a selective advantage upon CART19 pressure. CD123 haspreviously been validated as a marker of the leukemic stem cell in AML.Here it was shown that CD123 to be expressed in theimmunophenotypically-defined leukemic stem cell (LSC) in ALL, raisingthe possibility that targeting CD123 on LSC could promote ALLeradication.

To study the role of CART 123 in antigen-loss relapses a novel xenograftmodel of CD19-negative relapses was developed from primary blastsderived from a B-ALL patient (CHP101) enrolled in one of the CTL019trials of the University of Pennsylvania/Children's Hospital ofPhiladelphia. This patient, at baseline had a classic CD19+CD123+phenotype but then relapsed after CART19 treatment with CD19−CD123+disease. Using this model, it was demonstrated CART123 could eradicatethe relapsed disease, and in combination with CART19 could preventantigen-loss relapse. This is the first demonstration of a dual CARTcombination in a clinically relevant, patient-derived model. Inaddition, through use of intravital imaging, it was shown that CARTcells enter the marrow in less than 24 hours after intravenousinjection, search for their targets, and slowdown in order to interactwith cognate antigen-bearing cells. Furthermore, it was shown that adual signaling CART123/19 was more effective than either CART alone or apool of both CAR, consistent with previously published results.

Previously, it was shown the pre-clinical efficacy of anti-CD123chimeric antigen receptor for the treatment of acute myeloid leukemia.CART123 causes hematopoietic toxicity due to recognition of CD123 onhematopoietic stem and progenitor cells, a potentially major challengeto clinical translation as profound stem cell toxicity could lead topermanent myeloablation. It was hypothesized that to minimizehematopoietic toxicity, a novel construct that activated T cells onlyupon co-engagement of CD19 and CD123 simultaneously could obviate thishematopoietic toxicity. Here it was found that CART cells receiving anactivating signal from CD19 recognition and a stimulatory signal fromCD123 recognition could kill B-ALL cells as well as avoid the profoundhematopoietic toxicity that we have previously described. Although thisconcept was previously published using an artificial system of CD19/PSMArecognition, this clinically relevant construct represents a majoradvance in the field with a relatively clear path to clinicaltranslation. Notably, although such a dual CAR design will likely beassociated with reduced toxicity, it may leave unaddressed the issue ofantigen loss relapse by making CAR recognition more, rather than lessrestrictive. However, if targeting of CD123 successfully eradicates ALLstem cells, this approach could be both safe and efficacious.

In summary, demonstrated here is a novel and effective strategy to thetreatment of B-ALL by targeting CD123. This approach is particularlyattractive since CD123 is expressed in rare CD19-negative malignantcells in some patients with B-ALL and is retained in antigen-lossrelapses occurring after CD19-directed immunotherapies. Moreover, thecombination of CART19 with CART123 can prevent the occurrence ofCD19-negative relapses.

Example 18: Low Dose RAD001 Stimulates CART Proliferation in a CellCulture Model

The effect of low doses of RAD001 on CART cell proliferation in vitrowas evaluated by co-culturing CART-expressing cells with target cells inthe presence of different concentrations of RAD001.

Materials and Methods

Generation of CAR-Transduced T Cells

A humanized, anti-human CD19 CAR (huCART19) lentiviral transfer vectorwas used to produce the genomic material packaged into VSVg pseudotypedlentiviral particles. The amino acid and nucleotide sequence of thehumanized anti-human CD19 CAR (huCART19) is CAR 1, ID 104875, describedin PCT publication, WO2014/153270, filed Mar. 15, 2014, and isdesignated SEQ ID NOs. 85 and 31 therein.

Lentiviral transfer vector DNA is mixed with the three packagingcomponents VSVg env, gag/pol and rev in combination with lipofectaminereagent to transfect Lenti-X 293T cells. Medium is changed after 24 hand 30 h thereafter, the virus-containing media is collected, filteredand stored at −80° C. CARTs are generated by transduction of fresh orfrozen naïve T cells obtained by negative magnetic selection of healthydonor blood or leukopak. T cells are activated by incubation withanti-CD3/anti-CD28 beads for 24 h, after which viral supernatant orconcentrated virus (MOI=2 or 10, respectively) is added to the cultures.The modified T cells are allowed to expand for about 10 days. Thepercentage of cells transduced (expressing the CARs on the cell surface)and the level of CAR expression (relative fluorescence intensity, GeoMean) are determined by flow cytometric analysis between days 7 and 9.The combination of slowing growth rate and T cell size approaching −350fL determines the state for T cells to be cryopreserved for lateranalysis.

Evaluating Proliferation of CARTs

To evaluate the functionality of CARTs, the T cells are thawed andcounted, and viability is assessed by Cellometer. The number ofCAR-positive cells in each culture is normalized using non-transduced Tcells (UTD). The impact of RAD001 on CARTs was tested in titrations withRAD001, starting at 50 nM. The target cell line used in all co-cultureexperiments is NALM6 (Nalm-6), a human pre-B cell acute lymphoblasticleukemia (ALL) cell line expressing CD19 and transduced to expressluciferase.

For measuring the proliferation of CARTs, T cells are cultured withtarget cells at a ratio of 1:1. The assay is run for 4 days, when cellsare stained for CD3, CD4, CD8 and CAR expression. The number of T cellsis assessed by flow cytometry using counting beads as reference.

Results

The proliferative capacity of CART cells was tested in a 4 dayco-culture assay. The number of CAR-positive CD3-positive T cells (darkbars) and total CD3-positive T cells (light bars) was assessed afterculturing the CAR-transduced and non-transduced T cells with NALM6(Nalm-6) (FIG. 59 ). huCART19 cells expanded when cultured in thepresence of less than 0.016 nM of RAD001, and to a lesser extent athigher concentrations of the compound. Importantly, both at 0.0032 and0.016 nM RAD001 the proliferation was higher than observed without theaddition of RAD001. The non-transduced T cells (UTD) did not showdetectable expansion.

Example 19: Low Dose RAD001 Stimulates CART Expansion In Vivo

This example evaluates the ability of huCAR19 cells to proliferate invivo with different concentrations of RAD001.

Materials and Methods:

NALM6-luc cells: The NALM6 human acute lymphoblastic leukemia (ALL) cellline was developed from the peripheral blood of a patient with relapsedALL. The cells were then tagged with firefly luciferase. Thesesuspension cells grow in RPMI supplemented with 10% heat inactivatedfetal bovine serum.

Mice: 6 week old NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice werereceived from the Jackson Laboratory (stock number 005557).

Tumor implantation: NALM6-luc cells were grown and expanded in vitro inRPMI supplemented with 10% heat inactivated fetal bovine serum. Thecells were then transferred to a 15 ml conical tube and washed twicewith cold sterile PBS. NALM6-luc cells were then counted and resuspendedat a concentration of 10×10⁶ cells per milliliter of PBS. The cells wereplaced on ice and immediately (within one hour) implanted in the mice.NALM6-luc cells were injected intravenously via the tail vein in a 100μl volume, for a total of 1×10⁶ cells per mouse.

CAR T cell dosing: Mice were administered 5×10⁶ CAR T cells 7 days aftertumor implantation. Cells were partially thawed in a 37 degree Celsiuswater bath and then completely thawed by the addition of 1 ml of coldsterile PBS to the tube containing the cells. The thawed cells weretransferred to a 15 ml falcon tube and adjusted to a final volume of 10mls with PBS. The cells were washed twice at 1000 rpm for 10 minuteseach time and then counted on a hemocytometer. T cells were thenresuspended at a concentration of 50×10⁶ CAR T cells per ml of cold PBSand kept on ice until the mice were dosed. The mice were injectedintravenously via the tail vein with 100 μl of the CAR T cells for adose of 5×10⁶ CAR T cells per mouse. Eight mice per group were treatedeither with 100 μl of PBS alone (PBS), or humanized CD19 CAR T cells.

RAD001 dosing: A concentrated micro-emulsion of 50 mg equal to 1 mgRAD001 was formulated and then resuspended in D5W (dextrose 5% in water)at the time of dosing. Mice were orally dosed daily (via oral gavage)with 200 μl of the desired doses of RAD001.

PK analysis: Mice were dosed daily with RAD001 starting 7 days posttumor implantation. Dosing groups were as follows: 0.3 mg/kg, 1 mg/kg, 3mg/kg, and 10 mg/kg. Mice were bled on days 0 and 14 following the firstand last dose of RAD001, at the following time points for PK analysis:15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and24 hours.

Results:

The expansion and pharmacokinetics of RAD001 was tested in NSG mice withNALM6-luc tumors. Daily oral dosing of RAD001 alone did not have animpact on the growth of NALM6-luc tumors (FIG. 60 ). The pharmacokineticanalysis of RAD001 shows that it is fairly stable in the blood of tumorbearing mice (FIGS. 61A and 61B). Both the day 0 and day 14 PK analysesshow that the RAD001 concentrations in the blood is above 10 nm even 24hours after dosing at the lowest dose tested (0.3 mg/kg).

Based on these doses, huCAR19 CAR T cells were dosed with and withoutRAD001 to determine the proliferative ability of these cells. Thehighest dose used was 3 mg/kg based on the levels of RAD001 in the blood24 hours after dosing. As the concentration of RAD001 was above 10 nM 24hours after the final dose of RAD001, several lower doses of RAD001 wereused in the in vivo study with CAR T cells. The CAR T cells were dosedIV one day prior to the start of the daily oral RAD001 dosing. Mice weremonitored via FACS for T cell expansion.

The lowest doses of RAD001 show an enhanced proliferation of the CAR Tcells (FIGS. 62A and 62B). This enhanced proliferation is more evidentand prolonged with the CD4+ CAR T cells than the CD8+ CAR T cells.However, with the CD8+ CAR T cells, enhanced proliferation can be seenat early time points following the CAR T cell dose.

Example 20: Certain Patients with Primary DLBCL Show CD3+/PD1+ DualPositive Cancer Cells

Although there have been compelling advances in the cancer immunotherapyspace recently in the form of chimeric antigen receptor (CAR) modifiedT-cells and checkpoint inhibitors, advanced tools to explore thetherapeutic mechanisms of their combination are not widely available. Toaddress this growing need, a robust quantitative fluorescentimmunohistochemistry platform using multiplex AQUA (AutomatedQuantitative Analysis) technology was developed to evaluate checkpointinhibitor expression, enumerate CAR T cells and determine theinteraction between tumor cells and immune cells via novelco-localization algorithms. The utility of this method was characterizedboth in preclinical- and clinical model systems. In an immunodeficientmouse model of B-cell lymphoma, homing of CAR T cells to malignantB-cells in primary lymphoid organs was evaluated. The phenotype andfunctional status of the CART cells via multiplex analyses of CD4, CD8,PD1 and FOXP3 expression was determined. Additionally, to enablecombination immunotherapies in Diffuse Large B-Cell Lymphoma (DLBCL)setting, prevalence of adaptive immune resistance mechanisms in the formof PD1 and PD-L1 expression in immune- and tumor cell compartments wasexamined via landmarks created by cytoplasmic and nuclear stains in bothprimary and secondary biopsies from DLBCL patients (n=63). To supportpatient selection for CAR T trials, expression and prevalence ofrelevant tumor antigens that could not be scored reproducibly bytraditional methods were quantified to yield objective cut points. Thesequantitative multiplexed IHC methods for optimal selection of patientscan be utilized in upcoming novel combination immunotherapy trials.

Sample preparation, imaging, and analysis of imaging for DLBCL tissuesamples was performed on primary DLBCL (n=49) and secondary DLBCL (15)human patients.

Sample preparation. Formalin fixed paraffin embedded (FFPE) tissuesamples were dewaxed. The slides were then rehydrated through a seriesof xylene to alcohol washes before incubating in distilled water.Heat-induced antigen retrieval was then performed using elevatedpressure and temperature conditions, allowed to cool, and transferred toTris-buffered saline. Staining was then performed where the followingsteps were carried out. First, endogenous peroxidase was blockedfollowed by incubation with a protein-blocking solution to reducenonspecific antibody staining. Next, the slides were stained with amouse anti-PD1 primary antibody. Slides were then washed beforeincubation with an anti-mouse HRP secondary antibody. Slides were washedand then PD-1 staining was detected using TSA+ Cy® 5 (Perkin Elmer).Primary and secondary antibody reagents were then removed via microwave.The slides were again washed before staining with a rabbit anti-CD3primary antibody. Slides were washed and then incubated with a cocktailof anti-rabbit HRP secondary antibody plus 4′,6-diamidino-2-phenylindole(DAPI). Slides were washed and then CD3 staining was detected usingTSA-Cy® 3 (Perkin Elmer). Slides were washed a final time before theywere cover-slipped with mounting media and allowed to dry overnight atroom temperature.

Sample imaging and analysis. Fluorescence images were then acquiredusing the Vectra 2 Intelligent Slide Analysis System using the Vectrasoftware version 2.0.8 (Perkin Elmer). First, monochrome imaging of theslide at 4× magnification using DAPI was conducted. An automatedalgorithm (developed using inForm) was used to identify areas of theslide containing tissue.

The areas of the slide identified as containing tissue were imaged at 4×magnification for channels associated with DAPI (blue), Cy®3 (green),and Cy® 5 (red) to create RGB images. These 4× magnification images wereprocessed using an automated enrichment algorithm (developed usinginForm) in field of view selector to identify and rank possible 20×magnification fields of view according to the highest Cy® 3 expression.

The top 40 fields of view were imaged at 20× magnification across DAPI,Cy®3, and Cy® 5 wavelengths. Raw images were reviewed for acceptability,and images that were out of focus, lacked any tumor cells, were highlynecrotic, or contained high levels of fluorescence signal not associatedwith expected antibody localization (i.e., background staining) wererejected prior to analysis. Accepted images were processed usingAQUAduct (Perkin Elmer), wherein each fluorophore was spectrally unmixedby spectral unmixer into individual channels and saved as a separatefile.

The processed files were further analyzed using AQUAnalysis™ or througha fully automated process using AQUAserve™. Each DAPI image wasprocessed by cell masker to identify all cell nuclei within that image,and then dilated by 2 pixels to represent the approximate size of anentire cell. This resulting mask represented all cells within thatimage. Each Cy® 5 image was processed by biomarker masker to create abinary mask of all cells that are PD-1-positive. Each Cy® 3 image wasprocessed by biomarker masker to create a binary mask of all cells thatare CD3-positive. The binary masks for all cells PD-1-positive andCD3-positive were combined to create a binary mask of all cells that aredouble positive for PD-1 and CD3. The % biomarker positivity (PBP) forall CD3 cells expressing PD-1 was derived, using positivity calculator,by dividing the total area, measured in pixels and determined by areaevaluator, of the mask of all PD-1-positive tumor cells with the totalarea, measured in pixels and determined by area evaluator, of the maskof all CD3-positive cells. Representative values of PBP for allCD3-positive cells expressing PD-1 in primary and secondary DLBCL humansamples are shown in FIG. 63 . CD3 and PD-1 status showed thatprevalence rates of CD3+/PD-1+ cells in primary is higher than secondaryDLBCL setting, providing an opportunity to select patient for eithersingle or combination treatment.

A similar experiment was performed in which PD-L1 was detected using arabbit anti-PDL1 primary antibody and TSA+Cy5 (Perkin Elmer) on DLBCLtissue samples from primary DLBCL human patients. PD1 and CD3 were alsodetected on the same samples. The experiment showed that tumormicroenvironments comprise cells that express PD1, CD3, and PDL1. Theexperiment also identified a sub-population of cells that is CD3+PD1+(data not shown). These results support the model that a tumormicroenvironment fosters immune suppressive cells that can be targetedwith agents specific to PD1+ or PD-L1+ cells.

Example 21: Mutually Exclusive Expression of CD19 and PD-L1 in SamplesComprising DLBCL Cells

Sample preparation. Formalin fixed paraffin embedded (FFPE) tissuesamples were dewaxed. The slides were then rehydrated through a seriesof xylene to alcohol washes before incubating in distilled water.Heat-induced antigen retrieval was then performed using elevatedpressure and temperature conditions, allowed to cool, and transferred toTris-buffered saline. Staining was then performed where the followingsteps were carried out. First, endogenous peroxidase was blockedfollowed by incubation with a protein-blocking solution to reducenonspecific antibody staining. Next, the slides were stained with arabbit anti-PDL1 primary antibody. Slides were then washed beforeincubation with an anti-rabbit HRP secondary antibody. Slides werewashed and then PDL1 staining was detected using TSA+ Cy® 3 (PerkinElmer). Primary and secondary antibody reagents were then removed viamicrowave. The slides were again washed before staining with a mouseanti-CD19 primary antibody. Slides were washed and then incubated with acocktail of anti-mouse HRP secondary antibody plus4′,6-diamidino-2-phenylindole (DAPI). Slides were washed and then CD19staining was detected using TSA-Cy® 5 (Perkin Elmer). Slides were washeda final time before they were cover-slipped with mounting media andallowed to dry overnight at room temperature.

Sample imaging and analysis. Fluorescence images were then acquiredusing the Vectra 2 Intelligent Slide Analysis System using the Vectrasoftware version 2.0.8 (Perkin Elmer). First, monochrome imaging of theslide at 4× magnification using DAPI was conducted. An automatedalgorithm (developed using inForm) was used to identify areas of theslide containing tissue.

The areas of the slide identified as containing tissue were imaged at 4×magnification for channels associated with DAPI (blue), Cy®3 (green),and Cy® 5 (red) to create RGB images. These 4× magnification images wereprocessed using an automated enrichment algorithm (developed usinginForm) in field of view selector to identify and rank possible 20×magnification fields of view according to the highest Cy® 3 expression.

The top 40 fields of view were imaged at 20× magnification across DAPI,Cy®3, and Cy® 5 wavelengths. Raw images were reviewed for acceptability,and images that were out of focus, lacked any tumor cells, were highlynecrotic, or contained high levels of fluorescence signal not associatedwith expected antibody localization (i.e., background staining) wererejected prior to analysis. Accepted images were processed usingAQUAduct (Perkin Elmer), wherein each fluorophore was spectrally unmixedby spectral unmixer into individual channels and saved as a separatefile.

The processed files were further analyzed using AQUAnalysis™ or througha fully automated process using AQUAserve™ as described in the previousExample.

Representative values of PBP for all CD19-positive and PD-L1-positivecells in primary and secondary DLBCL human samples are shown in FIG. 64. CD19 and PDL1 expression varied in DLBCL samples. CD19 and PDL1expression tended to be mutually exclusive, i.e., in general, a givencell expressed CD19 or PD-L1 but not both. While not wishing to be boundby theory, this may be because CD19 is expressed in DLBCL tumor cellswhile PD-L1 is expressed in non-tumor cells, e.g., cells that supportthe tumor microenvironment. This observation suggests that a combinationtherapy of a CD19 inhibitor (e.g., a CD19 CAR-expressing cell) and aninhibitor of PD-L1 signalling may be useful for targeting these twopopulations of cells.

A similar experiment was performed to, e.g., demonstrate the capabilityof AQUA analysis to monitor CART19 efficacy. This study monitored CD19,CD3, and the CART19 nucleic acid in samples comprising mixed cells lineswith CART19+ Jurkat cells and CD19+ REH cells. CD19 and CD3 proteinswere detected by antibodies, and CART19 was detected using an RNA probeagainst the 3′ UTR of the CAR nucleic acid. The experiment showed thatthe cell line samples comprise cells that express CD19, CD3, and theCART19 (data not shown). The experiment also showed that the cell linesamples comprise a sub-population of cells that is CD3+/CART19+ (datanot shown). Proximity analysis was performed, which showed that CART19cells were physically proximal to CD19+ cells (data not shown). Theseexperiments support the model that CD3+ CART19 cells infiltrate a tumormicroenvironment comprising CD19+ cells and physical locations of CD19and CART19 cells translate into efficacy of the CART19 therapy.

Example 22: Bicistronic Expression of CARs

In this Example, the efficacy of two types of cell populations werecompared. In the first cell population, referred to as “pooled”, eachcell expresses one CAR. A first plurality of cells was transduced withCD19 CAR, a second plurality of cells was transduced with CD22 CAR orCD123 CAR, and then the two pluralities of cells were pooled. In thesecond type of cell population, a plurality of cells was transduced witha bicistronic vector expressing CD19 CAR and a second CAR, so that mostor all of the cells expressed both constructs. The second CAR was CD22CAR in some experiments and CD123 CAR in others. These cell populationsare illustrated in FIG. 65 .

Two novel constructs, diagrammed in FIG. 66 , were generated using theP2A system in order to express two full-length CARs in the same T cellusing a single bicistronic lentiviral vector. T cells were expandedaccording to a standard protocol and transduced using a singlelentivirus carrying both CAR19 and CAR123 (multiplicity of infection,MOI=3). A similar transduction was performed for CAR19 and CAR22 in thesame T cell population obtained using the described bicistroniclentiviral vector. FIG. 67 shows co-expression of CD19 and CD22 CARs.Distinct populations based on the specific expression of CAR19 and/orCAR123 can be recognized, including a Dual CAR19+/CAR123+ population anda double negative population (FIG. 68A).

The cells transduced with bicistronic CD19 CAR and CD123 CAR wascompared with pooled cells expressing either CD19 or CD123 CAR (FIG.68B). NSG mice were engrafted with a B-ALL cell line (NALM-6, CBG+). Atday 7 mice were randomized based on tumor burden (BLI, bioluminescence)to receive control T cells (UTD), CART19, CART123, the 1:1 pooledcombination of CART123 and CART19 or the Dual CART19/123 (same totalnumber of CAR+ cells). CD19 CAR-expressing cells alone (squares) andCD123 CAR-expressing cells alone (triangles) both showed initialeffectiveness compared to the control (circles) followed by risinglevels of leukemic cells. Pooled cells expressing CD19 or CD123(diamond) also showed initial effectiveness followed by rising levels ofleukemic cells. In contrast, cells transfected with the bicistronicvector (inverted triangles, “dual CART”) maintained a prolonged responseat least 60 days after treatment. This experiment indicates that dualCARTs exert a potent anti-leukemia effect that is not only superior to asingle CART treatment but is superior to a pooled CART cells.

Example 23: CART22 is Effective Against CD19-Neg B-ALL in an AnimalModel

CD19-negative B-ALL cells were tested for responsiveness to CD19CAR-expressing cells and CD22 CAR-expressing cells in an animal model.One million CD19-negative B-ALL cells were infused into mice on day 0,and 2e6 CAR+ T cells were infused on day 7 (after randomization). Tumorburden was measured by bioluminescence. As shown in FIG. 69 , while thecancer progressed in the negative control mice and CART19-treated mice,CART22 is able to clear CD19-negative ALL in NSG xenografts.

The assay was conducted as follows: 1e6 CD19-neg ALL cells (CBG+) wereinjected in NSG mice. At day 5 mice were randomized to receive either2e6 control untransduced T cells (UTD), CART19 or CART22 (m971 scFv).Mice were then followed up for tumor burden (bioluminescence).

Example 24: Low Levels of Immune Checkpoint Molecules are Associatedwith Improved Outcomes

Immune checkpoint molecules (PD-L1, PD1, LAG3, and TIM3) were detectedin samples from lymphoma patients by immunohistochemistry. Positive andnegative control tissues and cell lines were also performed. The immunecheckpoint expression analysis was performed using quantitative imageanalysis on a region of interest which can include tumor cells andnon-tumor cells such as immune cells. Samples were taken from tissue,lymph node, or bone marrow.

Immune checkpoint protein expression was compared in complete responders(CR) and patients having progressive disease (PD) following treatmentwith CD19-targeting CAR therapy. As shown in FIG. 70 , the CR patientstended to have low levels of PD-L1, PD1, LAG3, and TIM3 before and aftertreatment, while PD patients tended to have high levels of thesemolecules before and after treatment. This Example supports combinationtherapy with a CAR-expressing cell and an immune checkpoint inhibitor,and supports testing to determine immune checkpoint molecule levels inpatients receiving a CAR therapy.

Example 25: Functional Assays of CD22 CAR-Expressing Cells

Several CD22 CAR constructs were functionally validated in an NFATassay. Briefly the experiments were performed as follows. A lentiviralvector (pELPS) carrying a nucleic acid, encoding a CD22 CAR with aCD22-binding scFv domain was introduced by electroporation into a JurkatT cell line modified to express luciferase under the control of an NFATresponse element (JNL). The cells were cultured and allowed to expressthe CAR construct. The electroporated cells were applied to a platecoated with the target antigen (CD22). Detection of luciferase signal inthe coated plate was indicative of binding activity of the CD22 CAR toits antigen, leading to activation of the T cells and expression ofluciferase.

FIG. 71 is a graph showing the activation (in RLU) of several CD22 CARconstructs in the presence and absence of a m971 scFv competitor. Theseresults indicate that CD22-53 and CD22-12, and a subset of the otherscFvs, bind the antigen approximately as well as the m971 positivecontrol. The results also indicate that the different scFvs compete withm971 to different extents.

Sixteen additional human CD22 binding domains were tested and found tohave weak binding activity (data not shown), so were not pursuedfurther.

FIG. 72 is a graph showing the activation (in RLU) of several CD22CAR-expressing JNL cells including CD22-57, CD22-58, CD22-59, CD22-60,CD22-61, CD22-62, and CD22-63, the scFv sequences of which are providedherein. Three different target proteins (CD22-FL-Fc, CD22-D567-Fc, andCD22-D67) were used to coat the tissue culture plates; a negativecontrol (Fc) was also included. A mesothelin binding CAR (Meso-G07) wasused as a negative control. CD22-12 and CD22-53 were used as positivecontrols. The experiment indicated that all CARs (CD22-57, CD22-58,CD22-59, CD22-60, CD22-61, CD22-62, and CD22-63) were functional in thisassay. Furthermore, these results indicated that the CARs tested(including CD22-12 and -53) bind to the domains 6 and 7 of CD22. Domainmapping was performed on CD22 binding domains. Three different forms ofantigens were used: CD22 full-length with all 7 external domains,Domain567 (in which domains 1-4 were deleted) and Domain67 (in whichdomains 1-5 were deleted). While not wishing to be bound by theory, itappears that the binding of various CD22 clones maps to the epitopesillustrated in FIG. 75 .

CD22 CAR constructs were also tested for the ability to promotesecretion of IFN-gamma and IL-2. Briefly, transduced primary T cellsfrom healthy donors expressing the different CD22 CARs were co-culturedwith the CD22-positive target cells Raji-Luc and Daudi-Luc as well asthe negative control K562-Luc. T cells and target cell were cultured inan effector-to-target cell ratio (E:T) of 10 to 1. Supernatants wereharvested after 20-hr co-culture. FIG. 73 shows three bar graphsindicating IFN-gamma production in pg/mL. Co-culture with Raji-Luc (toppanel) and Daudi-luc (center panel) cell lines induced IFN-gammasecretion by hCD22-12, hCD22-53 CAR T cells as well as the two positivecontrols CAR19 and m971-HL. Notably, highest amounts were observed whenthe hCD22-53 cells were tested, and to a lesser extent, when thehCD22-12 cells were tested. Similar results were observed whenNalm6-Luc, Pfeiffer-Luc, and K562-CD22-Luc, and SEM-Luc cells weretested (data not shown). Minimal IFN-gamma secretion was observed whenthe K562-Luc negative control cell line was tested (bottom panel).

CD22-12 showed activity comparable to m971 in cell killing and cytokinesecretion assays (Example 9). Two scFvs, named CD22-64 and CD22-65, wereproduced by affinity maturation of hCD22-12. CAR constructs containingthese scFvs were tested for activity in an NFAT assay as describedabove. As shown in FIG. 74 , both CD22-64 and CD22-65 bind CD22 as wellor better than CD22-12 and CD22-53, leading to JNL activation. The barsin the figure represent, from left to right, CD22 full length-Fc; CD22D567-Fc; and an Fc only negative control used for coating of the plates.Testing four variants of CD22-12 suggested that LCDR3 and HCDR3contributed to binding to some extent (data not shown), and that HCDR3may tolerate more mutations than LCDR3.

EQUIVALENTS

The disclosures of each and every patent, patent application, andpublication cited herein are hereby incorporated herein by reference intheir entirety. While this invention has been disclosed with referenceto specific aspects, it is apparent that other aspects and variations ofthis invention may be devised by others skilled in the art withoutdeparting from the true spirit and scope of the invention. The appendedclaims are intended to be construed to include all such aspects andequivalent variations.

What is claimed is:
 1. A population of cells comprising: (a) a firstchimeric antigen receptor (CAR) molecule comprising an antigen-bindingdomain which is a CD19 binding domain, wherein the CD19 binding domaincomprises a scFv comprising the LC CDR1, LC CDR2, LC CDR3, HC CDR1, HCCDR2, and HC CDR3 of FMC63; and (b) a second CAR comprising anantigen-binding domain which is a CD20 binding domain.
 2. The populationof cells of claim 1, wherein the first CAR and the second CAR eachcomprise one, two, three, or all of: (a) a transmembrane domaincomprising a transmembrane domain of a protein selected from the groupconsisting of the alpha, beta, or zeta chain of the T-cell receptor,CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37,CD64, CD80, CD86, CD134, CD137, and CD154, wherein optionally the CD19and/or CD20 binding domain is connected to the transmembrane domain by ahinge region; (b) a costimulatory domain that is a functional signalingdomain obtained from a protein selected from the group consisting ofCD28, 4-1BB (CD137), OX40, CD2, CD27, ICAM-1, LFA-1 (CD11a/CD18), andICOS (CD278); (c) an intracellular signaling domain that comprises afunctional signaling domain of CD3 zeta or a functional signaling domainof 4-1BB; and (d) leader sequence.
 3. The population of cells of claim2, wherein the first CAR further comprises a CD28 costimulatory domainand the second CAR further comprises a 4-1BB costimulatory domain. 4.The population of cells of claim 3 wherein: (a) the CD28 costimulatorydomain comprises an amino acid sequence of SEQ ID NO: 1317, or asequence with 95-99% identity thereto; and/or (b) the 4-1BBcostimulatory domain comprises an amino acid sequence of SEQ ID NO: 16,or a sequence with 95-99% identity thereto.
 5. The population of cellsof claim 1, wherein the first CAR and second CAR each further comprise aCD3z signaling domain.
 6. The population of cells of claim 5, whereinthe CD3z signaling domain comprises an amino acid sequence of SEQ ID NO:17 or 43, or a sequence with 95-99% identity thereto.
 7. The populationof cells of claim 1, wherein the population of cells comprises T cellsor NK cells.
 8. The population of cells of claim 1, wherein the firstCAR is encoded by a first nucleic acid sequence and the second CAR isencoded by a second nucleic acid sequence, wherein the first and secondnucleic acid sequences are disposed on a single nucleic acid molecule.9. The population of cells of claim 8, wherein the first nucleic acidsequence and second nucleic acid sequence are connected by a nucleicacid encoding a T2A, P2A, E2A, or F2A site.
 10. An isolated nucleic acidmolecule comprising: (i) a first nucleic acid sequence encoding a firstCAR molecule comprising an antigen-binding domain which is a CD19binding domain, wherein the CD19 binding domain comprises a scFvcomprising the LC CDR1, LC CDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3of FMC6; and (ii) a second nucleic acid sequence encoding a second CARcomprising an antigen-binding domain which is a CD20 binding domain,wherein the first nucleic acid sequence and second nucleic acid sequenceare in the same nucleic acid molecule.
 11. The isolated nucleic acidmolecule of claim 10, wherein the first CAR and the second CAR eachcomprise one, two, three, or all of: (a) a transmembrane domaincomprising a transmembrane domain of a protein selected from the groupconsisting of the alpha, beta, or zeta chain of the T-cell receptor,CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37,CD64, CD80, CD86, CD134, CD137, and CD154, wherein optionally the CD19and/or CD20 binding domain is connected to the transmembrane domain by ahinge region; (b) a costimulatory domain that is a functional signalingdomain obtained from a protein selected from the group consisting ofCD28, 4-1BB (CD137), OX40, CD2, CD27, ICAM-1, LFA-1 (CD11a/CD18), andICOS (CD278); (c) an intracellular signaling domain that comprises afunctional signaling domain of CD3 zeta or a functional signaling domainof 4-1BB; and (d) leader sequence.
 12. The isolated nucleic acidmolecule of claim 11, wherein the first CAR further comprises a CD28costimulatory domain and the second CAR further comprises a 4-1BBcostimulatory domain.
 13. The isolated nucleic acid molecule of claim12, wherein: (a) the CD28 costimulatory domain comprises a nucleic acidsequence of SEQ ID NO: 1318, or a sequence with 95-99% identity thereto;and/or (b) the 4-1BB costimulatory domain comprises a nucleic acidsequence of SEQ ID NO: 60, or a sequence with 95-99% identity thereto.14. The isolated nucleic acid molecule of claim 10, wherein the firstCAR and second CAR each further comprise a CD3z signaling domain. 15.The isolated nucleic acid molecule of claim 14, wherein the CD3zsignaling domain comprises a nucleic acid sequence of SEQ ID NO: 101 or44, or a sequence with 95-99% identity thereto.
 16. The isolated nucleicacid molecule of claim 10, wherein the first nucleic acid sequence andsecond nucleic acid sequence are connected by a nucleic acid encoding aT2A, P2A, E2A, or F2A site.
 17. An isolated nucleic acid moleculecomprising, in a 5′ to 3′ orientation: a nucleic acid sequence encodingan antigen-binding domain that binds to CD19 comprising a scFvcomprising the LC CDR1, LC CDR2, LC CDR3, HC CDR1, HC CDR2, and HC CDR3of FMC63; a nucleic acid sequence encoding a CD28 transmembrane domain;a nucleic acid sequence encoding a CD28 costimulatory domain; a nucleicacid sequence encoding a CD3z intracellular signaling domain; a nucleicacid sequence encoding a T2A, P2A, E2A, or F2A site; a nucleic acidsequence encoding an antigen-binding domain that binds to CD20; anucleic acid sequence encoding a CD8 transmembrane domain; a nucleicacid sequence encoding a 4-1BB costimulatory domain; a nucleic acidsequence encoding a CD3z intracellular signaling domain.
 18. A vectorcomprising the isolated nucleic acid molecule of claim
 10. 19. A cellcomprising the isolated nucleic acid molecule of claim
 10. 20. A methodof making a cell, comprising transducing the cell with the vector ofclaim
 19. 21. A plurality of isolated CAR molecules encoded by theisolated nucleic acid molecule of claim
 10. 22. A method of treating acancer in a subject, the method comprising administering to the subjectthe population of cells of claim
 1. 23. A method of treating a cancer ina subject, the method comprising administering to the subject, theisolated nucleic acid molecule of claim
 10. 24. A method of treating acancer in a subject, the method comprising administering to the subject,the cell of claim 19.